<SEC-DOCUMENT>0001558370-20-001238.txt : 20200224
<SEC-HEADER>0001558370-20-001238.hdr.sgml : 20200224
<ACCEPTANCE-DATETIME>20200224163559
ACCESSION NUMBER:		0001558370-20-001238
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200224
DATE AS OF CHANGE:		20200224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Axogen, Inc.
		CENTRAL INDEX KEY:			0000805928
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				411301878
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36046
		FILM NUMBER:		20644857

	BUSINESS ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615
		BUSINESS PHONE:		(386) 462-6817

	MAIL ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AxoGen, Inc.
		DATE OF NAME CHANGE:	20111004

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LECTEC CORP /MN/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>axgn-20191231x10k0cc357.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.5.7293.39921 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 2/24/2020 9:33:36 PM -->
      <!-- iXBRL Library version: 1.0.7293.39928 -->
      <!-- iXBRL Service Job ID: 8ffedf2f-52fb-4169-a695-d16f258aedc2 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:axgn="http://www.axogeninc.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" xs:nil="true" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" name="us-gaap:CommitmentsAndContingencies" id="Tc_tMtHerkBPUaU0ej7Uz8Cww_31_3"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" xs:nil="true" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" name="us-gaap:CommitmentsAndContingencies" id="Tc_XQ1rYkr1_0-yQNzIOG0Jkw_31_6"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityIncorporationStateCountryCode" id="Tc_rqrQ3ho-OUOyVr7owf06qA_1_0">MN</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="_c344fd47_2394_4dca_b707_ae51747fa418">38900875</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="_f512fdbf_b9ff_4859_8380_dfc91859b80e">39589755</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_xxA6d2qDA0KMb3nNUfKzyA" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="_de056e84_5c37_441e_8d70_f8b60d255c1c">P17Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_2_6_2007_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_IQT4Hnendk61jLbD3SyI3A" decimals="0" name="us-gaap:AreaOfRealEstateProperty" id="_9adc0d0a_9f27_4b75_b561_f0f616fc58b6">19000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_1_23_2017_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_VHd28wBFnkarvgZ3-fAtGg" decimals="0" name="axgn:AreaOfRealEstatePropertyAdditional" id="_de7536fc_c71e_45d4_b4bd_cca7546a8119">1400</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_11_19_2018_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_oohE1k3520KrPLNnlA6-yg" decimals="0" name="axgn:AreaOfRealEstatePropertyAdditional" id="_842590dc_0853_48a1_94e3_0974e859a7d8">2800</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_11_21_2018_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_mqnOkqMEd06V_dbWfNINVg" decimals="0" name="axgn:AreaOfRealEstatePropertyAdditional" id="_2049e4b8_faac_41e8_83f3_7e116573faca">2500</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_A-7j6YugD0yFLat26CFF9g" decimals="0" name="us-gaap:AreaOfRealEstateProperty" id="_0d926b8e_ab68_494b_9c97_8808ab1309cf">12500</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityCentralIndexKey" id="Tc_IJWfjyMus0uvUNKT0625tA_2_1">0000805928</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:CurrentFiscalYearEndDate" id="Tc_A8V_Ke3pz0KPObwGFiYoiw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:DocumentFiscalYearFocus" id="Tc_XKDgGrkTgESuoE3GyMx0ig_4_1">2019</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:DocumentFiscalPeriodFocus" id="Tc_sCTDJzlxpkKC914YJsrHsQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:AmendmentFlag" id="Narr_1r3g88ErGkW29bOhTFOohA">false</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Tc_A4Fx7oi8o0qgiyXaY11oBA_4_0">us-gaap:LongTermDebtCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Tc_iS9N_npf70GWW2V_ErRjnw_5_0">us-gaap:LongTermDebtNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Tc_pGofsY-zPU6ke-fO75b00A_12_0">us-gaap:LongTermDebtCurrent us-gaap:LongTermDebtNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_CzAjyxtOdk2O6kk_VYsVbA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="_85e8adea_8926_4837_834b_5796d41281fc">P7Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_9_20_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_08A0hhoaQ0qebYXFMpGy1A" decimals="0" name="us-gaap:AreaOfRealEstateProperty" id="_8737cf0c_5377_4487_aceb_781cdeb5b2e6">1500</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="axgn-20191231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_G8SJ8nYBukqnwXb72_TUaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_QdTP5uBuUkm8aCMGR4HRdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_yxMu6JmduUiQWUtieKQOwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_4dIDit0lLkGoGloMyIZncQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_sonit0BwD0-XslHO4fwUog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_rHiawjIyP0aw2fguf5ppEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_YOXkkYOqUke7VD_DZQQEDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_UAgoENraVE6_3zK-NyR0vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_UBoSuOgnDkyJox-_uA5moQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_SJai84u14EuDL2IY6ZP7lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_SVGvuAZnpEa4kIr4fmffiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_5pNCsEIErU22bwU3noUy8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_JiZrmI4fMUOvyhPBobtrAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_7M-n1WyHmkSuJh3oSbSVVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CS4l3RjFjkG4cuMVEIJHOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OqYgr00JsUa249PGlgCbJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5iFiNf4eCU2t-jlDjLdgiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UsFg6g1V3k-jJJ9z3zX3kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-KZyjfz9K0yURx8oujgc-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36RWqiIIvUqIM5o6-tTfQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rABqkECIXEmoFHY4P39Btg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yopO1vpWDkSdAu8pQTBE6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_NvaE0ZF610qmwkn-m_kZkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_FuweD_vKdkCOcnSUpC4lMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_dOpDEESlqEODYTZJx6VStA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_ts6ch1E1YkaKgRGi-KlCzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_wAZ3pu-l8kyAOvBDAXRqzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_0ysv9tohn0Cnci0yKK3WTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_18_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_KoTtJ_qtIEWdKLFBvghyAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_18_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_CGrwMnPP4UGYxvkC4Exm0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_AsMXpgQA50yoxCfsHEU1FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:NewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_5M4EtFIS2UiIB7rFpvlMjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_14_2019_To_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_GGHIBITd6ES9mOn1M2PF1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:NewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-14</xbrli:startDate><xbrli:endDate>2019-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_j1ICqH5Z30Cj6yv7xX0hUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_17_2019_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_h_z9vINimUO30zz-EdrkPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_27_2018_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_XKWVUmRIiEOgStCdW6dO9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_kDpRBjGQ4ky9c7CfmO9qDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_kf1nPeinvkG_Rhf00UpwCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_C62IeF_A8kyKJEMkteQh9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_JJoSoSTdZU-4AUZvS_2qqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_zBQhnBxudEOrta0F6gp39g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_G1UD6bCPNE6Vk1FLD8sFmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Lew-fDnf_U63JMTITTXx7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_w1MuJpPwoUuQdyD6mVgyFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tXs-JMVGQEyiTIr2x0PXlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_8GcfaDwiVke9uA8EDTn7hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_CC9WNsq1-kOINeRZ-7lGZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_CzAjyxtOdk2O6kk_VYsVbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_6eAKFDAAb0yer27HykbH7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_VestingAxis_axgn_ShareBasedCompensationAwardTrancheFourMember_sY50ARTqmkOIAcnOP5sbtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">axgn:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember__vQAw7VfUE6OunzRu1K-bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_VxZyqVXjoUyc4jYXo3Wsgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_bxzrSUd6ckqbGlbKCkkNcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_ACgwMpqi40GSjcz2QnxS7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_OZPWCWKOxEOV_X4bbR494w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_gm7Ekd16kESYJkPMrHphbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_BvPsE8K_qU2AmBwEqGDfYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_05CtstIR4U6B9g5bHnLHdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_P3IHq2_ZwUq82grKCaDpZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_axgn_FurnitureAndOfficeEquipmentMember_eHb9YcMz8EqbrCnNH59ieA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_mTPBmF_K80agEXOisxdU-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_IKe6rTfzZ0ud8WUCTvHEOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CLATC9jILkmHQd664S3WNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_3Y3Zposxo06m_ckziI2URQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_axgn_FurnitureAndOfficeEquipmentMember_DX67Y23vfUOHXqqejMx78g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_11_2018_To_5_11_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_8cxhdgof3UO6xB-FFbptDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axgn:CommonStockIssuanceMay2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-11</xbrli:startDate><xbrli:endDate>2018-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_31_2018_pDS8UW-ipEGiRfiHlv5kzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_22_2018_To_5_22_2018_us-gaap_LongtermDebtTypeAxis_axgn_RevolvingLoanAgreementMember_8N4ZVro1vU-SRjTtIMuL6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">axgn:RevolvingLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_22_2018_To_5_22_2018_i3ypW9J1CEa7OLr3rjoRmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_okKh-SdZMEibF5PgZHtNtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MOuFDoRprUic4VVjiNOb9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yAQQYV4FD0OLKehglkYWNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_fWIoGNsj7Ui2pXQ3bkgU4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_V4e6rd3wUEG9C3qE3Hpw-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:JaColeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_NnCe9k1NpUacLG-xMiiljw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:AshleyAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_bByFAiGDsEK9OCAVsqZANg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_KuQDicj1c0SnADAaZVmqbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:JaColeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_ZUL32-Ode0O5GUOiGbojiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:AshleyAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_NXRoZ-NBZ0ePelC05RSaqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:ThirdExpansionLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-19</xbrli:startDate><xbrli:endDate>2018-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_oujYrCpym0y45N14NxtAYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:SecondExpansionLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-19</xbrli:startDate><xbrli:endDate>2018-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_IsEezefk-Eu1CFK7CxX86A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:ThirdExpansionLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-19</xbrli:startDate><xbrli:endDate>2018-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_U9D1ulBaeUqvJJI4uvH5oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:SecondExpansionLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-19</xbrli:startDate><xbrli:endDate>2018-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_ZBGX0n3gPUucFdPYU_PIgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_Pwl4eK2_UkO9SelPSqHkRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_FBZq-druJEiz_96TJNFlGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksMember_BbMESX-_v0KHSgS-XLTLvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksMember_Qd3k0h7qbE2DTTVHMaRmbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">axgn:PatentsAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_KC2GzeBS4kutQdKGNYDCsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_tm6tkYZA0UC_UdKqm7L5gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_PgGkObwHFk-tbBS04WJSyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_XpCasb7z-kOfYQrkb2g_dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_dGmAPQbXTkiY-aJQtxRmkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_V4yhWdQNTEehyUOL8K5GIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_3FvL10D5nEOeSMDNANv2Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_Ql1wJMAwvk-Sb_JOHEvrvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_R1UTHSkFFkGQk_FG_stL9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_QtnKkZ4CLk2X_HFK_HYUZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_aTc0csteMkS0guuaxwtDRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_22_2018_dzFQMjgQyUeSU6fLKCFqYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5zA3fXbvx0ylwp-9i_-FOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:RaymondLeasingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_1eKp0lMU00OTf_T3kLb7qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:BAndBOfficeSystemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_kNscByhTbEyGSk9W2JNlqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:RaymondLeasingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_7a23qUYeEESFI9Qda8I25Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:BAndBOfficeSystemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_GGJc28kiH0yWr2MZBgPxCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:RaymondLeasingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_K3AS51eTEE-YvIQB0nBIfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:CiscoCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_nwTNdrPqO0CQRQSSHeR4zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:BAndBOfficeSystemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_R55K8zUulUecXnhoaiBPkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:RaymondLeasingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5AiGbGmjpkCdVyBcVv8E_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:CiscoCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_wW9WLuWZOE66fVKEdCy_HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:BAndBOfficeSystemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_dwnRMOuleUGG7WL91vnSAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x8gKvx5oDUisUyE4r4cbmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qFCNsryetU6naqT7GbcEhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B8IECFly_kaRlwUWZ1F6ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TJlFr_r_RkuXuvZTAhvzYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_YTJ3Sc6qnUeCcLNGzq1uxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">axgn:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axgn:CommonStockIssuanceMay2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_8_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_IP-Mn3x-6EudoUgdTXzq8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axgn:CommonStockIssuanceMay2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_Or2PNLcVTkK03OOF11rmZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_NtuCJ8sKq0qVnPGFTPpTwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_2g6PdNw7sEqA9_PlVqHxDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_QK4ED2K6qEOV1Xg1-zGj_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_75NcZ12IJk-eikFk1KM3Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_cdH2QUZpnki1Cwgvsjs8vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_ANmFTxutV0-xFOoQ8_7FPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_j8zL172gGUqB0hFUPl1x4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Y5SbtUl8VkmtgzZCsagCyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_5jPMRknfREqoJu62tcfW5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_QEj-hDcpYE6iU9rJ3XeK7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_A0SgF-lS8EWuSRhFGPu_kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_fkX6ZqT47Uy7zsyx_wxs1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_x6KsE8qyC0SgbIbxY0R8XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_728oYVG9_kqeLbE5u8GVGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nysdIkyyg0WkBDmiLHyfzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ftL9sDUwHkWRUwmRLPxn4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Ljo8XdXd1UOQhteaj6n1Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_N02mc_9XDEmaoa7UwF0qCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_285oEZVmiEuWMlWvMBhBKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_Z-mVrl7y0E-H9TTKDpOGrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_0r35qKuFtEOBMm3qfUnZew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_yZ1Iu5dLmECLNXvQICHt7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_iTCpB9orK0Sjz-9gGwsP8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Psoi6DhJ7E2efXXbLdjXyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_puZ9vioqskyMdjdeNUCdsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_HEXGxa8jpUKp0M7bjLh6dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VRqBUSVw9EGAy-ARzd86JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_t1faoeA6yEG9189EF_P-Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KEeGgwBLD065_sx2yO_BVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_tglKryFxhkq8-SAK4HEuzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_A-7j6YugD0yFLat26CFF9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:JaColeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_x4yTeLpiWEyE5kq91aXN1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:AshleyAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_kMJbk8ZcGUK3JDwkyBnNog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_08A0hhoaQ0qebYXFMpGy1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_6_2007_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_IQT4Hnendk61jLbD3SyI3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_4tCIYMnwyk6Ob6QqnDHXvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2018_9F5KGFk5ekOKV8bdqwW0vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_UDTsEyjMukWLzOkrt7d4_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3xXv5tKLESPI6qfsNRBAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ix9c_2i7sEuWHRfmxUztXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_9ic9jzQW1ECZSI_uvWQc5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_21_2020_kNbwNoscBki-6ondKdMYyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_4_2019_To_2_4_2019_ln_X-b6a80Wb7o__1q1OhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zPNTOe5UAku8lMq39V0WUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pgmLVwXuIUS__MSTlzniug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2011_To_12_31_2011_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_vqWblD6hEkiSy0wcGyIdzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-12-01</xbrli:startDate><xbrli:endDate>2011-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_xxA6d2qDA0KMb3nNUfKzyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_NdmkMgAetEmBY0Ox4RWwMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_YaU4fSuYCEqRjlrkJR8zFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_OFAgoTompkmEhOalHj3_sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_raPo7Sf_yUa4X4qkmt6ISg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:NewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_XwSdGg8qkECo4xeg2jamwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_8_2018_To_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_95CgkAkKI0mIpKKHiaq65w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">axgn:UnderwriterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axgn:CommonStockIssuanceMay2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-08</xbrli:startDate><xbrli:endDate>2018-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2019_srt_LitigationCaseAxis_axgn_NovitzkiVsZaderejMember_IYCkqEqibkCICffbHpaANQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">axgn:NovitzkiVsZaderejMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_12_2019_srt_LitigationCaseAxis_axgn_NovitzkiVsZaderejMember_zFX_2N4KPUasTY6aVIbF6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">axgn:NovitzkiVsZaderejMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_w7VPQT2pRkub_N0KQzm0eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:TissueProcessingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_re7GROPgKUaFj-ZkUJDT4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:TissueProcessingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_xCSHLZgiMUuIzNw6sSuFGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:TissueProcessingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_do694XF7Vkun4p0EqDCKIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_26_2018_To_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_DNUFWr2HVU6UI2RUpDclJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:AshleyAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-26</xbrli:startDate><xbrli:endDate>2018-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_1_2019_0uPXfB4sV0SD97KHNevlsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_7eeOyFQI-kyot4WSOxp9WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_rhwnZKQoVkSq-3aU8DS-_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanEmployerMatchingContributionTranche2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_WwMtZh6dN0OytTHyKURZmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanEmployerMatchingContributionTranche1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_pv52m7zoikuufdq5oJOf0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_OuSBR749Ck6rO9M9pD5hrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:CiscoCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_8IfuLyTmxkeeHIrn5HAHCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:CiscoCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2017_To_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_vVyhRlB3k0qQ8T_w4fLYmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-18</xbrli:startDate><xbrli:endDate>2017-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_9_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_1bIsEkV_FkmHurO56ABv6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2018_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_mqnOkqMEd06V_dbWfNINVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:JaColeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_19_2018_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_V5WUDuaOrka-roEinNbOxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:ThirdExpansionLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_19_2018_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_oohE1k3520KrPLNnlA6-yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:SecondExpansionLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_23_2017_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_VHd28wBFnkarvgZ3-fAtGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_jWuqQcWDKE6x_Rz8ykfOzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_zbj4-_iSt0mMZxIh6JETbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_9_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_k2AvsINLE0CA1hy04sZUqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_bQ28F0w6C0GKznH2O5VZSw"><xbrli:measure>axgn:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_individual_c5Uqr2HKeUq8VhVxnbwwzQ"><xbrli:measure>axgn:individual</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_acre_uQoen29RI0aO7YAQ0QAY8Q"><xbrli:measure>utr:acre</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:1pt;padding-top:19pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_fdb3dc3e_b23a_47b0_a405_d0cc6351357d"></a></div><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Washington, D.C.  20549</b></p><div style="font-family:'Times New Roman';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:DocumentType" id="Narr_8X4WO4XfTU-Kg8cLgqsjeg"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:10.4pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:DocumentAnnualReport" id="Narr__csxq1N-yUelg0a1YjKpHQ"><b style="color:#000000;font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:bold;text-align:left;">&#9746;</b></ix:nonNumeric></span><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:4pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:DocumentPeriodEndDate" id="Narr_v5Oeh3IiEUSKE1WH2ArXUw"><b style="font-size:8pt;font-weight:bold;">DECEMBER 31, 2019</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Or</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:DocumentTransitionReport" id="Narr_sQKrMY1EAEe_iJAboO6NAw"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:4pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityFileNumber" id="Narr_Ftr6OvsUr0GwUIWUqB0rmA"><b style="font-size:8pt;font-weight:bold;">001-36046</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityRegistrantName" id="Narr_Ug_7ZWupSEidP8ye_cEBNQ"><b style="font-weight:bold;">AXOGEN,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_685af5ef_ca1c_4663_ad2f_867d8f591427"></a><a id="Tc_JF16hu8JZEiRWQ90J5VwNw_2_0"></a><a id="Tc_6DobA7HiakW3MrEMxYsuvg_2_2"></a><a id="Tc_cBs93JiSV0efQ8bpgeYxZg_3_0"></a><a id="Tc_6knAEveV6U6ZEIYJPpEcFw_3_2"></a><a id="Tc_1LXDx1JOEUytO7Yuz58BsQ_5_0"></a><a id="Tc_7JVwMJ6VYUeUf3S43URaaw_6_0"></a><a id="Tc_AtblbMfvxkaSN0c8lVAzZA_6_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Tc_rqrQ3ho-OUOyVr7owf06qA_1_0"><b style="color:#000000;font-family:'Times New Roman';font-size:8pt;font-style:normal;font-weight:bold;text-align:center;">MINNESOTA</b></span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityTaxIdentificationNumber" id="Tc_tWRCuR-yt0GniZQ93WZkDg_1_2"><b style="font-size:8pt;font-weight:bold;">41-1301878</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">(State or other jurisdiction of</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">(I.R.S. Employer</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">incorporation or organization)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityAddressAddressLine1" id="Narr_T5hG_LKVCECTa9f8Kzwqcg"><b style="font-size:8pt;font-weight:bold;">13631 Progress Blvd., Suite&#160;400</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityAddressCityOrTown" id="Narr_N7M2yrg27kagPQ3qpFkx-A"><b style="font-size:8pt;font-weight:bold;">Alachua</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityAddressStateOrProvince" id="Narr_IB9FN2G18kKvp8e-BjXtRw"><b style="font-size:8pt;font-weight:bold;">FL</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityAddressPostalZipCode" id="Tc_gCnq_dYBV02aUXB-CSF3yQ_5_2"><b style="font-size:8pt;font-weight:bold;">32615</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:CityAreaCode" id="Narr_ClOeacAogkqsk_Mo1bhRbg"><b style="font-size:8pt;font-weight:bold;">386</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">)</b><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:LocalPhoneNumber" id="Narr_FkF0XwwA40SZaKYXgIfBWQ"><b style="font-size:8pt;font-weight:bold;">462-6800</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:52.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:52.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p></td><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock, par value $0.01 per share</b></p></td></tr><tr><td style="vertical-align:top;width:52.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">(Title of class)</p></td></tr><tr><td style="vertical-align:top;width:52.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</p></td><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">None</b></p></td></tr><tr><td style="vertical-align:top;width:52.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:3.3pt;"><td style="vertical-align:top;width:32.97%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="height:3.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.12%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="height:3.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.42%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="height:3.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.05%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="height:3.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.42%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="height:3.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:32.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:1.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:32.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt 0pt 2pt 0pt;">Common Stock, $0.01 par value </p></td><td style="vertical-align:top;width:1.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt 0pt 2pt 0pt;">AXGN</p></td><td style="vertical-align:top;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt 0pt 2pt 0pt;">The Nasdaq Stock Market</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_5l3khw2ZWEKu4et0vKNq2g"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#8999;</span></span><span style="font-size:8pt;"> No </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#9723;</span></span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#9723;</span></span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityVoluntaryFilers" id="Narr_NP5W7N72V0idCjyFEke1OQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#8999;</span></span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityCurrentReportingStatus" id="Narr_dQY0qcW9_0aVRqmRzDSkeQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#8999;</span></span><span style="font-size:8pt;"> No </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#9723;</span></span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityInteractiveDataCurrent" id="Narr_RiTbQmABiEOMcdU0q3CMGQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#8999;</span></span><span style="font-size:8pt;"> No </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#9723;</span></span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="white-space:pre-wrap;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityFilerCategory" id="Narr_kaLf2K7mbUC5brYVy2lPsw"><span style="font-size:8pt;">Large accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#8999;</span></span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">Accelerated filer <span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#9723;</span></span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">Non-accelerated filer <span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#9723;</span></span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntitySmallBusiness" id="Narr_wc2v1-ozOUOf25UVJtpIQg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityEmergingGrowthCompany" id="Narr_dGx3c6kddEGmvf-o6Bilqw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#9723;</span></span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="dei:EntityShellCompany" id="Narr_WhWbluA9x0-5EMppaQurOw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Wingdings';font-size:8pt;"><span style="font-family:'Times New Roman';">&#8999;</span></span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">As of June 30, 2019, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2019_9ic9jzQW1ECZSI_uvWQc5g" decimals="0" name="dei:EntityPublicFloat" id="Narr_vuQU9CKl3kSgI7TKXvdozw">539,757,783</ix:nonFraction> based upon the last reported sale price of our common stock on the Nasdaq Capital Market.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">The number of shares outstanding of the Registrant&#8217;s common stock as of February&#160;21, 2020 was <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_21_2020_kNbwNoscBki-6ondKdMYyQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_DdadIm_9EkW8KVK2Gmgd8w">39,731,078</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">DOCUMENTS INCORPORATED BY REFERENCE</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">Portions of the Registrant&#8217;s definitive proxy statement to be filed pursuant to Regulation 14A within 120 days after the end of the Registrant&#8217;s fiscal year are incorporated by reference into Part&#160;III of this Form&#160;10-K.</p><p style="font-family:'Times New Roman';font-size:12pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri';font-size:12pt;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman';font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_b0bb1a36_d1c4_4027_b7c7_a72235bc926d"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="TOC"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF </b><b style="font-weight:bold;">CONTENTS</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><a href="#PARTI_526653"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART&#160;I</b></a></p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM1BUSINESS_6705"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM1BUSINESS_6705"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Business</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_83455"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_83455"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">42</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_234630"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1B.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_234630"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM2PROPERTIES_591651"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 2.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM2PROPERTIES_591651"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Properties</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_396505"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 3.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_396505"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_425837"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 4.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_425837"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><a href="#PARTII_982967"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART&#160;II</b></a></p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 5.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Market For Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_404548"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 6.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_404548"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Selected Financial Data</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 7.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 7A.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 8.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 9.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">114</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#Item9AControlsAndProcedures"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 9A.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#Item9AControlsAndProcedures"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">114</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_235573"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_235573"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">115</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><a href="#PARTIII_125825"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART&#160;III</b></a></p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 10.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_825365"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 11.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_825365"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 12.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 13.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 14.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 7.2pt 0pt 0pt;"><span style="font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 7.2pt 0pt 0pt;"><span style="font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 7.2pt 0pt 0pt;"><span style="font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><a href="#PartIV"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART&#160;IV</b></a></p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 15.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits, Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">117</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM16Form10KSummary"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 16.</span></a></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ITEM16Form10KSummary"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form 10-K Summary</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#bExhibits_852596"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibit&#160;Index</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#SIGNATURES_623302"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:top;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">125</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_593344da_28b5_443c_a006_fb861f682c3e"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, in reports filed with the U.S. Securities and Exchange Commission (including this Form 10-K), in press releases, and in other communications to shareholders or the investment community, Axogen,&#160;Inc. (including Axogen, Inc.&#8217;s wholly owned subsidiaries, Axogen Corporation, Axogen Processing Corporation and Axogen Europe GmbH, the &#8220;Company&#8221;, &#8220;Axogen&#8221;, &#8220;we&#8221;, &#8220;our&#8221;, or &#8220;us&#8221;) may provide forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, concerning possible or anticipated future results of operations or business developments. Words such as &quot;expects&quot;, &quot;anticipates&quot;, &quot;intends&quot;, &quot;plans&quot;, &quot;believes&quot;, &quot;seeks&quot;, &quot;estimates&quot;, &quot;projects&quot;, &quot;forecasts&quot;, &quot;continue&quot;, &quot;may&quot;, &quot;should&quot;, &quot;will&quot;, &#8220;goals,&#8221; variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our assessment of our internal controls over financial reporting, our growth, our 2020 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, and our visibility at and sponsorship of, conferences and educational events. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this Form 10-K should be evaluated together with the many uncertainties that affect the Company&#8217;s business and its market, particularly those discussed in the risk factors and cautionary statements set forth in the Company&#8217;s filings with the U.S. Securities and Exchange Commission, including as described in &#8220;Risk Factors&#8221; included in Item 1A of this Form 10-K. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, the Company assumes no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or otherwise.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_526653"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART&#160;</b><b style="font-weight:bold;">I</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="ITEM1BUSINESS_6705"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 1.  BUSINES</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">S</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_32c018b1_822b_439f_a4df_9281b30447d5"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">General </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves.&#160;Physical damage to a peripheral nerve,&#160;or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk32523255"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#39;s platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Graft, a biologically active off-the-shelf&#160;processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site;&#160;Axoguard<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Connector, a porcine submucosa extracellular matrix (&#8220;ECM&#8221;) coaptation aid for tensionless repair of severed peripheral nerves;&#160;Axoguard<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. Along with these core surgical products, Axogen also offers Axotouch<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Two-Point Discriminator, used to measure the innervation density of any surface area of the skin. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea and several other European and international countries.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Nerves can be damaged in several ways. When a nerve is cut due to a traumatic injury or inadvertently during a surgical procedure, functionality of the nerve may be compromised, causing the nerve to no longer carry the signals to and from the brain to the muscles and skin thereby reducing or eliminating functionality. Nerve damage or transection of this type generally requires a surgical repair. Traditionally, the standard has been to either suture the nerve ends together directly without tension or to bridge the gap between the nerve ends with a less important nerve surgically removed from elsewhere in the patient&#8217;s own body, referred to as nerve autograft. Nerves that are not repaired or heal abnormally can form a neuroma which may send altered signals to the brain resulting in the sensation of pain. This abnormal section of nerve can, under certain circumstances, be surgically cut out and the resulting gap repaired.  In addition, compression on a nerve, blunt force trauma or other physical irritations to a nerve can cause nerve damage that may alter the signal conduction of the nerve, result in pain, and may, in some instances, require surgical intervention to address the resulting nerve compression and inflammation.  Finally, when a woman undergoes a mastectomy due to breast cancer or prophylactically due to a genetic predisposition for breast cancer, the nerves are cut to allow the removal of the breast tissue.  This can result in a loss of sensation and the potential risk of a symptomatic neuroma.  When a woman chooses an autologous breast reconstruction after a mastectomy, sensation can, in certain cases, be returned through surgical intervention.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In order to improve the options available for the surgical repair and regeneration of peripheral nerves, Axogen has developed and licensed regenerative medicine technologies. Axogen&#8217;s innovative approach to regenerative medicine has resulted in first-in-class products that it believes are redefining the peripheral nerve repair market.  Axogen&#8217;s products are used by surgeons during surgical interventions to repair a wide variety of physical nerve damage or transection throughout the body, which can range from a simple laceration of a finger to a complex brachial plexus injury (an injury to the network of nerves that control the movement and sensation of the arm and hand) as well as nerve injuries caused by dental, orthopedic and other surgical procedures. Avance Nerve Graft provides surgeons an implant with the micro-architecture of a human nerve. This structure is essential and allows for bridging nerve gaps or transections up to 70mm in length. Additionally, Avance Nerve Graft has product and distribution synergies with&#160;Axoguard Nerve Protector, Axoguard Nerve Connector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. Axoguard products provide the </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">unique features of pliability, suturability, and translucence for visualization of the underlying nerve, while also allowing the extracellular matrix to remodel utilizing the patient&#8217;s own cells.  Avive Soft Tissue Membrane is a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Regenerative Medical Products Industry</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Regenerative medical products enable the repair, restoration, replacement or regeneration of tissue or organ systems of the body.&#160; Regenerative medical products are becoming common in various medical arenas because they have been shown to be effective repairing injured or defective tissues, such as bone, tendons, dermis and other tissues of the body.  Surgeons utilize regenerative medical products because they can provide the complex structure required for implant integration and regeneration in the body.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen believes the primary driver of sustained growth in the regenerative medical product market is continued favorable efficacy as compared to autograft tissue and synthetic medical products, and a wider understanding of this advantage by practitioners. Repair with nerve autograft requires a secondary recovery procedure to remove tissue from another location of the patient&#8217;s body to repair the injured area and results in loss of function at the site of donation. Further, nerve autograft may also be costly and time consuming and may result in complications at the second surgical site such as infection.  In addition to processed nerve allograft (Avance Nerve Graft), alternatives to nerve autograft include hollow-tube synthetic or collagen-based medical products that are designed to provide some restoration of function but may be limited by mechanisms of nerve healing and/or biocompatibility with the body. Regenerative medical products often provide more desirable conditions for reconstruction and regeneration of tissue, creating a superior solution for patients and physicians.  Axogen follows this trend, providing regenerative medical products for peripheral nerve repair.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Regenerative medicine products typically consist of and rely on:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">A scaffold or ECM to support the cells and/or provide the architecture of the tissue; and/or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">ii.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Cells to regenerate or remodel the scaffold.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen&#8217;s Avance Nerve Graft, Axoguard Nerve Protector, Axoguard Nerve Connector and Axoguard Nerve Cap are ECM scaffolds, and utilize the patient&#8217;s own cells to remodel or regenerate these scaffolds.  Avive Soft Tissue Membrane is a resorbable soft tissue covering to separate tissues in the surgical bed. </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Peripheral Nerves and Their Regeneration</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The peripheral nervous system, or PNS, consists of nerves that either extend outside of, or reside outside of, the central nervous system (primarily the brain and spinal cord).  Peripheral nerves provide the pathway for signals between the central nervous system and target organs, regulating movement (motor nerves) and touch (sensory nerves).  Therefore, if a peripheral nerve is crushed, severed, or otherwise physically damaged, its ability to deliver signals to or from the target organs is eliminated, or significantly reduced, and could result in a loss of sensation and/or motor functionality.  The axon portion of the nerve cell, consisting of cell cytoplasm and resembling a hair-like fiber, carries signals between the cell body and the target organ.  Axons can be quite long, even exceeding one meter, but are only a few micrometers in diameter.  A typical nerve consists of hundreds of axons that lie within long, thin tubes (endoneurial tubes).  Analogous to a wiring cable, these endoneurial tubes are bundled together in groups called fascicles, and each nerve may contain numerous fascicles.  This sheath structure provides protection for the axons and support for regeneration in the event of damage or transection.  Nerve damage or transection occurs when a sufficient number of axons have been crushed or transected (severed), thereby disrupting signals to or from the target motor or sensory organ.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Given the right conditions, peripheral nerves have the ability to regenerate.  Regenerating axons require the proper environmental conditions including structure and guidance of axons in a tension and compression free environment.  In an untreated severe crush injury or transected nerve, errant axons that are not guided by the nerve sheath structure or other mechanism can form painful and ineffective nerve proliferation (neuromas).  This condition can require revision surgery to relieve pain or bring back sensory and/or motor functionality. Therefore, the surgical treatment of peripheral </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">nerves due to damage or transection is typically focused on restoring nerve functionality by providing guidance to regenerating axons, minimizing the formation of neuromas and protecting the nerve to alleviate compression.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Peripheral Nerve Regeneration Market Overview</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Peripheral nerve injury (&#8220;PNI&#8221;) through damage or transection is a major source of physical disability impairing the ability to move muscles or to feel normal sensations.  Failure to treat peripheral nerve damage or transection can, in severe cases, lead to full loss of sensation and/or function, pain and, sometimes, amputation.  Many peripheral nerve patients who receive treatment do not optimally recover. They may suffer from both reduced, or no, muscle strength, and reduced, or no, sensitivity and pain.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Every day patients suffer traumatic bodily injuries that may result in damage or transection to peripheral nerves severe enough to require surgical treatment, including injuries from motor vehicle accidents, power tool injuries, gunshot wounds, dislocations, fractures, lacerations, or other forms of penetrating trauma.  The peripheral nerves commonly damaged or transected from these traumas include the digital, median, ulnar, radial, facial, spinal accessory and brachial plexus nerves. The &#8220;Trauma&#8221; portion of the Total Addressable Market (as defined below) encompasses the traumatic PNI described above but excludes the Oral Maxillofacial, (&#8220;OMF&#8221;), Upper Extremity Compressions and Breast (as such terms are defined below) portions of the Total Addressable Market.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Beyond the physical damage or transection to peripheral nerves resulting from traumatic bodily injuries described above, peripheral nerve damage or transection also occurs due to surgical intervention.  For example, nerve damage or transection can occur during dental and oral surgery procedures, OMF, such as third molar extractions, placement of dental implants, removal of tumors, orthognathic surgery and mandibular resection during which one or more sections of the trigeminal nerve can be damaged or transected.  This can result in numbness in certain areas of the face and mouth.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Breast reconstruction neurotization (&#8220;Breast&#8221;) is another portion of the Total Addressable Market.  Currently, when a woman undergoes autologous breast reconstruction after a mastectomy, she receives the shape of a natural breast, but oftentimes without experiencing any return of sensory feeling.  This forfeiture of sensation can have a profound effect on the woman&#8217;s quality of life.  In certain cases, sensation can be returned to the breast area with the use of the Company&#8217;s products through an innovative surgical technique we call Resensation</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;">.  The Company believes that the ideal breast reconstruction should restore breast size, shape, symmetry and softness, as well as sensation, without the potential risks and co-morbidity associated with autograft.  The Company believes the Resensation technique incorporates a patients&#8217; desire for the opportunity to return sensation in their breasts with a reproducible and efficient surgical approach for reconstructive plastic surgeons.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Peripheral nerves are also damaged due to compression injuries.  For instance, severe and recurrent carpal and cubital tunnel cases may result in complications and damage to the peripheral nerve that requires surgical intervention and protection of the peripheral nerve.  PNI caused by recurrent carpal tunnel syndrome and cubital tunnel syndrome constitutes the &#8220;Upper Extremity Compression&#8221; portion of the Total Addressable Market.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Peripheral nerve are also a source of chronic pain.  One of the causes of neuropathic pain is called a neuroma, a tangled mass of disorganized nerve and fibrous tissue resulting in aberrant nerve signals which the brain interprets as pain.  Traditionally these neuromas have been treated  using pain management methods including pharmacological agents which do not address the anatomical cause of the pain.  The surgical treatment of such pain involves a procedure to remove the painful neuroma and, subsequently, repair the resulting nerve gap or appropriately terminate the nerve end.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In the cases where a peripheral nerve is severed and the gap between its two ends is extremely small, the surgeon may be able to reconnect the peripheral nerve without tension through direct suturing as a coaptation aid (&#8220;Primary Repair&#8221;). When the gap in the nerve tissue is more than a few millimeters in length, the surgeon typically needs to use material to bridge the gap between the peripheral nerve ends to ensure a tension-free repair (&#8220;Gap Repair&#8221;).  Historically for a Gap Repair surgeons have relied on a nerve autotransplantation (autologous nerve grafting or nerve autograft).  In nerve autograft procedures, surgeons remove peripheral nerve from another part of the patient&#8217;s body, frequently the sural nerve from the back of the lower leg, to repair the damaged nerve.  Nerve autografting is often effective in </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">repairing a damaged peripheral nerve, but it presents a tradeoff, the surgeon can attempt to fix the damaged nerve but must create an additional nerve deficit at another location in the body.  For example, a patient may opt to get movement and feeling back in their finger while losing some sensation in their foot. </span>Additionally, Axogen believes the secondary surgery to obtain the needed nerve autograft may increase operating time by ~90 minutes based upon literature and the CMS 2020 Physician Fee Schedule reporting autograft intra service work time to be 61-147 minutes longer than allograft (Capek L, Clarke H M, Zuker R M. Endoscopic sural nerve harvest in the pediatric patient. Plast Reconstr Surg. 1996 Oct; 98(5): 884&#8211;888; 2020 Physician Fee Schedule, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Federal-Regulation-Notices-Items/CMS-1715-F; and 2017 RUC recommendations, https://www.ama-assn.org/sites/ama-assn.org/files/corp/media-browser/public/rbrvs/feb-2017-RUC-recommendations-FINAL.pdf<span style="white-space:pre-wrap;">).  Operating room expenses associated with longer procedure times are estimated to increase $2k to $4k, depending on case complexity, for each additional 30 minutes of operating time based on Cleveland Clinic 2019 Patient Price Information List (</span>https://my.clevelandclinic.org/-/scassets/files/org/locations/price-lists/main-campus-hospital-patient-price-list.ashx<span style="white-space:pre-wrap;">). The nerve harvest necessary in autograft nerve repair may also result in a 27% complication rate due to surgical site infection, delayed wound healing and chronic pain (Rappaport WD, Valente J, Hunter GC, Rance NE,et al. Clinical utilization and complications of sural nerve biopsy. Am J Surg. 1993 Sep; 166(3): 252-256).  Further, in the case of extreme trauma where multiple peripheral nerves need to be repaired, it may not be possible to recover enough nerve from the patient to complete the Gap Repair; and nerve autograft tissue may not provide an appropriate diameter match with the diameter of the injured nerve stump, an important factor in a successful repair outcome.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Drawbacks of repair with autograft nerve eventually led to the development of hollow tube conduits, or hollow tube nerve cuffs for Primary Repair and Gap Repair made of, for instance, bovine collagen or polyglycolic acid.  The hollow tube nerve cuff is typically an absorbable hollow tube that, unlike natural peripheral nerve, does not have internal microarchitecture and endoneurial tubes to support and guide regenerating axons; as a result, it is deficient in the qualities that natural peripheral nerve possesses to support nerve regeneration across a gap.  Hollow-tubes may also lack pliability and structural integrity needed when used around joints and may be difficult to use in a confined space.  Clinical data has demonstrated that hollow tubes are most effective when used in very short gaps, what Axogen defines as Primary Repair, and the reliability of successful nerve recovery diminishes as gap length increases with a 34% to 57% failure rate for hollow tube conduits in repairs with a greater than 5mm gap (Weber RA, Breidenbach WC, Brown RE, Jabaley ME, Mass DP. A randomized prospective study of polyglycolic acid conduits for digital nerve reconstruction in humans. Plast Reconstr Surg. 2000 Oct;106(5):1036-45; discussion 1046-8 and Wangensteen KJ, Kalliainen LK.  Collagen tube conduits in peripheral nerve repair: a retrospective analysis. Hand (N Y). 2010 Sep;5(3):273-7. doi: 10.1007/s11552-009-9245-0. Epub 2009 Nov 24).  </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Conduits filled with an inner matrix have been announced by competitors.  The availabity of such filled tube conduits for purchase in the United States is not clear at this time.  These filled conduits are purported to have greater ability to regenerate after peripheral nerve injury than a hollow tube conduit, but we believe there is very limited data supporting this position. See - &#8220;Competition&#8221;.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The shortcomings of hollow-tubes for peripheral nerve repair limit where they may be used effectively. Thus, Axogen believes the peripheral nerve repair market needs an alternative off-the-shelf product that offers other features such as a natural ECM scaffold and three-dimensional structure of a typical nerve for bridging nerve transections without the comorbidities of an additional surgical site required for harvest of autograft nerve tissue. Axogen believes its Avance Nerve Graft and Axoguard Nerve Connector products address the market needs for both Gap Repair and Primary Repair.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Compression on a peripheral nerve or blunt force trauma can also cause nerve damage that may require surgical intervention. In these cases, the peripheral nerve is not severed and thus does not create the need for a Primary Repair or Gap Repair.  However, the surgeon may want to protect and isolate the peripheral nerve during the healing process.  In these situations, peripheral nerve protection is provided by wrapping the nerve (&#8220;Nerve Protection&#8221;).</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:6pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">Axoguard</span><span style="font-size:6.5pt;vertical-align:super;"> </span><span style="font-size:10pt;">Nerve Protector is a porcine submucosa extracellular matrix used for Nerve Protection </span><span style="font-size:10pt;">and Avive Soft Tissue Membrane is a processed human umbilical cord used as a resorbable soft tissue covering</span><span style="font-size:10pt;white-space:pre-wrap;">.  Other Nerve Protection products are usually made from bovine collagen or polyglycolic acid and are typically absorbable. Axoguard Nerve Protector provides the unique features of pliability, suturability, and translucence for visualization of the underlying </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:6pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">peripheral nerve, while also allowing the patient&#8217;s own cells to incorporate into the extracellular matrix to remodel and separate the peripheral nerve from the surrounding tissue.</span><span style="font-size:10pt;"> </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">We estimate the United States PNI has a potential total addressable market for our current product portfolio for Trauma, OMF, Breast and Upper Extremity Compression of $2.7 billion (the &#8220;Total Addressable Market&#8221;).   </span><span style="white-space:pre-wrap;">Estimating the Total Addressable Market for nerve repair is challenging as there is not a simple data source for the incidence of peripheral nerve issues.  This is further complicated by the fact that nerves can be injured in many traumatic and surgical injuries and can be impacted from the head to the toe of a patient.  In addition, we believe nerves are often one of many structures injured in a trauma (i.e. amputation) or in surgery and the incidence of these nerve injuries are often not coded or tracked. Quantifying the procedures involving nerve repair may also be challenging.  While selected trauma and surgical procedures are dedicated to the repair of nerves (i.e. a pediatric brachial plexus procedure), most of the incidence of nerve repair is a step in a larger trauma (i.e. digital replant) or surgical procedure (i.e. mandible reconstruction).  CPT codes exist for surgeons to code for nerve repair, however, we believe the data substantially underestimates the total number of nerves repaired.  </span>Physicians are encouraged to document all steps of procedures.<span style="white-space:pre-wrap;">  Open trauma often involves many surgical steps including wound debridement, skin closure and one or more repairs of tendons, bone or joints, nerves, veins and arteries.  CPT codes may be inclusive of each other and may not be documented or reported in billing records. As a result, we believe CPT coding underrepresents the total number of nerve repairs performed in trauma.  Because we believe CPT claims are not fully representative of the true volumes of nerve repair surgery, we follow an &#8220;empirical&#8221; methodology to estimate the Total Addressable Market &#8211; using published clinical literature and procedure databases to make what we believe are the most objective assumptions.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">We estimate that the Trauma portion of the Total Addressable Market is approximately $1.9 billion based upon epidemiological studies regarding the general number of trauma patients, clinical literature review reporting  PNI incidence and physician interviews.  There are almost 137 million emergency department visits in the U.S. each year of which approximately 30 million are related to traumatic injuries (</span>2015 National Hospital Ambulatory Medical Care Survey, Publication of U.S. Department of Health&#160;<span style="white-space:pre-wrap;">&amp; Human Services).  We believe that this injury population includes more than 1.4 million patients suffering damage or transection to peripheral nerves resulting in over 700,000 nerve repair procedures (Noble, et al. J of Trauma Injury Infection and Critical Care 1998; Portincasa et al: Microsurgery 27:455-462, 2007).  We have estimated the portion of these nerve repair procedures due to trauma that would require Gap Repair, Primary Repair and/or Nerve Protection and applied, as we believed was appropriate in each procedure segment, the number of units and average sales price of Avance Nerve Graft and the average market price for nerve connectors, nerve protectors and soft tissue membrane products to determine the probable Total Addressable Market.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">We estimate that the OMF portion of the Total Addressable Market is approximately $300 million, based upon research indicating that approximately 56,000 PNI occur in the U.S. each year related to third molar surgeries, anesthetic injections, dental implants, orthognathic surgery and mandibular resection procedures. (Shih-Yun Wu et al: Systematic Review and Meta-Analysis on Incidence of Altered Sensation of Mandibular Implant Surgery - PLoS ONE 11(4): e0154082; <span style="white-space:pre-wrap;">Nguyen. Et al: Risk  Factors for Permanent  Injury  of Inferior  Alveolar  and  Lingual  Nerves  During Third  Molar  Surgery;  J Oral Maxillofac Surg. 2014 Dec;72(12)</span>; <span style="white-space:pre-wrap;">Cheung LK,  Leung  YY,  Chow  LK,  et  al.  Incidence  of neurosensory  deficits  and  recovery  after  lower  third molar  surgery:  a  prospective  clinical  study  of  4338 cases.  Int  J  Oral  Maxillofac  Surg  2010;39:320&#8211;6.; Transparency Market Research: Dental Implant Market - Global Industry Analysis and Forecast 2016 &#8211; 2024</span>; Cha et al, Maxillofacial Plastic and Reconstructive surgery (2016) 38:19 - Frequency of bone graft in implant surgery; <span style="white-space:pre-wrap;">Miloro ed. 2012: Text Book on trigeminal  nerve injuries</span>; Pogrel et al: J Am Dent Assoc. 2000 Jul;131(7):901-7: Permanent nerve involvement resulting from inferior alveolar nerve blocks; <span style="white-space:pre-wrap;">Agbaje et al: Int. J. Oral Maxillofac. Surg. 2015; 44: 447-451, J.O Systematic review of the incidence of inferior alveolar nerve injury in bilateral sagittal split osteotomy (BSSO) and the assessment of neurosensory disturbance).  We have applied the average sales price of the Avance Nerve Graft, Axoguard Nerve Connector and Axoguard Nerve Protector that address such PNI in order to derive the OMF portion of the Total Addressable Market.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In 2017, there were 106,295 breast reconstruction procedures in the US as reported in the 2017 plastic surgery statistic report published by the American Society of Plastic Surgery. The report details 19,316 of these reconstructions procedures were autologous flap reconstruction, and that 66.2% of the reconstructions were bilateral.  Removing those procedures that are not appropriate for neurotization, and based upon the Company&#8217;s assumption that approximately 50% of women may elect to have a dual neurotization for each flap, we estimate that the Breast portion of the Total </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Addressable Market is approximately $250 million.  (2017 ASPS Plastic Surgery Statistics Reports, Includes TRAM, DIEP, and &quot;Other Flaps&quot;, Distribution based on 2017 ASPS Data</span><b style="font-weight:bold;">).</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">We estimate that the Upper Extremity Compression portion of the Total Addressable Market is approximately $270 million, or 130,000 procedures<span style="color:#1f497d;">.</span><span style="white-space:pre-wrap;">  Extrapolating the 2016 Medicare National HCPCS Aggregate Summary Table to the total US population, we estimate that there are approximately 488,000 primary carpal tunnel and 95,000 primary cubital tunnel relief surgeries performed annually in the U.S. For carpal tunnel,&#160;we believe that our addressable procedure is the estimated 20% of carpal tunnel surgeries that require a revision procedure to address the recurrence of symptoms (Sotereanos et al, </span>Techniques in hand and Upper extremity surgery 1(1):35-40,1997). From the 95,000 primary cubital tunnel surgeries, we estimate that our addressable procedure potential comprises a small proportion of primary interventions and all revisions (J Seradge et al, Hand Surg 1998; 23A:483-491; Papatheodorou et al, J Hand Surg Am. 2015;40(5):987e992).&#160;<span style="white-space:pre-wrap;">  As a result, we estimate that approximately 97,500 carpal tunnel revision surgeries and 32,400 total cubital tunnel procedures are addressable each year in the U.S. to mitigate the recurrence of symptoms. These revision and primary surgeries are required due to compression of the peripheral nerve associated with soft tissue attachments from the surrounding tissue or tissue infiltration entrapping the nerve. To prevent additional recurrences, surgeons will opt for a Nerve Protection which includes a product such as the Axoguard Nerve Protector. In order to derive the Upper Extremity Compression portion of the Total Addressable Market, we multiplied the average market sales price of Axoguard</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>Nerve Protectors by the number of estimated procedures.<span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Although distribution and sales of  products in the Trauma, OMF, Breast and Extremity Compression portions of the Total Addressable Market constitute our primary revenue sources today, market expansion opportunities in lower extremity surgery, head and neck surgery, urology and the surgical treatment of pain offer us new and expanded revenue opportunities.  </span>The Company has begun an expansion into the surgical treatment of pain with an initial focus on traumatic injuries including amputation and orthopedic surgeries such as total hip arthroplasty, total knee arthroplasty, knee arthroscopy, Morton&#8217;s neuroma, foot and ankle procedures and wrist arthroscopy.<span style="white-space:pre-wrap;">  We conducted user evaluations and a post-market clinical study of neuroma revision using Axoguard Nerve Cap and launched the product in February of 2020.  The size of this market opportunity is challenging to identify as the cause of the chronic pain is often not diagnosed and there has not historically been a treatment to resolve the cause of the pain. The Company believes the market opportunity is sufficient to apply selected resources to the opportunity and there is a significant patient and societal need to reduce the use of pharmacologic solutions including opioids.  Axogen developed the Axoguard</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;"> Nerve Cap to protect a peripheral nerve end and separate the nerve end from the surrounding environment to reduce the development of symptomatic or painful neuromas (&#8220;Neuroma Management&#8221;).  An example application for Axoguard Nerve Cap is in a digital amputation whereby the severed nerves may form a painful neuroma if the nerve end is not properly terminated or capped.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Axogen&#8217;s Product Portfolio </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk536722702"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Overview of Axogen&#8217;s Products</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Axogen surgical solution product portfolio provides surgeons off-the-shelf products for a wide variety of peripheral nerve damage or transection.  The Company&#8217;s proprietary products and technologies are designed to overcome fundamental challenges in peripheral nerve repair. Axogen&#8217;s Avance Nerve Graft is the alternative to autografts and other off-the-shelf peripheral nerve repair products for nerve gaps up to 70mm in length.  Axoguard Nerve Connector is a coaptation aid for transected peripheral nerves.  Axoguard Nerve Protector is a protective wrap for peripheral nerves damaged by compression, or where the surgeon wants to protect and isolate the</span><span style="font-size:12pt;"> </span><span style="white-space:pre-wrap;">peripheral nerve during the healing process after surgery.  Avive</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>Soft Tissue Membrane provides a resorbable covering to keep tissue structures apart while providing the beneficial properties of a placental membrane.<b style="font-weight:bold;white-space:pre-wrap;">  </b>Axoguard Nerve Cap is a uniquely designed nerve termination device which provides a protective environment for the nerve end to reduce the development of painful neuroma. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Functional measurements play an important role in the evaluation of peripheral nerve function by assisting the healthcare professionals in detecting changes in sensation or muscle strength, assessing return of sensory or motor function, establishing effective treatment interventions, and providing feedback to the patients.  Evaluation and measurement of peripheral nerve function is also an important part of identifying nerve damage or transection and </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">determining treatment outcomes.  Axogen&#8217;s functional measurement product is the Axotouch Two-Point Discriminator tool for sensory function</span>.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Avance Nerve Graft </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:6pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">Avance Nerve Graft is a biologically active nerve implant with more than ten years of comprehensive clinical evidence intended for the surgical repair of peripheral nerve transections to support regeneration across the defect (a gap created when the nerve is severed).  It is intended to act as a bridge in order to guide and support axonal regeneration across a peripheral nerve gap caused by traumatic injury or surgical intervention.  Avance Nerve Graft is decellularized and sterile processed human peripheral nerve tissue.  Axogen developed the Avance Nerve Graft by following the guiding principle that the human body created the optimal</span><span style="font-size:12pt;"> </span><span style="font-size:10pt;white-space:pre-wrap;">peripheral nerve structure.  Axogen, through its licensing efforts and research, developed the Avance</span><span style="font-size:6.5pt;vertical-align:super;"> </span><span style="font-size:10pt;white-space:pre-wrap;">process, a proprietary method for processing recovered human peripheral nerve tissue in a manner that preserves the essential structure of the ECM while cleansing away cellular and noncellular debris.  Avance Nerve Graft provides the natural peripheral nerve structure of a nerve including the native laminin to guide the regenerating nerve fibers.  The nerve ECM is additionally processed to remove a natural inhibitor to regeneration called chondroitin sulphate proteoglycan (&#8220;CSPG&#8221;).    </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen believes that Avance Nerve Graft is the first off-the-shelf human nerve allograft for bridging nerve transections. Avance Nerve Graft is comprised of bundles of small diameter endoneurial tubes that are held together by an outer sheath called the epineurium.  Avance Nerve Graft has been processed to remove cellular and noncellular factors such as cells, fat, blood, and axonal debris, while preserving the three-dimensional laminin lined tubular bioscaffold (i.e. microarchitecture), epineurium and microvasculature of the peripheral nerve. After processing, Avance Nerve Graft is flexible and pliable, and its epineurium can be sutured in place allowing for tension-free approximation of the proximal and distal peripheral nerve stumps.  During the healing process, the body revascularizes and gradually remodels the graft into the patient&#8217;s own tissue while allowing the processed peripheral nerve allograft to physically support axonal regeneration across the peripheral nerve transection.  Avance Nerve Graft does not require immunosuppression for use.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">With lengths up to 70 mm and diameters up to 5 mm, Avance Nerve Graft allows surgeons to choose and trim the implant to the correct length for repairing the relevant peripheral nerve gap, as well as to match the diameter to the proximal and distal end of the severed peripheral nerve.  Avance Nerve Graft is stored frozen and utilizes packaging that maintains the graft in a sterile condition.  The packaging is typical for medical products so the surgical staff is familiar with opening the package for transfer of Avance Nerve Graft into the sterile surgical field. Such packaging also provides protection during shipment and storage and a reservoir for the addition of sterile fluid to aid in thawing the product. Avance Nerve Graft thaws in less than 10 minutes, and once thawed, it is ready for implantation.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Avance Nerve Graft provides the following key advantages:</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">A three-dimensional bioscaffold for bridging a peripheral nerve gap;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">A biologically active nerve therapy with more than 10 years of comprehensive clinical evidence;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;"> No patient donor-nerve surgery, therefore no comorbidities associated with a secondary surgical site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Available in a variety of diameters up to 5mm to meet a range of anatomical needs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Available in a variety of lengths up to 70mm, to meet a range of gap lengths;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Decellularized and cleansed extracellular matrix that remodels into patient&#8217;s own tissue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Structurally supports the body&#8217;s own regeneration process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Handles similar to an autograft, and is flexible and pliable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Alleviates tension at the repair site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Three-year shelf life; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Supplied sterile.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axoguard Nerve Connector</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axoguard Nerve Connector is a coaptation aid used to align and connect severed<span style="font-size:12pt;"> </span>peripheral nerve ends in a tensionless repair. The product is in a tubular shape with an open lumen on each end where the severed peripheral nerve </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">ends are placed.&#160;<span style="white-space:pre-wrap;"> It is typically used when the gap between the peripheral nerve ends is 5mm or less in length.  Axoguard Nerve Connector is made from a processed porcine ECM which allows the body&#8217;s natural healing process to repair the peripheral nerve while its tube shape isolates and protects the transected nerves during the healing process.&#160;</span><span style="white-space:pre-wrap;"> During healing, the patient&#8217;s own cells incorporate into the extracellular matrix product to remodel and form a tissue similar to the outermost layer of the peripheral nerve (nerve epineurium).  Axoguard Nerve Connector is provided sterile, for single use only, and in a variety of sizes to meet the surgeon&#8217;s needs.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axoguard Nerve Connector can be used:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">As an alternative to direct suture repair;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">As a peripheral nerve coaptation; Connector-Assisted Repair</span><sup style="color:#000000;font-family:'Times New Roman';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">&#174;</sup><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">To aid coaptation in direct repair, grafting, or cable grafting repairs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">To reinforce the coaptation site.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axoguard Nerve Connector has the following advantages:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Processed intact porcine extracellular matrix with an open, porous structure that allows for cell infiltration and remodeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Used to repair severed peripheral nerve tissue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Alleviates tension at the repair site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Remodels into the patient&#8217;s own tissue instead of degrading;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Reduces the number of required sutures (versus direct repair with suture) (Boechstyns, Jhand Surg. 2013;38:2405-2411);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Moves the location of sutures away from the coaptation face;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Reduces potential for fascicular mismatch;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Allows visualization of underlying</span><span style="color:#000000;font-family:'Times New Roman';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">peripheral nerve ends;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Provides a physical barrier preventing infiltration of surrounding tissues into the coaptation site and the potential for axonal sprouting outside the coaptation site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Available in seven different diameters and two different lengths to address a variety of nerve repair situations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Strong and flexible, easy to suture; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Stored at room temperature with a minimum of 18-month shelf life.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axoguard Nerve Protector</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axoguard Nerve Protector is a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps while preventing soft tissue attachments. It is designed to protect and isolate the peripheral nerve during the healing process after surgery by creating a barrier between the nerve tissue and the surrounding tissue bed.  The product is delivered in a slit tube format allowing it to be wrapped around peripheral nerve structures.  Axoguard Nerve Protector is made from a processed porcine ECM.  During healing, the ECM remodels allowing the protector to separate the peripheral nerve from the surrounding tissue.  Axoguard Nerve Protector competes against off-the-shelf biomaterials such as reconstituted collagen as well as the use of the patient&#8217;s own tissue such as vein and hypothenar fat pad wrapping.  Axoguard Nerve Protector is provided sterile, for single use only, and in a variety of sizes to meet the surgeon&#8217;s needs.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axoguard Nerve Protector can be used to:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Protect damaged peripheral nerves or nerve repair sites from surrounding tissue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Minimize risk of soft tissue attachments and entrapment in compressed peripheral nerves;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Protect peripheral nerves in a traumatized wound bed; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Reinforce a coaptation site.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axoguard Nerve Protector has the following advantages:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Processed porcine submucosa bioscaffold used to reinforce a coaptation site, wrap a partially severed peripheral nerve or protect peripheral nerve tissue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Creates a protective layer that isolates and protects the peripheral nerve in a traumatized wound bed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Remodels into the patient&#8217;s own tissue instead of degrading;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Easily conforms and provides 360 degree wrapping of damaged peripheral nerve tissue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Supports the body&#8217;s own natural wound healing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Minimizes the potential for soft tissue attachments and peripheral nerve entrapment by physically isolating the nerve during the healing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Allows peripheral nerve gliding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Strong and flexible, plus easy to suture;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Is available in five different widths and two different lengths to address a variety of peripheral nerve repair situations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Stored at room temperature with a minimum of 18-month shelf life.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Avive Soft Tissue Membrane</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Avive Soft Tissue Membrane is processed human umbilical cord membrane that may be used as a resorbable soft tissue covering t<span style="color:#1f497d;">o </span>separate tissues in the surgical bed<span style="color:#1f497d;white-space:pre-wrap;">.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">We believe, the medical community has for decades realized the beneficial qualities of human amniotic membrane and continues to utilize this natural tissue in applications across the body.  Avive Soft Tissue Membrane offers a resorbable anatomical covering to keep tissue surfaces apart.  Avive Soft Tissue Membrane is provided sterile and in a variety of sizes to meet the surgeon&#8217;s surgical needs.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Avive Soft Tissue Membrane can be used to:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Separate tissues in the surgical bed as a permeable membrane. </span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 90pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Avive Soft Tissue Membrane has the following advantages:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Umbilical cord amniotic membrane that is naturally resorbable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Is non-immunogenic;&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Processed to preserve the natural properties of umbilical cord amniotic membrane;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Comprised of umbilical cord amniotic membrane which is up to eight times thicker than amniotic membrane alone;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Long lasting (in animal studies, stays in place for at least 16 weeks);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Easy to handle, suture or secure during a surgical procedure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Conforms and stays in place at the application site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Chorion free (reducing the likelihood of immune response); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Room temperature storage with a two-year shelf life.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axoguard Nerve Cap</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axoguard Nerve Cap is a proprietary porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Every nerve that is cut and not reconstructed forms an entangled mass of disorganized nerve and fibrous tissue  that could cause debilitating pain called a symptomatic neuroma.  Neuromas are the main cause of pain in amputees which may lead to an inability to use their prosthesis.  Despite more than 30 different treatment methods, it is our belief that neuromas continue to be an unresolved problem in microsurgery.  We believe the Axoguard Nerve Cap can address </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">these painful neuroma and better address nerve pain than other methods including pharmacotherapy and chemical injections, among others. </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Axoguard Nerve Cap can be used to:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Reduce painful neuroma formation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Reduce pain.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Axoguard Nerve Cap has the following advantages:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Separates the nerve end from surrounding tissue, neurotrophic factors and mechanical stimulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Reduces painful neuroma formation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Can be sutured to surrounding soft tissue to anchor the nerve end;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Material gradually remodels into the patient&#8217;s own tissue to protect the nerve end; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Semi-translucent to allow for easy visualization of the nerve end during entubulation.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Acroval Neurosensory and Motor Testing System</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">To pursue our mission most effectively, we have made a strategic decision to place our full focus on innovations within our surgical solutions portfolio. Effective November 2019, Axogen discontinued all sales of the Acroval Neurosensory and Motor Testing System. We will continue to provide service and support for the existing systems in the market place. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axotouch Two Point Discriminator</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Axotouch Two-Point Discriminator tool can be used to measure the innervation density of any surface area of the skin. The discs are useful for determining sensation after damage to a peripheral nerve, following the progression of a repaired peripheral nerve, and during the evaluation of a person with possible peripheral nerve damage, such as compression.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Axotouch Two-Point Discriminator tool is a set of two aluminum discs each containing a series of prongs spaced between two to 15 millimeters apart. Additionally, 20 and 25 millimeter spacing is provided. A circular depression on either side of the disc allows ease of rotation. The discs can be rotated between a single prong for testing one-point and any of the other spaced prongs for testing two-point intervals.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axotouch Two-Point Discriminator has the following advantages:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Capable of measuring the innervation density of any skin surface;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Portable and easy to use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Strong aluminum design is resistant to bending;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bright colors allow for clear discrimination between discs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Clear numbering allows users to interpret results; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Reusable carry case protects discs.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tissue Recovery and Processing for Avance Nerve Graft and Avive Soft Tissue Membrane</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Avance Nerve Graft Processing Overview</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has developed the Avance Process, an advanced and proprietary technique to process Avance Nerve Graft from donated human peripheral nerve tissue.  The Avance Process requires special training over several months for each manufacturing associate who processes Avance Nerve Grafts.  The processing and manufacturing system for Avance </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:211.5pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Nerve Graft has required significant capital investment, and we seek to continually improve our manufacturing and quality assurance processes and systems.  Axogen&#8217;s Avance Process is depicted as follows:</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><img src="axgn-20191231x10k0cc357003.jpg" alt="Graphic" style="display:inline-block;height:210.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:422.25pt;" /></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Avance Nerve Graft and Avive Soft Tissue Membrane Processing </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen&#8217;s Avance process and processing of Avive Soft Tissue Membrane consists of several steps, including peripheral nerve tissue, in the case of Avance, and umbilical cord, in case of Avive, recovery/acquisition and testing, donor medical review and release, processing, packaging, and sterilization to meet or exceed all applicable U.S. Food and Drug Administration (the &#8220;FDA&#8221;), state, and international regulations and American Association of Tissue Banks (&#8220;AATB&#8221;) standards.  We have a number of contracts with recovery and acquisition agencies to supply peripheral nerve tissue and umbilical cord and believe these contracts, and the ability to enter into additional contracts, will provide us with the tissues we require for our Avance and Avive implants.   As an FDA registered tissue establishment, Axogen utilizes both its own personnel and a variety of subcontractors for recovery/acquisition, storage, testing, processing and sterilization of the donated peripheral nerve and umbilical cord tissue. Additionally, independent GMP and GLP complaint laboratories have been contracted by Axogen and its subcontractors to perform testing from donor eligibility through release.  The safety of Avance Nerve Graft and Avive Soft Tissue Membrane is supported by donor screening, process validation, process controls, and validated terminal sterilization methods. The Axogen Quality System has built in redundancies that are meant to control the release of each product for implantation only after such product meets our stringent quality control and product requirements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Avance Nerve Graft and Avive Soft Tissue Membrane Tissue Recovery/Acquisition and Processing Facility</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen partners with other FDA registered tissue establishments and AATB accredited recovery/acquisition agencies or recovery/acquisition agencies in compliance with AATB standards for human tissue recovery. After consent for donation is obtained, donations are screened and tested in detail for safety in compliance with the federal regulations and AATB standards on communicable disease transmission. <span style="white-space:pre-wrap;">  Axogen processes and packages Avance Nerve Graft and Avive Soft Tissue Membrane using its employees and equipment  pursuant to a License and Services Agreement, as amended (the &#8220;CTS Agreement&#8221;) with Community Blood Center (d/b/a Community Tissue Services) (&#8220;CTS&#8221;), Dayton, Ohio. CTS is an FDA registered tissue establishment.&#160; </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk1665900"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The current CTS Agreement terminates December 31, 2021, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#8217;s right to cure, in certain circumstances), or without cause upon 6 months prior notice whereby notice cannot be provided prior to March 1, 2021<span style="white-space:pre-wrap;">. Under the CTS Agreement Axogen pays CTS a facility fee for clean room/manufacturing, storage and office space.  CTS also provides services in support of Axogen&#8217;s manufacturing such as routine sterilization of daily supplies, providing disposable supplies, microbial services </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">and office support.  The service fee is based on a per donor batch rate.  The CTS facility provides a cost effective, quality controlled and licensed facility.  Axogen&#8217;s processing methods and process controls have been developed and validated to ensure product uniformity and quality.  Pursuant to the CTS Agreement, Axogen pays license fees on a monthly basis to CTS.  See &#8211; Item 8. Financial Statements and Supplementary Data &#8211; Notes to Consolidated Financial Statements - Footnote 14. Commitments and Contingencies - Service Agreements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is renovating a property it acquired which is located near the CTS facility and comprised of a 70,000 square foot building on approximately 8.6 acres of land.  It is expected that renovations will be completed by the termination date of the CTS Agreement to provide a new processing facility that can be included in our Biologics License Application (&#8220;BLA&#8221;) for Avance Nerve Graft.  The capacity of the property once operational, along with the ability for expansion, is expected to provide processing capabilities that will meet our intended sales growth.  </span>Axogen believes it can obtain certain economic incentives from state and local authorities associated with the renovations and additional employment at the facility, however, such incentives are not expected to be a material offset to the cost of the project as a whole. See &#8211; Item 8. Financial Statements and Supplementary Data &#8211; Notes to Consolidated Financial Statements - Footnote 14. Commitments and Contingencies - Service Agreements.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Avance Nerve Graft and Avive Soft Tissue Membrane Packaging</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">After processing, the packaging operation is performed in a controlled environment at CTS.  Each Avance Nerve Graft and Avive Soft Tissue Membrane is visually inspected and organized by size into finished product codes. The tissue implant is then packaged in primary packaging.  The outer pouch acts as the primary sterility and moisture barrier.    </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Avance Nerve Graft and Avive Soft Tissue Membrane Sterilization and Labeling</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">After being processed and packaged, Avance Nerve Graft and Avive Soft Tissue Membrane are then terminally sterilized and shipped to Axogen&#8217;s Burleson, Texas distribution facility (the &#8220;Distribution Facility&#8221;).  There the products receive their final labels and are released following a final stringent technical and quality review.  Orders for Avance Nerve Graft and Avive Soft Tissue Membrane are placed with Axogen&#8217;s customer care team and the products are packaged and shipped from the Distribution Facility.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Avance Nerve Graft and Avive Soft Tissue Membrane Product Release</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has established quality procedures for review of tissue recovery, relevant donor medical record review and release to processing that meet or exceed FDA requirements as defined in 21 CFR Part 1271, state regulations, international regulations and AATB standards.  The Axogen Quality System meets the requirements set forth under 21 CFR Part&#160;1271 for Human Cells, Tissues and Cellular and Tissue-Based Products, including Good Tissue Practices (&#8220;GTP&#8221;) and is compliant with the 21 CFR Part&#160;</span><span style="white-space:pre-wrap;">820 Quality System Regulations (&#8220;QSR&#8221;).  Furthermore, Axogen utilizes validated processes for the handling of raw material components, environmental control, processing, packaging and terminal sterilization.  In addition to ongoing monitoring activities for product conformity to specifications and sterility, shipping methods have been validated in accordance with applicable industry standards.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Manufacturing of Axogen Products Other Than Avance Nerve Graft and Avive Soft Tissue Membrane  </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Manufacturing for the Axoguard Product Line </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Axoguard product line is manufactured by Cook Biotech Incorporated, West Lafayette, Indiana (&#8220;Cook Biotech&#8221;), which was established in 1995 to develop and manufacture implants utilizing porcine extracellular matrix technology (&#8220;ECM&#8221;).  Axogen decided to expand its portfolio of products and felt that the unique ECM material offered by Cook Biotech provided the combination of properties needed in nerve reconstruction. Cook Biotech&#8217;s ECM material is pliable, capable of being sutured, translucent and allows the patient&#8217;s own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the nerve&#8217;s epineurium.  Cook Biotech has its own source of the raw material for the ECM material and manufactures Axoguard products from such sources.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2008, Cook Biotech entered into an agreement, amended in March 2012 and February 26, 2018 (the &#8220;Distribution Agreement&#8221;), with Axogen to distribute its ECM technology in the form of the Surgisis<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;"> Nerve Cuff, the form of a nerve wrap or patch, or the form of any other mutually agreed to configuration.  The Surgisis products were rebranded under Axogen&#8217;s Axoguard name and consist of the Axoguard Nerve Connector and Axoguard Nerve Protector. Axogen&#8217;s distribution rights are worldwide in the field of the peripheral and central nervous system, but excluding use of the products in the oral cavity for endodontic and periodontal applications and OMF surgery solely as they relate to dental, soft or hard tissue repair or reconstruction. We believe the exclusion does not limit our identified OMF market, but expansion into certain additional OMF market areas could be limited to the Avance Nerve Graft.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">We developed, patented and obtained regulatory approval on the Axoguard Nerve Cap which in its current configuration is made with Cook Biotech&#8217;s ECM material. Pursuant to the Nerve End Cap Supply Agreement dated June 27, 2017 (the &#8220;Supply Agreement&#8221;), Cook Biotech is the exclusive contract manufacturer of the Axoguard Nerve Cap and both parties have provided the other party the necessarily licenses to their technologies for operation of the Supply Agreement.  With respect to the license from Cook Biotech, we are able to sell the Axoguard Nerve Cap worldwide in the field of the peripheral and central nervous system, but subject to the same exclusions as Axoguard Nerve Connector and Protector.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Distribution Agreement terminates on June 30, 2027.  Although the agreement requires certain minimum purchases, through mutual agreement, the parties have not established such minimums and to date have not enforced such provision, and also establishes a formula for the transfer cost of the Axoguard Nerve Connector and Axoguard Nerve Protector. The Supply Agreement has a term through August 27, 2027, provided, however, that after June 27, 2022, either party may terminate the Supply Agreement upon 90 days written notice.  Under both the Distribution and Supply Agreements, Axogen provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Manufacturing for the Axotouch</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="font-style:italic;font-weight:bold;">Two Point Discriminator</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Axotouch Two Point Discriminator is contract manufactured by Viron Technologies, doing business as<span style="font-family:'Calibri';"> </span><span style="white-space:pre-wrap;">Cybernetics Research Laboratories (&#8220;CRL&#8221;), Tucson, Arizona.  Viron supplies the Axotouch unpackaged and they are packaged at Axogen&#8217;s distribution facility in Burleson, Texas.  </span><span style="white-space:pre-wrap;">We believe CRL has capacity to support any future volumes of Axotouch.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Sales and Marketing</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is focused on the developing market of peripheral nerve repair and regeneration, is committed to improving awareness of new surgical peripheral nerve repair options and is building additional scientific and clinical data to assist surgeons and patients in making informed choices with respect to the repair of peripheral nerve injuries.  Axogen believes that there is an opportunity to improve current approaches to peripheral nerve repair and that its approach will solidify its position as a leader in the field of peripheral nerve repair products. The following provides the key elements of Axogen&#8217;s sales and marketing strategy.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Increase Awareness of Axogen&#8217;s Products</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Prior to the introduction of Axogen&#8217;s portfolio of peripheral nerve repair products, surgeons had a limited number of options available to surgically repair damaged or transected peripheral nerves.  Axogen entered the market to improve the standard of care for nerve injury patients.   Axogen intends to increase market penetration and share by increasing awareness of the impact of nerve damage on quality of life, and improving the adoption of nerve repair techniques and Axogen&#8217;s products through the continued use of educational conferences and presentations, surgical resident and fellow training, scientific publications, and a knowledgeable and professional sales team.  Axogen works to increase the use of its products within active accounts as well as expand the overall customer base by adding new active accounts. Axogen defines an &#8220;active account&#8221; as an account </span>that has typically gone through the committee approval process, has at least one surgeon who has converted a portion of his or her treatment algorithms for peripheral nerve repair to the Axogen portfolio and has ordered Axogen products at least six times in the last 12 months<span style="white-space:pre-wrap;">.  Axogen is focused on plastic </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">reconstructive surgeons and orthopedic and plastic hand surgeons who perform surgeries on patients suffering traumatic nerve damage or transection, oral and maxillofacial surgeons who repair damaged oral nerves and certain plastic reconstructive surgeons who perform autologous flap breast neurotization.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Expand Clinical and Scientific Data Regarding the Performance of Axogen Products</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Generating clinical data is an important component of Axogen&#8217;s marketing strategy.  As of December 31, 2019, Axogen had over one hundred peer reviewed clinical papers.  Certain of these publications contain data on multiple products. Axogen will continue to accept patients, for which there are more than 2,000 Avance nerve repairs enrolled to date, in its RANGER</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;"> clinical study (defined below in &#8220;Government Regulations&#8221;), a utilization registry of Avance Nerve Graft.  An additional arm of the RANGER study has been initiated tracking neurotization outcomes in breast reconstruction (Sensation-NOW</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;">).  Six of the above mentioned publications and more than 65 scientific conference presentations have been generated to date from the registry.  A multicenter prospective randomized comparative pilot study of hollow tube conduits and Avance Nerve Graft has completed subject enrollment and outcome follow-up and has been published (Means et al).  Case series in digital nerve repair have been published from the Mayo Clinic, Georgetown University Medical Center and Philadelphia Hand Center and a case series in OMF have been published from UT Southwestern and University of Illinois-Chicago.  A number of additional investigator initiated case reports, studies and publications have been completed including breast neurotization, mandible reconstruction, compressive neuropathies and the surgical treatment of pain.  Case series in brachial plexus, neurotization of breast reconstruction and the surgical treatment of pain are also being developed.  Axogen also supports outside research and will continue to work with investigators working on grants with a translational focus.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Commitment to the Education of Best Practices in Peripheral Nerve Repair</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has established educational conferences and presentations and surgical resident and fellow training that we believe has positioned us as a leader in providing peripheral nerve repair best practices. In 2019, we trained three-quarters of hand and microsurgery surgeon fellows in the U.S. through such courses and training.  The Company provides education on peripheral nerve repair through its &#8220;Advances and Best Practices in Nerve Repair&#8221; national programs (&#8220;National Programs&#8221;) as well as local and regional educational events.  In calendar years 2017, 2018 and 2019, we conducted 15, 18, and 26 National Programs, respectively, and we expect to offer a similar range of programs in 2020.  These efforts are supported by on-line tools and discussion forums such as Nerve Matters, an on-line community of peripheral nerve surgeons where the surgeons can ask questions, present cases and share findings in the area of peripheral nerve repair.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Execute the Sales Process and Expand the Axogen Sales Team </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen provides full sales and distribution services through both a direct sales force and independent sales agencies.  As of December&#160;</span><span style="white-space:pre-wrap;">31, 2019, Axogen had 109 direct sales professionals and 19 independent sales agencies in the U.S.  Approximately 10% of global product revenue came from the direct channel.  By the end of 2020, Axogen anticipates the number of direct sales professionals in the U.S. will increase to between approximately 126 to 131.  Axogen&#8217;s product portfolio is available in 13 countries outside the U.S. through a number of independent in country distributors.  Axogen provides support and resources for independent agencies and distributors both within and outside the United States.  Axogen provides its products to hospitals, surgery centers and military hospitals, calling on surgeons including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons to review the benefits of the Axogen products.  While surgeons make the decision to implant Axogen&#8217;s products in appropriate patients, hospitals make the decision to purchase the products from Axogen.  In today&#8217;s budget constrained environment, hospital committees review new technologies for cost effectiveness as well as quality.  Axogen believes that it has been successful in meeting the needs of these hospital committees by demonstrating the cost/benefit of its products and providing a fair value to the hospital.</span><span style="font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Expand the Product Pipeline and Applications in Peripheral Nerve Repair</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has developed and continues to develop new and next generation products to support surgeons in their needs for repairing damaged or transected peripheral nerves.  Axogen believes additional opportunities exist to develop </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">or acquire complementary products in peripheral nerve repair.  In addition, there exists opportunities to expand the existing portfolio of products in new applications of peripheral nerve repair in lower extremity surgery, head and neck surgery, urology and the surgical treatment of pain.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen Strengths</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen believes that it has the following strengths in the field of peripheral nerve repair and regeneration:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Established Peripheral Nerve Repair Expertise</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has made a significant investment in understanding peripheral nerve anatomy and surgical peripheral nerve repair and regeneration.  This has been accomplished through interaction with leading academic centers throughout the United States and by striving to build an outstanding internal team of technical and clinical experts.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Commitment to the Promotion and Education of Best Practices in Peripheral Nerve Repair</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen has established educational conferences, presentations, webinars and surgical resident and fellow training that we believe is positioning us as a leader in providing peripheral nerve repair best practices. Axogen has developed the programs and speakers to train surgeons currently in practice as well as surgical fellows.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Clinical Data</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is developing a body of clinical evidence of its implants in real world situations surgeons face when treating their patients with peripheral nerve injuries.  This data provides support for surgeons in their clinical decision making and providing treatment options to their patients. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A pivotal multicenter prospective randomized comparative study (RECON<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="white-space:pre-wrap;">) of hollow tube conduits and Avance Nerve Graft to support the transition to a biological product is in process  See &#8220;Government Regulations &#8211; Clinical Trials&#8221;.  A multicenter, prospective, randomized and subject blinded study of Axoguard Nerve Cap as compared to neurectomy for the treatment of symptomatic neuroma (REPOSE</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="white-space:pre-wrap;">) is currently enrolling.  A registry study of Avive Soft Tissue Membrane in acute trauma have been initiated and subjects are being monitored for follow-up.  Finally, the Company has expanded RANGER to include an additional study arm called Sensation-NOW for breast neurotization and a contemporary cohort control for RANGER (MATCH</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup>) which provides reference controls for nerve autograft and manufactured conduits from participating registry centers.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Surgical Implant Commercialization Experience</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Axogen commercialization team consists of sales, marketing, and customer care professionals with backgrounds in the medical device and biotechnology industries. The team has strong experience in the introduction of technologies and has been instrumental in beginning to establish Avance Nerve Graft, Avive Soft Tissue Membrane and the Axoguard product lines as a new standard of care for the surgical treatment of peripheral nerve damage or transections in our core markets.  Axogen believes it can leverage these capabilities in expanding the commercial success of the current Axogen products, future peripheral nerve products and opportunities in new peripheral nerve surgical applications.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Avance Nerve Graft Performance</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has worked with leading institutions, researchers and surgeons to support innovation in the field of surgical peripheral nerve repair. We believe Axogen&#8217;s RANGER study (defined below in the section entitled &#8220;Government Regulations&#8221;) is the largest multi-center clinical study conducted in peripheral nerve gap repair.  Axogen is also conducting a Multicenter, Prospective, Randomized, Subject and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities (&#8220;RECON&#8221;). This study is the phase 3 trial to support its BLA for the Avance Nerve Graft. See &#8220;Government Regulations&#8221;.  The January 2012 edition of Microsurgery and November 2012 edition of The Journal of Hand Surgery, June 2015 edition of Journal </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">of Reconstructive Microsurgery and January 2017 edition of HAND each contain an article summarizing the RANGER study results.  The Brooks et al. publication reported on 55 Avance Nerve Graft nerve repairs and resulted in meaningful motor and sensory recovery in 87% of nerve transections between 5 and 50 mm.  Additionally, no implant related adverse events were reported.  (Brooks, D. N., Weber, R. V., Chao, J. D., Rinker, B. D., Zoldos, J., Robichaux, M. R., Ruggeri, S. B., Anderson, K. A., Bonatz, E. E., Wisotsky, S. M., Cho, M. S., Wilson, C., Cooper, E. O., Ingari, J. V., Safa, B., Parrett, B. M. and Buncke, G. M. (2012), Processed nerve allografts for peripheral nerve reconstruction: A multicenter study of utilization and outcomes in sensory, mixed, and motor nerve reconstructions. Microsurgery, 32: 1&#8212;14. doi: 10.1002/micr.20975 and Cho, et al. 2012, J Hand Surg Am 37(11):2340-9).  In the March 2019 the Journal, Plastic and Reconstructive Surgery Global Open, Safa et al reported on a cohort of the RANGER Registry focused functional motor recovery after repair with Avance Nerve Graft.  In the 22 repairs, the authors found that meaningful motor recovery was observed in 73% of the repairs and no safety concerns were identified. (Safa, Bauback MD; Shores, Jaimie T. MD; Ingari, John V. M; Weber, Renata V. MD; Cho, Mickey MD; Zoldos, Jozef MD; Niacaras, Timothy R. MD, PhD; Nesti, Leon J. MD, PhD; Thayer, Wesley P. MD, PhD; Buncke, Gregory M. MD. (2019)), Recovery of Motor Function after Mixed and Motor Nerve Repair with Processed Nerve Allograft. Plastic and Reconstructive Surgery &#8211; Global Open: March 2019 - Volume 7 - Issue 3 - p e2163 doi: 10.1097/GOX.000000000000216. At the 2019 American Society for Surgery of the Hand Annual Conference, the RANGER Investigator Team presented on the updated RANGER Registry findings.  The team reported overall meaningful recovery ranging from 82-84% and no safety concerns.  A meta-analysis of available clinical outcomes data from published papers on the leading synthetic collagen conduit showed meaningful improvement in only 40-74% of cases bridging a gap in the nerve. This data was further verified in a review of autograft alternative in the 2016 edition of Hand Clinics.  A similar meta-analysis for nerve autograft reported meaningful improvement in 60-88% of nerve repairs.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">International Opportunity for Revenue</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen currently focuses on the U.S. market, with additional foreign distribution and sales in Canada, United Kingdom, South Korea and certain other countries. The need for the surgical repair of damaged or transected nerves is a global issue. Through its ex-U.S. revenue, Axogen has demonstrated the capability to take its current peripheral nerve repair surgical portfolio into new geographical markets.  Axogen does not currently have European Union (&#8220;E.U.&#8221;) wide approval for Avance Nerve Graft as human tissue is approved in each individual country.  </span>Cook Biotech is currently renewing the Axoguard Nerve Connector and Nerve Protector CE Mark and although we believe such renewal is imminent, it has taken longer than anticipated and could experience continued delays.&#160; Until such renewal Axogen is able to sell only those products that are currently in inventory in the E.U., which inventory has not been sufficient to satisfy all product sales, and will no longer be available after February 2020.&#160; Although Axoguard product revenue in Europe is not material, the inability to supply physicians who wish to use &#160;Axoguard could have a negative effect on Axogen&#8217;s planned expansion in the E.U<span style="white-space:pre-wrap;">.  Avance Nerve Graft has been granted marketing authorization in Germany and commercial operations will begin in 2020</span><span style="font-size:12pt;white-space:pre-wrap;">.  </span>Currently, Avive Soft Tissue Membrane, Axoguard Nerve Cap and Axotouch Two Point Discriminator are<span style="white-space:pre-wrap;"> only available in the United States, but Axogen is taking action to introduce Avive Soft Tissue Membrane internationally, which introduction is subject to meeting the appropriate regulatory standards of a particular country and any appropriate E.U. wide regulation or directive.  In addition to regulatory approval, reimbursement approval is necessary to achieve material commercial use in most countries.  Avance Nerve graft has achieved NICE approval in the UK for digital nerve repair and reimbursement approval in South Korea up to 50mm in length.  To date, revenue from international distribution and sales have not been material, there are no material risks associated with foreign operations and we do not have dependencies as to international revenue.  See Risk Factors - Axogen&#8217;s operations must comply with FDA and other governmental requirements. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen believes it provides the most extensive product portfolio for peripheral nerve injuries available.  Our current development focus is to expand clinical data in both traumatic peripheral nerve repair and other surgical applications and to develop product line extensions of the Avance and Axoguard products.  Other peripheral nerve repair technologies may also be developed. In this regard, Axogen introduced: (1) an Axoguard Connector line extension in winter 2014 by providing a new longer 15mm product; (2) Axotouch in the fall of 2014; (3) Avive Soft Tissue Membrane launched in November 2016; and (4) Axoguard Nerve Cap fully released in the U.S. in February 2020.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen works with academic institutions in the expansion of treatments for peripheral nerve and is involved in a number of grants from government agencies related to nerve repair or use of our products and/or technologies. For the years ended December 31, 2019, 2018, and 2017, Axogen recognized grant revenue of approximately $301,000, $195,000 and $56,000, respectively.  For the years ended December 31, 2019, 2018 and 2017, Axogen spent approximately $17.5 million, $11.8 million, and $6.7 million, respectively, on total research and development expenses for product and clinical development. </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Competition </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The medical device and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. As such, Axogen cannot predict what products may be offered in the future that may compete with Axogen&#8217;s products.  In the peripheral nerve repair market, Axogen competes primarily against all transected and non-transected peripheral nerve repair approaches including direct suture repair, autograft and hollow-tube nerve conduits and materials used to wrap and protect damaged peripheral nerve tissue.  Finally, there are numerous companies that offer amnion products in a variety of formats, primarily in the area of wound care, which could be competitive with Axogen&#8217;s Avive product.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Because the requirements of the biomaterials used in peripheral nerve repair can vary based on the severity and location of the damaged nerve, the size and function of the nerve, surgical technique and patient preference, Axogen&#8217;s peripheral nerve repair products compete against both autograft materials (nerve in the case of a bridging repair and vein or fat in the case of a nerve protection repair), and a limited number of off-the-shelf alternatives for grafting and protecting.  Competitive aspects of our products focus on the overall value proposition of our products and their suitability for specific applications and can include composition and structure of the material, ease of use, clinical evidence, handling, and price. Axogen&#8217;s major competitors for off-the-shelf repair options in hollow-tube conduits and bio-absorbable wraps are:</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Integra LifeSciences Holding Corporation (Nasdaq: IART) (&#8220;Integra&#8221;).  Integra offers NeuraGen</span><sup style="color:#000000;font-family:'Times New Roman';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">&#174;</sup><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">, a hollow tube product made from reconstituted bovine collagen and NeuraWrap</span><sup style="color:#000000;font-family:'Times New Roman';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">TM</sup><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">, a reconstituted bovine collagen biomaterial used for nerve wrapping and has announced they will launch NeuraGen 3D Nerve Guide Matrix which we believe is the NeuraGen hollow tube collagen conduit filled with a porous inner matrix comprised of collagen and glycosaminoglycan (chondroitin-6-sulfate);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Baxter International,&#160;</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Inc.  (NYSE: BAX) (&#8220;Baxter&#8221;).  </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Baxter acquired Synovis which offers Neurotube, a hollow tube made of polyglycolic acid and announced distribution of Nerbridge, a hollow tube filled with porous collagen that according to &#8220;A Clinical Multi-Center Registry Study On Digital Nerve Repair Using A Biodegradable Nerve Conduit Of PGA With External And Internal Collagen Scaffolding Hirohisa Kusuhara, Md, Phd; Yu Sueyoshi, Md; Noritaka Isogai, Md, Phd Kindai University, Osaka-Sayama, Japan&#8221; the conduit and inner collagen had the greater ability to regenerate after peripheral nerve injury than hollow Nerbridge</span><sup style="color:#000000;font-family:'Times New Roman';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">&#174;</sup><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">&#8221;.  In 2018, Synovis licensed Neurocap Nerve Capping Device and Vivosorb Polymer Film from Polyganics; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Stryker Corporation (NYSE: SYK) (&#8220;Stryker&#8221;). Stryker offers the NeuroMatrix and Neuroflex products, both of which are hollow tubes derived from reconstituted bovine collagen and NeuroMend, a reconstituted bovine collagen biomaterial used for nerve wrapping.  All of these products are manufactured by Collagen Matrix Inc.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen believes that surgeons use Avance Nerve Graft because it provides them with the natural three-dimensional structure and familiar handling characteristics of a typical peripheral nerve for bridging<span style="font-size:12pt;"> </span><span style="white-space:pre-wrap;">peripheral nerve transections (severed peripheral nerves) without the comorbidities and additional surgical site of an autograft as well as confidence in the performance of the product as a result of the growing body of clinical literature.  Axoguard Nerve Protector and Axoguard Nerve Connector provide the unique features of pliability, suturability and translucence for visualization of the underlying nerve while also allowing the patient&#8217;s own cells to incorporate into the extracellular matrix to remodel. Axogen believes its Avive Soft Tissue Membrane, a resorbable soft tissue covering to separate tissues has favorable handling and absorption properties and Axoguard Nerve Cap, is a uniquely designed nerve termination device which provides a protective environment for the nerve ends to reduce the development of painful neuroma.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:6pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">Axogen believes any current or future competitors face the following important barriers to market entry as it relates to its peripheral nerve repair products.  Axogen&#8217;s intellectual property (&#8220;IP&#8221;), and that of its partners, including patents, patents-pending, trade secrets and know how, is believed to be an important barrier for its Avance Nerve Graft and Axoguard</span><span style="font-size:6.5pt;vertical-align:super;"> </span><span style="font-size:10pt;white-space:pre-wrap;">products.  Axogen has developed knowledge and experience in understanding and meeting FDA regulatory requirements for Avance Nerve Graft, including having made a substantial investment in conducting the preclinical and clinical testing necessary to support a submission for an FDA BLA.  Additionally, Axogen believes the ability to offer a portfolio of products focused on peripheral nerve repair provides a unique competitive position versus other entities that do not have this breadth of product offering.  However, due to its limited resources, its smaller size and its relatively early stage, Axogen believes it may face competitive challenges from larger entities and market factors that could negatively impact Axogen&#8217;s growth, including competitors&#8217; introduction of new products and competitors&#8217; bundling of products to achieve pricing benefits. </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen protects its IP through a combination of patents, trademarks, trade secrets, and copyrights.  In addition, Axogen safeguards its trade secrets and other confidential know-how, and carefully protects these and other IP rights when engaging with third parties.  For example, Axogen requires vendors, contract organizations, consultants, advisors and employees to execute confidentiality and nondisclosure agreements, and to appropriately protect any information disclosed to them by Axogen so as to preserve its confidential and/or trade secret status. Axogen also requires consultants, advisors and employees to assign to Axogen their rights to any IP arising out of their relationship with Axogen.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">License Agreements</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has entered into license agreements with University of Florida Research Foundation (the &#8220;UFRF&#8221;) and the University of Texas at Austin (&#8220;UTA&#8221;). Under the terms of these license agreements, Axogen holds exclusive worldwide licenses to underlying technologies used by Axogen in its Avance Nerve Graft.  The license agreements include both the right to issued patents and patents pending in the U.S. and international markets.  The effective term of the license agreements extends through the term of the related patents.  In the event of default, licensors may also terminate an agreement (after written notice) if Axogen fails to cure a breach.  The license agreements contain the following key terms:</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Payment of annual license maintenance fees, some of which may be credited against future royalty payments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Payment of royalty fees of 1%-3% based on net revenue of the licensed products, the level depending on the agreement, which may include a minimum quarterly royalty payment with discounts off royalty rates when royalty stacking applies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Payment of a percentage of sublicense fees received;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Reimbursement of certain legal expenses incurred for patent prosecution and defense; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other payments of various amounts based on achieving certain milestones.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Currently, Axogen pays royalties to UFRF and UTA specific to the licensed technologies related to the Avance Nerve Graft.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Patents</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As of the date of this Form&#160;<span style="white-space:pre-wrap;">10-K, Axogen owns or is the exclusive licensee of nineteen issued U.S. patents, about fifteen pending U.S. patent applications (including those for which Axogen has received a notice of allowance) and on the order of seventy international patents and patent applications with regard to its peripheral nerve products and other related technologies.  The following table identifies the issued U.S. patents owned or licensed by Axogen with regard to </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">its peripheral nerve products and other related technologies, including the patent number, the title of each patent, and the estimated expiration date of each patent.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="background-color:#ffffff;border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:19.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Patent&#160;No.</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:56.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:19.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;expiration&#160;date</b></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:19.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:56.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:top;width:19.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 6,972,168</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Materials and Methods for Nerve Grafting, Selection of Nerve Grafts, and in vitro Nerve Tissue Culture</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">August&#160;2022</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 7,402,319</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cell Free Tissue Replacement for Tissue Engineering</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">September&#160;2023</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 7,732,200</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Materials and Methods for Nerve Grafting, Selection of Nerve Grafts, and in vitro Nerve Tissue Culture</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">December&#160;2023</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 6,696,575</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Biodegradable, electrically conducting polymer for tissue engineering applications</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">March&#160;2022</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 7,851,447</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Materials and Methods for Nerve Repair</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">November&#160;2023</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 8,545,485</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Nerve Elevator and Method of Use</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">May&#160;2032</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 8,758,794</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cell Free Tissue Replacement for Tissue Engineering</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">September 2023</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 8,986,733</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Materials and Methods for Nerve Repair</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">August 2022</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US D777,917</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Two Point Discriminator Sensory Measurement Device</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">January 2032</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 9,690,975</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Quantitative Structural Assay of a Nerve Graft</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">July 2035</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 9,572,911</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Method for Decellularization of Tissue Grafts</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">March 2034</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 9,629,997</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Materials and Methods for Protecting Against Neuromas</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">December 2033</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 9,996,729</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Quantitative Structural Assay of a Nerve Graft</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">May 2035</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 9,597,429</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cell-Free Tissue Replacement for Tissue Engineering</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">September 2023</p></td></tr><tr><td style="vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 9,402,868</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Materials and Methods for Nerve Grafting</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">August 2022</p></td></tr><tr><td style="background-color:auto;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 10,311,281</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Quantitative Structural Assay of a Nerve Graft </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">May 2035</p></td></tr><tr><td style="background-color:auto;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 10,342,562</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Capture-Tool for Manipulating and Entubulating Nerves</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">May 2037</p></td></tr><tr><td style="background-color:auto;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 10.441,304</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Surgical Tool for Tissue Sizing and Transection</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">September 2037</p></td></tr><tr><td style="background-color:auto;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US 10,441,681</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Materials and Methods for Nerve Grafting</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">February 2023 </p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">With respect to our Avance Nerve Graft we have patent protection through at least September 2023 in the United States. In addition we also expect Avance Nerve Graft will receive Biosimilar Protection that would provide 12 years of data exclusivity. Finally, Axogen has Enforcement Discretion from FDA allowing continued distribution under controls applicable to Human Cellular and Tissue-based Products (&#8220;HCT/P&#8221;) with an agreed transition plan to a Biologic Product under a BLA.  We believe a competitive processed peripheral nerve allograft would need to successfully complete BLA </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Phase I, II and III clinical studies prior to clinical release, the completion of which we believe would take at least 8 years.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Additionally, Axogen entered into the Cook Biotech Distribution Agreement and Supply Agreement for the Axoguard products.  Cook Biotech believes it has know-how and trade secrets with respect to its ECM technology that provides certain competitive obstacles.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Because of the length of time and expense associated with bringing new products through development and the governmental approval process, medical technology companies have traditionally placed considerable importance on obtaining and maintaining patent protection for significant new technologies, products and processes. Axogen&#8217;s policy is to seek patent protection for, or where strategically preferable, maintain as trade secret, the inventions that it considers important to its products and the development of its business. Axogen has sought, and will continue to seek, patent protection for select proprietary technologies and other inventions emanating from its R&amp;D, including with respect to uses, methods, and compositions, in an effort to further fortify its IP stronghold in areas of import to the company and its growing product portfolio. In instances that patent protection is not possible, product value to Axogen&#8217;s portfolio can still be derived. </p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Trademarks, Trade Secrets and Copyrights </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen holds more than one hundred registered trademarks and has filed more than two hundred additional trademark applications worldwide to protect its trade names.  We believe these registrations allow Axogen to prevent competitors from, for example, using the same or a confusingly similar company name, or the same or confusingly similar product names within identified classes of goods which could otherwise wrongfully allow such competitors to capitalize on the Axogen brand, reputation and goodwill, and thereby improperly bolster their sales or reputations through, for example, consumer confusion, a false indication of Axogen&#8217;s endorsement, or of a false indication of corporate or contractual relationship with Axogen.  Axogen polices and enforces its marks.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen possesses trade secrets and material know-how in the following general subject matters: nerve and tissue processing, nerve repair, product testing methods, and pre-clinical and clinical expertise.  Axogen has registered copyrights for training tools and artistic renderings. </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Government Regulations</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Government Regulation Overview</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s products are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the U.S. and comparable authorities in other countries. In addition, its Avance Nerve Graft and Avive Soft Tissue Membrane must comply with the standards of the tissue bank industry&#8217;s accrediting organization, the AATB. </p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:6pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">Axogen distributes for Cook Biotech the Axoguard Nerve Connector and Axoguard Nerve Protector and Cook Biotech is the contract manufacturer for our Axoguard Nerve Cap. Cook Biotech is responsible for the regulatory compliance of the Axoguard Nerve Connector and Axoguard Nerve Protector and Axogen is responsible for the regulatory compliance of Axoguard Nerve Cap. Axoguard products are regulated as medical devices and subject to premarket notification requirements under section 510(k)&#160;of the Federal Food, Drug, and Cosmetic Act (the &#8220;FD&amp;C Act&#8221;), 21 CFR Part&#160;820 (&#8220;Quality System Regulation&#8221;) and related laws and regulations. Cook Biotech has obtained a 510(k)&#160;premarket clearance for Axoguard</span><span style="font-size:6.5pt;vertical-align:super;"> </span><span style="font-size:10pt;">Nerve Connector from the FDA for the use of porcine (pig) small intestine submucosa for the repair of peripheral nerve transections where gap closure can be achieved by flexion of the extremity. Cook Biotech has also obtained a 510(k)&#160;premarket clearance for Axoguard</span><span style="font-size:6.5pt;vertical-align:super;"> </span><span style="font-size:10pt;white-space:pre-wrap;">Nerve Protector for the repair of peripheral nerve damage in which there is no gap or where a gap closure is achieved by flexion of the extremity.  We sell the 510(k) cleared device under the trade name Axoguard Nerve Protector and Axoguard</span><span style="font-size:6.5pt;vertical-align:super;"> </span><span style="font-size:10pt;">Nerve Connector.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen also sells the Axoguard Nerve Cap.  This device, manufactured for Axogen by Cook Biotech and distributed from our Burleson facility, is a Class&#160;II device. The Axoguard Nerve Cap was cleared for market under 510(k) </span><span style="background-color:#f9f9f3;color:#23238e;white-space:pre-wrap;">K163446.  </span>It is classified by FDA under 21 CFR 882.5275 (Nerve Cuff, product code: JXI).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is responsible for the regulatory compliance of Avive Soft Tissue Membrane.  Avive Soft Tissue Membrane</span><span style="font-size:12pt;"> </span>is processed and distributed in accordance with FDA requirements for Human Cellular and Tissue-based Products (361 HCT/P) under 21 CFR Part 1271 regulations, US State regulations and the guidelines of the AATB. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen also distributes Axotouch Two-Point Discriminator.  This device is manufactured for Axogen and distributed from the Burleson Facility is a Class&#160;I device (general controls) that is exempt from premarket notification and the Quality System Regulation requirements except for the Recordkeeping and Complaint file requirements. It is classified by FDA under 21 CFR 882.1200 (Two-point discriminator, product code: GWI).</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In 2007, Axogen began to process and distribute its Avance Nerve Graft pursuant to Section&#160;361 of the PHS Act and 21 CFR Part&#160;1271 Human Cells, Tissues, and Cellular and Tissue Based Products controls. Such action was based on Axogen&#8217;s good faith belief that Avance Nerve Graft product was an HCT/P tissue product regulated solely under Section&#160;361. From October&#160;2008 through early 2010, Axogen was in communication with the FDA concerning the regulatory status of the Avance Nerve Graft product. In April&#160;2010, in response to a Request For Designation filed by Axogen, the FDA determined that Avance Nerve Graft was a biological product that would be reviewed and regulated by the U.S. FDA Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) under the requirements of Section 351 of the PHS Act. Section&#160;351 requires, among other things, an approved license to market a biological product.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen met with CBER in July&#160;2010 and, between July&#160;2010 and November&#160;2010, provided information to CBER that resulted in the FDA issuing a letter stating the agency&#8217;s intent to exercise enforcement discretion with respect to the continued introduction or delivery for introduction into interstate commerce of Avance Nerve Graft assuming that certain conditions are met relating to the transition of Avance Nerve Graft from regulation as an HCT/P under Section 361 to a biological product under section 351 of the PHS Act. Specifically, the FDA is permitting Avance Nerve Graft to be distributed, subject to FDA enforcement discretion, provided that:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen transitions to compliance with Section&#160;501(a)(2)(B)&#160;of the FD&amp;C Act, the current Good Manufacturing Practice, or cGMP, regulations in 21 CFR Parts 210 and 211 and the applicable regulations and standards in 21 CFR Parts 600-610 prior to initiation of a phase 3 clinical trial designed to demonstrate the safety, purity, and potency of Avance</span><span style="color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-style:normal;font-weight:normal;text-align:left;vertical-align:super;white-space:pre-wrap;">  </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Nerve Graft.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Axogen has performed several gap analyses of its quality system for compliance with 21 CFR Parts 210/211 and 600-610 regulations.  The gap analyses have identified areas in which our quality system could improve with respect to compliance to the regulations.  The transition is in process and we periodically review the 21 CFR Parts 210/211 and 600-610 regulations to ensure that we create and implement appropriate changes, including new quality procedures.  Through our internal auditing process, we periodically assess our compliance to the regulations.  As Axogen completes the phase 3 clinical trial and eventual BLA submission, we will retain an external audit firm with experience in auditing to 21 CFR Parts 210/211 and 600-610 regulations to verify quality system compliance to the regulations. </span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk536724500"></a><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen conducts a phase 3 clinical trial to demonstrate safety, purity and potency of Avance Nerve Graft under a Special Protocol Assessment (&#8220;SPA&#8221;).</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen and the FDA agreed to the SPA in August&#160;2011 and in accordance with FDA regulations in 21&#160;CFR &#167; Part&#160;312, Axogen submitted an Investigational New Drug Application (&#8220;IND&#8221;) to the FDA in April&#160;</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">2013.  The IND was approved and became effective in March 2015 and the phase 3 clinical trial was initiated in the second quarter of 2015.  The study completed initial enrollment in January 2019.  As required by the SPA and agreed to by FDA and Axogen, an independent statistical analysis was conducted to determine if greater study enrollment is appropriate to maintain the planned statistical power of the trial.  As part of that review, the targeted enrollment was increased to 220 subjects, and the number of participating centers was increased to up to 25. Enrollment of the additional subjects is underway and enrollment is expected to be completed by no later than the end of the second quarter 2020.  </span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk536724533"></a><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen continues to comply with the regulations and standards under 21 CFR Part&#160;1271.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen was audited by the FDA at its processing facility in March&#160;</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">2013, March 2015 and October 2016 and its Distribution Facility in October 2015.  The quality system was found to be in compliance with 21 CFR Part&#160;1271 and no FDA Form 483 observations were issued.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk536724628"></a><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">In February 2018. Axogen was audited by the FDA with respect to its Medical Device Quality System under 21 CFR Part 820 and its Human Tissue Quality System under 21 CFR Part 1271.  Such audit resulted in two Form 483 observations on general procedures on the Medical Device regulations and no Form 483 observations as to the Human Tissue Quality System.  </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">has taken corrective action to correct these observations and the FDA has accepted the corrective action plan.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;white-space:pre-wrap;"> o</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">In November 2018, Axogen was audited by the FDA with respect to its Human Tissue Quality System under 21 CFR Part 1271.  Such audit resulted in one Form 483 observation on tissue tracking.  Axogen has taken corrective action to correct this observation and the FDA has accepted the corrective action plan.</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen continues to exercise due diligence in executing its requirements under the transition program.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is working to ensure compliance with the applicable regulations through ongoing discussions with the FDA regarding the transition of the quality system to 21 CFR Parts 210/211 and 600-610 compliance with the FDA and through audits for compliance to 21 CFR Part 1271 and amendments to the IND providing updates to the phase III clinical trial. The final determination of regulatory compliance will be made by the FDA during the pre-license inspection as part of the BLA review.  If the FDA does not find Axogen to be in compliance, or if Axogen is unable to meet the required standards for preclinical studies, clinical studies and Chemistry, Manufacturing, and Controls (&#8220;CMC&#8221;), the approval of the BLA would be delayed or denied.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA will end the period of enforcement discretion upon a final determination of Axogen&#8217;s future BLA submission or if prior to the BLA submission, the FDA finds that Axogen does not meet the conditions for the transition plan, or is not exercising due diligence in executing the transition (e.g., study completion, or BLA submission is neither timely nor adequate). If final action on the BLA is negative or Axogen is found to not meet the conditions for the transition plan or its execution, Axogen will not be able to continue to distribute the Avance Nerve Graft. Axogen continues to work diligently to execute the transition plan, including maintaining regular communication with the FDA, and, in this context, continues to distribute Avance Nerve Graft.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The BLA application of Avance Nerve Graft, if approved, will require a potentially substantial user fee payment to the FDA, although certain exemptions, waivers and discounts of the user fees may apply, including certain waivers or discounts for small businesses.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Food and Drug Administration Safety and Innovation Act, referred to herein as FDASIA (Public Law 112-144), which was signed into law on July&#160;9, 2012, amended the FD&amp;C Act. FDASIA includes the Prescription Drug User Fee Amendments of 2012 which authorizes the FDA to continue to collect the following user fees from applicants who submit certain new drug and biological product applications and supplements:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Application Fee:</i><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> Each new BLA has a fee required upon submission. For Axogen fiscal year 2020, this fee for a BLA requiring clinical data is $2.9 million. The fee is adjusted each year so we cannot provide an accurate estimate of what our fee will be upon submission of our BLA. For small companies (fewer than 500 employees and no other approved biologic product on the market) submitting its first application, a waiver of the application fee is available. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;white-space:pre-wrap;">Axogen Program Fee:  </i><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">A program fee is assessed for each strength or potency in which the approved (non-revoked, non-suspended) product is manufactured in final dosage form.  The program fee is based on an estimate of the number of products that would be subject to, and for which the companies would pay, program fees.  The program fee is determined by dividing the adjusted total fee revenue from program fees </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">by the number of estimated products (based on previous year&#8217;s program fees) subject to the program fee (excluding program fee waivers and reductions granted by the FDA).  For Axogen fiscal year 2020, the program fee has been established at $325,000.  Axogen may have to pay a program fee after BLA approval.  </span></td></tr></table><a id="_Hlk536533316"></a><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The current version of PDUFA expires October 1, 2022.  New user fee amounts could be negotiated during the reauthorization process expected to take place starting in 2020.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In September 2018 the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation for Avance Nerve Graft. A regenerative medicine therapy is eligible for the designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such a disease or condition. The RMAT designation provides access to a streamlined approval process for regenerative medicine technologies and ensures continued informal meetings with the FDA in support of the BLA for Avance Nerve Graft.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company believes that any future, competitive peripheral nerve allograft would be required to follow the standard pathway for biologic licensing, which typically entails multiple clinical trials and takes many years. The FDA provided updated guidance in December 2017 which made clear that any processing that alters the biological characteristics of peripheral nerve tissue would be considered more than minimal manipulation, and therefore require a BLA prior to marketing.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 63pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has maintained a collaborative dialogue with the FDA and will continue to work closely with the FDA as it progresses towards its BLA submission. Upon BLA approval, Avance Nerve Graft we believe we will have 12 years of data exclusivity with regard to potential biosimilars.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">FDA &#8212; General</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk536726059"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">FDA regulations govern nearly all the activities that Axogen performs, or that are performed on its behalf, to ensure that medical products distributed domestically or exported internationally are safe and effective for their intended uses. The activities the FDA regulates include the following:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">product design, development and manufacture;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">product safety, testing, labeling and storage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">pre-clinical testing in animals and in the laboratory;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">clinical investigations in humans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">premarketing clearance, approval, or licensing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">record-keeping and document-retention procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">advertising and promotion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the import and export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">product marketing, sales and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">post-marketing surveillance and medical device reporting, including reporting of deaths, serious injuries, communicable diseases, device malfunctions or other adverse events; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">corrective actions, removals and recalls.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Failure to comply with applicable FDA regulatory requirements may subject Axogen to a variety of administrative or judicially-imposed penalties or sanctions and/or prevent it from obtaining or maintaining required approvals, clearances or licenses to manufacture and market its products. Such failure to comply with the applicable FDA requirements may subject Axogen to stringent administrative or judicial actions or sanctions, such as agency refusal to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution of products, injunctions, or civil or criminal prosecution.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">FDA&#8217;s Premarket Clearance and Approval Requirements - Medical Devices</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Unless an exemption applies, each medical device distributed commercially in the U.S. requires either a 510(k)&#160;premarket notification submission or a Pre-Market Approval (&#8220;PMA&#8221;) Application to the FDA. Medical devices are classified into one of three classes&#8212;Class&#160;I, Class&#160;II, or Class&#160;III&#8212;depending on the degree of risk, the level of control necessary to assure the safety and effectiveness of each medical device and how much is known about the type of device. For devices first intended for marketing after May&#160;28, 1976, pre-market review and clearance by the FDA for Class&#160;I and II medical devices is accomplished through the 510(k)&#160;pre-market notification procedure by finding a device substantially equivalent to a legally marketed Class&#160;I or II device, unless the device is exempt. The majority of Class&#160;I medical devices are exempt from the 510(k)&#160;<span style="white-space:pre-wrap;">premarket notification requirement.  Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices for which Class&#160;II controls are inadequate to assure safety or effectiveness, and novel devices, including devices deemed not substantially equivalent to a previously cleared 510(k)&#160;device, are placed in Class&#160;</span><span style="white-space:pre-wrap;">III.  Class&#160;III devices generally require an approved PMA prior to marketing.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A PMA must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction, the safety and effectiveness of the device.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">FDA&#8217;s Premarket Approval Requirements - Biologic Products</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Biological Product License Application (BLA) Pathway</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Biological products subject to BLA requirements are approved under the Public Health Service Act.  Biological products require FDA approval of a BLA to be marketed.  In order to be approved, a BLA must demonstrate the safety, purity and potency of the product candidate based on results of preclinical studies and clinical trials. A BLA must also contain extensive CMC and other manufacturing information, and the applicant must pass an FDA pre-approval inspection of the manufacturing facility or facilities at which the biologic product is produced to assess compliance with the FDA&#8217;s cGMP. Satisfaction of FDA approval requirements for biologics typically takes several years and the actual time required may vary substantially based on the type, complexity and novelty of the product.  Axogen cannot be certain that any BLA approvals for its products will be granted on a timely basis, or at all.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The steps for obtaining FDA approval of a BLA to market a biologic product in the U.S. include:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">completion of preclinical laboratory tests, animal studies and formulation studies under the FDA&#8217;s good laboratory practices regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">submission to the FDA of an IND, for human clinical testing, which must become effective before human clinical trials may begin and which must include independent Institutional Review Board, or IRB, approval at each clinical site before the trials may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">performance of an adequate and well-controlled clinical trial in accordance with Good Clinical Practices to establish the safety and efficacy of the product for each indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">submission to the FDA of a BLA, which contains detailed information about the CMC for the product, reports of the outcomes and full data sets of the clinical trials, and proposed labeling and packaging for the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">satisfactory review of the contents of the BLA by the FDA, including the satisfactory resolution of any questions raised during the review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP regulations, to assure that the facilities, methods and controls are adequate to ensure the product&#8217;s identity, strength, quality and purity; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">FDA approval of the BLA including agreement on post-marketing commitments, if applicable.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some preclinical testing may continue after the IND is submitted. The </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">IND must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about issues such as the conduct of the trials and or supporting preclinical data as outlined in the IND. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns or questions before clinical trials can proceed. In other words, submission of an IND may not result in the FDA allowing clinical trials to commence.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Biosimilar Biological Products</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A regulatory approval pathway for biosimilars was established by The Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), as part of the Patient Protection and Affordable Care Act of 2010. An important component of the legislation specified that a manufacturer of a reference biological product would be granted 12 years of non-patent data exclusivity before a biosimilar could be approved for marketing in the US. An application for a biosimilar product may not be submitted to FDA until four years after the approval date of the BLA for the reference biological product. BPCIA provides for an abbreviated licensure process for a biosimilar, <i style="font-style:italic;">i.e.</i>, a biological product that is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences compared to the reference product in terms of safety, purity and potency.<span style="font-size:12pt;white-space:pre-wrap;">  </span><span style="white-space:pre-wrap;">At its discretion, the FDA can waive a requirement for any required element in an application for a biosimilar product. In addition, the legislation distinguished approval of a biosimilar from approval of such a product as a substitute for the reference biological products. Where a product is approved as a biosimilar and additionally approved as a substitute for the reference biologic, it is considered an interchangeable product. Approval as interchangeable requires that the product is biosimilar and can be expected to produce the same clinical results as the reference product in any given patient, and if intended for repeat dosing, a demonstration that the risk in terms of safety or diminished efficacy of alternating or switching between the use of the interchangeable and reference product is not greater than the risk of using the reference product without such alternating or switching. Interchangeable products can be substituted for a reference product without intervention of the prescribing healthcare provider.  Most states have enacted or are considering laws that regulate the use and substitution of biosimilar and interchangeable products.   For example, Virginia requires licensure as interchangeable by the FDA for a pharmacist to dispense a biosimilar in place of a prescribed biological product (Virginia &#167; 54.1-3408.04).</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">FDA&#8217;s Pre-Approval and Pre-Licensing Requirements</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Before approving a BLA, the FDA generally inspects the facility or the facilities at which the product is manufactured. The FDA will not approve the product if it finds that the facility does not appear to be in cGMP compliance. If the FDA determines the application, manufacturing process or manufacturing facilities are not acceptable, it will either not approve the application or issue a complete response letter to indicate that the review cycle for an application is complete and that the application is not ready for approval.  The letter will describe specific deficiencies and, when possible, will outline recommended actions the applicant might take to get the application ready for approval. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. Axogen may encounter difficulties or unanticipated costs in its efforts to secure necessary governmental approvals, which could delay or preclude it from marketing its products. The FDA may limit the indications for use or place other conditions on any approvals that could restrict the commercial application of the products. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Post-Approval Requirements</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">After regulatory approval of a product is obtained, Axogen will be required to comply with a number of post-approval requirements. For example, as a condition of approval of a BLA, the FDA may require post marketing testing and surveillance to monitor the product&#8217;s continued safety or efficacy. In addition, holders of an approved BLA are required to keep extensive records, to report certain adverse reactions and production problems such as biologic </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">deviation reports to the FDA, to provide updated safety and efficacy information and to comply with requirements concerning advertising and promotional labeling for their products. Also, quality control and manufacturing procedures must continue to conform to cGMP regulations as well as the manufacturing conditions of approval set forth in the BLA. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP regulations, which impose certain procedural, substantive and recordkeeping requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Future FDA inspections may identify compliance issues at Axogen&#8217;s facilities or at the facilities of its contract manufacturers that may disrupt production or distribution, or require substantial resources to correct and prevent recurrence of any deficiencies. In addition, discovery of problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications. Finally, new government requirements, including those resulting from new legislation, may be established that could delay or prevent regulatory approval of Axogen products that are currently under development or regulatory activity.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that Axogen failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, such as issuing a FDA Form&#160;483 notice of inspectional observations, warning letter, or untitled letter, imposing civil money penalties, suspending or delaying issuance of approvals, requiring product recall, imposing a total or partial shutdown of production, withdrawal of approvals or clearances already granted, and pursuing product seizures, consent decrees or other injunctive relief, and criminal prosecution through the U.S. Department of Justice (the &#8220;DOJ&#8221;). The FDA can also require Axogen to repair, replace or refund the cost of devices that it manufactured or distributed. If any of these events were to occur, it could materially adversely affect Axogen&#8217;s business.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Clinical Trials</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trials are required to support a BLA or PMA and are sometimes required for 510(k)&#160;<span style="white-space:pre-wrap;">clearance. Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators. Clinical trials are conducted under strict requirements to ensure the protection of human subjects participating in the trial and under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring and safety, and the effectiveness criteria to be evaluated. Clinical trials for biological products require the submission and FDA acceptance of an IND and clinical trials for medical devices require the submission and FDA approval of an Investigational Device Exemption application, or IDE, unless the device regulations provide for an exemption from the IDE requirement.  Clinical trials for significant risk devices may not begin until the IDE is approved by the FDA and the Institutional Review Board (IRB) overseeing the particular clinical trial. If the product is considered a non-significant risk device under FDA regulations, the trial must only be approved by an IRB prior to its initiation.  A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND or IDE, for significant risk devices. In addition, for these studies, an IRB at each site at which the study is conducted must approve the protocol, subject consent form and any amendments for each site at which the study is conducted. All research subjects must be informed, among other things, about the risks and benefits of the investigational product and provide their informed consent in writing.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Clinical trials under an IND typically are conducted in three sequential phases, but the phases may overlap or be combined.  In Axogen&#8217;s case, Axogen believes that the Phase 3 clinical trial study for the Avance Nerve Graft represents the only new clinical data that will be required to evaluate safety and effectiveness.  Phase 1 clinical trials usually involve the initial introduction of the investigational product into a small group of healthy volunteers (e.g., 10 to 20) to evaluate the product&#8217;s safety (dosage tolerance and pharmacokinetics if a biologic product) and, if possible, to gain an early indication of its effectiveness.  Phase 2 clinical trials usually involve controlled trials in a larger but limited patient population (e.g., a few hundred) to:</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">evaluate dosage tolerance and appropriate dosage;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">identify possible adverse effects and safety risks; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">provide a preliminary evaluation of the efficacy of the product for specific indications.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Phase 3 clinical trials usually further evaluate clinical efficacy and test further for safety in an expanded patient population (e.g., a hundred to several thousand). Phase 3 clinical trials usually involve comparison with placebo, standard treatments or other comparators. Usually at least one well-controlled large Phase 3 or pivotal clinical trial demonstrating safety and efficacy is required to support a BLA. These trials are intended to establish the overall risk-benefit profile of the product and provide an adequate basis for physician labeling. Phase 3 trials are almost always larger, more time consuming, complex and costly than Phase 1 and Phase 2 clinical trials.  Phase 1, Phase 2 and Phase 3 clinical testing may not be completed successfully within any specified period, if at all. Furthermore, the FDA or Axogen may suspend or terminate clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk, have experienced a serious and unexpected adverse event, or that continued use in an investigational setting may be unethical. Similarly, an IRB can suspend or terminate approval of research if the research is not being conducted in accordance with the IRB&#8217;s requirements or if the research has been associated with unexpected serious harm to patients.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Investigational New Drug Application</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">For a biologic product, an IND must be submitted prior to the initiation of the clinical study.  The IND application must contain information in three broad areas:</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans.  Also included are any previous experiences with the product in humans (often foreign use).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Manufacturing Information - Information pertaining to the composition, manufacturer, stability, and controls used for manufacturing of the drug substance and the drug product.  This information is assessed to ensure that the company can adequately produce and supply consistent batches of the drug.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Clinical Protocols and Investigator Information - Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose subjects to unnecessary risks.  Also, information on the qualifications of clinical investigators&#8212;professionals (generally physicians) who oversee the administration of the experimental compound&#8212;to assess whether they are qualified to fulfill their clinical trial duties.  Finally, commitments to obtain informed consent from the research subjects, to obtain review of the study by an IRB, and to adhere to the investigational new drug regulations.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials.  During this time, the FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen Clinical Trials</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen has an active clinical research program to gather data on Avance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="white-space:pre-wrap;">Nerve Graft.  Axogen has completed two clinical studies and is performing two ongoing clinical studies and has plans to initiate further clinical studies. The ongoing studies are &#8220;A Multicenter Retrospective Study of Avance Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair (&#8220;RANGER&#8221;)&#8221; and &#8220;A Multicenter, Prospective, Randomized, Patient and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities (&#8220;RECON&#8221;)&#8221;. Completed studies are &#8220;A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and Avance Nerve Graft Evaluation Recovery Outcomes of the Nerve Repair in the Hand (&#8220;CHANGE&#8221;)&#8221; and a pilot study to evaluate the use of Avance Nerve Graft in the reconstruction of nerves following prostatectomy. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen will continue to accept patients in the RANGER clinical study, a utilization registry of Avance Nerve Graft. As of December 31, 2019, six publications and more than 65 scientific conference presentations have been generated to date from the registry.  The RANGER Study is an observational study in current enrollment. </span>It is designed to allow enrollment of up to a total of 5,000 subjects over the next several years. The follow-up for the RANGER Study is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">standard of care with a target of up to 36 months post peripheral nerve repair. At the time of the BLA submission, Axogen will submit an interim report in the BLA for the enrolled subjects. In 2013, a Matched Autograft and Tube Conduit Case Control Cohort Arm of RANGER (&#8220;MATCH<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup>&#8221;) comparative arm was added.&#160;<span style="white-space:pre-wrap;"> Subjects treated with Avance Nerve Graft were matched to the peripheral nerve autograft or tube conduit treated groups based on size of gap length. We anticipate having approximately 300 repairs with peripheral nerve autograft and/or tube conduit in the comparative arm.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen created an additional RANGER Study arm called Sensation Neurotization Outcomes for Women (&#8220;Sensation-NOW&#8221;).  This registry cohort is designed to assess breast sensation following reconstruction with or without neurotization.  The study is currently enrolling and is designed to enroll up to 2,000 subjects who have undergone mastectomy and breast reconstruction.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The RANGER Study database is also utilized to monitor different nerve repair techniques.&#160; As part of this, Axogen utilizes the database to support clinical evidence submissions for Axoguard and Avance Nerve Graft.&#160;</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has worked with leading institutions, researchers and surgeons to support innovation in the field of surgical peripheral nerve repair.  Axogen believes that RANGER is currently the largest multi-center observational clinical study conducted in peripheral nerve gap repair.  Axogen&#8217;s ongoing RECON study will also continue our clinical work, providing a new multi-center, prospective, randomized, clinical study on Avance Nerve Graft. The January 2012 edition of Microsurgery, November 2012 edition of The Journal of Hand Surgery June 2015 edition of Journal of Reconstructive Microsurgery, the January 2017 edition of HAND and the March 2019 edition of Plastic and Reconstructive Surgery Global, each contain an article summarizing RANGER study results (Brooks, et al. Processed nerve allografts for peripheral nerve reconstruction: A multicenter study of utilization and outcomes in sensory, mixed, and motor nerve reconstructions. Microsurgery, 2012 Jan; 32(1): 1-14; and Cho, et al. Functional outcome following nerve repair in the upper extremity using processed nerve allograft. J Hand Surg Am 2012 Nov; 37(11):2340-9 and Rinker, et al. Outcomes of short-gap sensory nerve injuries reconstructed with processed nerve allografts from a multicenter registry study. J Reconstr Microsurg 2015 Jun; 31(5):384-90).  Brooks et al. reported on 55 Avance Nerve Graft nerve repairs and resulted in meaningful motor and sensory recovery in 87% of nerve transections between 5 and 50 mm and no safety concerns were identified.  Cho et al. showed that Avance Nerve Graft provided 89% meaningful recovery for digital nerve injuries, and 80% meaningful recovery for motor function in mixed and motor nerve injuries and no safety concerns were identified. An expanded data milestone was presented at the 5th Vienna Symposium on Surgery of Peripheral Nerves in June 2014 and such expanded RANGER data provides that of the injuries repaired with the Avance Nerve Graft 90%, 80% and 87% achieved meaningful recovery for gap lengths of 5-14 mm, 15-29 mm and 30-65 mm, respectively. Rinker et al. reported on a subgroup from the RANGER registry on sensory recovery of short-gap digital nerve repairs between 5-15 mm using Avance Nerve Graft.  The study cohort included 24 subjects with 37 digital nerve repairs. Outcomes analysis demonstrated meaningful levels of sensory recovery. No implant related adverse experiences were reported in any of such reports.  In a second publication, Rinker et al. reported on a subgroup from RANGER with nerve gaps &gt;25 mm.  They found that in the population of 28 subjects, meaningful sensory recovery was reported in 86% of the repairs and no safety concerns were reported.  Isaacs and Safa reported on a subgroup of subjects with large diameter nerve injuries repaired with Avance Nerve Graft.  The study included 15 nerve repairs with 4-5 mm diameter Avance Nerve Grafts.  Outcomes analysis found that meaningful levels of sensory and motor function were achieved and no safety concerns were reported.  Safa et al 2019., reported on functional motor recovery after repair with Avance</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="white-space:pre-wrap;">Nerve Graft.  The study is a cohort of the RANGER Registry Program, and included 22 nerve repairs with sufficient follow up time to assess the motor function associated with the injured nerve.  The authors found that 73% of the repairs returned meaningful motor function and no safety concerns were identified.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The following describes available clinical outcomes data from published papers on the leading synthetic and collagen conduit.  Published papers on the leading synthetic collagen conduit by Weber, et al., 2000 and Wangensteen and Kalliainen, 2009, showed meaningful improvement: 74% in sensory nerves and 43% in sensory, mixed and motor nerves, respectively, of cases bridging a gap in the particular type of nerve. A paper published by Haug, et al., 2013 on the leading synthetic and collagen conduit showed meaningful improvement in 40% sensory nerves using the static 2-point discrimination test. Autograft studies where autograft and direct repair or direct suture were tested by Weber, et al., 2000, Kim and Kline 2001-2006, Frykman and Gramyk, 1991, Frykman and Gramyk, 1991 and Kallio, 1993, as interpreted by Brooks et al. 2012, reported meaningful recovery: 86% in sensory nerves, 67-86% in sensory and mixed </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">nerves, 80% in sensory nerves, 75-78% mixed nerves and 70% sensory nerves, respectively, of cases bridging a gap in the particular type of nerve. Published papers by Kim and Kline 2001-2006 and Frykman and Gramyk, 1991 reported successful recovery in 75% and 78% of mixed and motor nerves, respectively. A study by Kallio et al., 1993 showed recovery in 67% of mixed and motor nerves where recovery was defined as results indicating a classification of useful or better motor and sensory recovery.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="background-color:#c0c0c0;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The RECON study is a prospective, randomized, controlled, patient and evaluator blinded, comparative study of Avance Nerve Graft and Collagen Nerve Cuffs in the repair of peripheral nerve transections.  The study is a non-inferiority study designed to assess the outcome of peripheral nerve repair originally in approximately 170 subjects in up to 20 centers. Subjects will be followed over the course of 12 months to assess safety and efficacy outcomes with assessments being performed at various defined intervals up to 12 months.  The study completed initial subject enrollment in January 2019.  As required by the SPA and agreed to by FDA and Axogen, an independent statistical analysis was conducted to determine if greater study enrollment is appropriate to maintain the planned statistical power of the study.   As part of that review, the targeted enrollment was increased to 220 subjects, and the number of participating centers was increased to up to 25.  Enrollment of the additional subjects is underway and no outcome data is available at this time.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="background-color:#c0c0c0;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">CHANGE was a prospective randomized controlled pilot study of nerve cuffs and Avance Nerve Graft for the reconstruction of peripheral nerve transections in male and female subjects that sustained injury to at least one nerve in the hand, distal to the superficial palmar arch that after resection resulted in a nerve gap of &gt;5 mm and &#8804;20 mm. The study results were published by Means et al in the June 2016 edition of HAND.  The authors</span><span style="font-family:'Arial';font-size:12.5pt;"> </span>randomized 23 participants with 31 digital&#160;nerve&#160;injuries. Sixteen participants with 20 repairs had at least six months of follow-up while 12-month follow-up was available for 15 repairs. There were no significant differences in participant and baseline characteristics between treatment groups. The average static two-point discrimination (s2PD) for the Avance Nerve Graft was 5 &#177; 1 mm (n = 6) compared with 8 &#177; 5 mm (n = 9) for hollow conduits. All injuries randomized to processed nerve allograft returned some degree of s2PD as compared with 75% of the repairs in the conduit group. The authors concluded that in this pilot study, patients whose digital&#160;nerve&#160;reconstructions were performed with processed&#160;nerve&#160;allografts&#160;had significantly improved and more consistent functional sensory outcomes compared with hollow conduits. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="background-color:#c0c0c0;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A pilot study on the repair of the cavernous nerves in prostate cancer patients at Vanderbilt with 24-month follow-up has been completed. A total of 12 subjects were enrolled in this single center study. The primary objective of this study was to assess the technical feasibility of using Avance Nerve Graft for neurovascular bundle (NVB) reconstruction during Robotic Assisted Laparoscopic Prostatectomy (RALP). The secondary objective of the study was to assess the long-term safety and efficacy of NVB reconstruction by assessing quality of life and erectile function through validated questionnaires 24 months post-repair. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">ASM-CP-001 is a registry study to evaluate the role of Avive Soft Tissue Membrane in the management of nerve injury following acute trauma.  The study is designed to collect safety, functional and healthcare economic outcomes data in a select set of acute trauma injuries.  The study is designed to enroll up to 200 subjects</span><span style="font-size:12pt;"> </span><span style="white-space:pre-wrap;">has enrolled an initial tranche of the planned subjects.  Additional enrollment is on hold while the initial pilot subjects complete their study evaluations. </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is conducting REPOSE, a two-phase study comparing standard neurectomy to Axoguard Nerve Cap, a porcine small intestine submucosa-based nerve termination cap which leverages Axogen&#8217;s chambered technology to aid in the management of symptomatic or painful neuroma.  The first phase, a non-randomized pilot has completed enrollment.  The second phase, a prospective, randomized controlled study planned, is actively enrolling.  Overall enrollment is targeted at enrollment of up to 101 subjects, with approximately 15 in the open pilot phase followed by 86 in the randomized phase. The study will assess pain scores, quality of life and health outcomes over a 12-month follow-up period. Enrollment has been initiated. </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In addition to these clinical research programs, Axogen is developing additional clinical trials in peripheral nerve repair, mixed and motor nerve repair, breast neurotization and pain.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Clinical trials are subject to extensive recordkeeping and reporting requirements. Axogen&#8217;s clinical trials must be conducted under the oversight of an IRB for the relevant clinical trial sites and must comply with FDA regulations, including but not limited to those relating to good clinical practices. Axogen is also required to obtain the patients&#8217; written informed consent in form and substance that complies with both FDA requirements and state and federal privacy and human subject protection regulations. Axogen, the FDA or the IRB may suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the biological product or device, or may otherwise not be sufficient to obtain FDA approval to market the product in the U.S. Similarly, in Europe, the clinical study for a medicine product must be authorized by the Competent Authority in each Member State in which the clinical trial is to be conducted, and must receive a favorable opinion from an ethics committee.  See Risk Factors - Clinical trials can be long, expensive and results are ultimately uncertain, which could jeopardize Axogen&#8217;s ability to obtain regulatory approval and continue to market its Avance Nerve Graft product.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Pervasive and Continuing Regulation</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">There are numerous regulatory requirements that apply after a product is cleared or approved. For medical devices, these include, but are not limited to: the FDA&#8217;s regulations for device labeling (21 CFR Part 801), medical device reporting (21 CFR Part 803), reporting of corrections and removals (21 CFR Part 806), establishment registration and device listing requirements (21 C.F.R. Part 807); and compliance with the Quality System Regulation (&#8220;QSR&#8221;) per 21 CFR Part 820.  Distribution of medical devices is also subject to license/registration requirements in some states.  For tissue and biologic products, the regulatory requirements include: the FDA&#8217;s registration and listing requirements, donor eligibility requirements and compliance with Good Tissue Practices (&#8220;GTP&#8221;) in 21 CFR Part 1271 for human tissue products, compliance with the FDA&#8217;s cGMP in 21 CFR Parts 210, 211, and 600 for licensed biological products, and post-market BLA requirements (21 CFR Part 601). Among other things, these regulations require manufacturers, including third party manufacturers to:</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">comply with labeling regulations and FDA prohibitions against the false or misleading promotion or the promotion of products for uncleared, unapproved or off-label uses or indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">comply with requirements to obtain clearance or approval for certain changes affecting the product, including changes to the product&#8217;s manufacturing, labeling, or intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">report to the FDA certain adverse events, adverse reactions and deviations: (a)&#160;for medical devices, a report to FDA is required if the device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur; (b)&#160;for biologics, a deviation from current GMP or an unexpected or unforeseeable event that may affect the safety, purity, or potency of the product must be reported; and (c)&#160;for human tissue products, FDA requires reporting of certain adverse reactions involving a communicable disease related to an HCT/P that the company made available for distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">comply with post-approval restrictions or conditions, including post-approval study commitments and post-market safety and annual reporting requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">follow post-market surveillance regulations that may apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">follow requirements to issue notices of correction or removal, or conduct market withdrawals or recalls where quality or other issues arise.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has not received any reports of adverse events concerning the Avance Nerve Graft or Avive Soft Tissue Membrane products.  Eight adverse events have been reported by Cook Biotech for the Axoguard products (one each in 2013, 2014, 2015 and 2016 and two each in 2017, 2018 and 2019). Axogen reported one (1) biological deviation in 2019 for quality system issues related to human tissue distribution (no patient safety issues were involved).  Axogen has not had to submit any Medical Device Reports (&#8220;MDRs&#8221;) or tissue adverse reaction reports to the FDA. Although Axogen&#8217;s Axoguard products have had just eight adverse events reported to date, there may have been other incidents, including patient deaths, which may have occurred during procedures utilizing Axogen&#8217;s products without Axogen being aware of any such incidents.  In addition, there can be no assurance that in the future Axogen&#8217;s products will not cause or </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">contribute to an adverse event that would require Axogen to submit MDRs, biological deviation reports, or tissue adverse reaction reports to the FDA.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The advertising and promotion of medical products are also regulated by the Federal Trade Commission and by state regulatory and enforcement authorities. Recently, some promotional activities for FDA-regulated products have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. In addition, under the Federal Lanham Act and similar state laws, competitors and others can initiate litigation relating to advertising claims.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen is registered with the FDA as a tissue establishment for the Avance Nerve Graft and Avive Soft Tissue Membrane. The FDA has broad post-market and regulatory enforcement powers. Axogen is subject to unannounced inspections by the FDA to determine compliance with the GTP, GMP and other regulations, and these inspections may also include the manufacturing facilities of suppliers.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Failure by Axogen or by Axogen&#8217;s suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or other federal or state authorities, which may include any of the following sanctions, among others:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">warning letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">customer notifications, repair, replacement, refunds, recall or seizure of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">operating restrictions, partial suspension or total shutdown of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">suspension or termination of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">refusing our PMA or BLA for new products, new intended uses or modifications to existing products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">withdrawing or spending premarket approvals that have already been granted; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">criminal prosecution.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws  </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Educational Grants</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A medical product manufacturer may provide financial or in-kind support, including support by way of grants, to third-parties for the purpose of conducting medical educational activities. If these supported activities are considered by the FDA to be independent of the manufacturer, then the activities fall outside the FDA restrictions on promotion to which the manufacturer is subject.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA considers several factors in determining whether an educational event or activity is independent from the substantive influence of the product manufacturer and therefore non-promotional, including, but not limited to, the following:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether the intent of the funded activity is to present clearly defined educational content, free from commercial influence or bias;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether the third-party grant recipient and not the manufacturer has maintained control over selecting the faculty, speakers, audience, program content and materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether the program focuses on a single product of the manufacturer without a discussion of other relevant existing competitive products or treatment options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether there was meaningful disclosure to the audience, at the time of the program, regarding the manufacturer&#8217;s funding or other support of the program, any significant relationships between the provider, presenters, or speakers and the supporting manufacturer; and whether any unapproved uses will be discussed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether there are legal, business, or other relationships between the supporting manufacturer and provider or its employees that could enable the supporting manufacturer to exert influence over the content of the program;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether the individuals employed by the provider and involved in designing or conducting the educational activities are also involved in advising or assisting the company with respect to sales or marketing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether the information about the company&#8217;s products is further disseminated after the initial program, by or at the direction of the company, other than in response to an unsolicited request or through an independent provider; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether the provider is compliant with standards for independence, balance, objectivity, and scientific rigor when putting on ostensibly independent educational programs.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen seeks to ensure that the educational activities it supports through its grants program are in accordance with these criteria for independent educational activities. However, Axogen cannot provide assurance that the FDA or other government authorities would view the programs supported as being independent.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Fraud, Abuse and False Claims </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen is directly and indirectly subject to various federal and state laws governing relationships with healthcare providers and pertaining to healthcare fraud and abuse, including anti-kickback laws. In particular, the U.S. Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending a good or service for which payment may be made in whole or part under federal healthcare programs, such as the Medicare and Medicaid programs. Penalties for violations could include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. In implementing the statute, the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;) has issued a series of regulations, known as &#8220;safe harbors.&#8221; These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they will not be prosecuted under the Anti-Kickback Statute for activities that fit within a safe harbor. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy each applicable element of a safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG, and may be &#8220;at risk&#8221; activities unless a favorable advisory opinion is obtained from the OIG.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Federal False Claims Act (&#8220;FCA&#8221;) imposes civil liability on any person or entity that submits, or causes the submission of, a false or fraudulent claim to the U.S. government. Damages under the FCA can be significant and consist of the imposition of fines and penalties. The FCA also allows a private individual or entity with knowledge of past or present fraud against the federal government to sue on behalf of the government to recover the civil penalties and treble damages. The DOJ has previously alleged that the marketing and promotional practices of pharmaceutical and medical device manufacturers included the off-label promotion of products or the payment of prohibited kickbacks to doctors violated the FCA resulting in the submission of improper claims to federal and state healthcare entitlement programs such as Medicaid. In certain cases, manufacturers have entered into criminal and civil settlements with the federal government under which they entered into plea agreements, paid substantial monetary amounts and entered into corporate integrity agreements that require, among other things, substantial reporting and remedial actions going forward.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">AdvaMed is one of the primary voluntary U.S. trade associations for medical device manufacturers. This association has established guidelines and protocols for medical device manufacturers in their relationships with healthcare professionals on matters including research and development, product training and education, grants and charitable contributions, support of third-party educational conferences, and consulting arrangements. Adoption of the AdvaMed Code by a medical device manufacturer is voluntary, and while the OIG and other federal and state healthcare regulatory agencies encourage its adoption, they do not view adoption of the AdvaMed Code as proof of compliance with applicable laws. Axogen has incorporated the principles of the AdvaMed Code in its standard operating procedures, sales force training programs, and relationships with doctors. Key to the underlying principles of the AdvaMed Code is the need to focus the relationships between manufacturers and healthcare professionals on matters of training, education and scientific research, and limit payments between manufacturers and healthcare professionals to fair market value for legitimate services provided and payment of modest meal, travel and other expenses for a healthcare professional under limited circumstances. Axogen has incorporated these principles into its relationships with healthcare professionals </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">under its consulting agreements, payment of travel and lodging expenses, research and educational grant procedures and sponsorship of third-party conferences. In addition, Axogen has conducted and will continue to conduct training sessions on these principles.  Finally, the Sunshine act, as defined below, imposes additional  reporting and disclosure requirements on Axogen for any &#8220;transfer of value&#8221; made or distributed to physicians and teaching hospitals, as well as reporting of certain physician ownership interests.  Axogen cannot provide any assurance that regulatory or enforcement authorities will view its relationships with physicians or policies as being in compliance with applicable regulations and laws.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Regulation Outside of the United States</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Distribution and sales of medical products outside of the U.S. are subject to foreign governmental regulations that vary substantially from country to country. The time required to obtain certification or approval by a foreign country may be longer or shorter than that required for FDA clearance or approval and the requirements may be different.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">There are restrictions under U.S. law on the export from the U.S. of medical devices and biological product that cannot be legally distributed in the U.S. If a Class&#160;I or Class&#160;II device does not have 510(k)&#160;clearance and the manufacturer reasonably believes that the device could obtain 510(k)&#160;clearance in the U.S., then the device can be exported to a foreign country for commercial marketing without the submission of any type of export request or prior FDA approval if (i) the device is not sold or offered for sale in the U.S., (ii) is labeled for export only and (iii) satisfies certain criteria relating primarily to specifications of the foreign purchaser and compliance with the laws of the country to which it is being exported, known as Importing Country Criteria. An unapproved Class&#160;III device can be exported if it (i) complies with the criteria discussed above for devices that could obtain 510(k)&#160;clearance, (ii) meets certain other quality and labeling requirements, and (iii) has a valid marketing authorization from one of a list of countries listed in the FD&amp;C Act. If an unapproved Class&#160;<span style="white-space:pre-wrap;">III device does not have a valid marketing authorization from one of the listed countries, an export permit from the FDA is required in order to export it. An unapproved biological product can be exported without submitting an export request to FDA if the product has received a marketing authorization in one of a list of countries listed in the FD&amp;C Act and it meets applicable requirements of the FD&amp;C Act and the laws of the country to which it is exported.  An investigational biological product may also be exported under an IND if a listed investigator is in a foreign country and certain requirements specified in FDA&#8217;s regulations are met.  Axogen currently believes it complies with applicable regulations when exporting its products and Axogen intends to continue such compliance in the event there are any regulatory changes regarding its products in the United States.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The primary regulatory body in Europe is the E.U. which has adopted numerous directives and promulgated voluntary standards regulating the design, manufacture and labeling of, and clinical trials and adverse event reporting for, medical devices. Devices that comply with the requirements of a relevant directive will be entitled to bear CE marking, indicating that the device conforms to the essential requirements of the applicable directives and, accordingly, can be commercially distributed throughout the member states of the E.U. and other countries that comply with these directives. The method for assessing conformity varies depending on the type and class of the device, but normally involves an assessment by the manufacturer and a third-party assessment by a notified body, an independent and neutral institution appointed by a country to conduct the conformity assessment. This third-party assessment may consist of an audit of the manufacturer&#8217;s quality system and specific testing of the manufacturer&#8217;s device. Such an assessment is required for a manufacturer to commercially distribute the product throughout these countries.  In the second quarter of 2014, Axogen&#8217;s Quality System became registered to ISO 13485 for Receipt, Handling, Storage and Distribution of Medical Devices related to nerve repair.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Cook Biotech is responsible for all regulatory filings for the Axoguard Connector and Protector products including international registrations. Axogen works with Cook Biotech by providing the countries for Cook to register or get approval for these Axoguard products. Cook Biotech prepares the product filing documentation and submits this documentation to the Ministry of Health (&#8220;MOH&#8221;) for the country. Each country or region has its own regulations and the documentation required for submission varies. It typically takes less than nine months from the initiation of the project to obtain clearance in a given country or region. To date, the Axoguard Connector and Protector product lines were registered in May 2013 in Canada for distribution and in<b style="font-weight:bold;"> </b><span style="white-space:pre-wrap;">April 2013 the product lines were awarded the CE Mark allowing distribution into the E.U. and other countries that accept the CE Mark.  Cook Biotech is currently renewing the Axoguard product CE Mark and although we believe such renewal is imminent, it has taken longer than anticipated and </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">could experience continued delays.  Until such renewal Axogen is able to sell only those Axoguard products that are currently in inventory in the E.U., which inventory has not been sufficient to satisfy all product sales, and will no longer be available after February, 2020.  Although Axoguard product revenue in Europe is not material, the inability to supply physicians who wish to use  Axoguard could have a negative effect on Axogen&#8217;s planned expansion in the E.U.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the new European Medical Device Regulation (&#8220;EU MDR&#8221;) passed in the European Parliament on April 5, 2017 and went into effect on May 25, 2017, replacing the Medical Device Directive. The EU MDR is an extensive reform of the rules that govern the medical device industry in Europe. Under this regulation, manufacturers will have three (3) years to comply with a broad set of new rules for almost every kind of medical device. The EU MDR will require changes in the clinical evidence required for medical devices, post-market clinical follow-up evidence, annual reporting of safety information for Class III products, and bi-annual reporting for Class II products, Unique Device Identification (&#8220;UDI&#8221;) for all products, submission of core data elements to a European UDI database prior to placement of a device on the market, reclassification of medical devices, and multiple other labeling changes.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Under the new EU MDR rules, medical device companies will have to, among other things. do the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">provide significantly more clinical evidence to get new products to market and even to keep existing products on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">make changes to product labeling and make certain product data available to the public; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">conduct product portfolio assessments to determine the impact of the EU MDR on the Company&#39;s margins.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Overall, medical device companies can expect longer lead times to obtain product registrations (CE Mark Certification) in the EU and a substantially costlier pathway to compliance in the EU. We are not yet able to determine the costs of complying with these regulations, how the EU will interpret and enforce them, what the timelines for approvals of products will be and the overall effect of the EU MDR on the marketplace. Given the significant additional pre-market and post-market requirements imposed by the EU MDR, the overall impact of these new rules could have a material, adverse effect on the Company&#8217;s revenues and expenses.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The UK left the E.U. in January 2020.  From now until December 31, 2020, E.U. Law will remain applicable thus the placement on the market of medical devices may continue uninterrupted on both sides of the English Channel and the notified body certificates will remain valid while the UK and E.U. negotiate new arrangements.  Axogen registers its human tissue products in each individual E.U. country and each distributor in the UK has import authority for Axogen&#8217;s human tissue product.  It is expected that a licensed UK establishments that import or export tissues or cells will need written agreements with the relevant E.U. licensed establishments to continue importing and exporting with the E.U.  As Axogen ships directly to the UK from the U.S., we currently expect no delay in shipment of human tissue products into the UK in 2020.  Further, the RANGER clinical trial being performed at select hospitals in the UK would not be affected by Brexit as long as the products continue to come directly from the U.S.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">At this time it is unclear whether Axoguard will need a new and separate marketing authorization in the UK post-Brexit.  According to recent guidance issued by the UK government, any new rules will take effect on Jan. 1, 2021 and companies can &#8220;use the CE marking&#8221; if they are placing goods on the UK market during the transition period, currently expected to last through 2020.  Legislation has been recently proposed in Parliament that would update the UK regulatory framework for human and veterinary medicines, clinical trials and medical devices. We anticipate new rules to be developed over the next several months.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Tissue products are not currently regulated under the CE Mark</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is responsible for all regulatory filings for Avance Nerve Graft and Avive Soft Tissue Membrane including international registrations.  To obtain approvals Axogen will prepare the product filing documentation and submit this documentation to the Ministry of Health (&#8220;MOH&#8221;) for a country.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Although some standards of harmonization exist, each country in which Axogen conducts business has its own specific regulatory requirements. Axogen procures and processes its tissue for the Avance Nerve Graft and Avive Soft Tissue Membrane in the U.S., and markets the Avance Nerve Graft in Canada, the United Kingdom, and certain other countries under compliance with the individual country regulations.  These requirements are dynamic in nature and, as </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">such, are continually changing. New regulations may be promulgated at any time and with limited notice. Axogen will review the regulations at the time of submission of the product dossier for regulatory review. This review involves reviewing the appropriate MOH regulations, discussion with in-country distributors and use of consultants. It typically takes less than nine months from the initiation of the product to develop a product dossier (specific for that country), submission of the documentation and MOH review of the product filing. While Axogen believes that it is in compliance with all existing pertinent international and domestic laws and regulations, there can be no assurance that changes in governmental administrations and regulations will not negatively impact Axogen&#8217;s operations.  Avive Soft Tissue Membrane is currently available in the U.S. and has received regulatory registration allowing for distribution in both Canada and Austria.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA and international regulatory bodies conduct periodic compliance inspections of Axogen&#8217;s U.S. processing facilities. Axogen&#8217;s operations are registered with CBER, as a tissue establishment. Axogen is also accredited by the AATB and is licensed in the states of Florida, New York, California, Maryland, Delaware, Oregon and Illinois. Axogen believes that worldwide regulation of tissue products is likely to intensify as the international regulatory community focuses on the growing demand for these implant products and the attendant safety and efficacy issues of recipients. Changes in governing laws and regulations could have a material adverse effect on Axogen&#8217;s financial condition and results of operations. Axogen management further believes that it can help to mitigate this exposure by continuing to work closely with government and industry regulators.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Environmental</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s products, as well as the chemicals used in processing, are handled and disposed of in accordance with country-specific, federal, state and local environmental regulations. Since 2007, Axogen has used outside third parties to perform all biohazard waste disposal.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen contracts with independent, third parties to perform sterilization of its allografts. Because of the engagement of a third party to perform irradiation services, the requirements for compliance with radiation hazardous waste do not apply, and therefore Axogen does not anticipate that this engagement will have any material adverse effect upon its capital expenditures, results of operations or financial condition. However, Axogen is responsible for assuring that the service is being performed in accordance with applicable regulations. Although Axogen believes it is in compliance with all applicable environmental regulations, the failure to fully comply with any such regulations could result in the imposition of penalties, fines and/or sanctions which could have a material adverse effect on Axogen&#8217;s business.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Corporate History</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_DV_C19"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On September 30, 2011, Axogen Corporation (&#8220;AC&#8221;), a Delaware corporation, completed its business combination with LecTec Corporation (&#8220;LecTec&#8221;), a Minnesota corporation, in accordance with the terms of an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec, Nerve Merger Sub Corp., a subsidiary of LecTec (&#8220;Merger Sub&#8221;), and AC, which the parties amended on August 9, 2011 and September 30, 2011 (as amended, the &#8220;Merger Agreement&#8221;). Pursuant to the Merger Agreement, Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the &#8220;Merger&#8221;). Immediately following the Merger, LecTec changed its name to Axogen, Inc. In October 2011, Axogen Inc. moved its corporate headquarter facilities (principal executive office) from Texarkana, Texas to Alachua, Florida.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Our website address is http://www.Axogeninc.com<span style="white-space:pre-wrap;">.  We have included our website address as an inactive textual reference only.  We make available, free of charge through our website, our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material, or furnish it to the SEC.  We also similarly make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons.  We are not including the information contained at http://www.Axogeninc.com, or at any other website.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Employees </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">At December 31, 2019, Axogen had approximately 394 total employees, including approximately 23 part-time employees and approximately 371 full-time employees.  As of the date of this annual report on Form 10-K Axogen has not had a work stoppage and no employees are represented by a labor union.  Axogen believes its relationship with its employees is satisfactory.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Executive Officers of the Registrant </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following table lists the names and positions of the individuals who are, as of February&#160;24, 2020, executive officers of Axogen:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="background-color:#ffffff;border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr><td style="vertical-align:bottom;width:26.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:26.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:71.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.77%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Karen Zaderej</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:71.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Chairman, Chief Executive Officer and President</p></td></tr><tr><td style="vertical-align:top;width:26.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Peter J. Mariani</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Gregory&#160;G.&#160;Freitag,&#160;JD,&#160;CPA</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">General&#160;Counsel&#160;and&#160;Director</p></td></tr><tr><td style="vertical-align:top;width:26.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Eric A. Sandberg</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Chief Commercial Officer</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mark Friedman, Ph.D.</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Vice President of Regulatory Affairs and Quality Assurance</p></td></tr><tr><td style="background-color:auto;vertical-align:top;width:26.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maria Martinez</p></td><td style="background-color:auto;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Chief Human Resources Officer</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Isabelle Billet</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Chief Strategy and Business Development Officer</p></td></tr><tr><td style="background-color:auto;vertical-align:top;width:26.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Erick DeVinney</p></td><td style="background-color:auto;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Vice President of Clinical and Translational Sciences</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mike Donovan</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Vice President of Operations</p></td></tr><tr><td style="background-color:auto;vertical-align:top;width:26.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Angelo G. Scopelianos, Ph.D.</p></td><td style="background-color:auto;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:71.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Vice President of Research and Development</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Biographical information for each of our executive officers is included below.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Karen Zaderej, Chairman, Chief Executive Officer and President (Age 58)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Ms.&#160;Zaderej has served as Axogen&#8217;s President, Chief Executive Officer, a member of our board of directors (the &#8220;Board of Directors&#8221;) since September 2011 and became the Chairman of our Board of Directors in May 2018. She has served as the Chief Executive Officer of Axogen, and a member of Axogen&#8217;s board of directors since May&#160;2010. Ms.&#160;Zaderej joined Axogen in May&#160;2006 and served as Vice President of Marketing and Sales from May&#160;2006 to October&#160;2007 and as Chief Operating Officer from October&#160;2007 to May&#160;2010. From October&#160;2004 to May&#160;2006, Ms.&#160;Zaderej worked for Zaderej Medical Consulting, a consulting firm she founded, which assisted medical device companies in building and executing successful commercialization plans. From 1987 to 2004, Ms.&#160;Zaderej worked at Ethicon,&#160;Inc., a Johnson&#160;&amp; Johnson company, where she held senior positions in marketing, business development, and research&#160;&amp; development, as well as ran a manufacturing business. Ms.&#160;<span style="white-space:pre-wrap;">Zaderej is a Director of Viveve Medical, Inc., a public women&#39;s intimate health company.  Ms.&#160;Zaderej has a MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Peter Mariani, Chief Financial Officer (Age 56)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Mr. Mariani has been Axogen&#8217;s Chief Financial Officer since March 2016.  Prior to joining Axogen, he served as Chief Financial Officer of Lensar, Inc, a privately held laser refractive cataract surgery company, from July 2014 through January 2016, which was sold in December 2015.  From June 2011 to June 2014 Mr. Mariani served as Chief Financial Officer of Hansen Medical, a publicly traded medical device company developing robotic solutions for intravascular procedures.  From 2007 through 2010 Mr. Mariani served as Chief Financial Officer for two privately held companies: Harlan Laboratories (2007 &#8211; 2009); and BMW Constructors (2009 &#8211; 2010).  From 1994 through 2006 Mr. Mariani served in various senior financial roles with Guidant Corporation, a publicly traded leader in the development and sale of medical devices for the treatment of cardiovascular disease.  Mr. Mariani began his career with Guidant Corporation as Director of Corporate Financial Reporting where he supported the initial public offering of Guidant Corporation and ultimately served as Vice President, Controller and Chief Accounting Officer.  Mr. Mariani&#8217;s experience at Guidant Corporation included two years as Director of Financial Reporting, Guidant Vascular Intervention </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">in Santa Clara, California, and four years in Tokyo, Japan, mostly as Vice President Finance and Administration where he helped to facilitate the conversion and scale of the Japan business from a distributor network to a direct sales and marketing organization.  Following the 2006 sale of Guidant Corporation to Boston Scientific Corporation, Mr. Mariani co-led the initial integration of the two companies.  From 1987 to 1994, Mr. Mariani worked with Ernst and Young, LLP, where he served a diverse client base as a Certified Public Accountant.  Mr. Mariani received a Bachelor of Science Degree in Accounting from Indiana University.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Gregory G. Freitag, JD, CPA, General Counsel and Director (Age 58)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Mr.&#160;Freitag, JD, CPA, has been Axogen&#8217;s General Counsel and a member of our Board of Directors since September&#160;<span style="white-space:pre-wrap;">2011.  He was Axogen&#8217;s Chief Financial Officer from September&#160;2011 to May&#160;2014 and August 2015 to March 2016, and its Senior Vice President Business Development from May 2014 to October 2018. He was Chief Executive Officer, Chief Financial Officer and a board member of LecTec Corporation, an IP licensing and holding company that merged with Axogen in September&#160;2011, from June&#160;2010 through September&#160;</span><span style="white-space:pre-wrap;">2011.  From May&#160;2009 to the present, Mr.&#160;Freitag has been a principal of FreiMc, LLC, a healthcare and life science consulting and advisory firm he founded that provides strategic guidance and business development advisory services. Prior to founding FreiMc, LLC, Mr.&#160;Freitag was a Director of Business Development at Pfizer Health Solutions, a former subsidiary of Pfizer,&#160;Inc., from January&#160;2006 to May&#160;2009. From July&#160;2005 to January&#160;2006, Mr.&#160;Freitag worked for Guidant Corporation in its business development group. Prior to Guidant Corporation, Mr.&#160;Freitag was the Chief Executive Officer of HTS Biosystems, a biotechnology tools start-up company, from March&#160;2000 until its sale in early 2005. Mr.&#160;Freitag was the Chief Operating Officer, Chief Financial Officer and General Counsel of Quantech,&#160;Ltd., a public point of care diagnostic company, from December&#160;1995 to March&#160;2000. Prior to that time, Mr.&#160;Freitag practiced corporate law in Minneapolis, Minnesota. Mr.&#160;</span><span style="white-space:pre-wrap;">Freitag is also a director of PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical stage biopharmaceutical company developing immunotherapies for cancer and other disease areas such as infectious disease.  Mr.&#160;Freitag holds a JD from the University of Chicago and a BA Economics&#160;&amp; Business and Law&#160;&amp; Society from Macalester College, Minnesota.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Eric A. Sandberg, Chief Commercial Officer (Age 55)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Mr. Sandberg has served as Axogen&#8217;s Chief Commercial Officer since January 2019.  From 2016 until joining Axogen, he served as the Chief Executive Officer of Visura Technologies, Inc., a cardiologist-founded medical device company.  From 2016 until 2018, Mr. Sandberg served as the Chief Business Officer of Rhythm Therapeutics, Inc., an electrophysiologist-founded preclinical biotechnology company.  From 2014 until 2016, he served as the President and Chief Executive Officer of Tangent Medical Technologies, Inc., a medical device company.  Mr. Sandberg also served as Senior Vice President, Sales at CardioDx, Inc., a molecular diagnostics company, from 2008 until 2013.  Prior to joining CardioDx, Inc., Mr. Sandberg worked at Russell Reynolds Associates and held leadership positions across sales, marketing, corporate accounts, and business development at Guidant Corporation and Boston Scientific.  Mr. Sandberg currently serves as an observer on the Board of Directors of Visura Technologies, Inc.  Mr. Sandberg earned an MBA from Harvard Business School and a Bachelor of Science degree in mechanical engineering from Bradley University in Peoria, IL.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Mark Friedman, Ph.D., Vice President of Regulatory Affairs and Quality Assurance(Age 62)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Dr.&#160;Friedman has served as Axogen&#8217;s Vice President of Regulatory Affairs and Quality Assurance since November&#160;2011. He has also served as Axogen&#8217;s Director of Quality Assurance and Regulatory Affairs from September&#160;2006 to June&#160;2011. Prior to joining Axogen, Dr. Friedman held several regulatory and quality leadership positions at Enable Medical Corporation, a medical device company, including Director of Quality Assurance from 1997 to 1998 and Vice President of Quality and Regulatory from 1998 to 2001 and from 2004 to 2005. Dr. Friedman also worked for AtriCure, Inc., a company that develops, manufactures and sells surgical ablation systems to treat atrial fibrillation, as Vice President of Quality and Regulatory from 2001 to 2004 and as Vice President of Operations in 2004. AtriCure acquired Enable Medical in 2005. Dr. Friedman has over 25 years of experience in developing and directing regulatory strategy and quality systems for medical products, including 15 years with start-up medical product firms. Dr. Friedman has a Ph.D. in Chemistry specializing in protein biochemistry from the University of Cincinnati.<span style="font-size:12pt;"> </span>Dr. Friedman sits on various agency committees for the Alliance of Regenerative Medicine, Medical Device Manufacturer&#8217;s </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Association and American Association of Tissue Banks, working on improving regulatory laws and standards for regenerative products and medical devices.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Maria Martinez, Chief Human Resources Officer (Age 52)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Ms. Martinez has served as Axogen&#8217;s Chief Human Resources Officer since October 2018.  From January 2018 until joining Axogen as Chief Human Resources Officer, Ms. Martinez provided consulting services related to human resources through her consulting firm MDM Consulting Services, LLC. Prior to founding MDM , she was Chief Human Resources Officer at HSNi, a $3.5B interactive multichannel retailer overseeing nearly seven thousand employees in nine locations.&#160; Ms. Martinez joined HSNi in July 2010 and served as SVP Talent Management until she assumed the role of Chief Human Resources Officer.&#160; Prior to joining HSNi, Ms. Martinez was Vice President of Human Resources with Laser Spine Institute, LLC., a minimally invasive spine surgery company, having started with them in 2008.&#160; From 2007 to 2008, &#160;she worked at Bausch + Lomb, Inc. where she served as Director, Human Resources US Pharmaceuticals and, from 2005 to 2007, &#160;Ms. Martinez was Sr. Director, Human Resources Corporate with Darden Restaurants, Inc.&#160;&#160;Prior to 2005, Ms. Martinez held positions related to the field of human resources. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Ms. Martinez has a &#160;Master of Arts in &#160;Industrial/Organizational Psychology from the Florida Institute of Technology, Melbourne, FL and a Bachelor of Arts in Psychology; Bachelor of Arts in French, Minor in Italian from the University of South Florida, Tampa, FL.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Isabelle Billet, Chief Strategy and Business Development Officer (Age 58)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Ms. Billet has served as Axogen&#8217;s Chief Strategy and Business Development Officer since October 2018.  From July 2013 until joining Axogen as Chief Strategy and Business Development Officer, &#160;Ms. Billet worked for IBHC Advisors LLC, a consulting firm she founded which assisted medical device companies in their organic and inorganic growth strategies and supported private equity firms on their investment strategy and due diligence.&#160; From 2010 to 2013, Ms. Billet worked at Cardinal Health, Inc where she served as Senior Vice President of Marketing and Innovation for the Medical segment focusing on their private brand portfolio development. From 2005 to 2010, she was Vice President Marketing and New Business Development for C.R. Bard Medical division. She worked for Johnson and Johnson from 1992 to 2005, splitting her tenure between Advanced Sterilization Products and Ethicon, Inc in positions of increasing responsibilities in marketing and new business development in France, Europe and US. Ms. Billet spent the first 7 years of her career as the head pharmacist and material manager for a private hospital in France.  Ms. Billet is a member of the Clinical Innovations Board of Directors, a medical device company exclusively focused in Labor and Delivery and Neonates Intensive Care. She has an MBA from EM Lyon Business School, France and Cranfield School of Management, UK and a Doctorate in Pharmacy from Montpellier University in France.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Erick DeVinney, Vice President of Clinical and Translational Sciences (Age 44)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Mr.&#160;DeVinney has served as Axogen&#8217;s Vice President of Clinical and Translational Sciences since January&#160;<span style="white-space:pre-wrap;">2014.  From April 2007 until January 2014, Mr. DeVinney was the Director of Clinical and Translational Sciences for Axogen. Erick has over 14 years of experience in the successful planning and management of clinical development.  Prior to joining Axogen Mr. DeVinney served as Manager of Clinical Operations for Angiotech Pharmaceuticals from 2005 to 2007 and Clinical Program Lead for Pharmaceutical Research Associates International from 2001 to 2005.  Mr. DeVinney has been involved in the successful submission of numerous 510(k), IDE and NDA applications.  He has a BS in Chemistry from Virginia Commonwealth University.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Mike Donovan, Vice President of Operations (Age 55)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Mr.&#160;Donovan has served as Axogen&#8217;s Vice President of Operations since September 2015. Prior to September 2015, Mr. Donovan was Axogen&#8217;s Director of Operations from January 2011 until September 2015. From 1988 to 2010, Mr. Donovan held positions at Zimmer Holdings in manufacturing, continuous improvement, quality assurance and sterilization including Director of Manufacturing from 2002 to 2010. Mr. Donovan has a BS in Chemical Engineering and an MBA from the University of Akron.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Angelo G. Scopelianos, Ph.D., Vice President of Research and Development (65)</i></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Dr. Scopelianos has served as Axogen&#8217;s Vice President of Research and Development since September 2018.  From 2012 until joining Axogen, Dr. Scopelianos was an independent consultant specializing in medical devices. He began consulting after his retirement from a 24-year tenure at Johnson &amp; Johnson (J&amp;J). Angelo began at J&amp;J in 1988 as section manager of R&amp;D and held the escalating positions of manager of R&amp;D, director of R&amp;D, vice president of R&amp;D and finally from October 2010 to September 2012 senior vice president of R&amp;D. He joined J&amp;J after research leadership positions at EI Dupont de Nemours in Wilmington, Delaware, and Pennwalt Corporation. Angelo received his doctorate degree in organic chemistry from Pennsylvania State University, following completion of a Bachelor of Science degree from the State University of New York&#8212;Oneonta. He holds over 35 U.S. patents and numerous international patents, and his awards include the Outstanding Science Alumni Award by Penn State University; the Scientific Leadership Award in Biomaterials Science awarded by a consortium of NJ research universities:  Rutgers University, Princeton University and NJ Institute of Technology; the Johnson &amp; Johnson Philip B. Hofmann Award for technical achievements in scientific research; and an Honorary Doctor of Science Degree bestowed by the State University of New York.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_0fe187ed_e699_462a_8c06_5c73cf85d728"></a><a id="ITEM1ARISKFACTORS_83455"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 1A.  RISK FACTOR</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">S</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen&#8217;s business involves a number of risks, some of which are beyond its control.  The risk and uncertainties described below are not the only ones the Company faces.  Set forth below is a discussion of the risks and uncertainties that management believes to be material to Axogen.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related To The Company</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen has not experienced positive cash flow from its operations, and the ability to achieve positive cash flow from operations will depend on increasing revenue from distribution of its products, which may not be achievable.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen has historically operated with negative cash flow from its operations. As of December 31, 2019, Axogen had an accumulated deficit of approximately $180 million. If  revenue does not increase as anticipated, then it will continue to experience negative cash flows and adverse operating conditions. Axogen&#8217;s continuing capital needs and other factors could cause the Company to raise additional funds through public or private equity offerings, debt financings or from other sources. The sale of additional equity may result in dilution to Axogen&#8217;s shareholders. There is no assurance that Axogen will be able to secure funding on terms acceptable to it, or at all.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s revenue growth depends on its ability to expand its sales force, increase distribution and sales to existing customers and develop new customers, and there can be no assurance that these efforts will result in significant increases in sales.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">Axogen is in the process of investing in its distribution and sales channels composed of a combination of its direct sales force and independent agencies/distributors to allow it to increase distribution and sales to existing customers and reach new customers. There can be no assurance that these efforts will be successful in expanding Axogen&#8217;s revenue. Axogen currently distributes tissue and sells products directly through its sales force and indirectly through agency relationships. Axogen is engaged in an initiative to build and further expand sales and marketing capabilities. The incurrence of these expenses impacts Axogen&#8217;s operating results, and there can be no assurance of their effectiveness. If Axogen is unable to develop its sales force, increase sales to existing customers and attract new customers, it may not be able to grow revenue or maintain its current level of revenue generation.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s revenue depends primarily on four products.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="white-space:pre-wrap;">Substantially all of Axogen&#8217;s revenue is currently derived from only four products, Avance Nerve Graft, Avive Soft Tissue Membrane, Axoguard Nerve Protector and Axoguard Nerve Connector, for the treatment of peripheral nerve damage. Of these four products, Avance Nerve Graft represents approximately half of the Company&#8217;s total revenues.  Any disruption in Axogen&#8217;s ability to generate revenue from the distribution of tissue and sale of products will have a material adverse impact on Axogen&#8217;s business, results of operations, financial condition and growth prospects.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="white-space:pre-wrap;">The Axoguard Nerve Connector and Protector are only available through the Cook Biotech Distribution Agreement. The Distribution Agreement was amended February 26, 2018 to extend the termination date to June 30, 2027.  However, there are conditions for continuation of the agreement, including payment terms and minimum purchase requirements, that if breached could result in an earlier termination of the agreement; except that through mutual agreement the parties have not established such minimums and to date have not enforced such minimum purchase provision. Additionally, in the event that Axogen and Cook Biotech were to fail to reach an agreement as to minimum purchase quantities, Cook Biotech could terminate the agreement if it was deemed that Axogen had failed to generate commercially reasonable sales of Axoguard as measured by sales similar to a competitive product at the same stage in its commercial launch as verified by a mutually acceptable third party. Nerve Connector and Axoguard Nerve Protector and Cook Biotech is the contract manufacture for our Axoguard Nerve Cap.  Although there are products that Axogen believes it could develop or obtain that would replace the Axoguard products obtained through the agreements with Cook Biotech, the loss of the ability to sell the Axoguard Nerve Connector and Protector products, and the Axoguard Nerve Cap if it becomes a significant product line, could have a material adverse effect on Axogen&#8217;s business until other replacement products are available.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s success will be dependent on continued acceptance of its products by the medical community.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">Continued market acceptance of Axogen&#8217;s products will depend on its ability to demonstrate that its products are an attractive alternative to existing or new nerve reconstruction treatment options including both surgical techniques and products. The Company&#8217;s ability to do so will depend on surgeons&#8217; evaluations of clinical safety, efficacy, ease of use, reliability, and cost-effectiveness, including insurance reimbursement, of Axogen&#8217;s nerve repair products. For example, although Axogen&#8217;s Avance Nerve Graft follows stringent safety standards, including sterilization by gamma irradiation, Axogen believes that a small portion of the medical community has lingering concerns over the risk of disease transmission through the use of allografts in general. If the medical community and patients do not ultimately accept our products as safe and effective, or we are unable to raise awareness of our products and processes, our ability to sell the products may be materially and adversely affected, and the results of our operations may be adversely affected.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Negative publicity concerning methods of donating human tissue and screening of donated tissue, in the industry in which Axogen operates, may reduce demand for its products and negatively impact the supply of available donor tissue.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">Axogen is highly dependent on its ability to recover human peripheral nerve tissue from tissue donors for its Avance Nerve Graft product and acquire birth tissue for its Avive Soft Tissue Membrane. The availability of acceptable donors is relatively limited, and this availability is impacted by regulatory changes, general public opinion of the donation process and Axogen&#8217;s reputation for its handling of the donation process. Media reports or other negative publicity concerning both improper methods of tissue recovery from donors and disease transmission from donated tissue, including bones and tendons, may limit widespread acceptance of Axogen&#8217;s Avance Nerve Graft and Avive Soft Tissue Membrane. Unfavorable reports of improper or illegal tissue recovery practices, both in the U.S. and internationally, as well as incidents of improperly processed tissue leading to transmission of disease, may broadly affect the rate of future tissue donation and market acceptance of allograft technologies and donated tissue use. Potential patients may not be able to distinguish Axogen products, technologies, and tissue recovery and processing procedures from others engaged in tissue recovery. In addition, unfavorable reports could make families of potential donors or donors themselves from whom Axogen is required to obtain consent before processing tissue reluctant to agree to donate tissue to for-profit tissue processors. Any disruption in the supply could have negative consequences for Axogen&#8217;s revenue, operating results and continued operations.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen is highly dependent on the continued availability of its facilities and could be harmed if the facilities are unavailable for any prolonged period of time.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">Any failure in the physical infrastructure of Axogen&#8217;s facilities, including the facility it licenses from CTS, could lead to significant costs and disruptions that could reduce its revenues and harm its business reputation and financial results. Any natural or man-made event that impacts Axogen&#8217;s ability to utilize its facilities could have a significant impact on its operating results, reputation and ability to continue operations. This includes termination of the CTS Agreement which is subject to earlier termination by either party at any time for cause (subject to the non-terminating </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">party&#8217;s right to cure, in certain circumstances), or without cause by Axogen upon 6 months prior notice whereby such notice cannot be provided until March 1, 2021. Axogen believes it can find and make operational a new licensed facility in less than six months, if required.  In addition, Axogen acquired property which is located near the CTS facility and it is expected that renovations will be completed by the termination date of the CTS Agreement to provide a new processing facility that can be included in our BLA for the Avance Nerve Graft. However, the regulatory process for approval of facilities whether licensed or owned is time-consuming and unpredictable.  Axogen&#8217;s ability to license, renovate, rebuild or find acceptable service facilities takes a considerable amount of time and expense and could cause a significant disruption in service to its customers if it were to lose the availability of its production or distribution facilities.  Although Axogen has business interruption insurance which would, in instances other than service agreement termination, cover certain costs, it may not cover all costs nor help to regain Axogen&#8217;s standing in the market.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen must maintain high quality processing of its products.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen&#8217;s Avance Nerve Graft is processed through its Avance Process which requires careful calibration and precise, high-quality processing and manufacturing. Its Avive Soft Tissue Membrane is also human tissue that requires skill in its processing.  Achieving precision and quality control requires skill and diligence by its personnel. If it fails to achieve and maintain these high levels of quality control and processing standards, including avoidance of processing errors, defects or product failures, Axogen could experience recalls or withdrawals of its product, delays in delivery, cost overruns or other problems that would adversely affect its business.  Axogen reported one (1) biological deviations in 2019 for quality system issues related to human tissue distribution (no patient safety issues were involved) and corrective action was taken without a material adverse consequence to Axogen.  Axogen cannot completely eliminate the risk of errors, defects or failures. In addition, Axogen may experience difficulties in scaling-up processing of its Avance and Avive products, including problems related to yields, quality control and assurance, tissue availability, adequacy of control policies and procedures, and lack of skilled personnel. If Axogen is unable to process and produce its human tissue products on a timely basis, at acceptable quality and costs, and in sufficient quantities, or if it experiences unanticipated technological problems or delays in production, its business would be adversely affected.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Delays, interruptions or the cessation of production by Axogen&#8217;s third party suppliers of important materials or delays in qualifying new materials, may prevent or delay Axogen&#8217;s ability to manufacture or process the final products.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">Most of the raw materials used in the process for Avance Nerve Graft and Avive Soft Tissue Membrane are available from more than one supplier. However, there are materials within the manufacturing and production process that come from single suppliers. Axogen does not have written contracts with any of its single source suppliers, and at any time they could stop supplying Axogen&#8217;s orders. FDA review of a new supplier may be required if these materials become unavailable from Axogen&#8217;s current suppliers. Although there may be other suppliers that have equivalent materials that would be available to Axogen, FDA review of any alternate suppliers, if required, could take several months or years to obtain, if able to be obtained at all. Any delay, interruption or cessation of production by Axogen&#8217;s third party suppliers of important materials, or any delay in qualifying new materials, if necessary, would prevent or delay Axogen&#8217;s ability to manufacture products. In addition, an uncorrected impurity, a supplier&#8217;s variation in a raw material or testing, either unknown to Axogen or incompatible with its manufacturing process, or any other problem with Axogen&#8217;s materials, testing or components, would prevent or delay its ability to process tissue. These delays may limit Axogen&#8217;s ability to meet demand for its products and delay its clinical trial, which would have a material adverse impact on its business, results of operations and financial condition.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The failure of third parties to perform many necessary services for the commercialization of Avance Nerve Graft and Avive Soft Tissue Membrane, including services related to recovery/acquisition, distribution and transportation, would impair Axogen&#8217;s ability to meet commercial demand.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">Axogen relies upon third parties for certain recovery/acquisition, distribution and transportation services for its Avance Nerve Graft and Avive Soft Tissue Membrane. In accordance with product specifications, third parties ship Avance Nerve Graft in specially validated shipping containers at frozen temperatures. If any of the third parties that Axogen relies upon in its recovery/acquisition, distribution or transportation process fail to comply with applicable laws and regulations, fail to meet expected deadlines, or otherwise do not carry out their contractual duties to Axogen, or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">encounter physical damage or natural disaster at their facilities, Axogen&#8217;s ability to deliver product to meet commercial demand may be significantly impaired.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen is dependent on its relationships with independent agencies to generate revenue.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen derives material revenues through its relationships with independent agencies.  In 2019 approximately 10% of global product revenue was generated through independent agencies.  If certain agency relationships were terminated or discontinued for any reason, it could materially and adversely affect Axogen&#8217;s ability to generate revenues and profits.   If Axogen required additional agencies it may not be able to find additional agencies who will agree to market and distribute Axogen&#8217;s products on commercially reasonable terms, if at all. If Axogen is unable to establish new agency relationships or renew certain current distribution agreements on commercially acceptable terms, its operating results could suffer.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Loss of key members of management, who it needs to succeed, could adversely affect its business.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen&#8217;s future success depends on the continued efforts of the members of its executive management team. Competition for experienced management personnel in the healthcare industry is intense. If one or more of Axogen&#8217;s executives or other key personnel are unable or unwilling to continue in their present positions, or if Axogen is unable to attract and retain high quality executives or key personnel in the future, its business may be adversely affected.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s operating results will be harmed if it is unable to effectively manage and sustain its future growth or scale its operations.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">There can be no assurance that Axogen will be able to manage its future growth efficiently or profitably. Its business is unproven on a large scale and actual revenue and operating margins, or revenue and margin growth, may be less than expected. If Axogen is unable to scale its production capabilities efficiently or maintain pricing without significant discounting, it may fail to achieve expected operating margins, which would have a material and adverse effect on its operating results. Growth may also stress Axogen&#8217;s ability to adequately manage its operations, quality of products, safety and regulatory compliance. If growth significantly decreases it will negatively impact Axogen&#8217;s cash reserves, and it may be required to obtain additional financing, which may increase indebtedness or result in dilution to shareholders. Further, there can be no assurance that Axogen would be able to obtain additional financing on acceptable terms if all at.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">There may be significant fluctuations in Axogen&#8217;s operating results.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">Significant quarterly fluctuations in Axogen&#8217;s results of operations may be caused by, among other factors, its volume of revenues, seasonal changes in nerve repair activity, timing of sales force expansion and general economic conditions. There can be no assurance that the level of revenues and profits, if any, achieved by Axogen in any particular fiscal period, will not be significantly lower than in other comparable fiscal periods. Axogen&#8217;s expense levels are based, in part, on its expectations as to future revenues. As a result, if future revenues are below expectations, net income or loss may be disproportionately affected by a reduction in revenues, as any corresponding reduction in expenses may not be proportionate to the reduction in revenues.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s revenues depend upon prompt and adequate reimbursement from public and private insurers and national health systems.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">Political, economic and regulatory influences are subjecting the healthcare industry in the U.S. to fundamental change. The ability of a hospital or an ambulatory surgery center (&#8220;ASC&#8221;) to pay fees for Axogen&#8217;s products depends in part on the availability of adequate coverage and reimbursement from third-party payors for either our products specifically, the procedures associated with the use of our products, or both. Providers that purchase our products generally rely on third-party payors to reimburse all or part of the costs and fees associated with the procedures performed with our products or the products themselves. Adequate coverage and reimbursement from third-party payors, including governmental payors, such as Medicare and Medicaid, therefore, is important for obtaining product acceptance and widespread adoption in the marketplace.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk1665584"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">When our products (Avance Nerve Graft, Axoguard Connector, Axoguard Nerve Cap, Axoguard Protector, Avive Soft Tissue Membrane) are used in the operating room of a hospital, they are commonly treated as general supplies utilized in surgery and the cost is included in payment to the facility for the procedure. When Avance Nerve Graft and Axoguard Connector are used in an outpatient setting where the nerve repair is the primary reason for the procedure, facilities may use a Category I CPT code to facilitate payment.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk1638014"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">In January 2018, the American Medical Association created a Category&#160;I CPT code (64912) specific to nerve repair with nerve allograft (Avance Nerve Graft<span style="white-space:pre-wrap;">) and a separate code (+64913) for each additional strand of allograft used in a procedure. Category I CPT codes are used by providers to facilitate payment to the provider (either hospital or ASC) for outpatient procedures. Additionally, Category I CPT codes are used to facilitate payment to the surgeon, for both time spent in outpatient and inpatient procedures. Prior to January 2018, there was no designated Category I CPT code for nerve repair cases that included nerve allograft.  The Category I CPT code specific to nerve repair with nerve allograft, has allowed for nerve allograft repair cases to be uniquely identified in the Medicare claims data. This in turn allowed CMS visibility to nerve allograft nerve procedure costs, and thereby confirm nerve allograft qualified as a device intensive procedure leading to a 78% increase in Medicare payment for nerve allograft repair in ambulatory surgery centers beginning January 1, 2020.</span><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">The process for securing coding for a product or procedure is separate from the process of securing coverage and establishing a reimbursement payment rate. In the United States, coverage and reimbursement for medical devices vary among payors. In addition, payors review coverage policies on an ongoing basis and can, without notice, change or deny coverage for these new products and procedures. We estimate that commercial payors covering a significant number of U.S. covered lives have legacy non-coverage policies relating to our Avance Nerve Graft and our Axoguard product lines, designating these products investigational or experimental. Some commercial payors do not currently cover or reimburse our products because they have determined insufficient evidence of favorable clinical outcomes is available. Although some consider the Avance Nerve Graft and our Axoguard product lines investigational or experimental at this time, these payors may in the future determine sufficient evidence has been developed to cover and reimburse our products and related procedures. We are actively working to reverse these non-coverage decisions but cannot provide assurance that we will be successful in these efforts. If we are not successful in reversing existing non-coverage policies, or if other third-party payors issue similar policies, this could have a material adverse effect on our business and operations. Further, third-party payors who currently cover and reimburse customers for procedures using our products may in the future choose to decrease current levels of reimbursement or eliminate reimbursement altogether, either of which will cause our business to suffer.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">The amount of reimbursement received by our customers from third-party payors is dependent generally on fee schedules established by these payors for the existing CPT codes. For governmental payors, such as Medicare and Medicaid, the fee schedule amount is determined by statutory and regulatory formulas. For commercial payors, the reimbursement amount generally is dependent upon the specific contract terms between the provider and payor. We cannot provide assurance that government or commercial payors will continue to reimburse for procedures with our products using the existing codes, nor can we provide assurance that the payment rates will be adequate. If providers and physicians are unable to obtain reimbursement for the procedure at cost-effective levels when use of our products is included, this could have a material adverse effect on our business and operations. Hospitals and ASCs may not purchase our products if they do not receive payment sufficient to cover the cost of our products and related procedures. In addition, in the event that the current coding and/or payment methodology for these procedures changes, this could have a material adverse effect on our business and business operations.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are party to a number of pending lawsuits and other disputes which may have an adverse impact on our business, operations or financial condition.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18.2pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18.2pt;margin:0pt;">We are or may become a party to pending lawsuits and other disputes, including patent, product liability, securities violations or other lawsuits. These current and future matters, including the Einhorn securities litigation decribed in Item -3 Legal Proceedings, may result in a loss of patent protection, reduced revenue, incurrence of significant liabilities and diversion of our management&#8217;s time, attention and resources. Given the uncertain nature of litigation and other disputes generally, we are not able in all cases to estimate the amount or range of loss that could result from an unfavorable outcome in these current matters. In view of these uncertainties, the outcome of these matters may result in charges in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">excess of any established reserves, and, to the extent available, liability insurance. Even claims without merit could subject us to adverse publicity and require us to incur significant legal fees. While Axogen currently carries liability insurance, protracted litigation and other disputes, including any adverse outcomes, may have an adverse impact on our business, operations or financial condition. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen may be subject to future product liability litigation which could be expensive, and its insurance coverage may not be adequate.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Although Axogen is not currently subject to any product liability proceedings and it has no provision for product liability disbursements, it may incur material liabilities relating to product liability claims in the future, including product liability claims arising out of the usage of Axogen products. Although Axogen currently carries product liability insurance in an amount it believes is consistent with industry averages, its insurance coverage and any provision it may maintain in the future for product related liabilities may not be adequate and Axogen&#8217;s business could suffer material adverse consequences.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Technological change could reduce demand for Axogen&#8217;s products.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The medical technology industry is intensely competitive. Axogen competes with both U.S. and international entities that engage in the development and production of medical technologies and processes including:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">biotechnology, orthopedic, pharmaceutical, biomaterial, chemical and other companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">academic and scientific institutions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">public and private research organizations.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen products compete with autograft, hollow-tube conduits, commercially available wraps and amnion products, as well as with alternative medical procedures. For the foreseeable future, Axogen believes a significant number of surgeons will continue to choose to perform autograft procedures when feasible, despite the necessity of performing a second operation and its drawbacks. In addition, many members of the medical community will continue to prefer the use of hollow-tube conduits due in part to their familiarity with these products and the procedures required for their use. Amnion products are widely available and Axogen may not be able to distinguish the Avive Soft Tissue Membrane from such other products so as to produce significant revenue from its distribution.  Also, steady improvements have been made in synthetic human tissue substitutes, which could compete with Axogen&#8217;s products in the future. Unlike allografts, synthetic tissue technologies are not dependent on the availability of human or animal tissue. Although Axogen&#8217;s growth strategy contemplates the introduction of new technologies, the development of these technologies is a complex and uncertain process, requiring a high level of innovation, as well as the ability to accurately predict future technology and market trends. Axogen may not be able to respond effectively to technological changes and emerging industry standards, or to successfully identify, develop or support new technologies or enhancements to existing products in a timely and cost-effective manner, if at all. There can be no assurance that in the future Axogen&#8217;s competitors will not develop products that have superior performance or are less expensive relative to Axogen&#8217;s products rendering Axogen&#8217;s products obsolete or noncompetitive.  In this regard, Integra and Baxter each have or will commercialize a product consisting of a hollow tube conduit filled with material which they suggest is superior to their current hollow conduit products.  Due to Axogen&#8217;s limited resources, its smaller size and its relatively early stage, Axogen may face competitive challenges from these new products or existing products and barriers that are difficult to overcome and could negatively impact its growth.  Finally, a Chinese company provides a human peripheral nerve allograft in China, however, such product is not sold in markets of interest of Axogen because of Axogen&#8217;s IP protection in its identified markets.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen may be unsuccessful in commercializing its products outside the U.S.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">To date, Axogen has focused its commercialization efforts in the U.S., except for minor revenues in certain countries outside the U.S. Axogen intends to expand distribution and sales in these and other countries outside the U.S. and will need to comply with applicable foreign regulatory requirements, including obtaining the requisite approvals to do so.  The regulatory environment for Axogen&#8217;s portfolio of products is complex.  Avance Nerve Graft is distributed in Canada, United Kingdom, and certain other countries.  Axogen received approval to distribute Avance Nerve Graft in </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Germany in December 2019 and is making plans for a market launch in Germany in 2020.  Distribution in Spain currently allows only for compassionate use.  Axogen is not seeking approval for France and Italy at this time. Avive Soft Tissue Membrane is currently available in the U.S. and select other countries for expansion.  Cook Biotech is currently renewing the Axoguard </span>Nerve Connector and Nerve Protector <span style="white-space:pre-wrap;">CE Mark and although we believe such renewal is imminent, it has taken longer than anticipated and could experience continued delays.  Until such renewal Axogen is able to sell only those products that are currently in inventory in the E.U., which inventory has not been sufficient to satisfy all product sales, and will no longer be available after February, 2020.  Although Axoguard product revenue in Europe is not material, the inability to supply physicians who wish to use  Axoguard could have a negative effect on Axogen&#8217;s planned expansion in the E.U.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In addition, the United Kingdom exited the E.U. (&#8220;Brexit&#8221;) and Axogen cannot be sure what changes could occur or  the cost of regulatory compliance with both the United Kingdom and E.U.  Until such time as Axogen can obtain, if at all, the necessary registrations and approvals for its products, material expansion beyond the United States will be limited. </span><span style="font-size:12pt;"> </span>Finally, the cost of regulatory compliance for sales outside the U.S. can be significant and time consuming.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Further, Axogen will need to either enter into distribution agreements with third parties or develop a direct sales force in foreign markets. If it does not obtain adequate levels of reimbursement from third party payers outside of the U.S., it may be unable to develop and grow its revenue internationally. Outside of the U.S., reimbursement systems vary significantly by country. Many ex-U.S. markets have government-managed healthcare systems that govern reimbursement for medical devices, implants and procedures. Some ex-U.S. reimbursement systems provide for limited payments in a given period and therefore result in extended payment periods. If Axogen is unable to successfully commercialize its products internationally, its long-term growth prospects may be limited.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If Axogen does not manage tissue and tissue donation in an effective and efficient manner, it could adversely affect its business.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Many factors affect the supply, quantity and timing of donor medical releases, such as effectiveness of donor screening, the effective recovery of tissue, the timely receipt, recording, review and approval of required medical and testing documentation, changes in donor eligibility criteria and employee loss and turnover in Axogen&#8217;s and its contractor&#8217;s recovery department. Axogen can provide no assurance that tissue recovery or donor medical releases will occur at levels that will maximize processing efficiency and minimize Axogen&#8217;s costs.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If Axogen does not manage product inventory in an effective and efficient manner, it could adversely affect profitability.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Many factors affect the efficient use and planning of product inventory, such as effectiveness of predicting demand, effectiveness of preparing manufacturing to meet demand, efficiently meeting product mix and product demand requirements and product expiration. Axogen may be unable to manage its inventory efficiently, keep inventory within expected budget goals, keep its work-in-process inventory on hand or manage it efficiently, control expired product or keep sufficient product on hand to meet demand. Finally, Axogen can provide no assurance that it can keep inventory costs within its target levels.   Failure to do so may harm long term growth prospects.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s failure to protect its technology systems and comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against Axogen, and adversely impact Axogen&#8217;s operating results.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">We rely on information technology systems, including technology from third party vendors, to process, transmit and store electronic information in our day-to-day operations. Similar to other companies, the size and complexity of our information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, or other significant disruption. Our information systems require an ongoing commitment of resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards and the increasing need to protect patient and customer information. Any failure by us to maintain or protect our information technology systems and data integrity, including from cyber-attacks, intrusions or other breaches, could result in the unauthorized access to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">patient data and personally identifiable information, theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In the U.S., federal and state privacy and security laws require certain of our operations to protect the confidentiality of personal information including patient medical records and other health information.  Limiting and/or restricting the use of certain personal data and information, as well as added transparency obligations to data subjects is becoming an increasing focus as evidenced by the implementation of the California Consumer Privacy Act (&#8220;CCPA&#8221;) which became effective on January 1, 2020. In Europe, E.U. member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations. Moreover, the collection and use of personal health data in the E.U. is governed by the European Union General Data Protection Regulation (&#8220;GDPR&#8221;). The GDPR imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the E.U. to the United States, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to 4% of the annual global revenues of the noncompliant company. The recent implementation of the GDPR has increased Axogen&#8217;s responsibility and liability in relation to personal data that Axogen processes, including in clinical trials, and Axogen may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#39;s attention and increase Axogen&#8217;s cost of doing business. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Compliance with applicable data privacy and security laws and regulations (together with applicable industry standards) may increase Axogen&#8217;s costs of doing business. In this regard and in light of the CCPA&#8217;s implementation, Axogen expects that there will be other proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the E.U. and other jurisdictions, and Axogen cannot determine the impact such future laws, regulations and standards may have on its business.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s management has broad discretion in the use of Axogen&#8217;s cash and cash equivalents and, despite management&#8217;s efforts, cash and cash equivalents may be used in a manner that does not increase the value of shareholders&#8217; investments.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s management has broad discretion in the use of Axogen&#8217;s cash and cash equivalents, and investors must rely on the judgment of management regarding the use of such cash and cash equivalents. Management may invest Axogen&#8217;s cash and cash equivalents in short-term or long-term, investment-grade, interest-bearing securities. These investments may not yield favorable returns to shareholders. If Axogen does not invest or apply its cash and cash equivalents in ways that enhance shareholder value, Axogen may fail to achieve expected financial results, which could cause its stock price to decline.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen incurs costs as a result of operating as a public company, and its management is required to devote substantial time to compliance initiatives.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">As a public company, Axogen incurs legal, accounting and other expenses to comply with relevant securities laws and regulations, including, without limitation, the requirement of establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Axogen&#8217;s management devotes substantial time and financial resources to these compliance initiatives. Failure to comply with public company requirements could have a material adverse effect on Axogen&#8217;s business.  In addition, activity by shareholders or others that bring into question aspects of Axogen&#8217;s business, financial reporting or management&#8217;s integrity, whether based on facts, beliefs or baseless and contrived for individual economic gain, can have a negative impact on the price of Axogen&#8217;s stock and can result in substantial time and financial resources being expended to address the situation.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our business and stock price may be adversely affected if our internal controls are not effective.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires that public companies conduct a comprehensive evaluation of their internal control over financial reporting. To comply with this statute, each year we are required to document and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">test our internal control over financial reporting and our management is required to assess and issue a report concerning it.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Although we have systems in place to strengthen our internal control over financial reporting, we cannot assure you that we will not discover material weaknesses in the future or that no material weakness will result from any difficulties, errors, delays or disruptions while we implement and transition to new internal systems. The existence of one or more material weaknesses could result in errors in our financial statements, and substantial costs and resources may be required to rectify these or other internal control deficiencies. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market price of our common stock could decline significantly, we may be unable to obtain additional financing to operate and expand our business and our business and financial condition could be harmed.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our business and financial performance could be adversely affected, directly or indirectly, by disasters, by terrorist activities or by international hostilities.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Neither the occurrence nor the potential impact of disasters (such as hurricanes and other natural disasters), terrorist activities and international hostilities can be predicted. However, these occurrences could impact Axogen directly as a result of damage to our facilities or by preventing us from conducting our business in the ordinary course, or indirectly as a result of their impact on our customers, suppliers or other counterparties. We could also suffer adverse consequences to the extent that disasters, terrorist activities or international hostilities affect the financial markets or the economy in general or in any particular region.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s ability to mitigate the adverse consequences of such occurrences is in part dependent on the quality of our resiliency planning, and our ability, if any, to anticipate the nature of any such event that occurs. The adverse impact of disasters or terrorist activities or international hostilities also could be increased to the extent that there is a lack of preparedness on the part of national or regional emergency responders or on the part of other organizations and businesses that we deal with, particularly those that we depend upon but have no control over.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to the Regulatory Environment in which Axogen</b><span style="font-style:italic;font-weight:bold;"> </span><b style="font-weight:bold;">Operates</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s business is subject to continuing regulatory compliance by the FDA and other authorities which is costly and could result in negative effects on its business.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is subject to extensive regulation by foreign and domestic government entities, including compliance with regulations governing appropriate relationships with healthcare professionals, such as physicians, hospitals and those to whom and through whom we may market our products.  We are subject to various federal, state and territorial laws in the United States and other jurisdictions in which we conduct business. These include, for example, anti-kickback laws, false claims laws, health care fraud laws, and anti-bribery laws such as the United States Foreign Corrupt Practices Act. Violations of these laws can be punishable by criminal and/or civil sanctions, including, in some instances, fines, imprisonment and, within the United States, exclusion from participation in government healthcare programs, including Medicare, Medicaid and Veterans Administration health programs. These laws are administered and enforced by, among others, the U.S. Department of Justice (&#8220;DOJ&#8221;), the Office of Inspector General of the Department of Health and Human Services, state attorneys general, and their respective counterparts in the applicable foreign jurisdictions in which we conduct business. Many of these agencies have increased their enforcement activities with respect to medical device manufacturers in recent years.</span><span style="white-space:pre-wrap;"> There can also be changes to the regulations by foreign and domestic government entities that require Axogen to update or upgrade business processes or to perform additional validation activities for product or processes.  Compliance with such changes can be costly to implement or result in non-compliance, thus restricting the ability to distribute tissue or sell products that could have a material adverse effect.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Our products are also subject to regulation by the FDA in the U.S. The FDA regulates the development, clinical testing, marketing, distribution, manufacturing, labeling, and promotion of biological products, such as that of Axogen&#8217;s Avance Nerve Graft product. The FDA requires the approval of a biological product, like Avance Nerve Graft, through a BLA prior to marketing. Although Avance Nerve Graft product has not yet been approved by FDA through a BLA, FDA is permitting the product to be distributed, subject to FDA enforcement discretion, provided that  Axogen: (1)&#160; transitions </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:6pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">to compliance with section 501(a)(2)(B)&#160;of the FD&amp;C Act, the cGMP regulations in 21 CFR Parts 210 and 211 and the applicable regulations and standards in 21 CFR Parts 600-610 prior to initiation of a phase 3 clinical trial designed to demonstrate the safety, purity, and potency of Avance</span><span style="font-size:6.5pt;vertical-align:super;white-space:pre-wrap;">  </span><span style="font-size:10pt;">Nerve Graft; (2)&#160;conducts a phase 3 clinical trial to demonstrate safety, purity and potency of Avance Nerve Graft under an SPA; (3)&#160;continues to comply with the requirements of 21 CFR Part&#160;1271; and (4)&#160;</span><span style="font-size:10pt;white-space:pre-wrap;">exercises due diligence in executing the transition plan.  See &#8220;Business &#8212; Government Regulations &#8212; U.S. Government Regulation Review.&#8221; </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Avive Soft Tissue Membrane<span style="font-size:12pt;"> </span>is processed and distributed in accordance with FDA requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations and U.S. State regulations. The FDA also regulates medical devices, for example the Axoguard products, and requires them to be cleared through the 510(k)&#160;premarket notification process prior to marketing. The FDA&#8217;s premarket review process for new and modified existing devices that precedes product marketing can be time consuming and expensive. Some of the future products and enhancements to such products that Axogen expects to develop and market may require marketing clearance or approval from the FDA.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">There can be no assurance, however, that clearance or approval will be granted with respect to any of Axogen&#8217;s device products or enhancements of marketed products or that Axogen&#8217;s Avance Nerve Graft will meet FDA&#8217;s requirements for continued marketing and transition to a BLA or ultimately an approved BLA.  FDA review of Axogen&#8217;s devices or biological products may encounter significant delays during FDA&#8217;s premarket review process that would adversely affect Axogen&#8217;s ability to market its products or enhancements. In addition, there can be no assurance that Axogen products, including the Avance Nerve Graft, or enhancements will not be subject to a lengthy and expensive approval process with the FDA.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">It is possible that if regulatory clearances or approvals to market a product are obtained from the FDA, the clearances or approvals may contain limitations on the indicated uses of such product and other uses may be prohibited. Product approvals by the FDA can also be withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial approval. Furthermore, the FDA could limit or prevent the distribution of Axogen products, and the FDA has the power to require the recall of such products. FDA regulations depend heavily on administrative interpretation, and there can be no assurance that future interpretations made by the FDA or other regulatory bodies will not adversely affect Axogen&#8217;s operations. Axogen, and its facilities, may be inspected by the FDA from time to time to determine whether it is in compliance with various regulations relating to specifications, development, documentation, validation, testing, quality control and product labeling. A determination that Axogen is in violation of such regulations could lead to imposition of civil penalties, including fines, product recalls or product seizures and, in certain cases, criminal sanctions.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The use, misuse or off-label use of Axogen&#8217;s products may harm its reputation or the image of its products in the marketplace, or result in injuries that lead to product liability suits, which could be costly to Axogen&#8217;s business or result in FDA sanctions if the company is deemed to have engaged in off-label promotion. Axogen is seeking a biologics license through the BLA process for specific uses of Avance Nerve Graft under specific circumstances. Its promotional materials and training methods must comply with FDA requirements and other applicable laws and regulations, including the prohibition against off-label promotion. Axogen&#8217;s promotion of the Axoguard products, which are regulated as medical devices, also must comply with FDA&#8217;s requirements and must only use labeling that is consistent with the specific indication(s)&#160;for use included in the FDA substantial equivalence order that results in marketing the devices. Avive Soft Tissue Membrane<span style="font-size:12pt;"> </span><span style="white-space:pre-wrap;">is processed and distributed in accordance with FDA requirements for (HCT/P) under 21 CFR Part 1271 regulations and is to be dispensed only by or on the order of a licensed physician and is contraindicated for use in any patient in whom soft tissue implants are contraindicated.  The FDA does not restrict or regulate a physician&#8217;s use of a medical product within the practice of medicine, and Axogen cannot prevent a physician from using its products for an off-label use. However, the FD&amp;C Act and the FDA&#8217;s regulations restrict the kind of promotional communications that may be made about Axogen&#8217;s products and if the FDA determines that Axogen&#8217;s promotional or training materials constitute the unlawful promotion of an off-label use, it could request that Axogen modify its training or promotional materials and/or subject the Company to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, civil money penalties, seizure, injunction or criminal fines and penalties. Other federal, state or foreign governmental authorities might also take action if they consider Axogen promotion or training materials to constitute promotion of an uncleared or unapproved use, which could result in </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement, or exclusion from participation in federal health programs. In that event, Axogen&#8217;s reputation could be damaged and the use of its products in the marketplace could be impaired.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, there may be increased risk of injury if physicians or others attempt to use Axogen products off-label. Furthermore, the use of Axogen&#8217;s product for indications other than those for which its products have been approved, cleared or licensed by the FDA may not effectively treat the conditions not referenced in product indications, which could harm Axogen&#8217;s reputation in the marketplace among physicians and patients. Physicians may also misuse Axogen&#8217;s product or use improper techniques if they are not adequately trained in the particular use, potentially leading to injury and an increased risk of product liability. Product liability claims are expensive to defend and could divert management&#8217;s attention from its primary business and result in substantial damage awards against Axogen. Any of these events could harm Axogen&#8217;s business, results of operations and financial condition.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s Avance Nerve Graft product is currently allowed to be distributed pursuant to a transition plan with the FDA and a change in position by the FDA regarding its use of enforcement discretion to permit the sale of Avance Nerve Graft would have a material adverse effect on Axogen.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA considers Axogen&#8217;s Avance Nerve Graft product to be a biological product, subject to BLA approval requirements. Although the Avance Nerve Graft product has not yet been approved by FDA through a BLA, Axogen&#8217;s Avance Nerve Graft product is currently distributed under the controls applicable to a HCT/P pursuant to Section 361 of the Public Health Service Act and 21 CFR Part&#160;<span style="white-space:pre-wrap;">1271 of FDA&#8217;s regulations, subject to FDA&#8217;s enforcement discretion and Axogen&#8217;s compliance with a transition plan established by the FDA.  See &#8220;Business &#8212; Government Regulations &#8212; U.S. Government Regulation Review.&#8221;  Axogen has continued to communicate with the  CBER since the acceptance of the transition plan on clinical trial design, preclinical studies, Chemistry, Manufacturing, and Controls (&#8220;CMC&#8221;) for Avance Nerve Graft, and other issues related to the effective IND.  Subject to the FDA&#8217;s enforcement discretion, Axogen can commercially distribute Avance Nerve Graft until the FDA makes a final determination on an Avance Nerve Graft BLA submission, assuming Axogen remains in compliance with the transition plan and exercises due diligence in executing the transition plan. In the event that the FDA becomes dissatisfied with Axogen&#8217;s progress or actions with respect to the transition plan or the FDA changes its position for any reason regarding its use of enforcement discretion to permit Axogen to distribute Avance Nerve Graft product in accordance with the transition plan, Axogen would no longer be able to distribute Avance Nerve Graft, which would have a material adverse effect on Axogen&#8217;s operations and financial viability. In addition, if Axogen does not meet the conditions of the transition plan, or fails to comply with applicable regulatory requirements, the FDA could impose civil penalties, including fines, product seizures, injunctions or product recalls and, in certain cases, criminal sanctions.  These consequences also would have a material adverse effect on Axogen&#8217;s operations and financial viability.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s business is subject to continuing compliance to standards by various accreditation and registration bodies which is costly, and loss of accreditation or registration could result in negative effects on its business.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is subject to accreditation such as that by the AATB and as a Verified-Accredited Wholesale Distributor by National Association of Boards of Pharmacy.  Axogen has registration requirements such as that with ISO 13485 registration bodies.  These accreditations and regulations can affect distribution and sale of Axogen products on a state-by-state basis, within the United States and also affects distribution and sale of Axogen products outside of the United States. The loss of accreditation or registration could keep Axogen from selling and distributing its products which may have negative effects on its business.    </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s Axoguard and Avive products are subject to FDA and other regulatory requirements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s Axoguard product line is regulated as a medical device under the FD&amp;C Act and subject to premarket notification and clearance requirements under section 510(k)&#160;of the FD&amp;C Act, 21 CFR Part&#160;820 (Quality System Regulation) and other FDA regulations. Axogen distributes for Cook Biotech Axoguard Nerve Connector and Axoguard Protector products and Cook Biotech is responsible for the regulatory compliance of these products. Cook Biotech has obtained a 510(k)&#160;premarket clearance for Axoguard Nerve Connector from the FDA for porcine (pig) small intestine submucosa for the repair of peripheral nerve transections where gap closure can be achieved by flexion of the extremity. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cook Biotech has also obtained a 510(k)&#160;<span style="white-space:pre-wrap;">premarket clearance for Axoguard Nerve Protector for the repair of peripheral nerve damage in which there is no gap or where a gap closure is achieved by flexion of the extremity.  Axogen is responsible for the regulatory compliance of the Axoguard Nerve Cap.  Axogen has obtained a 510(k) premarket clearance for Axoguard Nerve Cap to protect a peripheral nerve end and separate the nerve from the surrounding environment and to prevent or to reduce the development of symptomatic or painful neuroma.  If Axogen or Cook Biotech fails to comply with applicable regulatory requirements, the FDA could deny or withdraw 510(k)&#160;clearance for the Axoguard products, or impose civil penalties, including fines, product seizures or product recalls and, in certain cases, criminal sanctions.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Avive Soft Tissue Membrane is processed and distributed in accordance with U.S. FDA requirements for Human Cellular and Tissue-based Products (361 HCT/P) and as such, complies with 21 CFR Part 1271 regulations, U.S. State regulations and the guidelines of the American Association of Tissue Banks (&#8220;AATB&#8221;).  FDA could determine that Avive Soft Tissue Membrane should be regulated under Section 351 of the Public Health Service Act and cannot be marketed without a BLA.&#160; If so, FDA could take enforcement action including requiring that Axogen remove the product from the market until a BLA is approved.&#160; If Axogen fails to comply with applicable regulatory requirements, the FDA could also impose civil penalties, including fines, product seizures or product recalls and, in certain cases, criminal sanctions.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s Axotouch product is subject to FDA and other regulatory requirements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s Axotouch product is regulated as a medical device under the FD&amp;C Act and subject to premarket notification and clearance requirements under section 510(k)&#160;of the FD&amp;C Act, 21 CFR Part&#160;<span style="white-space:pre-wrap;">820 (Quality System Regulation) and other FDA regulations.  If Axogen fails to comply with applicable regulatory requirements, the FDA could deny or withdraw 510(k)&#160;clearance for the product, or impose civil penalties, including fines, product seizures or product recalls and, in certain cases, criminal sanctions.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Defective Axogen product could lead to recall or other negative business conditions.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">If Axogen&#8217;s products are defective or otherwise pose safety risks, the FDA could require their recall or Axogen may initiate a voluntary recall of its products. The FDA may require recall of a marketed medical device product, such as the Axoguard products, in the event that it determines the medical device presents a reasonable probability of serious adverse health consequences or death. However, most device recalls do not rise to this level of health significance and result from voluntary action. The FDA has authority to recall biological products when a batch, lot or other quantity of the product presents an imminent or substantial hazard to the public health.  However, in such circumstances, the FDA usually initially requests voluntary recalls of biological products, such as the Avance Nerve Graft. If a company does not comply with an FDA request for a recall, the FDA can order one under the above-referenced circumstances or take other enforcement actions, such as product seizure. In addition, manufacturers may, on their own initiative, recall a product to remove or correct a deficiency or to remedy a violation of the FD&amp;C Act that may pose a risk to health. A government-mandated, government-requested or voluntary recall could occur as a result of an unacceptable risk to health, reports of safety issues, failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls and other field corrections for any of Axogen&#8217;s products would divert managerial and financial resources and have an adverse effect on its business, results of operations and financial condition. A recall could harm Axogen&#8217;s reputation with customers and negatively affect its sales. Axogen may initiate recalls involving some of its products in the future that it determines do not require notification of the FDA. If the FDA were to disagree with Axogen&#8217;s determinations, it could request that it report those actions as recalls, and take regulatory or enforcement action against Axogen or the product.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">If Axogen&#8217;s products cause or contribute to a death, a serious injury or any adverse reaction involving a communicable disease related to its products, or malfunction in certain ways, it will be subject to reporting regulations, which can result in voluntary corrective actions or agency enforcement actions. See &#8220;Business &#8212; Regulation &#8212; Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws &#8212; Pervasive and False Claims.&#8221;  If Axogen fails to report these events to the FDA within the required timeframes, or at all, the FDA could take regulatory or enforcement action against Axogen. Any adverse event involving Axogen&#8217;s products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection, mandatory recall or other enforcement action. Any corrective action, whether voluntary or involuntary, as </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">well as Axogen defending itself in a lawsuit, would require the dedication of time and capital, distract management from operating its business, and may harm Axogen&#8217;s reputation, business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen&#8217;s operations must comply with FDA and other governmental requirements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s operations require it to comply with the FDA&#8217;s and other governmental authorities&#8217; laws and regulations regarding the manufacture and production of medical products, which is costly and could subject Axogen to enforcement action. See &#8220;Business &#8212; Government Regulations &#8212; Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws &#8212; Fraud, Abuse and False Claims&#8221;. Any of these actions could impair Axogen&#8217;s ability to produce its products in a cost-effective and timely manner in order to meet customer demands. Axogen may also be required to bear other costs or take other actions that may have an adverse impact on its future revenue and its ability to generate profits. Furthermore, Axogen&#8217;s key material suppliers, licensors and or other contractors may not continue to be in compliance with all applicable regulatory requirements, which could result in Axogen&#8217;s failure to produce its products on a timely basis and in the required quantities, if at all.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Distribution of Axogen human tissue products outside the U.S. are subject to foreign regulatory requirements that vary from country to country. In the European Union (&#8220;E.U.&#8221;), human tissue regulations, if applicable, differ from one E.U. member state to the next. Because of the absence of a harmonized regulatory framework and the proposed regulation for advanced therapy medicinal products in the E.U., as well as for other countries, the approval process for human derived cell or tissue based medical products may be extensive, lengthy, expensive and unpredictable. Axogen products are subject to E.U. member states&#8217; regulations that govern the donation, procurement, testing, coding, traceability, processing, preservation, storage, and distribution of human tissues and cells and cellular or tissue-based products. In addition, some E.U. member states have their own tissue banking regulations. The inability to meet foreign regulatory requirements could materially affect Axogen&#8217;s future growth and compliance with such requirements could place a significant financial burden on Axogen.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In addition, the United Kingdom exited the E.U. (&#8220;Brexit&#8221;) and Axogen cannot be sure what changes could occur or  the cost of regulatory compliance with both the United Kingdom and E.U.  Until such time as Axogen can obtain, if at all, the necessary registrations and approvals for its products, material expansion beyond the United States will be limited.  Finally, the cost of regulatory compliance for sales outside the U.S. can be significant and time consuming.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Finally, regulations in both the United States and other countries are subject to constant change.  There can be no assurance that Axogen can meet the requirements of future regulations or that compliance with current regulations assures future capability to distribute and sell its products.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials can be long, expensive and results are ultimately uncertain which could jeopardize Axogen&#8217;s ability to obtain regulatory approval and continue to market its Avance Nerve Graft product.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen is required to perform a clinical trial for its Avance Nerve Graft under FDA&#8217;s statutory requirements to obtain approval of a BLA for the product. This trial is expensive, is expected to take several years to execute, and is subject to factors within and outside of Axogen&#8217;s control. The outcome of this trial is uncertain.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen submitted an IND for the RECON study of Avance Nerve Graft in April 2013 and received FDA approval in March 2015.   The phase 3 clinical trial was initiated in the second quarter of 2015. The RECON study is designed to assess the outcome of peripheral nerve repair in approximately 170 subjects in up to 20 centers. The study completed initial subject enrollment in January 2019.  No outcome data is available at this time.  As required by the SPA and agreed to by FDA and Axogen, an independent statistical analysis was conducted to determine if greater study enrollment was appropriate to maintain the planned statistical power of the study. Based on the results of this analysis, the study&#39;s independent biostatistician recommended continuation of the study with a one-time expansion in enrollment according to a pre-defined sample size re-estimation.  The recommendation was reviewed with the FDA, and, on April 19, 2019, the FDA provided the company with a Revised Special Protocol Assessment Agreement which confirmed the expanded sample size and allowed the study enrollment target to be increased by 50 subjects, to a total target of 220 subjects. Axogen may add up to five new study centers, for a total of 25 centers, to support enrollment and currently has </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">125 centers engaged. Axogen restarted enrollment of subjects and expects to complete enrollment during the summer of 2020 no later than the end of second quarter 2020.    </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen is working to ensure compliance with the applicable regulations by having ongoing discussions on the transition of the quality system to 21 CFR Parts 210/211 and 600-610 regulations with the FDA. Final determination of regulatory compliance with 21 CFR Parts 210/211 and 600-610 will be made during FDA&#8217;s pre-license inspection as part of the BLA review. If the FDA is unable to agree with Axogen, or Axogen is unable to meet the standards required of it by the FDA, regarding preclinical studies, clinical studies and CMC, the approval of Axogen&#8217;s BLA would not occur or be delayed.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen continues to work diligently with the FDA and, in this context, continues to distribute the Avance Nerve Graft products.  The FDA will end the period of enforcement discretion upon a final determination of Axogen&#8217;s BLA submission or if the FDA finds that Axogen does not meet the conditions for the transition plan or is not exercising due diligence in executing the transition (e.g., not progressing toward study completion or BLA submission in a timely or adequate fashion).  If final action on the BLA is negative or Axogen is found to not meet the conditions for the transition plan or its execution, Axogen will not be able to continue to distribute Avance Nerve Graft, and Axogen&#8217;s business and financial condition will be materially adversely affected.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The results of non-clinical studies do not necessarily predict future clinical trial results and predecessor clinical trial results may not be repeated in subsequent clinical trials. Additionally, the FDA may disagree with Axogen&#8217;s interpretation of the data from its non-clinical studies and clinical trials and may require the company to pursue additional non-clinical studies or clinical trials, or not approve Axogen&#8217;s BLA. If Axogen is unable to demonstrate the safety and efficacy of its product through its clinical trials, it will be unable to obtain regulatory approval to market the Avance Nerve Graft and will not be able to continue to provide it.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen will rely on third parties to conduct its clinical trial and they may not perform as contractually required or expected.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen will rely on third parties, such as contract research organizations (&#8220;CROs&#8221;), medical institutions, clinical investigators and contract laboratories to conduct its clinical trial and certain nonclinical studies. Axogen and its CROs are required to comply with all applicable regulations governing clinical research, including good clinical practice, or GCP. The FDA enforces these regulations through periodic inspections of trial sponsors, principal investigators, CROs and trial sites. If Axogen or its CROs fail to comply with applicable FDA regulations, the data generated in its clinical trials may be deemed unreliable and the FDA may require Axogen to perform additional clinical trials before approving its applications. Axogen cannot be certain that, upon inspection, the FDA and similar foreign regulatory authorities will determine that Axogen&#8217;s clinical trial complies or complied with clinical trial regulations, including GCP. In addition, Axogen&#8217;s clinical trial must be conducted with product produced under applicable cGMP regulations. Failure to comply with the clinical trial regulations may require Axogen to repeat clinical trials, which would delay the regulatory approval process. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to Axogen&#8217;s clinical protocols or regulatory requirements or for other reasons, Axogen&#8217;s non-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and it would not be able to obtain regulatory approval for its products on a timely basis, if at all, and its business, results of operations, financial condition and growth prospects would be adversely affected. Furthermore, Axogen&#8217;s third party clinical trial investigators may be delayed in conducting its clinical trials for reasons outside of their control.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">U.S. governmental regulation could restrict the use of Axogen&#8217;s Avance Nerve Graft and Avive Soft Tissue Membrane product, restrict Axogen&#8217;s procurement of tissue or increase costs.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to the FDA requirements for biological products, Avance Nerve Graft will continue to be subject to, as is Avive Soft Tissue Membrane, various requirements for human tissue under 21 CFR Part&#160;1271 controls. Human tissues intended for transplantation have been regulated by the FDA since 1993. In May&#160;2005, three new comprehensive regulations went into effect that address manufacturing activities associated with HCT/P. The first regulation requires that companies that produce and distribute HCT/Ps register with the FDA. The second regulation provides criteria that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">must be met for donors to be eligible to donate tissues and is referred to as the &#8220;Donor Eligibility&#8221; rule. The third regulation&#160;governs the processing and distribution of the tissues and is often referred to as the &#8220;Current Good Tissue Practices&#8221; rule. The Current Good Tissue Practices rule&#160;covers all stages of allograft processing, from procurement of tissue to distribution of final allografts. Together, the three basic requirements of 21 CFR Part&#160;<span style="white-space:pre-wrap;">1271 are designed to ensure that sound, high quality practices are followed to reduce the risk of tissue contamination and of communicable disease transmission to recipients. These regulations increased regulatory scrutiny within the industry in which Axogen operates and have led to increased enforcement actions, which affects the conduct of its business.  In addition, new guidance was issued by the FDA in late 2017 on Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use which could have potential implications on the regulatory status of Avive and future HCT/P products is being evaluated by the Company.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;"> Additional regulations or guidance documents may be implemented by the FDA in the future.  These changes may require new documentation requirements, process changes or testing that could increase costs and regulatory burden.  See &#8220;Business &#8212; Government Regulations.&#8221;  These regulations can also increase the cost of tissue recovery activities. Finally, Avance Nerve Graft and Avive Soft Tissue Membrane are subject to certain state and local regulations, as well as compliance with the standards of the tissue bank industry&#8217;s accrediting organization, the AATB.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The procurement and transplantation of allograft nerve tissue is also subject to federal law pursuant to the National Organ Transplant Act (&#8220;NOTA&#8221;), a criminal statute which prohibits the purchase and sale of human organs used in human transplantation, including nerve and related tissue, for &#8220;valuable consideration.&#8221; NOTA only permits reasonable payments associated with the removal, transportation, processing, preservation, quality control, implantation and storage of human nerve tissue. Axogen makes payments to certain of its clients and tissue banks for their services related to recovering allograft nerve and umbilical cord tissue on its behalf. If NOTA is interpreted or enforced in a manner which prevents Axogen from receiving payment for services it renders, or which prevents it from paying tissue banks or certain of its clients for the services they render for Axogen, its business could be materially and adversely affected.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen has engaged, through its marketing employees, independent sales agents and sales representatives in ongoing efforts designed to educate the medical community as to the benefits of Axogen products, and Axogen intends to continue its educational activities. Although Axogen believes that NOTA permits payments in connection with these educational efforts as reasonable payments associated with the processing, transportation and implantation of Axogen products, payments in connection with such education efforts are not exempt from NOTA&#8217;s restrictions and Axogen&#8217;s inability to make such payments in connection with its education efforts may prevent it from paying Axogen sales representatives for their education efforts and could adversely affect Axogen&#8217;s business and prospects. No federal agency or court has determined whether NOTA is, or will be, applicable to every allograft nerve tissue-based material which Axogen&#8217;s processing technologies may generate. Assuming that NOTA applies to Axogen&#8217;s processing of allograft nerve and umbilical cord tissue, Axogen believes that it complies with NOTA, but there can be no assurance that more restrictive interpretations of, or amendments to, NOTA will not be adopted in the future, which would call into question one or more aspects of Axogen&#8217;s method of operations.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Other regulatory entities include state agencies with statutes covering tissue banking. Regulations issued by Florida, New York, California and Maryland, among other states, are particularly relevant to Axogen&#8217;s business. Most states do not currently have tissue banking regulations. However, incidents of allograft related issues in the industry may stimulate the development of regulation in other states. It is possible that third parties may make allegations against Axogen or against donor recovery groups or tissue banks about non-compliance with applicable FDA regulations or other relevant statutes or regulations. Allegations like these could cause regulators or other authorities to take investigative or other action, or could cause negative publicity for Axogen&#8217;s business and the industry in which it operates.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare policy changes may have a material adverse effect on Axogen.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In March&#160;2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (the &#8220;Act&#8221;), which Act substantially changes the way healthcare is financed by both governmental and private insurers, and encourages improvements in the quality of healthcare items and services. While implementation of the Act has been uneven, several provisions significantly impact </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">the biotechnology and medical device industries and could have a material adverse impact on numerous aspects of Axogen&#8217;s business.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">This Act includes, among other things, the following measures:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities and conduct comparative clinical effectiveness research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">reporting and disclosure requirements on healthcare manufacturers for any &#8220;transfer of value&#8221; made or distributed to physicians and teaching hospitals, as well as reporting of certain physician ownership interests (&#8220;Sunshine Act&#8221;); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">payment system reforms, including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a new abbreviated pathway for the licensure of biologic products that are demonstrated to be biosimilar or biosimilar and interchangeable with a licensed biologic product.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">There are also a number of states (such as Vermont, Massachusetts, Minnesota) with their own Sunshine Acts-type reporting and disclosure requirements on healthcare manufacturers for any &#8220;transfer of value&#8221; made or distributed to physicians and teaching hospitals, as well as reporting of certain physician ownership interests, for applicable entities within that state.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In the future, there may continue to be additional proposals relating to the reform of the U.S. healthcare system. Certain of these proposals could limit the prices Axogen is able to charge for its products or the amounts of reimbursement available for its products and could also limit the acceptance and availability of its products. The adoption of some or all of these proposals could have a material adverse effect on Axogen&#8217;s business, results of operations and financial condition.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, initiatives sponsored by government agencies, legislative bodies and the private sector in the U.S. and elsewhere to limit the growth of healthcare costs, especially for drugs and biologics, including price regulation and competitive pricing, are ongoing in markets where Axogen does business. Axogen could experience an adverse impact on operating results due to increased pricing pressure in the U.S. and in other markets. Governments, hospitals, pharmacy benefit managers (PBMs) and other third-party payors could reduce the amount of approved reimbursement for Axogen&#8217;s products, deny coverage altogether, or impose new requirements on manufacturers to justify their prices. Reductions in reimbursement levels or coverage or other cost-containment measures could unfavorably affect Axogen&#8217;s future operating results.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Axogen&#8217;s Intellectual Property</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Failure to protect Axogen&#8217;s IP rights could result in costly and time-consuming litigation and its loss of any potential competitive advantage.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s success will depend, to a large extent, on its ability to successfully obtain and maintain patents, prevent misappropriation or infringement of IP, maintain trade secret protection, and conduct operations without violating or infringing on the IP rights of third parties. See &#8220;Business &#8212; Intellectual Property.&#8221; There can be no assurance that Axogen&#8217;s patented and patent-pending technologies will provide it with a competitive advantage, that Axogen will be able to develop or acquire additional technology that is patentable, or that third parties will not develop and offer technologies which are similar to Axogen&#8217;s. Moreover, Axogen can provide no assurance that confidentiality agreements with its employees, consultants and other parties, agreements to protect trade secrets or similar agreements intended to protect unpatented technology or prevent unauthorized use, disclosure, or misappropriation will not be breached by those third parties. IP litigation is extremely expensive and time-consuming, and it is often difficult, if not impossible, to predict the outcome of such litigation. A failure by Axogen to protect its IP, or a breach by third parties of agreements aimed at protecting Axogen&#8217;s IP, could have a materially adverse effect on its business and operating results and its ability to successfully compete in its industry.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Future protection for Axogen&#8217;s proprietary rights is uncertain, and may impact its ability to successfully compete in its industry.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The degree of future protection for Axogen&#8217;s proprietary rights is uncertain. Axogen cannot ensure that:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">it, or its licensors, were the first to make the inventions covered by each of Axogen&#8217;s patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">it, or its licensors, were the first to file patent applications for these inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">others will not independently develop similar or alternative technologies or duplicate any of Axogen&#8217;s technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">any of Axogen&#8217;s pending patent applications will result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">any of Axogen&#8217;s issued patents or those of its licensors are valid and enforceable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">any patents issued to Axogen or its collaborators will provide any competitive advantages or will not be challenged by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">it will develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the patents of others will not have a material adverse effect on our business rights; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the measures Axogen relies on to protect its IP underlying its products are adequate to prevent third parties from using, disclosing or misappropriating that IP, all of which could harm its ability to compete in the market.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s commercial success depends in part on its ability and the ability of its collaborators and licensors to avoid infringing patents and proprietary rights of third parties which could expose it to litigation or commercially unfavorable licensing arrangements. Third parties may accuse Axogen or collaborators and licensors of employing their proprietary technology in Axogen products, or in the materials or processes used to make Axogen products, without authorization. Any legal action against Axogen collaborators, licensors or it claiming damages and/or seeking to enjoin Axogen&#8217;s commercial activities relating to the affected products, materials and processes could, in addition to subjecting Axogen to potential liability for damages, require it or its collaborators and licensors to obtain a license to continue to utilize the affected materials or processes or to manufacture or market the affected products. Axogen cannot predict whether it or its collaborators and licensors would prevail in any of these actions or whether any license required under any of these patents would be made available on commercially reasonable terms, if at all. If Axogen were unable to obtain such a license, it and its collaborators and licensors may be unable to continue to utilize the affected materials or processes, or manufacture or market the affected products, or Axogen may be obligated by a court to pay substantial royalties and/or other damages to the patent holder. Even if Axogen were able to obtain such a license, the terms of such a license could substantially reduce the commercial value of the affected product or products and impair Axogen&#8217;s prospects for profitability. Accordingly, Axogen cannot predict whether, or to what extent, the commercial value of the affected product or products or Axogen&#8217;s prospects for profitability may be harmed as a result of any of the liabilities discussed above. Furthermore, infringement and other IP claims, with or without merit, can be expensive and time-consuming to litigate and can divert management&#8217;s attention from its core business. Axogen and its licensors may be unable to obtain and enforce IP rights to adequately protect its products and related IP.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The patent protection for our products may expire before we are able to maximize their commercial value which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The patents for our commercialized products and products in development have varying expiration dates and, when these patents expire, we may be subject to increased competition and we may not be able to recover our development costs. For example, the material U.S. patents covering the formulations used in our Axoguard product line, which are held by Cook Biotech, have expired.  Expiration of these patents could adversely affect our ability to successfully execute our business strategy to maximize the value of Axoguard products and could negatively impact our future financial condition and results of operations.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Others may claim an ownership interest in Axogen IP which could expose it to litigation and have a significant adverse effect on its prospects.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A third party may claim an ownership interest in one or more of Axogen&#8217;s patents or other IP. A third party could bring legal actions against Axogen claiming it infringes their patents or proprietary rights, and seek monetary damages </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">and/or enjoin clinical testing, manufacturing and marketing of the affected product or products. While Axogen believes it owns the right, title and interest in the patents for which it or its licensors have applied and Axogen&#8217;s other IP (including that which is licensed from third parties), and is presently unaware of any claims or assertions by third-parties with respect to Axogen&#8217;s patents or IP, it cannot guarantee that a third party will not assert a claim or an interest in any of such patents or IP. If Axogen becomes involved in any litigation, it could consume a substantial portion of Axogen&#8217;s resources and cause a significant diversion of effort by Axogen&#8217;s technical and management personnel regardless of the outcome of the litigation. If any of these actions were successful, in addition to any potential liability for damages, Axogen could be required to obtain a license to continue to manufacture or market the affected product, in which case Axogen may be required to pay substantial royalties or grant cross-licenses to Axogen&#8217;s patents. Axogen cannot, however, assure that any such license will be available on acceptable terms, if at all. Ultimately, Axogen could be prevented from commercializing a product or be forced to cease some aspect of its business operations as a result of claims of patent infringement or violation of other IP rights, which could have a material and adverse effect on Axogen&#8217;s business, financial condition, and results of operations. Further, the outcome of IP litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of the adverse party. This is especially true in IP cases that may turn on the testimony of experts as to technical facts or the scope or meaning of patent claims upon which experts may reasonably disagree.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen depends on maintenance of exclusive licenses.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen depends fundamentally on keeping and satisfying the terms of exclusive licenses of its nerve repair technologies from UFRF and UTA. Nonetheless, a disagreement between Axogen and either licensor could have a negative impact on its ability to operate its business effectively. In addition, Axogen could learn that the technologies it has licensed do not perform as purported, are not efficacious, or are not the property of the licensor, any of which would have an immediate and negative impact on Axogen&#8217;s business.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Axogen trademarks are valuable</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In the U.S. and other countries, we currently hold trademark registrations and have trademark applications pending, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the same. As our products mature, our reliance on our trademarks to protect our brand and, in part, differentiate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting, registering or using trademarks, including trade dress, that infringe, dilute or otherwise violate our trademark rights, our business could be materially adversely affected.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">An active trading market in our common stock may not be maintained.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The trading market in our common stock has been extremely volatile. The quotation of our common stock on The Nasdaq Capital Market does not assure that a meaningful, consistent and liquid trading market will exist. We cannot predict whether an active market for our common stock will be maintained in the future. An absence of an active trading market could adversely affect our shareholders&#8217; ability to sell our common stock at current market prices in short time periods, or possibly at all. Additionally, market visibility for our common stock may be limited and such lack of visibility may have a depressive effect on the market price for our common stock. As of December 31, 2019, approximately 41.4% of our outstanding shares of common stock was held by our officers, directors, beneficial owners of 5% or more of our securities and their respective affiliates, which adversely affects the liquidity of the trading market for our common stock, in as much as federal securities laws restrict sales of our shares by these shareholders. If our affiliates continue to hold their shares of common stock, there will be limited trading volume in our common stock, which may make it more difficult for investors to sell their shares or increase the volatility of our stock price.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The price of Axogen&#8217;s common stock could be highly volatile due to a number of factors, which could lead to losses by investors and costly securities litigation.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;AXGN.&#8221;  The stock market in general, and the market for medical technology companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies.  The trading price of our common stock has experienced substantial volatility and is likely to continue to be highly volatile in response to a number of factors including, without limitation, the following:</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">fluctuations in price and volume due to investor speculation and other factors that may not be tied to the financial performance of Axogen;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">performance by Axogen in the execution of its business plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">financial viability; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">actual or anticipated variations in our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">announcements of developments by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">market conditions in our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">adoption of new accounting standards affecting our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">introduction of new products by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">sales of our common stock or other securities in the open market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">regulatory developments in both the United States and foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">performance of products sold and advertised by licensees in the marketplace;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">economic and other external factors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">period-to-period fluctuations in financial results; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">other events or factors, including the other factors described in this &#8220;Risk Factors&#8221; section, many of which are beyond our control.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The stock market is subject to significant price and volume fluctuations. In the past, and several recent situations, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has been initiated against such company. Axogen has experienced such situation and is subject to a class action.  Litigation initiated against us, including that which we are currently involved, whether or not successful, could result in substantial costs and diversion of our management&#8217;s attention and resources, which could harm our business and financial condition.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk32528925"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On January 9, 2019, Plaintiff Neil Einhorn, on behalf of himself and others similarly situated, filed a putative class action complaint alleging violations of the federal securities laws against Axogen, Inc., certain of its directors and officers (&#8220;Individual Defendants&#8221;), and Axogen&#8217;s 2017 Offering Underwriters and 2018 Offering Underwriters (collectively, with the Individual Defendants, the &#8220;Defendants&#8221;), captioned Einhorn v. Axogen, Inc., et al., No. 8:19-cv-00069 (M.D. Fl.).  Plaintiff asserts that Defendants made false or misleading statements in connection with the Company&#8217;s November 2017 registration statement issued regarding its secondary public offering in November 2017 and May 2018 registration statement issued regarding its secondary public offering in May 2018, and during a class period of August 7, 2017 to December 18, 2018.   In particular, Plaintiff asserts that Defendants issued false and misleading statements and failed to disclose to investors: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company&#8217;s pricing alienated customers and threatened the Company&#8217;s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company&#8217;s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company&#8217;s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company&#8217;s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company&#8217;s key operating metrics, such as number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.  Axogen was served on January 15, 2019.  </span>On February 4, 2019, the court granted the parties&#8217; stipulated motion which provided that Axogen is not required to file a response to the complaint until <span style="font-size:12pt;">thirty days</span>&#160;after Plaintiff files a consolidated amended complaint.<span style="font-size:12pt;">&#160;</span>On June 19, 2019, Plaintiff filed an Amended Class Action Complaint, and on July 22, 2019, Defendants filed a motion to dismiss. Plaintiff filed opposing papers on August 12, 2019. The Court held a status hearing on September 11, 2019 and stayed all deadlines regarding the parties&#8217; obligations to file a case management report. On December 4, 2019 the parties&#8217; presented oral arguments and are currently awaiting the court&#8217;s ruling.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We do not anticipate paying any cash dividends in the foreseeable future.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The operation and expansion of our business will continue to require funding. We do not anticipate that we will pay any cash dividends on our common stock for the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our Board of Directors and will depend upon results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant. Accordingly, if any investor purchases shares of common stock, realization of a gain on such investment will depend on the appreciation of the price of our common stock, which may never occur. Investors seeking cash dividends in the foreseeable future should not purchase our common stock.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Anti-takeover provisions in Minnesota law may deter acquisition bids for us that you might consider favorable.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">We are governed by the provisions of Sections 302A.671, 302A.673 and 302A.675 of the Minnesota Business Corporation Act (the &#8220;MBCA&#8221;). These provisions may discourage a negotiated acquisition or unsolicited takeover of us and deprive our shareholders of an opportunity to sell their common stock at a premium over the market price.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In general, Section&#160;302A.671 of the MBCA provides that a corporation&#8217;s shares acquired in a control share acquisition have no voting rights unless voting rights are approved in a prescribed manner. A &#8220;control share acquisition&#8221; is a direct or indirect acquisition of beneficial ownership of shares that would, when added to all other shares beneficially owned by the acquiring person, entitle the acquiring person to have voting power of 20% or more in the election of directors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In general, Section&#160;302A.673 of the MBCA prohibits a public Minnesota corporation from engaging in a business combination with an interested shareholder for a period of four years after the date of the transaction in which the person became an interested shareholder, unless the business combination is approved in a prescribed manner. The term &#8220;business combination&#8221; includes mergers, asset sales and other transactions resulting in a financial benefit to the interested shareholder. An &#8220;interested shareholder&#8221; is a person who is the beneficial owner, directly or indirectly, of 10% or more of a corporation&#8217;s voting stock or who is an affiliate or associate of the corporation, and who, at any time within four years before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the corporation&#8217;s voting stock. Section&#160;302A.673 does not apply if a committee of our Board of Directors consisting of all of its disinterested directors (excluding current and former officers) approves the proposed transaction or the interested shareholder&#8217;s acquisition of shares before the interested shareholder becomes an interested shareholder.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">If a tender offer is made for our common stock, Section&#160;302A.675 of the MBCA precludes the offeror from acquiring additional shares of stock (including in acquisitions pursuant to mergers, consolidations or statutory share exchanges) within two years following the completion of the tender offer, unless shareholders selling their shares in the later acquisition are given the opportunity to sell their shares on terms that are substantially the same as those contained in the earlier tender offer. Section&#160;302A.675 does not apply if a committee of our Board of Directors consisting of all of its disinterested directors (excluding its current and former officers) approves the proposed acquisition before any shares are acquired pursuant to the earlier tender offer.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_7d682dbe_5ec5_47f9_bd06_171202310dad"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_234630"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 1B.  UNRESOLVED STAFF COMMENT</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">S</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_c91738fb_fb08_4c0d_af4a_051893efb847"></a><a id="ITEM2PROPERTIES_591651"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 2.  PROPERTIE</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">S </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company and SNH Medical Office Properties Trust, a Maryland real estate investment trust (&#8220;SNH&#8221;), are parties to that certain lease dated as of February 6, 2007, as amended, (the &#8220;Primary Lease&#8221;) pursuant to which the Company leases its approximately nineteen thousand square foot corporate headquarters facility in the Progress Center at 13631 Progress Boulevard, Alachua, Florida 32615 (the &#8220;Primary Premises&#8221;). The annual cost for the Primary Premises ranges from approximately $353 to $363 through the end of the term of the lease, which expires on October 31, 2021.  On January 23, 2017 the Company entered into a lease (the &#8220;First Expansion Lease&#8221;) with SNH for one thousand four hundred square feet at 13709 Progress Boulevard, Alachua, Florida 32615 (this property was purchased by Nucleic Acids Licensing, LLC in February 2019) (the &#8220;First Expansion Premises&#8221;) adjacent to the Primary Premises.  The Company has entered into the Second Expansion Lease and Third Expansion Lease, as defined below, which relate to properties that are adjacent to the Primary Premises and First Expansion Premises resulting in the Company having approximately eighteen thousand square feet for its corporate headquarters and certain research space in the Progress Center in Alachua, Florida.  </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On November 19, 2018, the Company entered into a Lease (the &#8220;Second Expansion Lease&#8221;) with SNH for two thousand eight hundred square feet at 13709 Progress Boulevard, Suites S-160, S-162 and S-164, Alachua, Florida 32615 (the &#8220;Second Expansion Premises&#8221;). Pursuant to the Second Expansion Lease, the Company is to use the Second Expansion Premises for general office uses. The Second Expansion Lease commenced December 1, 2018 and expires November 30, 2020. The annual cost of the Second Expansion Premises is approximately $45 for the first twelve months of the term and $46 for the final twleve months. The Company is also obligated to pay for certain taxes, insurance costs and electricity costs incurred by SNH.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On November 19, 2018, AC entered into a Lease (the &#8220;Third Expansion Lease&#8221;) with SNH for two thousand square feet at 13709 Progress Boulevard, Suites S-175, S-177 and S-179, Alachua, Florida 32615 (the &#8220;Third Expansion Premises&#8221;). Pursuant to the Third Expansion Lease, the Company is to use the Third Expansion Premises for general office and biomedical research uses. The Third Expansion Lease commenced December 1, 2018 and its term expires November 30, 2020.  The annual cost of the Third Expansion Premises is approximately $37 for the first twelve months of the term and $35 for the final eleven months. The Company is also obligated to pay for certain taxes, insurance costs and electricity costs incurred by SNH.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On November 21, 2018, the Company, entered into Commercial Lease Amendment 3 (the &#8220;Burleson Amendment&#8221;), to the Commercial Lease dated April 21, 2015, as amended, with Ja-Cole L.P. Under the terms of the Burleson Amendment, the Company leased an additional two thousand five hundred square feet of warehouse/office space in Burleson, Texas (collectively with the space leased under the Commercial Lease with Ja-Cole L.P. prior to the effectiveness of the Burleson Amendment, the &#8220;Burleson Facility&#8221;).  The Burleson Facility will now comprise a total of twelve thousand five hundred square feet, all of which, pursuant to the Burleson Amendment, will be leased until April 30, 2022.  The annual rental cost of the entire Burleson Facility is now approximately $113 through December 31, 2020, $116 for the calendar year 2021 and until April 2022. The Burleson Facility houses raw material storage and product distribution while allowing same day order fulfillment for both the east and west coasts of the United States.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On October 26, 2018 (the &#8220;Ashley Avenue Lease Effective Date&#8221;), the Company entered into a Lease (the &#8220;Ashley Avenue Lease&#8221;) with Ashley Avenue Associates I, LLC., a Delaware limited liability company (&#8220;Ashley&#8221;), for the lease by the Company of approximately fifteen thousand square feet of office space on the second floor of the building located at 1000 N. Ashley Drive, Tampa, Florida 33602 (the &#8220;Ashley Avenue Premises&#8221;).  Pursuant to the Ashley Avenue Lease, the Company will use the Ashley Avenue Premises for general office purposes.  The initial term of the Ashley Avenue Lease commenced on December 1, 2018 and expires on November 30, 2020. The Company has an option to terminate the lease after eighteen months by providing Ashley with four months advance written notice.  The rental cost for the Ashley Avenue Premises was approximately $381 for the first twelve-month period, and approximately $360 for the final eleven month period. The Company is also obligated to pay for its pro rata share of the building&#8217;s property taxes, utilities, administrative costs, common area maintenance and management fees, excluding any capital improvements or any damage due to fire, hurricane or other casualty.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On September 20, 2018, the Company entered into an agreement with Heights Union, LLC, a Florida limited liability company (&#8220;Heights Union&#8221;), for the lease of seventy-five thousand square feet of office space (the &#8220;Heights Union Premises&#8221;) in a one hundred and fifty thousand square foot office building that Heights Union intends to construct and complete on or before September 30, 2020, on an area of land in Tampa, Florida.  Pursuant to the Heights Union lease, the Company will use the Heights Union Premises for general office, medical laboratory, training and meeting purposes.  The annual costs of the Heights Union Premises ranges from approximately $2.4 million to $3.3 million during the term of the lease.  </span>Axogen believes it can obtain certain economic incentives from state authorities associated with the employment at the facility; but such incentives are not expected to be a material offset to the expenses of the project as a whole.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On August 6, 2015, Axogen entered into the CTS Agreement with CTS, an FDA registered tissue establishment.  Processing of the Avance Nerve Graft pursuant to the CTS Agreement began in February 2016.  The CTS Agreement terminates December 31, 2021, subject to earlier termination by either party for cause (subject to the non-terminating party&#8217;s right to cure, in certain circumstances), or without cause upon 6 months&#8217; notice whereby notice cannot be provided prior to March 1, 2021.  Under the CTS Agreement, Axogen pays CTS a facility fee for clean room/manufacturing, storage and office space.  CTS also provides services in support of Axogen&#8217;s manufacturing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Effective June 8, 2018, AC entered into an Agreement for Purchase and Sale of Real Property with ARC CRVANOH001, LLC, a Delaware limited liability company (&#8220;ARC&#8221;), for the acquisition (the &#8220;Acquisition&#8221;) by AC of certain real property located in Vandalia, Ohio<span style="font-size:12pt;"> </span><span style="white-space:pre-wrap;">comprised of a 70,000 square foot building on approximately 8.6 acres of land.  AC thereafter transferred its rights and obligations under the Agreement to Axogen Processing Corporation, incorporated for purposes of the Acquisition. On July 31, 2018, Axogen Processing Corporation completed the Acquisition pursuant to the terms of the Agreement for Purchase and Sale of Real Property.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, Axogen leases space and maintains records at certain other facilities, including Axogen&#8217;s prior corporate headquarters at 1407 South Kings Highway, Texarkana, Texas 75501.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The aggregate cost of all of Axogen&#8217;s and its subsidiaries&#8217; properties is approximately $1.9 million per year.  Axogen believes that its facilities will be sufficient to operate its business for the next 12 months and that current lease obligations will not change materially.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_8aba2e31_46c0_442c_9224_b59ee13c930c"></a><a id="ITEM3LEGALPROCEEDINGS_396505"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 3.  LEGAL PROCEEDING</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">S </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Except as provided below, Axogen and its subsidiaries do not have any active or pending material legal proceedings:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">On January 9, 2019, Plaintiff Neil Einhorn, on behalf of himself and others similarly situated, filed a putative class action complaint in the United Stated District Court for the Middle District of Florida alleging violations of the federal securities laws against Axogen, Inc., certain of its directors and officers (&#8220;Individual Defendants&#8221;), and Axogen&#8217;s 2017 Offering Underwriters and 2018 Offering Underwriters (collectively, with the Individual Defendants, the &#8220;Defendants&#8221;), captioned Einhorn v. Axogen, Inc., et al., No. 8:19-cv-00069 (M.D. Fla.).  Plaintiff asserts that Defendants made false or misleading statements in connection with the Company&#8217;s November 2017 registration statement issued regarding its secondary public offering in November 2017 and May 2018 registration statement issued regarding its secondary public offering in May 2018, and during a class period of August 7, 2017 to December 18, 2018.   In particular, Plaintiff asserts that Defendants issued false and misleading statements and failed to disclose to investors: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company&#8217;s pricing alienated customers and threatened the Company&#8217;s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company&#8217;s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company&#8217;s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company&#8217;s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company&#8217;s key operating metrics, such as number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.  Axogen was served on January 15, 2019.  </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On February 4, 2019, the court granted the parties&#8217; stipulated motion which provided that Axogen is not required to file a response to the complaint until thirty days&#160;after Plaintiff files a consolidated amended complaint.&#160;On June 19, 2019, Plaintiff filed an Amended Class Action Complaint, and on July 22, 2019, Defendants filed a motion to dismiss. Plaintiff filed opposing papers on August 12, 2019. The Court held a status hearing on September 11, 2019 and stayed all deadlines regarding the parties&#8217; obligations to file a case management report. On December 4, 2019 the parties&#8217; presented oral arguments and are currently awaiting the court&#8217;s ruling.</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">.  Plaintiff is seeking compensatory damages, reimbursement of expenses and costs, including counsel and expert fees and such other relief as the court deems just and proper. The Company and Individual Defendants dispute the allegations and intend to vigorously defend against the Complaint.  The amount of loss, if any, cannot be reasonably estimated at this time.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Jackson v. Zaderej, et al., No. 8:19-cv-01976 U.S. District Court (M.D. FL). On August 12, 2019, Plaintiff Harvey Jackson, derivatively on behalf of Axogen, filed a verified shareholder derivative complaint for violations of securities laws, breach of fiduciary duty, waste of corporate assets and unjust enrichment against Quentin S. Blackford, Gregory G. Freitag, Mark Gold, Jamie M. Grooms, Alan M. Levine, Peter J. Mariani, Guido Neels, Robert J. Rudelius, Amy Wendell, and Karen Zaderej (the &#8220;Individual Defendants&#8221;) and Nominal Defendant Axogen, Inc. (&#8220;Axogen&#8221;) (collectively, &#8220;Defendants&#8221;).  Plaintiff asserts that the Individual Defendants, who are current or former Axogen officers or directors, issued a false proxy statement for the election of directors in violation of Section 14(a) of the Securities Exchange Act of 1934, breached their fiduciary duties, wasted corporate assets and were unjustly enriched by allowing Axogen to make false public statements to investors based on the same claims in the report issued December 18, 2018 by Seligman Investments (the same allegations that form the basis for the Einhorn matter and the Bussey shareholder demand).  Plaintiff demands judgment in the Company&#8217;s favor against all Individual Defendants as follows: (A) declaring that Plaintiff may maintain this action on behalf of Axogen, and that Plaintiff is an adequate representative of Company; (B) declaring that the Individual Defendants have breached and/or aided and abetted the breach of their fiduciary duties to Axogen; (C) determining and awarding to Axogen the damages </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">sustained by it because of the violations set forth above from each of the Individual Defendants, jointly and severally, together with pre- and post-judgment interest thereon; (D) directing Axogen and the Individual Defendants to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable laws and protect Axogen and its shareholders from a repeat of the damaging events described therein, including, but not limited to, putting forward for shareholder vote the following resolutions for amendments to the Company&#8217;s Bylaws or Articles of Incorporation and the following actions as may be necessary to ensure proper corporate governance policies: (i)  a proposal to strengthen the Board&#8217;s supervision of operations and develop and implement procedures for greater shareholder input into the policies and guidelines of the Board, (ii) a provision to permit the shareholders of Axogen to nominate at least six candidates for election to the Board; and (iii) a proposal to ensure the establishment of effective oversight of compliance with applicable laws, rules, and regulations; (E) awarding Axogen restitution from Individual Defendants, and each of them; (F) awarding Plaintiff the costs and disbursements of this action, including reasonable attorneys&#8217; and experts&#8217; fees, costs, and expenses; and (G) granting such other and further relief as the Court may deem just and proper.  The Defendants filed a motion to dismiss on October 22, 2019.  In response, Plaintiffs voluntarily withdrew their complaint and the matter was dismissed without prejudice by the court on November 5, 2019.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Novitzki v. Zaderej, et al, 19-CA-11745 DIV L (13th Judicial Circuit, Hillsborough Cnty., Fl.).  On November 11, 2019,  Plaintiff Joseph Novitzki, derivatively on behalf of Axogen, filed a verified stockholder derivative complaint for breach of fiduciary duty, waste of corporate assets and unjust enrichment against Karen Zaderej,  Gregory G. Freitag, Peter J. Mariani, Amy Wendell, Robert J. Rudelius, Mark Gold, Guido Neels, and Jamie M. Grooms (the &#8220;Individual Defendants&#8221;) and Nominal Defendant Axogen, Inc. (&#8220;Axogen&#8221;) (collectively, &#8220;Defendants&#8221;). Plaintiff asserts that the Individual Defendants, who are current or former Axogen officers or directors, breached their fiduciary duties, wasted corporate assets and were unjustly enriched by allowing Axogen to make false public statements to investors based on the same claims in the report issued December 18, 2018 by Seligman Investments (the same allegations that form the basis for the Einhorn matter and the Bussey shareholder demand).  Plaintiff demands judgment in the Company&#8217;s favor against all Individual Defendants as follows: (a) against all of the defendants and in favor of the Company for the amount of damages sustained by the Company as a result of the defendants&#39; breaches of fiduciary duties, waste of corporate assets, and unjust enrichment; (B) directing Axogen to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable laws and to protect Axogen and its stockholders from a repeat of the damaging events described herein, including, but not limited to, putting forward for stockholder vote, resolutions for amendments to the Company&#39;s Bylaws or Articles of Incorporation and taking such other action as may be necessary to place before stockholders for a vote of the following corporate governance policies: (1) directing Axogen to employ an independent, third-party expert to calculate the Company&#39;s market size (including the dollar values of Axogen&#39;s total addressable market and portion of the market relating to extremity trauma and OMF); (2) a provision to control insider selling; (3) a proposal to strengthen Axogen&#39;s oversight of its disclosure procedures; (4) a proposal to strengthen the Company&#39;s controls over financial reporting; (5) a proposal to strengthen the Board&#39;s supervision of operations and develop and implement procedures for greater stockholder input into the policies and guidelines of the Board; and (6) a provision to permit the stockholders of Axogen to nominate at least three candidates for election to the Board; (C) extraordinary equitable and/or injunctive relief as permitted by law, equity, and state statutory provisions sued hereunder, including attaching, impounding, imposing a constructive trust on, or otherwise restricting the proceeds of defendants&#39; trading activities or their other assets so as to assure that plaintiff on behalf of Axogen has an effective remedy; (D) Awarding to Axogen restitution from defendants, and each of them, and ordering disgorgement of all profits, benefits, and other compensation obtained by the defendants, including all ill-gotten gains from insider selling by defendants; (E) awarding to plaintiff the costs and disbursements of the action, including reasonable attorneys&#39; fees, accountants&#39; and experts&#39; fees, costs, and expenses; and (F) granting such other and further relief as the Court deems just and proper.  After Defendants&#8217; counsel had multiple discussions with Plaintiff&#8217;s counsel pointing out that it&#8217;s complaint was deficient for the same reasons argued in Jackson, the Plaintiff agreed to voluntarily dismiss the complaint without prejudice, which the court so-ordered on January 24, 2020.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_7fc8bf8c_ecf1_4f2d_8348_6738e30ce2a2"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM4MINESAFETYDISCLOSURES_425837"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 4.  MINE SAFETY DISCLOSURE</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">S</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_3aac42a3_7070_41b7_907f_29709148ce57"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:208.52pt;"><a id="PARTII_982967"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART&#160;I</b><b style="font-weight:bold;">I</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 5.  MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIE</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">S  </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen&#8217;s common stock is traded on the Nasdaq Capital Market under the symbol &#8220;AXGN.&#8221;  On February 21, 2020, the last reported closing sale price of the Company common stock on the Nasdaq Capital Market was $14.70 per share. </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Shareholders</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">As of February 21, 2020, the Company had 39,730,976 shares of common stock outstanding, and approximately 240 common shareholders of record, based upon information received from our stock transfer agent.  However, this number does not include beneficial owners whose shares were held of record by nominees or broker dealers.  The Company estimates that there are more than 9,769 individual owners.  </span>Additional information called for by this item is incorporated herein by reference to the following sections of this Report: Note&#160;11 &#8220;Equity Compensation Plans&#8221; of the Notes to Consolidated Financial Statements included in Item 8; and Item&#160;12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#160;&#8211; Equity Compensation Plan Information&#8221;.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Stock Performance Graph</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The following graph compares the cumulative total shareholder return on our common stock for the period from December 31, 2015 to December 31, 2019 with (i) the Nasdaq Stock Market Composite Index; and (ii) the Nasdaq Stock Market Biotechnology Index.  The graph assumes an investment of $100 in our common stock and the respective indices for the period of December 31, 2014 to December 31, 2019.  The comparisons set forth in the graph are provided pursuant to SEC rules and are not intended to forecast or be indicative of the future performance of our common stock or either of the included indices.  The performance graph shall not be deemed incorporated by reference by any general statement incorporating by reference this annual report into any filing under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended, except to the extent we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><img src="axgn-20191231x10k0cc357004.jpg" alt="Graphic" style="display:inline-block;height:208.47pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:438.69pt;" /></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">We did not repurchase any of our securities in the fourth quarter of 2019.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">We had no sales of unregistered securities in 2019.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_c9998e61_2235_4461_9444_a1f5beb8c6ca"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM6SELECTEDFINANCIALDATA_404548"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 6.  SELECTED FINANCIAL DAT</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">A</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The selected financial data set forth below has been derived from our audited financial statements.  This data should be read in conjunction with the financial statements, the notes thereto and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this report.   Dollar amounts are in thousands, except per share amounts.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.78%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:49.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2016</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2015</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Statement of Operations Data:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 106,712</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 83,937</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,108</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,331</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,349</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,923</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,311</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,467</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,848</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Gross Profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89,363</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71,014</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,115</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,641</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,483</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Costs and Expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71,950</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,617</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,636</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,089</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,514</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,773</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,699</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,212</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,237</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,305</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,124</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,731</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,133</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,423</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total costs and expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 120,769</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,514</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,066</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 42,771</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,749</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31,406)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20,500)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,951)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,130)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,266)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Investment income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,525</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (40)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,127)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,217)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,386)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,989)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Interest expense - deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (81)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (246)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (875)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (128)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss on extinguishment of debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,186)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (53)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total other income (expense)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,271</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,897)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,494)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,281)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,090)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29,135)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (22,397)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,445)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,411)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,356)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss per common share - basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.74)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.60)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.31)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.47)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.51)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2016</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2015</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Data:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 135,021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,953</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 55,741</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,051</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 154,643</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 160,173</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 58,875</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,360</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,700</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,880</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,044</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,719</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,081</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,709</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total long-term obligations, net of current maturities and deferred financing fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,610</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 147</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,974</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,358</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,795</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,490</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,191</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,693</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,439</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,504</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total shareholders&#39; equity </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 132,153</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 146,982</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,182</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,921</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,196</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_b3f6c8be_1100_4fe4_9f76_d541a868c4bc"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 7.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">S</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The following information should be read in conjunction with &#8220;Selected Financial Data&#8221; contained in Item 6 of this Form 10-K, our consolidated financial statements and the notes thereto contained in Item 8 of this Form 10-K, the &#8220;Cautionary Notice Regarding Forward-Looking Statements&#8221; contained in Part&#160;</span><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">1 of this Form 10-K, &#8220;Risk Factors&#8221; contained in Item 1A of this Form 10-K, and the other information appearing elsewhere in, or incorporated by reference into, this Form 10-K.  Dollar amounts referenced in this Item 7 are in thousands, except per share amounts.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">We are the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.  We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves.&#160;Physical damage to a peripheral nerve,&#160;or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site, Axoguard<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Connector, a porcine submucosa extracellular matrix (&#8220;ECM&#8221;) coaptation aid for tensionless repair of severed peripheral nerves, Axoguard<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, Axoguard<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma and Avive<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier.<span style="white-space:pre-wrap;">  Along with these core surgical products, we also offer the Axotouch</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Two-Point Discriminator, used to measure the inervation density of any surface area of the skin. Our portfolio of products is available in the United States, Canada, the United Kingdom, South Korea and several European and other international countries.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Revenue from the distribution of Axogen&#8217;s peripheral nerve repair products, the Avance Nerve Graft, Axoguard Nerve Connector and Axoguard Nerve Protector and Avive Soft Tissue Membrane, in the United States is the main contributor to Axogen&#8217;s total reported sales and has been the key component of its growth to date. Axogen revenues increased in 2019 compared to 2018 primarily as a result of continuing revenue growth through product penetration in, and increases of the number of, active accounts, and to a lesser extent, the development and growth of new accounts. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">We have experienced that surgeons initially are cautious adopters for peripheral nerve repair products. Surgeons typically start with a few cases and then wait and see the results of these initial cases. Active accounts are usually past this wait period and have developed some level of product reorder. These active accounts have typically gone through the committee approval process, have at least one surgeon who has converted a portion of his or her treatment algorithms of peripheral nerve repair to the Axogen portfolio and have ordered Axogen products at least six times in the last twelve months.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As such, revenue growth primarily occurs from increased purchasing from active accounts, followed by revenue growth from new accounts.&#160; Each new period of measurement is thus benefited from growth in active accounts which may include those that were new accounts in the prior measurement period.&#160; &#160;<span style="white-space:pre-wrap;">Axogen has continued to broaden its sales and marketing focus which is expected to have a positive contribution to its revenue growth in the long term. In 2019, the Company continued to invest in the development of our commercial team, infrastructure capabilities, clinical studies, product development and research, as well as surgeon education.  As a result, the growth in these expenses outpaced our revenue growth.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Comparison of the Years Ended December&#160;31, 2019 and 2018</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts and as percentages of total revenue:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_f3a3b3f8_ab94_4f3d_85de_f83bb4bb085e"></a><a id="_f0b6842d_f2fd_455e_b804_6d2f7e546f5f"></a><a id="_301878c8_df18_4487_82a1_f5403676cf7b"></a><a id="_603a543c_4c1e_4c78_94a7_9afea0a244b2"></a><a id="_39bc5f72_8cee_4823_a27d_587778695d2d"></a><a id="_4eeda0d7_9366_407e_be89_425a8e88abb1"></a><a id="_9cce3d65_d6ed_4535_ad7a_da213401a134"></a><a id="_accf812f_ce97_4932_8c7b_aa25308193e4"></a><a id="_12f413f1_6936_43aa_985f_f64f4cce67b4"></a><a id="_13843009_4803_4b93_aaa5_d3ef8763caf2"></a><a id="_7b90fb61_a907_4bf3_9f64_9764ce2f9855"></a><a id="_0ac498d2_18eb_4a85_b3c8_d70837e2d3fd"></a><a id="_b94b43f5_cdad_4c00_95a7_077aa859a80a"></a><a id="_1ec872dc_53a8_4272_b7c0_27f4308d931f"></a><a id="_7cf7d1e5_e8ca_4624_9a54_98ca3ad17ba5"></a><a id="_2d4b14fa_1d89_498f_b111_1109c802793e"></a><a id="_647a357e_56a8_460c_b159_bc72a6c5a4f3"></a><a id="_ee462260_6dd4_499e_96cf_92ff20514cb3"></a><a id="_e35afc17_aaac_4038_b03c_03a9c69b1484"></a><a id="_e77bb2ff_16f8_482e_801c_b0906692d723"></a><a id="_9b3162fa_0eda_43d5_9e2a_aaae6721e401"></a><a id="_85733159_31be_42f7_83d8_d7463f3d3b51"></a><a id="_21484a3e_7264_49cf_9f62_a87b8761b3a3"></a><a id="_ea5c3e4d_b401_4c96_933b_dd4a79e7387f"></a><a id="_af65d53c_9795_46bd_8191_b5fe3c25a6f3"></a><a id="_c9d2f496_de01_4b3f_85d9_0c648f785762"></a><a id="_365751b9_a0f3_40e8_8046_a2636670c4fe"></a><a id="_7e780273_d30c_47e0_a08f_94609fed7e72"></a><a id="_06c82054_adf3_4829_ad5a_983d658b8db1"></a><a id="_456ca27f_8588_4a6a_8864_b8d48e8ab5e2"></a><a id="_972ef5c0_7326_4262_bf16_eff15cac990a"></a><a id="_2eba064c_78de_4d48_9a91_58821352c3aa"></a><a id="_0b3979ce_af22_4daf_9e4e_9e4b290a31e2"></a><a id="_82d9df09_e0cf_434c_bf83_a3b84db7648f"></a><a id="_bb982cd1_ebc3_470b_8964_2f07fb22fd2d"></a><a id="_66a99afb_2915_440a_84d3_1f15f227e7de"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:46.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Year Ended  December 31,  </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:46.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 106,712</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 83,937</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,349</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,923</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross profit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89,363</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83.7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71,014</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">84.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales and marketing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71,950</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67.4</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,617</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">67.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,514</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,773</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,305</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29.3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,124</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">27.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 120,769</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 113.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,514</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">109.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31,406)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29.4)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20,500)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(24.4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Investment income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,364</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,525</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (40)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,127)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(1.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense &#8212; deferred financing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (81)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,186)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(2.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expense </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (53)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total other expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,271</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,897)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(2.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net Loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29,135)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(27.3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (22,397)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(26.7)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Revenues</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Revenues for the year ended December&#160;31, 2019 increased 27.1% to $106,712 as compared to $83,937 for the year ended December&#160;31, 2018. Revenue growth for the year was primarily the result of <span style="white-space:pre-wrap;">increases in unit volume, as well as the net impact of price increases and changes in product mix.  </span>Our revenue growth was largely driven by increased revenue in active accounts as well as the addition of new active accounts.<span style="font-family:'Calibri';font-size:14pt;"> </span><span style="white-space:pre-wrap;">In the fourth quarter of 2019, we had 797 active accounts, an increase of 12% from 712 at the end of 2018.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Gross Profit</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk33446516"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Gross profit for the year ended December&#160;31, 2019 increased 25.8% to $89,363 as compared to $71,014 for the year ended December&#160;31, 2018.  The increase was primarily attributable to the increased revenue, but slightly offset by increased processing costs, inventory write downs and additional inventory reserves.<span style="white-space:pre-wrap;">  Gross profit margin in 2019 decreased to 83.7% % as compared to 84.6% in 2018.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Costs and Expenses</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Total cost and expenses increased 32.0% to $120,769 for the year ended December&#160;31, 2019 as compared to $91,514 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2018.  The increase was primarily due to variable costs associated with increased sales activity, expansion of our commercial team, expanding product development and clinical study activities, expanded surgeon education programs, and increases in compensation and general expenses associated with ongoing expansions of  infrastructure to support the Company&#8217;s growth.  In addition, general and administrative expenses include approximately $2,467 of litigation expenses</span> and certain expenses associated therewith, as a result of the ongoing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">litigation described in Legal Proceedings and other litigation that was dismissed during 2019 (the &#8220;Litigation&#8221;) in the period ending December 31, 2019 as compared to $0 in the prior year period.  </span>As a percentage of revenues, total cost and expenses increased to 113.1% in 2019 compared to 109.0% in 2018.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Sales and marketing expenses increased 27.1% to $71,950 for the year ended December&#160;31, 2019 as compared to $56,617 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2018. The increase was primarily due to: (a) increased compensation expenses related to Axogen&#8217;s direct sales force as a result of increased sales and hiring of additional personnel; (b) increased travel expenses to support the commercial team&#8217;s activities; (c) expansion of the Company&#8217;s surgeon education program; and (d) increased marketing activity.  As a percentage of revenues, sales and marketing expenses were 67.4% for the year ended December&#160;31, 2019 compared to 67.5% for the year ended December&#160;31, 2018.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">General and administrative expenses increased 35.4% to $31,305 for the year ended December&#160;31, 2019 as compared to $23,124 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2018. The increase was primarily the result of increased expenses related to infrastructure expansion to support the Company&#8217;s growth, including professional fees, salaries, and an increase of $1,982 of non-cash stock compensation.  As mentioned above, the Company also recorded $2,467 of legal fees associated the Litigation.  As a percentage of revenues, general and administrative expenses increased to 29.3% for the year ended December&#160;31, 2019 compared to 27.5% for the year ended December&#160;31, 2018.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development expenses increased 48.8% to $17,514 in the year ended December&#160;31, 2019 as compared to $11,773 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2018.  </span>Research and development costs include Axogen&#8217;s product development and clinical efforts substantially focused on its Biologics License Application, or BLA, for the <span style="white-space:pre-wrap;">Avance Nerve Graft, the Sensation-NOW and RECON studies and the development of new or next generation products.  </span><span style="white-space:pre-wrap;">The increase in expenses for 2019 relate to expenditures for these activities and hiring additional personnel to support clinical and product development activity.  It is expected that costs associated with the BLA will continue to increase as we continue to invest in completing the license application.  Axogen continues to conduct product development efforts focused on both new peripheral nerve products and new peripheral nerve applications for our existing products.  Axogen pursues research grants to support research and early product development.  Axogen&#8217;s increased product and clinical pipeline development initiatives contributed to the increase in research and development expenses in 2019</span><span style="white-space:pre-wrap;">.  As a result, research and development expenses increased to 16.4% in 2019 from 14.0% in 2018, as a percentage of revenues.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Other Income and Expenses</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_MailEndCompose"></a><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">For the year ended December 31, 2019, we recognized $2,364 of investment income from our asset management and cash investment sweep accounts as compared to $1,525 for the year ended December 31, 2018.  Interest expense decreased to $40 as compared to $1,127 for the year ended December&#160;31, 2018 as a result of the Company paying, in full, the Term Loan and Revolving Loan with MidCap, as defined in &#8220;Term and Revolving Loan Agreements in the prior year ended December&#160;</span><span style="white-space:pre-wrap;">31, 2018.  </span>For the year ended December 31, 2018, we incurred a loss on the extinguishment of the debt of $2,186 for exit, prepayment fees and the amortization of the remaining balance of the deferred financing costs for which there was no such activity in the current year.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Income Taxes</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen had no income tax expenses or income tax benefit for 2019 or 2018 due to incurrence of net operating loss for the year, the benefits of which have been fully value allowed.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Comparison of the Years Ended December&#160;31, 2018 and 2017</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts and as percentages of total revenue:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_01fa5018_c174_456c_8438_2d7aaea74db3"></a><a id="_05e04ad2_1859_47f8_bfca_5c59d525dce7"></a><a id="_58158b56_d8a2_4acf_be11_df355aad6e75"></a><a id="_c1192ab1_cdf9_4f6f_8646_aa9823d177ae"></a><a id="_c7ca64ff_d418_4e58_aa8d_ceb5fef6ead5"></a><a id="_5e0cabe6_8cd4_495c_a3fc_422cda5b770f"></a><a id="_5fc08c4b_09ac_430c_b7e0_c0b3a400cbc0"></a><a id="_a17c16f2_20fb_49dd_9455_e7e95f1e9ae9"></a><a id="_fde9a981_10f5_413c_b8ae_8716dd1b5ecd"></a><a id="_32dcb1d4_d8ad_4c62_9987_9002036154cd"></a><a id="_cfecdb55_f2d3_41c6_aa7d_efd8b5d76fb9"></a><a id="_8ff2b6e0_ac88_4e61_8a2d_2e501066a3ac"></a><a id="_db230297_abfa_468e_ae73_63922d490b47"></a><a id="_c51e4006_aa61_4525_b066_41c25499211b"></a><a id="_7da0c63d_cb51_425f_9296_d50a5eb9a530"></a><a id="_b32edfc1_6123_4ca1_84f3_31873a0640af"></a><a id="_6e2474a0_870a_4fb7_821b_7e632facc7da"></a><a id="_f3e33ddb_49f4_4f7d_a7bc_21f176b8d603"></a><a id="_81a6f19b_52b9_4c01_a284_999abefde808"></a><a id="_d917f30f_d37c_4636_af35_f2c2bd23ab17"></a><a id="_e15e993b_f2d3_47da_a2e1_26da19bb5bc5"></a><a id="_72ed8f50_4727_45cf_8e4a_990b53a69a85"></a><a id="_1dfebde3_afea_4ba8_b60a_c88bd4cf2fbe"></a><a id="_671a8edd_3973_4436_b37e_403e29cf3947"></a><a id="_cf29bdc5_0870_4cea_8afa_dddd59d27a89"></a><a id="_9c1e28b5_953b_488c_b5c4_ab5bf78a6e02"></a><a id="_7ccd6018_35c7_4a56_b019_ea452bd401fe"></a><a id="_6f139e79_e385_4398_9015_8986123e13b4"></a><a id="_100f03f7_550d_4c1f_ad65_f834e70681f6"></a><a id="_7a43bdda_f1ef_458c_a59b_dc22ea2d193e"></a><a id="_72271272_4237_45e2_851e_3301707d2dc3"></a><a id="_54cfbced_3769_4902_8892_380800269733"></a><a id="_160ba3e7_2a46_436a_b3e6_e0ee214d3a3c"></a><a id="_fe569528_58dc_44d8_9e13_2b8dfc3f41ca"></a><a id="_03bdbcd3_a0dd_4450_9e81_679c7df25c2a"></a><a id="_073ea852_3855_4a1d_8db0_81989bf8ef78"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:46.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Year Ended  December 31,  </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:46.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 83,937</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,426</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,923</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,311</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross profit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71,014</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">84.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,115</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">84.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales and marketing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,617</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">67.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,636</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,773</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,699</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,124</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">27.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,731</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,514</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">109.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,066</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">97.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20,500)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(24.4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,951)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(13.2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Investment income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,525</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,127)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(1.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,217)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(3.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense &#8212; deferred financing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (81)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (246)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(0.4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,186)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(2.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expense </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total other expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,897)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(2.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,494)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(4.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net Loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (22,397)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(26.7)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,445)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(17.3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Revenues</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Revenues for the year ended December&#160;31, 2018 increased 38.9% to $83,937 as compared to $60,426 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2017. This increase was primarily a result of continuing growth in active accounts from improved penetration within these active accounts, as well as an increase in the number of active accounts.  In the fourth quarter of 2018, we had 712 active accounts, an increase of 20% from 591 at the end of 2017.  In addition, the Company received grant revenue of $195 in the year ended December&#160;31, 2018, as compared to grant revenue of $56 in the year ended December&#160;31, 2017.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Gross Profit</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Gross profit for the year ended December&#160;31, 2018 increased 38.9% to $71,014 as compared to $51,115 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2017.  This increase was consistent with and primarily attributable to the increased revenues in 2018.  Gross profit margin in 2018 was unchanged at 84.6% as compared to 84.6% in 2017.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Costs and Expenses</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Total cost and expenses increased 54.9% to $91,514 for the year ended December&#160;31, 2018 as compared to $59,066 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2017.  The increase was primarily due to variable costs associated with increased sales activity, expansion of our commercial team, expanding product development and clinical study activities, expanded surgeon education programs, and increases in compensation and general expenses associated with ongoing expansions of  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">infrastructure to support the Company&#8217;s growth.  As a percentage of revenues, total cost and expenses increased to 109.0% in 2018 compared to 97.8% in 2017.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Sales and marketing expenses increased 50.4% to $56,617 for the year ended December&#160;31, 2018 as compared to $37,636 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2017. The increase was primarily due to: (a) increased compensation expenses related to Axogen&#8217;s direct sales force as a result of increased sales and hiring of additional personnel; (b) increased travel expenses to support the commercial team&#8217;s activities; (c) expansion of the Company&#8217;s surgeon education program; and (d) increased marketing activity.  As a percentage of revenues, sales and marketing expenses were 67.5% for the year ended December&#160;31, 2018 compared to 62.3% for the year ended December&#160;31, 2017.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">General and administrative expenses increased 57.0% to $23,124 for the year ended December&#160;31, 2018 as compared to $14,731 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2017. The increase was primarily the result of increased expenses related to infrastructure expansion to support the Company&#8217;s growth, including professional fees, salaries, and $4,007 of non-cash stock compensation.  As a percentage of revenues, general and administrative expenses increased to 27.5% for the year ended December&#160;31, 2018 compared to 24.4% for the year ended December&#160;31, 2017.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development expenses increased 75.7% to $11,773 in the year ended December&#160;31, 2018 as compared to $6,699 for the year ended December&#160;<span style="white-space:pre-wrap;">31, 2017.  </span>Research and development costs include Axogen&#8217;s product development and clinical efforts substantially focused on its Biologics License Application, or BLA, for the Avance Nerve Graft and the RECON and RANGER studies<span style="white-space:pre-wrap;">. These activities vary from quarter to quarter due to the timing of certain projects.  The increase in expenses for 2018 relate to expenditures for these clinical activities, including the pivotal clinical trial to support the BLA, and hiring additional personal to support clinical and product development activity as well as expenses associated with the new processing facility.  It is expected that costs associated with the BLA will continue to increase as we continue to invest in completing the license application.  Axogen continues to conduct product development efforts focused on both new peripheral nerve products and new peripheral nerve applications for our existing products.  Axogen pursues research grants to support research and early product development.  Axogen&#8217;s increased product and clinical pipeline development initiatives contributed to the increase in research and development expenses in 2018, with grant revenue offsetting a portion of this activity</span><span style="white-space:pre-wrap;">.  As a result, research and development expenses increased to 14.0% in 2018 from 11.1% in 2017, as a percentage of revenues.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Other Income and Expenses</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">For the year ended December 31, 2018, we recognized $1,525 of investment income from our asset management and cash investment sweep accounts that were opened during the second quarter of 2018.  As a result of the prepayment in full of the Term Loan and Revolving Loan with MidCap, as defined in &#8220;Term and Revolving Loan Agreements&#8221; below, during the second quarter of 2018, interest expense decreased 49.2% to $1,127 in 2018 as compared to $2,217 for the year ended December&#160;31, 2017, and interest expense &#8211; deferred financing costs decreased 67.1% to $81 for the years ended December 31, 2018 as compared to $246 for the year ended December 31, 2017. &#160;</span><span style="white-space:pre-wrap;">For the year ended December 31, 2018, we incurred a loss on the extinguishment of the debt of $2,186 for exit, prepayment fees and the amortization of the remaining balance of the deferred financing costs.  Other expenses decreased 9.7% to $28 for the year ended December 31, 2018, as compared to $31 for the year ended December 31, 2017.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Income Taxes</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen had no income tax expenses or income tax benefit for 2018 or 2017 due to incurrence of net operating loss for the year, the benefits of which have been fully value allowed.  Axogen does not believe there are any additional tax expenses or benefits currently available.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flow Information</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">As of December 31, 2019, the Company had cash, cash equivalents, investments, and restricted cash of $102,510, a decrease of $20,095 from $122,605 at December 31, 2018, primarily as a result of the net operating cash flow of $19,872 and capital outlays of $4,664 for the build out of the Company&#8217;s Axogen Processing Center, or APC, in Vandalia, Ohio.  These expenditures were offset by proceeds throughout the year from stock option exercises of $4,002.  </span>Cash disbursements in 2018 included $25,599 for the prepayment in full of the Term Loan and Revolving Loan with MidCap, as defined in &#8220;Term and Revolving Loan Agreements&#8221; below, and $5,030 for the acquisition of the APC.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen had working capital of approximately $114,141 and a current ratio of 6.5 at December&#160;31, 2019, compared to working capital of $137,909 and a current ratio of 11.6 at December&#160;31, 2018. The decrease in working capital at December&#160;31, 2019 as compared to December&#160;31, 2018<span style="white-space:pre-wrap;">, was primarily due to the use of working capital to fund operations, including increased compensation from hiring additional personnel to support the business, the payment in 2019 of the 2018 performance bonus, 2018 annual sales awards and related costs.  In addition, working capital has also been utilized to commence the buildout of our APC facility.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s future capital requirements depend on a number of factors including, without limitation, revenue increases consistent with its business plan, cost of products and acquisition and/or development of new products. Axogen could face increasing capital needs. Such capital needs could be substantial depending on the extent to which Axogen is unable to increase revenue.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">If Axogen needs additional capital in the future, it may raise additional funds through public or private equity offerings, debt financings or from other sources.  The sale of additional equity would result in dilution to Axogen&#8217;s shareholders. There is no assurance that Axogen will be able to secure funding on terms acceptable to it, or at all. The increasing need for capital could also make it more difficult to obtain funding through either equity or debt.  Should additional capital not become available to Axogen as needed, Axogen may be required to take certain action, such as slowing sales and marketing expansion, delaying regulatory approvals or reducing headcount.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Net Cash Used in Operating Activities</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen used $19,872 of cash for operating activities in 2019, as compared to using $17,862 of cash for operating activities in 2018.  This increase in cash used in operating activities was primarily attributed to the increase in the net loss, accounts receivable and inventory for the year ended December 31, 2019 as compared to 2018, partially offset by the decrease in accounts payable and accrued expenses and non-cash stock compensation during 2019.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Net Cash Provided by/Used in Investing Activities</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Investing activities for 2019 provided  $27,271 of cash as compared to using $98,193 during 2018.  The Company allowed short term investments to mature or sold  short term investments to fund the operations.  These inflows of cash were offset by the increase in purchases of property and equipment, primarily our facility in Vandalia, Ohio.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Net Cash Provided by Financing Activities</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Financing activities in 2019 provided $4,031 of cash as compared to providing $109,842 of cash in 2018. The decrease was the result of <span style="white-space:pre-wrap;">the net proceeds of the May 2018 public stock offering in the prior year.  The prior year also included a $25,599 of payments to extinguish the Company&#8217;s debt, including the prepayment of the Term Loan and Revolving Loan with MidCap, as defined in &#8220;Term and Revolving Loan Agreements&#8221; below, and related fees.  Proceeds from the exercise of stock options provided $4,002, $3,884 and $1,434 of cash for the years ended December 31, 2019, 2018 and 2017, respectively.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Operating Cash Requirements</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On July 9, 2019,&#160;Axogen&#160;entered into a Standard Form of Agreement Between Owner and Design-Builder (the &#8220;Design-Build Agreement&#8221;) with CRB Builders, L.L.C., a Missouri limited liability company (&#8220;CRB&#8221;),&#160;pursuant to which CRB will renovate and retrofit the APC (See Footnote 14 Commitment and Contingencies in the Notes to the Condensed Financial Statements).&#160; The Company anticipates spending up to approximately $37,737 for renovations, equipment and furniture over the next twelve months and up to $40,906 over the next 18 months.&#160;&#160;</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As previously disclosed the Company previously entered into an agreement with Heights Union, LLC, a Florida limited liability company (&#8220;Heights Union&#8221;), for the lease of seventy-five thousand square feet of office space.&#160; Pursuant to the Heights Union lease, the Company will use the Heights Union Premises for general office, medical laboratory, training and meeting purposes.&#160;&#160;The Company anticipates occupying the premises by the second quarter of 2020.&#160; Associated with the lease, the Company anticipates spending up to $7,490 for leasehold improvements, equipment and furniture and fixtures over the next twelve months.&#160; </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2019, we had cash, cash equivalents, investments and restricted cash totaling $102,510 and total current liabilities of $20,880. Based on current estimates, we believe that our existing cash, cash equivalents and investments will allow us to fund our operations through at least the next 12 months.&#160;</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Credit Facilities</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On October 25, 2016, the Company entered into Term Loan and a Revolving Loan with MidCap Financial Trust (&#8220;MidCap&#8221;) maturing on May 1, 2021.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company had the option at any time to prepay the Term Loan in whole or in part, subject to payment of a prepayment fee and an exit fee.  On May 22, 2018, the Company exercised its option and paid $22,599 to prepay the Term Loan in full, which included exit and pre-payment fees totaling $1,470.  In addition, on May 22, 2018, the Company charged to interest expense the unamortized deferred financing costs associated with the Term Loan of $473.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company also had the option to terminate or permanently reduce the Revolving Loan prior to the maturity date subject to its payment of a deferred origination fee. On May 22, 2018, the Company exercised its option to terminate and paid $2,958 to prepay the Revolving Loan in full, which amount included fees of $236.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:14.4pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Contractual Obligations and Commitments </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The following table summarizes our obligations with regard to our contractual obligations as of December 31, 2019, and the expected timing of maturities of these contractual obligations.  This table should be read in conjunction with the notes to consolidated financial statements included elsewhere in this annual report on Form 10-K.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_d703fec9_6267_452f_97e4_2373cdb9aacc"></a><a id="_61ef64d6_0a5e_4bc1_830b_b54f9d6269e5"></a><a id="_f812b9aa_b533_4081_98d2_59a39ed463ba"></a><a id="_3934ef92_bb90_4063_aa30_4f6a782915ee"></a><a id="_eaba0263_fddd_4578_8932_fdf436d075d1"></a><a id="_221527d7_3d92_41bd_b39b_85f8c2c1745f"></a><a id="_2fdf1f60_f9c8_4b38_91fb_69b359ca92f7"></a><a id="_39302643_501a_4ef3_b06d_223237a947b8"></a><a id="_b6b1f926_b03e_4677_829b_fc3da12f0874"></a><a id="_671a2989_e3d1_4be1_841a_ac59d3f2a348"></a><a id="_af2f5fd8_b840_4b1e_8120_da9d884bd629"></a><a id="_dd4059fc_e7cf_4e7c_a68e_db63910943d7"></a><a id="_d91a3b20_f305_4dcd_b5e9_951a0bed3cce"></a><a id="_d4a144a1_79fe_40f2_b651_2e024a6e2514"></a><a id="_f8e6fd69_5046_42c5_a9fb_1f27bf4c99ae"></a><a id="_9af28946_77ac_4fcd_9555_e995fc93fab6"></a><a id="_12313292_31c7_48d0_aafd_4910fcc1a430"></a><a id="_4f1803d9_2d7c_459d_a81d_8594690883bb"></a><a id="_9108d6aa_8097_4ab1_997c_4fed187b274e"></a><a id="_b5ca9925_6c2c_442c_b14e_e9f9bd22aae1"></a><a id="_e84f4ec4_2620_4718_9f76_9efb72d38b86"></a><a id="_79325922_70ec_4708_9441_808aeee8dd9c"></a><a id="_8a681ed3_ce32_4d61_9414_566b0990f9b8"></a><a id="_066877c0_ca68_4005_ac2c_b65ba6368544"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Contractual Obligations</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 1 year</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1-3 years</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3-5 years</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More than 5 years</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">APC Commitment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,601</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,737</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,864</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Tampa Commitment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,833</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,490</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,343</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,720</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,664</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,580</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,225</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,251</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finance Leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 52</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 95,206</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,910</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,816</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,229</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,251</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Service Agreements disclosed in Footnote 14 Commitments and Contingencies do not have annual firm commitments.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As noted above, on July 9, 2019,&#160;the Company&#160;entered into the Design-Build Agreement with CRB,&#160;pursuant to which CRB will renovate and retrofit the property.&#160; Once completed, the Company will use the property for material processing, medical laboratory, general office, training and meeting purposes.&#160; The Design-Build Agreement contains several design phase milestones beginning in July 2019 and sets the&#160;date for Substantial Completion (as defined in the Design-Build Agreement)&#160;in the third quarter of 2020, subject to adjustment in accordance with the terms of the Design-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Build Agreement.&#160;The estimated cost pursuant to the Design-Build Agreement&#160;is $30,400. &#160;Additional costs associated with the renovation, purchasing of furniture and equipment,&#160;validation and certification of the property are estimated to be $14,400.&#160;&#160;</span><span style="white-space:pre-wrap;">These capital expenditure costs will be incurred as they arise until the anticipated full transition of material processing to the property by early 2022.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company expects to receive certain economic development grants from state and local authorities totaling up to approximately $2,685 including $1,250 of cash grants to offset costs to acquire and develop the property.&#160; The economic development grants are subject to certain job creation milestones by 2023 and related contingencies.&#160;</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Public Offering of Common Stock</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On November 16, 2017, Axogen entered into a certain underwriting agreement (the &#8220;Leerink Underwriting Agreement&#8221;) with Leerink Partners LLC, as representative of the several underwriters named therein (collectively, the &#8220;2017 Offering Underwriters&#8221;) and Essex, pursuant to which (i) the Company agreed to issue and sell 700,000 shares of the Company&#8217;s common stock pursuant to a registration statement on Form S-3 (File No. 333-207829), filed with the SEC on November 5, 2015, and declared effective by the SEC on December 11, 2015, and the prospectus contained therein, as supplemented by the prospectus supplement dated November 16, 2017, and (ii) Essex agreed to sell 1,000,000 shares of the Company&#8217;s common stock pursuant to a registration statement on Form S-3 (File No. 333-220770), filed with the SEC on October 2, 2017, and declared effective by the SEC on October 11, 2017, and the prospectus contained therein, as supplemented by the Prospectus Supplement, in an underwritten registered public offering at an offering price of  $21.00 per share.  The Company and Essex granted the 2017 Offering Underwriters a 30-day option to purchase up to an aggregate of 255,000 additional shares of common stock, at the public offering price, less the underwriting discounts and commissions, which was exercised in full on November 16, 2017.  The Company received net proceeds of approximately $15,655 after deducting the underwriting discounts and commissions and estimated offering expenses.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On May 8, 2018, the Company entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the &#8220;2018 Offering Underwriters&#8221;), pursuant to which the Company agreed to issue and sell 3,000,000 shares of the Company&#8217;s common stock in an underwritten registered public offering at an offering price of $41.00 per share (the &#8220;2018 Offering&#8221;).  The Company granted the 2018 Offering Underwriters a 30-day option to purchase up to an aggregate of 450,000 additional shares of common stock, at the public offering price, less the underwriting discounts and commissions, which was exercised in full on May 9, 2018.  The 2018 Offering closed on May 11, 2018, and the Company received proceeds of approximately $132,707 from the sale of the shares (including the sale of 450,000 additional shares issued upon exercise of the 2018 Offering Underwriters&#8217; overallotment option), after deducting the underwriting discounts and commissions and estimated offering expenses.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen does not have any off-balance sheet arrangements.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Effect of Inflation</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Inflation has not had a significant impact on our historical operations, and we do not expect it to have a significant impact on our results of operations or financial condition in the foreseeable future.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The discussion and analysis of the Company&#8217;s financial condition and results of operations is based upon the Company&#8217;s consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;USGAAP&#8221;). The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amount of expenses during the period reported. Management bases its estimates and judgments on historical experience, observance of trends in the industry, information provided by outside sources and on various other factors that are believed to be reasonable under </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">the circumstances. Actual results may differ from these estimates under different assumptions or conditions.  We have described our significant accounting policies in Note 3 &#8211; Summary of Significant Accounting Policies to our consolidated financial statements included in this Form 10-K.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Revenue Recognition</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection.  Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products and services to the Company&#8217;s customers.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract.   These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#8217;s cost.   The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and, therefore, the Company has determined it is appropriate to recognize revenue when:  i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement.  Determining the timing of revenue recognition for such contracts is subject to significant judgment, because an evaluation must be made regarding the distributor&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company.  Changes in these assessments could have a significant impact on the timing of revenue recognition from sales to distributors.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A portion of the Company&#39;s product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of sales.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#8217;s contracts vary; however, as a common business practice, payment terms are typically due in full within 30 to 60 days of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material.  The Company has several contracts with distributors in international markets which include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Allowance for Doubtful Accounts Receivable</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">We evaluate the collectability of accounts receivable to determine the appropriate allowance for doubtful accounts. In determining the amount of the allowance, we consider the aging of account balances, historical credit losses, customer-specific information and other relevant factors. We review accounts receivable and adjust the allowance based on current circumstances and charge off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. Our history of write-offs against the allowance has not been significant.  The allowance for doubtful accounts balance was $1,092 and $1,117 at December 31, 2019 and 2018, respectively.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Investments</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company invests primarily in U.S. Government securities, corporate bonds, commercial paper and asset-backed securities and classifies all investments as available-for-sale. Investments are recorded at fair value. The Company has elected the fair value option (&#8220;FVO&#8221;) for all of its available-for-sale investments.  The FVO election results in all changes in unrealized gains and losses being included in investment income in the Consolidated Statements of Operations.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Inventories</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Inventories are comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve&#160;Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane, Acroval Neurosensory and Motor Testing System, Axotouch Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company monitors the shelf life of its products and historical expiration and spoilage trends, and writes-off inventory based on the estimated amount of inventory that will not be distributed before expiration or spoilage.  To estimate the amount of inventory that will expire prior to being sold, the Company reviews inventory quantities on hand, historical and projected sales, and historical expiration trends. The Company&#8217;s calculation of the amount of inventory that will expire prior to sale has two components: 1) a demand or consumption based component that compares projected sales to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being sold. The Company&#8217;s model assumes that inventory will be sold on a first-in-first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that a significant portion of the Company&#8217;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written-down involves significant judgments and estimates.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company account for share-based compensation for all share-based payment awards, including stock options, restricted stock units, performance stock units and stock purchases related to an employee stock purchase plan, based on their estimated fair values. We estimate the fair value of time-based options on the date of grant using the multi-point Black-Scholes option pricing model (Black-Scholes model). Our determination of fair value of share-based payment awards is affected by our stock price, as well as assumptions regarding a number of subjective variables. These variables include but are not limited to our expected stock price volatility over the term of the awards.  The value of the portion of the awards that are ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Operations.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimate the fair value of restricted stock unit and performance stock unit awards based upon the grant date closing market price of our common stock.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company also have an employee stock purchase plan (ESPP) which is available to all eligible employees as defined by the plan document. Under the ESPP, shares of our common stock may be purchased at a discount, currently fifteen percent (15%). We estimate the number of shares to be purchased under the ESPP at the beginning of the purchase period and calculate estimated compensation expense using the Black-Scholes model based upon the fair value </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">of the stock at the beginning of the purchase period. Compensation expense is recognized over each purchase period, and expense is adjusted at the time of stock purchase.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company believes our critical accounting policies regarding revenue recognition, allowance for uncollectible accounts receivable, investments, inventories and share-based employee compensation affect our more significant judgments and estimates used in the preparation of our consolidated financial statements. The Company bases our judgments and estimates on historical experience, current conditions and other reasonable factors.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Leases</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company adopted ASU No. 2016-02&#8212;Leases (Topic 842), as of January 1, 2019, (the &#8220;Application Date&#8221;) using the modified retrospective approach. The Company will continue to report financial information for fiscal years prior to 2019 under the previous lease accounting standards. The modified retrospective approach provides a method for recording on the balance sheet as of January 1, 2019, leases that have commenced on or before the Application Date. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company elected the package of practical expedients permitted under the transition guidance, which allowed us to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Company also elected the practical expedient allowing us to not separate the lease and non-lease components for all classes of underlying assets, apart from equipment. The Company did not elect the practical expedient to use hindsight to determine the lease term for leases at January 1, 2019. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company made an accounting policy election to not recognize right-to-use assets and lease liabilities that arise from short term leases, which are defined as leases with a lease term of 12 months or less at the lease commencement date.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Adoption of the new standard resulted in the recording of right-to-use assets and lease liabilities of approximately $3,786 and $3,823, respectively, and the derecognition of capital lease assets, capital lease liabilities, and operating lease deferred rent of $96, $63, and $70, respectively, as of January 1, 2019 with zero cumulative-effect adjustment to retained earnings. The new standard did not materially impact our consolidated net earnings.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">See Note 3 &#8211; Summary of Significant Accounting Policies to our Consolidated Financial Statements for further information.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_08be9c2a_ac53_4d7e_99e4_fbd215b46e7b"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Item 7A.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Interest Rate Risk</i></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company is exposed to market risk from interest rates.  For our cash, cash equivalents and investments, a change in interest rates affects the amount of interest income that can be earned. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company invests its cash primarily in money market accounts, U.S. government agencies and securities, corporate bonds and commercial paper. Although the Company believes its cash to be invested in a conservative manner, with cash preservation being the primary investment objective, the value of the securities held will fluctuate with changes in the financial markets including, among other things, changes in interest rates, credit quality and general volatility. This risk is managed by investing in high quality investment grade securities with short-term maturities.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalent balances and investments in corporate bonds. Certain of Axogen&#8217;s cash and cash equivalents balances exceed FDIC insured limits or are invested in money market accounts with investment banks that are not FDIC-insured. The Company places its cash and cash equivalents in what it believes to be credit-worthy financial institutions. As of December 31, 2019, $35,224 of the cash and cash equivalents balance was in excess of FDIC limits. </p><a id="_2ce4249a_ab8f_4ffd_b95f_3a78b1446f02"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DAT</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">A</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTENTS</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ReportOfIndependentReg_2018"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 2019 AND 2018</span></a></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#ReportOfIndependentReg_2017"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 2017</span></a></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#BALANCESHEETS_194574"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2019 AND 2018</span></a></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONS_83571"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2019, 2018 AND 2017</span></a></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">87</p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#SHAREHOLDERSEQUITY_23589"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY FOR THE YEARS ENDED DECEMBER 31, 2019, 2018 AND 2017</span></a></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#CASHFLOWS_180433"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2019, 2018 AND 2017</span></a></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_4"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="#Schedule_II_Valuation_Accounts"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS</span></a></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">117</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ReportOfIndependentReg_2018"></a><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="font-family:'Times New Roman';"> </span></p><p style="font-family:'Arial';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">To the shareholders and the Board of Directors of Axogen, Inc. </span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Opinions on the Financial Statements and Internal Control over Financial Reporting </b></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">We have audited the accompanying consolidated balance sheets of Axogen, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2019 and 2018, the related consolidated statements of operations, shareholders&#8217; equity, and cash flows, for the years ended December 31, 2019 and 2018, and the related notes and the schedule listed in the Index at Item 15(a)(2) (collectively referred to as the &#8220;financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in </span><i style="font-family:'Times New Roman';font-style:italic;">Internal Control &#8212; Integrated Framework (2013)</i><span style="font-family:'Times New Roman';"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for the years ended December 31, 2019 and 2018, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in </span><i style="font-family:'Times New Roman';font-style:italic;">Internal Control &#8212; Integrated Framework (2013)</i><span style="font-family:'Times New Roman';"> issued by COSO.</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';"> </span><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Basis for Opinions</b></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;"> </b><span style="font-family:'Times New Roman';font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">The Company&#8217;s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on these financial statements and an opinion on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';"> </span><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">Our audit of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Definition and Limitations of Internal Control over Financial Reporting </b></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;"> </b><span style="font-family:'Times New Roman';font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';font-style:italic;font-weight:bold;">Inventory &#8211; Valuation Associated with Excess and Obsolete (E&amp;O) Inventory &#8212; Refer to Notes 3 and 4 to the financial statements</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';font-style:italic;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman';font-style:italic;">Critical Audit Matter Description </i></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">Inventories are comprised of unprocessed tissue, work-in-process, and implantable tissue and devices (finished goods) and are valued at the lower of cost or net realizable value. &#160;The Company reviews inventory quantities to assess whether inventory will expire prior to being sold. &#160;To estimate the amount of inventory that will expire prior to being sold, the Company reviews inventory quantities on hand, historical and projected sales, and historical expiration trends. The Company&#8217;s calculation of the amount of inventory that will expire prior to sale has two components: 1) a demand or consumption based component that compares projected sales to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being sold. The Company&#8217;s model assumes that inventory will be sold on a first-in-first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that a significant portion of the Company&#8217;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written-down involves significant judgments and estimates. </span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';">Given the significant judgments associated with evaluating the valuation of E&amp;O inventory, auditing the reasonableness of management&#8217;s estimates and assumptions involved especially subjective judgment and an increased extent of effort.</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman';font-style:italic;">How the Critical Audit Matter Was Addressed in the Audit</i></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman';">Our audit procedures related to the Company&#8217;s valuation of E&amp;O inventory included the following, among others: </span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We tested the effectiveness of controls over the E&amp;O inventory valuation. &#160;The controls we tested included those over the calculation and accuracy and completeness of underlying data used in the calculation. </span></td></tr></table><p style="font-family:'Arial';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We performed procedures to evaluate management&#8217;s ability to accurately forecast by comparing the historical expiring inventory estimates to subsequent inventory destructions and expirations. &#160;</span></td></tr></table><p style="font-family:'Arial';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We obtained the Company&#8217;s E&amp;O calculation and tested the mathematical accuracy.</span></td></tr></table><p style="font-family:'Arial';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We assessed the reasonableness of the assumptions used in the E&amp;O calculation by developing an independent expectation and comparing our independent expectation to the results of the Company&#8217;s calculation. </span></td></tr></table><p style="font-family:'Arial';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We tested the accuracy and completeness of the underlying data used in the calculation of the Company&#8217;s expiring inventory model.</span></td></tr></table><p style="font-family:'Arial';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We made inquiries of the Company&#8217;s employees outside of the accounting department and evaluated other areas of the audit to identify business, product, or industry changes that may impact the inputs in the inventory valuation calculation.</span></td></tr></table><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';"> </span><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';">/s/ Deloitte &amp; Touche LLP </span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';">Miami, Florida </span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';">February 24, 2020 </span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">We have served as the Company&#39;s auditor since 2018.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ReportOfIndependentReg_2017"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 2017</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">To the Shareholders and </p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Board of Directors of</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Axogen, Inc.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated statements of operations, shareholders&#8217; equity and cash flows for the year ended December 31, 2017 of Axogen, Inc. and Subsidiaries (the &quot;Company&#8221;), and the related notes and financial statement schedules listed in the index appearing under item 15(a)(2) (collectively referred to as the &quot;consolidated financial statements&quot;). </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the Company&#8217;s results of operations and cash flows for the year ended December 31, 2017 in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control Over Financial Reporting. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';">Our audit of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">/s/ Lurie, LLP</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Minneapolis, Minnesota</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">February 28, 2018</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">We served as the Company&#8217;s auditor from 2004 to 2018</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_fff1b83b_6f9e_493a_9f29_9a81bef09a65"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AXOGEN,&#160;INC.</b></p><a id="BALANCESHEETS_194574"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED BALANCE SHEET</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019 and 2018</b></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In Thousands, Except Share Amounts)</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_d311b9a8_f6e9_4a40_b953_90d0e2695526"></a><a id="Tc_-Dy17x2SFkG5bfNoGovmuQ_2_2"></a><a id="Tc_dymXDk4-G0enJH2bfFKLCw_2_5"></a><a id="Tc_lpiEhtRXtEGSvATS9Rxw1A_3_2"></a><a id="Tc_s0-QtaCn7kKTCBQc2PjjdA_3_5"></a><a id="Tc_IQC3LkcVoEihMnx65C7gdw_4_0"></a><a id="Tc_xC_FXZ9NfEarfbFC8n1GSw_5_0"></a><a id="Tc_JpmosVIAJk6Rx-XZ_HBWPA_6_0"></a><a id="Tc_3nBh4rZbjEm-qXGSX5QwkQ_6_2"></a><a id="Tc_3SeHU6XlqUir042ljM9zzw_6_5"></a><a id="Tc_-DTZ-jz0cUuG3W77bc4l9Q_7_0"></a><a id="Tc_C1Pa3H4EuEWetLlyjU4P_w_8_0"></a><a id="Tc_66rsWK3_m0ynFthYXDTLpw_9_0"></a><a id="Tc_raK3QFtoXE6tF-j7cxW8fQ_10_0"></a><a id="Tc_3cS7alD0ZkG_b8YTisq4Hg_11_0"></a><a id="Tc_nFyVfxhN3UaLwjA7wH7_MQ_12_0"></a><a id="Tc_z4N3rqdxzk2tpIqXw3at1w_13_0"></a><a id="Tc_KL_16PEbOUC-ySwf68y6Yw_14_0"></a><a id="Tc_cmCj7b1ITkSa4koRtPlcYw_14_6"></a><a id="Tc_fclOukbS4kOkk7hZaNzL1Q_15_0"></a><a id="Tc_kKHtKn0cp0ma0Pn2RM0C8w_15_6"></a><a id="Tc_3PRM8RCgR0mOhrwSkkTYjQ_16_0"></a><a id="Tc_l5oz4wbnfE-24Io_G57OcA_17_0"></a><a id="Tc_38mNpcB-XkWkOfNGtUkIqw_17_2"></a><a id="Tc_zjcuMM_RVkabfbXAwxhOMw_17_5"></a><a id="Tc_T82s5Q8ftUCURZsVMyIARA_19_0"></a><a id="Tc_My1-psmybkWXVBy4BB6LwQ_20_0"></a><a id="Tc_L04I-yKYPke0mmjXCh5vHg_21_0"></a><a id="Tc_bwdtWLK0tkmL5rA9KrEbzA_22_0"></a><a id="Tc_h5V_ojE44keBJXVxMy9g4w_23_0"></a><a id="Tc_t5wf4wZdWEOmMclDfTt4Rw_24_0"></a><a id="Tc_ZVl8y-iFYEq1OxWryeanCQ_26_0"></a><a id="Tc_4vjUIVtxDECYu4PT89dttw_27_0"></a><a id="Tc_uXixoCFRp0uaMxPeHiNxaA_27_3"></a><a id="Tc_s--WZYAFOUmyqwXw_sa5_w_28_0"></a><a id="Tc_qxugqkE1q0G28i7ixnxc4g_29_0"></a><a id="Tc_p_tJxwGCBkGpXU1G8BNoLg_31_0"></a><a id="Tc_TrnfIysVAUyC_xSOS7lmww_33_0"></a><a id="Tc_edI5sUxClUy1QUJIvnRQAw_34_0"></a><a id="Tc_WsQzhcfMF0CbvJ-zAk1Ybg_35_0"></a><a id="Tc_FygC0z-pL0GlPiX1InyLBg_36_0"></a><a id="Tc_iIFKLZxUdUyFEmQ8qKyKrg_37_0"></a><a id="Tc_lR5RnOHbukOYKuzp4_ZuAQ_38_0"></a><a id="Tc_DVSQ55LyrUSi6syTVPKqfQ_38_2"></a><a id="Tc_9EaRJpoB5k-HADQlvStBqw_38_5"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_kwkVALLapk69Lq2WgJTR3w_6_3">35,724</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_lVYgP93J8UuJ6xvPebsrkg_6_6">24,294</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_89lYeUehfEWypTM-sywO3w_7_3">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_GPpvlC7S-kC-PT-s3fcgVQ_7_6">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_yCb4dC6Sok2GAKWlpx4xbw_8_3">60,786</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_h4Y2C1tW8E-imJxLDNzr2A_8_6">92,311</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="Narr_XEZAWaPOy0S356fQXDmNrQ">1,092</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="Narr_J20H-_D4O0O5-zT_d7O-AA">1,117</ix:nonFraction>, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_WhP1NhhxOkq6odO2cJBgaA_9_3">16,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_VUORrc7ZFkWl4L0zdTBtWw_9_6">15,321</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_YtcdAMdIPku8Lf6F91dbyw_10_3">13,861</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_8me8hasd-0u94icanVW_RQ_10_6">11,982</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_oFlkEngcg0uuihayQSiyxA_11_3">1,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_DNbC_XYM_0Ku2el_jLDvpA_11_6">1,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_O_vju-o1YU-OJxsyvSs4Ag_12_3">135,021</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_YPJTRr6wwUaowZIFXrLnJg_12_6">150,953</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_3IdwaVja8E-iHF0qxB6jGg_13_3">14,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_FhuaHXCHTkuzu03umdtWxg_13_6">8,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating lease right-of-use assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_u8fBj3Z3p0Crwxrv_ViOtA_14_3">3,133</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Finance lease right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_Iz5WHezojkW-1NmRj38oTA_15_3">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Intangible assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_oQDQfK-uOUCLJJe_q00gFQ_16_3">1,515</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_lfbwaT6UAkiguPzkxEutaQ_16_6">1,181</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_r23VunldY0aQDz2Mjb-9jw_17_3">154,643</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_drWvHLn8lEaq2JPeGa818g_17_6">160,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Shareholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_NjylFXLXmEm9Dhp38uYUWA_21_3">19,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_7Us7hxbUfEa63mOXPBX3Nw_21_6">12,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Current maturities of long term obligations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_9x5tZ2TzrEWPY0-inEZJBQ_22_3">1,736</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_R5yQoldO6Eyqt0o0Mf5VsA_22_6">28</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contract liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_c3pcsRqGPEuru5PK2q7_MQ_23_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_WiMWXhxyOEGimBwwctOrYg_23_6">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_69Xv3KrPaECrztt3h03fMg_24_3">20,880</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_SBE4Fo_gAkaJapjaCckPWg_24_6">13,044</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Long Term Obligations, net of current maturities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_t7eehxLbj0iGL0FDUwwgEA_26_3">1,595</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_Qq3HPDQieka9ESVX1pP1Yg_26_6">35</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other long-term liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_i3pEBHCgpkeYYtAKc446Aw_27_6">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Contract liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_PZUWLAFRpUKY4j9r-ueaOA_28_3">15</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_kOSda7hiFkOofDKFS4FlwQ_28_6">42</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_t_KaaYgID06E_PI6TEIT2Q_29_3">22,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_TqVpDJ975ECrwcYSBI-yrQ_29_6">13,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Commitments and contingencies - see Note 14</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;">Common stock, </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_OHwwhzgOtk-3EcAskUdaWQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Z1xn36EVoEC0R1CgTPd3iA">0.01</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;"> par value per share; </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_LEgo6wZ9r0SFsVIDLoGlMw"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_xZY35HbGkEeDu_htN9amwQ">100,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;"> shares authorized; </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_FdmXMEOR9UueVMwOhWxGyg">39,589,755</ix:nonFraction></span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_wip7ONGEukqy_P1w3NGyRQ">38,900,875</ix:nonFraction></span><span style="font-size:10pt;"> shares </span><span style="-sec-ix-hidden:_f512fdbf_b9ff_4859_8380_dfc91859b80e"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span><span style="font-size:10pt;"> and </span><span style="-sec-ix-hidden:_c344fd47_2394_4dca_b707_ae51747fa418"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_H2F1WIW-A0CpVcy3z3VTTw_34_3">396</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_rlPRHZGd-Em18NtVDFXBtg_34_6">389</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_yvGBl3tBRke8aWK5jHTK4g_35_3">311,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_oVEF76FY1kWEw36u2yG-IQ_35_6">297,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_oBgjgfaMy0un2ArtyO4FJA_36_3">179,861</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_ESrmnJaSX02lZG3_gfqY5g_36_6">150,726</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QfIbWWJwpEaOOAuW93gi2w_37_3">132,153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5jWgI6X580mcD9jIJusYXg_37_6">146,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total liabilities and shareholders&#8217; equity</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_i8Sybx3MUk6kpKmNWi85-g_38_3">154,643</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_wTPlgUPuH06NLi-QZOQoCw_38_6">160,173</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these consolidated financial statements.</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_2f8a8f4a_dea0_4943_a11d_7521f00b904f"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AXOGEN,&#160;INC.</b></p><a id="STATEMENTSOFOPERATIONS_83571"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATION</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years ended December&#160;31, 2019, 2018 and 2017</b></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In Thousands, Except Per Share Amounts)</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_c86c8311_4445_469f_b9a2_40948823c435"></a><a id="Tc_x8CVg6oKqkaZw05yKVsUyg_3_2"></a><a id="Tc_mI0qpNzNmkKphR_hypN73g_3_5"></a><a id="Tc_fCSsFeaDREGB5Hg-qkzoTA_3_8"></a><a id="Tc_6_EfI_cecEmwKpKfFypWFA_5_0"></a><a id="Tc_8bCfzBxHTUS8VEF8mWWjdA_5_2"></a><a id="Tc_LGkNrTPpQki4gkOXzBeYDA_5_5"></a><a id="Tc_RpJ9kuVs9kqSwx7vE1pR4Q_5_8"></a><a id="Tc_e_sKhatLS0aRsK6GSLmftw_6_0"></a><a id="Tc_ac-cmwutfEWPZiIcJ9qaVA_7_0"></a><a id="Tc_kowxcRjUVE-rSFExXMQLgg_8_0"></a><a id="Tc_tU9fbahxD0q2jr33WDzMdw_9_0"></a><a id="Tc_wUm0HkNmKk6JP50Yv5JmUQ_10_0"></a><a id="Tc_KsR3ROaZ5kiCZ4gVxYCbaQ_11_0"></a><a id="Tc_lMISlEU1u06uPET0-oNnNw_12_0"></a><a id="Tc_kpF_H508L0md9M7hrvDv8Q_13_0"></a><a id="Tc_g0sbHI92NEega9Y351FqSg_14_0"></a><a id="Tc_kAA4eV2FF0ai6AXSuAyqpQ_15_0"></a><a id="Tc_f3S1-ZrNL0arBKV_UmbhOQ_15_9"></a><a id="Tc_I5bATVAJ7E-FLDBwcJlXoA_16_0"></a><a id="Tc_qloporhyH0q-iTzqHeefjw_17_0"></a><a id="Tc_xn27sQzBYEad_8Rq7IAj4A_17_3"></a><a id="Tc_-wgTJSamK0Ok-2q5boJM6A_18_0"></a><a id="Tc_d3ujy19EfUeQvGOy0F1Hkg_18_3"></a><a id="Tc_YUCNPZG7E0mMbNqJgUce-A_18_9"></a><a id="Tc_HuREM3-NgkeAfBA-C6eJcA_19_0"></a><a id="Tc_N37-AiQTO0CshQvqBnx_1g_20_0"></a><a id="Tc_9TtQxRRGO0qlYBIW_9KUHQ_21_0"></a><a id="Tc_iU4SYySp8UCB0dJHOl3fPg_22_0"></a><a id="Tc_MevdvDZtdkqZ7n0tBjIUTg_23_0"></a><a id="Tc_YW4d5460NUa77Yvt-MdD5A_23_2"></a><a id="Tc_DpyAqT7f2UmYgYsa5XxfqA_23_5"></a><a id="Tc_SYDyTlWoskicassoejPHaA_23_8"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:-0.08654785%;padding-left:0pt;padding-right:0pt;width:100.17%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenues</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_5uFeZ4e2p0-x_dOhHHI5iw_5_3">106,712</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_RjVqx7GbBU2b34y4I2Pf6g_5_6">83,937</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_9YcdTeiDG0Cgqb-FVCxRVA_5_9">60,426</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cost of goods sold</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_G-zvTTVKfUiA-hYaOx8jlg_6_3">17,349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_zs2hvCRNpUi1_DaJysU-fg_6_6">12,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_vwHAbV6rakqYe-UeAxy-rA_6_9">9,311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Gross profit</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_ifXCWwAqP0mJgtLoJSJxOw_7_3">89,363</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_5raCIm-PrkiaHzGUUp5yMA_7_6">71,014</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_0bDfhXhZZEu5K-Bn05X1Kg_7_9">51,115</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Costs and expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales and marketing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_8lDr95AUCE-I5f3Rk2q5cw_9_3">71,950</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_mOY63Dm9e0WOi3QLwKRcgg_9_6">56,617</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_WRwaOvYPbUWW4-fydV3ZmA_9_9">37,636</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_NsPKuXk-DEyDtf3oKYCR9w_10_3">17,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_9M7JHFtDc0-cer588SiLRA_10_6">11,773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_HdTmSlQaCUuYQyfb4Vxq0w_10_9">6,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_KUWTu1X1pEy2uwbkEkQgZg_11_3">31,305</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_TCBJgj4nqEyvjgljVrTsBw_11_6">23,124</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_l15cH3v2O0e16hVMeU_NZA_11_9">14,731</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total costs and expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_24KR8pZ8GEmBH1GEHuifeQ_12_3">120,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_2Rd__A8bm0WSVNMzlSEMMQ_12_6">91,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_dR1oYmFu9kaTmCzifsBrqQ_12_9">59,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Fqm7JHA6QU2eJ7JBlNYUqA_13_3">31,406</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_yKNNeFAfQUCoz9-mcqEjSA_13_6">20,500</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_D5v-x9nbK0S2yx9JXs36mA_13_9">7,951</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Investment income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="Tc_iZBua7vlUk-wI81SPzbw9g_15_3">2,364</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="Tc_eR2jCufa5kSfWivWOU15jw_15_6">1,525</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_IEYl6oDfmEWaB9wKgiIxzg_16_3">40</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_0FI5nf3UbkWcFzSSMytCvA_16_6">1,127</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_qc63ZJ8HF0KmsQ3wwqu0jQ_16_9">2,217</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense &#8212; deferred financing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_4zo40exa5UekUFeGSStgJw_17_6">81</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_7emt1B4qRk6j2_kfogh8Pw_17_9">246</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_ZGqMFS3ywEaf7jSKs_xV_Q_18_6">2,186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expense </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_11RyFo8AlkKXtI7s6NQ3og_19_3">53</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_zIYZBslg_EWV_ghrPJDkLA_19_6">28</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_zHgD4VjqRkGehCLvFO_REA_19_9">31</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total other income (expense), net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_CLjySgKXtkexI6F07HTl0w_20_3">2,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_MtzCHwqll0i1yBjYeuFW7w_20_6">1,897</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_dOK9Hbvf2kys1LTYQAXPTA_20_9">2,494</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Loss</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YarWz0sEwEGltC0F-9N4dw_21_3">29,135</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3wi4iEdKuE-uuHXXzW0--w_21_6">22,397</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HqTzVRBgRE2xWBErq-YFVQ_21_9">10,445</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Weighted average common shares outstanding &#8212; basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_RoZBkJMPG02ySQhYyvrvvg_22_3">39,235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_JCaVtSicqkGgoPP64k40Mg_22_6">37,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_weOGJ45qr0W6msYVNPImzA_22_9">33,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss per common share &#8212; basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_Djw7cIuOWEuulABL8_By-w_23_3">0.74</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_XZuLDYKP2UC7keC3CtJj6A_23_6">0.60</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_f5V4kBeMKkmxm8xWQ585Sw_23_9">0.31</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these consolidated financial statements.</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_45cb3328_dc2a_480c_b2d1_90149ebd9205"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AXOGEN,&#160;INC.</b></p><a id="SHAREHOLDERSEQUITY_23589"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUIT</b><b style="font-weight:bold;">Y </b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years ended December&#160;31, 2019, 2018 and 2017</b></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In Thousands)</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_5b044bf5_59ef_4d0d_b1f9_2b766af96075"></a><a id="Tc_D00ejppVnUu2W38rteiiSA_1_7"></a><a id="Tc_6tHm87udfEis4tUXiZJ1ww_1_13"></a><a id="Tc_j7i1cv_J3kKKgQ5imryjXA_2_2"></a><a id="Tc_emXSUqVjm0eRtLll5qyIIw_2_7"></a><a id="Tc_U94ZOUjvCUegIQEUjj7eNA_2_10"></a><a id="Tc_5fQ2VbsutUmUgvQbi-AqIg_2_13"></a><a id="Tc_er9Rg0MKqE2guITA09S2uA_3_2"></a><a id="Tc_5OvUfLDrrkSFOkAV6DcL2w_3_4"></a><a id="Tc_FWtgonuHCkOizN_J8vnwAg_3_7"></a><a id="Tc_ArLK4RYj7E2_gvJ3zl6RMw_3_10"></a><a id="Tc_gobeARxyDkurmkbzHLYsog_3_13"></a><a id="Tc_sbdiSQy-o06P1j01XGmQvw_4_0"></a><a id="Tc_rIcq6kv-VE6mjtVUuH0EZw_4_4"></a><a id="Tc_HlzgpaJKQ06bBdJ7F0NJAg_4_7"></a><a id="Tc_V8UPkhN6mkCaiGFVyXwwYg_4_10"></a><a id="Tc_cqZ7XWFAwEaTkh0iR0IXTQ_4_13"></a><a id="Tc_pJp_VOFS-UW5CuOfI2JEhQ_6_0"></a><a id="Tc_VWXYwHbXhUK7LF-BK1sHzA_6_2"></a><a id="Tc_EZy35TxPBk2OFwnaUIMQhA_6_5"></a><a id="Tc_lgkh_WWVIEOlrG-QuHkXww_6_11"></a><a id="Tc_Q2Q27ze3UU6H6zSXXiyVew_7_0"></a><a id="Tc_fiifWUv0z0i6ODuntPXPKA_7_11"></a><a id="Tc_3jyiBDxt9UmU1HMBh81xag_8_0"></a><a id="Tc_-wg8sVa0JEy2zpcoz8ajAg_8_11"></a><a id="Tc_Qk2wMhBK2kiOg7LZSjUZmw_9_0"></a><a id="Tc_J4PHBnM0mkqENvPQ-UWNxw_9_2"></a><a id="Tc_HhgTBNMJ_kCl3OQB4UPyXQ_9_5"></a><a id="Tc_3yhWg30TIUSV2k7QIE-GCA_9_8"></a><a id="Tc_z0sCDeta70GgKY6veElUBA_11_0"></a><a id="Tc__GJw8yzJ70mhREesdrShRQ_11_4"></a><a id="Tc_RmbOw68Sa0GAWVOFM4OwEA_11_7"></a><a id="Tc_0f2T_bKlEUqL6ldQt7Jo_g_11_10"></a><a id="Tc_DjyQWAqtWUSTL87h2OLqOg_11_13"></a><a id="Tc_HEDq-uCdskqnzyHV6ZkSTQ_13_0"></a><a id="Tc_DmhvYRc-ZkiaFfpya7B9uA_13_2"></a><a id="Tc_KUCNFWBAfUCU3Zx6hfAG2A_13_5"></a><a id="Tc_BZxLRslCdUurqzVG6olLbA_13_11"></a><a id="Tc_SDLeSE50GEmEo9_3wqJxrw_14_0"></a><a id="Tc_ldrY0FnNpUa2pqwlTtqqTQ_14_11"></a><a id="Tc_6fbyKoDS6UejYe5_cPChpA_15_0"></a><a id="Tc_2XPfAAXwC0Gj9UbNymckoA_15_11"></a><a id="Tc_XgtB8OCEg0ebsnaENbDWPA_16_0"></a><a id="Tc_UNOwyIOqeka0wbbF1vTxbw_16_2"></a><a id="Tc_3Lu812neyUywqjwEaBJbFw_16_5"></a><a id="Tc_koglVVAP6kujsfZypOdzHQ_16_8"></a><a id="Tc_DcQuZtlEkEq-DVfRonfC6Q_18_0"></a><a id="Tc_CIBi7N9VhUaR3hzwV6aEjg_18_4"></a><a id="Tc_rCHqQy3IUESGFw76pp2FZQ_18_7"></a><a id="Tc_43TS3P7ap0yb7HPLiKhvHQ_18_10"></a><a id="Tc_inHwN27wZUmm6AfqZ8cNAw_18_13"></a><a id="Tc_TXdJQMrpYUySKhelZ3L0Cw_20_0"></a><a id="Tc_WnHHbL-P80GDv267G616HQ_20_2"></a><a id="Tc_TLhy1b9A9UiZjdhHSEFP5w_20_5"></a><a id="Tc_M6jNJPRbg0WuWubP8mkUSQ_20_11"></a><a id="Tc_0zAsfnfPG0u3k_viyjTYCw_21_0"></a><a id="Tc_RCw5pdBk-UaZ9qb9zBQ_-A_21_11"></a><a id="Tc_DmwGbaG2UkKThPbUvQgfdg_22_0"></a><a id="Tc_RHt5oUtA5kWe60GnHMMvWw_22_2"></a><a id="Tc_Cj7oSGGqMEC0-eR64kiX5g_22_5"></a><a id="Tc_LnVjVTS3rUqQx1BCLepwZA_22_8"></a><a id="Tc_bGs1q4J9f0KB_NLLqb0e3Q_24_0"></a><a id="Tc_pcNQUneTokmALjn-RP1Ogw_24_4"></a><a id="Tc_Cj4TDIZ4RUWrTbOujglqXw_24_7"></a><a id="Tc_n8uJAkoA802NsmQkPPTSjQ_24_10"></a><a id="Tc_pgvKv5X8hUugv6j3V9j28w_24_13"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shareholders&#8217;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity/(Deficit)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, December 31, 2016</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TJlFr_r_RkuXuvZTAhvzYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_rIUI8C5B4UyQUaxpFDgS1A_4_2">33,009</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TJlFr_r_RkuXuvZTAhvzYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VT9Rcw8K4ES9MX4-E-mArg_4_5">330</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yopO1vpWDkSdAu8pQTBE6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Wy6gT2FRi0uNGanSebgJ-A_4_8">132,475</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rABqkECIXEmoFHY4P39Btg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_8jTdj6cLh0m7OkNYZTKxLQ_4_11">117,884</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2016_Or2PNLcVTkK03OOF11rmZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ztl9qNqCxU2xjxV93QnAug_4_14">14,921</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ix9c_2i7sEuWHRfmxUztXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_n7Kq84l1dUS5TMsVeh5nXg_6_8">3,609</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_uRh3Z4Xr_U2UzIESBlewgQ_6_14">3,609</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_vlz6cp98WEG_1CN6t8J35w_7_2">536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_HWyOMgB4SkOnt7yBtKURRA_7_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ix9c_2i7sEuWHRfmxUztXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_SuMLSMZY9kSU2u1otpEyew_7_8">1,429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_DZwpC2ylc0W3ebw-ulNSYg_7_14">1,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Issuance of common shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_lmJxXcNG5UqKy_ZXvV31AQ_8_2">805</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_B7KVGkxhaUK8-tSSekQnPw_8_5">8</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ix9c_2i7sEuWHRfmxUztXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_IWwFJ8UrjUmHaa7peGD80A_8_8">15,655</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_4AkVdSSlIkSJ24Q854Z3ow_8_14">15,663</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yAQQYV4FD0OLKehglkYWNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jjWYk1owRkWrtry5Q3fIIQ_9_11">10,445</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_r42jY2XB-EGaa6afOjaVMw_9_14">10,445</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, December 31, 2017</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B8IECFly_kaRlwUWZ1F6ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_kZQWTBvxq0ySwVkpN7_smw_11_2">34,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B8IECFly_kaRlwUWZ1F6ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_krLB0g7JOEWp6yNq83SEnQ_11_5">343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36RWqiIIvUqIM5o6-tTfQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lvyc9jw6bEmUB3QKyhCEyg_11_8">153,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-KZyjfz9K0yURx8oujgc-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_hr_55x_h_U246unZTY6CHg_11_11">128,329</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_niMj4QeCeUGESsaE3ZBkxA_11_14">25,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3xXv5tKLESPI6qfsNRBAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_JQya2kSwNka3o1vkiokESA_13_8">7,606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_MxlGPcay206K3mcIQduWug_13_14">7,606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_yirINkaCfUeMx63-5B8JkA_14_2">1,101</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_7ukawtFr9UawYLVZLIZ9pw_14_5">11</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3xXv5tKLESPI6qfsNRBAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_7hH1_dYq0EqZrb2YrD0hmg_14_8">3,873</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_KmZioDU370ekA6a4ivZxtw_14_14">3,884</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Issuance of common shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_bwpi45b1ok6B8dbZn5-0tg_15_2">3,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_43Lakk0FoUW1IQ_d0DRv8A_15_5">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3xXv5tKLESPI6qfsNRBAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_N-LzobPW7kqbhgCL2GZnzg_15_8">132,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_tS-LLSUx_UCPJv47tuZk6g_15_14">132,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MOuFDoRprUic4VVjiNOb9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_CHu6F50uMESN_q5t8og96Q_16_11">22,397</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_AS1ZzhL5jU6xIuY7wI77-g_16_14">22,397</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, December 31, 2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qFCNsryetU6naqT7GbcEhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_cIuLBqyaeUW125a6cPra2A_18_2">38,901</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qFCNsryetU6naqT7GbcEhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2XCZ0S7xIkiNYfFe5tPR9A_18_5">389</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UsFg6g1V3k-jJJ9z3zX3kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_95Inbj9ZIkmg-AGcPBfrGw_18_8">297,319</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5iFiNf4eCU2t-jlDjLdgiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_U7BsptEW-EeK32VPkyhHQw_18_11">150,726</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ccSkS0V-4EuiniV0Uzfj7w_18_14">146,982</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zPNTOe5UAku8lMq39V0WUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_6xmPvuiPn0qfPl5OQEAfkg_20_8">10,304</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_PPi_Mb-D2UC6EzbuDrITDg_20_14">10,304</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Exercise of stock options and employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pgmLVwXuIUS__MSTlzniug" decimals="-3" format="ixt:numdotdecimal" name="axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="Tc_9qbA69Uxa0muH-J-3yJOLg_21_2">689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pgmLVwXuIUS__MSTlzniug" decimals="-3" format="ixt:numdotdecimal" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="Tc_d1O3G6yySUCBATsGO1vGZA_21_5">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zPNTOe5UAku8lMq39V0WUg" decimals="-3" format="ixt:numdotdecimal" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="Tc_hkY5o_m29UapZFwKG_ml0A_21_8">3,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="Tc_P9l4Nz7lJUmcpZudplkLoQ_21_14">4,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_okKh-SdZMEibF5PgZHtNtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_dJzKYXshRUKEshZBjdDhbw_22_11">29,135</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4MLupdImFUyg7TFeqETVzA_22_14">29,135</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, December 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x8gKvx5oDUisUyE4r4cbmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_4y3-anFJPkOlUY-yLkRV1Q_24_2">39,590</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x8gKvx5oDUisUyE4r4cbmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8zw5r5K0oEisMP6waDKIHg_24_5">396</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OqYgr00JsUa249PGlgCbJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1lVsxW0cDkaesHdgmi-YnA_24_8">311,618</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CS4l3RjFjkG4cuMVEIJHOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_m2zMuoBGtkaXOBCZRTYjvA_24_11">179,861</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_T0PQf0l_YE-A2KnwddHNXQ_24_14">132,153</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these consolidated financial statements.</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_4f722fda_7967_4b48_9acf_d61d5a3f3cc7"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AXOGEN,&#160;INC.</b></p><a id="CASHFLOWS_180433"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOW</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years ended December&#160;31, 2019, 2018 and 2017</b></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In Thousands)</b></p><a id="_3e6a68e3_97c1_4a21_831e_83d5092f4797"></a><a id="Tc_65MQ7ulHZUCQNgKvQZRG1w_1_2"></a><a id="Tc_1e0lm0QtskWAzrcGep-Bmw_2_2"></a><a id="Tc_uzAZA9iSTUKMvaQ609gZQQ_2_5"></a><a id="Tc_EhXrDH5LZk652iE7KZnbfg_2_8"></a><a id="Tc_oSW_ZxlvOk-NQXTALSb61g_3_2"></a><a id="Tc_fPy861r-VEKm8sTOfZ0GYw_3_5"></a><a id="Tc_VeK6eBc8-k-OULb68puYXA_3_8"></a><a id="Tc_S1S40nzBTEWmtB01CLZc1Q_4_0"></a><a id="Tc_N2bVEQCnf02OK0eSMhP-wA_5_0"></a><a id="Tc_M058Jt4XeEWvkOJ5ypcn5Q_5_2"></a><a id="Tc_7GVGjUkoTEKL2pXVLuqEoA_5_5"></a><a id="Tc_tuOoSLujQ0W8bvk1CPXhqQ_5_8"></a><a id="Tc_MNV_J_7BvkS2-WCy3Ztrbw_6_0"></a><a id="Tc_cfMTIHJRZEqotfWWAWv-cQ_7_0"></a><a id="Tc_-V-y8TWK20eR_UyKHvwRkg_8_0"></a><a id="Tc_TQtbSN4jaU-qvXvzJ_DixQ_8_6"></a><a id="Tc_s6cBVQwOXkiJ4mbRHaEM-A_8_9"></a><a id="Tc_iD4l1gA5i0uu29fGPxBgRQ_9_0"></a><a id="Tc_no5LyZcZokGsQIjY1Zf7dA_10_0"></a><a id="Tc_NsvN0xGx3EyZcIHfXyPB2A_10_6"></a><a id="Tc_6yzpdr4D10urVWSDrPiiZw_10_9"></a><a id="Tc_3bvfpMdiYEq_qEypsYWe3A_11_0"></a><a id="Tc_pgPCcZvQ9UyyZVj17SSl-Q_11_3"></a><a id="Tc_c1_BZNUQ3kODhIYUVfXzrw_12_0"></a><a id="Tc_LS1rn7mibES0pSsASGvpmA_12_3"></a><a id="Tc_CV1fvVZ_UEef6vhwB2X-LA_12_9"></a><a id="Tc_bzniY1NrFkSls489IX-2aw_13_0"></a><a id="Tc_FZCZnk5570CdH1ZQq-HqXg_13_3"></a><a id="Tc_hrIziMVwKUSuhav2JvEUXg_13_9"></a><a id="Tc_DKST3vkM1UWvpI1cEBqFvw_14_0"></a><a id="Tc_wZC_n0ZYL0aCK-XysC2kYg_15_0"></a><a id="Tc_Im1s_SIb90qphH9SBC-6Zg_16_0"></a><a id="Tc_jgQ_-81zs0CiiFA1nk4Abg_16_9"></a><a id="Tc_ph8K0C0gCkCW1QW_2QH2XQ_17_0"></a><a id="Tc_Nic3pe3BtU6IyrB4EuCcZA_18_0"></a><a id="Tc_CQp_pjvYUEW55-xHJt1HKQ_19_0"></a><a id="Tc_Pjq3pg0svU6bQtgANlLRYw_20_0"></a><a id="Tc_knj82HMmA065_riIKa_k5A_21_0"></a><a id="Tc_F1SOVoL6LE60dfqc9ARUCg_22_0"></a><a id="Tc_mE8S0Pb07kqaKGvLefkkWg_23_0"></a><a id="Tc_3ujpDnyLxk-aNlGOgB3UHQ_23_6"></a><a id="Tc_-MdbuHcjzk-lnp8mffeWdQ_23_9"></a><a id="Tc_-ymTMJCU0k6YNHmvMwZ5FA_24_0"></a><a id="Tc_JOJyI55AFUmqE5eS96gP0Q_24_6"></a><a id="Tc_vyJDOTrhCkSkyOJD-dZMog_24_9"></a><a id="Tc_5MutaAHM1U-QHsnAK7VgWQ_25_0"></a><a id="Tc_KBzyKYLtJ0unvLpsSWlpEw_26_0"></a><a id="Tc_TYzTxfQ6VESzw77H4PtiYQ_28_0"></a><a id="Tc_8aGW_9b4cEeaJwa8fkkBdQ_29_0"></a><a id="Tc_h4xmeI-F-Uu1VuQY9ReyWw_30_0"></a><a id="Tc_-UQtwpZYf0ySyt6FCGO4xQ_30_9"></a><a id="Tc_gXpV-tZfp0KT2RmSmkp4Xg_31_0"></a><a id="Tc_gNJL4pVbSE6qVG2asEx2vA_31_9"></a><a id="Tc_yM3TWB6pPEWQ_l3ffg3qfA_32_0"></a><a id="Tc_ru2gwY7TH0up6axWSNPl6w_33_0"></a><a id="Tc_rkPmK6D15EGngxOcM76x6g_35_0"></a><a id="Tc_KCGHpvMnHEuaC6LBa4zt6Q_36_0"></a><a id="Tc_xCHqbIxgxkW8Zcw1InGMsg_36_3"></a><a id="Tc_Q__1sGa1cUqOYL0rvoHeDQ_37_0"></a><a id="Tc_fx1cOhHvUkCddenOiyrqRQ_37_3"></a><a id="Tc_nxVy3j41oU-50SI10pB-Gg_38_0"></a><a id="Tc_cKFcnASD1Umqymp0CcWU2w_38_3"></a><a id="Tc_JTVEbbbtvUCEi_o-RLH_aQ_39_0"></a><a id="Tc_xUTtrgVayk2VBBzBCO4Mkg_39_3"></a><a id="Tc_1gGjka9Qc0CprPfAFhcf8A_40_0"></a><a id="Tc_CJLkQu-_EUObZnb1_dl4Iw_40_3"></a><a id="Tc_G72mugJZ_kCZ-B52ps2yOg_41_0"></a><a id="Tc_t-dobF4rbEqLMsYod69k0w_41_6"></a><a id="Tc_liaSGyfz2EWQsy3D5k6R-g_41_9"></a><a id="Tc_OOYE_sej-EqkrinKLxwHzQ_42_0"></a><a id="Tc_-om-XZk2RECHYnVrQ0SyKg_43_0"></a><a id="Tc_ubTzTNylNUO7e6Y0YiFyTw_44_0"></a><a id="Tc_08Flt0tIAkOPCSZmBaZsfg_45_0"></a><a id="Tc_o7dHhLjJ6k-Sr4r1DlIQ5g_46_0"></a><a id="Tc_KHAP_i9ANEaPl9CSEBTJIQ_46_2"></a><a id="Tc_npte6csDjUSLHH_67XUwbg_46_5"></a><a id="Tc_0sPmVZt2vUm0u3reYdOAMQ_46_8"></a><a id="Tc_2fUvbUIEPESlc7-XU5JTrQ_48_0"></a><a id="Tc_Gg3z27rzQUyGxM9fFbMCEA_49_0"></a><a id="Tc_H84v5qFir0OBQZck4s9fFQ_49_2"></a><a id="Tc_Ff05xFGYPkS_iaR3FdeJfQ_49_5"></a><a id="Tc_5bc87CIowUSXX7mBu1o_LA_49_8"></a><a id="Tc_HoJ1U2fYvkCpNi4NDXXxPQ_50_0"></a><a id="Tc_eFzlO1iCokC9u-HCQbm8ZA_51_0"></a><a id="Tc_1IANsv7QP0mdFQ_CTbXfbw_51_2"></a><a id="Tc_RaItrHO6lUW5VRgmQ2Rc-w_51_5"></a><a id="Tc_-wHpqxEQZ0-1uO_Lzdek2g_51_8"></a><a id="Tc_g9wotHQjIkaWhMeydxusxQ_52_0"></a><a id="Tc_i3odK_nNHkOuyzRsg4hkTw_52_2"></a><a id="Tc_gwann0M1nECJNT_Hs8SWJQ_52_3"></a><a id="Tc_R_vhS4iKKU6bp6URFcAOdQ_52_5"></a><a id="Tc_uOQTWlFhbkmpYTahJEljBg_52_6"></a><a id="Tc_uz3u1F1CxEScCIVwCdWBhg_52_8"></a><a id="Tc_PwZqYGRSYE6bP-rlUoVfsg_53_0"></a><a id="Tc_Cp5jrv9d6UKz7dW9Mce4OA_53_2"></a><a id="Tc_wxsCGrLatEO2btFu8VKifQ_53_5"></a><a id="Tc_mfZAZOnq60OD5N89o7bIAg_53_6"></a><a id="Tc_sWqGPxQBGE2JbsCAA8qgxw_53_8"></a><a id="Tc_Nm7E7KcK5EWAl3Vg-fBFsg_53_9"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="color:#0000ff;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:34.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="color:#0000ff;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VFPw03bdYUC7e2w3dsb42A_5_3">29,135</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VPPkyeLaT0C8jVUR7l965Q_5_6">22,397</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_xiu7nMpoHE2dmfPWwBeAeg_5_9">10,445</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-family:'Calibri';"><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_qNHDc_-8dkCoMxN4PYzXtg_7_3">933</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_23qXT-xvME2UyY2bjB8mEQ_7_6">774</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_cQwLyTFHzkaf2FegS4fPqg_7_9">488</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-family:'Calibri';"><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="axgn:RightOfUseAssetAmortization" scale="3" id="Tc_UMpgGNJkkkCFUkZ-vm1XgQ_8_3">1,821</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Amortization of intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-family:'Calibri';"><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_JZlZF7BwK0GghLp8dtemfw_9_3">123</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_8Dn7JGhLeEmaog74Ahh5bQ_9_6">77</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_GJP_buW6J0WKTDNbV_9-2A_9_9">79</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Impairment loss on intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="Tc_nqmBWbLW0USh6Nahr4RRFQ_10_3">104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Amortization of deferred financing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_POeaxBhaRUChHTtOrEPL-g_11_6">81</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_xhpuOHVjDUmGsuj5vmCFeQ_11_9">246</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Loss on disposal of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_XDkYGnIE3kyqkXzEUJ0W3w_12_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Loss on extinguishment of debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_7x20Y_yH5E6hZKCz5yFzHA_13_6">2,186</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Provision for bad debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="Tc_IpidGCSAsE2BEEVyG1Nmjw_14_3">514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="Tc_gVtVL4mlREuz-AA4CwcPjw_14_6">852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="Tc_jI-t9IBYUU21kdbudcUrSA_14_9">223</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Provision for inventory writedown</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_u4J7NJOJZEiOWRb-rK6d7w_15_3">1,887</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_1Nfqus3x00SRmWUxdN_dhA_15_6">1,343</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_sgXYfNcNsU6-tarfOFnvRg_15_9">1,438</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Changes in investment gains and losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="Tc_yGvbNYNOCUiuRcgsa_tPtQ_16_3">972</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="Tc_i8NDlRNFw0WQa6fXGrI4XA_16_6">721</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Share-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_7kpRdGwmtkWrAY-FLgeU1A_17_3">10,304</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_7p72__I0bk2jmLDet4GoTQ_17_6">7,606</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_2ZhsTdn3R02EFK5_54GNZg_17_9">3,609</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Change in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_nNFQvmITvkSpMpIw5ebpKQ_19_3">2,136</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_WVnYUUzYMkCqI7Vvzyf7Wg_19_6">5,108</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_ZJyIZXaXkEWrBppK6C21bw_19_9">3,236</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_QPPGOjYnmk6CM0iXObUOIw_20_3">3,767</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_e4INEmEw_EuamPSCB_IQVQ_20_6">6,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_0x3bzeqITUeM95pa1-J8Sg_20_9">3,295</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses and other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_SlSne_HpzkaaB7-YRaoSAQ_21_3">661</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_a1TFaqaGj0KVRuYQU4E70g_21_6">192</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_WpYpth3S80m4KnCKh4YMVA_21_9">342</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_LSb6Xi16RU25HMj7ph5PvQ_22_3">2,920</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_DnInC6doQUGVv5Odgj6jTQ_22_6">3,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_KccQJj7WokK2ZOfZGxVl5A_22_9">1,927</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Operating lease obligations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_JvUSKvMZekmsB_4XzJzv1Q_23_3">1,773</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Cash paid for interest portion of finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="Tc_MmvMO8Kma0CaG4_YitzBDQ_24_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Contract and other liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_cj8FpJCWpUCp3QHko5OrEQ_25_3">30</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_su_GIImviU6LdTLsHZOsNg_25_6">66</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_TgnzewHMlEyGSul9hMlxKQ_25_9">70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_NTV66NuLv0GbTYGYST8OWw_26_3">19,872</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_2iTl1SUdeEGi0Zhvase9Xw_26_6">17,862</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_I6dxkaih7EODq-ysX4nvjg_26_9">9,238</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Purchase of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_vRjUNMEfXEyNe4pPd1knkQ_29_3">4,664</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_L7TFzIdCJU2UaOq2RmVG2A_29_6">6,282</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_BagK7tNyAkqC-ir0ElFJTQ_29_9">1,105</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Purchase of investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="Tc_CUV27eQ7xU-KgVUwWL8skA_30_3">121,074</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="Tc_rqjIh59-KkOfCUOPUDyjeg_30_6">114,736</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Proceeds from sale of investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="Tc_qGNU5-G74UOAF8GK-H8RXA_31_3">153,571</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="Tc_I-oTT1OOFkqCHklc5v0PCA_31_6">23,146</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Cash payments for intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_NsgqWsOrdUKU1gu-izU14w_32_3">562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_CbJB8hy5mESoKlr1Y6mkVA_32_6">321</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_nzuG9NETREaj9SEoeME_5Q_32_9">187</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by / (used for) investing activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_ScWSIqKOnkyHn_D-sFV13A_33_3">27,271</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_kXrQimHr3UyKIWjmHeDRJw_33_6">98,193</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_wtoJYZBR0EmlCzc3F35uug_33_9">1,292</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Proceeds from issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_YVfTMwYXCk28pNo10UbeVg_36_6">132,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_npGVblWDzUalL9Hx4adBsA_36_9">15,891</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Cash paid for equity offering</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_u4h_lv0fxUGaxi8K-OYQOA_37_6">257</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_NmUeHJtmNk6Vkbf2consHg_37_9">228</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Borrowing on revolving loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="Tc_esaWjXNYz0m2E3nE1LhoGA_38_6">26,253</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="Tc_NxMHJ8ku1Ee_kGtleOVRfg_38_9">57,599</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Payments on revolving loan and prepayment penalties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" id="Tc_rzVhOsAlOE-RbBL-pe2R3w_39_6">30,489</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" id="Tc_UtZnHF6FtESdY3B1F6myWQ_39_9">57,624</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Repayments of long-term debt and prepayment penalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_wDdSbw5ZYkiEEkKiKLzlqw_40_6">22,513</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_Xl411Leh0UKo_g8zhLpiRw_40_9">21</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Cash paid for debt portion of finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_ghyUuE7ASU2A2lBtqxnGvQ_41_3">29</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_bhg7fjmKg0yBgaiI0_TKcA_42_3">4,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_GzE5sxrfFku89QlbMTQyfQ_42_6">3,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_NTe_7vmwD0GW4W0Pe2_yxg_42_9">1,434</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_ASwSDfoe_k2-UJqp_JIcZw_43_3">4,031</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Feuhl0VALkCegsaLqn7s3A_43_6">109,842</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_ImkgTGOoikiltwpoRYk5Aw_43_9">17,022</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net increase in cash, cash equivalents, and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_BatDMI1BKEqqMRxnnqIofg_44_3">11,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_FbcYUqT-_kS_EAuVb73cZw_44_6">6,213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_1OigzP8q3EyrfG4XqJhxYg_44_9">6,492</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash, cash equivalents, and restricted cash, beginning of period</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_0Q6mebTXDEegr3VR_bGH3Q_45_3">30,294</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_2vNny78Nv06hOgoTQI8LCg_45_6">36,507</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2016_Or2PNLcVTkK03OOF11rmZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_be9HspyXRESWCpxd9-VD6g_45_9">30,015</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_RubPa-mok02vQj2MAG7Ztg_46_3">41,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_KGu54C1Qb0-AyR_ILq3GMA_46_6">30,294</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_AtsNVyGzN0a9PdLioC5qMQ_46_9">36,507</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosures of cash flow activity:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Cash paid for interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_DxYPwnUDpkaEXPqnDR7RvQ_49_3">34</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_-8Hatbxg50K50v5Xz_3sqw_49_6">1,325</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_uL4k7Bx9AUW5Jh5Ic7m9Tw_49_9">2,198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of non-cash investing and financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Acquisition of fixed assets in accounts payable and accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_vkoMEz8sGUW8ikWa96eCDg_51_3">3,212</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_yCP4k_AwVEul2PZ8ATIhDQ_51_6">335</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_6CNkvNWP2EaASbjUEhAgEA_51_9">55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Capital lease additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="Tc_d54KzXJNz0ubWakCk1ypmA_52_9">62</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Right-of-use asset and operating lease liability (Adoption of ASC 842)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability" scale="3" id="Tc_Y9iDW22RXES_NQCBLJVAXA_53_3">26</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these consolidated financial statements.</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_165436dd_550e_4f2d_9325_d3d9d56a9994"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AXOGEN,&#160;INC.</b></p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_4"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019, 2018 and 2017</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In Thousands, Except Per Share Amounts)</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:BasisOfAccounting" id="Tb_1v7u51TSg0GoqNf80GsuOA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">1.</b></span><b style="font-weight:bold;">Basis of Presentation </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying consolidated financial statements include the accounts of Axogen,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Axogen&#8221;) and its wholly owned subsidiaries, Axogen Corporation (&#8220;AC&#8221;), Axogen Processing Corporation (&#8220;APC&#8221;) and Axogen Europe GmbH, as of December&#160;31, 2019 and December&#160;31, 2018 and for the three years ended December 31, 2019. The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All intercompany accounts and transactions have been eliminated in consolidation.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:NatureOfOperations" id="Tb_YHNSelNOo06izqu0VKqrYA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">2.</b></span><b style="font-weight:bold;">Organization and Business </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is a global provider of innovative surgical solutions for physical damage or transection to peripheral nerves.  Axogen is focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen&#8217;s products are designed to restore nerve function and are used to treat patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site, Axoguard Nerve Connector, a porcine submucosa extracellular matrix (&#8220;ECM&#8221;) coaptation aid for tensionless repair of severed peripheral nerves, Axoguard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, Axoguard<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissues in the surgical bed.<span style="white-space:pre-wrap;">  Along with these core surgical products, Axogen also offers the Axotouch Two-Point Discriminator a measurement tool for use by healthcare professionals detect changes in sensation. The Company&#8217;s portfolio of products is available in the United States, Canada, Germany, South Korea and other European and international countries.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Avance Nerve Graft and Avive Soft Tissue Membrane are processed in the United States by Axogen at its processing facility in Dayton, Ohio.  </span>Axoguard Nerve Cap<span style="white-space:pre-wrap;"> is manufactured by Cook Biotech in the United States for sale by Axogen and Axoguard Nerve Connector and Axoguard Nerve Protector are manufactured in the United States by Cook Biotech and are distributed worldwide exclusively by Axogen.  The Axotouch Two Point Discriminator is contract manufactured by Viron Technologies, LLC (formerly Cybernetics Research Laboratories) (&#8220;Viron&#8221;) Tucson, Arizona.  Viron supplies the Axotouch unpackaged and they are packaged at Axogen&#8217;s distribution facility in Burleson, Texas.  Axogen maintains its corporate offices in Alachua, Florida and is the parent company of its wholly owned operating subsidiaries, AC, APC and Axogen Europe GmbH.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ilLcUrYUFEOCGZ8Lh4PGQg_1_2"></a><a id="Tc_0Mvzaoo1EEOutlhkg0XZBA_1_5"></a><a id="Tc_y6Qbv9lWckmfeaNnGnwb4Q_2_2"></a><a id="Tc_W7km-kQyjkytMT9naVtNig_2_5"></a><a id="Tc_dGh8Q-uMd0e-znJZlpbP2w_3_0"></a><a id="Tc_PgcLRBwxkESdweTpXp_1jQ_3_2"></a><a id="Tc_HnMRE6inY0COKyIbc4XHOA_3_5"></a><a id="Tc_mJOuTTZcYUGyNQw12Pmx9Q_4_0"></a><a id="Tc_ZPKZoGAfKE60XYsj_2VBcg_5_0"></a><a id="Tc_Iku3it88m0GbjjY7CtiEOw_5_2"></a><a id="Tc_6rSEKZaZxUaP-KCFuakK8g_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_hY-iMNnWbk6kPCh-MFsc5A" continuedAt="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">3.</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_00v7js9cYk20f5gT3vUdSA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Cash and Cash Equivalents and Concentration</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying consolidated financial statements.  The Company has not experienced any losses related to these balances; however, as of December 31, 2019, </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="3" id="Narr__icn5YWTK0ibfOQM11JqkQ">35,224</ix:nonFraction><span style="white-space:pre-wrap;"> of the cash and cash equivalents balance was in excess of FDIC limits.   As of December 31, 2019 and 2018, the Company had restricted cash balances of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Narr_8fosJphQQUOJr4kyDZtWQA">6,000</ix:nonFraction><span style="white-space:pre-wrap;"> as collateral for an irrevocable standby letter of credit.  </span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_v2wuM0mXK0ugPpxZQ1m_4A" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_9eHQ6CneW0K3mMn8uGgRaw_3_3">35,724</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_9NUPj35v8k239uZv3-R3Gg_3_6">24,294</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_BcQBzEjJcUqrlBeColgVAw_4_3">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_X_li6WjOVU6wo67tHBUfQw_4_6">6,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_j4omIA5MJEKo-QZUdC1ksA_5_3">41,724</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_bhoH6l3ifkSKzVkkaM_2pw_5_6">30,294</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:InvestmentPolicyTextBlock" id="Tb_fGGfXei8Ek62mo2Sy9rC-w" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Investments</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company invests primarily in U.S. Government securities, corporate bonds, commercial paper and asset-backed securities and classifies all investments as available-for-sale. Investments are recorded at fair value. The Company has elected the fair value option (FVO) for all of its available-for-sale investments.  The FVO election results in all changes in unrealized gains and losses being included in investment income in the Consolidated Statements of Operations.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_VzalU1m2K0mzyfGvLixbZg" continuedAt="Tb_VzalU1m2K0mzyfGvLixbZg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Revenue Recognition</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On January 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 606, &#8220;Revenue from Contracts with Customers&#8221;, utilizing the modified retrospective method applied to contracts that were not completed.  The adoption of the standard did not have a material impact on the timing and amounts of the Company&#8217;s revenue, processes or internal controls.  Upon adoption, the Company did not have any material remaining performance obligations, significant judgements, or material costs to obtain or fulfill contracts with its customers.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection.  Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products and services to the Company&#8217;s customers.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract.   These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#8217;s cost.   The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and, therefore, the Company has determined it is appropriate to recognize revenue when:  i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement.  Determining the timing of revenue recognition for such contracts is subject to significant judgment, because an evaluation must be made regarding the distributor&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company.  Changes in these assessments could have a significant impact on the timing of revenue recognition from sales to distributors.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_gVIo_oFNV0amfgE-9Wn9mQ_1_0"></a><a id="Tc_pAUgtpZ-J0G8KI-3c-Wy_w_2_2"></a><a id="Tc_QjgO_LDmjkqlMxlavuV_yg_2_5"></a><a id="Tc_zNOWKD3fP0aHf3-KRU8elg_2_8"></a><a id="Tc_v2FaZJWnakq3TmHc1wuodA_3_0"></a><a id="Tc_q9pOZyp25UytyC-vrktqzQ_3_2"></a><a id="Tc_66QXdTgZ8kiLCgJsmgGHCg_4_0"></a><a id="Tc_qlnRaNQu_E6wYn0-N7Pzpw_5_0"></a><a id="Tc__PFlOIw2-02avU0tOsquFA_7_0"></a><a id="Tc_xCIrYfDr6EmRZfNR1_pG2Q_7_2"></a><a id="Tc_crN2dng1PU-fmgvtfTXM3g_8_0"></a><a id="Tc_DseuN78dgUCHslEHbnbBdg_9_0"></a><ix:continuation id="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont1" continuedAt="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont2"><ix:continuation id="Tb_VzalU1m2K0mzyfGvLixbZg_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A portion of the Company&#39;s product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of sales.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#8217;s contracts vary; however, as a common business practice, payment terms are typically due in full within </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_jWuqQcWDKE6x_Rz8ykfOzA" format="ixt-sec:durday" name="axgn:AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" id="Narr_WFtelxmamEe-pZn2Zpvi-w"><span style="font-size:10pt;">30</span></ix:nonNumeric><span style="font-size:10pt;"> to </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_zbj4-_iSt0mMZxIh6JETbg" format="ixt-sec:durwordsen" name="axgn:AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" id="Narr_KHzHpjgu20-egmgbNJlczg"><span style="font-size:10pt;">60 days</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material.  The Company has several contracts with distributors in international markets which include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In connection with the Acroval Neurosensory and Motor Testing System, the Company sold extended warranty and service packages to some of its customers who purchase this evaluation and measurement tool, and the prepayment of these extended warranties represent contract liabilities until the performance obligations are satisfied ratably over the term of the contract. The sale of the aforementioned extended warranty represents the only performance obligation the Company satisfies over time and creates the contract liability disclosed below.  The opening and closing balances of the Company&#8217;s contract receivables and liabilities are as follows:</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="Tb_RDYfXMSQEkWHejVyRI9I7Q" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Balances</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:44.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Receivables</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Liabilities, Current</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Liabilities, Long-Term</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Opening, January 1, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms" scale="3" id="Tc_xnDYQoVsMEySOEi3BWl1vA_3_3">11,065</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_MJzUc6byLEmG5fmNG_TFeQ_3_6">32</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_LJwzZQUiG0CSsZl3Fts6fw_3_9">69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Closing, December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms" scale="3" id="Tc_m4qct9GOukaBrlC2mhyWqg_4_3">15,321</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_I5vxFbGJKkGgN27nirsgfg_4_6">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_kcytb0psrk-NcyY1eScO5Q_4_9">42</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Increase (decrease)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="axgn:IncreaseDecreaseInContractReceivable" scale="3" id="Tc_NKxveS7ozkaC5Pc98nuGdg_5_3">4,256</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="axgn:IncreaseDecreaseInContractWithCustomerLiabilityCurrent" sign="-" scale="3" id="Tc_2SJtIGEg9k6_pFbr1BLnkg_5_6">14</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="axgn:IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent" sign="-" scale="3" id="Tc_XK_3jprjkUKaAJW69FwyTw_5_9">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Opening, January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms" scale="3" id="Tc_TWj36lLZjEqOW49nbFBL7Q_7_3">15,321</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_X2FYaBnltEW-nCCPanNsVg_7_6">18</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_-awDT7axskaWpDVhborX0A_7_9">42</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Closing, December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms" scale="3" id="Tc_5dJ07_OGeEm4ve7Zby5rDg_8_3">16,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_43kTwNW0LkGXdWicMA02kg_8_6">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_J4940l26FkeZ4HekW19J-g_8_9">15</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Increase (decrease)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="axgn:IncreaseDecreaseInContractReceivable" scale="3" id="Tc_kIVzn7aghUmm5xo5O5smFw_9_3">1,623</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="axgn:IncreaseDecreaseInContractWithCustomerLiabilityCurrent" sign="-" scale="3" id="Tc_dHhOSQ-K0UqaghE2-4RwGQ_9_6">4</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="axgn:IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent" sign="-" scale="3" id="Tc_v6NKOYAZ3UetlBXEj105xA_9_9">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="Tb_wwueKyll0UiHqwCyEj4bLg" continuedAt="Tb_wwueKyll0UiHqwCyEj4bLg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company evaluates the collectability of accounts receivable to determine the appropriate allowance for doubtful accounts. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in general and administrative expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The Company&#8217;s history of write-offs has not been significant.  The allowance for doubtful accounts balance was approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="Narr_yf-spbULykSthXtyRpiXIQ">1,092</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="Narr_t_6iNfTDx02eo-VlgIP85Q">1,117</ix:nonFraction> at December&#160;31, 2019 and 2018, respectively.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont2" continuedAt="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont3"><ix:continuation id="Tb_wwueKyll0UiHqwCyEj4bLg_cont1"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company&#8217;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures.</p></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:InventoryPolicyTextBlock" id="Tb_f6FjdIxpEEaY4EXfOJWSQA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Inventories</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Inventories are comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve&#160;Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane, Acroval Neurosensory and Motor Testing System, Axotouch Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company monitors the shelf life of its products and historical expiration and spoilage trends, and writes-off inventory based on the estimated amount of inventory that will not be distributed before expiration or spoilage.  To estimate the amount of inventory that will expire prior to being sold, the Company reviews inventory quantities on hand, historical and projected sales, and historical expiration trends. The Company&#8217;s calculation of the amount of inventory that will expire prior to sale has two components: 1) a demand or consumption based component that compares projected sales to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being sold. The Company&#8217;s model assumes that inventory will be sold on a first-in-first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that a significant portion of the Company&#8217;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written-down involves significant judgments and estimates.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_ixyEznbs_0yKPG6KvBLlCg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Leases</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02&#8212;Leases (Topic 842) (&#8220;ASU 2016.02&#8221;), as of January 1, 2019, (the &#8220;Application Date&#8221;) using the modified retrospective approach. The Company will continue to report financial information for fiscal years prior to 2019 under the previous lease accounting standards. The modified retrospective approach provides a method for recording on the balance sheet as of January 1, 2019, leases that have commenced on or before the Application Date. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company elected the package of practical expedients permitted under the transition guidance, which allowed us to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Company also elected the practical expedient allowing us to not separate the lease and non-lease components for all classes of underlying assets, apart from equipment. &#160;The Company did not elect the practical expedient to use hindsight to determine the lease term for leases at January 1, 2019. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company made an accounting policy election to not recognize right-to-use assets and lease liabilities that arise from short term leases, which are defined as leases with a lease term of 12 months or less at the lease commencement date.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Adoption of the new standard resulted in the recording of right-to-use assets and lease liabilities of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="axgn:FinanceAndOperatingLeaseRightOfUseAsset" scale="3" id="Narr_bNGcuZ0OYEe5r06J18YHRQ">3,786</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="axgn:FinanceAndOperatingLeaseLiabilities" scale="3" id="Narr_BJReYRWUCEuQ5fuC2gvkpg">3,823</ix:nonFraction>, respectively, and the derecognition of capital lease assets, capital lease liabilities, and operating lease deferred rent of $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_1_1_2019_0uPXfB4sV0SD97KHNevlsw" decimals="-3" format="ixt:numdotdecimal" name="axgn:DerecognitionOfCapitalLeaseAssets" scale="3" id="Narr_-nwvswrMLEenlNVxNKmQJA">96</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_1_1_2019_0uPXfB4sV0SD97KHNevlsw" decimals="-3" format="ixt:numdotdecimal" name="axgn:DerecognitionOfCapitalLeaseLiabilities" scale="3" id="Narr_H6Fe_Na2BkOUnmJaZRjSFA">63</ix:nonFraction>, and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_1_1_2019_0uPXfB4sV0SD97KHNevlsw" decimals="-3" format="ixt:numdotdecimal" name="axgn:DerecognitionOfDeferredRent" scale="3" id="Narr_pOAiHCQGaU2M8iVrKEcaAQ">70</ix:nonFraction>, respectively, as of January 1, 2019 with zero cumulative-effect adjustment to retained earnings. The new standard did not materially impact our consolidated net earnings.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont3" continuedAt="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont4"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_nBf81xwpyEGafL1wDKDmlQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Net Loss Per Share</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Basic and diluted net loss per share is computed in accordance with FASB ASC 260, &#8220;Earnings Per Share&#8221; (ASC 260), by dividing the net loss by the weighted average number of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, options and awards of <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_32ME4rRE8UC25CPpkaDvZg">1,556,818</ix:nonFraction><span style="white-space:pre-wrap;">,  </span><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_-_jXuud6QkOIV1sppvbZZQ">2,621,440</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_2w1Jwq7gJ0CrqFRnY24ttA">2,253,399</ix:nonFraction> which were outstanding as of December 31, 2019, 2018 and 2017, respectively, were not included in the computation of diluted net loss per shares because dilutive shares are not factored into the calculation of net loss per share when a loss applicable to common shares as they would be anti-dilutive. See additional outstanding shares as disclosed in Note 11, &#8220;Equity Compensation Plans&#8221; that could potentially be dilutive.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_bNpjyNKkxEqjEANo_xstfA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Research and Development Costs</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred and were $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Narr_02Tq9wY32UeTybgNilxHxA">17,514</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Narr_kpuuhDsghUi6_FqKZUCdfg">11,773</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Narr_DIkeopdZX0meldAYlfgtxA"><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Narr_PVlrW7NABkuSCZQw2HX8-g">6,699</ix:nonFraction></ix:nonFraction> for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_0K4rPQmX8Eau8d3czyzpsQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Stock-Based Compensation</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company measures all employee stock-based compensation awards using the fair value, including stock options, restricted stock, performance stock and stock purchases related to an employee stock purchase plan.  The share-based compensation recognized under ASC 718 for years ended December 31, 2019, 2018 and 2017 was </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Narr_W-u6B01LtUOCQStj1zU8Nw">10,304</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Narr_scnEyarDe0KFT23Ws9pEVw">7,606</ix:nonFraction>,and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Narr__nzfifaVwUGkn0pmC8q6Fw">3,609</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of time-based options on the date of grant using the Multi-Point Black-Scholes option-pricing model (Black-Scholes model). The Company&#8217;s determination of fair value is affected by the Company&#8217;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#8217;s expected stock price volatility over the term of the awards.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of restricted stock based upon the grant date closing market price of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company also has an employee stock purchase plan (ESPP) which is available to all eligible employees as defined by the plan document. Under the ESPP, shares of the Company&#8217;s common stock may be purchased at a discount.  The Company estimates the number of shares to be purchased under the ESPP at the beginning of each purchase period based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model and records estimated compensation expense during the period. Expense is adjusted at the time of stock purchase.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">With respect to performance stock units (&#8220;PSUs&#8221;), the number of shares that vest and are issued to the recipient is based upon the Company&#8217;s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company&#8217;s closing stock price on the grant date and its estimate of achieving such performance targets. For further discussion and disclosures, see Note 11 &#8211; Equity Compensation Plans.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:UseOfEstimates" id="Tb_6BFuq8P08k-yRmw2cXNvYw" continuedAt="Tb_6BFuq8P08k-yRmw2cXNvYw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Use of Estimates</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Management believes the critical accounting policies regarding revenue recognition, allowance for uncollectible accounts receivable, investments, inventories and share-based employee compensation affect our more significant judgments and estimates used in the </span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont4" continuedAt="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont5"><ix:continuation id="Tb_6BFuq8P08k-yRmw2cXNvYw_cont1"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">preparation of the Company&#8217;s consolidated financial statements.  Actual results could differ materially from those estimates.</span></p></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;text-indent:13.5pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_s6y00AWIqkK_o2YPQam09Q" continuedAt="Tb_s6y00AWIqkK_o2YPQam09Q_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In February 2016, the FASB issued ASU 2016-02. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-11, Targeted Improvements to ASC 842, Leases (&#8220;ASU 2018-11&#8221;).  ASU 2018-11 provided entities with an alternative modified transition method to elect not to recast the comparative periods presented when adopting ASC 842.  The impact of the adoption is disclosed in the Leases section of Note 3, Summary of Significant Accounting Policies.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In August 2018, the FASB issued ASU No. 2018-15, Guidance on Cloud Computing Arrangements (&#8220;ASU 2018-15&#8221;).  ASU 2018-15 provides guidance on implementation costs incurred in a cloud computing arrangement (CCA) that is a service contract and aligns the accounting for such costs with the guidance on capitalizing costs associated with developing or obtaining internal-use software.  Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized.  This update is effective for annual and interim reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently evaluating the impact this standard will have on the Company&#8217;s consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;).  The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  We are currently evaluating the impact the standard may have on our consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In May 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses, Topic 815, Derivatives and Hedging and Topic 825, Financial Instruments (&#8220;ASU 2019-04&#8221;).  ASU 2019-04 clarifies certain aspects of accounting for credit losses, hedging activities, and financial instruments.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In May 2019, the FASB issued ASU No. 2019-05, Targeted Transition Relief (&#8220;ASU 2019-05&#8221;).  ASU 2019-05 provides transition relief for entities adopting ASU 2016-13, Measurement of Credit Losses on Financial Instruments.  The amendment allows entities to irrevocably elect, upon adoption of ASU  2016-13, the fair value option on financial instruments that (1) were previously recorded at amortized costs and (2) are within the scope of ASC 326-20, Financial Instruments &#8211; Credit Losses: Measured at Amortized Costs, if the instruments are eligible for the fair value option under ASC 825-10, Financial Instruments: Overall.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In November 2019, the FASB issued ASU No. 2019-11, Credit Losses (Topic 326), Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses.  This amendment amends certain aspects of the new credit loss standard, ASU 2016-13 (ASC 326).  As the Company has not adopted ASU 2016-13, the effective date of this amendment is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hY-iMNnWbk6kPCh-MFsc5A_cont5"><ix:continuation id="Tb_s6y00AWIqkK_o2YPQam09Q_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) (&#8220;ASU 2019-12&#8221;), Simplifying the Accounting for Income Taxes.  This amendment simplifies the </span>accounting for&#160;income&#160;taxes&#160;by removing certain exceptions to the general principles and improve consistent application or and simplify accordance with accounting principles generally accepted in the United States for other areas of&#160;Topic&#160;740&#160;<span style="white-space:pre-wrap;">by clarifying and amending existing guidance.  This update is effective for annual and interim reporting periods beginning after</span><span style="background-color:#ffffff;color:#333333;"> December 15, 2020. Early adoption is permitted but requires simultaneous adoption of all provisions of ASU 2019-12. </span>The Company does not expect this standard will have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company&#8217;s consolidated financial condition, results of operations, or disclosures.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;text-indent:13.5pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="Tc_u6U1paDUjUmmn4ciGVw7Lw_1_2"></a><a id="Tc_fyALvi4WHUeqlfe27pZB8A_1_5"></a><a id="Tc_yVutK2mzM0GkNkNThzE2mQ_2_2"></a><a id="Tc_SjEaAQC1ykGQd27QkqYANw_2_5"></a><a id="Tc_d4GrvazW10yNjMi4jXKn6g_4_0"></a><a id="Tc_HD_C85SHukqMAMBDoXCWVA_4_2"></a><a id="Tc_H1q7dHLTsU-zad-q4_Rp5g_4_5"></a><a id="Tc__3xbrdolkkiz4OVBjKbUxg_5_0"></a><a id="Tc_890PLS9mN0yV2KCel9_w5w_6_0"></a><a id="Tc_Psh8Xmv8kUaVfHCRRedNyw_7_0"></a><a id="Tc_hqg99PCAu0uNp24blTAFrA_7_2"></a><a id="Tc_mufALY-S3064ywLsZR-DiA_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_wlt_XxvwLEafjM0dOJmKWw" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">4. </b></span><b style="font-weight:bold;">Inventories</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Inventories are comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve&#160;Protector, Avive Soft Tissue Membrane, Axoguard Nerve Cap, Acroval Neurosensory and Motor Testing System, Axotouch Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value and consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_XtI4zGGBMUW7TN9bypI0fg" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_xRnBQpznUEug30mwUjyKpA_4_3">10,403</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_zksoGwzOe0W6JQ0uIVNcZw_4_6">9,194</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_n_Tk_sO7uU2H3ZXIfdF6VA_5_3">730</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_BGrtFjb3uEaJwH_CqXaCGQ_5_6">454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_8g5cPV7IpEe8DtpCwCBStA_6_3">2,728</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_9wvCQgyJTEybwqm5idq6jg_6_6">2,334</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Inventories</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_YBOJ06gJSEa3vMS5SVdmfQ_7_3">13,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc__0TJSzBtr0CfOav5fc0V4Q_7_6">11,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">For the years ended December&#160;31, 2019, 2018 and 2017, the Company had recorded a provision for inventory write-downs of $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Narr_-P3IXPAZLUyRWuyGLTOPfQ">1,887</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Narr_eX9wK4EQDEiYqUb2vmaOMw">1,343</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Narr_5MOl3nmSHEKuK0BfNkiCDQ">1,438</ix:nonFraction>, respectively, primarily relating to product expiration.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_Hib_b4c3fUmQJtc0Lt6dLA" continuedAt="Tb_Hib_b4c3fUmQJtc0Lt6dLA_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">5.</b></span><b style="font-weight:bold;">Fair Value of Investments</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company has elected the FVO for all investments in debt securities.  Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows:</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Level 2 &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company classifies cash and investments in U.S. government securities as Level 1 within the fair value hierarchy.  Accounts receivable, short-term other assets, accounts payable and accrued liabilities are also classified as Level 1.  The carrying amounts of these assets and liabilities approximate their fair values due to their relatively short-term nature. Investments in corporate bonds and commercial paper are classified as Level 2 within the fair value hierarchy. The fair value of long-term debt is estimated by calculating the net present value of future debt payments at current market interest rates and is classified as Level 2. &#8195;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_5Cq3c09nZEy2HeB-9qSgpw_1_2"></a><a id="Tc_v0uLWdS9VEmuwZXUeRFlUg_1_5"></a><a id="Tc_4vRCFv04NUO0WfyUc3MJBg_1_8"></a><a id="Tc_kJ24VVBH7kCKlwY7P_tSNw_1_11"></a><a id="Tc_dDHzoZhzzEy7ZJCMkCReMA_2_0"></a><a id="Tc_iAz01TTPpEWfR0wuyvL6zg_3_0"></a><a id="Tc_LqejakPOtkqPmbhJ55P0cw_4_0"></a><a id="Tc_oON2t4I_S0-mMeq_0LW46w_4_2"></a><a id="Tc_oDLBqHIRqk-ilt9h72zflA_4_5"></a><a id="Tc_0x4zL93N906ZdL05Pm-skg_4_6"></a><a id="Tc_ViBkVugUz0qHbf-M9JyP7w_4_8"></a><a id="Tc_v6mF0PascUKrW_Bx622NIw_4_9"></a><a id="Tc_cNufIXpZlEqBV-MN37Pw1A_4_11"></a><a id="Tc_vSiMBuxWNUC66uJNXGkNhQ_5_0"></a><a id="Tc_8MCsR8kcYEaqiNnUP61NPg_5_6"></a><a id="Tc_s7RuoDeOPkCYuHxvFdjU-g_5_9"></a><a id="Tc_VzfWMwRS-UymFmlRIOHSCw_6_0"></a><a id="Tc_fvihmAzUPE2t1CpssHBgXw_6_3"></a><a id="Tc_xfI0U_wmhUejyRypTKA1Sw_6_9"></a><a id="Tc_xEVPuEN7J0OFMnxHT9jzJA_7_0"></a><a id="Tc_JKrC7icyAEmSryecoQgmZg_7_3"></a><a id="Tc_xjCP5StFkECxpRJv4lEZiA_7_9"></a><a id="Tc_7oHoZqEGLEGfkLIQM40JCA_8_0"></a><a id="Tc_ao59GGTIQU6pIAfHxgL00w_8_3"></a><a id="Tc_jnnvzk1rakS89693JQy1vw_8_9"></a><a id="Tc_pJSOOutdVEmiwT2_BAtlGg_9_0"></a><a id="Tc_AcQsWn9w4k2E2YzgtbY3Qg_9_2"></a><a id="Tc_jYYLm3vCzEWCdLb-Vr44aA_9_5"></a><a id="Tc_kkwx7IfLG0KxveVFD0Z2wg_9_8"></a><a id="Tc_PYXzkpVQwEmTCXDaGbwxtw_9_9"></a><a id="Tc_RoZDuu2BcE65AHX1eIFA8Q_9_11"></a><a id="Tc_IeyJHBZEQEGqojDktQHd5g_11_2"></a><a id="Tc_rMtqzM0NNEOuCmqWMyj3ww_11_5"></a><a id="Tc_IgDtY9L12USzUfdwDyTxiA_11_8"></a><a id="Tc_uqgEuw-i6USp3XmCjm5snA_11_11"></a><a id="Tc_X0RpHH2OrEedKwR1YonrGQ_12_0"></a><a id="Tc_QhnyS5W5NE6Kn5A9DM9DgA_13_0"></a><a id="Tc_-SwJD7siA0GlWwRhxE-22Q_14_0"></a><a id="Tc_QTbBzhtWWkODQz7tMFbPUg_14_2"></a><a id="Tc_N5BP7U65uUmcJbidFEMttw_14_5"></a><a id="Tc_Vg7GB1NhHUu7naFwj0xbOQ_14_6"></a><a id="Tc_SnzTxxq2PkaBNMArJaC-mw_14_8"></a><a id="Tc_Re9rYv7k40SKYrXbYs49LQ_14_9"></a><a id="Tc_C9G82pL9IEuylFnrtaJ5UQ_14_11"></a><a id="Tc_W5VHjp9xikuG-yw48qLyaA_15_0"></a><a id="Tc_y86Y6lrlTkCxpDslOv5RXQ_15_6"></a><a id="Tc_Myo4Gb8OvEmNRGrfcFIxbw_15_9"></a><a id="Tc__HDhUTgpAkabT7pcQDMcXw_16_0"></a><a id="Tc_4_XGG7kSpkGzLU0JYu9qjg_16_3"></a><a id="Tc_SFcwCUkyWkmkGcSdzY4PDQ_16_9"></a><a id="Tc_TS7myDCtG0yXvZlMAqxjnA_17_0"></a><a id="Tc_WxFvWkdsFUeK_e_Esfou6g_17_3"></a><a id="Tc_MExbEB5Xg024T76ixuxXmw_17_9"></a><a id="Tc_gYuRJ_GCm0mB9KRW-1-CiQ_18_0"></a><a id="Tc_ppQBP_L5oUitnMNWjm5Qxw_18_3"></a><a id="Tc_tBuq6Stvh0WU3JmwXAyx3g_18_9"></a><a id="Tc_HRqEV8WEPUeEdZ7drY6WMA_19_0"></a><a id="Tc_PSMmNUrjDUOa58msMLWb2Q_19_2"></a><a id="Tc_fydJ85tXQk-2buEUKLQELw_19_5"></a><a id="Tc_BSDeArzAg0Wi0OPixZSgrA_19_8"></a><a id="Tc_NVfKgtLFJkGmKHI14EkVBQ_19_9"></a><a id="Tc_Yv0b9Esp4E6jCrWzWp8JJQ_19_11"></a><ix:continuation id="Tb_Hib_b4c3fUmQJtc0Lt6dLA_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following table represents the Company&#8217;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December 31, 2019:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_AvQbec-YOUmWKlmegsgWNA" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Y5SbtUl8VkmtgzZCsagCyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_qX7Kc8o-vEKARu0Mw6fdJg_4_3">26,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_QEj-hDcpYE6iU9rJ3XeK7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_jfXcsGvCXEitHlQAxBaheg_4_12">26,812</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. government securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_j8zL172gGUqB0hFUPl1x4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Jdqq0tKyoUuIab2WykA7lA_5_3">4,544</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_5jPMRknfREqoJu62tcfW5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_H9GkLkhN3k202yIw3nlFpw_5_12">4,544</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_cdH2QUZpnki1Cwgvsjs8vw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_nu7gHFbDdk6TJM_RoSvdfg_6_6">17,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_fkX6ZqT47Uy7zsyx_wxs1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_T04Puau3PECxdR2BSDLv7A_6_12">17,754</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_75NcZ12IJk-eikFk1KM3Og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ALnhK0cFvEa2s9PAU_xtAQ_7_6">24,679</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_A0SgF-lS8EWuSRhFGPu_kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Yt6dWdzVRkKUYu17Yu-oAg_7_12">24,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_ANmFTxutV0-xFOoQ8_7FPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_dsvhqcttoEK2WXpDoEKAsA_8_6">13,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_x6KsE8qyC0SgbIbxY0R8XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_1uSQpDRsmE--2MRsEkPAZQ_8_12">13,808</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nysdIkyyg0WkBDmiLHyfzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_FiIW3SYj-06NvzhlgLEwpg_9_3">31,356</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_728oYVG9_kqeLbE5u8GVGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_6cN2Miohc0-j8qyGIcxLWw_9_6">56,241</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ftL9sDUwHkWRUwmRLPxn4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_qdIz-w4MakGBAVCzpOwC4Q_9_12">87,597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_0r35qKuFtEOBMm3qfUnZew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_wCVpezpd_0Gm3JM522f9cA_14_3">12,947</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_iTCpB9orK0Sjz-9gGwsP8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_yA0esCMPHUuteLI6uDbCBA_14_12">12,947</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. government securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_Z-mVrl7y0E-H9TTKDpOGrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_4qjzBbkAHE6ASbG9oD2OpQ_15_3">15,923</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_yZ1Iu5dLmECLNXvQICHt7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_pacgkdgkdkqoTZxW5bKqJw_15_12">15,923</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_N02mc_9XDEmaoa7UwF0qCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_L8r_1iB4ekiEX6kZApVe4g_16_6">31,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_puZ9vioqskyMdjdeNUCdsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_hNP7XVpGRUWc_9bPX__WUQ_16_12">31,495</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Ljo8XdXd1UOQhteaj6n1Lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_nc75SjuD-0qxct5K6KQgGg_17_6">27,869</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Psoi6DhJ7E2efXXbLdjXyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_oO5k74mTjUObX8s0-YCPsw_17_12">27,869</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_285oEZVmiEuWMlWvMBhBKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-Y8yHHWiRUSkEPgxYFC0Jw_18_6">17,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_HEXGxa8jpUKp0M7bjLh6dw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_uSKKW8fnKkevOwHbrYAE2w_18_12">17,025</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_t1faoeA6yEG9189EF_P-Mw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_kvu223o-1k6porUItV3P4A_19_3">28,870</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VRqBUSVw9EGAy-ARzd86JA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_fxC242c-Cku3VqH2dFPmXA_19_6">76,389</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KEeGgwBLD065_sx2yO_BVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_TcxuplfSIka2ny5Xqa5WLg_19_12">105,259</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">There were no changes in the levels or methodology of the measurement of financial assets or liabilities during the year ended December 31, 2019 and December 31, 2018.  The maturity date of all of the Company&#8217;s investments is less than one year.</span></p></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Tc_zZ45F4lDLkSB6fKZTsjCAA_1_2"></a><a id="Tc_GBjNc7btyEyJJ8bRInsW9w_1_5"></a><a id="Tc_sisqEUxDlkCexCvZmSvEpQ_2_2"></a><a id="Tc_cvMiA7g_v0ib7WbhXNTPlg_2_5"></a><a id="Tc_rR1JIhQgkkOQ_jYZZCYHpA_4_0"></a><a id="Tc_V9z4ML4UzkeyEpVURT4P4Q_4_2"></a><a id="Tc_Mmebe5g_EkK8i5h1cD4wHA_4_5"></a><a id="Tc_Quc_QEXSrU2E9WuCVB8yzw_5_0"></a><a id="Tc_DsoOQLNXOkKn55--Kw9UpA_6_0"></a><a id="Tc_WnY7MDewm0GTourrMolCsQ_7_0"></a><a id="Tc_ef89FvmcE0uDZB-oob4Kmg_8_0"></a><a id="Tc_yn5v9zgUXk-LtTO2cZMAOw_9_0"></a><a id="Tc_O3X07xfrOEaHWWL2PB50QQ_10_0"></a><a id="Tc_Q6jNxyeyckaAo5WyBK_2pQ_11_0"></a><a id="Tc_UBMgECXytkWDn_Olzj6jWQ_11_2"></a><a id="Tc_KynuELYGz0OoaRWBk4611w_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_WkHYpXt68kWcRuuFavco5Q" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">6.</b></span><b style="font-weight:bold;">Property and Equipment </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Property and equipment consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_yXwkpiCo2Eig7yzafBmVOQ" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Furniture and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_axgn_FurnitureAndOfficeEquipmentMember_eHb9YcMz8EqbrCnNH59ieA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_L2UmNW_KiEuw_FEQJoMcCg_4_3">2,059</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_axgn_FurnitureAndOfficeEquipmentMember_DX67Y23vfUOHXqqejMx78g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ceFy4nOSHU2f3K4093lyeA_4_6">1,763</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_gm7Ekd16kESYJkPMrHphbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_DENUJGIzvkWE_lv0pp1vDA_5_3">2,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_mTPBmF_K80agEXOisxdU-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_zU3qVxjbeES1Ctukg8mOtA_5_6">1,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Processing equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_05CtstIR4U6B9g5bHnLHdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_4d8Q6SjpfEmC2Eg6Ys6wHA_6_3">2,772</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CLATC9jILkmHQd664S3WNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_YWvN_o31Y0KLuaEBHpsihA_6_6">2,349</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_BvPsE8K_qU2AmBwEqGDfYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_hatFt3FsqU6J72MSlACbzw_7_3">731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_IKe6rTfzZ0ud8WUCTvHEOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_bHU1RxD5EUmox3T1G1LU9g_7_6">731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Projects in process</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_P3IHq2_ZwUq82grKCaDpZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_JwBVJ1NckEmsR5lSFlhjNQ_8_3">10,886</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_3Y3Zposxo06m_ckziI2URQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_0ZTAaNCDmU2zqS3MoYFR3Q_8_6">4,906</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, at cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_iQl1YOv__kWXMhQ4H4f8JQ_9_3">18,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_0GpNtP_Cq06yJ0qAiD4e_g_9_6">10,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_FP_HHq_-cUGYoeK_Yy3Nzw_10_3">3,764</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_nxzk8b2apUGBmHB-rsH3Xw_10_6">2,861</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_FxTLzshwO0aIQsvnpaxhsw_11_3">14,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_XkKBQJCOuE6AyCmIOpzpZA_11_6">8,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Depreciation expense for the years ended December 31, 2019, 2018 and 2017 was $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_qotLgJBJrkifP44wbEl6jA">933</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_utJCmHyf0kqCBMQZCJzs0Q">774</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_nZnsnYO8e0mXXU2iHikObQ">488</ix:nonFraction>, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_aySJfesQ1U-OqyKIJn0YbA_1_2"></a><a id="Tc_UOAdMvs5B0WI0I4K6F6Bcw_1_5"></a><a id="Tc_a11GsMq0jkmOWFB9p_o8GA_2_2"></a><a id="Tc_221FdUVYjES8c2YDroyzJA_2_5"></a><a id="Tc_stp47pqwG0a1gXFOiugSvA_4_0"></a><a id="Tc_jj-sZeJ3kUyQM01skWKypg_4_2"></a><a id="Tc_a3tMIIHnEU2EVo5zbNzQhw_4_5"></a><a id="Tc_CyH5aLEJQ02jltEiSnyJ4A_5_0"></a><a id="Tc_KryEvTFoUUKVwwDyEDBgag_6_0"></a><a id="Tc_p4NWgrvNs0yHi8wcjJNjSQ_6_2"></a><a id="Tc_50u6Bh8LoEmMVlKIdnsHDg_6_5"></a><a id="Tc_yJ8W3ZujyUu-Es4F03N2YQ_8_0"></a><a id="Tc_9AXeJVgluUmD9-fdWAi_dQ_10_0"></a><a id="Tc_Bd-Is-QfsE2AbNrWXqHgeA_11_0"></a><a id="Tc_RD9JKPzUvU6csvcqoSgU_g_12_0"></a><a id="Tc_rCbYXwr_vkOvHGJL2SDVpg_12_2"></a><a id="Tc_9jfCxGRD8EiUTd8VBKg-Dg_12_5"></a><a id="Tc_D1V2MDYCKkW86ampxLfGwA_13_0"></a><a id="Tc_VpOk759F30Gyx8LhvpSDQw_13_2"></a><a id="Tc_jIFgDTwSHkuJufBEw0coGg_13_5"></a><a id="Tc_jI2tEB7IkU6VBWvvGKcsJA_1_0"></a><a id="Tc_mVQLddPxk0elWROgP4T6Wg_2_0"></a><a id="Tc_dFsT-IeTCUqPJAPuxjaJrg_3_0"></a><a id="Tc_i9siH1Egd0SR6dhueUBujw_4_0"></a><a id="Tc_JxNE2xYxV02xkEIovYTLAA_5_0"></a><a id="Tc_hYb5TVIyK0GcETddtS1FNw_6_0"></a><a id="Tc_ymVLkAOG0E-_6rhb6wRQ9g_7_0"></a><a id="Tc__v6QjfDaYUCYYaR1oUbWkw_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="Tb_67WHsYfW10mc0koC4LgBIg" continuedAt="Tb_67WHsYfW10mc0koC4LgBIg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">7.</b></span><b style="font-weight:bold;">Intangible Assets </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s intangible assets consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_3hEmrE97_USNBpNvdhbPiQ" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">License agreements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_tm6tkYZA0UC_UdKqm7L5gQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_4X5HNR-xJkizS2in3A9bkA_4_3">1,067</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_XpCasb7z-kOfYQrkb2g_dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_4HG4FiwhdkCtcUhb9ZfuPg_4_6">1,034</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less: accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_tm6tkYZA0UC_UdKqm7L5gQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_Slx5NIVQa0-sujDoCRDBoA_5_3">647</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_XpCasb7z-kOfYQrkb2g_dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_uShwaRv5iEC95xRUkXFGKA_5_6">553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">License agreements, net</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_tm6tkYZA0UC_UdKqm7L5gQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_BAI05aJ67kCl4uXk1lRtjQ_6_3">420</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_XpCasb7z-kOfYQrkb2g_dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_ItEN6yiJ5Eer7uuaMpQLVw_6_6">481</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Trademarks</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksMember_BbMESX-_v0KHSgS-XLTLvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_zGIasJBZ6kKq96hi0ZkiCw_8_3">334</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksMember_Qd3k0h7qbE2DTTVHMaRmbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_WZLlLN_tHEuD4dE8Q3geTw_8_6">255</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Patents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_KC2GzeBS4kutQdKGNYDCsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_WHdoaVntA02tf4vWwx6yUA_10_3">845</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_PgGkObwHFk-tbBS04WJSyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_PlKfcfc2YkCgCmTPoYBTLg_10_6">500</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less: accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_KC2GzeBS4kutQdKGNYDCsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_DHd5Fw7L7kmmer6VaqavXQ_11_3">84</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_PgGkObwHFk-tbBS04WJSyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_g2QHSBeR10qHqi2c69qgFA_11_6">55</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Patents, net</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_KC2GzeBS4kutQdKGNYDCsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_4UQq386GQECKKYW9JWV7Og_12_3">761</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_PgGkObwHFk-tbBS04WJSyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_byrGP_83-kCfq7uW81X8Rg_12_6">445</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Intangible assets, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_4dMMVqeKEUWEZkV1av2WlA_13_3">1,515</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_wFdp-UjEcU69RnHbEiP-gg_13_6">1,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">License agreements are being amortized over periods ranging from </span><span style="-sec-ix-hidden:_de056e84_5c37_441e_8d70_f8b60d255c1c"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seventeen</span></span><span style="font-size:10pt;"> to </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_OFAgoTompkmEhOalHj3_sA" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr_3B0Fl7P8ckO4FHcKQK889A"><span style="font-size:10pt;">twenty years</span></ix:nonNumeric><span style="font-size:10pt;">. Patents are being amortized over periods up to </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_FBZq-druJEiz_96TJNFlGQ" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr_4k9ZacAAGE-Q06EDUw1MsQ"><span style="font-size:10pt;">twenty years</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;">.  Amortization expense for 2019, 2018 and 2017 was approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Narr_LipcdIRxdUuUxM_u6Mh7IA">123</ix:nonFraction></span><span style="font-size:10pt;">, </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Narr_QKuPYMMuFUqlmFCtz1GYrQ">77</ix:nonFraction></span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Narr_JeUMAS-L4E-ha0YNKr6loQ">79</ix:nonFraction></span><span style="font-size:10pt;">, respectively. In January 2019, the Company rebranded its logo and product name designs, as a result the Company recorded a </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_1_31_2019_UDTsEyjMukWLzOkrt7d4_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Narr_GcX7mABs20asghx-GmKIHA">104</ix:nonFraction></span><span style="font-size:10pt;"> charge related to the previous logo and product design names. This charge is recorded in the &#8220;General and Administrative&#8221; in the Statement of Operations. As of December&#160;31, 2019, future amortization of patents and license agreements are as follows:</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Tb_ai1ti-GmSE6t7IxofKVyig" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:77.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="Tc_gejYu5JofkSiC2c8uzjgAA_2_1">137</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_1q1DYbIt0Eq9x7422dbOpA_3_1">137</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc_fWIBvUKUFki6A39_SOtUMQ_4_1">138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_K9Vp-nEgbUmK5Kzd8eG90g_5_1">119</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="Tc_y2b-4nNADkG5X6tkD2qkdw_6_1">47</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="Tc_L5QKPJH5Z02RCGnXEf-kRA_7_1">603</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">TOTAL</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_C1ozrCz6_kiUzqc1ZQ6-Qw_8_1">1,181</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">License Agreements</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The Company has entered into multiple license agreements with the University of Florida Research Foundation and the University of Texas at Austin (together, the &#8220;License Agreements&#8221;). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg" format="ixt-sec:durwordsen" name="axgn:NoticePeriodForTerminationOfLicenseAgreements" id="Narr_1qlT5e5_T0aDta_4mPDKMg"><span style="font-size:10pt;">60 days</span></ix:nonNumeric><span style="font-size:10pt;"> prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen pays royalty fees ranging from </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_xxA6d2qDA0KMb3nNUfKzyA" decimals="2" format="ixt:numdotdecimal" name="axgn:RoyaltyFeesPercentageUnderLicenseAgreements" scale="-2" id="Narr_ggiCQNbvzEmQ3TKhdCCbpw">1</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> to </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_OFAgoTompkmEhOalHj3_sA" decimals="2" format="ixt:numdotdecimal" name="axgn:RoyaltyFeesPercentageUnderLicenseAgreements" scale="-2" id="Narr_LaRlxLUUE0KFyRfkkjaztA">3</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> under the License Agreements based on net sales of licensed products.&#160;One of the agreements also contains a minimum royalty of </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg" decimals="-3" format="ixt:numdotdecimal" name="axgn:MinimumRoyaltyOfLicenseAgreement" scale="3" id="Narr_9yNAQt04OUK0itJjsNCaJw">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees.&#160;Also, when Axogen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_OFAgoTompkmEhOalHj3_sA" decimals="4" format="ixt:numdotdecimal" name="axgn:PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" scale="-2" id="Narr_w0vpdgTWGUyus72sxz9TDA">3.75</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If Axogen sublicenses technologies covered by the License Agreements to third parties, Axogen would pay a percentage of sublicense fees received from the third party to the licensor.&#160;Currently, Axogen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-</span></td></tr></table></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_67WHsYfW10mc0koC4LgBIg_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">licensee under the License Agreements and does not owe any sub-licensee fees for its own use of the technologies;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Currently, under the University of Texas at Austin&#8217;s agreement, Axogen would owe a </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg" decimals="-3" format="ixt:numdotdecimal" name="axgn:MilestonePaymentContingentUponReceiptOfGrant" scale="3" id="Narr_ChitVy6K80aTbPyCoxF_Bw">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.&#160;A milestone fee to the University of Florida Research Foundation of </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg" decimals="-3" format="ixt:numdotdecimal" name="axgn:MilestonePaymentContingentUponFDApproval" scale="3" id="Narr_7GmafeS6mk-N9N-4Mts3eQ">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> is due if Axogen receives FDA approval of its Avance Nerve Graft, a milestone fee of </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg" decimals="-3" format="ixt:numdotdecimal" name="axgn:MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" scale="3" id="Narr_0mPt3CVHYUCtojh-ndRYwg">25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> is due upon the first commercial use of certain licensed technology to provide services to manufacture products for third parties and a milestone fee of </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg" decimals="-3" format="ixt:numdotdecimal" name="axgn:MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" scale="3" id="Narr_Xj3BgDWL6UylkVyVqw9E-g">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> is due upon the first use to manufacture products that utilize certain technology that is not currently incorporated into Axogen products.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 57.6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Royalty fees were $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_bxzrSUd6ckqbGlbKCkkNcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="3" id="Narr_ZeYlrIHUsEyPHgxTyZd05g">2,119</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_ACgwMpqi40GSjcz2QnxS7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="3" id="Narr_Wj3a5yEUGkeHRAcIULl8aw">1,661</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_OZPWCWKOxEOV_X4bbR494w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="3" id="Narr_SYe2Bn5ikEWjnLK3o6VyEA">1,195</ix:nonFraction> for the years ended December 31, 2019, 2018 and 2017, respectively, and are included in sales and marketing expense on the accompanying consolidated statements of operations.</p></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="Tc_2L9jLStlkk2rDm2zeehCrg_1_2"></a><a id="Tc_8RSwiVaSAUCdx1281ecvlA_1_5"></a><a id="Tc_UId_2RarNEqKl-bvtrdRTg_2_2"></a><a id="Tc_UcuIvoxERk2GcEmUVeSDlA_2_5"></a><a id="Tc_xlOisQ-JPkm4fazBuytApA_4_0"></a><a id="Tc_rEzJeJ8HFkWwylZvXY45nw_4_2"></a><a id="Tc_QZki3zaYmUGa5-Egbh4u3g_4_5"></a><a id="Tc_c_ooSTiAXk29YEAO3euxJQ_5_0"></a><a id="Tc_2t6nWEDQNEq0bEGfNvE4xw_6_0"></a><a id="Tc_yblVAy6RcEml87W7uPcFcA_7_0"></a><a id="Tc_Ll-77nykgkGBjIUqrV0EZw_7_2"></a><a id="Tc_iXKxsQFB8UiOrPQG0GXhBA_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_fqa9zVfkOEmzHCUkIZcNBA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">8.</b></span><b style="font-weight:bold;">Accounts Payable and Accrued Expenses</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Accounts payable and accrued expenses consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_QtMZvKdedUa89f4NopvFcw" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_E5LSEXg_jUGCGJxrND1fQw_4_3">8,262</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_FD_WwVuHfkqqrILXv5PnSQ_4_6">4,517</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_HoldUTZgZEizfrqDhfsm9Q_5_3">3,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_kF9HBbh3h0yV3n_lecRnRA_5_6">2,004</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Accrued compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_anDZPv1UqkKc0ejfqJoY2Q_6_3">7,631</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_EtI37-N2NUCE9Z486LA_pQ_6_6">6,477</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Accounts Payable and Accrued Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_od7FLwBZGU-HWzV7VtVxsA_7_3">19,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_yIZYcT8RJUWH_eTs4lMFkQ_7_6">12,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_9ZStx48WV0yNu83H-8P62A_1_2"></a><a id="Tc_SKr6o2b1SEe7khvQv65RNw_1_5"></a><a id="Tc_uaz7D1hQlkSVxGzoJl8-mw_2_2"></a><a id="Tc_5wJ6d7sF9UWB4owfFLcn2g_2_5"></a><a id="Tc_SONgLMgr3UqHLr6rZRTvpg_5_0"></a><a id="Tc_oMbw6oGoUUmZbIeP_p5Ilw_5_3"></a><a id="Tc_xaud8j13ykCSYDPpsXmgQg_7_0"></a><a id="Tc_i5Aq0sY0o0Wkb8xGlSJeiA_7_3"></a><a id="Tc_T7wC8Zs9JkOQ1H5BRbwrAA_9_0"></a><a id="Tc_YOq62Pw720-FIt4TE05sTw_9_3"></a><a id="Tc_3rDmJaIGuEO4RcR2aVjLYQ_10_0"></a><a id="Tc_muGRg5hA5UWYHxHCqMTO1w_10_3"></a><a id="Tc_JlznG8W6D029Qgi3E7wD9Q_11_0"></a><a id="Tc_oujgOQa81E6UEpdmAeLMoA_11_3"></a><a id="Tc_Wmk2H6avLEekE-sd6c_09g_11_6"></a><a id="Tc_vMmvVDbV5E2AJY-8gSOXhQ_12_0"></a><a id="Tc_pkN5EVAm7U2nbJ8yoWIr6A_12_3"></a><a id="Tc_5RBbKCOfNUmbumhROY-92g_13_0"></a><a id="Tc_0iw1zoSOwkS3wX9BPR9_yA_13_2"></a><a id="Tc_chbzCD_U-0iQpnSY0IV5Vw_13_3"></a><a id="Tc_aN05IgbIq0KvamrVQZI10A_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:LongTermDebtTextBlock" id="Tb_gMzWAr3Z-EumZMyj5uYggA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">9.</b></span><b style="font-weight:bold;">Term Loan Agreements and Long-Term Debt</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Term Loan Agreement and Long-Term Debt consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_PoKJJYQkoEudEcSXHF3dlA" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Equipment Lease Agreement with Cisco Capital for a total lease amount of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5AiGbGmjpkCdVyBcVv8E_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_bUam91XP_kCj3WjYW2Rfmw"><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_K3AS51eTEE-YvIQB0nBIfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_zs1FU35tmUa60REaciUidA">59</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;"> which has a </span><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_8IfuLyTmxkeeHIrn5HAHCA" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_U5rJP8XkPE2aNWjh07_VzA"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_OuSBR749Ck6rO9M9pD5hrg" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_lMBM027tkUqqzs7ScTElxw"><span style="font-size:10pt;">36 month</span></ix:nonNumeric></ix:nonNumeric><span style="font-size:10pt;"> term and requires no lease payments for the first </span><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_8IfuLyTmxkeeHIrn5HAHCA" format="ixt-sec:durwordsen" name="axgn:DebtInstrumentNoPaymentsRequiredTerm" id="Narr_ZM22oZi840SbRNhbem5l2A"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_OuSBR749Ck6rO9M9pD5hrg" format="ixt-sec:durwordsen" name="axgn:DebtInstrumentNoPaymentsRequiredTerm" id="Narr_J-1_hDCV2UGB4msd1S5XjQ"><span style="font-size:10pt;">three months</span></ix:nonNumeric></ix:nonNumeric><span style="font-size:10pt;"> of the lease and </span><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_8IfuLyTmxkeeHIrn5HAHCA" format="ixt-sec:durmonth" name="axgn:DebtInstrumentInterestAndPrincipalPaymentsTerm" id="Narr_VdO8hoFmJkSp7IqbTUcZuQ"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_OuSBR749Ck6rO9M9pD5hrg" format="ixt-sec:durmonth" name="axgn:DebtInstrumentInterestAndPrincipalPaymentsTerm" id="Narr_-AEX652ohEyh0941XGE-cQ"><span style="font-size:10pt;">33</span></ix:nonNumeric></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> equal payments of principal and interest until the end of the term.  Interest on the lease is payable monthly at </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5AiGbGmjpkCdVyBcVv8E_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_MDi02j-q5Ee8Ots6HRzSmQ"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_K3AS51eTEE-YvIQB0nBIfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_ocXXUKib60O7wvz8DmXBJA">3.5</ix:nonFraction></ix:nonFraction>%</span><span style="font-size:10pt;"> per annum.</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5AiGbGmjpkCdVyBcVv8E_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtAndCapitalLeaseObligations" scale="3" id="Tc_k5tX3KbZS0mJo8IYCqjxYw_5_6">15</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Equipment Lease Agreement with Raymond Leasing Corporation for a total lease amount of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_R55K8zUulUecXnhoaiBPkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_07ZOdumfgEGBvV-5wR3v9Q"><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_GGJc28kiH0yWr2MZBgPxCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_klXg-NIbME2faE48OpawvA">30</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;"> which has a </span><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_kNscByhTbEyGSk9W2JNlqA" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_6n2qAeY13kKfyGF77Ig81w"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5zA3fXbvx0ylwp-9i_-FOg" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_3DaEjdx_rkSn9TcdESWPTg"><span style="font-size:10pt;">48 month</span></ix:nonNumeric></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_R55K8zUulUecXnhoaiBPkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_PlzUuNVO00-jwBrxCDwMog"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_GGJc28kiH0yWr2MZBgPxCQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_0odxvd6XLke4vFzotveQvA">6.7</ix:nonFraction></ix:nonFraction>%</span><span style="font-size:10pt;"> per annum.</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_R55K8zUulUecXnhoaiBPkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtAndCapitalLeaseObligations" scale="3" id="Tc_ZQmgaVhTkEW8qrmjIZhWQA_7_6">22</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Equipment Lease Agreement with B&amp;B Office Systems for a total lease amount of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_wW9WLuWZOE66fVKEdCy_HA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_kkKGO2Bkdkqh9UffoQF26g"><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_nwTNdrPqO0CQRQSSHeR4zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_OHQoc8mXoUKJCLW8v7KjCA">32</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;"> which has a </span><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_7a23qUYeEESFI9Qda8I25Q" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_fSwQ9D4bFUiJ7TEkS340Jg"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_1eKp0lMU00OTf_T3kLb7qw" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_iWL6yXBqNk-mMDzVrxHRVA"><span style="font-size:10pt;">60 month</span></ix:nonNumeric></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_wW9WLuWZOE66fVKEdCy_HA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_gFTVLbWLvUuaC0Zdasvzjw"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_nwTNdrPqO0CQRQSSHeR4zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_vaDsDTlH-U-aXmk222FOhQ">8.5</ix:nonFraction></ix:nonFraction>%</span><span style="font-size:10pt;"> per annum.</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_wW9WLuWZOE66fVKEdCy_HA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtAndCapitalLeaseObligations" scale="3" id="Tc_DT8ucecaz0S8GaH65x30ww_9_6">26</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtAndCapitalLeaseObligations" scale="3" id="Tc_SWeppeFtKk6u8J1bJS0ltA_10_6">63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less current revolving loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less current maturities of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_wgbr7gXhZ0qyLBxUs1-1cA_12_6">28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Long-term portion</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">  &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="axgn:LongTermDebtNoncurrentExcludingDeferredRevenue" scale="3" id="Tc_-vuEZwZyb0C_fEPH8oxQpw_13_6">35</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Credit Facilities</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">MidCap Term Loan Agreement </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On October 25, 2016, the Company entered into Term Loan and a Revolving Loan with MidCap Financial Trust (&#8220;MidCap&#8221;) maturing on May 1, 2021.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company had the option at any time to prepay the Term Loan in whole or in part, subject to payment of a prepayment fee and an exit fee.  On May 22, 2018, the Company exercised its option and paid </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_5_22_2018_To_5_22_2018_i3ypW9J1CEa7OLr3rjoRmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Narr_a8lOLtgQhEmCN3xckelhWg">22,599</ix:nonFraction> to prepay the Term Loan in full, which included exit and pre-payment fees totaling $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_5_22_2018_To_5_22_2018_i3ypW9J1CEa7OLr3rjoRmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="Narr_RCHqJaNG9ES0VRt0Z9vioQ">1,470</ix:nonFraction><span style="white-space:pre-wrap;">.  In addition, on May 22, 2018, the Company charged to interest expense the unamortized deferred financing costs associated with the Term Loan of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_5_22_2018_dzFQMjgQyUeSU6fLKCFqYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Narr_sM8SRpCja0qR7pnOLrbtMg">473</ix:nonFraction>.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company also had the option to terminate or permanently reduce the Revolving Loan prior to the maturity date subject to its payment of a deferred origination fee. On May 22, 2018, the Company exercised its option to terminate and paid $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_5_22_2018_To_5_22_2018_us-gaap_LongtermDebtTypeAxis_axgn_RevolvingLoanAgreementMember_8N4ZVro1vU-SRjTtIMuL6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Narr_M1mbTzWcSkiqv2Wt_FaWog">2,958</ix:nonFraction> to prepay the Revolving Loan in full, which amount included fees of $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_5_22_2018_To_5_22_2018_us-gaap_LongtermDebtTypeAxis_axgn_RevolvingLoanAgreementMember_8N4ZVro1vU-SRjTtIMuL6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="Narr_0iuyK7aYXUebtZBnVnqQ0A">236</ix:nonFraction>.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_JZ1yb41Z4Ea_8cAazA4Utw" continuedAt="Tb_JZ1yb41Z4Ea_8cAazA4Utw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">10.</b></span><b style="font-weight:bold;">Public Offering of Common Stock </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Axogen,&#160;Inc. Classes of Stock</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen,&#160;Inc.&#8217;s authorized capital stock consists of <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_NdtCumbmdUmu5AmZEiibng"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_mQdxV7yI-EWjkCC-85ar7A">100,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_o0Psfn2Nz0OJEJyTo3THGQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_V_baPHa0EEiIZ3iics96zQ">0.01</ix:nonFraction></ix:nonFraction> per share. The authorized capital stock is divisible into the classes and series, has the designation, voting rights, and other rights and preferences and is subject to the restrictions that the Axogen Board of Directors may establish from time to time. Unless otherwise designated by the Axogen Board of Directors, all shares are common stock. Axogen has not designated any shares other than common stock.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_JZ1yb41Z4Ea_8cAazA4Utw_cont1"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Public Offerings</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On May 8, 2018, the Company entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the &#8220;2018 Offering Underwriters&#8221;), pursuant to which the Company agreed to issue and sell </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_5_8_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_IP-Mn3x-6EudoUgdTXzq8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_j6O_xqLeuUy7W7Qii3PF6Q">3,000,000</ix:nonFraction></span><span style="font-size:10pt;"> shares of the Company&#8217;s common stock in an underwritten registered public offering at an offering price of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_5_8_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_IP-Mn3x-6EudoUgdTXzq8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_5zygemKSnEWgidkNDfN4mQ">41.00</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> per share (the &#8220;2018 Offering&#8221;).  The Company granted the 2018 Offering Underwriters a </span><ix:nonNumeric contextRef="Duration_5_8_2018_To_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_95CgkAkKI0mIpKKHiaq65w" format="ixt-sec:durday" name="axgn:NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" id="Narr_fTh9obCvLk6DKCuas4eFAA"><span style="font-size:10pt;">30</span></ix:nonNumeric><span style="font-size:10pt;">-day option to purchase up to an aggregate of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_YTJ3Sc6qnUeCcLNGzq1uxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_hzWuGI16r0yNmGgxoTyGEg">450,000</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> additional shares of common stock, at the public offering price, less the underwriting discounts and commissions, which was exercised in full on May 9, 2018.  The 2018 Offering closed on May 11, 2018, and the Company received proceeds of approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_5_11_2018_To_5_11_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_8cxhdgof3UO6xB-FFbptDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr__Et0-Lcd7UiVGNDoIfpCLg">132,707</ix:nonFraction></span><span style="font-size:10pt;"> from the sale of the shares (including the sale of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_YTJ3Sc6qnUeCcLNGzq1uxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_674PoPN7SE-14yhJv5TzCg">450,000</ix:nonFraction></span><span style="font-size:10pt;"> additional shares issued upon exercise of the 2018 Offering Underwriters&#8217; overallotment option), after deducting the underwriting discounts and commissions and estimated offering expenses.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_dmMWaC-ppEq1jHqIr8kE2w" continuedAt="Tb_dmMWaC-ppEq1jHqIr8kE2w_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">11.</b></span><b style="font-weight:bold;">Equity Compensation Plans </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company maintains two share-based incentive plans:  the Axogen 2017 Stock Incentive Plan, as amended (&#8220;2017 Plan&#8221;), and the Axogen 2017 Employee Stock Purchase Plan (&#8220;2017 ESPP&#8221;). </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Stock Incentive Plan</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">At the 2019 Annual Meeting of Shareholders held on August 14, 2019, the shareholders approved the Axogen 2019 Long-Term Incentive Plan (the &#8220;New Axogen Plan&#8221;), which allows for issuance of incentive stock options, non-qualified stock options, performance stock units (&#8220;PSUs&#8221;) and restricted stock units (&#8220;RSUs&#8221;) to employees, directors and consultants at exercise prices not less than the fair market value at the date of grant.  The number of shares of common stock authorized for issuance under the New Axogen Plan is (A) </span><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_raPo7Sf_yUa4X4qkmt6ISg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_7hgKKQPqrUecQT8LDV0CUg">3,385,482</ix:nonFraction> shares, comprised of (i) <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_8_14_2019_To_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_GGHIBITd6ES9mOn1M2PF1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_v3YWd4O2ZEa3f9J_9aSnLA">3,000,000</ix:nonFraction> new authorized shares and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_raPo7Sf_yUa4X4qkmt6ISg" decimals="0" format="ixt:numdotdecimal" name="axgn:NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" scale="0" id="Narr_c-U1u8kC50uQomv19bTUug">385,482</ix:nonFraction><span style="white-space:pre-wrap;"> unallocated shares of common stock available for issuance as of August 14, 2019 pursuant to the Company&#8217;s 2010 Stock Incentive Plan, as amended and restated (the &#8220;Prior Axogen Plan&#8221;), that were not then subject to outstanding awards; plus (B) shares under the Prior Axogen Plan and the New Axogen Plan that are cancelled, forfeited, expired, unearned or settled in cash, in any such case that does not result in the issuance of common stock.  Following shareholder approval of the New Axogen Plan, no future awards will be made under the Prior Axogen Plan. As of December 31, 2019, </span><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_AsMXpgQA50yoxCfsHEU1FA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_ogu7OEJlo0uGBMljve0F1Q">3,265,188</ix:nonFraction> shares of common stock were available for issuance under the New Axogen Plan.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The options granted to employees prior to July 1, 2017 typically vest </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tXs-JMVGQEyiTIr2x0PXlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_og3ReeO1f0y_rWAIlnjuSA">25</ix:nonFraction>%</span><span style="font-size:10pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tXs-JMVGQEyiTIr2x0PXlw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_hoOpqKFslUS1Rrf7Yhq7Gg"><span style="font-size:10pt;">one year</span></ix:nonNumeric><span style="font-size:10pt;"> after the grant date and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_w1MuJpPwoUuQdyD6mVgyFA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_QhAWMemgqUqOpBRy9EywZA">12.5</ix:nonFraction>%</span><span style="font-size:10pt;"> every six months thereafter for the remaining </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_w1MuJpPwoUuQdyD6mVgyFA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_MlL-DpIE3UqcAVqOiaQdXw"><span style="font-size:10pt;">three-year</span></ix:nonNumeric><span style="font-size:10pt;"> period until fully vested after </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_CC9WNsq1-kOINeRZ-7lGZA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_hXbEZ0OsZU2cgZhTl0RNoQ"><span style="font-size:10pt;">four years</span></ix:nonNumeric><span style="font-size:10pt;">.</span> <span style="font-size:10pt;">The options granted to employees after July 1, 2017 typically vest </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Lew-fDnf_U63JMTITTXx7Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_LRs8RrWFP0eFxtPd4TJk8w">50</ix:nonFraction>%</span><span style="font-size:10pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Lew-fDnf_U63JMTITTXx7Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_3ji6jK4_gUaaw3kZOxfseA"><span style="font-size:10pt;">two years</span></ix:nonNumeric><span style="font-size:10pt;"> after the grant date and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_G1UD6bCPNE6Vk1FLD8sFmw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_zRVR9gMMBEaHI7HlDUmnNA">12.5</ix:nonFraction>%</span><span style="font-size:10pt;"> every six months thereafter for the remaining </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_VxZyqVXjoUyc4jYXo3Wsgw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ALB2soxmO0SI1_XD3YDOSw"><span style="font-size:10pt;">two-year</span></ix:nonNumeric><span style="font-size:10pt;"> period until fully vested after </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_8GcfaDwiVke9uA8EDTn7hA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_noFZHkIJQUaemmJy3PCwSw"><span style="font-size:10pt;">four years</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;">.  The options granted to directors and certain options granted from time to time to certain executive officers have vested ratably over </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember__vQAw7VfUE6OunzRu1K-bQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_4gDHhHAkPUeRg4z9eFiOow"><span style="font-size:10pt;">three years</span></ix:nonNumeric><span style="font-size:10pt;">, </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_VestingAxis_axgn_ShareBasedCompensationAwardTrancheFourMember_sY50ARTqmkOIAcnOP5sbtw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_9mJERlbD0ECYCINMLvV9dQ">25</ix:nonFraction>%</span><span style="font-size:10pt;"> per quarter over </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_VestingAxis_axgn_ShareBasedCompensationAwardTrancheFourMember_sY50ARTqmkOIAcnOP5sbtw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_BQJpiM8CjUmeSTT2Sv5M-w"><span style="font-size:10pt;">one year</span></ix:nonNumeric><span style="font-size:10pt;"> or had no vesting period. Options typically have terms ranging from </span><span style="-sec-ix-hidden:_85e8adea_8926_4837_834b_5796d41281fc"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seven</span></span><span style="font-size:10pt;"> to </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_6eAKFDAAb0yer27HykbH7g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ND9jiTG5SEGxUZMbCCbH-g"><span style="font-size:10pt;">ten years</span></ix:nonNumeric><span style="font-size:10pt;">. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company recognized stock-based compensation expense, which consisted of compensation expense related to employee stock options, PSUs, RSUs and the 2017 ESPP based on the value of share-based payment awards that are ultimately expected to vest during the period, of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_-tru8YDdlEaGF3QvS9irnA">10,304</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_M0bDFRBJ_02qOlncLCLqZA">7,606</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_Sgst3B-EHU6xlbfJLMC0Ow">3,609</ix:nonFraction><span style="white-space:pre-wrap;"> for the fiscal year ended December 31, 2019, 2018, and 2017, respectively.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of each option award issued under such plans on the date of grant using a Multiple Point Black-Scholes option-pricing model which uses a weighted average of historical volatility and peer company volatility. The Company determines the expected life of each award giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. </p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_kmXV4DXzIEG0vDzfsgLWpg_1_7"></a><a id="Tc_Z-2ktbN-LU2YH624uH-uJA_2_4"></a><a id="Tc_vBB5cHplrUih0E_mXO0QiQ_2_7"></a><a id="Tc_NYffjIvEtEqmEOkVdIAYHg_3_2"></a><a id="Tc_uWVSkv_1KUCKjwZZAkfquw_3_4"></a><a id="Tc_ZMYkopPEek6QuAdou_1cmQ_3_7"></a><a id="Tc_GW_-mwvv1UucjQyNftKtlQ_3_9"></a><a id="Tc_OTV12eCHO0WWkZ_bpTTZMg_4_2"></a><a id="Tc_IHljs5n1jk631vM2FR65MQ_4_4"></a><a id="Tc_Bdai7g08Zk6ZX2pOg2mF4w_4_7"></a><a id="Tc_Zc_aEhObqkexBjolOwmlZA_4_9"></a><a id="Tc_cBiJgYG_WkOoc4uYqwAnmQ_5_0"></a><a id="Tc_qUg0umJBt0OmKLQ9FQ-rdw_5_2"></a><a id="Tc_kka5ducP3E6a8rqbTGAiww_5_4"></a><a id="Tc_z6p73Ai-eU2ttQ_qRVF2ZA_5_7"></a><a id="Tc_Wt90l0q0RUOkoVQ1NFXM7g_5_9"></a><a id="Tc_uobZj7abhUe-Y0y0gNLzQQ_6_0"></a><a id="Tc_O40swK5a_Eifwi4Hnz7wDg_6_4"></a><a id="Tc_-rsuThVlxUuFjcap6UWYPQ_6_9"></a><a id="Tc_1jD34zkVuUyeKdOjPmNDaw_7_0"></a><a id="Tc_WyU_rihSpEGsE9_kw2A_oQ_8_0"></a><a id="Tc_xsPviNanoEuctmxFAAWc-Q_9_0"></a><a id="Tc_PE2Ai7mJ6ESa0HXWeoio9g_10_0"></a><a id="Tc_83AAuRUVbkemch7D5fqfNQ_10_4"></a><a id="Tc_z3hqzf3l7UKIi7IosVwe0Q_10_9"></a><a id="Tc_CpS21Dm7B0SZLOiinC-oDQ_11_0"></a><a id="Tc_hO_ziA0Do0eQ21Iz0uFfmA_12_0"></a><a id="Tc_6r3C15TgBkuBaDt7yNNJyw_13_0"></a><a id="Tc_UiI_-nku9EGtuIAPmTtBNA_14_0"></a><a id="Tc_IR3a6YcVcEWaY3CS2ceFEA_14_4"></a><a id="Tc_FprxQJdLcUys8hRmLSMt0g_14_9"></a><a id="Tc_FRhronYv70OM6k0RyxgFbA_15_0"></a><a id="Tc_Jm8lrCO65U28TltqyR7F2w_15_4"></a><a id="Tc_qAXZzSkEjUWQ0fEFWM_qfA_15_9"></a><a id="Tc_69HrGW8pLUSOiSHIVJ2SRg_16_0"></a><a id="Tc_pnrTn-zDU061NdFUuEmaxw_16_4"></a><a id="Tc_fLopK2We1028RNQLfTDDxQ_16_9"></a><a id="Tc_BNst8jS1T0KM2DDMPVhjcQ_1_4"></a><a id="Tc_cY0lxNlygE6xuWChPZ-jfw_2_2"></a><a id="Tc_kJQ_ZEXYJkm5bixVZNAAkQ_2_4"></a><a id="Tc_HGSSddvRG0-Az3mwa6AUFA_3_2"></a><a id="Tc_NDHMulFrokyaer5CMEIrew_3_4"></a><a id="Tc_gLsCmuMHJ06-783XXJT1sg_4_0"></a><a id="Tc_YIOMg_-8K0CfAXV89C9aGw_4_2"></a><a id="Tc_jkf1ireABEqwSuUyd_eRhw_4_4"></a><a id="Tc_T7ngvP90vkW_xyUyIODz9Q_5_0"></a><a id="Tc_3nyof1AlK0W8R1SUmEpRpw_5_4"></a><a id="Tc_Pcf98fxAs0y4py2onYplnQ_6_0"></a><a id="Tc_Qi04pmgYnUiV_Lq230BtmA_7_0"></a><a id="Tc_rM8AjoRPu0euV7i3BaM5gw_8_0"></a><a id="Tc_rcyqhmBN7ku3jf_eL7McdA_9_0"></a><a id="Tc_HK0B88GuZEKtcMsy-LbVsw_10_0"></a><a id="Tc_XRq8jd-JqkSsu2i_kewInw_11_0"></a><a id="Tc_D83mwWNVjUuAXhXQpJd2Wg_12_0"></a><a id="Tc_2oUZBtJEhkiwgK4AYlKROQ_13_0"></a><ix:continuation id="Tb_dmMWaC-ppEq1jHqIr8kE2w_cont1" continuedAt="Tb_dmMWaC-ppEq1jHqIr8kE2w_cont2"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Activity under the Prior Axogen Plan and the New Axogen Plan during 2019 and 2018 was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="Tb_0QIEGDgXDka45hZ6tdM4zw" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:1pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Time-Based Stock Options</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term(Years)</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2017:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_FuweD_vKdkCOcnSUpC4lMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_dtfmz7OAokWY1-Pp958BJA_6_2">4,304,201</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_FuweD_vKdkCOcnSUpC4lMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_gE4cRUTej0SuTfxLM9jfqQ_6_5">7.28</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_dOpDEESlqEODYTZJx6VStA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_KFnqEPU6HUmQkO3cv3Kjew_6_7"><span style="font-size:10pt;"> 5.39</span></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_FuweD_vKdkCOcnSUpC4lMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_llEqhUL_DU-x2fO4AsH6HQ_6_10">90,473</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_u6MEJHDmKEeuAyu_kFErSw_7_2">656,250</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_MXgSc7wEhkqM6dt3ucaS-w_7_5">29.48</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_R-qP6J9f-024Pl0pmXsgSQ_8_2">40,473</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__1rKPeU2QUq0yi6NcR8ZPQ_8_5">9.56</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_g21QhloOIkyjX_9-S0VfKA_9_2">1,026,807</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_7rLrHtJ0DkewxKm5XWSWfw_9_5">3.72</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2018:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_NvaE0ZF610qmwkn-m_kZkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_YXtqHhvgzUKGFN7LhnOWCw_10_2">3,893,171</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_NvaE0ZF610qmwkn-m_kZkw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_5TYw0J2AN0CJRrQOX1CPJw_10_5">11.94</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_hax3tgcHlUizJdIyVdJj6Q_10_7"><span style="font-size:10pt;"> 5.95</span></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_NvaE0ZF610qmwkn-m_kZkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_XgGNUHN4NUeOaLWD40kfFQ_10_10">41,020</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_YMPzJDPPL0-eCeBefdv8Qw_11_2">344,176</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_4wM7jOPxmUqypn-BYzYHhg_11_5">18.07</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_YIxeouN6oEK77vDa6qaEOA_12_2">287,609</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_d3BEItKGSkGKZ-rWuGivUQ_12_5">22.75</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_VZquvzaoG0mAvSth9i-c0Q_13_2">529,557</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_i8IJfGbcSkuwtIU4NCrKYg_13_5">5.21</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_DCM3_zySTUmvKJIoTmHq8A_14_2">3,420,181</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_wIyFsjv380CQ9E7UeDwwkA_14_5">12.69</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_xKl6VvLkdUShDnne6beP6A_14_7"><span style="font-size:10pt;"> 5.70</span></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_LlB0Le_uxkeE-kJ6IZcRfg_14_10">26,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Vested and expected to vest</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_LldVqm480U2UQwaUCzFm9g_15_2">3,420,181</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_EN5tLauKLUGQygt4rVgVTA_15_5">12.69</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_BPYobo-dJ0qeTseRpmp2ww_15_7"><span style="font-size:10pt;"> 5.68</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="Tc_ekjGOqcp-Uum3hIjdxxFEA_15_10">26,074</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Exercisable at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_Gw9RtdiN3U6ARWdz81MQ0g_16_2">2,099,616</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_Mh58Is31HEaBA92QsLdevA_16_5">7.90</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_WILEy3pclU2Bjag8TcloPA_16_7"><span style="font-size:10pt;"> 4.10</span></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_soPjGZfZDke871TMHdVacA_16_10">22,712</ix:nonFraction></p></td></tr></table></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_1506ocbMwU6IPu5iK3iqbQ" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Restricted and Performance Stock Units</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2017:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_JJoSoSTdZU-4AUZvS_2qqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_TTPWeGK3GEiVnMunDZCuSg_5_2">610,730</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_JJoSoSTdZU-4AUZvS_2qqw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_NJ3Uk0zTvkynIppgp2zTFA_5_5">21.14</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_vNcChWf6nEyqqRFxvrTjKg_6_2">516,433</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_01zdKahyAkStKABfgCZhdw_6_5">23.34</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Released</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_8lv051MAsEWmPBLHzQcNfQ_7_2">7,150</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_aCJcEU7zEk6MP-9Y_Z3GCQ_7_5">8.95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_5hmDUDnMWk6yz5C_eCxDWA_8_2">13,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_lov3FIoAU0WNC_kWkQeJPA_8_5">25.89</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2018:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_C62IeF_A8kyKJEMkteQh9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_X-nTubOR1E2pCT92IZcsDg_9_2">1,106,363</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_C62IeF_A8kyKJEMkteQh9g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_MyhvyKd3PEq0PPMPPdoAVA_9_5">22.18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_ao4j9mzeY0-jdKH-0jwq4Q_10_2">217,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_7ZEUnoZxv0m4wEQjKRCJBA_10_5">17.60</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Released</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_EaZVpOqeNESGPwW3MP6lKg_11_2">86,405</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_NLALTKyMaEWn59GA2lkrHw_11_5">16.77</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_V4X6aXWwP02fyO8FAQEX6g_12_2">123,407</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_ZaCjBcpCe0iUsqJ7wRFS3A_12_5">22.97</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_kf1nPeinvkG_Rhf00UpwCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_3OsS8B-L_kaaFKmG1JQDSg_13_2">1,113,697</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_kf1nPeinvkG_Rhf00UpwCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_FJTnn-JzC0ilB3qp0KNKEw_13_5">21.62</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The intrinsic value of equity awards exercised during the years ended December 31, 2019, 2018 and 2017 was $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_ts6ch1E1YkaKgRGi-KlCzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_8F6fZ12quEOfrlCdN2q6bA">9,553</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_wAZ3pu-l8kyAOvBDAXRqzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_VTGoYgmvY0SLZSBTqRfikw">34,229</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_0ysv9tohn0Cnci0yKK3WTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_cVM0s_8MIEWWywaV67DXzw">7,783</ix:nonFraction><span style="white-space:pre-wrap;">, respectively. As a result of the Company&#8217;s full valuation allowance on its net deferred tax assets, no tax benefit was recognized related to the exercises of stock options.  The exercise price per share of each option is equal to the fair market value of the underlying share on the date of grant.  For 2019, 2018 and 2017, </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_Ho5IEtSXlUGzaNyUFAUCdg">4,002</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_3Wg8yroaYUGsfADvSmZ_Zg">3,884</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_bvZCRYC5nkiC14eGABnLMA">1,434</ix:nonFraction><span style="white-space:pre-wrap;">, respectively, in cash proceeds were included in the Company&#8217;s Consolidated Statements of Cash Flows as a result of the exercise of stock options.  The total fair value of restricted stock vested during 2019, 2018 and 2017 was </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="Narr_nK1CVjx8i02s8fnVyKtUHw">1,467</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="Narr_CWW_xJF5cUKEw3EoYdh5Rw">196</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="Narr_5w9mwtQ4kkGmZ8INEhUgFw">108</ix:nonFraction><span style="white-space:pre-wrap;">.  The Company issues registered shares of common stock to satisfy stock option exercises and restricted stock grants.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">As of December 31, 2019, there was </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_R1UTHSkFFkGQk_FG_stL9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Narr_Clti2_7Ng06YWvmJVX_rgg">19,460</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> of unrecognized compensation costs related to non-vested stock options and restricted stock awards.  This cost is expected to be recognized over a weighted-average period of </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_Ql1wJMAwvk-Sb_JOHEvrvw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_wGa2w3_cMkqHZspSRhX7bA"><span style="font-size:10pt;">2.14</span></ix:nonNumeric><span style="font-size:10pt;"> years for stock options and </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_3FvL10D5nEOeSMDNANv2Kg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_FeG0mh-oO0GkRLPzsj1D8g"><span style="font-size:10pt;">2.63</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> years for restricted stock awards.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On December 18, 2017, December 27, 2018 and December 17, 2019, the Compensation Committee of the Board of Directors also approved PSU awards to certain employees related to their work on the Company&#8217;s BLA.  The PSU awards consist of a targeted total award of </span><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_kDpRBjGQ4ky9c7CfmO9qDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_cXOU29X6FEedj-m_m6vMxw">200,000</ix:nonFraction><span style="white-space:pre-wrap;"> shares. The number of shares are allocated to certain milestones related to the BLA submission to and approval by the FDA.  The performance measure is based upon achieving each of the specific milestones and will vest </span><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_12_18_2017_To_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_vVyhRlB3k0qQ8T_w4fLYmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_XRJu-Md-yU6NxsYxCnuhYQ">50</ix:nonFraction>%<span style="white-space:pre-wrap;"> upon achieving each of the milestones and 50% one year later.  The Company estimated the  fair value of the PSUs based on its closing stock price at the time of grant and its estimate of achieving such performance target and will record compensation expense as the milestones are achieved. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dmMWaC-ppEq1jHqIr8kE2w_cont2" continuedAt="Tb_dmMWaC-ppEq1jHqIr8kE2w_cont3"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">expense will be adjusted based upon the Company&#8217;s estimate of achieving such performance target. The number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on the actual performance metrics as set forth in the applicable PSU award agreement.   The amount actually awarded will be based upon achievement of the performance measures and can range from </span><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_18_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_KoTtJ_qtIEWdKLFBvghyAw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_pPi9D_E2Y0aTzDnv1c5JPg">zero</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_18_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_CGrwMnPP4UGYxvkC4Exm0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_b7OjGuc4R064QBeWswUBmA">200,000</ix:nonFraction><span style="white-space:pre-wrap;"> shares.  The fair value of the common stock on the grant date was </span>$<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_17_2019_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_h_z9vINimUO30zz-EdrkPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_qCV-hATKsU27fF8RHWWN4w">16.88</ix:nonFraction> on December 17, 2019, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_27_2018_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_XKWVUmRIiEOgStCdW6dO9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_kmRjuy7svUK_TMFmmJLfwg">19.17</ix:nonFraction> on December 27, 2018 and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="As_Of_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_kDpRBjGQ4ky9c7CfmO9qDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_9caEiLfPOEC2uPGHLihLfA">27.00</ix:nonFraction><span style="white-space:pre-wrap;"> on December 18, 2017.  The total unrecognized future compensation expense related to this PSU, assuming achievement of </span><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_12_18_2017_To_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_vVyhRlB3k0qQ8T_w4fLYmg" decimals="INF" format="ixt:numdotdecimal" name="axgn:CompensationCostNotYetRecognizedAssumedPercentageAchieved" scale="-2" id="Narr_TTNpGzfqd0KiSP2vCYCCcg">100</ix:nonFraction>% of the target award is $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_V4yhWdQNTEehyUOL8K5GIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_xoKfYtwMQU-kY3F9wBo1xA">17,682</ix:nonFraction>. Assuming the minimum of <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_NdmkMgAetEmBY0Ox4RWwMg" decimals="INF" format="ixt:numdotdecimal" name="axgn:PhantomStockUnitPayoutOpportunity" scale="-2" id="Narr_BaNson-ZxE61U8Lm7_lfxw">0</ix:nonFraction>% and the maximum of <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_YaU4fSuYCEqRjlrkJR8zFA" decimals="INF" format="ixt:numdotdecimal" name="axgn:PhantomStockUnitPayoutOpportunity" scale="-2" id="Narr_j8BnE-q9Ck6ixrT1MLaB8w">100</ix:nonFraction>% payout opportunity for the PSU, the range of total future compensation expense related to this PSU award is between $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_dGmAPQbXTkiY-aJQtxRmkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_hNxnWRb07EKGIXNfsGEtJg">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_V4yhWdQNTEehyUOL8K5GIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_mSMv2Ml1a0mQOnYGOjJmOg">17,682</ix:nonFraction> as of December 31, 2019.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The 2017 ESPP, which was effective as of January 1, 2018, allows for eligible employees to acquire shares of our common stock through payroll deductions at a discount from market value (currently </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_do694XF7Vkun4p0EqDCKIw" decimals="INF" format="ixt:numdotdecimal" name="axgn:EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" scale="-2" id="Narr_oGqYvIoGPkKutocleBGLQQ">15</ix:nonFraction>%</span><span style="font-size:10pt;white-space:pre-wrap;">) of the lesser of the closing price of the Company&#8217;s common stock on the first day or last day of the offering period.  The offering period is currently </span><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_do694XF7Vkun4p0EqDCKIw" format="ixt-sec:durwordsen" name="axgn:EmployeeStockPurchasePlanOfferingPeriod" id="Narr_dia8s1s9c0qJOy9ecf1bGg"><span style="font-size:10pt;">six months</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;">, and the offering prices are subject to change.  Participants may not purchase more than </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_do694XF7Vkun4p0EqDCKIw" decimals="-3" format="ixt:numdotdecimal" name="axgn:EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" scale="3" id="Narr_YA7NSBDr4EeiP2TbLkZePA">25</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> of the Company&#8217;s common stock in a calendar year.  As of December 31, 2019 , there were </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_5M4EtFIS2UiIB7rFpvlMjQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_QvIVFn7KHkGZK2cI-8JPDA">600,000</ix:nonFraction></span><span style="font-size:10pt;"> shares of common stock authorized for issuance under the 2017 ESPP and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_j1ICqH5Z30Cj6yv7xX0hUQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_xINPs2bhoUSm8O55smvTrg">450,305</ix:nonFraction></span><span style="font-size:10pt;"> were available for future issuance.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Valuation and Expense Information Under FASB ASC 718</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of each option grant using a Multiple Point Black-Scholes option-pricing model which uses a weighted average of historical volatility and peer company volatility. The Company determines the expected life giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ldwvhLOeTECRIYz5ZxGM9w_1_0"></a><a id="Tc_HMpvmfiFcEuKn56T4q5sgg_1_2"></a><a id="Tc_3eobbZNkcEe6H0_SZVtwQw_1_4"></a><a id="Tc_WDETCBiqNUOkzcQ7mR_7JA_1_6"></a><a id="Tc_q70oHlRXzkSwH-58QVTshQ_3_0"></a><a id="Tc_a37glR03AUmcCcnFtTORbw_4_0"></a><a id="Tc_QjfOZ8FeckqMgn264uoCww_4_3"></a><a id="Tc_eNmYiXz98k-_5tCjTSFu9g_4_5"></a><a id="Tc_CVZGjxuhgkmggK75uPEwgw_4_7"></a><a id="Tc_gyO3GltmSECupInNEeJwPg_5_0"></a><a id="Tc_xALgFacpqESC6Bji_Yvc7g_5_3"></a><a id="Tc_DqadS1Eh-EWl1ZBZk461PQ_5_5"></a><a id="Tc_OcQ9v0uJqkSIm1vWWDFX8A_5_7"></a><a id="Tc_k_ACBcJ0SEiqNMYJ19onnQ_6_0"></a><a id="Tc_e6e4t4fKCUusi6wRd4ed1w_6_2"></a><a id="Tc_Rw7NdApNV0yuBP_H08S-8Q_6_3"></a><a id="Tc_iKKZXtluv0Ch_MDirrYGpg_6_4"></a><a id="Tc_XlI00CtKQUWuDHTwsFz0FA_6_5"></a><a id="Tc_VSjlkqNvdU2Srvtc1JytDg_6_6"></a><a id="Tc_fcNUytP6Ek2UjXDW0EBdMQ_6_7"></a><a id="Tc_fROTDacE0UaYJAnnqWInxg_1_2"></a><a id="Tc_V2_9-9RlgEad8xXeSQFuZQ_1_5"></a><a id="Tc_dKaA9E6pcUiHbxDNUTtQGg_1_8"></a><a id="Tc_uNeKaBjVlkmsdTjU457H5A_2_0"></a><a id="Tc_FZEeoltJ8027HZckdML7GA_2_2"></a><a id="Tc_CCEO0kk34UaK8Ld8jQ3v0g_2_5"></a><a id="Tc_EN0X3YV0_0i7c-3v2I32Pg_2_8"></a><a id="Tc_gSIlLBviI0OoPmNMlAokbA_3_0"></a><ix:continuation id="Tb_dmMWaC-ppEq1jHqIr8kE2w_cont3"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company used the following weighted-average assumptions for stock options granted during the year ended December&#160;31:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_8nFpBqc4O06YDszATG17hw" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:68.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_glMSXcQLUk-_-CPmbw8BIg_3_2"><span style="font-size:10pt;"> 5.76</span></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_ftBfTK_750yMgs0jl0wdSQ_3_4"><span style="font-size:10pt;"> 6.22</span></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_eH9Q8WRGd0Cs1j2iNvHOUw_3_6"><span style="font-size:10pt;"> 6.16</span></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_a5TQzErUlEe1ehVtB7u2_Q_4_2">54.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_hVJsEAJk-02OnBlh4-1ejA_4_4">50.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_6efmFC0F1kWtJ5-T76_hEQ_4_6">50.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_yKKs8O58Ok-SQko1TMc_8Q_5_2">1.71</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_oFA5Esu7dkWJeXwoVLRjuA_5_4">2.70</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_XfeuTb7vwEOkHjmRmc6qUw_5_6">2.12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of restricted stock awards is based on the market value of the Company&#8217;s common stock on the date of the awards.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Based on the assumptions noted above, the weighted average estimated grant date fair value per share of the stock options and restricted stock granted for the years ended December 31, 2019, 2018 and 2017, respectively, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="Tb_wmwJxR2MA0GuDwLANws1rQ" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_JA_eFekv10ScHBF-_axoLw_2_3">18.07</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_jpHUBdNU00yEj6ngoq-rLQ_2_6">15.05</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_dOpDEESlqEODYTZJx6VStA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_fMAsg1V-uEiR5uqMBQcmOg_2_9">8.41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Restricted and performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_S0-UmaJGlE-HpKYR3Xyh9Q_3_3">17.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_EHZdfkeY-UWipk-F-yrsfA_3_6">23.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_zBQhnBxudEOrta0F6gp39g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_3hMUrGAXTUe2LkCPW1ne0w_3_9">26.24</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="Tc_xNoC2-usU0OYXbWNOQojVg_1_0"></a><a id="Tc_6vC2sPd4c0K3OMh8ZKXR1w_1_2"></a><a id="Tc_U2Yf9L0vZUe-EOgIMtTATQ_1_5"></a><a id="Tc__xL0bdPA2060g9Ob4dgnzQ_1_8"></a><a id="Tc_7I2jQYy0Y0CUS6Y5E5vmjw_3_0"></a><a id="Tc_5_ic43dyUEShdeWtE42KvA_4_0"></a><a id="Tc_HaxZXQWom0ulNaqopc7B1g_4_2"></a><a id="Tc_F1i2QvYtBUy65lT6TNehcg_4_5"></a><a id="Tc_HPQ1Qjy3XkOve7VjL_bD_w_4_8"></a><a id="Tc_T5_B8PXTo0yDXKYk2jpQBw_5_0"></a><a id="Tc_EReZvb-knEmNQpgJOI-WpQ_6_0"></a><a id="Tc_wF5bIvReWE6-27XBGiiLRQ_6_9"></a><a id="Tc_95ur3wOhpkmnoNOapmjrLQ_7_0"></a><a id="Tc_1txH7PqMnUqCVU185h-Zfw_7_3"></a><a id="Tc_XL1xaT6DaUW1gGEnFx6uPQ_7_6"></a><a id="Tc_i8leTWpvb0eyusXzuQjWMA_8_0"></a><a id="Tc_F7ytxCSdG0qM-uvW6qQDYQ_8_3"></a><a id="Tc_EC_ZVy7q_0uQ_TXDcVPW4w_8_9"></a><a id="Tc_mF4rHD8iwECu-EoFytxPaA_9_0"></a><a id="Tc_QZJ7d5ZXGEOuqu4AL4I2LQ_10_0"></a><a id="Tc_4rrL9hrw_ESZm0Wxz3WAig_10_6"></a><a id="Tc_muGbLlazSkKFGeC5V0XPgQ_10_9"></a><a id="Tc_D_BxbOBT20mKwxtcdQDx8A_11_0"></a><a id="Tc_EzIksp3Jr0SeYRSkCG1huQ_12_0"></a><a id="Tc_0PQlguVdQEGrkuOkSTMiCA_13_0"></a><a id="Tc_L5CVbdVe5UGTB-z-Jt_K5w_14_0"></a><a id="Tc_SLIZa22QcEOiZ5ZV90RCFw_14_3"></a><a id="Tc_wzae3p33ukerqlu1weC3bw_14_6"></a><a id="Tc_2ZCZpO8BqUGbUDwoAgv1YA_15_0"></a><a id="Tc_ZAjt83uDc06e8TgtM4t1RA_15_9"></a><a id="Tc_fjuBe7HtEkeL1k4adlDiGQ_16_0"></a><a id="Tc_waPXr-uq4kWe4I5Y3jKUdA_16_3"></a><a id="Tc_iccO9tGrHkqnic1kRlRgcQ_16_6"></a><a id="Tc_8chjbwM34UibAZWyJLTNcw_16_9"></a><a id="Tc_6KuHMIl3qUeZ16nSf74YKg_17_0"></a><a id="Tc_BaDv4h5g0UWkHnbrZKPyvw_18_0"></a><a id="Tc_gof5bylSg0OT3X-ipZnKyA_19_0"></a><a id="Tc_C0-CExdcu06kdIXxpprniw_19_2"></a><a id="Tc_w9bF1EsdHEyky85E-Hf0IA_19_5"></a><a id="Tc_qPlapz4e60qsps3hv9Y2cg_19_8"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_G4RfHp9gQEGJvkD7HKgaFA" continuedAt="Tb_G4RfHp9gQEGJvkD7HKgaFA_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">12.  Income Taxes </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax basis, as measured by enacted state and federal rates as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_-bZ1P7Y_tEyTnXkTH3tedA" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:-0.13806152%;padding-left:0pt;padding-right:0pt;width:100.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_JflhykEOy0WQWXFHepHdLQ_4_3">36,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_xgnL-3NVI0SVVFzclo5M8w_4_6">30,588</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_mIkFgAK49ESPhhxKF-ujBw_4_9">27,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Inventory write down</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="Tc_4MmfXD92KE-HvUIbMt5XUw_5_3">317</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="Tc_ovH9VVrh2U62ssCFqPPQNg_5_6">273</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="Tc_ZAHEqcldf0y3LwToLbmZ9g_5_9">206</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Depreciation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_0IoFfPWnGUaPhnBu-K0HYA_6_3">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_G4odTc6jpEqjwGh4EqzVvA_6_6">117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Amortization</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_Fhh_Bpj8-E6slNx6YAaorw_7_9">23</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Interest limitation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="axgn:DeferredTaxAssetsInterestLimitation" scale="3" id="Tc_MR92_RFB3E26PAn-9hk9aw_8_6">336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Allowance for doubtful accounts</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="Tc_TSzfYD9vnE6qzjoLiu3q6g_9_3">274</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="Tc_KWukBJu2AkO0pOI7ltlH6g_9_6">285</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="Tc_SHZidhchekCoHfc83lOK1A_9_9">117</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Right-of-use liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="axgn:DeferredTaxAssetsRightOfUseLiability" scale="3" id="Tc_ggpjVMTbf0yBI0B-417psg_10_3">837</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Stock-based compensation</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_BBNOGHOusEymC4gSJtCnlw_11_3">3,140</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_rdmYKrSENUm0_EGoe-sc9A_11_6">2,335</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_-ydBbq_KvkOZF_BTmU3L4g_11_9">520</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_pxEUhmKZOUKmffTlX5bRoQ_12_3">40,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_5_mUH2sVB0mLgYieu5Q0qQ_12_6">33,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_th-gR6duGk2LrLz57GWn3g_12_9">28,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred tax liabilities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Depreciation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_CNJ_95c_50ylgqLvOvHo3w_14_9">81</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Amortization</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" scale="3" id="Tc_JYr_f4zgPUyrcXXH9MrWJA_15_3">206</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" scale="3" id="Tc_DkFLbPZ4SkeCr_I1a-IQkw_15_6">43</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Right-of-use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (809)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract liabilities</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="3" id="Tc_Oum9iiH_BkGsiCoWB4cctg_17_3">7</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="3" id="Tc_qMx7u-i3AEOAqKUYmJuB8A_17_6">15</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="3" id="Tc_xZ80x8VNn0W6zLTSXV_C-g_17_9">6</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="axgn:DeferredTaxAssetsLiabilities" scale="3" id="Tc_3jwLyHJIEkClVI6RrVMHrA_18_3">39,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="axgn:DeferredTaxAssetsLiabilities" scale="3" id="Tc_vxXOefsnskGfeg-3Qd1vLQ_18_6">33,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="axgn:DeferredTaxAssetsLiabilities" scale="3" id="Tc_jzmeEB38NUW66wdykjDf4g_18_9">28,357</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Pd27ZU8u-kqswWrxguy_gQ_19_3">39,932</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_HV8YeF9KNkO1uuaqjWZ7Hg_19_6">33,876</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_h50k-PBrR0i-Xt_zWxNPjA_19_9">28,357</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The difference between the financial statement income tax and the income tax benefit using statutory rates is primarily due to the increase in the valuation allowance.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December&#160;31, 2019 and 2018:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_fTQ9UJHKpEC1yuHGm74Y5A" continuedAt="Tb_fTQ9UJHKpEC1yuHGm74Y5A_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_DVCXNsQqAEqSunvwaSLODQ_1_2"></a><a id="Tc_O5S9HRDdfkudqxZNTotonw_2_3"></a><a id="Tc_O6IwERXfEUmCne8jGPXIMQ_2_6"></a><a id="Tc__jVy_wkChE-lHvMm4TWaLQ_3_0"></a><a id="Tc_NAKmfJbSok2JfVoQ6fvJAw_3_4"></a><a id="Tc_sEsorplp_k2kSU4N0YaQ0Q_3_7"></a><a id="Tc_iUQCrGjPm0qsuxdDmfEJaw_4_0"></a><a id="Tc_sn-VdcGCiU-5rxMYPbCaiw_5_0"></a><a id="Tc_yrbX8DATUkmE9ssWt-F9NQ_6_0"></a><a id="Tc_BY2Y3acHeUWVMe__5zevVA_7_0"></a><a id="Tc_VIbf0asOUky4roaTP3Sgjw_7_3"></a><a id="Tc_gVzWzth4Ak-ho0_Z2rYeIg_7_4"></a><a id="Tc_hhUNROa66Em_Y6gcLzj94Q_7_6"></a><a id="Tc_O1gDO6VCKUiQ1IEDqmBxTQ_7_7"></a><ix:continuation id="Tb_G4RfHp9gQEGJvkD7HKgaFA_cont1" continuedAt="Tb_G4RfHp9gQEGJvkD7HKgaFA_cont2"><ix:continuation id="Tb_fTQ9UJHKpEC1yuHGm74Y5A_cont1"><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:11pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';"> </span><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:27.84%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December</b><b style="font-family:'Calibri';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.85%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Federal tax rate</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_XzFf4b7iMkyNW2Bkw-XVyg_3_3">21.0</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_qipR0PSKikyasIu8oOgeKA_3_6">21.0</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">State Taxes - Net of Federal Benefit</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_RAM13ccpZ06Ng17s33UnjQ_4_3">4.1</ix:nonFraction></span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_KfoYyzf4vUaju_5rlgruRg_4_6">4.1</ix:nonFraction></span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Permanent items and other deductions</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (<ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" sign="-" scale="-2" id="Tc_YdnqLVxiIEW0Ar1ofbsDuQ_5_3">4.3</ix:nonFraction>)</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (<ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" sign="-" scale="-2" id="Tc_99cgwxrJHkemu3ZOttMXtg_5_6">0.5</ix:nonFraction>)</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (<ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_8QJZ5G0vvEGSMvSrxpnGww_6_3">20.8</ix:nonFraction>)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (<ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_IZsqQrJ9f0KMl-mDtN8PXA_6_6">24.6</ix:nonFraction>)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Arial';font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Arial';font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2019 and 2018, management assessed the realizability of deferred tax assets. Management evaluated the need for an amount of any valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, <i style="font-style:italic;">Income Taxes</i>, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the Company&#8217;s deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more likely than not (a probability level of more than 50%) that the Company may not realize the benefit of its deferred tax assets. In assessing the realization of the Company&#8217;s deferred tax assets, the Company considers all available evidence, both positive and negative. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that &#8220;a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.&#8221; Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2019.  The valuation allowance increased by </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Narr_9jwquxZQA02xha9r0Gl3tw">6,056</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Narr_aDo5fondqEG7N9MXIPROUg">5,519</ix:nonFraction><span style="white-space:pre-wrap;"> during 2019 and 2018, primarily as a result of current year increase in the net operating loss carry forward.  During 2017, the valuation allowance decreased by </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="3" id="Narr_S53zTb_BMEGsJugnaJuOdg">10,754</ix:nonFraction>, primarily due to the remeasurement of the Company&#8217;s deferred tax assets and liabilities as a result of the Tax Reform enacted on December 22, 2017.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As of December&#160;31, 2019, the Company had tax-effected net operating loss carry forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Narr_x90ienZlp0uJ_3tTKuISoQ">36,250</ix:nonFraction><span style="white-space:pre-wrap;"> to offset future taxable income which expire in various years through 2039.  Federal net operating losses incurred in tax years beginning on or after January 1, 2018 are carried forward indefinitely.  A portion of the net operating loss carry forwards may expire due to limitations imposed by section 382 of the Internal Revenue Code.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. In the normal course of business the Company is subject to examination by taxing authorities throughout the country. These audits could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with federal, state and local laws. The Company&#8217;s tax years since 2017 remain subject to examination by federal, state and foreign tax authorities.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842 &#8211; Leases, on January 1, 2019. Under Topic 842, the Company is required to recognize the assets and liabilities that arise from most operating leases on the balance sheet. Upon adoption, <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_dwnRMOuleUGG7WL91vnSAg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:CumulativeEffectOnRetainedEarningsTax1" scale="3" id="Narr_aw0s_VHLB0GFKtGHikWLAw">no</ix:nonFraction> change in retained earnings was recorded related to income taxes as the Company maintains a full valuation allowance. As of the implementation date, an adjustment of $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_pv52m7zoikuufdq5oJOf0A" decimals="-3" format="ixt:numdotdecimal" name="axgn:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Narr_M-TF5yj-Qka10WWIXAmIqQ">951</ix:nonFraction> was recorded as a deferred tax liability and an adjustment of $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_pv52m7zoikuufdq5oJOf0A" decimals="-3" format="ixt:numdotdecimal" name="axgn:DeferredTaxAssetsRightOfUseLiability" scale="3" id="Narr_NOgZszpolEmqwEmJXwIAKw">961</ix:nonFraction> was recorded as a deferred tax asset. See above for more information about the non-income tax impact of the adoption of the new leasing standard.</p><p style="font-family:'Times New Roman';font-size:5pt;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017, subjects a U.S. shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</span><span style="font-size:12pt;"> </span><span style="font-size:10pt;">The Company has elected to account for GILTI in the year the tax is incurred.</span>&#160;</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_G4RfHp9gQEGJvkD7HKgaFA_cont2"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company had <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_qxMuVEAtD0CgAKiROdYzdQ"><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_l9IK_i6Q70uTcIA8T9r-LA"><ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_835OmAkTW0mctVu1U0Yp9w">no</ix:nonFraction></ix:nonFraction></ix:nonFraction><span style="white-space:pre-wrap;"> income tax expense or income tax benefit for 2017, 2018 and 2019 due to incurrence of net operating losses.  The Company does not believe there are any additional tax refund opportunities currently available.</span></p></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_7eOEQFCcPEiZSOp-KZLK_w" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">13.  Employee Benefit Plan</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company sponsors the Axogen 401(k) plan (the 401(k) Plan), a defined contribution plan covering substantially all employees of the Company.  All full-time employees who have attained the age of </span><ix:nonFraction unitRef="Unit_Standard_item_bQ28F0w6C0GKznH2O5VZSw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_7eeOyFQI-kyot4WSOxp9WA" decimals="0" format="ixt:numdotdecimal" name="axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" scale="0" id="Narr_0VPW2CBFFUiUJOqkGcig1w">21</ix:nonFraction> are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_WwMtZh6dN0OytTHyKURZmg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_oAX4h2PgNUOhUwFW3chJFQ">3</ix:nonFraction>% on the first <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_WwMtZh6dN0OytTHyKURZmg" decimals="2" format="ixt:numdotdecimal" name="axgn:DefinedContributionPlanEmployeeContributionPercentMatched" scale="-2" id="Narr_1_C62FbWpka6r1-MKxEZVQ">3</ix:nonFraction>% of the employee&#8217;s annual salary and <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_rhwnZKQoVkSq-3aU8DS-_w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_SHowmfyiiEiAAiT78gD9Rg">1</ix:nonFraction>% of the next <ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_rhwnZKQoVkSq-3aU8DS-_w" decimals="2" format="ixt:numdotdecimal" name="axgn:DefinedContributionPlanEmployeeContributionPercentMatched" scale="-2" id="Narr_p85CemymtkGUH8kXWmQqlg">2</ix:nonFraction>%<span style="white-space:pre-wrap;"> of the employee&#8217;s annual salary as long as the employee participates in the 401(k) Plan. Both employee contributions and Company contributions vest immediately.  The Company contributed </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_7eeOyFQI-kyot4WSOxp9WA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="Narr_MKWAO9HoOUWW0oHohoHrqQ">988</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_QtnKkZ4CLk2X_HFK_HYUZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="Narr_syw-e69-bEa4RvN27ezMMQ">650</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_aTc0csteMkS0guuaxwtDRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="Narr_CZ2l2rhUF0uC07Ho1nJQQw">439</ix:nonFraction> in matching funds during the years ended December 31, 2019, 2018 and 2017, respectively. </p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_1FNV_e0a8UGT3elVOhd27g" continuedAt="Tb_1FNV_e0a8UGT3elVOhd27g_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">14.  Commitments and Contingencies</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">We lease office space, medical lab and research space, a distribution center, a tissue processing center and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Certain of our leases include options for the Company to extend the lease term. None of the options were reasonably certain of exercise and therefore are not included in the measure of our lease obligations and right-to-use assets. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Certain of our lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The Company and SNH Medical Office Properties Trust, a Maryland real estate investment trust (&#8220;SNH&#8221;), are parties to that certain lease dated as of February 6, 2007, as amended, (the &#8220;Primary Lease&#8221;) pursuant to which the Company leases its approximately </span><span style="-sec-ix-hidden:_9adc0d0a_9f27_4b75_b561_f0f616fc58b6"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">nineteen</span></span><span style="font-size:10pt;"> thousand square foot corporate headquarters facility in the Progress Center at 13631 Progress Boulevard, Alachua, Florida 32615 (the &#8220;Primary Premises&#8221;). The annual cost for the Primary Premises ranges from </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_fWIoGNsj7Ui2pXQ3bkgU4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_U2ylJFekxkav2rbvpwB7Ow">353</ix:nonFraction></span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_bByFAiGDsEK9OCAVsqZANg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_m5y9sYQeM0SXEriISDmrtA">363</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> through the end of the term of the lease, which expires on October 31, 2021.  On January 23, 2017 the Company entered into a lease (the &#8220;First Expansion Lease&#8221;) with SNH for one thousand </span><span style="-sec-ix-hidden:_de7536fc_c71e_45d4_b4bd_cca7546a8119"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four</span></span><span style="font-size:10pt;white-space:pre-wrap;"> hundred square feet at 13709 Progress Boulevard, Alachua, Florida 32615 (this property was purchased by Nucleic Acids Licensing, LLC in February 2019) (the &#8220;First Expansion Premises&#8221;) adjacent to the Primary Premises.  The Company has entered into the Second Expansion Lease and Third Expansion Lease, as defined below, which relate to properties that are adjacent to the Primary Premises and First Expansion Premises resulting in the Company having approximately </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_tglKryFxhkq8-SAK4HEuzg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AreaOfRealEstateProperty" scale="3" id="Narr_8COppuYo-EOgBtzv81RDlg">twenty</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> thousand square feet for its corporate headquarters and certain research space in the Progress Center in Alachua, Florida.  </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On November 19, 2018, the Company entered into a Lease (the &#8220;Second Expansion Lease&#8221;) with SNH for two thousand </span><span style="-sec-ix-hidden:_842590dc_0853_48a1_94e3_0974e859a7d8"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">eight</span></span><span style="font-size:10pt;"> hundred square feet at 13709 Progress Boulevard, Suites S-160, S-162 and S-164, Alachua, Florida 32615 (the &#8220;Second Expansion Premises&#8221;). Pursuant to the Second Expansion Lease, AC is to use the Second Expansion Premises for general office uses. The Second Expansion Lease commenced December 1, 2018 and expires November 30, 2020. The annual cost of the Second Expansion Premises is approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_oujYrCpym0y45N14NxtAYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_tya6AOvpnESnPQoK5QAtBA">45</ix:nonFraction></span><span style="font-size:10pt;"> for the first twelve months of the term and </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_U9D1ulBaeUqvJJI4uvH5oA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_Y-1jPOQN8keA3_JpVT8p6Q">46</ix:nonFraction></span><span style="font-size:10pt;"> for the final twelve months. The Company is also obligated to pay for certain taxes, insurance costs and electricity costs incurred by SNH.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On November 19, 2018, AC entered into a Lease (the &#8220;Third Expansion Lease&#8221;) with SNH for <ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_11_19_2018_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_V5WUDuaOrka-roEinNbOxA" decimals="0" format="ixt-sec:numwordsen" name="axgn:AreaOfRealEstatePropertyAdditional" scale="3" id="Narr_kfJxqomY90CUM1foeQZQVw">two</ix:nonFraction><span style="white-space:pre-wrap;"> thousand square feet at 13709 Progress Boulevard, Suites S-175, S-177 and S-179, Alachua, Florida 32615 (the &#8220;Third Expansion Premises&#8221;). Pursuant to the Third Expansion Lease, the Company is to use the Third Expansion Premises for general office and biomedical research uses. The Third Expansion Lease commenced December 1, 2018 and its term expires November 30, 2020.  The annual cost of the Third Expansion Premises is approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_NXRoZ-NBZ0ePelC05RSaqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_2kKvzcWOVkqYRvZyt3_KZQ">37</ix:nonFraction> for the first twelve months of the term and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_IsEezefk-Eu1CFK7CxX86A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_gtO3_urEu0CkDQdMcV0qaA">35</ix:nonFraction> for the final eleven months. The Company is also obligated to pay for certain taxes, insurance costs and electricity costs incurred by SNH.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_uHWkBOFI2UGzYt5GMM-hqg_1_2"></a><a id="Tc_CmUZxVanmkyjquNiPPXGyA_2_0"></a><a id="Tc_PIOrsRQ__kuNke4F7Z5J5g_3_0"></a><a id="Tc_DY6savH8kkiUpmqBw3BXLw_4_0"></a><a id="Tc_HTEO3fCIGkyOoGw_42Fh9Q_4_2"></a><a id="Tc_VZm8cnQf7E-nnAR9U6ZnXw_5_0"></a><a id="Tc_etmAdv2ON0m9Hv3EIkugqw_6_0"></a><a id="Tc_Gke_YTevAUKsN3sky-QCUQ_7_0"></a><a id="Tc_3fA_xTkyYkS58MgQZ2H_7g_8_0"></a><a id="Tc_cAPy0RZFwUq6qPzY3YMnEw_9_0"></a><a id="Tc_w-Svnzz-A0yWr2ZsntVlGA_9_2"></a><a id="Tc_Wo1wd1nss0-q-yV1xbJwUA_1_2"></a><a id="Tc_P8kfwH9qvEukryCiCtEaRg_2_0"></a><a id="Tc_YJIYZPi56kODg6CYoeEC-A_3_0"></a><a id="Tc_0y8RM_LFIUGfsBsNiMHdhQ_3_2"></a><ix:continuation id="Tb_1FNV_e0a8UGT3elVOhd27g_cont1" continuedAt="Tb_1FNV_e0a8UGT3elVOhd27g_cont2"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On November 21, 2018, the Company, entered into Commercial Lease Amendment 3 (the &#8220;Burleson Amendment&#8221;), to the Commercial Lease dated April 21, 2015, as amended, with Ja-Cole L.P. Under the terms of the Burleson Amendment, the Company leased an additional </span><span style="-sec-ix-hidden:_2049e4b8_faac_41e8_83f3_7e116573faca"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">two</span></span><span style="font-size:10pt;white-space:pre-wrap;"> thousand five hundred square feet of warehouse/office space in Burleson, Texas (collectively with the space leased under the Commercial Lease with Ja-Cole L.P. prior to the effectiveness of the Burleson Amendment, the &#8220;Burleson Facility&#8221;).  The Burleson Facility will now comprise a total of </span><span style="-sec-ix-hidden:_0d926b8e_ab68_494b_9c97_8808ab1309cf"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">twelve</span></span><span style="font-size:10pt;white-space:pre-wrap;"> thousand five hundred square feet, all of which, pursuant to the Burleson Amendment, will be leased until April 30, 2022.  The annual rental cost of the entire Burleson Facility is now approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_V4e6rd3wUEG9C3qE3Hpw-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_-8XkohERV0S7stot3Ms8dw">113</ix:nonFraction></span><span style="font-size:10pt;"> through December 31, 2020, </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_KuQDicj1c0SnADAaZVmqbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_Rt_hdB_1lE-CLUIcxTpVxw">116</ix:nonFraction></span><span style="font-size:10pt;"> for the calendar year 2021 and until April 2022. The Burleson Facility houses raw material storage and product distribution while allowing same day order fulfillment for both the east and west coasts of the United States.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On October 26, 2018, the Company entered into a Lease (the &#8220;Ashley Avenue Lease&#8221;) with Ashley Avenue Associates I, LLC., a Delaware limited liability company (&#8220;Ashley&#8221;), for the lease by the Company of approximately </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_x4yTeLpiWEyE5kq91aXN1A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AreaOfRealEstateProperty" scale="3" id="Narr_xjYPBbAP40KBrOQ0JQiBXw">fifteen</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> thousand square feet of office space on the second floor of the building located at 1000 N. Ashley Drive, Tampa, Florida 33602 (the &#8220;Ashley Avenue Premises&#8221;).  Pursuant to the Ashley Avenue Lease, the Company will use the Ashley Avenue Premises for general office purposes.  The initial term of the Ashley Avenue Lease commenced on December 1, 2018 and expires on November 30, 2020. The Company has an option to terminate the lease after </span><ix:nonNumeric contextRef="Duration_10_26_2018_To_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_DNUFWr2HVU6UI2RUpDclJQ" format="ixt-sec:durwordsen" name="axgn:EarlyTerminationPeriod" id="Narr_eHnKIlW5ukujpy8wd4MAAA"><span style="font-size:10pt;">eighteen months</span></ix:nonNumeric><span style="font-size:10pt;"> by providing Ashley with </span><ix:nonNumeric contextRef="Duration_10_26_2018_To_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_DNUFWr2HVU6UI2RUpDclJQ" format="ixt-sec:durwordsen" name="axgn:NoticePeriodForTerminationOfAgreement" id="Narr_bRqt2VW5sEK62kQMlRxlqg"><span style="font-size:10pt;">four months</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> advance written notice.  The rental cost for the Ashley Avenue Premises will be </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_NnCe9k1NpUacLG-xMiiljw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_sW5S5MIRb0mig9caCmxxjQ">381</ix:nonFraction></span><span style="font-size:10pt;"> for the first twelve month period, and </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_ZUL32-Ode0O5GUOiGbojiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_S0ZbmkKhnkaW-oXTLDSZSQ">360</ix:nonFraction></span><span style="font-size:10pt;"> for the final eleven month period. The Company will also be obligated to pay for its pro rata share of the building&#8217;s property taxes, utilities, administrative costs, common area maintenance and management fees, excluding any capital improvements or any damage due to fire, hurricane or other casualty.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On September 20, 2018, the Company entered into an agreement with Heights Union, LLC, a Florida limited liability company (&#8220;Heights Union&#8221;), for the lease of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_9_20_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_kMJbk8ZcGUK3JDwkyBnNog" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AreaOfRealEstateProperty" scale="3" id="Narr_HChMeb8vUUSfrujLoM3oYQ">seventy-five</ix:nonFraction></span><span style="font-size:10pt;"> thousand square feet of office space (the &#8220;Heights Union Premises&#8221;) in a one </span><span style="-sec-ix-hidden:_8737cf0c_5377_4487_aceb_781cdeb5b2e6"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">hundred and fifty</span></span><span style="font-size:10pt;white-space:pre-wrap;"> thousand square foot office building that Heights Union intends to construct and complete on or before September 30, 2020, on an area of land in Tampa, Florida.  Pursuant to the Heights Union lease, the Company will use the Heights Union Premises for general office, medical laboratory, training and meeting purposes.  The annual costs of the Heights Union Premises ranges from </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_9_20_2018_To_9_20_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_ZBGX0n3gPUucFdPYU_PIgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_OJORAtvft0qJ3IkrntpjXA">2,400</ix:nonFraction></span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_9_20_2018_To_9_20_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_Pwl4eK2_UkO9SelPSqHkRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="3" id="Narr_J4-enbzRUUme2ijAw0HtUA">3,308</ix:nonFraction></span><span style="font-size:10pt;"> during the term of the lease. Axogen believes it can obtain certain economic incentives from state authorities associated with the employment at the facility; such incentives are not expected to be a material offset to the expenses of the project as a whole.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, Axogen leases space and maintains records at certain other facilities, including the Company&#8217;s prior corporate headquarters at 1407 South Kings Highway, Texarkana, Texas 75501.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The components of total lease expense for the year ended December 31, 2019 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:LeaseCostTableTextBlock" id="Tb_t4KvIghRlUK_d8SSgmSeUA" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">For the Fiscal Year Ended December 31, 2019:</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Finance lease costs</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Amortization of right-to-use assets</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_uPZSIXRCLUq-WFWXOlJtbA_4_3">22</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Interest on lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_nGjx_d1jwU6wZ3zKLhS61w_5_3">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Operating lease costs</b></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_BU2pGiXtqEaxfbeaSkxOBA_6_3">1,910</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short term lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="3" id="Tc_cK0qEWaCpkC8KbHeI-mPKA_7_3">41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Variable lease costs</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_vOue4WYqKUSfShtxZYTptA_8_3">17</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_QHdVLRsdcEKQ706augjTWA_9_3">1,994</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The short-term lease cost shown above reasonably reflects the Company&#8217;s ongoing short-term lease commitment. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Supplemental balance sheet information related to leases as of December 31, 2019 was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="axgn:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" id="Tb_ZzB_Gw_SHUaRWetZkYyZMw" continuedAt="Tb_ZzB_Gw_SHUaRWetZkYyZMw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_H8aUcCLkkEq1B_z62y0IAA_3_3">3,133</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_nUB4KJowXE-tUjj03LJhPw_4_2"></a><a id="Tc__XOjO7ZWLUaWnC9jG6ob2A_5_2"></a><a id="Tc_lSNrhyUwXUKjBDoErMhGCQ_6_0"></a><a id="Tc_urslX-GSOEuYPvchrBzdnA_7_0"></a><a id="Tc_DrdhAdsA3UKrj9ugRAQQ5w_7_2"></a><a id="Tc_xqcjhCeF-kmYCo14kjCcLw_8_0"></a><a id="Tc_TCSFJpxS70CpCeMTXj5c4A_8_2"></a><a id="Tc_JL5SVQ0LLEa-juebU5NGtQ_9_0"></a><a id="Tc_XKMI4dxumUyPDstlJXo77g_9_2"></a><a id="Tc_DIwcb1KyXE2kVsatusvzqg_1_2"></a><a id="Tc_220PfnLTmkGeALGG6jjdVA_2_0"></a><a id="Tc_6417OEiMhkGmVNyfSfaa9Q_2_2"></a><a id="Tc_TKRbZB4ox0Gf26Kqat1liQ_3_0"></a><a id="Tc_gKh-atq91U6jJWsbMlvCJw_3_2"></a><a id="Tc_YCxKsBs01Eu9mGCcfCFloA_4_0"></a><a id="Tc_MYKAyUIfKkaYrJqjvbmckg_5_0"></a><a id="Tc_JTHQlW_pL0K5_QbzOLu4_Q_6_0"></a><a id="Tc_T2OcruWe-EKt5mpBcVZziQ_7_0"></a><a id="Tc_nN2AWN37-UK-ipE74b7u-g_1_2"></a><a id="Tc_lNTW6SKIvE-4fuNem3hKIg_1_5"></a><a id="Tc_aHCIPEvgDk6ZRFzfVL30Ow_2_0"></a><a id="Tc_Tpkha-NFVkKSHu26P-Ng2Q_2_2"></a><a id="Tc_p1jAJEEEbkOJDw4AK1mXmg_2_5"></a><a id="Tc_fwbA18xhtkid-6uDqZPQGQ_3_0"></a><a id="Tc_vxJiCtUg5kuU2VaEExQPmQ_4_0"></a><a id="Tc_EkqoL5kLMEeX20iv51T-vw_5_0"></a><a id="Tc_5enpwxP68Uu8Kc4Z14tpYQ_6_0"></a><a id="Tc_16yZOgpoFE2SnNtJP_4iQA_7_0"></a><a id="Tc_9KfuYg8W8ECuWN1eUDXIAA_8_0"></a><a id="Tc_NRxoItWnnUqKjkUMhpA2iw_8_6"></a><a id="Tc_7792mO2sX0qfxzzh4SRz8A_9_0"></a><a id="Tc_YDu6RfRn-EiCaFgdMQkEFw_9_2"></a><a id="Tc_US79IIgieEKr5Abiuf5q_Q_9_5"></a><a id="Tc_55xU6MlCLEGQ29SyMCuHnA_10_0"></a><a id="Tc_iASJwP6ZhU2uRWhvWEhaDg_10_6"></a><a id="Tc_P4bOcw7m90S_tjWWE-EEqw_11_0"></a><a id="Tc_lsr0fwRk00mfuOPjLMl8Og_12_2"></a><a id="Tc_2-6d-ReQOU2IbNYi7OOJOw_12_5"></a><ix:continuation id="Tb_1FNV_e0a8UGT3elVOhd27g_cont2" continuedAt="Tb_1FNV_e0a8UGT3elVOhd27g_cont3"><ix:continuation id="Tb_ZzB_Gw_SHUaRWetZkYyZMw_cont1"><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Tc_A4Fx7oi8o0qgiyXaY11oBA_4_0"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Current maturities of long-term obligations</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_aRB8_r_DEEeqkTWxfUF2-A_4_3">1,719</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Tc_iS9N_npf70GWW2V_ErRjnw_5_0"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Long term obligations</span></span></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_9MJpl1n8_0KWbUcV4f216A_5_3">1,565</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease right-of-use assets</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_aS9s_fxNkUKAg3Wy4XT5bg_7_3">87</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current maturities of long-term obligations</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_XCzsWLNfHkGtiz2mvo1v5w_8_3">17</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long term obligations</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_sldT4kiTGkyDZhapHglLRw_9_3">30</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Other information related to leases was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="axgn:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" id="Tb_1uWn7DRPdkqHxfdePtYbVw" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for amounts included in the measurement of operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="3" id="Tc_LGteJM8PUEqaTucB89_OxQ_2_3">1,773</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-to-use assets obtained in exchange for new finance lease liabilities</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_lreyMzE3LEGp0oe4M57ZfA_3_3">16</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average remaining lease term - finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_bGPOge2tNU65eWg-JgTRpQ_4_3"><span style="font-size:10pt;"> 3</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_3i7cU-OsN0S3C6VZE-2Lsg_5_3"><span style="font-size:10pt;"> 2</span></ix:nonNumeric></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average discount rate - finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_rMUthb2qNEas4dVdnyoiXw_6_3">7.28</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_yzzyRxl8CEemdnXRdHL0BQ_7_3">6.28</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The weighted-average discount rate for the majority of the Company&#8217;s leases is based on the Company&#8217;s estimated incremental borrowing rate since the rates implicit in the leases were not determinable. The Company&#8217;s incremental borrowing rate is based on Management&#8217;s estimate of the rate of interest the Company would have to pay to borrow on a fully collateralized basis over a similar term an amount equal to the lease payments. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Future minimum lease payments under non-cancellable leases as of December 31, 2019 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="axgn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_RQylyzh-1E62bEvnJbCMeg" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_jQ7ijQjzok6vEBHsRT6m9Q_3_3">2,664</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_LUTTeHjl2kCHcaZ14sFmcw_3_6">19</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_EKQSx63wWUKdT8Qjhzj8hw_4_3">4,007</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_GFLQbA4NKEu682toRuPtVA_4_6">19</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_kNj4wal26E-Fcli9HHeQdQ_5_3">2,573</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_1vx6GuDslEOgkP4gqG5Zyw_5_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_Gp7p4SpnuUSjRGeiSJ9rbQ_6_3">2,581</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_5h8iSKnMoEebX76U0OEdiQ_6_6">3</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_6qmNS66Oekm6EsYYcWqxjA_7_3">2,644</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_Pcn1j929aEiv0dwRj6wbDA_7_6">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_XbwSRyPFMkGYuWwqGZOJFQ_8_3">27,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Future Minimum Lease Payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_xHHQ_i5oVEG72G6450kZIQ_9_3">41,720</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_sxJtbnqGgkCA9CP8gyaB2w_9_6">52</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less future payments for leases that have not yet commenced</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="axgn:LesseeOperatingLeaseLiabilityFuturePaymentsAmount" scale="3" id="Tc_ChxF1u4sSE6bT2Kb0y6uFg_10_3">38,246</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest on commenced leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_59mNXASw4EqyynsAoOPFLw_11_3">190</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_DcWAgnVxB0iSn8Z9lkDp6g_11_6">5</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Tc_pGofsY-zPU6ke-fO75b00A_12_0"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Total Lease Liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_SKvStTcQ2UGb9I4KH2kEpQ_12_3">3,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_i5kmAdzrVUSt0qylsTCo-Q_12_6">47</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The lease for office space in Tampa, Florida with Heights Union, LLC, a Florida limited liability company, has not commenced and is therefore not included in the measurement of right-to-use assets and lease liabilities.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_bWJGop77xU6s8pIdUd2bog_2_0"></a><a id="Tc_LwF3gXuW90aryyfXVYJdUQ_2_2"></a><a id="Tc_71ug6GLwnEORXWZKeK_Ivw_2_5"></a><a id="Tc_kfFh_8c-xESc96vmia94pQ_3_0"></a><a id="Tc_CPnxKbUMAkaSyjjU-77usw_4_0"></a><a id="Tc_eCD3QMseRUOl0z1PA7CokQ_5_0"></a><a id="Tc_XeyXA2rktky9hmHHQQdMnw_6_0"></a><a id="Tc_mrWh464pKkukMS_6MXapyA_7_0"></a><a id="Tc_2HzpfE_yp0-Evn5DDxMGrg_7_6"></a><a id="Tc_qIYG0LMXhkyHsx462iKANg_8_0"></a><a id="Tc_QWZJb1y6QU6EEgpobVEgBg_8_6"></a><a id="Tc_D8X84egRIk25a5QlIsp6yQ_9_0"></a><a id="Tc_nLSZCy_qB0-Iyy49PXAPDQ_9_2"></a><a id="Tc_AIHs1SS7Mk2SfaqGjs4s6Q_9_5"></a><ix:continuation id="Tb_1FNV_e0a8UGT3elVOhd27g_cont3" continuedAt="Tb_1FNV_e0a8UGT3elVOhd27g_cont4"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As previously disclosed in our 2018 Annual Report on Form 10-K, which followed the lease accounting guidance prior to our adoption of ASC 842, future commitments relating to noncancelable operating and capital leases as of December 31, 2018 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="axgn:ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock" id="Tb_XWsjmXWyZkOIxsoOIuhdFg" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="Tc_4q4nKL5lYUiUaVfTmXfiTw_3_3">1,866</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="Tc_d_wo1B_uxUymvx3RiLDb7Q_3_6">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="Tc_dbnJ2PcF30yHDdkMuz_ETQ_4_3">2,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="Tc_z5hCbHN_706w-MByAgmxPw_4_6">13</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="Tc_t-jjKoNuVUWbRpxaNxgiiQ_5_3">3,970</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="Tc_omkhM29lZEO_dye52rbQ2g_5_6">15</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="Tc_aatYkIGaCkSloEd8lFVmtw_6_3">2,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="Tc_f1fj7snzIUWAT_9vqtEh6w_6_6">7</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="Tc_MVHXTLgPl0ufKEZw0BOABA_7_3">2,574</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="Tc_3tImnYJ25UKDNqwMk0UAgg_8_3">30,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="Tc_ju98FT1Ci0610eFmTUIpzg_9_3">43,579</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDue" scale="3" id="Tc_Ab1dpZ7PYUuRQjTlHM6XyA_9_6">63</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Total rent expense for the Company&#8217;s leased office and lab space for the years ended December&#160;31, 2019, 2018 and 2017 was $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="3" id="Narr_kSXXSg4rmU65EaD-WsDxfA">516</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="3" id="Narr_037Kkv6Bz02nMMBfQGakPA">484</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="3" id="Narr_RN3jqktS00OJQ2uQYD_ZFg">494</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Service Agreements</b></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On August 6, 2015, Axogen entered into a License and Services Agreement with Community Blood Center (d/b/a Community Tissue Services) (&#8220;CTS&#8221;), Dayton, Ohio, an FDA registered tissue establishment.  Processing of the Avance Nerve Graft pursuant to the CTS agreement began in February 2016.  Subsequent to the year ended December 31, 2018, on February 22, 2019, Axogen Corporation and CTS entered into a fourth amendment to the License and Services Agreement wherein the term of the agreement was extended such that the Occupancy Date in section 12.01 of the agreement shall end on December 31, 2021, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#8217;s right to cure, in certain circumstances), or by Axogen without cause upon six months&#8217; prior notice, </span>whereby notice cannot be provided prior to March 1, 2021<span style="white-space:pre-wrap;">.  Under the CTS agreement Axogen pays CTS a facility fee for clean room/manufacturing, storage and office space, which has been determined to be an embedded operating lease.  CTS also provides services in support of Axogen&#8217;s manufacturing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support.  </span>Pursuant to the CTS Agreement, Axogen pays license fees and the operating lease amounts, on a monthly basis to CTS which total an annual amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_w7VPQT2pRkub_N0KQzm0eg" decimals="-3" format="ixt:numdotdecimal" name="axgn:LicenseFeeAmount" scale="3" id="Narr_6TyLd2Dack-sf9ZJy_vMyw">2,148</ix:nonFraction> for the year ended December 31, 2019, $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_re7GROPgKUaFj-ZkUJDT4A" decimals="-3" format="ixt:numdotdecimal" name="axgn:LicenseFeeAmount" scale="3" id="Narr_6a4T44UZS0GPQTo8OX7RjA">1,931</ix:nonFraction> for the year ended December 31, 2018 and $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_xCSHLZgiMUuIzNw6sSuFGw" decimals="-3" format="ixt:numdotdecimal" name="axgn:LicenseFeeAmount" scale="3" id="Narr_CKa10Z2_n0yZRyqgOCiiVA">1,409</ix:nonFraction> for the year ended December 31, 2017.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In December&#160;<span style="white-space:pre-wrap;">2011, the Company also entered into a Master Services Agreement for Clinical Research and Related Services.  The Company was required to pay </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_12_1_2011_To_12_31_2011_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_vqWblD6hEkiSy0wcGyIdzA" decimals="-3" format="ixt:numdotdecimal" name="axgn:ServiceAgreementAmountPaidUponExecutionOfAgreement" scale="3" id="Narr_x5SYQJTCBk6w50i8ggYEgA">151</ix:nonFraction><span style="white-space:pre-wrap;"> upon execution of this agreement and the remainder monthly based on activities associated with the execution of Axogen&#8217;s phase 3 pivotal clinical trial to support a BLA for Avance Nerve Graft.    </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In August&#160;2008, the Company entered into an agreement to distribute the Axoguard Nerve Connector and Nerve Protector products worldwide in the field of peripheral nerve repair, and the parties subsequently amended the agreement on February 26, 2018. Pursuant to the February 2018 amendment, the agreement expires on June 30, 2027. The Cook Biotech Distribution Agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforced such provision, and establishes a formula for the transfer cost of the Axoguard products. Under the Distribution Agreement, Axogen provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In June 27, 2017, the Company entered into the Nerve End Cap Supply Agreement with Cook Biotech whereby Cook Biotech is the exclusive contract manufacturer of the Axoguard Nerve Cap and both parties have provided the other party the necessarily licenses to their technologies for operation of the Supply Agreement.  The Supply Agreement has a term through August 27, 2027, provided, however, that after June 27, 2022, either party may terminate the Supply Agreement upon 90 days written notice.  Under the Supply Agreement Axogen provides purchase orders to Cook Biotech and Cook Biotech fulfills the purchase orders.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1FNV_e0a8UGT3elVOhd27g_cont4" continuedAt="Tb_1FNV_e0a8UGT3elVOhd27g_cont5"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Certain executive officers of the Company are parties to employment contracts.  Such contracts have severance payments for certain conditions including change of control.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Concentrations</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Vendor</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Substantially all of Axogen&#8217;s revenue is currently derived from <ix:nonFraction unitRef="Unit_Standard_item_bQ28F0w6C0GKznH2O5VZSw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_XwSdGg8qkECo4xeg2jamwA" decimals="INF" format="ixt-sec:numwordsen" name="axgn:NumberOfProductsFromWhichRevenueIsDerived" scale="0" id="Narr_Fwuy7K3aFkKJGGxK64ow-Q">four</ix:nonFraction><span style="white-space:pre-wrap;"> products, Avance Nerve Graft, Axoguard Nerve Protector, Axoguard Nerve Connector and Avive Soft Tissue Membrane.  Axogen has an exclusive distribution agreement with Cook Biotech for the purchase of Axoguard Nerve Connector and Axoguard Nerve Protector which expires </span>June 30, 2027.<span style="white-space:pre-wrap;">  The Cook Biotech Distribution Agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforced such provision, and establishes a formula for the transfer cost of the Axoguard Nerve Connector and Axoguard Nerve Protector.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:6pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">The agreement allows for termination provisions for both parties.  Although there are products that Axogen believes it could develop or obtain that would replace the Axoguard products, the loss of the ability to sell the Axoguard</span><span style="font-size:6.5pt;vertical-align:super;"> </span><span style="font-size:10pt;">products could have a material adverse effect on Axogen&#8217;s business until other replacement products would be available.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Processor</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is highly dependent on the continued availability of its processing facilities at CTS and could be harmed if the physical infrastructure of this facility is unavailable for any prolonged period of time.  In addition, disruptions could lead to significant costs and reductions in revenues, as well as a potential harm to the Axogen&#8217;s business reputation and financial results. The CTS agreement terminates December 31, 2021, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#8217;s right to cure, in certain circumstances), or by Axogen without cause, upon 6 months&#8217; prior notice, </span>whereby notice cannot be provided prior to March 1, 2021<span style="white-space:pre-wrap;">.  Although Axogen believes it can find and make operational a new facility in less than six months </span><span style="white-space:pre-wrap;">if required. In addition, Axogen acquired property which is located near the CTS facility and it is expected that renovations will be completed by the termination date of the CTS Agreement to provide a new processing facility that can be included in our BLA for the Avance Nerve Graft. However, the regulatory process for approval of facilities whether licensed or owned is time-consuming and unpredictable.  Axogen&#8217;s ability to license, renovate, rebuild or find acceptable service facilities takes a considerable amount of time and expense and could cause a significant disruption in service to its customers if it were to lose the availability of it production or distribution facilities.  </span> Although Axogen has business interruption insurance which would, in instances other than lease termination, cover certain costs, it may not cover all costs nor help to regain Axogen&#8217;s standing in the market.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In July 2018, Axogen purchased a facility (the &#8220;APC&#8221;) in Vandalia, Ohio, located near the CTS processing facility where Avance Nerve Graft and Avive Soft Tissue Membrane are currently processed.  The APC, when and if operational, will be </span>the new processing facility for Avance&#160;Nerve Graft and Avive Soft Tissue Membrane&#160;to provide continued capacity for growth and to support the transition of Avance Nerve Graft from a 361 HCT/P tissue product to a&#160;<span style="white-space:pre-wrap;">biologic product.  The APC </span>is comprised of a <ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_7_31_2018_9F5KGFk5ekOKV8bdqwW0vQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_i5SCw2SC10e_SzVLoSiUHg">70,000</ix:nonFraction> square foot building on approximately <ix:nonFraction unitRef="Unit_Standard_acre_uQoen29RI0aO7YAQ0QAY8Q" contextRef="As_Of_7_31_2018_9F5KGFk5ekOKV8bdqwW0vQ" decimals="1" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_Y77DPVpZFk6M6b_yxB1QjQ">8.6</ix:nonFraction><span style="white-space:pre-wrap;"> acres of land.  The Company paid </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_7_1_2018_To_7_31_2018_pDS8UW-ipEGiRfiHlv5kzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireLandHeldForUse" scale="3" id="Narr_lKOra9J210yLnvS3Oj8yQg">731</ix:nonFraction><span style="white-space:pre-wrap;"> for the land and is recorded as Land within our property and equipment account on our balance sheet.   The Company paid </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_7_1_2018_To_7_31_2018_pDS8UW-ipEGiRfiHlv5kzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBuildings" scale="3" id="Narr_fMn0OWlVVUumKFHafJtLlg">4,300</ix:nonFraction> for the building and this is recorded as projects in process as part of the property and equipment on the balance sheet. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On July 9, 2019,&#160;Axogen&#160;entered into a Standard Form of Agreement Between Owner and Design-Builder (the &#8220;Design-Build Agreement&#8221;) with CRB Builders, L.L.C., a Missouri limited liability company (&#8220;CRB&#8221;),&#160;pursuant to which CRB will renovate and retrofit the APC.&#160; The Design-Build Agreement contains several design phase milestones that began in July 2019 and sets the&#160;date for Substantial Completion (as defined in the Design-Build Agreement)&#160;in the third quarter of 2020, subject to adjustment in accordance with the terms of the Design-Build Agreement.&#160;The estimated cost pursuant to the Design-Build Agreement&#160;is $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_7_9_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_k2AvsINLE0CA1hy04sZUqg" decimals="-3" format="ixt:numdotdecimal" name="axgn:EstimatedCostRelatingToDesignBuildAgreement" scale="3" id="Narr_wG_0zDYkP0ijcjJaMh9JBQ">29,000</ix:nonFraction>. &#160;Additional costs associated with the renovation, purchasing of furniture and equipment,&#160;validation and certification of the APC are estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_7_9_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_k2AvsINLE0CA1hy04sZUqg" decimals="-3" format="ixt:numdotdecimal" name="axgn:AdditionalCostsAssociatedWithDesignBuildAgreement" scale="3" id="Narr_stdi_CF4EEGX2kYF0OkP8A">14,400</ix:nonFraction>.&#160;&#160;<span style="white-space:pre-wrap;">These capital expenditure costs will be incurred as they arise until the anticipated full transition of material processing to the APC by early 2022.  </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1FNV_e0a8UGT3elVOhd27g_cont5" continuedAt="Tb_1FNV_e0a8UGT3elVOhd27g_cont6"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">As of December 31, 2019, the Company has recorded </span>$<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_QK4ED2K6qEOV1Xg1-zGj_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="3" id="Narr_tsp6z14StUqFFg4DoMb5Bw">6,066</ix:nonFraction> related to renovations and design build. These items are recorded as projects in process as part of the property and equipment on the balance sheet.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen expects to receive certain economic development grants from state and local authorities totaling up to $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_7_9_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_1bIsEkV_FkmHurO56ABv6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="3" id="Narr_Da19SMgVaUu6XGdu8deKWA">2,685</ix:nonFraction> including $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_7_9_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_1bIsEkV_FkmHurO56ABv6Q" decimals="-3" format="ixt:numdotdecimal" name="axgn:CashGrantsReceivable" scale="3" id="Narr_xfPGGviueEuZbE-X15QTbA">1,250</ix:nonFraction> of cash grants to offset costs to acquire and develop the APC.&#160; The economic development grants are subject to certain job creation milestones by 2023 and related contingencies.&#160;</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As previously disclosed the Company previously entered into an agreement with Heights Union, LLC, a Florida limited liability company (&#8220;Heights Union&#8221;), for the lease of <ix:nonFraction unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA" contextRef="As_Of_9_30_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_4tCIYMnwyk6Ob6QqnDHXvg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AreaOfLand" scale="3" id="Narr_X2cYLHJZfkaJ16q9aMjUXQ">seventy-five</ix:nonFraction> thousand square feet of office space.&#160; Pursuant to the Heights Union lease, the Company will use the Heights Union Premises for general office, medical laboratory, training and meeting purposes.&#160;&#160;The Company anticipates occupying the premises by the second quarter of 2020.&#160; Associated with the lease, the Company anticipates spending up to $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_6_30_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_NtuCJ8sKq0qVnPGFTPpTwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="3" id="Narr_VrlpJA7tXEKQ7Rd3mcbo-Q">9,833</ix:nonFraction> for leasehold improvements, equipment and furniture and fixtures.&#160; As of December 31, 2019, the Company has recorded $<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_2g6PdNw7sEqA9_PlVqHxDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="3" id="Narr_FQZMR0ntg02e38mP4wXEeA">441</ix:nonFraction> of leasehold improvements to the new facility.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Litigation </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">On January 9, 2019, Plaintiff Neil Einhorn, on behalf of himself and others similarly situated, filed a putative class action complaint in the United Stated District Court for the Middle District of Florida alleging violations of the federal securities laws against Axogen, Inc., certain of its directors and officers (&#8220;Individual Defendants&#8221;), and Axogen&#8217;s 2017 Offering Underwriters and 2018 Offering Underwriters (collectively, with the Individual Defendants, the &#8220;Defendants&#8221;), captioned Einhorn v. Axogen, Inc., et al., No. 8:19-cv-00069 (M.D. Fla.).  Plaintiff asserts that Defendants made false or misleading statements in connection with the Company&#8217;s November 2017 registration statement issued regarding its secondary public offering in November 2017 and May 2018 registration statement issued regarding its secondary public offering in May 2018, and during a class period of August 7, 2017 to December 18, 2018.   In particular, Plaintiff asserts that Defendants issued false and misleading statements and failed to disclose to investors: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company&#8217;s pricing alienated customers and threatened the Company&#8217;s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company&#8217;s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company&#8217;s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company&#8217;s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company&#8217;s key operating metrics, such as number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.  Axogen was served on January 15, 2019.  </span><span style="font-size:10pt;">On February 4, 2019, the court granted the parties&#8217; stipulated motion which provided that Axogen is not required to file a response to the complaint until </span><ix:nonNumeric contextRef="Duration_2_4_2019_To_2_4_2019_ln_X-b6a80Wb7o__1q1OhQ" format="ixt-sec:durwordsen" name="axgn:ThresholdPeriodForNotFilingResponseToComplaint" id="Narr_jiGmRpj86kmGBPGmZ5zCbw"><span style="font-size:10pt;">thirty days</span></ix:nonNumeric><span style="font-size:10pt;">&#160;after Plaintiff files a consolidated amended complaint.&#160;On June 19, 2019, Plaintiff filed an Amended Class Action Complaint, and on July 22, 2019, Defendants filed a motion to dismiss. Plaintiff filed opposing papers on August 12, 2019. The Court held a status hearing on September 11, 2019 and stayed all deadlines regarding the parties&#8217; obligations to file a case management report. On December 4, 2019 the parties&#8217; presented oral arguments and are currently awaiting the court&#8217;s ruling.</span><span style="font-size:10pt;white-space:pre-wrap;">  Plaintiff is seeking compensatory damages, reimbursement of expenses and costs, including counsel and expert fees and such other relief as the court deems just and proper. The Company and Individual Defendants dispute the allegations and intend to vigorously defend against the Complaint.  The amount of loss, if any, cannot be reasonably estimated at this time.</span></p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;white-space:pre-wrap;">Jackson v. Zaderej, et al., No. 8:19-cv-01976 U.S. District Court (M.D. FL). On August 12, 2019, Plaintiff Harvey Jackson, derivatively on behalf of Axogen, filed a verified shareholder derivative complaint for violations of securities laws, breach of fiduciary duty, waste of corporate assets and unjust enrichment against Quentin S. Blackford, Gregory G. Freitag, Mark Gold, Jamie M. Grooms, Alan M. Levine, Peter J. Mariani, Guido Neels, Robert J. Rudelius, Amy Wendell, and Karen Zaderej (the &#8220;Individual Defendants&#8221;) and Nominal Defendant Axogen, Inc. (&#8220;Axogen&#8221;) (collectively, &#8220;Defendants&#8221;).  Plaintiff asserts that the Individual Defendants, who are current or former Axogen officers or directors, issued a false proxy statement for the election of directors in violation of Section 14(a) of the Securities Exchange Act of 1934, breached their fiduciary duties, wasted corporate assets and were unjustly enriched by allowing </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1FNV_e0a8UGT3elVOhd27g_cont6" continuedAt="Tb_1FNV_e0a8UGT3elVOhd27g_cont7"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">Axogen to make false public statements to investors based on the same claims in the report issued December 18, 2018 by Seligman Investments (the same allegations that form the basis for the Einhorn matter and the Bussey shareholder demand).  Plaintiff demands judgment in the Company&#8217;s favor against all Individual Defendants as follows: (A) declaring that Plaintiff may maintain this action on behalf of Axogen, and that Plaintiff is an adequate representative of Company; (B) declaring that the Individual Defendants have breached and/or aided and abetted the breach of their fiduciary duties to Axogen; (C) determining and awarding to Axogen the damages sustained by it because of the violations set forth above from each of the Individual Defendants, jointly and severally, together with pre- and post-judgment interest thereon; (D) directing Axogen and the Individual Defendants to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable laws and protect Axogen and its shareholders from a repeat of the damaging events described therein, including, but not limited to, putting forward for shareholder vote the following resolutions for amendments to the Company&#8217;s Bylaws or Articles of Incorporation and the following actions as may be necessary to ensure proper corporate governance policies: (i)  a proposal to strengthen the Board&#8217;s supervision of operations and develop and implement procedures for greater shareholder input into the policies and guidelines of the Board, (ii) a provision to permit the shareholders of Axogen to nominate at least </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_individual_c5Uqr2HKeUq8VhVxnbwwzQ" contextRef="As_Of_8_12_2019_srt_LitigationCaseAxis_axgn_NovitzkiVsZaderejMember_zFX_2N4KPUasTY6aVIbF6Q" decimals="INF" format="ixt-sec:numwordsen" name="axgn:MinimumNumberOfCandidateElectedToBoard" scale="0" id="Narr_RipZ_TRogECH_54qD_PA4w">six</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> candidates for election to the Board; and (iii) a proposal to ensure the establishment of effective oversight of compliance with applicable laws, rules, and regulations; (E) awarding Axogen restitution from Individual Defendants, and each of them; (F) awarding Plaintiff the costs and disbursements of this action, including reasonable attorneys&#8217; and experts&#8217; fees, costs, and expenses; and (G) granting such other and further relief as the Court may deem just and proper.  The Defendants filed a motion to dismiss on October 22, 2019.  In response, Plaintiffs voluntarily withdrew their complaint and the matter was dismissed without prejudice by the court on November 5, 2019.</span></p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;white-space:pre-wrap;">Novitzki v. Zaderej, et al, 19-CA-11745 DIV L (13th Judicial Circuit, Hillsborough Cnty., Fl.).  On November 11, 2019,  Plaintiff Joseph Novitzki, derivatively on behalf of Axogen, filed a verified stockholder derivative complaint for breach of fiduciary duty, waste of corporate assets and unjust enrichment against Karen Zaderej,  Gregory G. Freitag, Peter J. Mariani, Amy Wendell, Robert J. Rudelius, Mark Gold, Guido Neels, and Jamie M. Grooms (the &#8220;Individual Defendants&#8221;) and Nominal Defendant Axogen, Inc. (&#8220;Axogen&#8221;) (collectively, &#8220;Defendants&#8221;). Plaintiff asserts that the Individual Defendants, who are current or former Axogen officers or directors, breached their fiduciary duties, wasted corporate assets and were unjustly enriched by allowing Axogen to make false public statements to investors based on the same claims in the report issued December 18, 2018 by Seligman Investments (the same allegations that form the basis for the Einhorn matter and the Bussey shareholder demand).  Plaintiff demands judgment in the Company&#8217;s favor against all Individual Defendants as follows: (a) against all of the defendants and in favor of the Company for the amount of damages sustained by the Company as a result of the defendants&#39; breaches of fiduciary duties, waste of corporate assets, and unjust enrichment; (B) directing Axogen to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable laws and to protect Axogen and its stockholders from a repeat of the damaging events described herein, including, but not limited to, putting forward for stockholder vote, resolutions for amendments to the Company&#39;s Bylaws or Articles of Incorporation and taking such other action as may be necessary to place before stockholders for a vote of the following corporate governance policies: (1) directing Axogen to employ an independent, third-party expert to calculate the Company&#39;s market size (including the dollar values of Axogen&#39;s total addressable market and portion of the market relating to extremity trauma and OMF); (2) a provision to control insider selling; (3) a proposal to strengthen Axogen&#39;s oversight of its disclosure procedures; (4) a proposal to strengthen the Company&#39;s controls over financial reporting; (5) a proposal to strengthen the Board&#39;s supervision of operations and develop and implement procedures for greater stockholder input into the policies and guidelines of the Board; and (6) a provision to permit the stockholders of Axogen to nominate at least </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_individual_c5Uqr2HKeUq8VhVxnbwwzQ" contextRef="As_Of_11_11_2019_srt_LitigationCaseAxis_axgn_NovitzkiVsZaderejMember_IYCkqEqibkCICffbHpaANQ" decimals="INF" format="ixt-sec:numwordsen" name="axgn:MinimumNumberOfCandidateElectedToBoard" scale="0" id="Narr_7qaHi8Eg5kOmkw3h8PEBdQ">three</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> candidates for election to the Board; (C) extraordinary equitable and/or injunctive relief as permitted by law, equity, and state statutory provisions sued hereunder, including attaching, impounding, imposing a constructive trust on, or otherwise restricting the proceeds of defendants&#39; trading activities or their other assets so as to assure that plaintiff on behalf of Axogen has an effective remedy; (D) Awarding to Axogen restitution from defendants, and each of them, and ordering disgorgement of all profits, benefits, and other compensation obtained by the defendants, including all ill-gotten gains from insider selling by defendants; (E) awarding to plaintiff the costs and disbursements of the action, including reasonable attorneys&#39; fees, accountants&#39; and experts&#39; fees, costs, and expenses; and (F) granting such other and further relief as the Court deems just and proper.  After Defendants&#8217; counsel had multiple discussions with Plaintiff&#8217;s counsel pointing out that it&#8217;s complaint was deficient for the same reasons argued in Jackson, the Plaintiff agreed to voluntarily dismiss the complaint without prejudice, which the court so-ordered on January 24, 2020.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1FNV_e0a8UGT3elVOhd27g_cont7"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">These matters are subject to various uncertainties and it is possible that it may be resolved unfavorably to the Company.  However, while it in not possible to predict with certainty the outcome of the matter, the Company and the Individual Defendants dispute the allegations and intend to vigorously defend themselves.  </span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="Tb_qroj44DO1kOYyh-H2igJIQ" continuedAt="Tb_qroj44DO1kOYyh-H2igJIQ_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc__kc5IEpV7UOeYYoFMpjaaQ_1_1"></a><a id="Tc_MeUMRDZvl0qnLJI9JG4V2w_2_2"></a><a id="Tc_oA2x_Rx5sU6S_3gfCu6DPA_2_4"></a><a id="Tc_eJFurIIZWkCXc5xk4BnH2Q_2_6"></a><a id="Tc_igpCnEZMjEKtED56iisVZw_2_8"></a><a id="Tc_IZHCToK-CEa8TtO1QJydmA_2_10"></a><a id="Tc_1WRh_4UHK0CANqm8wdHrig_3_0"></a><a id="Tc_nn2Zegzfh0azjeCjZ9xeNw_4_0"></a><a id="Tc_Rz7btYMxAEySg3ISi-Ki0A_4_1"></a><a id="Tc_PpUpLiZkfkqcEoUnjzH3vw_4_3"></a><a id="Tc_hDuDQoB-n0m8lAjeQwCovQ_4_5"></a><a id="Tc_vWwsNsTnFESoFX0HPvAv_Q_4_7"></a><a id="Tc_T_jqpP4Q1UKYuXLCpbyoJA_4_9"></a><a id="Tc_aHKrgEUoC0iOh6mwh8xQAw_5_0"></a><a id="Tc_TjgYp77W8k-EhQrG76SdGw_6_0"></a><a id="Tc_F_Lub-lk9kGLt7Rb_DmUaA_7_0"></a><a id="Tc_MQG-pLQkBUmYsDr8LoyFaQ_9_0"></a><a id="Tc_7RzyP_gV6kCDCQiyto1izg_10_0"></a><a id="Tc_S1Gvjh5QbUaE0nUVwfX_aw_10_1"></a><a id="Tc_ScJdXUn6QEq35V7jCowlow_10_3"></a><a id="Tc_gDQy8UPJ_UiId4dhsF_09Q_10_5"></a><a id="Tc_VhPsRYUE7ECg_piuIm4l5Q_10_7"></a><a id="Tc_u7Sz1Tntl0euWnZkEXMhxQ_10_9"></a><a id="Tc_DaeuK26fjEmtTcUvfZT1wA_11_0"></a><a id="Tc_KoK7b7QwDk2H5-BpaZIjHQ_12_0"></a><a id="Tc_l-mv_mekxkG9-7Bo1YM32w_13_0"></a><ix:continuation id="Tb_qroj44DO1kOYyh-H2igJIQ_cont1"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">15.  Quarterly Results of Operations (Unaudited)</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of the quarterly results of operations for the years ended December 31, 2019 and 2018:</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="Tb_vAOJbljVB0muyYrkxwH5_A" escape="true"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quarter</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">First</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Second</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Third</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fourth</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_uVtV6574W0WFhAPddRljew_4_2">23,285</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_K_lyCgFIZkeX-_CAUZFhBQ_4_4">26,701</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc__MSenSayT0-ej2zFP3pG2w_4_6">28,564</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_kKijsOmx-UO7RoaKo3WX9g_4_8">28,162</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bxOCOJX190CfOdMJyN9FwQ_4_10">106,712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_awZiZuFZyEK_n-kZydB8kQ_5_2">19,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_9QBdHDzF3kymw5oaLb7a1w_5_4">22,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_OcSVxFNQYU-wEvdG_ixFrA_5_6">24,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_QGNIeseffE-jMdfg4MB8bA_5_8">23,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_id1wwklyrU-c8B8Q9i0DHA_5_10">89,363</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_p6UEQvFYD0e8NPuLUz-7dA_6_2">9,504</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_96I6eaVlhUGzZhSHyfGI9A_6_4">7,022</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-SwQ3Jo-ukW72s-A3iGTyg_6_6">5,571</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_DroqQIwtk0-S0B29CY20cA_6_8">7,038</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NzODcg6TjEOoONzlvuWYuQ_6_10">29,135</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss per common share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_Fr8-dCwwIkCfdUKfnfjeEA_7_2">0.24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_d89zT8za4kSTx1k-4ZKe3Q_7_4">0.18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_bRULy3HxWUqq4PxqpvysOQ_7_6">0.14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_vgyhW0gvYE-Rxf-QjLZnRg_7_8">0.18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_nP1g8F3zJ06NctK_YgPA5Q_7_10">0.74</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_FGczl3bu9kSt1a6TuNRI5A_10_2">17,260</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_BtA0IhWScUyFKglQLL5BNQ_10_4">20,584</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_iER5mvrggkWfne0LxGSriQ_10_6">22,660</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_HmdnI6Pbz0yKeHyvNBgEfA_10_8">23,433</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_gVhkNYno5UyLfkYdnXtRZw_10_10">83,937</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_nb4TQSjOW0iMCRcX3zT4kw_11_2">14,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_kPOW6JY3PUuxJ5-i_Qd5qw_11_4">17,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_piF1cl2o3UKOAD_FPFC2mg_11_6">19,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_NaDGWYgupEiFnVosth0RaA_11_8">19,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_LqsAUAZ-C0GAv7aC713blQ_11_10">71,014</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UqLy5rTvN0CWbms4JrzCdw_12_2">5,644</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_eQbeqACZ3UG0RQP25OnvbA_12_4">7,427</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Kg7nb6LP6U2RUh81JJ7cKw_12_6">4,102</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_g-k7xJ3arUCGIsAxcoxk4g_12_8">5,224</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6bM65j6PqkmewFqu-dEwXQ_12_10">22,397</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss per common share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_9dsJ3_0UdUeztezjeRC1eg_13_2">0.16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_PVrv2nWXbEG12gqoPYzjVA_13_4">0.20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_IIVeVt9KX0KFiOEtMiq8BQ_13_6">0.11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_BPC8cOLoMk-zsr2xtcap0Q_13_8">0.13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA" contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_t5uBWPpm4UeHBmwsL2epmg_13_10">0.60</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_4958fe55_e012_46cb_84fe_5c33c97cc253"></a><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSUR</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">E</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_e1717887_678d_432d_b29d_eaf6d1939a70"></a><a id="Item9AControlsAndProcedures"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 9A.  CONTROLS AND PROCEDURES</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company maintains &#8220;disclosure controls and procedures&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;<span style="white-space:pre-wrap;">and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, and Board of Directors, as appropriate, to allow timely decisions regarding required disclosure.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Changes in Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In the ordinary course of business, we routinely enhance our information systems by either upgrading current systems or implementing new ones. There were no changes in our internal control over financial reporting that occurred during the three months ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Our management is responsible for establishing and maintaining internal control over financial reporting, as such term is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;<span style="white-space:pre-wrap;">of the Exchange Act.  The Company&#8217;s internal control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Because of inherent limitations, a system of internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate due to change in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2019.  In making this assessment, the Company&#8217;s management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013).  Based on their evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company&#8217;s independent registered public accounting firm, Deloitte &amp; Touche LLP, who audited the consolidated financial statements included in this Annual Report on Form 10-K, has issued an attestation report on the effectiveness of managements internal control over financial reporting as of December 31, 2019.  This report states that the internal control over financial reporting was effective and appears on page 81 of this Annual Report on Form 10-K.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_36ce366c_2208_4b2d_a3b7_5d9ccf2874c3"></a><a id="ITEM9BOTHERINFORMATION_235573"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 9B.  OTHER INFORMATIO</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">N</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_eb7b4bde_06ad_4882_a363_c194603d6428"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIII_125825"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART II</b><b style="font-weight:bold;">I</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">.</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Information required by this item concerning our directors will be set forth under the caption &#8220;Election of Directors&#8221; in our definitive proxy statement for our 2020 annual meeting, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Information required by this item concerning compliance with Section 16(a) of the Exchange Act, as amended, will be set forth under the caption &#8220;Section 16(a) Beneficial Ownership Reporting Compliance&#8221; in our definitive proxy statement for our 2020 annual meeting, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Information required by this item concerning the audit committee of the Company, the audit committee financial expert of the Company and any material changes to the way in which security holders may recommend nominees to the Company&#8217;s Board of Directors will be set forth under the caption &#8220;Corporate Governance&#8221; in our definitive proxy statement for our 2020 annual meeting, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Board of Directors adopted a Code of Ethics, which is posted on our website http://ir.Axogeninc.com/governance.cfm that is applicable to all employees and directors. We will provide copies of our Code of Business Conduct and Ethics without charge upon request. To obtain a copy, please visit our website or send your written request to Investors Relations, 13631 Progress Blvd., Suite 400, Alachua, FL 32615. With respect to any amendments or waivers of this Code of Business Conduct and Ethics (to the extent applicable to the Company&#8217;s chief executive officer, principal accounting officer or controller, or persons performing similar functions) the Company intends to either post such amendments or waivers on its website or disclose such amendments or waivers pursuant to a Current Report on Form 8-K.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_b69d3ab8_49cd_4198_a797_462c1ab60997"></a><a id="ITEM11EXECUTIVECOMPENSATION_825365"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 11.  EXECUTIVE COMPENSATION</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">.</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Information required by this item will be set forth under the caption &#8220;Executive Compensation&#8221; in our definitive proxy statement for our 2020 annual meeting, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_844a8105_2461_418b_b5b0_3878503e41d5"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTER</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">S</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Information required by this item concerning ownership will be set forth under the caption &#8220;Security Ownership of Certain Beneficial Owners&#8221;, &#8220;Security Ownership of Directors and Executive Officers&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our definitive proxy statement for our 2020 annual meeting, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_51d3ffb2_b70b_4366_804a_5235bbc8606c"></a><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENC</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">E</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Information required by this item concerning ownership will be set forth under the caption &#8220;Corporate Governance &#8212; Director Independence&#8221; and &#8220;Certain Relationships and Related Transactions&#8221; in our definitive proxy statement for our 2020 annual meeting, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_8643b312_1451_4de2_a87f_445fe46b2357"></a><a id="ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 14.  PRINCIPAL ACCOUNTING FEES AND SERVICE</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">S</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Information required by this item concerning ownership will be set forth under the caption &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; in our definitive proxy statement for our 2020 annual meeting, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_66b4cdb6_bb95_4e9a_b9d8_0bca3d6ac724"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PartIV"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART IV</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"> </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Financial Statements and Financial Statement Schedules</b></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The financial statements required by Item 15(a) are filed in Item 8 of this annual report on Form 10-K.  Schedules not included have been omitted because they are not applicable or because the required information is included in the Consolidated Financial Statements and notes thereto.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="Schedule_II_Valuation_Accounts"></a><a id="_2a439f7f_f93b_48b2_a106_9d4d39f7245a"></a><a id="Tc_IrZXzRtwvEenC63P5ax3oQ_1_2"></a><a id="Tc_P6afXD1OXUGJBGh4m_28cw_1_4"></a><a id="Tc_wwmpRLoNDkyY_dK3JBBOFg_1_6"></a><a id="Tc_Sk_4GnXtW06I8jK_b0Naig_1_8"></a><a id="Tc_oxGLQ_sVdUq1d1Izc6uLLA_2_0"></a><a id="Tc_poxDnQ2AC0qy8GXSl2W4Mw_3_0"></a><a id="Tc_Rn9ILZqlVU6YYduhC0NJlA_4_0"></a><a id="Tc_40vQoHO5z0icY_3yPF56fg_5_0"></a><a id="Tc_MVHwesXkwkCw4XM3mPtqKg_7_0"></a><a id="Tc_flpb4Jgsq0yZYHc4GXDOEA_8_0"></a><a id="Tc_jbJ0S3Ao2EKMNUDJhuJpeg_8_4"></a><a id="Tc_GpLtmS0oN0WjO-dJif7sCA_9_0"></a><a id="Tc_XSPg_r0siEC2zr9rhSgowg_9_6"></a><a id="Tc_SXQa7w5d-06Lsn2t7JYANw_10_0"></a><a id="Tc_imqy_1W-Rk-6_ZNa5jOyIg_10_6"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="Tb_NGWBZu_OhUCxVYgvrtW7hA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Schedule II &#8211; Valuation and Qualifying Accounts</p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:1.8pt;text-indent:-1.8pt;margin:0pt 0pt 0pt 27pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AXOGEN, INC.</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SCHEDULE II &#8211; VALUATION AND QUALIFYING ACCOUNTS</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THREE YEARS ENDED DECEMBER 31, 2019, 2018 AND 2017</b></p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:1.8pt;text-align:center;text-indent:-1.8pt;margin:0pt 0pt 0pt 27pt;"><span style="font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">Balance at Beginning of Year</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">Additions</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">Deductions (Chargeoffs)</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">Balance at End of Year</p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Allowance for doubtful accounts</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_7M-n1WyHmkSuJh3oSbSVVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_r15BRZLMUkCUMCwffpmC7A_3_2">272</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_rHiawjIyP0aw2fguf5ppEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="3" id="Tc_gCIht4eRVU2GsV3EyBhJ0g_3_4">223</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_rHiawjIyP0aw2fguf5ppEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_2fBLG4UEskGPMj8o5k_XhA_3_6">34</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_5pNCsEIErU22bwU3noUy8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_517rf0oBGEOPCyp5IKCifg_3_8">461</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_5pNCsEIErU22bwU3noUy8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_SwVbAN4iBUig1fMLnkzz-A_4_2">461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_4dIDit0lLkGoGloMyIZncQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="3" id="Tc_-I6QW5aIhk-0aJCb44Axbg_4_4">852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_4dIDit0lLkGoGloMyIZncQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_tEDFQQ_ZIkOk_sYKgreYlQ_4_6">196</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_SJai84u14EuDL2IY6ZP7lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_g_k4HwfvjEeeXV1F_iT-Kw_4_8">1,117</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_SJai84u14EuDL2IY6ZP7lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_eCFYMTRA2UCWi-DEaL-KfQ_5_2">1,117</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_yxMu6JmduUiQWUtieKQOwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="3" id="Tc_I1vrDWROXkSkdai0NXxM-Q_5_4">514</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_yxMu6JmduUiQWUtieKQOwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_DSLFa9rhmkGITuCNK1HHfQ_5_6">539</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_UAgoENraVE6_3zK-NyR0vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_uBZ-Ox9ws0-XmXqxYhZU-w_5_8">1,092</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Valuation allowance for deferred tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_JiZrmI4fMUOvyhPBobtrAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_FF5O0FELjE6BHRkCnTiMfw_8_2">39,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_sonit0BwD0-XslHO4fwUog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_LQcbhnp7vU6-9yXwUnbnhA_8_6">10,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_SVGvuAZnpEa4kIr4fmffiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_mW1Z2qOvu0aYaEjKShi_EQ_8_8">28,357</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_SVGvuAZnpEa4kIr4fmffiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_O8hY5yooDkG-u5BlIrjtiw_9_2">28,357</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_QdTP5uBuUkm8aCMGR4HRdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="3" id="Tc_BCVW6iqB70eyDf22Gq2fug_9_4">5,519</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_UBoSuOgnDkyJox-_uA5moQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_pjrwRZ19kU68BCUEzxVXng_9_8">33,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_UBoSuOgnDkyJox-_uA5moQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_SELEmu38Q0SrLU2Ak-7kIQ_10_2">33,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_G8SJ8nYBukqnwXb72_TUaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="3" id="Tc_6f_YHAzhR02mgxCewt1U-g_10_4">5,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ" contextRef="As_Of_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_YOXkkYOqUke7VD_DZQQEDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_v1rg6IdciE6TKoRuYX64sg_10_8">39,853</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="bExhibits_852596"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">(b) <b style="font-weight:bold;">Exhibits</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following exhibits are included in this annual report on Form 10-K or incorporated by reference in the Form 10-K. </p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:11.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019010165/ex-3d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Articles of Incorporation of Axogen, Inc.</span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed on November 6, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019003793/ex-3d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen, Inc. </span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Bylaws. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, filed on May 2, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">+4.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="ex-4d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Description of Securities of Axogen, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018001268/axgn-20171231ex429a90a9a.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Registration Rights Agreement, dated as of August 26, 2015, between Axogen, Inc. and Essex Woodlands Fund IX, L.P. (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2016, filed on March 1, 2017)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">*10.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex101.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Patent License Agreement, dated as of August 3, 2005, by and between Axogen Corporation and the Board of Regents of the University of Texas System (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">*10.2.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex102.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Standard Exclusive License Agreement with Sublicensing Terms, dated as of February 21, 2006, by and between Axogen Corporation and the University of Florida Research Foundation, Inc. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.2.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837016006614/axgn-20160705ex1021b4b12.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to the Amended and Restated Standard Exclusive License Agreement No. A5140, effective as of July 5, 2016, by and between Axogen Corporation and the University of Florida Research Foundation, Inc. (incorporated by reference to Exhibit 10.2.1 to the Company&#8217;s Current Report on Form 8-K filed on July 11, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">*10.3</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex103.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Sid Martin Biotechnology Development Institute Incubator License Agreement, dated as of September 26, 2006, by and between Axogen, Inc. and the University of Florida Research Foundation, Inc. (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">*10.4.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex1041.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, by and between Axogen Corporation and LifeNet Health (incorporated by reference to Exhibit 10.4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">*10.4.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex1042.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of August 9, 2011, by and between Axogen Corporation and LifeNet Health (incorporated by reference to Exhibit 10.4.2 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">*10.4.3</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312512116287/d311224dex1043.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of March 12, 2012, by and between Axogen Corporation and LifeNet Health (incorporated by reference to Exhibit 10.4.3 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2011, filed on March 15, 2012).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">*10.4.4</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000110465914080372/a14-19656_1ex10d4d3.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Fourth Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of September 8, 2014, by and between Axogen Corporation and LifeNet Health  (incorporated by reference to Exhibit 10.4.3 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2014, filed on November 13, 2014).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">*10.5.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex105.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Distribution Agreement, dated as of August 27, 2008, by and between Axogen, Inc. and Cook Biotech Incorporated (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.5.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312512116287/d311224dex1052.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment No. 1 to Distribution Agreement, dated as of February 24, 2012, by and between Axogen, Inc. and Cook Biotech Incorporated (incorporated by reference to Exhibit 10.5.2 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 15, 2012).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.5.3</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018001268/axgn-20171231ex1053f032c.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment No. 2 to Distribution Agreement, dated as of February 26, 2018, by and between Axogen, Inc. and Cook Biotech Incorporated (incorporated by reference to Exhibit 10.5.3 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2016, filed on March 1, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.6</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837016004559/axgn-20160526xdef14a.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Appendix A to the Company&#8217;s Proxy Statement filed on April 8, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.7.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex1081.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Employment Agreement, effective as of October 15, 2007, by and between Axogen Corporation and Karen Zaderej (incorporated by reference to Exhibit 10.8.1 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.9.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312511311516/d253759dex1010.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Lease dated as of February 6, 2007, by and between Axogen Corporation and WIGSHAW, LLC (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, filed on November 14, 2011).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.9.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312513103379/d445191dex1023.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to Lease, dated as of February 27, 2013 to lease dated as of February 6, 2007, by and between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 12, 2013).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.9.3</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000110465914017051/a14-5254_1ex10d10d3.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third Amendment to Lease, dated November 12, 2013 to lease dated as of February 6, 2007, by and between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.10.3 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013, filed on March 6, 2014).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.9.4</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837016004242/axgn-20160316ex10104d7c3.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Fourth Amendment to Lease, dated as of March 16, 2016, by and between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.10.4 to the Company&#8217;s Current Report on Form 8-K filed on March 18, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.10.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000095013707014632/c18884exv99w2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Employee Incentive Stock Option Agreement (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on September 26, 2007).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.10.2</p></td><td style="vertical-align:top;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex101028e10.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended Form of Employee Incentive Stock Option Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Exhibit 10.10.2 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2016, filed on March 1, 2017).</span></a><span style="white-space:pre-wrap;">  </span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.11.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000119312512116287/d311224dex1021.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Employment Agreement, effective as of October 1, 2011, by and between Axogen, Inc. and Gregory Freitag (incorporated by reference to Exhibit 10.21 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 15, 2012).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.11.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000110465914056392/a14-13908_1ex10d16d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment No. 1 to Executive Employment Agreement, dated as of May 11, 2014, by and between Axogen, Inc. and Greg Freitag (incorporated by reference to Exhibit 10.16.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed on August 4, 2014).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.11.3</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837015002338/axgn-20150930ex104ccc933.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment No. 2 to Employment Agreement, dated as of August 6, 2015, by and between Gregory G. Freitag and Axogen, Inc. (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed on November 5, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.11.4</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837016006237/axgn-20160526ex101e60318.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment No. 3 to Employment Agreement, dated as of June 1, 2016, by and between Greg Freitag and Axogen, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 31, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.11.5</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018007978/ex-10d5.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment No. 4 to Employment Agreement, dated as of October 29, 2018, by and between Greg Freitag and Axogen, Inc. (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed on October 29, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.12.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000110465915029417/a15-9591_1ex10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Commercial Lease, dated April 21, 2015, by and between Axogen Corporation and Ja-Cole, L.P. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 22, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.12.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000110465915029417/a15-9591_1ex10d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Addendum to Commercial Lease, dated April 21, 2015 by and between Axogen Corporation and Ja-Cole, L.P. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on April 22, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.12.3</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837016008901/axgn-20161025ex1021766d8.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Commercial Lease Amendment 2, dated as of October 25, 2016, by and between Axogen Corporation and Ja-Cole L.P. (incorporated by reference to Exhibit 10.2.1 to the Company&#8217;s Current Report on Form 8-K filed on October 31, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.12.4 </p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018009452/ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Commercial Lease Amendment 3, dated November&#160;21, 2018 by and between Ja-Cole&#160;L.P. and Axogen Corporation (</span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 26, 2018)</span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837015002338/axgn-20150930ex1034b785d.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">License and Services Agreement, dated as of August 6, 2015, by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services) (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed on November 5, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.13.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019001095/axgn-20181231ex10131074a.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Fourth Amendment to License and Services Agreement, dated as of February 22, 2019,  by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services).  </span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(incorporated by reference to Exhibit 10.13.1 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2018, filed on February 26, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.15</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0.7pt 0pt 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000110465915006646/a15-3271_1ex10d4.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Securities Purchase Agreement dated as of November 12, 2014, between Axogen, Inc., and PDL BioPharma, Inc. (incorporated by reference to Exhibit 10.4 to Amendment No. 1 on Form 8-K/A to the Company&#8217;s Current Report on Form 8-K filed on November&#160;13, 2014, filed on February 4, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.16</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837015002338/axgn-20150930ex101477a56.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Securities Purchase Agreement, dated as of August 26, 2015, between Axogen, Inc and Essex Woodlands Fund IX, L.P. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed on November 5, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.17</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837015002338/axgn-20150930ex102f235f2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Development, License &amp; Option Agreement, dated as of November 3, 2014, by and between Axogen Corporation and Sensory Management Services LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed on November 5, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.18</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837016005287/axgn-20160331ex101b3bc76.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Employment Agreement, dated as of February 25, 2016, by and between Axogen Corporation and Peter Mariani </span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed on May 4, 2016)</span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.19</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837016004114/axgn-20160314ex101871480.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Employment Agreement, dated as of March 11, 2016, by and between Axogen Corporation and Kevin Leach (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on March 14, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">* 10.20</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex1020ff12e.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Credit and Security Agreement (Term Loan), dated as of October 25, 2016, by and among Axogen, Inc., Axogen Corporation, MidCap Financial Trust, MidCap Funding XIII Trust and MidCap Funding V Trust (incorporated by reference to Exhibit 10.20 to the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> * 10.21</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex1021432c1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Credit and Security Agreement (Revolving Loan), dated as of October 25, 2016, by and among Axogen, Inc., Axogen Corporation and MidCap Financial Trust (incorporated by reference to Exhibit 10.2 to the Company&#8217;s quarterly report on Form 10-Q for the quarter ended September 30, 2015, filed on November 5, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex102219b9a.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Non-Incentive Stock Option Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Exhibit 10.22 to the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">*10.23</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex1023b18e9.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of May 26, 2016 (incorporated by reference to Exhibit 10.23 to the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.24</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex10240391a.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Retention Stock Unit Award Agreement, dated December 29, 2016, by and between Axogen, Inc. and  Karen Zaderej, pursuant to Axogen, Inc. 2010 Stock Incentive Plan</span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">, as amended and restated as of March 23, 2016 (incorporated by reference to Exhibit 10.24 to the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837017000217/axgn-20170123ex10189a766.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Lease, dated as of January 23, 2017, by and between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 26, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.26</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018001268/axgn-20171231ex1026fc96d.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 2018 Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 </span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(incorporated by reference to Exhibit 10.26 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2017, filed on March 1, 2018)</span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.27</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837017009035/ex-1d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Underwriting Agreement by and between the Company, EW Healthcare Partners L.P. and Leerink Partners LLC, as representative of the underwriters named therein, dated November 16, 2017 (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on November 16, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.28</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018001268/axgn-20171231ex1028ea35c.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restricted Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Exhibit 10.28 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2016, filed on March 1, 2017).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.29</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018002975/ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Current Premises Election Notice, dated as of April 10, 2018, by and between Axogen Corporation and</span><span style="font-family:'Times New Roman';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 13, 2018).</span></a> </p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.30</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000110465918032939/a18-13017_4ex1d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Underwriting Agreement by and among the Company, Jefferies LLC and Leerink Partners LLC, as representatives of the underwriters named therein, dated May 8, 2018 (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on May 14, 2018).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.31</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018005570/ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Agreement For Purchase and Sale of Real Property, dated as of June 8, 2018 by and between ARC CRVANOH001, LLC and Axogen Corporation, </span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on July 12, 2018).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.32</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018007414/ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Employment Agreement dated September 4, 2018, by and between Axogen Corporation and Angelo Scopelianos (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 7, 2018).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.33</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018007510/ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Letter Agreement effective September 20, 2018 by between Axogen Corporation and SNH Medical Office Properties Trust </span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 21, 2018).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.34</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018007510/ex-10d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Office Lease dated September 20, 2018 by and between Axogen, Inc., Axogen Corporation and Heights Union, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on September 21, 2018).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.35 </p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018007978/ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Agreement of Lease dated October 26, 2018, by and between Ashley Avenue Associates I, LLC and Axogen Corporation (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on October 29, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.36</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018007978/ex-10d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Employment Agreement, dated as of October 29, 2018, by and between Axogen Corporation and Isabelle Billet (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on October 29, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.37</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018007978/ex-10d3.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Incentive Stock Option Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of October 29, 2018 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on October 29, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.38</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018007978/ex-10d4.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restricted Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of October 29, 2018 (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on October 29, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.39</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018007978/ex-10d6.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Employment Agreement, dated as of October 29, 2018, by and between Axogen Corporation and Maria Martinez (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed on October 29, 2018).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.40 </p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018009452/ex-10d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Lease, dated November&#160;19, 2018 by and between SNH Medical Office Properties Trust and Axogen Corporation (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on November 26, 2018).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.41 </p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018009452/ex-10d3.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Lease, dated November&#160;19, 2018 by and between SNH Medical Office Properties Trust and Axogen Corporation (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on November 26, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.42 </p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837018009452/ex-10d4.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First Amendment to Lease dated as of November&#160;19, 2018 by and between SNH Medical Office Properties Trust and Axogen Corporation (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on November 26, 2018).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.43</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019000158/axgn-20190115ex10179a2ca.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Separation Agreement and General Release, dated January 15, 2019, between Axogen Corporation and Jon Gingrich (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 16, 2019).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.44</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019000180/ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Separation Agreement and General Release, dated January 18, 2019, between Axogen Corporation and Shawn McCarrey (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 18, 2019).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.45</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019000195/ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Employment Agreement dated as of January 21, 2019, by and between Axogen Corporation and Eric Sandberg (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 22, 2019).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.46</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019000195/ex-10d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Non-Qualified Stock Option Inducement Award Agreement to be granted by Axogen, Inc. to Eric Sandberg on January 22, 2019 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on January 22, 2019).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.47</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019001095/axgn-20181231ex1047ad382.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of April 5, 2017 (incorporated by reference to Exhibit 10.47 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2018, filed on February 26, 2019).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.48</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019004464/axgn-20190331ex101f8ceb7.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Commercial Lease Amendment 4, dated March 12, 2019, by and between Ja-Cole&#160;L.P. and Axogen Corporation (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, filed on May 8, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">10.49</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019006084/ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Standard Form of Agreement Between Owner and Design-Builder, dated as of July 9, 2019, by and between Axogen Corporation and CRB Builders, L.L.C. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on July 9, 2019).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">**10.50</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/805928/000155837019010165/ex-10d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen Inc. 2019 Long-Term Incentive Plan and forms of award notices and agreements thereunder (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed on November 6, 2019).</span></a></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">***+10.51</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="ex-10d51.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Nerve End Cap Supply Agreement, dated June 27, 2017, by and between Cook Biotech Incorporated and Axogen Corporation.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">+21.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="ex-21d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Subsidiaries of the Registrant.</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">+23.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="ex-23d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consent of Lurie, LLP.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">+23.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="ex-23d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">C</span><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">onsent of Deloitte &amp; Touche, LLP.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">++24.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Power of Attorney.</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">+31.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="ex-31d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Executive Officer.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">+31.2</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="ex-31d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Financial Officer.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">+++32.1</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="ex-32d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Chief Executive Officer and Chief Financial Officer Certifications pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">+101</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">+104</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Inline XBRL f<span style="background-color:#ffffff;color:#212529;">or the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set.</span></p></td></tr><tr><td style="vertical-align:top;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:94.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">*</p></td><td colspan="2" style="vertical-align:top;width:94.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as amended.  The confidential portions have been deleted and filed separately with the United States Securities and Exchange Commission.</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:94.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">**</p></td><td colspan="2" style="vertical-align:top;width:94.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Management contract or compensatory plan or arrangement.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:94.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">***</p></td><td colspan="2" style="vertical-align:top;width:94.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Confidential treatment has been requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">+</p></td><td colspan="2" style="vertical-align:top;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Filed herewith.</p></td></tr><tr><td style="vertical-align:top;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">++</p></td><td colspan="2" style="vertical-align:top;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Included on signature page.</p></td></tr><tr><td style="vertical-align:top;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4pt;"><td style="vertical-align:top;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">+++</p></td><td colspan="2" style="vertical-align:top;width:90.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Furnished herewith.</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:28.8pt;text-indent:-28.8pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_872bd4d4_8530_4713_8247_efd0895c46d0"></a><a id="ITEM16Form10KSummary"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">ITEM 16.  Form 10-K Summary</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:27.35pt;text-indent:-27.35pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri';font-size:12pt;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_c2d4bba1_636f_4655_ac1f_c8d52f82ee9d"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_623302"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-indent:18pt;margin:0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">AXOGEN, INC</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Karen Zaderej</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Karen Zaderej</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Chief Executive Officer</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-indent:18pt;margin:0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Karen Zaderej (with full power to act alone), as his or her true and lawful attorney-in-fact and agent, with full powers of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the Annual Report on Form 10-K of Axogen, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their substitute or substitutes, lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-indent:18pt;margin:0pt;">In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Karen Zaderej</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Karen Zaderej, Chief Executive Officer, President and Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Peter Mariani</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Peter Mariani, CFO</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">(Principal Financial Officer)</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">(Principal Accounting Officer)</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Gregory G. Freitag</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Gregory G. Freitag, General Counsel and Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Dr. Mark Gold</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Mark Gold, M.D.</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Guido J. Neels </p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Guido J. Neels </p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Robert J. Rudelius</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Robert J. Rudelius</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Amy Wendell</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Amy Wendell</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Quentin S. Blackford</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Quentin S. Blackford</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Alan M. Levine</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">February 24, 2020</p></td></tr><tr><td style="vertical-align:top;width:48.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Alan M. Levine</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex-4d1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 2/24/2020 2:33:02 PM-->
<html>
	<head>
		<title>
			axgn_Ex_4.1
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt 0pt 10pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit 4.1</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">As of December 31, 2019, the only class of securities of Axogen, Inc., a Minnesota corporation (the &#x201C;Company&#x201D;), registered under Section 12 of the Securities Exchange Act of 1934, as amended, is common stock, par value $0.01 per share (&#x201C;Common Stock&#x201D;).&nbsp;&nbsp;The Company&#x2019;s Common Stock is listed on the Nasdaq Capital Market under the symbol &#x201C;AXGN&#x201D;.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Under the Company&#x2019;s Amended and Restated Articles of Incorporation (the &#x201C;Articles&#x201D;), the Company is authorized to issue up to 100,000,000 shares of Common Stock, par value $0.01 per share. As of February 21, 2020, 39,731,078 shares of Common Stock were issued and outstanding.</font>
		</p>
		<p style="margin:0pt 0pt 10pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Dividends, Voting Rights and Liquidation</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">The holders of shares of Common Stock: (i)&nbsp;have equal, ratable rights to dividends from funds legally available therefor, when, as and if declared by the Board of Directors of the Company, (ii)&nbsp;are entitled to share ratably in all assets available for distribution to holders of shares of Common Stock upon liquidation, dissolution or winding up of the Company&#x2019;s affairs, (iii)&nbsp;do not have preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions applicable thereto and (iv)&nbsp;are entitled to one vote per share on all matters which shareholders may vote on at all meetings of shareholders. Except as otherwise required by statute, the Articles or the Company&#x2019;s Amended and Restated Bylaws, all matters are decided by a majority vote of the number of shares entitled to vote at the time of the vote.</font>
		</p>
		<p style="margin:0pt 0pt 10pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Transfer Agent and Registrar</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Broadridge Corporate Issuer Solutions,&nbsp;Inc. is the transfer agent and registrar for the Company&#x2019;s Common Stock.</font>
		</p>
		<p style="margin:0pt 0pt 10pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Minnesota Anti-Takeover Laws</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">The Company is governed by the provisions of Sections&nbsp;302A.671, 302A.673 and 302A.675 of the MBCA. These provisions may discourage a negotiated acquisition or unsolicited takeover of the Company and deprive the Company&#x2019;s shareholders of an opportunity to sell their Common Stock at a premium over the market price.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">In general, Section&nbsp;302A.671 of the MBCA provides that a corporation&#x2019;s shares acquired in a control share acquisition have no voting rights unless voting rights are approved in a prescribed manner. A &#x201C;control share acquisition&#x201D; is a direct or indirect acquisition of beneficial ownership of shares that would, when added to all other shares beneficially owned by the acquiring person, entitle the acquiring person to have voting power of 20% or more in the election of directors.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">In general, Section&nbsp;302A.673 of the MBCA prohibits a public Minnesota corporation from engaging in a business combination with an interested shareholder for a period of four years after the date of the transaction in which the person became an interested shareholder, unless the business combination is approved in a prescribed manner. The term &#x201C;business combination&#x201D; includes mergers, asset sales and other transactions resulting in a financial benefit to the interested shareholder. An &#x201C;interested shareholder&#x201D; is a person who is the beneficial owner, directly or indirectly, of 10% or more of a corporation's voting stock or who is an affiliate or associate of the corporation, and who, at any time within four years before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the corporation's voting stock. Section&nbsp;302A.673 does not apply if a committee of the Company&#x2019;s Board of Directors consisting of all of its disinterested directors (excluding current and former officers) approves the proposed transaction or the interested shareholder's acquisition of shares before the interested shareholder becomes an interested shareholder.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">If a tender offer is made for the Company&#x2019;s Common Stock, Section&nbsp;302A.675 of the MBCA precludes the offeror from acquiring additional shares of stock (including in acquisitions pursuant to mergers, consolidations or statutory share exchanges) within two years following the completion of the tender offer, unless shareholders selling their shares in the later acquisition are given the opportunity to sell their shares on terms that are substantially the same as those contained in the earlier tender offer. Section&nbsp;302A.675 does not apply if a committee of the Company&#x2019;s Board of Directors consisting of all of its disinterested directors (excluding its current and former officers) approves the proposed acquisition before any shares are acquired pursuant to the earlier tender offer.</font>
		</p>
		<p style="margin:0pt 0pt 10pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Registration Rights</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">In connection with that certain Securities Purchase Agreement, dated as of August&nbsp;26, 2015, between the Company and EW Healthcare Partners&nbsp;L.P., formerly named Essex Woodlands Fund IX,&nbsp;L.P. ("Essex"), the Company also entered into a Registration Rights Agreement with Essex, pursuant to which the Company granted Essex certain demand and "piggy-back" registration rights with respect to its shares of the Company&#x2019;s Common Stock. The resale of all of Essex's shares has been registered pursuant to the Registration Rights Agreement.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.5pt;color:#000;background-color:#000;" align="left"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.51
<SEQUENCE>3
<FILENAME>ex-10d51.htm
<DESCRIPTION>EX-10.51
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 2/24/2020 2:33:03 PM-->
<html>
	<head>
		<title>
			axgn_Ex_10.51
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit 10.51</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked &#x201C;***&#x201D;</font><sub style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">.</sub>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">NERVE END CAP SUPPLY AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Commercial Supply Agreement (this "Agreement") is entered into and effective this day of&nbsp;June, 2017, by and between Cook Biotech Incorporated, an Indiana corporation ("</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">COOK</font><font style="display:inline;font-family:Times New Roman,Times,serif;">"), having a place of business at 1425 Innovation Place, West Lafayette, Indiana 47906, and AxoGen Corporation, a Delaware corporation having a place of business at 13631,&nbsp;Suite 400, Progress Blvd, Alachua, FL, 32615 </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">("PURCHASER" </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;text-decoration:underline;">or&nbsp;"DISTRIBUTOR"</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">RECITALS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.&nbsp;PURCHASER is engaged in the sale and marketing of medical devices;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.&nbsp;COOK is engaged in the manufacture and sale of medical devices;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">3.&nbsp;PURCHASER and COOK desire to have COOK manufacture certain medical devices for use in surgical procedures for peripheral nerve termination, for sale to and resale by PURCHASER.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 3.6pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">NOW, THEREFORE,</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in consideration of the mutual covenants and agreements contained herein, the parties agree as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 1, DEFINITIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">As used in this Agreement the following words and phrases shall have the following meanings:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Affiliate"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of a party hereto shall mean any entity that controls or is controlled by such party, or is under common control with such party. For purposes of this definition, an entity shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of the voting equity of another entity (or other comparable ownership interest for an entity other than a corporation)..</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Cancellation Foes"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall be the fees payable by PURCHASER for modification or cancellation of a Finn Purchase Order.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Confidential Information"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean all information and data provided by one party to the other party except any portion of such information and data which:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;is known to the recipient as evidenced by its written records before receipt thereof from the disclosing party;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)&nbsp;is disclosed to the recipient by a third person who has the right to make such disclosure;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iii)&nbsp;is or becomes part of the public domain through no fault of the recipient; or</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iv) the recipient can reasonably establish is independently developed by recipient without access to the information disclosed by the disclosing party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Contract Requirements"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean one hundred percent (100%) of the quantity of a Device used, sold and/or distributed by PURCHASER in the Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Current Good Manufacturing Practices" </font><font style="display:inline;font-family:Times New Roman,Times,serif;">or</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "cGMP"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean the good manufacturing practices required by the FDA and set forth in the FD&amp;C Act or FDA Regulations (including without limitation 21 CFR 820), policies or guidelines, in effect at any time during the term of this Agreement, for the manufacture of Devices.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Delivery Date"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean the date that Device is delivered to a common carrier chosen by COOK.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Device or Devices"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean the medical device(s) defined on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit "A"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> attached hereto and by reference made a part hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Device History Record"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean a compilation of records containing the manufacturing history for the Device.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.9</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Device Master Record"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean, with respect to the Device a compilation of records containing the procedures and specifications for the Device.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.10</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Distribution Agreement"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean the Distribution Agreement between PURCHASER and COOK dated August 27, 2008 as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.11</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Effective Date"</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;shall mean the date of this Agreement as set forth above.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.12</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "FDA"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean the United States Food and Drug Administration or any successor entity thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.13</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "FD&amp;C Act"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean the United States Federal Food, Drug and Cosmetic Act, as may be amended from time to time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.14</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Lot"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean a specific quantity of a Device comprising a number of Units mutually agreed upon between PURCHASER and COOK, and that (a) is intended to have uniform character and quality within specified limits, and (b) is manufactured according to a single manufacturing order during the same cycle of manufacturing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.15</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Purchase Order"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean written orders from PURCHASER to COOK which shall specify (a) the quantity of Devices ordered, (b) delivery dates, and (c) delivery destinations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.16</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Regulatory Authority" </font><font style="display:inline;font-family:Times New Roman,Times,serif;">shall mean those agencies or authorities responsible for regulation of the Devices in United States. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.17</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Specifications"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean the specifications for the Devices that are set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit "A"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> as may be modified by agreement of the parties hereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">1.18.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> "Territory"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall mean worldwide.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 2, PURCHASE AND SUPPLY OF DEVICE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Agreement to Purchase and Supply.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Pursuant to the terms and conditions of this Agreement, PURCHASER shall purchase from COOK the Contract Requirements of Device, and COOK shall use good faith efforts to manufacture and deliver to PURCHASER the Contract Requirements of Device in accordance with this Agreement. During the Term, COOK shall exclusively sell the Device to PURCHASER subject to the terms and conditions of this Agreement; for clarity, nothing in this Agreement will limit COOK's right to make, use, sell, offer to sell or import products other than the Device.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Reproduction, Rework or Reprocessing.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> If during the manufacture of any Lot, any reprocessing, rework, or reproduction is required in order to meet the Specifications, COOK shall conduct such reprocessing, rework, or reproduction in compliance with cGMPs. Any reprocessing, rework or reproduction which is not covered by cGMPs must be approved in writing by PURCHASER prior to implementation. Unless such reprocessing, rework or reproduction is required solely as a result of changes required to be made to the Specifications as agreed to by the parties, or the negligence or willful misconduct of PURCHASER, COOK shall be responsible for all costs and expenses incurred in connection with such reprocessing, rework or reproduction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Cook Storage.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.3.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Device Storage.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> In no event shall COOK be required to store Devices for more than thirty (30) days after the Device is manufactured without COOK's prior written consent and PURCHASER' s agreement to reimburse COOK for all costs incurred in connection with such storage.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.3.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Third Party Storage.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> COOK shall be permitted to store Devices in third party storage facilities. After more than thirty (30) days from the date the Device is manufactured, COOK shall have no liability for, and PURCHASER releases all claims against COOK arising out of, any damage or loss to Devices, arising out of, or in connection with, the storage in such third-party facility.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> PURCHASER Storage, Records, Distribution and Labeling</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.4.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Storage and Distribution.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> PURCHASER shall distribute, handle, store and warehouse Devices in a manner that is consistent with cGMP.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.4.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Records.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> PURCHASER shall maintain records and documentation relating to Devices in accordance with cGMP. Records shall include, without limitation, the name, address and telephone numbers of purchasers of Devices or products incorporating Devices and catalogue</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">and lot numbers for such products or Devices. COOK shall have reasonable access to review and inspect such records.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.4.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Labeling.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;PURCHASER shall label all products incorporating Devices in compliance with cGMP, 21 CFR Part 801.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">2.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;PURCHASER Efforts</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;PURCHASER shall use commercially reasonable efforts to promote, train the sales force on and solicit the sale of all Devices within the Field in the Territory, and use its commercially reasonable efforts to not promote or solicit the sale of the Device for use outside of the Field unless agreed to by the parties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 3, FORECASTS, ORDERS, and CAPACITY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">3.1 Forecasts and Order Limits.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;PURCHASER will provide COOK with an initial stocking order of Devices. Commencing on the date of this Agreement through the Term, PURCHASER shall provide to COOK weekly purchase orders. Such purchase orders will become the standard for this Agreement and continue for the Term without regard to any termination of the Distribution Agreement. Notwithstanding anything else contained herein, in no event shall COOK be obligated to accept an order for a quantity of the Device for any single month which is in excess of two hundred percent (200%) of the average number delivered to PURCHASER in three (3) months prior to such single month.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">3.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Purchase Orders</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;Prior to or on the tenth (10</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) calendar day of each month, PURCHASER shall submit Purchase Orders to COOK covering PURCHASER's purchases of Device pursuant to this Agreement at a minimum to replenish its stocking order pursuant to Section&nbsp;3.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">. &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">PURCHASER shall not, without the written consent of COOK, designate a delivery date in a Purchase Order earlier than Thirty (30) calendar days from the date PURCHASER submits the Purchase Order. COOK shall provide a confirmation of receipt of each Purchase Order setting forth the delivery date that COOK will meet for such order. Upon PURCHASER's receipt of the confirmation, such Purchase Order shall become a "Firm Purchase Order." If COOK is unable to meet the specified delivery date, COOK shall so notify PURCHASER and provide to PURCHASER an alternative delivery date which shall not be more than fifteen (15) calendar days later than the initial delivery date designated by PURCHASER in its Purchase Order. In the event that PURCHASER modifies or cancels a Firm Purchase Order without COOK's written consent, PURCHASER shall pay a cancellation fee equal to fifty percent (50%) of the Purchase Price of the Devices for such Purchase Order. To the extent of any conflict between Purchase Orders submitted by PURCHASER and this Agreement, this Agreement shall control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 4, PRICE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">4.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Device Purchase Price</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;The price to be paid by PURCHASER for Devices ("Purchase Price") shall be set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit "B"</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;attached hereto and by reference made a part hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">4.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Purchase Price Adjustment</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;Prior to the start of each calendar year, starting for the&nbsp;calendar year 2019, the parties will negotiate in good faith an increase in the Purchase</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Price based on changes in the Consumer Price Index and royalty obligations of COOK, and any adjustment as required in this Section 4.2. Upon thirty (30) days written notice to DISTRIBUTOR, COOK may adjust the price of the Device during the Term to reflect changes in the cost of materials, wages and FDA or other regulatory testing requirements paid by COOK in connection with the manufacture of the device,</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">without written agreement of DISTRIBUTOR. In no event shall COOK make such an adjustment more than once in any given twelve month period, and unless COOK demonstrates that a greater increase is needed due to increased cost of materials or FDA or other regulatory testing requirements for the Device, in no event shall any increase in the Purchase Price be more than the percentage increase of the Consumer Price Index for that year, with the following two exceptions ("Greater Increase Conditions"): 1) COOK reasonably demonstrates to DISTRIBUTOR that a greater increase in the Purchase Price is needed due to an unusual increase in the cost of direct Device materials, in which case the increase in the Purchase Price of a unit of product shall be less than or equal to the increase in the direct material costs of the Device on a per unit basis;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">or 2) COOK reasonably demonstrates to DISTRIBUTOR that a greater increase in the Purchase Price is needed due to the direct costs of new testing requirements for the Device from the FDA or another regulatory agency, in which case the increase in the Purchase Price of a unit of product shall be less than or equal to the increase in the costs of the End Cap Device due to the direct costs of new testing requirements on a per unit basis. If COOK claims a Greater Increase Condition exists, DISTRIBUTOR may audit the claimed Greater Increase Condition in the following manner: during normal business hours upon reasonable notice COOK will allow a certified public accountant representing DISTRIBUTOR and reasonably acceptable to COOK and who enters into a reasonable confidentiality agreement with COOK, to visit the offices of COOK to inspect books and records directly related to the Greater Increase Condition in sufficient detail to verify the existence of the Greater Increase Condition. In the event the claimed Greater Increase Condition is shown not to exist, COOK will reimburse DISTRIBUTOR for the reasonable cost of such audit and the Purchase Price will not be adjusted for the claimed Greater Increase Condition. </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">"Consumer Price Index" </font><font style="display:inline;font-family:Times New Roman,Times,serif;">means the consumer price index for all urban consumers as published by the Bureau of Labor Statistics of the U.S. Department of Labor or any successor agency that assumes responsibility for the preparation of such index.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 5, SHIPMENT AND INVOICING</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">5.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Delivery Terms.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> COOK shall pack the Device with regularly used packing material, shall label the Device in accordance with PURCHASER's supplied label content and formatting conforming to governmental regulation, and Devices shall be delivered to PURCHASER, or to a location designated by PURCHASER in the Purchase Order, in finished packaged form ready for sale to end-users DDP (Incoterms, 2010) PURCHASER's facility in Burlington, Texas, by a common carrier designated by COOK, at COOKS' s expense. Title to the Device shall pass to Distributor when delivered to PURCHASER's facility pursuant to the terms set forth above.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">5.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Shipment Out of U.S.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> PURCHASER will be the exporter of record for any Device shipped outside of the United States. PURCHASER warrants that all shipments of Device outside of the United States will be made in compliance with all applicable United States export laws and regulations, including the Export Administration Act, and all applicable import laws and regulations.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">5.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Payment Terms.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;PURCHASER shall pay COOK for the Device net thirty (30) days from the date of the receipt of proper invoice for the Device where such invoice shall be delivered along with the relevant shipment of the Device. Payments shall be made in U.S. dollars by check delivered to COOK by overnight delivery with a reputable overnight delivery service. Each invoice shall be payable by PURCHASER in accordance with the terms noted above. Payments not received within the times noted above shall bear interest at the lesser of (a) the maximum rate permitted by law, and (b) 1.5% per month on the outstanding balance compounded monthly.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">5.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Default in Payment Obligations.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;In addition to all other remedies available to COOK in the event of a PURCHASER default, if PURCHASER fails to make payments as required&nbsp;hereunder, COOK may refuse all further Purchase Orders, refuse to manufacture Devices until PURCHASER's account is paid in full, modify the foregoing terms of payment, place the account on a letter of credit basis, require full or partial payment in advance, suspend deliveries of Devices until PURCHASER provides assurance of performance reasonably satisfactory to COOK, and/or take other reasonable means as COOK may determine.</font>
		</p>
		<p style="margin:0pt 0pt 8.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 6, ACCEPTANCE OF DEVICE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">6.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Device Conformity.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;Within thirty (30) calendar days from the date of shipment of the Device to PURCHASER, PURCHASER shall determine whether Device conforms to the Specifications.</font>
		</p>
		<p style="margin:0pt 0pt 8.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">6.1.1 If (a) any shipment of Device conforms to the Specifications, or (b) PURCHASER fails to notify COOK within the applicable time period that any shipment of Device does not conform to the Specifications, then PURCHASER shall be deemed to have accepted the Device and waived its right to revoke acceptance.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">6.1.2 If PURCHASER believes any shipment of Device does not conform to the Specifications, including after acceptance as to those Specifications that cannot be inspected for conformity until the Device package is opened ("Post Acceptance Conformity"), it shall notify COOK by telephone including a detailed explanation of the non-conformity and shall confirm such notice&nbsp;in writing via overnight or e-mail delivery to COOK. Upon receipt of such notice, COOK will investigate such alleged non-conformity, and (i) if COOK agrees such Device is non-conforming, deliver to PURCHASER a corrective action plan within thirty (30) calendar days after receipt of PURCHASER's written notice of non-conformity, or such additional time as is reasonably required if such investigation or plan requires data from sources other than PURCHASER or COOK, or (ii) if COOK disagrees with PURCHASER's determination that the shipment of Device is non-conforming, COOK shall so notify PURCHASER by telephone within the fifteen (15) calendar day period and confirm such notice in writing by overnight or e-mail delivery.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">6.1.3 if the parties dispute whether a shipment of Device is conforming or non-conforming, including Post Acceptance Conformity, the shipment of Device will be submitted to a mutually acceptable laboratory or consultant for resolution, whose determination of conformity or non-conformity, and the cause thereof of non-conformity, shall be binding upon the parties. The</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">PURCHASER shall bear the costs of such laboratory or consultant, except as set forth in Section 6.2.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">6.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Remedies for Non Conforming Device.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">6.2.1 In the event COOK agrees that the Devices are non-conforming or the laboratory determines that the Devices are non-conforming, COOK shall replace such non-conforming Devices as soon as commercially reasonable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">6.2.2 PURCHASER shall pay for all Devices, including replacement Devices, except as specifically set forth in Section 6.2.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">6.2.3 In the event COOK agrees, or the laboratory or consultant determines, that the Devices are non&nbsp;conforming solely as a result of the negligence or willful misconduct of COOK, then, to the extent paid for by PURCHASER, COOK will credit the Purchase Price for the replacement Device to PURCHASER, and shall bear the costs of such laboratory or consultant.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 7, TERM AND TERMINATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">7.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Term.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;The term of this Agreement commences on the Effective Date and continues in full force and effect until August 27, 2027 unless extended by mutual agreement of the parties or earlier terminated in accordance with this Article 7 (the "Term").</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">7.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Early Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;Either party may terminate this Agreement, effective immediately, without demand or judicial resolution, upon written notice to the other party, in the event of any of the following:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)<font style="display:inline;font-family:Times New Roman,Times,serif;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>a breach of any obligation to pay money under this Agreement, unless such obligation is<br>disputed in good faith by the non-paying party, which breach is not cured within thirty (30) days after receiving written notice of such breach from the non-breaching party;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)<font style="display:inline;font-family:Times New Roman,Times,serif;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>a breach of any non-monetary representation or warranty or obligation contemplated in<br>this Agreement, which breach is not cured within sixty (60) calendar days after receiving written notice of such breach from the non-breaching party;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iii)<font style="display:inline;font-family:Times New Roman,Times,serif;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>the other party's inability to pay its debts as the same become due; any assignment by the other party for the benefit of its creditors; the appointment of a receiver, liquidator, or committee of creditors for all or substantially all of the other party's business or assets; the filing of a petition for voluntary or involuntary bankruptcy or similar proceeding by or against the other party or the liquidation of the other party;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iii)<font style="display:inline;font-family:Times New Roman,Times,serif;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>the expropriation, confiscation, or nationalization of all or substantially all of the other party's business or assets;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iv)<font style="display:inline;font-family:Times New Roman,Times,serif;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>on a country-by-country basis, the introduction of any bill in the legislature of any national or governmental subdivision or the passage or issuance of any provision, statute, decree,</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">order, notice, rule or document having the force of law within any country within the Territory granting independent sales representatives, distributors, or dealers the right to receive extra contractual indemnification from principals upon the latter's termination or refusal to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">renew </font><font style="display:inline;font-family:Times New Roman,Times,serif;">applicable agreements between the parties; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(v)<font style="display:inline;font-family:Times New Roman,Times,serif;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>on a country-by-country basis, any change in the law which restricts, limits or prohibits&nbsp;the importation, sale, marketing or distribution of the Device.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">7.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Additional Termination Rights.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;After the fifth anniversary of the Term, either PURCHASER or Cook may terminate this Agreement, without cause, at any time upon ninety (90) days prior written notice of termination to Cook.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)&nbsp;COOK may terminate this Agreement at any time upon written notice to PURCHASER with respect to any Device in any and all countries within the Territory based on: i) a third party allegation or a judgment issued by a court of proper jurisdiction that such Device infringes a third party patent not licensed to PURCHASER in a country where such Device is being marketed; or ii) PURCHASER's failure to generate commercially reasonable sales in </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Territory </font><font style="display:inline;font-family:Times New Roman,Times,serif;">of Device as measured by sales similar to a competitive product at the&nbsp;same stage in its commercial launch as verified by a mutually acceptable third-party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">7.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Additional Rights and Remedies.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;Subject to Section 12.1, termination under this Article 7 shall be in addition to the other rights and remedies of&nbsp;the terminating party. Termination of this Agreement for any reason shall not relieve any party of any obligations accruing prior to such termination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">7.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Non-cancelable Costs and Expenses.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> In the event of the termination or cancellation of this Agreement, except by PURCHASER as a result of a breach by COOK under Section 7.2, PURCHASER shall (a) reimburse COOK for all Device materials and components ordered prior to termination and not cancelable at no cost to COOK, and (b) pay COOK the cancellation fees as set forth in Section 3.2. In addition, in the event of termination or cancellation for any reason, PURCHASER shall pay prices described in Article 4 for (i) all work-in-process commenced by COOK and (ii) all finished goods of COOK. COOK shall ship such materials to PURCHASER pursuant to Section 5.1. PURCHASER shall make payment for all expenses described in this Section 7.5 thirty (30) days from the invoice date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">7.6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Survival.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;Termination, expiration, cancellation or abandonment of this Agreement through any means or for any reason, except as set forth in Section 7.1, shall be without prejudice to the rights and remedies of either party with respect to any antecedent breach of any of the provisions of this Agreement. The provisions of Articles 7, 11, 12, 13, 14, 15, 16 and 17 hereof shall survive expiration or termination of this Agreement.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 8, MANUFACTURE OF DEVICES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">8.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Manufacture</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. COOK shall manufacture Devices in accordance with cGMP, the Specifications and the Quality Technical Agreement Version -01 between the PURCHASER and COOK, as amended from time to time by agreement of PURCHASER and&nbsp;COOK. Manufacturing deviations and investigations which occur during manufacture of Devices and which do not cause the manufacture to be non-compliant with cGMP shall not be deemed to cause such Device to be non-conforming.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">8.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Permits and Licenses.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> PURCHASER shall have sole responsibility, at its expense, for obtaining all government and statutory permits, approvals, registrations, certificates and licenses, and shell satisfy all governmental and other statutory requirements necessary or required for the sale, marketing and commercialization of each Device manufactured by COOK&nbsp;hereunder. COOK shall be responsible, at its expense, to obtain and maintain all government and statutory permits, approvals, registrations, certificates and licenses required for it to carry out manufacturing obligations hereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">8.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Regulatory Requirements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. Each party promptly shall notify the other of new regulatory requirements of which it becomes aware which are relevant to the manufacture of Devices under this Agreement and which are required by the FDA, any other applicable regulatory authority or other applicable laws or governmental regulations, and shall confer with each other with respect to the best means to comply with such requirements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">8.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Changes in Manufacturing:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">8.4.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Changes to Device</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Master Record and Specifications.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> COOK agrees to inform PURCHASER within fifteen (15) days of the result of any regulatory development or changes that materially affect the manufacture of the Devices. COOK shall notify PURCHASER of and require written approval from PURCHASER for changes to the Device Master Record prior to the manufacture of subsequent Lots of the Device.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">8.4.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Device-Specific Changes.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> If facility, equipment, process or system changes are required of COOK as a result of requirements set forth by the FDA or any other regulatory authority, and such regulatory changes apply primarily to the manufacture of the Device, then PURCHASER and COOK will review such requirements and agree in writing to such regulatory changes, and PURCHASER shall bear 100% of the reasonable costs thereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 9, REGULATORY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">9.1 </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Regulatory Approvals</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. PURCHASER will be solely responsible for obtaining all regulatory approvals necessary for the sale, marketing and distribution of Devices or products incorporating Devices.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">9.2 </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Regulatory Authority Inspections</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. COOK will notify PURCHASER within five (5) calendar days of all contacts with regulatory authorities (both written and verbal) related to Devices. COOK shall inform PURCHASER of the result of any regulatory inspection which directly affects the manufacture of Devices. In the event of an FDA inspection which directly involves a Device, PURCHASER shall be immediately informed of the issuance of the Notice of</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Inspection (FDA Form 482). In the event that there are Inspectional&nbsp;Observations (FDA Form 483), PURCHASER shall be informed immediately and shall have the opportunity to review and provide COOK with comments to COOK's response. PURCHASER shall provide its comments to the response of these observations within ten (10) calendar days. The contents of COOK's response shall be determined by COOK in its sole discretion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 10, TRADEMARKS AND PATENTS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">10.1 PURCHASER grants to COOK a non-exclusive, royalty free license to use the PURCHASER's trademarks for the sole purpose of allowing COOK to fulfill its responsibilities under this Agreement. Such license shall not be transferable in whole or in part without prior written approval from PURCHASER, which will not be unreasonably withheld.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">10.2 PURCHASER shall be solely responsible for selecting, registering and enforcing PURCHASER's trademarks used to identify the Device and except as set forth in Section 10.1 and shall have sole and exclusive rights in such PURCHASER Trademarks.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">10.3 COOK acknowledges PURCHASER'S right, title and interest in the trade name that PURCHASER uses for the Device (provided such trade name does not use or incorporate or adopt any of the Trademarks or Cook's company names or any confusingly similar word or symbol), its trademarks and trade names listed in product sheets issued by PURCHASER (collectively "Purchaser Trademarks"), and COOK shall not at any time do or cause to be done any act or thing which directly or indirectly challenges, impairs or adversely affects the Purchaser Trademarks or PURCHASER's goodwill therein. COOK shall not acquire any right, title, or interest in the Purchaser Trademarks by virtue of the execution, performance or termination of this Agreement. COOK shall not use any Purchaser Trademark, without PURCHASER's prior written consent. All goodwill resulting from COOK's use of the Purchaser Trademarks shall inure to the benefit of PURCHASER. COOK will have no liability under this Agreement for any delay or failure to perform its obligations hereunder to the extent that such delay or failure is due to PURCHASER's failure to provide clear, timely and reasonable instructions with respect to COOKs use of Purchaser Trademarks in connection with the Device.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">10.4 PURCHASER acknowledges COOK's exclusive right, title and interest in the trademarks and trade names listed in all catalog and product sheets issued by COOK (collectively "Cook Trademarks"), and PURCHASER shall not at any time do or cause to be done any act or thing which directly or indirectly challenges, impairs or adversely affects the Cook Trademarks or COOK's goodwill therein. PURCHASER shall not acquire any right, title, or interest in the Cook Trademarks by virtue of the execution, performance or termination of this Agreement. PURCHASER shall not use any Trademark, without COOK's prior written consent. Any goodwill resulting from PURCHASER's use of the Cook Trademarks shall inure to the benefit of COOK.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">10.5 Except as provided expressly herein, PURCHASER may not use the Cook Trademarks or COOK's name in connection with the importation, marketing, distribution and sale of the Device. PURCHASER shall not use or adopt the Cook Trademarks or any confusingly similar word or symbol as part of its company name. PURCHASER shall submit to COOK for approval, prior to use,</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">distribution, or disclosure of any advertising, promotion or publicity media in which COOK's name or the Cook Trademarks are to be used. The package label for the Device processed by COOK and delivered pursuant to this Agreement shall be designed by PURCHASER and follow applicable laws and regulations including stating "Manufactured for AxoGen Corporation" or variations thereof in small print. PURCHASER shall be responsible for all costs of repackaging and re-labeling the Device and any revision of the Device brochures and other educational materials, to the extent such repackaging, re-labeling and/or revisions are required due to Purchaser Trademark issues that arise with respect to the Device. COOK shall be responsible for all costs of repackaging and relabeling the Device and any revision of the Device brochures and other educational materials, to the extent such repackaging, re-labeling and/or revisions are required due to Cook Trademark issues that arise with respect to the Device. Notwithstanding the foregoing, COOK shall have the right to review and request the correction or deletion, at PURCHASER's expense, of any misleading, or false material from any such media.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">10.6 PURCHASER will be solely responsible, at its sole expense, for, and except as otherwise provided in this Agreement, shall have the sole right to make all decisions and determinations with respect to marketing and sales of the Device, all subject to and in compliance with all applicable laws and regulations and the terms and conditions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">10.7 COOK reserves the right to bring such legal action in the courts or administrative agencies of any country within the Territory as may be required to prevent the infringement, imitation, unauthorized sale, purchase or distribution, illegal use, or misuse of the Cook Trademarks or COOK's name. PURCHASER promptly shall notify COOK of any infringement, imitation, unauthorized sale, purchase or distribution, illegal use, or misuse of the Cook Trademarks or COOK's name which comes to PURCHASER's attention, and shall render any assistance which COOK may reasonably request in protecting the Cook Trademarks or COOK's name.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">10.8 PURCHASER grants to COOK a non-transferable, irrevocable, non-exclusive, royalty free license under any and all Applicable Purchaser Patents, to manufacture and sell the Devices to be supplied to PURCHASER by COOK pursuant to this Agreement, for the sole purpose of allowing COOK to perform under this Agreement. "Applicable Purchaser Patents" shall mean any patent or patent application owned by PURCHASER including at least one claim that encompasses Devices or their use or manufacture. Such licenses shall not be transferable in whole or in part without prior written approval from PURCHASER, which will not be unreasonably withheld. Except for the rights expressly granted, no right, title, or interest of any nature whatsoever is granted under the Applicable Purchaser Patents whether by implication, estoppel, reliance, or otherwise, by PURCHASER to COOK. Accordingly, all rights with respect to any know-how, patent or other intellectual property rights that are not specifically granted herein are reserved by PURCHASER.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">10.9 COOK grants to PURCHASER a non-transferable, irrevocable, non-exclusive, royalty free license under any and all Applicable COOK Patents, to use, offer to sell, sell and import the Devices supplied to PURCHASER by COOK pursuant to this Agreement, for the sole purpose of allowing PURCHASER to perform under this Agreement. "Applicable Cook Patents" shall mean any patent or patent application owned by COOK including at least one claim that encompasses Devices or their use. Such license shall not be transferable in whole or in part</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">without prior written approval from COOK, which will not be unreasonably withheld. Except for the rights expressly granted, no right, title, or interest of any nature whatsoever is granted under the Applicable Cook Patents whether by implication, estoppel, reliance, or otherwise, by COOK to PURCHASER. Accordingly, all rights with respect to any know-how, patent or other intellectual property rights that are not specifically granted herein are reserved by COOK.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 11, REPRESENTATIONS AND WARRANTIES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">11.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Mutual Representations.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Each party hereby represents and warrants to the other party that (a) the person executing this Agreement is authorized to execute this Agreement; (b) this Agreement is legal and valid and the obligations binding upon such party are enforceable by their terms; and (c) the execution, delivery and performance of this Agreement does not conflict with any agreement, instrument or understanding, oral or written, to which such party may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">11.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> COOK Warranty.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> COOK represents and warrants that:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;the Devices shall be: (i) manufactured in accordance with cGMP and the Specifications; (ii) be true to label when packaged and delivered to PURCHASER; (iii) be free from defects in materials and workmanship; and (iv) shall have a minimum shelf life of fourteen (14) months from the date of delivery. COOK represents and warrants that it has obtained (or will obtain prior to manufacturing Devices), and will remain in compliance with during the term of this Agreement, all permits, licenses and other authorizations (the "Permits") which are required under federal, state and local laws, rules and regulations applicable to the manufacture only of Devices; provided, however, COOK shall have no obligation to obtain Permits relating to the sale, marketing, distribution or use of Devices or with respect to the labeling of Devices; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;COOK agrees to undertake and to cause its suppliers, if any, to undertake such quality control and inspection procedures as required by the FDA ("Quality Plan"). COOK will, upon written request of the DISTRIBUTOR, share its Quality Plan with the DISTRIBUTOR prior to delivery of the initial Device order and on an annual basis thereafter. DISTRIBUTOR shall-have the right (at its expense) from time to time but no more frequently than once a calendar year, and upon reasonable advance written request and during normal business hours, to inspect the facilities of COOK and any manufacturing facilities, storage/handling facilities and any other facilities or entities used by COOK or third parties, on behalf of COOK for the supply, manufacture and storage of the Device to review their compliance with the requirements of Section 351 of the Public Health Services Act that apply to the Device and all other applicable laws and regulations for the Device in the United States or comparable laws and regulations of foreign regulatory authorities for the Territory; provided, however, if during the course of any such inspection DISTRIBUTOR determines that COOK is not in compliance with the requirements of the Quality Plan, including but not limited to compliance with Section 351 of the Public Health Services Act that apply to the Device or any other applicable laws and regulations that apply to the Device or comparable regulations of foreign regulatory authorities for Territory (a "Non-Compliant Item"), DISTRIBUTOR shall be permitted to perform such additional</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">inspections within a calendar year as are required for the sole purpose of confirming that COOK has corrected, and is then in compliance with, any Non-Complaint Item discovered in DISTRIBUTOR's immediately preceding inspection. Any information that DISTRIBUTOR learns in the course of such inspections shall be deemed the Confidential Information of COOK, subject to DISTRIBUTOR's confidentiality obligations hereunder, may be used by DISTRIBUTOR for the sole purpose of ensuring compliance by COOK with its obligations under this Section 11.2, and may not be otherwise used or disclosed by DISTRIBUTOR without the prior written consent of COOK. COOK shall not be required, in the course of such inspections to reveal any trade secrets to DISTRIBUTOR. DISTRIBUTOR agrees to work with COOK in order to assist its compliance with Section 351 of the Public Health Services Act as it applies to the End Cap Product and other applicable laws and regulations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">COOK makes no representation or warranty with respect to printed materials supplied by PURCHASER or its consignee.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">11.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Disclaimer of Warranties.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Except for those warranties set forth in Sections 11.1 and 11.2 of this Agreement, COOK makes no other warranties, written, oral, express or implied, with respect to Devices or the manufacture of Devices. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT HEREBY ARE DISCLAIMED BY COOK. NO WARRANTIES OF COOK MAY BE CHANGED BY ANY REPRESENTATIVES OF COOK. PURCHASER accepts Devices subject to the terms hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">11.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> PURCHASER Warranties</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. PURCHASER warrants that (a) it has the right to give COOK any information provided by PURCHASER hereunder, and that COOK has the right to use such information for the manufacture of Devices, and (b) PURCHASER has no knowledge of any (i) patents or other intellectual rights that would be infringed by COOK's manufacture of Devices under this Agreement, or (ii) proprietary rights of third parties which would be violated by COOK's performance hereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 12, LIMITATION OF LIABILITY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">12.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Limitation of Liability.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> PURCHASER's sole and exclusive remedy for breach of this Agreement is limited to those remedies set forth in Article 6 and at COOK's decision, in COOK's sole discretion, to either replace the non-conforming Device or reimburse PURCHASER for the Purchase Price for the non-conforming Device. Under no circumstances shall COOK be liable for loss of use or profits or other collateral, special, consequential or other damages, losses, or expenses, including but not limited to the cost of cover or the cost of a recall in connection with or by reason of the manufacture and delivery of Devices under this Agreement whether such claims are founded in tort or contract. The foregoing constitutes the sole and exclusive remedy of PURCHASER and the sole and exclusive liability of COOK. All claims by PURCHASER for breach or default under this Agreement shall be brought within one (1) year after the cause of action accrued or shall be deemed waived. Notwithstanding the foregoing, in the event that COOK was negligent in the manufacture of the Device and such</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">negligence results in a recall of the Device, Cook shall be liable for the actual out of pocket costs related to such recall.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 13, INDEMNIFICATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">13.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;PURCHASER Indemnification.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;PURCHASER shall indemnify, defend and hold harmless COOK and its directors, officers, employees, subcontractors, agents and Affiliates from and against any and all liabilities, obligations, penalties, claims, judgments, demands, actions, disbursements of any kind and nature, suits, losses, damages, costs and expenses (including, without limitation, reasonable attorney's fees) arising out of or in connection with property damage or personal injury (including without limitation death) of third parties (collectively "Claims") in connection with (a) PURCHASER's storage, promotion, labeling, marketing, distribution, use or sale of Devices or products incorporating Devices, (b) PURCHASER's violation of any regulatory rules, regulations or laws relating to the sale, marketing or distribution of Devices or products incorporating Devices, (c) PURCHASER's negligence or willful misconduct, (d) PURCHASER's breach of this Agreement, or (e) any claim that the use, sale, manufacture, marketing or distribution of Devices or products incorporating Devices by COOK or PURCHASER violates the patent, trademark, copyright or other proprietary rights of any third party, except to the extent any of the foregoing (a) or (e) is caused solely by the negligence or willful misconduct of the Indemnified Parties or solely by the breach by COOK of its obligations under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">13.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;COOK Indemnification.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;COOK shall indemnify, defend and hold harmless PURCHASER and its directors, officers, employees, subcontractors, agents and Affiliates from and against any and all Claims in connection with (a) Cook's violation of any regulatory rules, regulations or laws relating to the manufacturing of the Devices, (b) COOK's negligence or willful misconduct, or (c) COOK's breach of this Agreement, except to the extent any of the foregoing (a) is caused solely by the negligence or willful misconduct of the Indemnified Parties or solely by the breach by PURCHASER of its obligations under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">13.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Indemnitee Obligations.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;A party (the "Indemnitee") which intends to claim indemnification under this Article 13 shall promptly notify the other party (the "Indemnitor") in writing of any action, claim or other matter in respect of which the Indemnitee or other of its Affiliates, or any of their respective directors, officers, employees, subcontractors, or agents, intend to claim such indemnification; provided, however, that failure to provide such notice within a reasonable period of time shall not relieve the Indemnitor of any of its obligations hereunder except to the extent the Indemnitor is prejudiced by such failure. The Indemnitee shall permit, and shall cause its Affiliates, and their respective directors, officers, employees, subcontractors and agents to permit, the Indemnitor, at its discretion, to settle any such action, claim or other matter, and the Indemnitee agrees to the complete control of such defense or settlement by the Indemnitor. Notwithstanding the foregoing, the Indemnitor shall not enter into any settlement that would adversely affect the indemnitee's rights hereunder,&nbsp;or impose any obligations on the Indemnitee in addition to those set forth herein, in order for it to exercise such rights, without Indemnitee's prior written consent, which shall not be unreasonably withheld or&nbsp;delayed. No such action, claim or other matter shall be settled without the prior written consent of the Indemnitor, which shall not be unreasonably withheld or delayed. The Indemnitee, its</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Affiliates, and their respective directors, officers, employees, subcontractors and agents shall fully cooperate with the Indemnitor and its legal representatives in the investigation and defense of any action, claim or other matter covered by the indemnification obligations of this Article13. The Indemnitee shall have the right, but not the obligation, to be represented in such defense by counsel of its own selection and at its own expense.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 14, INSURANCE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">14.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;PURCHASER Insurance.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;PURCHASER shall procure and maintain during the Term of this Agreement and for a period one (1) year beyond the expiration date of Device, Commercial General Liability Insurance, including without limitation, Product Liability and Contractual Liability coverage (the "PURCHASER Insurance"). The PURCHASER Insurance shall cover amounts not less than ten million dollars ($10,000,000) combined single limit and shall be with an insurance carrier reasonably acceptable to COOK. COOK shall be named as an additional insured on the PURCHASER Insurance and PURCHASER promptly shall deliver a certificate of PURCHASER Insurance and endorsement of additional insured to COOK evidencing such coverage. If PURCHASER fails to furnish such certificates or endorsements, or if at any time during the Term of this Agreement COOK is notified of the cancellation or lapse of the PURCHASER Insurance, and PURCHASER fails to rectify the same within ten (10) calendar days after notice from COOK, in addition to all other remedies available to COOK hereunder, COOK, at its option, may obtain the PURCHASER Insurance and PURCHASER promptly shall reimburse COOK for the cost of the same. Any deductible and/or self insurance retention shall&nbsp;be the sole responsibility of PURCHASER.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">14.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;COOK Insurance</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;COOK shall procure and maintain during the Term of this Agreement and for a period one (1) year beyond the expiration date of Device, Commercial General Liability Insurance, including without limitation, Product Liability and Contractual Liability coverage (the "COOK Insurance"). The COOK Insurance shall cover amounts not less than ten million dollars ($10,000,000) combined single limit. COOK promptly shall deliver a certificate of COOK Insurance to PURCHASER evidencing such coverage. Any deductible and/or self insurance retention shall be the sole responsibility of COOK.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 15, RECALL OF DEVICE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">15.1 In the event PURCHASER shall be required to recall any Device because such Device may violate local, state or federal laws or regulations, the laws or regulations of any applicable foreign government or agency or the Specifications, or in the event that PURCHASER or COOK elects to institute a voluntary recall, PURCHASER shall be responsible for coordinating such recall. PURCHASER promptly shall notify COOK if any Device is the subject of a recall and provide COOK with a copy of all documents relating to such recall. COOK shall cooperate with PURCHASER in connection with any recall, at PURCHASER' s expense except as otherwise provided herein.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 16, INTELLECTUAL PROPERTY </font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">16.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Existing Intellectual Property.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;Except as the parties may otherwise expressly agree in writing, each party shall continue to own its existing patents, trademarks, copyrights, trade secrets and other intellectual property, without conferring any interests therein on the other party. Without limiting the generality of the preceding sentence, COOK shall retain all right, title and interest to its patents and trademarks arising under the United States Patent Act, the United States Trademark Act, the United States Copyright Act and all other applicable laws, rules and regulations (collectively, "COOK's Intellectual Property") that are incorporated in and related to all Devices. Without limiting the generality of the first sentence, PURCHASER shall retain all right, title and interest to its patents and trademarks arising under the United States Patent Act, the United States Trademark Act, the United States Copyright Act and all other applicable laws, rules and regulations (collectively, "PURCHASER's Intellectual Property") that are incorporated in and related to all Devices. Neither PURCHASER nor any third party shall acquire any right, title or interest in COOK's Intellectual Property or PURCHASER's Intellectual Property by virtue of this Agreement or otherwise, except to the extent expressly provided herein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">16.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Individually Owned Inventions.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;Except as the parties may otherwise agree in writing, all Inventions (as defined herein) which are conceived, reduced to practice, or created by a party in the course of performing its obligations under this Agreement shall be solely owned and subject to use and exploitation by the inventing party without a duty to account to the other party. For&nbsp;purposes of this Agreement, "Invention" shall mean information relating to any innovation, improvement, development, discovery, computer program, device, trade secret, method, know- how, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">16.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Jointly Owned Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;All Inventions which are conceived, reduced to practice, or created jointly by the parties and/or their respective agents (i.e., employees or agents who would be or are properly named as co-inventors under the laws of the United States on any patent application claiming such inventions) in the course of the performance of this Agreement shall be owned jointly by the parties. Each party shall have full rights to exploit such Inventions for its own commercial purposes without any obligation to the other. The parties shall share equally in the cost of mutually agreed patent filings with respect to all such jointly owned Inventions. The decision to file for patent coverage on jointly owned Inventions shall be mutually agreed upon. Patent counsel for COOK shall file and prosecute patent applications based on&nbsp;such</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">joint Inventions and, upon request in writing from PURCHASER, shall provide copies of all correspondence to and from patent office(s) to PURCHASER or counsel for PURCHASER and give reasonable consideration to comments received from PURCHASER or counsel for PURCHASER in such filing and prosecution.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">16.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Disclaimer.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;Except as otherwise expressly provided herein, nothing contained in this Agreement shall be construed or interpreted, either expressly or by implication, estoppel or otherwise, as: (i) a grant, transfer or other conveyance by either party to the other of any right, title, license or other interest of any kind in any of its Inventions or other intellectual property, (ii) creating an obligation on the part of either party to make any such grant, transfer or other&nbsp;conveyance or (iii) requiring either party to participate with the other party in any cooperative development program or project of any kind or to continue with any such program or project.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">16.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Rights in Intellectual Property.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;The party owning any Intellectual Property shall have the world wide right to control the drafting, filing, prosecution and maintenance of patents covering the Inventions relating to such Intellectual Property, including decisions about the countries in which to file patent applications. Patent costs associated with the patent activities described in this Section shall be borne by the sole owner. Each party will cooperate with the other party in the filing and prosecution of patent applications. Such cooperation will include, but not be limited to, furnishing supporting data and affidavits for the prosecution of patent applications and completing and signing forms needed for the prosecution, assignment and maintenance of patent applications.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">16.6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Confidentiality of Intellectual Property.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Intellectual Property shall be deemed to be the Confidential Information of the party owning such Intellectual Property. The protection of each party's Confidential Information is described in Article 17. Any disclosure of information by one party to the other under the provisions of this Article 17 shall be treated as the disclosing party's Confidential Information under this Agreement. It shall be the responsibility of the party preparing a patent application to obtain the written permission of the other party to use or disclose the other party's Confidential Information in the patent application before the application is filed and for other disclosures made during the prosecution of the patent application.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 17, CONFIDENTIAL INFORMATION, NONDISCLOSURE AND PUBLICITY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">17.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Confidentiality.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;It is contemplated that in the course of the performance of this Agreement each party may, from time to time, disclose Confidential Information to the other. Each party agrees to take all reasonable steps to prevent disclosure of Confidential Information to third parties. No provision of this Agreement shall be construed so as to preclude disclosure of Confidential Information as may be reasonably necessary to secure from any governmental agency necessary approvals or licenses or to obtain patents with respect to the Device.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">17.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Litigation and Governmental Disclosure.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Each party may disclose Confidential Information hereunder to the extent such disclosure is reasonably necessary for prosecuting or defending litigation, complying with applicable governmental regulations or conducting pre-clinical or clinical trials, provided that if a party is required by law or regulation to make any such disclosure of the other party's Confidential Information it will, except where impractical for necessary disclosures, for example in the event of a medical emergency, give reasonable advance notice to the other party of such disclosure requirement and will use good faith efforts to assist such other party to secure a protective order or confidential treatment of such Confidential Information required to be disclosed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">17.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Limitation of Disclosure.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The parties agree that, except as otherwise may be required by applicable laws, regulations, rules or orders, including without limitation the rules and regulations promulgated by the United States Securities and Exchange Commission, and except as may be authorized in Section 18.4, no information concerning this Agreement and the transactions contemplated herein shall be made public by either party without the prior written consent of the other.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">17.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Publicity and SEC Filings.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;The parties agree that the public announcement of the execution of this Agreement shall only be by one or more press releases mutually agreed to by the parties. The failure of a party to return a draft of a press release with its proposed amendments or modifications to such press release to the other party within five (5) days of such party's receipt of such press release shall be deemed as such party's approval of such press release as received by such party. Each party agrees that it shall cooperate fully and in a timely manner with the other with respect to all disclosures to the Securities and Exchange Commission and any other governmental or regulatory agencies, including requests for confidential treatment of Confidential Information of either party included in any such disclosure.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">17.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;Duration of Confidentiality.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;All obligations of confidentiality and non-use imposed upon the parties under this Agreement shall expire ten (10) years after the expiration or earlier termination of this Agreement; provided, however, that Confidential Information which constitutes the trade secrets of a party shall be kept confidential indefinitely, subject to the limitations set forth in Sections 17.3 through 17.5.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 18, FORCE MAJEURE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">18.1 Any delay in the performance of any of the duties or obligations of either party hereto (except the payment of money) caused by an event outside the affected party's reasonable control shall not be considered a breach of this Agreement, and unless provided to the contrary herein, the time required for performance shall be extended for a period equal to the period of such delay. Such events shall include without limitation, acts of God; acts of public enemies; insurrections; riots; injunctions; embargoes; labor disputes, including strikes, lockouts, job actions, or boycotts; fires; explosions; floods; shortages of material or energy; delays in the delivery of raw materials; acts or orders of any government or agency thereof or other unforeseeable causes beyond the reasonable control and without the fault or negligence of the party so affected. The party so affected shall give prompt notice to the other party of such cause and a good faith estimate of the continuing effect of the force majeure condition and duration of the affected party's nonperformance, and shall take whatever reasonable steps are appropriate to relieve the effect of such causes as rapidly as possible. If the period of nonperformance by COOK because of COOK force majeure conditions exceeds ninety (90) calendar days, PURCHASER may terminate this Agreement by written notice to COOK. If the period of nonperformance by PURCHASER because of PURCHASER force majeure conditions exceeds ninety (90) calendar days, COOK may terminate this Agreement by written notice to PURCHASER.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 19, NOTICES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">19.1 All notices hereunder shall be delivered personally or by facsimile (confirmed by overnight delivery), or by overnight delivery with a reputable overnight delivery service, to the following addresses of the respective parties:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;">
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">If to COOK:</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Cook Biotech Incorporated</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">1425 Innovation Place</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">West Lafayette, IN 47906</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn: President</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">If to PURCHASER:</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Axogen, Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">13859 Progress Blvd, Suite 400</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Alachua, FL 32615</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:162.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:188.85pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn: General Counsel</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notices shall be effective upon receipt if personally delivered, on the day following the date of transmission if sent by facsimile, and on the second business day following the date of delivery to the overnight delivery service if sent by overnight delivery. A party may change its address listed above by notice to the other party given in accordance with this section.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 20, APPLICABLE LAW</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">20.1 This Agreement is being delivered and executed in the State of Indiana. In any action brought regarding the validity, construction and enforcement of this Agreement, it shall be governed in all respects by the laws of the State of Indiana, without regard to the principals of conflicts of laws. The courts of the State of Indiana shall have personal jurisdiction over the parties hereto in all matters arising hereunder, and venue for such suit will be in a state of federal court for the City of Bloomington, Indiana.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 21, ASSIGNMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">21.1 Neither COOK nor PURCHASER may assign or transfer this Agreement or any of its rights or obligations hereunder without the prior written consent of the other party. Notwithstanding the foregoing, either party, without the consent of the other party, may assign this Agreement and all of its rights or obligations hereunder to a successor or an Affiliate, or in connection with a merger or sale of all or substantially all of the stock or assets of such assigning party to which this Agreement pertains; provided, that such assignee shall be obligated in writing to assume all of the assignor's obligations hereunder; provided that PURCHASER may not assign this Agreement, or its rights or obligations hereunder, to Boston Scientific or any of Boston Scientific's affiliates..</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 22, TAXES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">22.1 PURCHASER shall pay all national, state, municipal or other sales, use, excise, import, property, value added, or other similar taxes, assessments or tariffs assessed upon or levied against the sale of Device to PURCHASER pursuant to this Agreement or the sale or distribution of Device by PURCHASER (or at PURCHASER's sole expense, defend against the imposition of such taxes and expenses). COOK shall notify PURCHASER of any such taxes that any governmental authority is seeking to collect from COOK, and PURCHASER may assume the defense thereof in COOK's name, if necessary, and COOK agrees to fully cooperate in such&nbsp;defense to the extent of the capacity of COOK, at PURCHASER's expense. COOK shall pay all national, state, municipal or other taxes on the income resulting from the sale by COOK of the Device to PURCHASER under this Agreement, including but not limited to, gross income,</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">adjusted gross income, supplemental net income, gross receipts, excess profit taxes, or other similar taxes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 23, SUCCESSORS AND ASSIGNS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">23.1 This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their successors and permitted assigns.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 24, ENTIRE AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">24.1 This Agreement constitutes the entire agreement between the parties concerning the subject matter hereof and supersedes all written or oral prior agreements or understandings with respect thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 25, SEVERABILITY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">25.1 If any term or provision of this Agreement shall for any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if such term or provision, to the extent the same shall have been held to be invalid, illegal or unenforceable, had never been contained herein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 26, WAIVER AND MODIFICATION OF AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">26.1 No waiver or modification of any of the terms of this Agreement shall be valid unless in writing and signed by authorized representatives of both parties hereto. Failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of such rights nor shall a waiver by either party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Article 27, INDEPENDENT CONTRACTOR</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">27A COOK shall act as an independent contractor for PURCHASER in providing the services required hereunder and shall not be considered an agent or joint venturer with PURCHASER.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">IN WITNESS WHEREOF</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &nbsp;the parties have caused this Agreement to be signed by their duly authorized representatives as of the later date written below.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:44.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:43.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:49.18%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&#x201C;COOK&#x201D; </font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:48.32%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&#x201C;PURCHASER&#x201D;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:49.18%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:48.32%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:49.18%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">COOK BIOTECH INCORPORATED</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:48.32%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">AXOGEN CORPORATION</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:49.18%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:48.32%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="bottom" style="width:44.18%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Umesh Patel</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.98%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="bottom" style="width:43.34%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Karen Zaderej</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:44.18%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.98%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:43.34%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
				<td valign="bottom" style="width:44.18%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Umesh Patel</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.98%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
				<td valign="bottom" style="width:43.34%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Karen Zaderej</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:44.18%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.98%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:43.34%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
				<td valign="bottom" style="width:44.18%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">President</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.98%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
				<td valign="bottom" style="width:43.34%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">President and CEO</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:44.18%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.98%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:43.34%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:</font></p>
				</td>
				<td valign="bottom" style="width:44.18%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">29 Jun 17</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.98%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:</font></p>
				</td>
				<td valign="bottom" style="width:43.34%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">07-13-2017</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit "A"</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Device and Specifications</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">"Device"</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> means extracellular </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">matrix ("ECM") </font><font style="display:inline;font-family:Times New Roman,Times,serif;">tissue technology which, a provided in the Specifications, is comprised of Small Intestinal Submucosa (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">"SIS") </font><font style="display:inline;font-family:Times New Roman,Times,serif;">technology for use in the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Field </font><font style="display:inline;font-family:Times New Roman,Times,serif;">and in the form of a tubular cap closed at one end and open at the other, or in any other form agreed by the parties in writing during the Term to be added to this Agreement. </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">"Field" means </font><font style="display:inline;font-family:Times New Roman,Times,serif;">use in the peripheral nervous system and the central nervous system to cap off nerve stumps, and expressly excludes uses&nbsp;in the oral cavity for endodontic and periodontal applications and oral and maxillofacial surgery solely as they relate to dental, soft or hard, tissue repair or reconstruction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Specifications:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">As provided in Document Number: D00025721, Title CAPB-1LCHDFFTAG. Revision 1 attached hereto.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">***</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit "B"</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:49.54%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Device Purchase Price:</font></p>
				</td>
				<td valign="bottom" style="width:50.46%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">US$*** per unit</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex-21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 2/24/2020 2:33:04 PM-->
<html>
	<head>
		<title>
			axgn_Ex_21.1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">EXHIBIT&nbsp;21.1</font>
		</p>
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">SUBSIDIARY OF AXOGEN,&nbsp;INC.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2019, &nbsp;Axogen Inc. had three sole subsidiaries:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp; Axogen Corporation, a Delaware corporation;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">2.&nbsp; Axogen Europe GmbH, an Austrian corporation; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">3.&nbsp; Axogen Processing Corporation, a Delaware corporation.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex-23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 2/24/2020 2:33:05 PM-->
<html>
	<head>
		<title>
			axgn_Ex_23.1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-indent:14.4pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">EXHIBIT&nbsp;23.1</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We consent to the incorporation by reference in the Registration Statements of Axogen, Inc. on Form S-3 (File Nos. 333-224713, 333-220770 and 333-207829) and Form S-8 (File Nos. 333-227105, 333-222019, 333-218290, 333-211660, 333-201238, 333-177980, 333-230418, 333-233416 and 333-173539) of our report dated February 28, 2018, relating to the consolidated statements of operations, shareholders&#x2019; equity and cash flows for the year ended December 31, 2017 of Axogen, Inc. and Subsidiaries, which appears in this Annual Report on Form 10-K of Axogen, Inc. for the year ended December 31, 2019.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ LURIE, LLP</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Minneapolis, Minnesota</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">February 24, 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>ex-23d2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 2/24/2020 2:33:05 PM-->
<html>
	<head>
		<title>
			axgn_Ex_23.2
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit 23.2</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">We consent to the incorporation by reference in Registration Statements Nos. 333-224713, 333-207829 and 333-220770 on Form S-3&nbsp;and Registration Statements Nos. 333-227105, 333-222019, 333-218290, 333-211660, 333-201238, 333-177980, 333-230418, 333-233416 and 333-173539 on Form S-8 of our report dated February 24, 2020, relating to the financial statements and financial statement schedule of Axogen, Inc., and the effectiveness of Axogen, Inc.&#x2019;s internal control over financial reporting appearing in this Annual Report on Form 10-K of Axogen, Inc. for the year ended December 31, 2019.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">/s/ DELOITTE &amp; TOUCHE LLP</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Miami, Florida</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">February 24, 2020</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex-31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 2/24/2020 2:33:06 PM-->
<html>
	<head>
		<title>
			axgn_Ex_31.1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">EXHIBIT&nbsp;31.1</font>
		</p>
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION&nbsp;302 OF THE<br>SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">I, Karen Zaderej, certify that:</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">1. I have reviewed this annual report on Form&nbsp;10-K of Axogen,&nbsp;Inc.;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">4. The registrant&#x2019;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">a)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">b)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">c)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">d)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">5. The registrant&#x2019;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">a)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">b)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Date: February 24, 2020</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ Karen Zaderej</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Karen Zaderej</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex-31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 2/24/2020 2:33:07 PM-->
<html>
	<head>
		<title>
			axgn_Ex_31.2
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">EXHIBIT&nbsp;31.2</font>
		</p>
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION&nbsp;302 OF THE<br>SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">I, Peter Mariani, certify that:</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">1. I have reviewed this annual report on Form&nbsp;10-K of Axogen,&nbsp;Inc.;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">4. The registrant&#x2019;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">a)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">b)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">c)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">d)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">5. The registrant&#x2019;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
		</p>
		<p style="margin:0pt;text-indent:13.5pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">a)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">b)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 31.5pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Date: February 24, 2020</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">Ge</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ Peter Mariani</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Peter Mariani</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex-32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 2/24/2020 2:33:08 PM-->
<html>
	<head>
		<title>
			axgn_Ex_32.1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;line-height:100%;text-align:right;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">EXHIBIT&nbsp;32.1</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:right;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">CERTIFICATION PURSUANT TO SECTION&nbsp;906 OF THE SARBANES &#x2014;OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">In connection with the Annual Report of Axogen,&nbsp;Inc. (the &#x201C;Company&#x201D;) on Form&nbsp;10-K for the year ended December&nbsp;31, 2019 as filed with the Securities and Exchange Commission (the &#x201C;Report&#x201D;),&nbsp;I, Karen Zaderej, Chief Executive Officer and Peter Mariani, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 25.85pt;line-height:100%;text-indent: -11.45pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">1.<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 5pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:3pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 25.85pt;line-height:100%;text-indent: -11.45pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 25.9pt;line-height:100%;text-indent: -11.5pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">2.<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 5pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:3pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 25.9pt;line-height:100%;text-indent: -11.5pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">/s/ Karen Zaderej</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Karen Zaderej</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">February 24, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">/s/ Peter Mariani</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Peter Mariani</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Chief Financial Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">February 24, 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>axgn-20191231x10k0cc357003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 axgn-20191231x10k0cc357003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &F TT# 2(  A$! Q$!_\0
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M:E?.4TG22PSC<P+G\AP*V--\$:18@-+&;J0=6EZ?]\]*Z*.-(D"1HJ(.BJ,
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MVJ:A;ZQ,DMK<6, DSU^4Y(QUQ^'2L7QWI^KQ>-X/%$L7B;3]/OM/C!?1?]?
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M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M9.JZI-IUW:A(/.A<,90O+@#'*COC/3\JTH)XKF%)H9%>-QE64\&LK5_^0G9?
M[DG]*II)-I4SW%NK26[G=-;@9Y_O)[^H[_7KKR7BK$<UF=+145O<0W4"3P2+
M)$XRK*>#4M9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?VS?_P#0,B_\"O\ [&FT4<L>P7?<=_;-_P#] R+_ ,"O_L:/[9O_ /H&1?\
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M_GF?^^V_QH_L^V_YYG_OMO\ &CV?F',=-17,_P!GVW_/,_\ ?;?XT?V?;?\
M/,_]]M_C1[/S#F.FHKF?[/MO^>9_[[;_ !H^P6P.0C ^HD8?UH]GYAS'345S
M!M'3)M[^]@8]UF+@?\!?</TJQ'?:M;X#-!>(/[R^6_YC(/Y"DZ;Z#YC?HK,M
M-;M;B86\H>UN3TCF&-W^ZW1OP.?:M.H::W*3N%%%%( HHHH **** "BBB@ H
MHHH BNK=+JUEMY!E)$*G\:XCP%.]IJ&HZ3(>48L ?4'!_I7>5P3C^S?BBI&
MESS_ -]+_P#%"N[">_3J4O*_W'EX]>SK4:ZZ2Y7Z2.]HHHKA/4.:\>,1X7E
M[R(#^=00QB+P1I2@8S);M^<@/]:F\>_\BQ)_UU3^=-_YDO2?K:_^A+7>O]UC
M_B_0\M?\C";_ +B_-ENBBN6\:Z]JFBQ:5%I"69NK^]6U#7BLR*"K'.%(/:L&
M['>E<ZFJ6K:19:W8FRU"'S;<LKE=Q7E3D<@@]17-:+XV MM8'B22QM'TF<03
M7,#GR9"1D;<\Y[8Y-:L7C/PY/I2:I'J]LUDTHA\T$X5ST5NZGZXHN@LRQ=>&
M])O=2DU"XLUDN);8VLA+'#Q$YVE<X/Y57T[P?H>EI.EM9L4GC,3K-,\HV'JH
MW$X'L*I#QC;SZW9BUO+)](FLI;IY3O\ ,.PXRO&-HYSW]*N:?XS\.:M?BPT_
M5[:>[:/S%B4G)&,\9[XZCJ.]&G]?/_@AJ,M_ _AZVL+BQ73]]M< !XY97D&
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MNM/6Z<KL#B/ R[Y;&<GH":V(/"BP0>(HOMA8:S([D^7CR=R!,=?FZ9[5F+X
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MW2K:PNBEJSQ2789"$<#/*YW >A(Q535_ 3:M?6#OK#I9VGEGR1:QE\ICE9,
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M31.X^BBBH&%%%% !1110 4444 %<%XK7R_&^C3+P2T0S])/_ *]=[7!>-/\
MD:='_P!Y?_0Q7=E_\:WD_P CR\W_ -VOYQ_,[VBBBN$]0YGQ[_R+$G_75/YT
MTD#P5I)) &;7D_[RT[Q[_P BQ)_UU3^=:&APQ7'AC3XYHTD0V\>5=00>!V-=
MU[86+_O/\CS(ZYA/_ OS95\Z+_GHG_?0KD_''A\>)QHL&RWGM;>_6:YCD< &
M/:P/UZBO0/[)TW_H'VG_ 'Y7_"C^R=-_Z!]I_P!^5_PKF<TST%%H\R\6^"K:
M\\/V-EH,-K;K8W:W(MDE, EP""-Z\JW/#5D_\(3<R:*L:V-O;33:I;W4\,FH
MM=%D0_,6=\9..P%>Q_V3IO\ T#[3_ORO^%']DZ;_ - ^T_[\K_A0II._]=/\
MAV9YEXPTJ>75YM8C:'['!HMU;N=XR&89&!6%X2T?5=5M?!MU<0:?:6&E6_G)
M-%-NDGWI@ K@;>O/)R:]I;1]+=2KZ;9LI&"# I!'Y4D>BZ5%&L<>F62(HPJK
M H 'L,4E)+^O7_,&FU_7DOT/)+7P=?P>%=(L=MJ+NVUL7TI$J_ZL2ELY[G:1
MQ54>!;M-?N1+:Q7EI/??:UN6U:2)4&X'#0@89ACK]*]G_LG3?^@?:?\ ?E?\
M*/[)TW_H'VG_ 'Y7_"GSK^OE_D#3?]>O^9YM#X?U"&W\7^1-;076J3E[64L&
MXV #/IR#6'HOA'5X+O4;FYBC@-SI4EH%DU-KIC*>ARP&T'T' KV7^R=-_P"@
M?:?]^5_PH_LG3?\ H'VG_?E?\*3E%_=;\+!9_J>?W.C74OPO?05:'[<=.^SA
M?,&W?MQUK*UWPIJ%Q+I$NG26V/\ 1EU"-Y /]405=?4CYE]\CTKU7^R=-_Z!
M]I_WY7_"C^R=-_Z!]I_WY7_"G[17YB>32QXSJ7@6[E\2:I+]FCO[/4;@3B5M
M6D@6+IP\2C#X(X_"NG\/:')IWBKQ)J%R+?R+]X?(8."2JQ[6!].:[_\ LG3?
M^@?:?]^5_P */[)TW_H'VG_?E?\ "E&44K%--GD&B^"-0CU.[BU"Y@33K2VN
M+72RD@+*)6)+$=B!@4WP=X+NM(U737O[*%3IRLJW?]K22A\J5RD)&$SGFO8?
M[)TW_H'VG_?E?\*/[)TW_H'VG_?E?\*:FE_7]=P:;.'\:Z9/KFE6=O9-"TD5
M_!.VZ0+\B-DU#KFD7-]XPTO4X/LSV]O9W,,@DDX+.!M!'4CCFN^_LG3?^@?:
M?]^5_P */[)TW_H'VG_?E?\ "ESK^O2P6?\ 7WGD6F^&M6ATO5;2:QM%L)(5
MBM],DU$RKD-DE9-H*+CH.<'%1MX9\1RZ%;/)+;27EGJL=];VDUV'/EI_RS:;
M:,GT)'2O8?[)TW_H'VG_ 'Y7_"C^R=-_Z!]I_P!^5_PIJ:6O]=Q<K/&KOP=K
M>L6WB.2\^QVUQ?W5O<PQ171*D1CE"X (],XZUTG@GP_/I,U]>W.G?8I;E8U(
M;4I+QV"YY+,!@<\ 5Z#_ &3IO_0/M/\ ORO^%8&C #1;, 8 A7C\*J#3V$T]
MB]5=WFN;@V5D5\_ +R$96$'N?4^@[T,T]U<&SLL>;QYDI&5A4]SZGT']*W+*
MRAL+?R80<$[F8\L[=R3W-$I<H)7"QL8;"#RHLDD[G=CEG;U)]:P+V[MK;Q%>
MB>XAB)BB(#N%S][UKJ*:T:,<LBD^I%9QE9W935T<S_:FG_\ /_:_]_E_QH_M
M33_^?^U_[_+_ (UTODQ?\\D_[Y%'DQ?\\D_[Y%5[1=A<IS7]J:?_ ,_]K_W^
M7_&C^U-/_P"?^U_[_+_C72^3%_SR3_OD4>3%_P \D_[Y%'M%V#E.:_M33_\
MG_M?^_R_XT?VII__ #_VO_?Y?\:Z7R8O^>2?]\BCR8O^>2?]\BCVB[!RG-?V
MII__ #_VO_?Y?\:/[4T__G_M?^_R_P"-=+Y,7_/)/^^11Y,7_/)/^^11[1=@
MY3FO[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :Z7R8O^>2?]\BCR8O^>2?
M]\BCVB[!RG-?VII__/\ VO\ W^7_ !H_M33_ /G_ +7_ +_+_C72^3%_SR3_
M +Y%'DQ?\\D_[Y%'M%V#E.:_M33_ /G_ +7_ +_+_C1_:FG_ //_ &O_ '^7
M_&NE\F+_ )Y)_P!\BCR8O^>2?]\BCVB[!RG-?VII_P#S_P!K_P!_E_QH_M33
M_P#G_M?^_P O^-=+Y,7_ #R3_OD4>3%_SR3_ +Y%'M%V#E.:_M33_P#G_M?^
M_P O^-']J:?_ ,_]K_W^7_&NE\F+_GDG_?(H\F+_ )Y)_P!\BCVB[!RG-?VI
MI_\ S_VO_?Y?\:/[4T__ )_[7_O\O^-=+Y,7_/)/^^11Y,7_ #R3_OD4>T78
M.4YV*_LYY!'%=P2.>BI("?RJQ4FM1HKV)5%!\X]!_LFH)94AB:21@J*,DGM5
MIW5R6K"R2)%&TDC!4499CT HL;!]1D6ZO(RMJN## W5S_><?R'XGT"V.GO?R
M+=7L92W4AH;=^I/]YQ_(=NO7IO5$YVT148]6%<G]NM+?5M52:Z@C?[2#M>0
M_P"K3UKK*88HV.612?4BIA+E')7.:_M33_\ G_M?^_R_XT?VII__ #_VO_?Y
M?\:Z7R8O^>2?]\BCR8O^>2?]\BJ]HNPN4YK^U-/_ .?^U_[_ "_XT?VII_\
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MI?)B_P">2?\ ?(H\F+_GDG_?(H]HNP<IS7]J:?\ \_\ :_\ ?Y?\:/[4T_\
MY_[7_O\ +_C72^3%_P \D_[Y%'DQ?\\D_P"^11[1=@Y3FO[4T_\ Y_[7_O\
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M<9<J9+5Q;*R@L+<0P+@9W,Q.2['J2>YJQ114;E!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 8OB&:.!+.65PB+,22?]TTRP
MTY[V1;R]1EB4[H+=A^3./7T';Z]->>U@N6B:>)9#"_F1[AG:W8_6IJOGM&R)
MMK<****@H**** "BBB@ KSKQ-XUUVQ\<2:!I<WARUCCM([@RZQ,\>\LQ&U2I
MYZ>E>BUY?XH\.:L_Q%EUN+P98>([*2QC@1;NXA3RG5F)(#JWJ.U'5#Z,ZZ\\
M::#HNVWUO6;"UO4CC:6/S"!EAP5SR1D&G:IXX\,Z*]NFHZU:VYN8Q+#N8GS$
M/1@1VKGCX6U"\\4^(-4NM,@2*_T6.UA4NC[9-K;D^G(&> :QK[0_&$.@>%M&
MC\/QZAIUC;1M?6POXX?-F7[J,3G*@C/'7\*%KO\ UO\ Y?B+^OR_S/1?^$ET
M;['>W9U&$06+[+ER3B)N.#^8_.J=WXZ\+6%RUM=Z[903JZHT<DFU@6 (X^A'
M-<#XHT"YOOB7I^E0&.&QUQ(KO5+=2"1]GY[=C\JY]JT-3\$ZI=-\0W2QA9]8
MAB2P8NF7VQX(Z_+\V.N*.E_ZT_IAUM_6IW&G^*=!U6ZNK:PU>TN)K4;IUCE!
MV#U/M[TFD>*] U^YFMM*U:UNYX/]8D3Y([9]Q[BN+U/P)J-]JD*VT,5K;GPV
M^FM*K* DQ*D# YQP>0*C\ >#]8TO7+>[U?3KB V5JUM'/-K378?.!^[C*_(O
M&<$\<<4[*_\ 7G_P/O%TO_73^OD:/C+Q!XUT+6+./38- DL+^[CM+8W)F\T.
MPZOMX SGIGC%;EEXHMK5X-+U_4M,BUTE4DM[9VV[FR5"[N>0*B\8Z-?:O<>'
MGLHA(MGJL5S/EPNV-<Y//7Z"J5KX7O#X]\4:I-$L=OJ%E#;VUR&!<$*P? ZC
MM]<4EM]_Y(>[^[\S;L/%WA[4]5ETNQUBSN+Z/.Z&.0%N.N/7\*9;^-/#5WJD
MNF6^M6<M[$"7A23)&!D_7 ]*\Z\&?#[7M)U72H]2L9/+THN8KQ]9>6$DJPS%
M;[?ESD9R1WINB>"O&*>+]%OM4@D,.GWDKR2G4]\3(RL 8H, 1CD ]SZ4[:I!
MT9VNB_$WPKK=C>7<&I)%%9OB;SN-J[MH?C/RD]/Z5:;XA>$%BFE/B+3]D+B-
MR)@<,>GU_"N,O?"GB>;P9XE\-#2H62>[:XL[D72_OP\NXJ5.-N!W)YKH+CPG
M,_C#4=0CT^W^S2:)]B@;"#$F3\H'4#&/:ETO_6U_^ #^*W];_P!,Z#4_%6@Z
M-8V][J.K6MO;7 !AD>3B0'H1ZBF7OC#P[IUM;W-YK-G#!<QM+!(T@VR*N,E3
MWZBO-[[P%XCBT_PQ<VUM<3W%AIOV*XM+35?L4BDX.1( 01Q@COQ6YI?@F]L=
M6\'RFQC6VTR*Z\]6N/.,3R$%<,P!8]>0*=M;?UU!&SJ_Q+\+:-9:;>3:DDMM
MJ,FR&2$AA@?><\C"CC/?D<5H^(?%VD>&O#G]NWTY-FP4Q^6,M+N&0%SCDCGF
MN*?P?K]IX9"V>GPR7EKXA?4X;4SJ@EBW-@!N0IPV>:['Q7IE]X@\#:AI\,4<
M5]=6N%C9\JK\';N^O&:E_"VOZT';WK?UN8VM>./#D5EIFMOJD"V$\<IBDSRY
M! ( ZDY&*U_#T,.JPP:X\T=P)!NMEC<,D2GOQP6]3VZ"N8NM-\5IJFB>)X_#
M=K=7UM8O9S::]^H,)W<.DA7:<CK^5=)X$T"[\.^'3;7WDK<S7$MS)'"<I$78
MML4]P,UKS:-+^M2+;,Z:BBBLR@HHHH **** "BBB@ HHHH **** "L[5M-%[
M")8L)>0@F&3^:GU4]Q]#VK1HIIV=T#5SG+6<7-LDP!&X<J>JD<$?@<BIJ@\L
M6^L:A OW69;A5]-XP?S96/XU/709!1110!+X?<K'>6IS^XN#MS_=8!Q^I(_"
MMBL+204UZ]YXDMH3CW#29_F*W:QJ?$7'8****@H**** "BBB@ K@O&G_ "-.
MC_[R_P#H8KO:X+QI_P C3H_^\O\ Z&*[LO\ XWR?Y'F9O_NWSC^:.]HHHKA/
M3.9\>_\ (L2?]=4_G6OH7_(OZ;_UZQ?^@"LCQ[_R+$G_ %U3^=:^A?\ (OZ;
M_P!>L7_H KLE_ND?\3_)'FP_Y&$_\*_-E^BBBN,](**** "BBB@ HHHH ***
M* &USVK>,-+TFX%O-)NE[A>U;TK;8F.<8%?.'B6_D@U^^,JEW:0X/MFID^6-
MTCMR_"PQ-5PG*R2N>U:;X[T?4;P6JR%)6.%W=ZZ@8(&.E?*,&HS7&K6 A1E=
M)UY!]Q7U-82>980/G)*#-.+<HWL3C\/3P];DINZ:OJ6<48]J6BF<@F!Z4;1Z
M"EHH 3:/04;1Z"EHH 3:/04;1Z4M% !1110 4444 %%<1XEUCQ$?'.F^'M$O
M+*T6XLI+EY;FV,W*L!@ ,OK4FA^-MMKK$7B9K:RNM'G6&XEC)\N0,,HRCKSZ
M=<T+:_\ 6]@>]CLZ*YNV\>^&KO3;Z_BU'$%BF^Y\R"2-XU[$HRAL>^*FTGQI
MX>UR\FM-/U%99H8_-96C= 4_O*6 ##W&: -ZBN<T[QYX:U;4ET^RU,27#DB/
M,3JLN.NQV4*_X$U8T;Q=H?B&ZEM]*O3<21 E\0NH7#;2,D 9SVSGOTH VZ*\
MMN_&NJR?$/5M"7Q'HNDPVLT,5O#=VQ>2?>BD@'>.<G'3O4MWXOUBTUOQ?#_:
M5I##I]S916WVJ%BD8D'S#]VI8DGIG./:FE=7_KI_F$O=W/3:*YC6/B%X8T&^
M>RU#4'2X0JKK%:RRA6/0$HI )]"<USGB_P 8ZGI^D^*IK+4K1&TZ2T$/EPMY
MD*R%-WF;UVG(8XQG ]#2&E=V/2J*XV?Q]I-YX?U>72-6MQ?V%FT[&ZAE5$P.
M'(VY9,]U!]JPI_&.L1:]<(-3M%MT\,KJ 9X6\@3%@/,X7S-N.WZ9IV_K[W^@
MOZ_+_,]/HKB(OB-I\'B'3M!O!(]S<V,=PUS!!*8R[;< #9G!SG)X'0X-;<?C
M#0IK"RO8[[?!>W/V2W(B?+RY*[=N,CD'J !19B3ZFY16/K?BG1O#LUO%JMYY
M$ERKM"OENY?9C=C:#SR..I[56'CGPV=#761J:&R>0Q*PC?>7'\'EXW[O;&:0
MSH:*YT^._#2Z.FJMJB+9O.+;>T;@K(>BLN,J?J!6E%J!U71?MFCNC-*A,#7$
M;HN>F2I ;% &A17">&O$?B&?QCK?AS4FL;Q[&W2:.ZMXVB0,W2-AEL'_  JU
MX/\ $&L:IXA\2:9JQM"=,GCCC-LA489 QZG)Z]::5_S [&BN0\1>(-5/BBS\
M,:";:*^FMVNIKFY0ND,8.!\H(W$G/<=*Q/$?B+Q7HVL>'-$?5-'M[C4/M'G7
MLENQCP@4J=I<8)R>,FDM1V/2J*\XUKQ%XAM-8T/1X->T:%[JSEGGOY;;,3E2
M,;1Y@P"#ZFNB\"^(+OQ)X:6^O8HDG6:2$O#GRY0C8WKGL:=KBV.EHHHI %%%
M% !1110 56OK^TTRS>[OKB.WMTQNDD;"C)P.?K5FN3^)-U)9^!;^>)8F=6CP
M)8ED7F11RK @_E0P.D%G9M>"_%M ;HQ^6+CRQOV==N[KCOBK%>7ZQJGB>XUO
MQ/#IVO?8+;2;&&YAC6UC?<QC+$$D?=./KZ8K%\8_$'Q#%;V?]D7;17*:3'J%
MRJB!$^8'O+DOT^Z@S[TK_P!??_DP2O\ UZ?YGM5(S*BEF("@9)/85Y7_ ,)?
MJ^L:KHU@VN0:#%-HR:C)<&)&\^0D H-_ 4=3CFEL4O$^*VLR2>)&9&TZ&9;<
MQ1!+A2KX49&<#KQSSSFJ::_'\/\ A@3O_7]=STRQO[34[..\LKB.XMI,[)8S
ME6P<'!^HJQ7DFD>++S0?#OA/5;R>*/1[F&XANHXX(XT60%F1AM QG:1@<<U0
MU;QGXJ@T'1(8K^9=7U"VEOW51;1!(MV57?*-O ., $GUI/3^OZ[ M3VJBO#(
MM6U7Q'J7PZUF\UUM/EO(KD.Z1QA%=002-PQE@,8/3M4DGCKQS=^*KW["MNME
M::C]D^SRW-M&I0, =RN1(6(Y!!QST-5RZV_K>PKZ7/:;N[MK"V>YNYXX($&6
MDD8*H^I-9EIXM\/7VF3ZE:ZS92V4!Q+.LHVI]3VKF/B<R+)X7:^ _L@:JAO2
M_P!P#:=F[VW8ZU8\76>@>(M#>TM=:TVQN!/#(EPI1E\Q<LBN,\CAN#4]+_UT
M'U-X>+_#K:(VLKK-F=-1MC7(E&P-G&"?7-3Z3XAT?7H'GTK4[6\BC^^T,@;;
M]?2O&_%&OWFK_#S7+.YMM.^VZ?JMK"UU9?\ 'O<G>I#9Z^@/I6IXG\*^(;/P
M[XI\1W#6B:C>V4=NUKI0;8L2L-S98 LQ7/;I3\_ZV3_4.J7];GH]MXS\-7FI
M_P!FVVN6$M[G A28%B?0>M;E>6MXGL]-U#PQ8Z-9^'KK0KV:*"W,3DW$+;2=
MQ3&!C'7.<UZE0T),****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH Y
MZZ_Y&2[_ .O6#_T*6I*CNO\ D9+O_KU@_P#0I:DKH6R,GN%%%%,!=-_Y#LO_
M %[+_P"A&MRL/3?^0[+_ ->R_P#H1K<K&I\1<=@HHHJ"@HHHH **** "N"\:
M?\C3H_\ O+_Z&*[VN"\:?\C3H_\ O+_Z&*[LO_C?)_D>9F_^[?./YH[VBBBN
M$],YGQ[_ ,BQ)_UU3^=:^A?\B_IO_7K%_P"@"LCQ[_R+$G_75/YUKZ%_R+^F
M_P#7K%_Z *[)?[I'_$_R1YL/^1A/_"OS9?HHHKC/2"BBB@ HHHH **** "BB
MB@".1 Z,IZ$8KRGQ-X/L]0O+F25VCEC4E"!U^M>L&N2UYDENIE7!^0Y(JXI-
M-,*=25*K&<-SA/#O@VULI+:4/YEQ,PW9'0>U>QVT*V]M'$/X1BN,T8QQ7-IN
MZ$=37< @@$=*J>D4D*<Y5*SE/<<.E% Z45D,**** "BBB@ HHHH **** "BB
MB@#BO$F@^(Y/&VG>(=!73)?LUG);/%?321Y+,#D;4;TK/F^'NIW&CW\TVH6S
MZ[=ZA%J#/L80;H\;(\==N._7FO1:*%I_7G?\P>O]?(\VO_!'B'7;;Q#>:G+I
MD.IZCIZV,,5L[F%%#;LLQ4$DGVXK7N_!US>:U;7#2PQVRZ+)ITA1B'#-CE>.
M@P>]=E11TM_77_,//^NG^1YSI?@SQ&TOA^TU>;2ET[0I!)!):%S+.0I4;@0
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MJT_!FCZGH&AG2M1GAGCMIG6TD1B6,&<H'R!\PSCOP!S7144(&%%%% !1110
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M*[LO_C?)_D>9F_\ NWSC^:.]HHHKA/3.9\>_\BQ)_P!=4_G6OH7_ "+^F_\
M7K%_Z *R/'O_ "+$G_75/YUKZ%_R+^F_]>L7_H KLE_ND?\ $_R1YL/^1A/_
M  K\V7Z***XST@HHHH *#12,0JDGM0!%<3+#$6)Y[5AW-PX.?XFZFK-S<B1F
MD<_NTX ]345E:O>2^=+PE:)6,6[Z_<3Z3:!5\TJ0"<C-:K#<C+ZC%"J%  &
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M.-Q'(R.I->KO%')C?&K8Z;AG%*T:. '16 Y (S3O_7W@CPVXU_4;KP9+=_\
M"37%JG]MW1 FNI('GA#?+$LN"8R,C"\9Z5ZYX5O6U'PKI=XZW*M+;HQ%UCS>
MG5L=3[]ZU3#$R[3&A&<X*CKZT_&!@4=+>GY ]7<****0!1110 4444 %%%%
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MRT=XJ?<^W1'_ &7)KKPTHTY<[LWYG#BXRJQY(W7I;_ASI\8]J4#UK &IW/\
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M7B+QGX+U#39YDL[JUOBT9;&2J8Y .#@CK1OM_5@VW/3&M+=YTG>WB:5.%D*
MLOT/:@VEL=V;>([GWM\@Y;U/O[UY;X/\;G1/ 7AV"6UN=2U"_>X\M?.12P65
M\_-(P!..@SDUZI;R^?;QR^6\>]0VQQAESV/O5-6;$G<Q_$_AJ#Q)HUQ8&=[.
M28HQN(44ME#E=P(PPSV-4/"G@H>'+Z[U&ZU)]0U"Z18GE^SQVZ!%S@!(P!WZ
MUU=%2M!O4C-O TZSM#&9E&%D*C<!Z ]:;%9VT$KR0V\,<C_?9$ +?4CK4U%
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ME[_;&G_98Y/*>?[2FQ7SC:6S@'/;K1TM_78?]?J8FA>#;JRU<ZMKFNRZS>K
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M[987#J<'!P1QU!%3TVWK<04444AA1110 445BZ_J\]C;2PZ=")]0,32(AZ*
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M"P4Z<^:IT.V'' I:**\P]<**** "N"\:?\C3H_\ O+_Z&*[VN"\:?\C3H_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJG\ZU= ;=X=TT_\ 3M&/_'179+_=(_XG^1YL/^1A/_"OS9HT445QGI!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ_\  ^\UO''CW2_#^EZK9PZK'#K<=E)+ @C+['VDIN."H).,!NOO4M]XCO\
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M1C+_  +\V:E%%%<1Z04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBMX8X8Q_#&H4?D*EHH *@FL;2XF2::U@DE3[KO&"R_0GI4]% !1110 4444
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M<21]X%CZY-9>O>._$OA_2[*&2UTR]U:\G*QG3XI9XU38&YC!WD_0^_M1+1M
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2^6[6-E#P^8NU2I^;MW Z\]*AL/B!+!/X<TZ739C%J%G!)]MN[M5+,ZCA3L
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MH\G3[7JW8J#R?Q->BJH50JC  P!7?7_<4%1ZO5_HCR<*_K6*EB?LQ]V/ZO\
M06BBBN ]8**** //_$NF7'A[5TU[3!B,MF5,<*3US[&NQT?5K?6;!+JW/7AT
MSRC>AJY-#'<0O#,@>-P596'!!KSV_P!/U#P7J9U#3MTE@YPR$Y 'HW]#7HP:
MQ4%3D[36S[^1X]2,L!5=:"O3E\2[/NO+N>BT5FZ-KEGK=J);9\.!\\3?>0_Y
M[UI5P3A*$N62LSU:=2-2*G!W3"BBBI+"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E-7\(7,WB!M>T+5
MSI6I2PB&X+6XGBF4?=W(2.1V.:PKCX4FX\/QV,NLI+=#4FU*26>R62&21@=P
M:$M@KR<#/%>D44?U^H[_ -?@><VGPJ6STF&PCU5 L>M)JV4LPB_+UC"JP"CT
M(Z#M6I?^ S??\)?_ ,3+9_PD,4<?^HS]GVILS][YL]>U=E7,:IXYT_3=;?24
MLM2O[F%5>Y^PVWF+;*W0N<CKZ#)]J-_=[_\  _R0:[_U_6I##X),6JWU]_:&
M?M6DIINSR?N[01OSNYZ]/UJ*V\!_9QX5!U(D:#;R0$B'!GWQ[,CYOEQU[UU"
M:C9R:@^GI<1F\2(3-#GY@A. Q'IFK5.[_KY_YLE)+1?UM_DCS70/A,NAZ]IN
MI#4[:3^SY9'39IR1RRJX88DE#9<C=U/ITKK-9\-?VOXCT+5_M7E?V4\K>5Y>
M[S=Z@=<\8QZ&KVN:O%H6CW&I36UU<I  3%:Q[Y&R0.!D9ZU@S^/8+;5-;M)-
M,O)%TJW@G8VX\R27S<\!.,$8]:6^G8=NI!'X \OP#>^%_P"TL_:9GE^T^1]W
M=)OQMW<^G6F^*_AZOB;4-/O/MMNAM8#;M%=6*7*,IQEE5CA6XZ\UVRMN0, 1
MD9P>M+18/,X&W^&]QIUGH']EZZ;:_P!(BD@6X:U#K+$YR5*;N#QP<_A19_#5
MK6+34;66F:SUE]5:1[< RE@<H<-@?>Z_I74W?B&PM]+U&_A,EZNGEDGBM%\R
M0.H!* ?WN1Q[UH6MP+JTAN%1T65%<+(,,N1G!'8T[O?^NX>7]=CS2#X/1P:Y
M!J"ZM 1!J8U%"VGIY[?-N*/-NW,/3T]#6M<?#ZZEM/$]A'K833]<9Y?):T#-
M!*X4%MVX;A\O3 ^M=U12Z<O3_AO\D'6YQ%SX$U"&_:]T3Q!_9\T]G%:7>^T$
MRRK&,!E!8;6Y/K4^C^ +70]4T>ZL[MO)TVPELQ$Z9,A=@Q<MG@YSQCO7844[
MO^OZ\Q)6_K^NQB^%?#__  C.AC3?M/VG$\LOF>7L^^[/C&3TW8K:HHI-W&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M$X&3TH *XGQ?X@>:0:'IF9)Y3ME9>W^R/ZT[Q'XN;S/[,T4F:Z<[6D09VGT7
MU/O5WPKX6724^V7F'OY!R2<^6#V^OJ:]"C2CAX^VK;]%^K\CR,17EBYO#8=Z
M?:EV79>9>\-Z&FAZ8L)PUP^&F8=SZ#V%;-%%<52<JDG*6[/3I4H4H*G!62"B
MBBH- HHHH *;)&DL;)(H9&&"K#((IU% '"ZMX/NM/N?[1\/R,CJ<F$-@C_=]
M1[&IM*\=*)!::U"UO,O!E"G&?<=17:5G:IH>GZO'MN[=6;M(O##\:[HXJ-1<
MF(5_/K_P3RYX"=&3J8.7+WB_A?\ E\BY;W,%U$);>5)4/1D;(J6N#F\$ZGIL
MIGT34F!'1&8J3^/0_C3!XC\5:7\NH::9@O5_+QG\5XH^IQGK1FGY/1B_M&=+
M3$TW'S6J^]'?T5Q$?Q&@4[;G3ID/^RP/Z'%6!\1=)[V]X/HB_P#Q50\!B%]D
MT6;8-_\ +Q?B=?17(_\ "Q-'_P">%[_W[7_XJC_A8FC_ //"]_[]K_\ %4OJ
M6(_D97]J8/\ Y^(ZZBN1_P"%B:/_ ,\+W_OVO_Q5'_"Q-'_YX7O_ '[7_P"*
MH^I8C^1A_:F#_P"?B.NHKD?^%B:/_P \+W_OVO\ \51_PL31_P#GA>_]^U_^
M*H^I8C^1A_:F#_Y^(ZZBN1_X6)H__/"]_P"_:_\ Q5'_  L31_\ GA>_]^U_
M^*H^I8C^1A_:F#_Y^(ZZBN1_X6)H_P#SPO?^_:__ !5'_"Q-'_YX7O\ W[7_
M .*H^I8C^1A_:F#_ .?B.NHKD?\ A8FC_P#/"]_[]K_\51_PL31_^>%[_P!^
MU_\ BJ/J6(_D8?VI@_\ GXCKJ*Y'_A8FC_\ /"]_[]K_ /%4?\+$T?\ YX7O
M_?M?_BJ/J6(_D8?VI@_^?B.NHKD?^%B:/_SPO?\ OVO_ ,51_P +$T?_ )X7
MO_?M?_BJ/J6(_D8?VI@_^?B.NHKD?^%B:/\ \\+W_OVO_P 51_PL31_^>%[_
M -^U_P#BJ/J6(_D8?VI@_P#GXCKJ*Y'_ (6)H_\ SPO?^_:__%4?\+$T?_GA
M>_\ ?M?_ (JCZEB/Y&']J8/_ )^(ZZBN1_X6)H__ #PO?^_:_P#Q5'_"Q-'_
M .>%[_W[7_XJCZEB/Y&']J8/_GXCKJ*Y'_A8FC_\\+W_ +]K_P#%4?\ "Q-'
M_P">%[_W[7_XJCZEB/Y&']J8/_GXCKJ*Y'_A8FC_ //"]_[]K_\ %4?\+$T?
M_GA>_P#?M?\ XJCZEB/Y&']J8/\ Y^(ZZBN1_P"%B:/_ ,\+W_OVO_Q5'_"Q
M-'_YX7O_ '[7_P"*H^I8C^1A_:F#_P"?B.NHKD?^%B:/_P \+W_OVO\ \51_
MPL31_P#GA>_]^U_^*H^I8C^1A_:F#_Y^(ZZBN1_X6)H__/"]_P"_:_\ Q5'_
M  L31_\ GA>_]^U_^*H^I8C^1A_:F#_Y^(ZZBN1_X6)H_P#SPO?^_:__ !5'
M_"Q-'_YX7O\ W[7_ .*H^I8C^1A_:F#_ .?B.NHKD?\ A8FC_P#/"]_[]K_\
M51_PL31_^>%[_P!^U_\ BJ/J6(_D8?VI@_\ GXCKJ*Y'_A8FC_\ /"]_[]K_
M /%4?\+$T?\ YX7O_?M?_BJ/J6(_D8?VI@_^?B.NHKD?^%B:/_SPO?\ OVO_
M ,51_P +$T?_ )X7O_?M?_BJ/J6(_D8?VI@_^?B.NHKD?^%B:/\ \\+W_OVO
M_P 51_PL31_^>%[_ -^U_P#BJ/J6(_D8?VI@_P#GXCKJ*Y'_ (6)H_\ SPO?
M^_:__%4?\+$T?_GA>_\ ?M?_ (JCZEB/Y&']J8/_ )^(ZZBN1_X6)H__ #PO
M?^_:_P#Q5'_"Q-'_ .>%[_W[7_XJCZEB/Y&']J8/_GXCKJ*Y'_A8FC_\\+W_
M +]K_P#%4?\ "Q-'_P">%[_W[7_XJCZEB/Y&']J8/_GXCKJ*Y'_A8FC_ //"
M]_[]K_\ %4?\+$T?_GA>_P#?M?\ XJCZEB/Y&']J8/\ Y^(ZZO)/'QMK7Q#<
MZCH#ZU9>+E1(XTMK21X;X#& W!0@9QDD$8KK?^%B:/\ \\+W_OVO_P 51_PL
M31_^>%[_ -^U_P#BJ/J.(O?D8?VK@_\ GXCCYM#MK;XKC4+[39DU*\TQ)+29
M!*T0O1D-DJ2 .GWN*P? 6EZFOBFSO+K4]135]TG]I6[V%R"_RMQ+*SF,CI@J
M/3BO3O\ A8FC_P#/"]_[]K_\51_PL31_^>%[_P!^U_\ BJ:P6(_D8O[4P?\
MS\1YT?#LD7P2U/4A#?/K-P&B;?)(S"-;GA53. ,#/ [FI?%-G?&Y\=O%;7!,
MNGZ>(RB-\Q&<@>N*] _X6)H__/"]_P"_:_\ Q5'_  L31_\ GA>_]^U_^*IK
M!XA._(Q_VK@[6]HOZM_D<9K5MH-W\7;*2ZM[RUFLQ%(TZ17#_:YB!L0;0455
MX)/&3^-<]I4>I2?$;3=3\N]M[M]4:"]@:&Y9DB.X#?*S>6RD<@*../2O5/\
MA8FC_P#/"]_[]K_\51_PL31_^>%[_P!^U_\ BJ2P6(5O<>@GF>#::]HCSA-
MT[2=/^(5K;:;>0ZR?/-N0LS![9@A&T\J3NS_ +7X58UFVM9+]E\56VL2P#2[
M?^QQ:K.468)\W^KZ/NQRW%=__P +$T?_ )X7O_?M?_BJ/^%B:/\ \\+W_OVO
M_P 52^I8BUN1]/PN/^U,'>_M%U_&W^1QEKX<O]<UOP[8^*%OY - ?[4JS21A
MWWKA9"A&2 >1GJ*[7X;"Z3P+8Q79F,D32QCS\[]JR,%SGGH!3?\ A8FC_P#/
M"]_[]K_\51_PL31_^>%[_P!^U_\ BJIX/$?R/^FW^I*S/!_\_%_2.NHKD?\
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AV192-(QA$51[#%.HHJ2PHHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>axgn-20191231x10k0cc357004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 axgn-20191231x10k0cc357004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &A VX# 2(  A$! Q$!_\0
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M?_GDM'V2W_YY+4U% $/V2W_YY+1]DM_^>2U-10!#]DM_^>2T?9+?_GDM344
M0_9+?_GDM'V2W_YY+4U% $/V2W_YY+1]DM_^>2U-10!#]DM_^>2T?9+?_GDM
M344 0_9+?_GDM'V2W_YY+4U% $/V2W_YY+1]DM_^>2U-10!#]DM_^>2T?9+?
M_GDM344 0_9+?_GDM'V2W_YY+4U% $/V2W_YY+1]DM_^>2U-10!#]DM_^>2T
M?9+?_GDM344 0_9+?_GDM'V2W_YY+4U% $/V2W_YY+1]DM_^>2U-10!#]DM_
M^>2T?9+?_GDM344 0_9+?_GDM'V2W_YY+4U% $/V2W_YY+1]DM_^>2U-10!#
M]DM_^>2T?9+?_GDM344 0_9+?_GDM'V2W_YY+4U% $/V2W_YY+1]DM_^>2U-
M10!#]DM_^>2T?9+?_GDM344 0_9+?_GDM'V2W_YY+4U% $/V2W_YY+1]DM_^
M>2U-10!#]DM_^>2T?9+?_GDM344 0_9+?_GDM'V2W_YY+4U% $/V2W_YY+1]
MDM_^>2U-10!#]DM_^>2T?9+?_GDM344 0_9+?_GDM'V2W_YY+4U% $/V2W_Y
MY+1]DM_^>2U-10!#]DM_^>2T?9+?_GDM344 0_9+?_GDM'V2W_YY+4U% $/V
M2W_YY+1]DM_^>2U-10!#]DM_^>2T?9+?_GDM344 0_9+?_GDM'V2W_YY+4U%
M $/V2W_YY+1]DM_^>2U-10!#]DM_^>2T?9+?_GDM344 0_9+?_GDM'V2W_YY
M+4U% $/V2W_YY+1]DM_^>2U-10!#]DM_^>2T?9+?_GDM344 0_9+?_GDM'V2
MW_YY+4U% $/V2W_YY+1]DM_^>2U-10!#]DM_^>2T?9+?_GDM344 0_9+?_GD
MM'V2W_YY+4U% $/V2W_YY+5/4(EAC0Q?NR3R5[UI5GZL&,4>TX^;TH LV7_'
MG%QCY>E/G@2Y@>&3.QQ@X)!Q]13+//V.+/7;3YXC- \:R/$6& Z=5]Q0!A^'
MK>*UU/5X8DVHLJ8_[XJ#Q69/.L6M8$N[J-RRVTGW7!&.:GM/#LFE37%W#J-]
M<S2CYDD=<,>QZ4X^'Y+NRM#=7URE]"#FXB8!N>W2@#GK9$D@@MYX_*>2\W3V
MW15.[@#VZU+J\*6VH7UM;((H)E7S43@=!Z=*WO\ A&+4Z>UL]Q.\K2"0W+$>
M9N'(.<8I8O#-JME=6\T\]P]R ))I2"YQT[4 5EMH++Q-:?98DB\R':X08! R
M>E=)63IF@QZ=<-</=7%W,5V!YV!*KZ# %:U !5<W7SLJQ2/M."5'>K%06_\
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M4,MO*0?858;[I^E16G_'I'G'3M0 W[2W_/M-^0H^TM_S[2_D*L44 5_M+?\
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MU*G^K7Z"HKPXLY3Q]T]:E3_5K]!0 ZBBB@ IDW^ID_W3_*GTR;_42?[I_E0
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M"6WCF@0?=D4$&@#DUN94,1N+N2ZM+>["BYE.2<MW(XP,4[6)8[F_OKJ%P]O
MJ^8Z\CH/SKL!IMBMG]C%I"+8_P#++8-OY40Z;96ULUM#:0QP-]Z-4 4_A0!B
MK<0WOB6T-K(LHCAW.4.0!R.M=)56STVRT\,+.TA@W?>\M N?RJU0 53CD=)9
MPD!8%^H(]*N57MO]9<=?]9W^E !Y\W_/JW_?0H\^;_GU;_OH58HH K^?-_SZ
MM_WT*//F_P"?9NG]X58HH HVTLRPX%N6Y)R&'K4WGS?\^K?]]"BS_P"/?O\
M>;K]:L4 5_/F_P"?5O\ OH4>?-_SZM_WT*L44 5GFF\M_P#1FZ?WA3()IE@C
M MV;"CD,.:M2?ZI_H:CM?^/6+K]T=: &^?-_SZM_WT*//F_Y]6_[Z%6** *_
MGS?\^K?]]"HKF:9K9Q]G9<CJ6'%7:@O/^/27K]WM0 U9YL ?9F^NX4OGS?\
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M 5_/F_Y]6_[Z%'GS?\^K?]]"K%% %?SYO^?5O^^A41EE^V!O(;/E]-P]:NU
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M+_=%.E_U3_[IIMM_Q[1=?NCK0!+6?JQ(BCPN?FK0K/U8,8H]IQ\WI0!9LO\
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MJQ10!15YOMKD1+NV#C?[U-YES_SP7_ONA?\ C^DZ?ZL?S-6* *_F77_/NO\
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M-QCYBN!Q^IKU-_\ C^BX_@;G\JR/!GAJ/PGX7L])24S&)1ODQC<WKCM6N_\
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MT:L44 5]UY_<A_[Z-(S7>TY2+'U-6::_W&^AH J6QNA;1A4BV[1C)-2[KO\
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MH&3Q9\9].\/22'[(C1QJ/[N_&[^54OA=<KX&^+EUH][!(&N0;5#_ '>0P)_
M4 ?2"FY^U,=D6[8,\GUJ;==_W(?^^C0A_P!/DY/^K''XFK% %?==_P!R+_OH
MT;KO^Y#_ -]&K%% %?==_P!R'_OHU$3/]M'RQ[O+]3ZU=J _\?PZ?ZL_SH 3
M==_W(?\ OHT;KO\ N0_]]&K%% %?==_W(?\ OHT;KO\ N0_]]&K%% %&W-R$
M;:D6-[=2>N:FW7?]R+_OHT6G^K?DG]XW7ZU8H K[KO\ N0_]]&C==_W(?^^C
M5BB@"L3=X/R18^IJ.V-T+=-J18QQDFKC?=/TJ&S_ ./2+DGCO0 FZ[_N0_\
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MY58JO<9\^VQG[Y_E0!8HHHH **** *[Y^WQ]<>6W\Q5BJ[Y^WQ]<;&_F*L4
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M7\87VHQ)-Y?V2W>;&,EB < ?B* /=?V>KZ.;P1-9J?GMYV+#TW$D?RKU<_\
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MW_?9JQ10!6>T4(Q\R7H3]\TRWM4:WC;S)>5'1ZM2?ZM_H:9:_P#'K%T^Z.E
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MTY/%WQ$O]7U"$3"$><=XR QS@_F*^G0,# H HSVRK+#AI#N?NW3CM4WV-?\
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M1?\ GI+_ -]FK%% %?[&O_/6;_OLU'/:JL$A#R'"G@OP:N5%<_\ 'K+W^4T
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M,>?;<9^<_P JL57N/]?;<#[Y_E0!8HHHH **** *[X_M"/CGRVY_$58JN_\
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MQS\1IYK.U%Q=IY062"$# 4$=?QKZ#^%/@M/"'A6$7$"QZE<#?<$_>'^S^'-
M&II'@3P[X9T[%CIT(EC3_7NH+Y]<UIQ>&-"6XBNUTBR%PGS+*(5W ^H-:%V1
M]DEP03M-2(1L7D=!0 ^BDW#U%&X>HH 6F3?ZB3_=/\J=N'J*9,P\B3D?=/\
M*@ @_P"/>/\ W1_*I*B@8?9X^1]T?RJ3</44 +12;AZBC</44 07/^MM^O\
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MNM/- B9,AER>,^]?6%<5\5?#$WBOP+=V5LV)XR)T&,[BN3M_&@!/!&LVFH>
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M^VP^K?\ ?)H L457^VP^K?\ ?!H%Y"3C+?\ ?)H +(YM^WWFZ?6K%4;6ZC6
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M74I(+E5D92Q(QZDDUWWAKX"Q0WZSZYJC2^6P<+;H0<@]\@U[RD]O$%1%*@#
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M5@2<?=Q77?$+Q_%X$TJ&\>QDNFE.%4':/Q.#BOGK0_'UEX=OA>Z;X"LH[@#
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M+?&#0?$FGW$N'M[FWB:5X&YX SP>_2O(O$/Q?T_7;=+&;P?9SZ9#A8V=F1U
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M&O+]<^ FB:OXCDOX9C96<A!:W@XQQR1D'J>:]0N;A715$<G#J>5QWJ;[6O\
MSSEZX^X: /(+_P#9TT![6;[!J%Y'<D?NS*P* ^X S6QX0^#]CINC_8_$XMM9
M96)BW*V(Q[9KTC[4N<>7+_WP:/M2X)\N7C_8- '#:O\ !CP7JELL4.EI8,K!
MO,M>&/MSGBK_ (L\ :3XHT33M%O&FCMK9\QF(@,/EQW%=5]J7C]W+S_L&H)K
ME3-"0L@VL<@KUX[4 >7+^SKX4# _;=2.#T,B\_\ CM4]5_9ST62SD&E:E=17
M1^X;@AD'X 9KV3[6N ?+EY_V#1]J7./+E_[X- 'GOPU^$\'@22:\N+L7=]*N
MPL@P@7KP#S71>*? >@>*[61;^PA-QL*QSA<,AQU%=!]J7G]W+Q_L&@72D9\N
M7_OB@#D/"G@#2O"VD'1-OVJ*=6,QD&=_/?\ .I_%'PWT#Q3I%MIEQ$UM!;-N
MB^S84C\P?6NB>X NT;RY,!#_  \U-]J7./+E_P"^#0!Q6E_!WP3IUBEM+H\-
MZR_\MKCES]<8K-UGX$>#]5NQ/#%/IZ@8\JU8!3[\@UZ/]J7!/ER\?[!H^U+Q
M^[EY_P!@T >;Z'\"_"^AZK#J$<MY<20G<J3.I7/X 5W]S8VU[)=031(RRP[&
M.T9P<BK/VI<X\N7_ +XJ!;A5O)'\M\%5'"\]Z ,7P?X$TGP5%=IIOF.;J7S7
M:7!(/. ,#IS6]J&FV6K6<EG?VT=Q;R##QN,@BG_:ER1Y<O'^P:/M:[<^7+_W
MP: /,-1^ 'A*_OY;F-[NT1SD0P,H1?ID&JO_  SIX4_Y_M3_ ._B_P#Q->L_
M:ER!Y<O/^P:#=J,_NY>/]@T >1_\,[^%?/V?;M2QMS_K%]?]VNL\%?"_1? M
MY/=:=/=2R3*%/GL#@#/3 'K75_: +L-LDP4QC9[U+]J7./+E_P"^* )ZR[7P
MYH]CJUQJMMI\,5_<#$LZCYG^OY"KGVM<$^7+_P!\&E^U+Q^[EY_V#0!/7.W_
M (1\/>)0DNL:5;WCQ,ZHTH.5&:VOM:X_U<O7'W#4-K<JL1!5VR[<JOO0!SO_
M  JOP-_T+-C_ -\G_&C_ (57X&_Z%FQ_[Y/^-=3]J7./+E_[XI/M:X_U<O7'
MW#0!P-C\$O!MIJD]X]C]HCDSMMY3F-/H!S73:3X*\->'YWN=)T>VM)BN"\8.
M<?G6R;M1G]W+Q_L&D:Z4J1Y<O3^Y0 D$44]E")$5Q@$;AFK.,# JE;7(2UC!
M20D #(2IC=J,_NY>/]@T 5M7T33-?L_LFJV<5W;YSY<@R,TW2_#^DZ+9+9Z?
M8006ZG(15XS^-6_M2Y_U<O3/W#0+M3C]W+S_ +!H CNK:W%K*?(BX4_P"I$M
M;?8O[B+H/X!45Q<A[:0!) 2" 2E2+=*% \N7I_<H ;+IME,R-):Q,8SE3L'!
MJU4 NU./W<O/^P:3[6N/]7+UQ]PT )'I]G#>27<=O&MQ(,/(!R:FE_U+_P"Z
M:B^UI_SSE_[X--ENE,3CRY>01]P^E #DMX9(4+PQL2HSE0>U2&")E"M$A Z
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MK,L2Q!XP=B]%]A56UUC2=09[5952X*XDA;AU]C6E:P0VMK'!;@")%"J <\4
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M-J5G*A0_+YRY/% $WAJV,6EQ2^?(R2H&6(GY8QZ+[5LUG:$8FT*R, (B,2[
M7W$#'KWK1H *Y[5-1U+[=+#81P,EN@>195)+@]AS[5T-5_L4'VI[G:?,==K<
M\$4 <:+:XOKBVOKRW@@6=O+C,((DC/KG..WI7:6L)M[9(R[2%1R[=3]:CFT^
MWG,)92/);>@4X&:M4 %%%% &6^K0^3=N\1(MWV8/\1X_QK%@M[:^OP9=/ETR
M\<9CE1P2_J.,BM'5="N+IF-E>"V\P[I R;@3^=/T_2KU+E)]1O%N&B&(]B;
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MB />NFLK8VML(S/)-CD-(>:P[3P_J*1Q6MWJ,<UI&P(18=IXY'.:Z4#  ]*
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M9EYH 7PO;!-,CN$ED\J5<I;Y^2(>B]ZW*RO#;0-X?LS; B#9\@+[^/KWK5H
M*R=:O;N P6UD(_/G8@-(,J,<UK5!/9Q7,D4D@.^(Y4@XQ0!QEW]OU..9KRRL
M_*LSF7*G,F.ZX/'3O75:/:_9K(8FED5P&42'.T8Z"I[BQ@N;>6%EVK*,,5X)
MJ:*-88DC7[JC S0 ^BBB@#-?5(&6]$D)VVV V?XN*PXX;:_OU:?3I=.N9/\
M53HX);VXK2U?0[B\WFRNQ;&7_6ADW!OPS18Z1?K<12:C>I<"'F,)'LP3QZT
M;$,9BA1"[.5&-S=34E%% !6/JFL/;SFUMK![R0#,@5@ H/KFMBL:_P!)O9+M
M[C3[U;=I !(&CW[L=._% &/;-9:S,LL^FR6,[DI%.K#((],?2NLMXC!;I$TC
M2%1C>W4UG1Z+Y=M:1"?_ %$GF,<?>/.?IUK6H **** .=FO-8O+VZ%BEH;6V
M?8T<JDNY'/!S@?C6>(]/U'5[5K6%K&]E#^=(G$B%<97TP<]<5L?VAH6F7]QO
MU&WAG=OWD;S 8/T]:IK>Z)>>*;2:SGAGNVC<%X9@<#CJ!UH Z5%VHJEBV!C)
MZFJ&K$B*/"Y^:M"L_5@QBCVG'S>E %FR_P"/.+C'R]*GJ"SS]CBSUVU/0 44
M44 %%%% !1110!2U338M4LFMY,#NK%0VT^N#Q36T>P:W,1M+?)7;N\E<].O2
MK]% %>PM%L+&&U1BRQJ%!(QG%6*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH S$T.S74)[IH8G$V,H\2G![G/7FG+HUK'J<5[#''"T<93;'&
M #D@Y./I6C10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534M
M/BU.R>VEP >58J#M/K@U;HH H_V/8>1Y9L[<G;MW>2N?KTJ33K)=.L(;1&++
M$H4$C&:M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F#0[/
M^T9KMXHG\T#*/$IY[G)YK3HH SO[&M$U*&]ACCA:)&3;'&!NSCKCZ5HT44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5U&PBU*R>VEQAN02 =
MI['!J-='L! (S:6S';MW>2N3[]*O44 5=.L4TZPBM$8LL8P#C%6J** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?[$LSJ4MX\43^:N&1XE//
MKD\TIT:T74(+R&*.%HE88CC W9]?RK1HH *SM7V^5'N./F-:-9^K$B*/"Y^:
M@"S98^QQ8.1MZU/4%E_QYQ<8^7I4] !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 45S^I>)&L-<CLA 'A^02R9Y0N<+^N:M7NKMI
M^I11W*QI9RH=LV3G?V'\Z -:BN=;Q'.MC%*;/]_=2%+6('EO=O3O5BSN]>6Z
M2/4;&U$;@_/:NS;3[Y H VJ*YK0O$\NJ7-W;W%ND+QL_DE22'53@G\ZU=%U!
M]4TJ&[=%1GSE5.1U(H T**** "BBB@ HHHH **** "BBB@ HI'.U">.!WKFM
M"\43:I;7;7%M'#+$K/& 3AT'&?SH Z:BL!O$$B>%K?53 GG3JFR,$X+-P!^=
M*/$1/AJ35#!^]C!#1>C#@_AD4 ;U%<V=8UFWTR>ZN[.SRJ!HS%(Q4Y(&"2.O
M--77-8L3;RZO96JVLS!/,MG9BC'@9R!QDT =-16!K_B(Z/+ L<*S!U,LG/W8
MQU(_,58U/63:0VRVL0FNKHXA0G@G&>?:@#7HK"M-5U2&_BM-7M+>(S ^6]NY
M9<CJ#FC6M6U"SU"UL[""U=YE+;KARH !'I]: -VBL+3M:NKNPNWGB@BN+9]C
M$,3&3P>#U[U9GU_3K&W@DO[V&%I5R,$D'Z4 :E%8,_C#18+VWMFNU)G7<K#H
M/K^=6[SQ#I.GS+%=7T44C#(4YY% &G169=>(=)L_*^T7T4?FC*9S\U5&\4V5
MMJ%U#>SPP0Q",QR$GY@RYH WJ*S;GQ!I-I&DEQ?11HZ>8I.>5SC/YU/'JEC-
M8&^CN4:U SYO:@"W161%XCTV\MYWL+N*X>)2Q49H'B&RMM-M[K4;B*V,V< D
MD=3_ (4 :]%9<OB/1X+..[DOXE@D)".<X.*?9Z]I=^(S:WL4HD.$VYY- &C1
M4,5W!-/+#'*K21'#J.JFIJ "BBB@ HHHH **** "BBB@ HHHH **YNW\3R/X
MGN=+F@18$81QS*3EGP#@_AFK]GJS3PZE+)&BK:2N@*G[P49H U:*PM#U^34H
M;@W-N(I(L.%4YW(>5/Y5!IVLZO>XN#9VOV)BP4I(QD7&>6'0=* .DHKDX->\
M026/]HG3K)K/[Q$<C&3;W.,8K3U'7/(T2*_LXQ-).56%&.,LW0&@#9HK&3Q!
M"?#XU1UP<8,8Z[LXQ^=4SK.MV8CN-1L+9+-V"YA=BZY.!D'B@#I:*SM5U3[!
M:(T*"2>9@D*$\,QZ9]JCTNYU9Y'CU6T@B.W<KP,67'H<]Z -6BLM?$>CM>FS
M74(C<!MNSG.:1_$NC1W*V[ZA")F<H%R>6!P10!JT5GV>MZ9J#2K:7D<IB^^%
MS\M1+XET9KB.W74(3+)]Q>>: -6BLN?Q'H]K>?9)K^))\@;#G/-)=>)-&LK@
M6]QJ$4<IP0ISGF@#5HK"OO$UII1F>]FA$2L @C)+G)[BK3>(=*33X[^2\C2V
M<X5SGK0!IT54L]3L]1MVGLKA)D'=:H6WB*V%JT]_+%;#S&1,D\X&: -JBJ5E
MJ^GZC;M<6EU'+$OWF7H*RIO%UA)>6=OI]Q!<M-/Y4@!.5&#S^E '145DMXFT
M5+MK1M0A$ZD@ISUJT-6L&6)ENHR)6V)@_>/I0!<HHHH **** "BBB@ HHHH
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M* .(L[*Y70&O;>)C=V]U*X1A@NN]OE_'BMOP?YA\+61E0I(5)96&"#N-;E%
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M5*HPXR!G\:FUKQ5:7NGPVENEP)994#EX' C 89R<5V]-=%D1D=0RL,$$<$4
M8.M(8;.ROH5,\=JZLX3GY.Y'KTJQ;:Q#K4$Z6*S8$9R[QE,-Z8(%:L44<$:Q
MQ(J(HP%48 I] ' QW-M+H5OHBV<W]HHZ!T\H@ A@2=^,?K4_]EK_ ,(I=126
MVZ1KJ3=E3EOF/-=O10!S#6HAU^ QQ;$_LPJ2%X!R/UKGK&^M+CPK;:9#:2F]
M=E('EG'WOO;L8_7M7H[*'0J>A&#4%C90Z?9QVL (BC&%W')H XF&X@T_2+W1
M[JVDDU&5G"@1,1)N/'S8P/SJ(2Q:1,?L5S.;Y]HDMIK=FBS@="!U_&O0Z* .
M)U"":?\ M*1K9@<QN5VYX#9./7BF:R8[Q],U%)[RWL4C=&EMXR'5CC VD$]O
M2NYHH YGPQ!8[;RXL[V]NG<X=KI"ISCMP*SH+0RW>EB6W9T6[E)#*<#Y!@FN
MWHH Y'4;6=KS7X[>)@&MX]@48#?*<@50N[BVU-M(BT^TE\VWE D?RBFSY"".
M1SS7>T4 >9VUO8P6L5GJ6IZO%-$1OMUB+("#G (4\?C5_1[22S\1I>O;R?8K
MAF6%2,^62?O'_>ZUWM% !1110 4444 %%%% !1110 4444 %%%% !6?JQ(BC
MPN?FK0K/U8,8H]IQ\WI0!9LO^/.+C'R]*GJM:2*MI&&=0=O/-3>;'_ST7\Z
M'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.@!]%,\V/_GHOYT>;
M'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.@!]%,\V/
M_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.
M@!]%,\V/_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='
MFQ_\]%_.@!]%,\V/_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?13/-
MC_YZ+^='FQ_\]%_.@!]%,\V/_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?_/1?
MSH ?13/-C_YZ+^='FQ_\]%_.@!]%,\V/_GHOYT>;'_ST7\Z 'T4SS8_^>B_G
M1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.@!]%,\V/_GHOYT>;'_ST7\Z 'T4S
MS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.@!]%,\V/_GHOYT>;'_ST
M7\Z 'T4SS8_^>B?G1YL?_/1?SH ?13/-C_YZ)^='FQ_\]%_.@!]%,\V/_GHO
MYT>;'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.@!]%
M,\V/_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\
M]%_.@!]%,\V/_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ
M+^='FQ_\]%_.@!]%,\V/_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?
M13/-C_YZ+^='FQ_\]%_.@!]%,\V/_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?
M_/1?SH ?13/-C_YZ+^='FQ_\]%_.@!]%,\V/_GHOYT>;'_ST7\Z 'T4SS8_^
M>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.@!]%,\V/_GHOYT>;'_ST7\Z
M'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.@!]%,\V/_GHOYT>;
M'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.@!]%,\V/
M_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?_/1?SH ?13/-C_YZ+^='FQ_\]%_.
M@!]9VK[?*CW''S&KWFQ_\]%_.J&J.#%'LP_/8T 9,OWS]!_.F+]]_P#?%%%
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M  #^M%% "-_JS_NBED_U9_X#_*BB@!'_ /9A_*G2=1_OFBB@!!_K(_\ >/\
M.C^./Z&BB@!%^^O^Y0WWS_N?THHH 7^.3Z#^E!_UDG^\/YT44 *GWF_WQ21_
M^S_THHH (_N#_@7\J1?]6/\ =-%% "_\LO\ @']:1O\ 5G_=%%% "R?ZL_\
M ?Y42=#_ +P_E110 LG4?[])_P M$_WC_.BB@ _CC_&A?OK_ +E%% "'[Y_W
M*7^.3Z"BB@ /^LD^H_G2I]YO]\444 )'_P"S_P!*(_N#ZG^5%% "+_JQ_NM2
M_P#++_@']:** $/^J/\ NC^=*_\ JS]%HHH ).A_WA_*A^H_WZ**  _?3_>-
M'\<?XT44  ^^O^Y2'[__  "BB@!?XW_W11_RTD^HHHH 5?O-_OBD3K_P.BB@
M C^X/J?Y4B?ZL?0T44 */]5_P _SI#_JO^ C^=%% "O_ *L_1:)/NGZC^5%%
M !)U'^_0?OI_OFBB@ _CC_&@??3_ ':** $_C_X!2G[[_P"Z*** #^.3ZBA?
5OM_OBBB@ C_]GJ>+_5+]*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>axgn-20191231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.7293.39921 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2020 9:33:36 PM-->
<!--Modified on: 2/24/2020 9:33:36 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:axgn="http://www.axogeninc.com/20191231" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://www.axogeninc.com/20191231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails">
        <link:definition>40302 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40401 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>40601 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" id="DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails">
        <link:definition>40701 - Disclosure - Intangible Assets - Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" id="DisclosureAccountsPayableAndAccruedExpensesDetails">
        <link:definition>40801 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" id="DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails">
        <link:definition>40901 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails" id="DisclosureIncomeTaxesTemporaryDifferencesDetails">
        <link:definition>41201 - Disclosure - Income Taxes - Temporary Differences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" id="DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails">
        <link:definition>41202 - Disclosure - Income Taxes - Effective Income Tax Rate and Other information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" id="DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2">
        <link:definition>41304 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" id="DisclosureCommitmentsAndContingenciesLeaseExpenseDetails">
        <link:definition>41402 - Disclosure - Commitments and Contingencies - Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails">
        <link:definition>41405 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" id="StatementConsolidatedStatementsOfChangesInShareholdersEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness" id="DisclosureOrganizationAndBusiness">
        <link:definition>10201 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10401 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10601 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>10701 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses" id="DisclosureAccountsPayableAndAccruedExpenses">
        <link:definition>10801 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebt" id="DisclosureTermLoanAgreementsAndLongTermDebt">
        <link:definition>10901 - Disclosure - Term Loan Agreements and Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock" id="DisclosurePublicOfferingOfCommonStock">
        <link:definition>11001 - Disclosure - Public Offering of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlans" id="DisclosureEquityCompensationPlans">
        <link:definition>11101 - Disclosure - Equity Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>11301 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11401 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30403 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30603 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
        <link:definition>30703 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" id="DisclosureAccountsPayableAndAccruedExpensesTables">
        <link:definition>30803 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtTables" id="DisclosureTermLoanAgreementsAndLongTermDebtTables">
        <link:definition>30903 - Disclosure - Term Loan Agreements and Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansTables" id="DisclosureEquityCompensationPlansTables">
        <link:definition>31103 - Disclosure - Equity Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31203 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31403 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40301 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails" id="DisclosureFairValueOfInvestmentsDetails">
        <link:definition>40501 - Disclosure - Fair Value of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails" id="DisclosureIntangibleAssetsLicenseAgreementsDetails">
        <link:definition>40702 - Disclosure - Intangible Assets - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails" id="DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails">
        <link:definition>40902 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt - Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails" id="DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails">
        <link:definition>40903 - Disclosure - Term Loan Agreements and Long-Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails" id="DisclosurePublicOfferingOfCommonStockDetails">
        <link:definition>41001 - Disclosure - Public Offering of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails" id="DisclosurePublicOfferingOfCommonStockPublicOfferingDetails">
        <link:definition>41002 - Disclosure - Public Offering of Common Stock - Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails" id="DisclosureEquityCompensationPlansNarrativeDetails">
        <link:definition>41101 - Disclosure - Equity Compensation Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails" id="DisclosureEquityCompensationPlansStockAwardActivityDetails">
        <link:definition>41102 - Disclosure - Equity Compensation Plans - Stock Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails" id="DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails">
        <link:definition>41103 - Disclosure - Equity Compensation Plans - Summary of Weighted-Average Assumptions Used (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails" id="DisclosureEquityCompensationPlansGrantDateFairValueDetails">
        <link:definition>41104 - Disclosure - Equity Compensation Plans - Grant Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails" id="DisclosureEmployeeBenefitPlanDetails">
        <link:definition>41301 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" id="DisclosureCommitmentsAndContingenciesLeasesDetails">
        <link:definition>41401 - Disclosure - Commitments and Contingencies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails" id="DisclosureCommitmentsAndContingenciesServiceAgreementsDetails">
        <link:definition>41406 - Disclosure - Commitments and Contingencies - Service Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails" id="DisclosureCommitmentsAndContingenciesConcentrationsDetails">
        <link:definition>41407 - Disclosure - Commitments and Contingencies - Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails" id="DisclosureCommitmentsAndContingenciesLitigationDetails">
        <link:definition>41408 - Disclosure - Commitments and Contingencies - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails" id="DisclosureScheduleIiValuationAndQualifyingAccountsDetails">
        <link:definition>41601 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureFairValueOfInvestments" id="DisclosureFairValueOfInvestments">
        <link:definition>10501 - Disclosure - Fair Value of Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnaudited" id="DisclosureQuarterlyResultsOfOperationsUnaudited">
        <link:definition>11501 - Disclosure - Quarterly Results of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts" id="DisclosureScheduleIiValuationAndQualifyingAccounts">
        <link:definition>11601 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsTables" id="DisclosureFairValueOfInvestmentsTables">
        <link:definition>30503 - Disclosure - Fair Value of Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedTables" id="DisclosureQuarterlyResultsOfOperationsUnauditedTables">
        <link:definition>31501 - Disclosure - Quarterly Results of Operations (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails">
        <link:definition>40303 - Disclosure - Summary of Significant Accounting Policies - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails" id="DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails">
        <link:definition>41403 - Disclosure - Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails" id="DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails">
        <link:definition>41404 - Disclosure - Commitments and Contingencies - Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedDetails" id="DisclosureQuarterlyResultsOfOperationsUnauditedDetails">
        <link:definition>41501 - Disclosure - Quarterly Results of Operations (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="axgn-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="axgn-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="axgn-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="axgn-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" name="AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="AxoGen2010StockIncentivePlanMember" id="axgn_AxoGen2010StockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsLiabilities" id="axgn_DeferredTaxAssetsLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <element id="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" name="DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="DirectorsAndOfficersStockOptionsMember" id="axgn_DirectorsAndOfficersStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EarlyTerminationPeriod" id="axgn_EarlyTerminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeConsultantsAndDirectorsStockOptionsMember" id="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="axgn_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" id="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePaymentContingentUponReceiptOfGrant" id="axgn_MilestonePaymentContingentUponReceiptOfGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MinimumRoyaltyOfLicenseAgreement" id="axgn_MinimumRoyaltyOfLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NoticePeriodForTerminationOfLicenseAgreements" id="axgn_NoticePeriodForTerminationOfLicenseAgreements" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfProductsFromWhichRevenueIsDerived" id="axgn_NumberOfProductsFromWhichRevenueIsDerived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <element id="axgn_OrganizationAndBusinessAbstract" name="OrganizationAndBusinessAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" id="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <element id="axgn_RoyaltyFeesPercentageUnderLicenseAgreements" name="RoyaltyFeesPercentageUnderLicenseAgreements" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="TissueProcessingAgreementMember" id="axgn_TissueProcessingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="axgn_AreaOfRealEstatePropertyAdditional" name="AreaOfRealEstatePropertyAdditional" nillable="true" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_NoticePeriodForTerminationOfAgreement" name="NoticePeriodForTerminationOfAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_Axogen401kPlanMember" name="Axogen401kPlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DefinedContributionPlanEmployeeContributionPercentMatched" name="DefinedContributionPlanEmployeeContributionPercentMatched" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" name="Axogen401kPlanEmployerMatchingContributionTranche1Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" name="Axogen401kPlanEmployerMatchingContributionTranche2Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_MilestonePaymentContingentUponFDApproval" name="MilestonePaymentContingentUponFDApproval" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" name="MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" name="MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm" name="DebtInstrumentInterestAndPrincipalPaymentsTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DebtInstrumentNoPaymentsRequiredTerm" name="DebtInstrumentNoPaymentsRequiredTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_PhantomStockUnitPayoutOpportunity" name="PhantomStockUnitPayoutOpportunity" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_SHNMedicalOfficePropertiesTrustMember" name="SHNMedicalOfficePropertiesTrustMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_JaColeMember" name="JaColeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_Axogen2017EmployeeStockPurchasePlanMember" name="Axogen2017EmployeeStockPurchasePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_CiscoCapitalMember" name="CiscoCapitalMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_RaymondLeasingCorporationMember" name="RaymondLeasingCorporationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_BAndBOfficeSystemsMember" name="BAndBOfficeSystemsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved" name="CompensationCostNotYetRecognizedAssumedPercentageAchieved" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_PerformanceSharesBiologicLicenseApplicationMember" name="PerformanceSharesBiologicLicenseApplicationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_ShareBasedCompensationAwardTrancheFourMember" name="ShareBasedCompensationAwardTrancheFourMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_IncreaseDecreaseInContractReceivable" name="IncreaseDecreaseInContractReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent" name="IncreaseDecreaseInContractWithCustomerLiabilityCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent" name="IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_CommonStockIssuanceMay2018OfferingMember" name="CommonStockIssuanceMay2018OfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_HeightsUnionMember" name="HeightsUnionMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_HeightsUnionPremisesMember" name="HeightsUnionPremisesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_AshleyAvenueLeaseMember" name="AshleyAvenueLeaseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" name="StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_UnderwriterMember" name="UnderwriterMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" name="NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" name="EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_EmployeeStockPurchasePlanOfferingPeriod" name="EmployeeStockPurchasePlanOfferingPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" name="EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_LicenseFeeAmount" name="LicenseFeeAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" name="ServiceAgreementAmountPaidUponExecutionOfAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_SecondExpansionLeaseMember" name="SecondExpansionLeaseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_ThirdExpansionLeaseMember" name="ThirdExpansionLeaseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DeferredTaxAssetsInterestLimitation" name="DeferredTaxAssetsInterestLimitation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_RevolvingLoanAgreementMember" name="RevolvingLoanAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_LeasesFinanceAbstract" name="LeasesFinanceAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount" name="LesseeOperatingLeaseLiabilityFuturePaymentsAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" name="ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_RightOfUseAssetAmortization" name="RightOfUseAssetAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_ThresholdPeriodForNotFilingResponseToComplaint" name="ThresholdPeriodForNotFilingResponseToComplaint" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" name="FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DerecognitionOfCapitalLeaseAssets" name="DerecognitionOfCapitalLeaseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DerecognitionOfCapitalLeaseLiabilities" name="DerecognitionOfCapitalLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DerecognitionOfDeferredRent" name="DerecognitionOfDeferredRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_FinanceAndOperatingLeaseRightOfUseAsset" name="FinanceAndOperatingLeaseRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_FinanceAndOperatingLeaseLiabilities" name="FinanceAndOperatingLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock" name="ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DesignBuildAgreementMember" name="DesignBuildAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_EstimatedCostRelatingToDesignBuildAgreement" name="EstimatedCostRelatingToDesignBuildAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" name="AdditionalCostsAssociatedWithDesignBuildAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_CashGrantsReceivable" name="CashGrantsReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" name="NoncashRightOfUseAssetsAndOperatingLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_NewAxogenPlanMember" name="NewAxogenPlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" name="NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue" name="LongTermDebtNoncurrentExcludingDeferredRevenue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_PatentsAndLicenseAgreementsMember" name="PatentsAndLicenseAgreementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DeferredTaxAssetsRightOfUseLiability" name="DeferredTaxAssetsRightOfUseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_MinimumNumberOfCandidateElectedToBoard" name="MinimumNumberOfCandidateElectedToBoard" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_NovitzkiVsZaderejMember" name="NovitzkiVsZaderejMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="axgn_RestrictedAndPerformanceStockUnitsMember" name="RestrictedAndPerformanceStockUnitsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>axgn-20191231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.7293.39921 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2020 9:33:36 PM-->
<!--Modified on: 2/24/2020 9:33:36 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails" roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureInventoriesDetails" roleURI="http://www.axogeninc.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIncomeTaxesTemporaryDifferencesDetails" roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637181768131930271" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_637181768131930271" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637181768131930271" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637181768131930271" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637181768131930271" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_637181768131930271" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637181768131930271" xlink:to="us-gaap_RestrictedCash_637181768131930271" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637181768131930271" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637181768131930271" xlink:to="us-gaap_ShortTermInvestments_637181768131930271" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637181768131940269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637181768131930271" xlink:to="us-gaap_AccountsReceivableNetCurrent_637181768131940269" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637181768131940269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637181768131930271" xlink:to="us-gaap_InventoryNet_637181768131940269" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637181768131940269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637181768131930271" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637181768131940269" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637181768131940269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637181768131940269" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637181768131940269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637181768131940269" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637181768131940269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637181768131940269" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637181768131940269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637181768131940269" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637181768131940269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637181768131940269" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637181768131940269" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637181768131940269" xlink:to="us-gaap_LiabilitiesCurrent_637181768131940269" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637181768131950260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637181768131940269" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637181768131950260" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637181768131950260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637181768131940269" xlink:to="us-gaap_LongTermDebtCurrent_637181768131950260" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637181768131950260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637181768131940269" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637181768131950260" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637181768131950260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637181768131940269" xlink:to="us-gaap_LongTermDebtNoncurrent_637181768131950260" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637181768131950260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637181768131940269" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637181768131950260" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637181768131950260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637181768131940269" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637181768131950260" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637181768131950260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637181768131950260" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637181768131950260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637181768131950260" xlink:to="us-gaap_CommonStockValue_637181768131950260" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637181768131960253" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637181768131950260" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637181768131960253" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637181768131960253" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637181768131950260" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637181768131960253" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635440476568820979" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637181768131960253" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_635440476568820979" xlink:to="us-gaap_OperatingIncomeLoss_637181768131960253" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637181768131960253" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637181768131960253" xlink:to="us-gaap_GrossProfit_637181768131960253" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637181768131960253" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637181768131960253" xlink:to="us-gaap_Revenues_637181768131960253" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637181768131960253" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637181768131960253" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637181768131960253" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637181768131960253" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637181768131960253" xlink:to="us-gaap_CostsAndExpenses_637181768131960253" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_637181768131960253" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637181768131960253" xlink:to="us-gaap_SellingAndMarketingExpense_637181768131960253" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637181768131960253" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637181768131960253" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637181768131960253" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637181768131970262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637181768131960253" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637181768131970262" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637181768131970262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_635440476568820979" xlink:to="us-gaap_NonoperatingIncomeExpense_637181768131970262" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637181768131970262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637181768131970262" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637181768131970262" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating_637181768131970262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637181768131970262" xlink:to="us-gaap_InvestmentIncomeNonoperating_637181768131970262" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637181768131970262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637181768131970262" xlink:to="us-gaap_InterestExpense_637181768131970262" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637181768131970262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637181768131970262" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637181768131970262" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637181768131970262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637181768131970262" xlink:to="us-gaap_OtherNonoperatingExpense_637181768131970262" order="5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637181768131980262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_NetIncomeLoss_637181768131980262" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_637181768131980262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_637181768131980262" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_637181768131980262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_637181768131980262" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_637181768131980262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_InventoryWriteDown_637181768131980262" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_637181768131980262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_637181768131980262" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637181768131980262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637181768131980262" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637181768131980262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637181768131980262" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637181768131980262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_Depreciation_637181768131980262" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_637181768131980262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_AmortizationOfIntangibleAssets_637181768131980262" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RightOfUseAssetAmortization" xlink:label="axgn_RightOfUseAssetAmortization_637181768131990268" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="axgn_RightOfUseAssetAmortization_637181768131990268" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637181768131990268" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_AmortizationOfFinancingCosts_637181768131990268" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637181768131990268" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_ShareBasedCompensation_637181768131990268" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637181768131990268" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637181768131990268" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637181768131990268" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_IncreaseDecreaseInInventories_637181768131990268" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637181768131990268" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637181768131990268" order="15" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637181768131990268" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637181768131990268" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_637181768131990268" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_637181768131990268" order="17" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637181768131990268" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_OperatingLeasePayments_637181768131990268" order="18" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637181768132000259" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768131970262" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637181768132000259" order="19" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637181768132000259" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637181768132000259" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_637181768132000259" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637181768132000259" xlink:to="us-gaap_PaymentsToAcquireInvestments_637181768132000259" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_637181768132000259" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637181768132000259" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_637181768132000259" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637181768132000259" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637181768132000259" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637181768132000259" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_637181768132000259" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637181768132000259" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_637181768132000259" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132000259" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132000259" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637181768132010258" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132000259" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637181768132010258" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit_637181768132010258" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132000259" xlink:to="us-gaap_ProceedsFromLinesOfCredit_637181768132010258" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637181768132010258" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132000259" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637181768132010258" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_637181768132010258" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132000259" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_637181768132010258" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637181768132010258" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132000259" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637181768132010258" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637181768132010258" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132000259" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637181768132010258" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637181768132010258" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132000259" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637181768132010258" order="7" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637181768132020260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637181768132020260" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_637181768132020260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash_637181768132020260" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637181768132020260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637181768132020260" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637181768132020260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637181768132020260" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637181768132020260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637181768132020260" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637181768132030270" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637181768132030270" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637181768132030270" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637181768132030270" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Intangible Assets - Components of Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_637181768132030270" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_637181768132030270" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637181768132030270" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637181768132030270" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accounts Payable and Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637181768132030270" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent_637181768132030270" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637181768132030270" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637181768132030270" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637181768132030270" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_637181768132030270" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637181768132030270" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtCurrent_637181768132030270" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637181768132040264" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtNoncurrent_637181768132040264" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Temporary Differences (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsLiabilities" xlink:label="axgn_DeferredTaxAssetsLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637181768132040264" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="axgn_DeferredTaxAssetsLiabilities" xlink:to="us-gaap_DeferredTaxAssetsGross_637181768132040264" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637181768132040264" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637181768132040264" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637181768132040264" order="1" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_637181768132040264" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637181768132040264" xlink:to="us-gaap_DeferredTaxAssetsInventory_637181768132040264" order="2" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsRightOfUseLiability" xlink:label="axgn_DeferredTaxAssetsRightOfUseLiability_637181768132040264" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637181768132040264" xlink:to="axgn_DeferredTaxAssetsRightOfUseLiability_637181768132040264" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637181768132040264" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637181768132040264" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637181768132040264" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637181768132040264" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637181768132040264" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637181768132040264" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsInterestLimitation" xlink:label="axgn_DeferredTaxAssetsInterestLimitation_637181768132040264" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637181768132040264" xlink:to="axgn_DeferredTaxAssetsInterestLimitation_637181768132040264" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_637181768132040264" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637181768132040264" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_637181768132040264" order="7" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637181768132050265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637181768132040264" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637181768132050265" order="8" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637181768132050265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="axgn_DeferredTaxAssetsLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637181768132050265" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_637181768132050265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="axgn_DeferredTaxAssetsLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_637181768132050265" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="axgn_DeferredTaxLiabilitiesRightOfUseAsset_637181768132050265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="axgn_DeferredTaxAssetsLiabilities" xlink:to="axgn_DeferredTaxLiabilitiesRightOfUseAsset_637181768132050265" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_637181768132050265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="axgn_DeferredTaxAssetsLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_637181768132050265" order="5" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Effective Income Tax Rate and Other information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637181768132050265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637181768132050265" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637181768132050265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637181768132050265" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_637181768132050265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_637181768132050265" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637181768132060265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637181768132060265" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" xlink:type="extended" xlink:title="41304 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_637181768132060265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_637181768132060265" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_637181768132060265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability_637181768132060265" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount" xlink:label="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount_637181768132060265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount_637181768132060265" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637181768132070275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637181768132070275" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637181768132070275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_637181768132070275" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Commitments and Contingencies - Lease Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637181768132070275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637181768132070275" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_637181768132070275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense_637181768132070275" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637181768132070275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_637181768132070275" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_637181768132070275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_637181768132070275" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637181768132070275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_637181768132070275" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41405 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_637181768132070275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_637181768132070275" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_637181768132080263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_637181768132080263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_637181768132080263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_637181768132080263" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_637181768132080263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_637181768132080263" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637181768132080263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637181768132080263" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_637181768132080263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_637181768132080263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_637181768132080263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_637181768132080263" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_637181768132080263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_637181768132080263" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_637181768132080263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_637181768132080263" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637181768132080263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637181768132080263" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637181768132090263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637181768132090263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637181768132090263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637181768132090263" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637181768132090263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637181768132090263" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637181768132090263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637181768132090263" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637181768132090263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637181768132090263" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637181768132090263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637181768132090263" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637181768132090263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637181768132090263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637181768132090263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637181768132090263" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_637181768132100265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_637181768132100265" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637181768132100265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637181768132100265" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_637181768132100265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_637181768132100265" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>axgn-20191231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.7293.39921 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2020 9:33:36 PM-->
<!--Modified on: 2/24/2020 9:33:36 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#StatementConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureFairValueOfInvestmentsDetails" roleURI="http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIntangibleAssetsLicenseAgreementsDetails" roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails" roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails" roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosurePublicOfferingOfCommonStockDetails" roleURI="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEquityCompensationPlansNarrativeDetails" roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEquityCompensationPlansStockAwardActivityDetails" roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEquityCompensationPlansGrantDateFairValueDetails" roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesServiceAgreementsDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesConcentrationsDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesLitigationDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureScheduleIiValuationAndQualifyingAccountsDetails" roleURI="http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <definitionLink xlink:role="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637181768132110277" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637181768132110277" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637181768132140253" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637181768132140253" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FinanceAndOperatingLeaseRightOfUseAsset" xlink:label="axgn_FinanceAndOperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="axgn_FinanceAndOperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FinanceAndOperatingLeaseLiabilities" xlink:label="axgn_FinanceAndOperatingLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="axgn_FinanceAndOperatingLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DerecognitionOfCapitalLeaseAssets" xlink:label="axgn_DerecognitionOfCapitalLeaseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="axgn_DerecognitionOfCapitalLeaseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DerecognitionOfCapitalLeaseLiabilities" xlink:label="axgn_DerecognitionOfCapitalLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="axgn_DerecognitionOfCapitalLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DerecognitionOfDeferredRent" xlink:label="axgn_DerecognitionOfDeferredRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="axgn_DerecognitionOfDeferredRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:label="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Investments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637181768132160271" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637181768132160271" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637181768132160271" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637181768132160271" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637181768132170281" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637181768132170281" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BondsMember" xlink:label="us-gaap_BondsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_BondsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637181768132180271" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637181768132180271" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FurnitureAndOfficeEquipmentMember" xlink:label="axgn_FurnitureAndOfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="axgn_FurnitureAndOfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Intangible Assets - Components of Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768132200279" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768132200279" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PatentsAndLicenseAgreementsMember" xlink:label="axgn_PatentsAndLicenseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="axgn_PatentsAndLicenseAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Intangible Assets - License Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637181768132240291" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637181768132240291" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NoticePeriodForTerminationOfLicenseAgreements" xlink:label="axgn_NoticePeriodForTerminationOfLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="axgn_NoticePeriodForTerminationOfLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:label="axgn_RoyaltyFeesPercentageUnderLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="axgn_RoyaltyFeesPercentageUnderLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MinimumRoyaltyOfLicenseAgreement" xlink:label="axgn_MinimumRoyaltyOfLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="axgn_MinimumRoyaltyOfLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:label="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponReceiptOfGrant" xlink:label="axgn_MilestonePaymentContingentUponReceiptOfGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="axgn_MilestonePaymentContingentUponReceiptOfGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponFDApproval" xlink:label="axgn_MilestonePaymentContingentUponFDApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="axgn_MilestonePaymentContingentUponFDApproval" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" xlink:label="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" xlink:label="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637181768132270286" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637181768132270286" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="us-gaap_CapitalLeaseObligationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_CapitalLeaseObligationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637181768132270286" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637181768132270286" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CiscoCapitalMember" xlink:label="axgn_CiscoCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axgn_CiscoCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RaymondLeasingCorporationMember" xlink:label="axgn_RaymondLeasingCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axgn_RaymondLeasingCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_BAndBOfficeSystemsMember" xlink:label="axgn_BAndBOfficeSystemsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axgn_BAndBOfficeSystemsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtAndCapitalLeaseObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LongTermDebtNoncurrentExcludingDeferredRevenue" xlink:label="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt - Terms (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="us-gaap_CapitalLeaseObligationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_CapitalLeaseObligationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CiscoCapitalMember" xlink:label="axgn_CiscoCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axgn_CiscoCapitalMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RaymondLeasingCorporationMember" xlink:label="axgn_RaymondLeasingCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axgn_RaymondLeasingCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_BAndBOfficeSystemsMember" xlink:label="axgn_BAndBOfficeSystemsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axgn_BAndBOfficeSystemsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DebtInstrumentNoPaymentsRequiredTerm" xlink:label="axgn_DebtInstrumentNoPaymentsRequiredTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axgn_DebtInstrumentNoPaymentsRequiredTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm" xlink:label="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Term Loan Agreements and Long-Term Debt - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637181768132310282" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_637181768132310282" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RevolvingLoanAgreementMember" xlink:label="axgn_RevolvingLoanAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="axgn_RevolvingLoanAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Public Offering of Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637181768132320292" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637181768132320292" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CommonStockIssuanceMay2018OfferingMember" xlink:label="axgn_CommonStockIssuanceMay2018OfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="axgn_CommonStockIssuanceMay2018OfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637181768132450283" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637181768132450283" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_UnderwriterMember" xlink:label="axgn_UnderwriterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="axgn_UnderwriterMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" xlink:label="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Equity Compensation Plans - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637181768132470290" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637181768132470290" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AxoGen2010StockIncentivePlanMember" xlink:label="axgn_AxoGen2010StockIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="axgn_AxoGen2010StockIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:label="axgn_Axogen2017EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="axgn_Axogen2017EmployeeStockPurchasePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NewAxogenPlanMember" xlink:label="axgn_NewAxogenPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="axgn_NewAxogenPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768132480302" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768132480302" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DirectorsAndOfficersStockOptionsMember" xlink:label="axgn_DirectorsAndOfficersStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="axgn_DirectorsAndOfficersStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:label="axgn_PerformanceSharesBiologicLicenseApplicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="axgn_PerformanceSharesBiologicLicenseApplicationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637181768132490292" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_637181768132490292" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:label="axgn_ShareBasedCompensationAwardTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="axgn_ShareBasedCompensationAwardTrancheFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" xlink:label="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved" xlink:label="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PhantomStockUnitPayoutOpportunity" xlink:label="axgn_PhantomStockUnitPayoutOpportunity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axgn_PhantomStockUnitPayoutOpportunity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:label="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:label="axgn_EmployeeStockPurchasePlanOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axgn_EmployeeStockPurchasePlanOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:label="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Equity Compensation Plans - Stock Award Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RestrictedAndPerformanceStockUnitsMember" xlink:label="axgn_RestrictedAndPerformanceStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="axgn_RestrictedAndPerformanceStockUnitsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Equity Compensation Plans - Grant Date Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RestrictedAndPerformanceStockUnitsMember" xlink:label="axgn_RestrictedAndPerformanceStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="axgn_RestrictedAndPerformanceStockUnitsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Effective Income Tax Rate and Other information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637181768132640307" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_637181768132640307" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsTax1" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsTax1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CumulativeEffectOnRetainedEarningsTax1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="axgn_DeferredTaxLiabilitiesRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="axgn_DeferredTaxLiabilitiesRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsRightOfUseLiability" xlink:label="axgn_DeferredTaxAssetsRightOfUseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="axgn_DeferredTaxAssetsRightOfUseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Employee Benefit Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637181768132660302" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_637181768132660302" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen401kPlanMember" xlink:label="axgn_Axogen401kPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="axgn_Axogen401kPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="axgn_Axogen401kPlanMember" xlink:to="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="axgn_Axogen401kPlanMember" xlink:to="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:label="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:label="axgn_DefinedContributionPlanEmployeeContributionPercentMatched" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="axgn_DefinedContributionPlanEmployeeContributionPercentMatched" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_637181768132670309" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_637181768132670309" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_SHNMedicalOfficePropertiesTrustMember" xlink:label="axgn_SHNMedicalOfficePropertiesTrustMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="axgn_SHNMedicalOfficePropertiesTrustMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_JaColeMember" xlink:label="axgn_JaColeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="axgn_JaColeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AshleyAvenueLeaseMember" xlink:label="axgn_AshleyAvenueLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="axgn_AshleyAvenueLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_HeightsUnionMember" xlink:label="axgn_HeightsUnionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="axgn_HeightsUnionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_HeightsUnionPremisesMember" xlink:label="axgn_HeightsUnionPremisesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="axgn_HeightsUnionPremisesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637181768132690314" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637181768132690314" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_SecondExpansionLeaseMember" xlink:label="axgn_SecondExpansionLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="axgn_SecondExpansionLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ThirdExpansionLeaseMember" xlink:label="axgn_ThirdExpansionLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="axgn_ThirdExpansionLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AreaOfRealEstatePropertyAdditional" xlink:label="axgn_AreaOfRealEstatePropertyAdditional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="axgn_AreaOfRealEstatePropertyAdditional" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EarlyTerminationPeriod" xlink:label="axgn_EarlyTerminationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="axgn_EarlyTerminationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NoticePeriodForTerminationOfAgreement" xlink:label="axgn_NoticePeriodForTerminationOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="axgn_NoticePeriodForTerminationOfAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails" xlink:type="extended" xlink:title="41406 - Disclosure - Commitments and Contingencies - Service Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_637181768132710303" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_637181768132710303" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_TissueProcessingAgreementMember" xlink:label="axgn_TissueProcessingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="axgn_TissueProcessingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:label="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LicenseFeeAmount" xlink:label="axgn_LicenseFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="axgn_LicenseFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:label="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails" xlink:type="extended" xlink:title="41407 - Disclosure - Commitments and Contingencies - Concentrations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_HeightsUnionMember" xlink:label="axgn_HeightsUnionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="axgn_HeightsUnionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637181768132730311" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637181768132730311" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637181768132730311" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637181768132730311" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DesignBuildAgreementMember" xlink:label="axgn_DesignBuildAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="axgn_DesignBuildAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NumberOfProductsFromWhichRevenueIsDerived" xlink:label="axgn_NumberOfProductsFromWhichRevenueIsDerived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="axgn_NumberOfProductsFromWhichRevenueIsDerived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AreaOfLand" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireLandHeldForUse" xlink:label="us-gaap_PaymentsToAcquireLandHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_PaymentsToAcquireLandHeldForUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBuildings" xlink:label="us-gaap_PaymentsToAcquireBuildings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_PaymentsToAcquireBuildings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:label="axgn_EstimatedCostRelatingToDesignBuildAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="axgn_EstimatedCostRelatingToDesignBuildAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:label="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="us-gaap_BuildingsAndImprovementsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_BuildingsAndImprovementsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_GrantsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CashGrantsReceivable" xlink:label="axgn_CashGrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="axgn_CashGrantsReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails" xlink:type="extended" xlink:title="41408 - Disclosure - Commitments and Contingencies - Litigation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_637181768132770311" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain_637181768132770311" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NovitzkiVsZaderejMember" xlink:label="axgn_NovitzkiVsZaderejMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="axgn_NovitzkiVsZaderejMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ThresholdPeriodForNotFilingResponseToComplaint" xlink:label="axgn_ThresholdPeriodForNotFilingResponseToComplaint" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="axgn_ThresholdPeriodForNotFilingResponseToComplaint" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MinimumNumberOfCandidateElectedToBoard" xlink:label="axgn_MinimumNumberOfCandidateElectedToBoard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="axgn_MinimumNumberOfCandidateElectedToBoard" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_637181768132780315" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_637181768132780315" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForCreditLossMember" xlink:label="us-gaap_AllowanceForCreditLossMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForCreditLossMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>axgn-20191231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.7293.39921 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2020 9:33:36 PM-->
<!--Modified on: 2/24/2020 9:33:36 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net of allowance for doubtful accounts of $1,092 and $1,117, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less current maturities of long-term obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current maturities of long term obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Liabilities, Current, Closing balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Liabilities, Current, Opening balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities, current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Obligations, net of current maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Liabilities, Long-Term, Closing balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Liabilities, Long-Term, Opening balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies - see Note 14</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.01 par value per share; 100,000,000 shares authorized; 39,589,755 and 38,900,875 shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Doubtful Accounts Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold (COGS)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and Marketing Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Financing Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense - deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per common share - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Changes in Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options and employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options and employee stock purchase plan (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RightOfUseAssetAmortization" xlink:label="axgn_RightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_RightOfUseAssetAmortization" xlink:to="axgn_RightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_RightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of amortization expense attributable to right-of-use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_RightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right Of Use Asset Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_RightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Asset Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss on intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of deferred financing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for bad debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for inventory writedown</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-downs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gain (Loss) on Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in investment gains and losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Payment on Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest portion of finance leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments for intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by / (used for) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for equity offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering expenses paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing on revolving loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on revolving loan and prepayment penalties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of long-term debt and prepayment penalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of long-term obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for debt portion of finance leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash, cash equivalents, and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents, and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash flow activity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of fixed assets in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Lease Obligations Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital lease additions</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xlink:label="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xlink:to="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the noncash amount of right of use assets and operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Right of Use Assets and Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset and operating lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_OrganizationAndBusinessAbstract" xlink:label="axgn_OrganizationAndBusinessAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_OrganizationAndBusinessAbstract" xlink:to="axgn_OrganizationAndBusinessAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_OrganizationAndBusinessAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_OrganizationAndBusinessAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Agreements and Long-Term Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Agreements and Long-Term Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Compensation Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Compensation Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Results of Operations (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Results of Operations (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="srt_ValuationAndQualifyingAccountsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsAbstract" xlink:to="srt_ValuationAndQualifyingAccountsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule II - Valuation and Qualifying Accounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule II - Valuation and Qualifying Accounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents and Concentration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Asset and Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of balances of contract receivables and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of fair value financial assets measured on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of long-term obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock unit activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted-average assumptions for options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of weighted average estimated grant date fair value per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of effective income tax rate differs from the statutory federal income tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of total lease expense</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Tabular disclosure for supplemental balance sheet information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of supplemental balance sheet information related to leases</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:label="axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for the information other information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other Information Related to Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other information related to leases</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance and Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance and Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock" xlink:label="axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock" xlink:to="axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Payments for Operating and Capital Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Payments for Operating and Capital Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of commitments relating to noncancelable operating and capital leases prior to adoption of ASC 842</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of quarterly results of operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Uninsured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents balance outside of FDIC limit</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FinanceAndOperatingLeaseRightOfUseAsset" xlink:label="axgn_FinanceAndOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_FinanceAndOperatingLeaseRightOfUseAsset" xlink:to="axgn_FinanceAndOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_FinanceAndOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance and operating lease, right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_FinanceAndOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance and operating lease, right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_FinanceAndOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets recorded</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FinanceAndOperatingLeaseLiabilities" xlink:label="axgn_FinanceAndOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_FinanceAndOperatingLeaseLiabilities" xlink:to="axgn_FinanceAndOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_FinanceAndOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance and operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_FinanceAndOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance and operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_FinanceAndOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities recorded</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DerecognitionOfCapitalLeaseAssets" xlink:label="axgn_DerecognitionOfCapitalLeaseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DerecognitionOfCapitalLeaseAssets" xlink:to="axgn_DerecognitionOfCapitalLeaseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DerecognitionOfCapitalLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derecognition of capital lease assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DerecognitionOfCapitalLeaseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derecognition of capital lease assets</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DerecognitionOfCapitalLeaseLiabilities" xlink:label="axgn_DerecognitionOfCapitalLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DerecognitionOfCapitalLeaseLiabilities" xlink:to="axgn_DerecognitionOfCapitalLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DerecognitionOfCapitalLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derecognition of capital lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DerecognitionOfCapitalLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derecognition of capital lease liabilities</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DerecognitionOfDeferredRent" xlink:label="axgn_DerecognitionOfDeferredRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DerecognitionOfDeferredRent" xlink:to="axgn_DerecognitionOfDeferredRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DerecognitionOfDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derecognition of deferred rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DerecognitionOfDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derecognition of deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities excluded from computation of net loss per share</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:label="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:to="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the age of specific types of trade accounts and notes receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Doubtful Accounts Receivable Age of Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Age of doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms" xlink:label="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms" xlink:to="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Receivables, Closing balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Receivables, Opening balance</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_IncreaseDecreaseInContractReceivable" xlink:label="axgn_IncreaseDecreaseInContractReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_IncreaseDecreaseInContractReceivable" xlink:to="axgn_IncreaseDecreaseInContractReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_IncreaseDecreaseInContractReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_IncreaseDecreaseInContractReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_IncreaseDecreaseInContractReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase/(decrease)</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent" xlink:to="axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase/(decrease)</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent" xlink:to="axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase/(decrease)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work in process</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FurnitureAndOfficeEquipmentMember" xlink:label="axgn_FurnitureAndOfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_FurnitureAndOfficeEquipmentMember" xlink:to="axgn_FurnitureAndOfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment and tangible personal property commonly used in offices.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture And Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Processing equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, at cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets consist of:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-lived intangible assets, gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization period of intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future amortization of patents and license agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NoticePeriodForTerminationOfLicenseAgreements" xlink:label="axgn_NoticePeriodForTerminationOfLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_NoticePeriodForTerminationOfLicenseAgreements" xlink:to="axgn_NoticePeriodForTerminationOfLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_NoticePeriodForTerminationOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period for termination of license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_NoticePeriodForTerminationOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice Period for Termination of License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_NoticePeriodForTerminationOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period for termination of license agreements</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:label="axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:to="axgn_RoyaltyFeesPercentageUnderLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_RoyaltyFeesPercentageUnderLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty fees percentage under license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_RoyaltyFeesPercentageUnderLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Fees Percentage under License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_RoyaltyFeesPercentageUnderLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty fees range under the license agreements</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MinimumRoyaltyOfLicenseAgreement" xlink:label="axgn_MinimumRoyaltyOfLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_MinimumRoyaltyOfLicenseAgreement" xlink:to="axgn_MinimumRoyaltyOfLicenseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_MinimumRoyaltyOfLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_MinimumRoyaltyOfLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Royalty of License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_MinimumRoyaltyOfLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum royalty of agreements</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:label="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:to="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Capping Royalties for Multiple Royalty Payments to Licensors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty stack cap for royalties paid to more than one licensor for sales of the same product</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponReceiptOfGrant" xlink:label="axgn_MilestonePaymentContingentUponReceiptOfGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_MilestonePaymentContingentUponReceiptOfGrant" xlink:to="axgn_MilestonePaymentContingentUponReceiptOfGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_MilestonePaymentContingentUponReceiptOfGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_MilestonePaymentContingentUponReceiptOfGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Contingent upon Receipt of Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_MilestonePaymentContingentUponReceiptOfGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone fee upon receiving a Phase II Small Business Innovation Research</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponFDApproval" xlink:label="axgn_MilestonePaymentContingentUponFDApproval" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_MilestonePaymentContingentUponFDApproval" xlink:to="axgn_MilestonePaymentContingentUponFDApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_MilestonePaymentContingentUponFDApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of milestone payment due if AxoGen receives FDA approval of its Avance Nerve Graft.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_MilestonePaymentContingentUponFDApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Contingent Upon F D A Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_MilestonePaymentContingentUponFDApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone fee upon FDA approval</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" xlink:label="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" xlink:to="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of milestone payment due upon first commercial use of certain licensed technology to provide services to manufacture products for third parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Contingent Upon First Commercial Use of Certain Licensed Technology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone fee upon first commercial use of certain licensed technology</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" xlink:label="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" xlink:to="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of milestone payment due upon first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Contingent Upon First Use to Manufacture Products Utilizing Certain Technology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty fees included in sales and marketing expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous Accruals Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Compensation Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note Payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndCapitalLeaseObligations" xlink:to="us-gaap_DebtAndCapitalLeaseObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term obligations</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LongTermDebtNoncurrentExcludingDeferredRevenue" xlink:label="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue" xlink:to="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding deferred revenue, amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Noncurrent Excluding Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest payable, percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate stated (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of debt</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DebtInstrumentNoPaymentsRequiredTerm" xlink:label="axgn_DebtInstrumentNoPaymentsRequiredTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DebtInstrumentNoPaymentsRequiredTerm" xlink:to="axgn_DebtInstrumentNoPaymentsRequiredTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DebtInstrumentNoPaymentsRequiredTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time between issuance and maturity of debt instrument, during which no payments are required to be made, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DebtInstrumentNoPaymentsRequiredTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, No Payments Required, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_DebtInstrumentNoPaymentsRequiredTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No payments required, term</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm" xlink:label="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm" xlink:to="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time between issuance and maturity of debt instrument, during which interest and principal payments are required, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest and Principal Payments, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and principal payments, term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exit and/or prepayment fees paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" xlink:label="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" xlink:to="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days to underwriter to purchase additional common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Days To Underwriter To Purchase Additional Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days to underwriter to purchase additional common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AxoGen2010StockIncentivePlanMember" xlink:label="axgn_AxoGen2010StockIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_AxoGen2010StockIncentivePlanMember" xlink:to="axgn_AxoGen2010StockIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_AxoGen2010StockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The AxoGen 2010 Stock Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_AxoGen2010StockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Axo Gen2010 Stock Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_AxoGen2010StockIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AxoGen 2010 Stock Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DirectorsAndOfficersStockOptionsMember" xlink:label="axgn_DirectorsAndOfficersStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DirectorsAndOfficersStockOptionsMember" xlink:to="axgn_DirectorsAndOfficersStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DirectorsAndOfficersStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby an officer or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DirectorsAndOfficersStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors And Officers Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_DirectorsAndOfficersStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors and Officers Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares available for issuance</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" xlink:label="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" xlink:to="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Unallocated Shares Of Common Stock Available For Issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Unallocated Shares Of Common Stock Available For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of unallocated shares available for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares authorized for future issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of restricted stock vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future stock compensation expense related to nonvested awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation costs related to non-vested stock options and restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period of recognition of unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted Average Grant Date Fair Value, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted Average Grant Date Fair Value, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date fair value</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved" xlink:label="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved" xlink:to="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Cost Not Yet Recognized, Assumed Percentage Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Cost Not Yet Recognized, Assumed Percentage Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed achievement percentage of PSUs to calculate unrecognized cost</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PhantomStockUnitPayoutOpportunity" xlink:label="axgn_PhantomStockUnitPayoutOpportunity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_PhantomStockUnitPayoutOpportunity" xlink:to="axgn_PhantomStockUnitPayoutOpportunity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_PhantomStockUnitPayoutOpportunity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the payout opportunity of Phantom Stock Units, as a percent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_PhantomStockUnitPayoutOpportunity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phantom Stock Unit, Payout Opportunity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_PhantomStockUnitPayoutOpportunity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payout opportunity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to PSUs</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:label="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:to="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Discount from Market Value on Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Discount from Market Value on Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount from market value on common stock</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:label="axgn_EmployeeStockPurchasePlanOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:to="axgn_EmployeeStockPurchasePlanOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_EmployeeStockPurchasePlanOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_EmployeeStockPurchasePlanOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_EmployeeStockPurchasePlanOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering period</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:label="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:to="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount available to participants per year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average estimated grant date fair value per share</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby an employee, consultant or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Consultants And Directors Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Consultants and Directors Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RestrictedAndPerformanceStockUnitsMember" xlink:label="axgn_RestrictedAndPerformanceStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_RestrictedAndPerformanceStockUnitsMember" xlink:to="axgn_RestrictedAndPerformanceStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_RestrictedAndPerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted and Performance Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_RestrictedAndPerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted And Performance Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_RestrictedAndPerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted and Performance Stock Units [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Time-Based Stock Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Outstanding at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Outstanding at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Outstanding at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Outstanding at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted and Performance Stock Units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Released</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, Grant Date Fair Value (per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average estimated grant date fair value per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Released, Grant Date Fair Value (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited, Grant Date Fair Value (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Differences between the carrying amount of assets and liabilities for financial reporting purposes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write down</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsInterestLimitation" xlink:label="axgn_DeferredTaxAssetsInterestLimitation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DeferredTaxAssetsInterestLimitation" xlink:to="axgn_DeferredTaxAssetsInterestLimitation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DeferredTaxAssetsInterestLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Interest Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DeferredTaxAssetsInterestLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Interest Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_DeferredTaxAssetsInterestLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest limitation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsRightOfUseLiability" xlink:label="axgn_DeferredTaxAssetsRightOfUseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DeferredTaxAssetsRightOfUseLiability" xlink:to="axgn_DeferredTaxAssetsRightOfUseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DeferredTaxAssetsRightOfUseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from right-of-use liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DeferredTaxAssetsRightOfUseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Right-of-use Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_DeferredTaxAssetsRightOfUseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="axgn_DeferredTaxAssetsRightOfUseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="axgn_DeferredTaxLiabilitiesRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="axgn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax consequences attributable to taxable temporary differences derived from right-of-use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Right-of-use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="axgn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:to="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Tax Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsLiabilities" xlink:label="axgn_DeferredTaxAssetsLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DeferredTaxAssetsLiabilities" xlink:to="axgn_DeferredTaxAssetsLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DeferredTaxAssetsLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DeferredTaxAssetsLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets (Liabilities)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="axgn_DeferredTaxAssetsLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal tax benefit rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State Taxes - Net of Federal Benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Deduction, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent items and other deductions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Change in Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsTax1" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsTax1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOnRetainedEarningsTax1" xlink:to="us-gaap_CumulativeEffectOnRetainedEarningsTax1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsTax1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect on Retained Earnings, Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsTax1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in retained earnings related to income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (expense) benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:label="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:to="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined contribution plan minimum age limit for eligibility to participate in plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Minimum Age Limit for Eligibility to Participate in Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Age limit for eligibility to participate in the plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Matching contributions</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:label="axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:to="axgn_DefinedContributionPlanEmployeeContributionPercentMatched_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DefinedContributionPlanEmployeeContributionPercentMatched_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee contribution, as a percent of annual salary, that is matched by the employer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DefinedContributionPlanEmployeeContributionPercentMatched_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employee Contribution, Percent Matched</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_DefinedContributionPlanEmployeeContributionPercentMatched_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee contribution matched, percent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contributions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Operating Leased Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leased Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Size of building space</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Lease Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual lease expense</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AreaOfRealEstatePropertyAdditional" xlink:label="axgn_AreaOfRealEstatePropertyAdditional" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_AreaOfRealEstatePropertyAdditional" xlink:to="axgn_AreaOfRealEstatePropertyAdditional_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_AreaOfRealEstatePropertyAdditional_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the additional area of a real estate property due to agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_AreaOfRealEstatePropertyAdditional_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area Of Real Estate Property Additional</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_AreaOfRealEstatePropertyAdditional_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional leased office space in square feet</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EarlyTerminationPeriod" xlink:label="axgn_EarlyTerminationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_EarlyTerminationPeriod" xlink:to="axgn_EarlyTerminationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_EarlyTerminationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after which the reporting entity has the right to terminate the lease before the expiration of the lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_EarlyTerminationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Early Termination Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_EarlyTerminationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to early termination of lease</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NoticePeriodForTerminationOfAgreement" xlink:label="axgn_NoticePeriodForTerminationOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_NoticePeriodForTerminationOfAgreement" xlink:to="axgn_NoticePeriodForTerminationOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_NoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the notice period for termination of the agreement by either parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_NoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice Period For Termination Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_NoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period for termination of contract</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current maturities of long-term obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LeasesFinanceAbstract" xlink:label="axgn_LeasesFinanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_LeasesFinanceAbstract" xlink:to="axgn_LeasesFinanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_LeasesFinanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_LeasesFinanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases Finance Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_LeasesFinanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current maturities of long-term obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Lease Income, Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for amounts included in the measurement of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-to-use assets obtained in exchange for new finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term - finance leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term - operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate - finance leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate - operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Future Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount" xlink:label="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount" xlink:to="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount represents lessee operating lease lability future payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Future Payments Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less future payments for leases that have not yet commenced</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less imputed interest on commenced leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Lease Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease Liabilities, Payments, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Future Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less imputed interest on commenced leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Lease Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Future Minimum Payments Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Future Minimum Payments Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Future Minimum Payments Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Commitment, Excluding Long-term Commitment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Commitment, Excluding Long-term Commitment [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Commitment Excluding Longterm Commitment [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Commitment, Excluding Long-term Commitment [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_TissueProcessingAgreementMember" xlink:label="axgn_TissueProcessingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_TissueProcessingAgreementMember" xlink:to="axgn_TissueProcessingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_TissueProcessingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment for minimum annual purchases from a tissue processing vendor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_TissueProcessingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tissue Processing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_TissueProcessingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tissue Processing Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:label="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:to="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment for clinical research and related services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Master Services Agreement For Clinical Research And Related Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Master Services Agreement For Clinical Research and Related Services [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Commitment, Excluding Long-term Commitment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service Agreements</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LicenseFeeAmount" xlink:label="axgn_LicenseFeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_LicenseFeeAmount" xlink:to="axgn_LicenseFeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_LicenseFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License fee amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_LicenseFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License fee amount</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:label="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:to="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service agreement amount paid upon execution of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service agreement amount paid upon execution of agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NumberOfProductsFromWhichRevenueIsDerived" xlink:label="axgn_NumberOfProductsFromWhichRevenueIsDerived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_NumberOfProductsFromWhichRevenueIsDerived" xlink:to="axgn_NumberOfProductsFromWhichRevenueIsDerived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_NumberOfProductsFromWhichRevenueIsDerived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of products from which revenue is derived by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_NumberOfProductsFromWhichRevenueIsDerived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Products From Which Revenue Is Derived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_NumberOfProductsFromWhichRevenueIsDerived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of products from which revenue is derived</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of land where building resides</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireLandHeldForUse" xlink:label="us-gaap_PaymentsToAcquireLandHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLandHeldForUse" xlink:to="us-gaap_PaymentsToAcquireLandHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLandHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Land Held-for-use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireLandHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to acquire Land</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBuildings" xlink:label="us-gaap_PaymentsToAcquireBuildings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBuildings" xlink:to="us-gaap_PaymentsToAcquireBuildings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBuildings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Buildings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBuildings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to acquire Building</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:label="axgn_EstimatedCostRelatingToDesignBuildAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:to="axgn_EstimatedCostRelatingToDesignBuildAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_EstimatedCostRelatingToDesignBuildAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of estimated cost relating to design build agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_EstimatedCostRelatingToDesignBuildAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Cost Relating to Design Build Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_EstimatedCostRelatingToDesignBuildAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated cost relating to design build agreement</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:label="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:to="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the additional amount associated with design build agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Costs Associated with Design Build Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional costs associated with design build agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="us-gaap_BuildingsAndImprovementsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingsAndImprovementsGross" xlink:to="us-gaap_BuildingsAndImprovementsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingsAndImprovementsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buildings and Improvements, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingsAndImprovementsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses related to improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable economic development grants from state and local authorities</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CashGrantsReceivable" xlink:label="axgn_CashGrantsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_CashGrantsReceivable" xlink:to="axgn_CashGrantsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_CashGrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of cash grants receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_CashGrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_CashGrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash grants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ThresholdPeriodForNotFilingResponseToComplaint" xlink:label="axgn_ThresholdPeriodForNotFilingResponseToComplaint" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_ThresholdPeriodForNotFilingResponseToComplaint" xlink:to="axgn_ThresholdPeriodForNotFilingResponseToComplaint_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_ThresholdPeriodForNotFilingResponseToComplaint_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period for not filing response to complaint.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_ThresholdPeriodForNotFilingResponseToComplaint_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period for Not Filing Response to Complaint</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_ThresholdPeriodForNotFilingResponseToComplaint_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period for not filing response to complaint</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MinimumNumberOfCandidateElectedToBoard" xlink:label="axgn_MinimumNumberOfCandidateElectedToBoard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_MinimumNumberOfCandidateElectedToBoard" xlink:to="axgn_MinimumNumberOfCandidateElectedToBoard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_MinimumNumberOfCandidateElectedToBoard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum number of candidates elected to board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_MinimumNumberOfCandidateElectedToBoard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Number of Candidate Elected to Board</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_MinimumNumberOfCandidateElectedToBoard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum number of candidates elected to board</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deductions (Chargeoffs)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quoted Prices in Active Markets for Identical Assets (Level 1)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Other Observable Inputs (Level 2)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S Government Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. government securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BondsMember" xlink:label="us-gaap_BondsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BondsMember" xlink:to="us-gaap_BondsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BondsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BondsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate bonds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Backed Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset-backed securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction In Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Projects in process</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trademarks [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trademarks</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PatentsAndLicenseAgreementsMember" xlink:label="axgn_PatentsAndLicenseAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_PatentsAndLicenseAgreementsMember" xlink:to="axgn_PatentsAndLicenseAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_PatentsAndLicenseAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents And License Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_PatentsAndLicenseAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents And License Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_PatentsAndLicenseAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents And License Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling And Marketing Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and Marketing Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="us-gaap_CapitalLeaseObligationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsMember" xlink:to="us-gaap_CapitalLeaseObligationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Lease Obligations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment Lease Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CiscoCapitalMember" xlink:label="axgn_CiscoCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_CiscoCapitalMember" xlink:to="axgn_CiscoCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_CiscoCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Cisco Capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_CiscoCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cisco Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_CiscoCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cisco Capital</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RaymondLeasingCorporationMember" xlink:label="axgn_RaymondLeasingCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_RaymondLeasingCorporationMember" xlink:to="axgn_RaymondLeasingCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_RaymondLeasingCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Raymond leasing corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_RaymondLeasingCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raymond Leasing Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_RaymondLeasingCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raymond Leasing Corporation</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_BAndBOfficeSystemsMember" xlink:label="axgn_BAndBOfficeSystemsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_BAndBOfficeSystemsMember" xlink:to="axgn_BAndBOfficeSystemsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_BAndBOfficeSystemsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to B&amp;B Office systems.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_BAndBOfficeSystemsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B And B Office Systems [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_BAndBOfficeSystemsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">B&amp;B Office Systems</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RevolvingLoanAgreementMember" xlink:label="axgn_RevolvingLoanAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_RevolvingLoanAgreementMember" xlink:to="axgn_RevolvingLoanAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_RevolvingLoanAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revolving Loan Agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_RevolvingLoanAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revolving Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_RevolvingLoanAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revolving Loan Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CommonStockIssuanceMay2018OfferingMember" xlink:label="axgn_CommonStockIssuanceMay2018OfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_CommonStockIssuanceMay2018OfferingMember" xlink:to="axgn_CommonStockIssuanceMay2018OfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_CommonStockIssuanceMay2018OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to May 2018 offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_CommonStockIssuanceMay2018OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Issuance May2018 Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_CommonStockIssuanceMay2018OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">May 2018 Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_UnderwriterMember" xlink:label="axgn_UnderwriterMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_UnderwriterMember" xlink:to="axgn_UnderwriterMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_UnderwriterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriter [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_UnderwriterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriter [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_UnderwriterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriter</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:label="axgn_Axogen2017EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:to="axgn_Axogen2017EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_Axogen2017EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AxoGen 2017 Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_Axogen2017EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Axogen2017 Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_Axogen2017EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AxoGen 2017 Employee Stock Purchase Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NewAxogenPlanMember" xlink:label="axgn_NewAxogenPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_NewAxogenPlanMember" xlink:to="axgn_NewAxogenPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_NewAxogenPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information relating to New Axogen Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_NewAxogenPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Axogen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_NewAxogenPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Axogen Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PSUs</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:label="axgn_PerformanceSharesBiologicLicenseApplicationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:to="axgn_PerformanceSharesBiologicLicenseApplicationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_PerformanceSharesBiologicLicenseApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares or units awarded based on Biologic License Application milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_PerformanceSharesBiologicLicenseApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Shares Biologic License Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_PerformanceSharesBiologicLicenseApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PSU - BLA Milestones [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Year After Grant Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Every Six Months</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Years After Grant Date</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:label="axgn_ShareBasedCompensationAwardTrancheFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:to="axgn_ShareBasedCompensationAwardTrancheFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fourth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per Quarter, Over One Year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for New Accounting Pronouncements [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Adoption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Adoption [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update201602 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASU 2016-02</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen401kPlanMember" xlink:label="axgn_Axogen401kPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_Axogen401kPlanMember" xlink:to="axgn_Axogen401kPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_Axogen401kPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the AxoGen 401K plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_Axogen401kPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Axogen401k Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_Axogen401kPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AxoGen 401K Plan</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:to="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the first tranche of the AxoGen 401K plan where the employer matches a percent of employee contributions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Axogen401k Plan Employer Matching Contribution Tranche1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Axogen 401K Plan, employer's contribution on first 3% of employee contribution</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:to="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the second tranche of the AxoGen 401K plan where the employer matches a percent of employee contributions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Axogen401k Plan Employer Matching Contribution Tranche2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Axogen 401K Plan, employer's contribution on next 2% of employee contribution</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Arrangement, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Arrangement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Arrangement, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_SHNMedicalOfficePropertiesTrustMember" xlink:label="axgn_SHNMedicalOfficePropertiesTrustMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_SHNMedicalOfficePropertiesTrustMember" xlink:to="axgn_SHNMedicalOfficePropertiesTrustMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_SHNMedicalOfficePropertiesTrustMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SNH Medical Office Properties Trust, the lessor of the reporting entity's corporate headquarters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_SHNMedicalOfficePropertiesTrustMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">S H N Medical Office Properties Trust [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_SHNMedicalOfficePropertiesTrustMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SNH</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_JaColeMember" xlink:label="axgn_JaColeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_JaColeMember" xlink:to="axgn_JaColeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_JaColeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ja-cole, the lessor of the reporting entity's warehouse and office space located in Burleson, Texas.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_JaColeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ja Cole [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_JaColeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ja-Cole</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AshleyAvenueLeaseMember" xlink:label="axgn_AshleyAvenueLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_AshleyAvenueLeaseMember" xlink:to="axgn_AshleyAvenueLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_AshleyAvenueLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ashley Avenue Lease [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_AshleyAvenueLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ashley Avenue Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_AshleyAvenueLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ashley Avenue Lease</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_HeightsUnionMember" xlink:label="axgn_HeightsUnionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_HeightsUnionMember" xlink:to="axgn_HeightsUnionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_HeightsUnionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Heights Union, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_HeightsUnionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heights Union [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_HeightsUnionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heights Union</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_HeightsUnionPremisesMember" xlink:label="axgn_HeightsUnionPremisesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_HeightsUnionPremisesMember" xlink:to="axgn_HeightsUnionPremisesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_HeightsUnionPremisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heights Union Premises [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_HeightsUnionPremisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heights Union Premises [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_HeightsUnionPremisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heights Union Premises</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_SecondExpansionLeaseMember" xlink:label="axgn_SecondExpansionLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_SecondExpansionLeaseMember" xlink:to="axgn_SecondExpansionLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_SecondExpansionLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Expansion Lease [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_SecondExpansionLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Expansion Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_SecondExpansionLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Expansion Lease [Member]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ThirdExpansionLeaseMember" xlink:label="axgn_ThirdExpansionLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_ThirdExpansionLeaseMember" xlink:to="axgn_ThirdExpansionLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_ThirdExpansionLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Expansion Lease [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_ThirdExpansionLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Expansion Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_ThirdExpansionLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Expansion Lease [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DesignBuildAgreementMember" xlink:label="axgn_DesignBuildAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_DesignBuildAgreementMember" xlink:to="axgn_DesignBuildAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_DesignBuildAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to design build agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_DesignBuildAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Design Build Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_DesignBuildAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Design build agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NovitzkiVsZaderejMember" xlink:label="axgn_NovitzkiVsZaderejMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axgn_NovitzkiVsZaderejMember" xlink:to="axgn_NovitzkiVsZaderejMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="axgn_NovitzkiVsZaderejMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for case of Novitzki v. Zaderej.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="axgn_NovitzkiVsZaderejMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novitzki Vs Zaderej [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="axgn_NovitzkiVsZaderejMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Case of Novitzki vs Zaderej</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances And Reserves [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForCreditLossMember" xlink:label="us-gaap_AllowanceForCreditLossMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForCreditLossMember" xlink:to="us-gaap_AllowanceForCreditLossMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForCreditLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance For Credit Loss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForCreditLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance Of Deferred Tax Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance for deferred tax assets</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>axgn-20191231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.7293.39921 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2020 9:33:36 PM-->
<!--Modified on: 2/24/2020 9:33:36 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#StatementConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureBasisOfPresentation" roleURI="http://www.axogeninc.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureOrganizationAndBusiness" roleURI="http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureInventories" roleURI="http://www.axogeninc.com/role/DisclosureInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureFairValueOfInvestments" roleURI="http://www.axogeninc.com/role/DisclosureFairValueOfInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.axogeninc.com/role/DisclosurePropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIntangibleAssets" roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureAccountsPayableAndAccruedExpenses" roleURI="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureTermLoanAgreementsAndLongTermDebt" roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosurePublicOfferingOfCommonStock" roleURI="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEquityCompensationPlans" roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIncomeTaxes" roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureQuarterlyResultsOfOperationsUnaudited" roleURI="http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureScheduleIiValuationAndQualifyingAccounts" roleURI="http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureInventoriesTables" roleURI="http://www.axogeninc.com/role/DisclosureInventoriesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureFairValueOfInvestmentsTables" roleURI="http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIntangibleAssetsTables" roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureAccountsPayableAndAccruedExpensesTables" roleURI="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureTermLoanAgreementsAndLongTermDebtTables" roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEquityCompensationPlansTables" roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureQuarterlyResultsOfOperationsUnauditedTables" roleURI="http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails" roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails" roleURI="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureInventoriesDetails" roleURI="http://www.axogeninc.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureFairValueOfInvestmentsDetails" roleURI="http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIntangibleAssetsLicenseAgreementsDetails" roleURI="http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails" roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails" roleURI="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosurePublicOfferingOfCommonStockDetails" roleURI="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosurePublicOfferingOfCommonStockPublicOfferingDetails" roleURI="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEquityCompensationPlansNarrativeDetails" roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEquityCompensationPlansStockAwardActivityDetails" roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails" roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEquityCompensationPlansGrantDateFairValueDetails" roleURI="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIncomeTaxesTemporaryDifferencesDetails" roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" roleURI="http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesLeasesDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesServiceAgreementsDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesConcentrationsDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureCommitmentsAndContingenciesLitigationDetails" roleURI="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureQuarterlyResultsOfOperationsUnauditedDetails" roleURI="http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="axgn-20191231.xsd#DisclosureScheduleIiValuationAndQualifyingAccountsDetails" roleURI="http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637181768132810298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637181768132810298" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637181768132810298" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637181768132810298" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637181768132810298" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637181768132810298" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637181768132810298" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637181768132810298" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637181768132810298" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637181768132810298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637181768132810298" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637181768132820305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637181768132820305" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637181768132820305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637181768132820305" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637181768132820305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637181768132820305" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637181768132820305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637181768132820305" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637181768132820305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637181768132820305" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637181768132820305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637181768132820305" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637181768132820305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637181768132820305" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637181768132830316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637181768132830316" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637181768132830316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637181768132830316" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637181768132830316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637181768132830316" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637181768132830316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637181768132830316" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637181768132830316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637181768132830316" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637181768132830316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637181768132830316" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637181768132830316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637181768132830316" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637181768132830316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637181768132830316" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637181768132830316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637181768132830316" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637181768132840303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637181768132840303" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637181768132840303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637181768132840303" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637181768132840303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637181768132840303" order="29" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637181768132840303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637181768132840303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637181768132840303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637181768132840303" xlink:to="us-gaap_AssetsCurrentAbstract_637181768132840303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637181768132840303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637181768132840303" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637181768132840303" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637181768132840303" xlink:to="us-gaap_RestrictedCash_637181768132850315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637181768132840303" xlink:to="us-gaap_ShortTermInvestments_637181768132850315" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637181768132840303" xlink:to="us-gaap_AccountsReceivableNetCurrent_637181768132850315" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637181768132840303" xlink:to="us-gaap_InventoryNet_637181768132850315" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637181768132840303" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637181768132850315" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637181768132840303" xlink:to="us-gaap_AssetsCurrent_637181768132850315" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637181768132840303" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637181768132850315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637181768132840303" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637181768132850315" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637181768132840303" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637181768132850315" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637181768132840303" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637181768132850315" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637181768132840303" xlink:to="us-gaap_Assets_637181768132850315" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637181768132860305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637181768132860305" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637181768132860305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637181768132860305" xlink:to="us-gaap_LongTermDebtCurrent_637181768132860305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637181768132860305" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637181768132860305" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637181768132860305" xlink:to="us-gaap_LiabilitiesCurrent_637181768132860305" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" xlink:to="us-gaap_LongTermDebtNoncurrent_637181768132860305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637181768132860305" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637181768132860305" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" xlink:to="us-gaap_Liabilities_637181768132860305" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637181768132860305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" xlink:to="us-gaap_CommitmentsAndContingencies_637181768132860305" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637181768132870306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" xlink:to="us-gaap_StockholdersEquityAbstract_637181768132870306" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637181768132870306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637181768132870306" xlink:to="us-gaap_CommonStockValue_637181768132870306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637181768132870306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637181768132870306" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637181768132870306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637181768132870306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637181768132870306" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637181768132870306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637181768132870306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637181768132870306" xlink:to="us-gaap_StockholdersEquity_637181768132870306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637181768132870306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637181768132850315" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637181768132870306" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_637181768132880308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637181768132880308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637181768132880308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637181768132880308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637181768132880308" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_Revenues_637181768132880308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637181768132880308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit_637181768132880308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_637181768132880308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637181768132880308" xlink:to="us-gaap_SellingAndMarketingExpense_637181768132880308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637181768132880308" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637181768132880308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637181768132880308" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637181768132880308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637181768132880308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637181768132880308" xlink:to="us-gaap_CostsAndExpenses_637181768132880308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637181768132880308" xlink:to="us-gaap_OperatingIncomeLoss_637181768132890312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637181768132890312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637181768132890312" xlink:to="us-gaap_InvestmentIncomeNonoperating_637181768132890312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637181768132890312" xlink:to="us-gaap_InterestExpense_637181768132890312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637181768132890312" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637181768132890312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637181768132890312" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637181768132890312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637181768132890312" xlink:to="us-gaap_OtherNonoperatingExpense_637181768132890312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637181768132890312" xlink:to="us-gaap_NonoperatingIncomeExpense_637181768132890312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637181768132890312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637181768132890312" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637181768132890312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637181768132890312" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637181768132900306" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637181768132900306" xlink:to="us-gaap_StatementEquityComponentsAxis_637181768132900306" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637181768132900306" xlink:to="us-gaap_CommonStockMember_637181768132900306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637181768132900306" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637181768132900306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637181768132900306" xlink:to="us-gaap_RetainedEarningsMember_637181768132900306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637181768132900306" xlink:to="us-gaap_EquityComponentDomain_637181768132900306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637181768132900306" xlink:to="us-gaap_StatementLineItems_637181768132900306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768132900306" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" xlink:to="us-gaap_StockholdersEquity_637181768132900306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637181768132900306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" xlink:to="us-gaap_CommonStockSharesOutstanding_637181768132900306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" xlink:to="us-gaap_NetIncomeLoss_637181768132910312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637181768132910312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637181768132910312" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637181768132910312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637181768132910312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637181768132910312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637181768132910312" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637181768132910312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" xlink:to="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_637181768132910312" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_637181768132910312" xlink:to="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_637181768132910312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" xlink:to="us-gaap_StockholdersEquity_637181768132910312" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637181768132910312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637181768132900306" xlink:to="us-gaap_CommonStockSharesOutstanding_637181768132910312" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_635951042978174212" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637181768132920308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635951042978174212" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637181768132920308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637181768132920308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637181768132920308" xlink:to="us-gaap_NetIncomeLoss_637181768132920308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637181768132920308" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637181768132920308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_Depreciation_637181768132920308" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RightOfUseAssetAmortization" xlink:label="axgn_RightOfUseAssetAmortization_637181768132920308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="axgn_RightOfUseAssetAmortization_637181768132920308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_637181768132920308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_AmortizationOfIntangibleAssets_637181768132920308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_637181768132920308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_637181768132920308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_AmortizationOfFinancingCosts_637181768132930330" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637181768132930330" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637181768132930330" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_637181768132930330" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_InventoryWriteDown_637181768132930330" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_637181768132930330" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_ShareBasedCompensation_637181768132930330" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637181768132920308" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637181768132930330" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637181768132930330" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637181768132930330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637181768132930330" xlink:to="us-gaap_IncreaseDecreaseInInventories_637181768132930330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637181768132930330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637181768132930330" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637181768132930330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637181768132940313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637181768132930330" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637181768132940313" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637181768132940313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637181768132930330" xlink:to="us-gaap_OperatingLeasePayments_637181768132940313" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_637181768132940313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637181768132930330" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_637181768132940313" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637181768132940313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637181768132930330" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637181768132940313" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768132940313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637181768132920308" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637181768132940313" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637181768132940313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635951042978174212" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637181768132940313" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637181768132940313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637181768132940313" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637181768132940313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments_637181768132940313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637181768132940313" xlink:to="us-gaap_PaymentsToAcquireInvestments_637181768132940313" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_637181768132940313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637181768132940313" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_637181768132940313" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_637181768132950309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637181768132940313" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_637181768132950309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637181768132950309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637181768132940313" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637181768132950309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635951042978174212" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637181768132950309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637181768132950309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637181768132950309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637181768132950309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit_637181768132950309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" xlink:to="us-gaap_ProceedsFromLinesOfCredit_637181768132950309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_637181768132950309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_637181768132950309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637181768132960318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637181768132960318" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637181768132960318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637181768132960318" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637181768132960318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637181768132960318" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132960318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637181768132950309" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637181768132960318" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637181768132960318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635951042978174212" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637181768132960318" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637181768132960318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635951042978174212" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637181768132960318" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6371817681329603181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635951042978174212" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6371817681329603181" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637181768132970311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635951042978174212" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637181768132970311" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637181768132970311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637181768132970311" xlink:to="us-gaap_InterestPaidNet_637181768132970311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637181768132970311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635951042978174212" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637181768132970311" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637181768132970311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637181768132970311" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637181768132970311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_637181768132970311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637181768132970311" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_637181768132970311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xlink:label="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_637181768132970311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637181768132970311" xlink:to="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_637181768132970311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_637181768132980309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccounting_637181768132980309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness" xlink:type="extended" xlink:title="10201 - Disclosure - Organization and Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_OrganizationAndBusinessAbstract" xlink:label="axgn_OrganizationAndBusinessAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637181768132980309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axgn_OrganizationAndBusinessAbstract" xlink:to="us-gaap_NatureOfOperations_637181768132980309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637181768132980309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637181768132980309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10401 - Disclosure - Inventories" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637181768132980309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_637181768132980309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureFairValueOfInvestments" xlink:type="extended" xlink:title="10501 - Disclosure - Fair Value of Investments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637181768132990322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637181768132990322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10601 - Disclosure - Property and Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637181768133080316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637181768133080316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureIntangibleAssets" xlink:type="extended" xlink:title="10701 - Disclosure - Intangible Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_637181768133080316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_637181768133080316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses" xlink:type="extended" xlink:title="10801 - Disclosure - Accounts Payable and Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637181768133080316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637181768133080316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebt" xlink:type="extended" xlink:title="10901 - Disclosure - Term Loan Agreements and Long-Term Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_637181768133080316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_637181768133080316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock" xlink:type="extended" xlink:title="11001 - Disclosure - Public Offering of Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637181768133080316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637181768133080316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureEquityCompensationPlans" xlink:type="extended" xlink:title="11101 - Disclosure - Equity Compensation Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637181768133090325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637181768133090325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637181768133090325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637181768133090325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="11301 - Disclosure - Employee Benefit Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_635978669781153422" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637181768133090325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_635978669781153422" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637181768133090325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11401 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637181768133090325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637181768133090325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnaudited" xlink:type="extended" xlink:title="11501 - Disclosure - Quarterly Results of Operations (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_637181768133090325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_637181768133090325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts" xlink:type="extended" xlink:title="11601 - Disclosure - Schedule II - Valuation and Qualifying Accounts" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="srt_ValuationAndQualifyingAccountsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_637181768133100322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637181768133100322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock_637181768133100322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637181768133100322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_637181768133100322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_637181768133100322" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637181768133100322" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637181768133100322" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637181768133100322" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637181768133100322" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637181768133100322" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637181768133100322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637181768133100322" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637181768133110318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637181768133110318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_637181768133110318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_637181768133110318" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Inventories (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_636232629809897883" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637181768133110318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636232629809897883" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637181768133110318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Fair Value of Investments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637181768133110318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637181768133110318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30603 - Disclosure - Property and Equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637181768133110318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637181768133110318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Intangible Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_637181768133120321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_637181768133120321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_637181768133120321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_637181768133120321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Accounts Payable and Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_635606464244948744" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637181768133120321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_635606464244948744" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637181768133120321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtTables" xlink:type="extended" xlink:title="30903 - Disclosure - Term Loan Agreements and Long-Term Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_637181768133120321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_637181768133120321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansTables" xlink:type="extended" xlink:title="31103 - Disclosure - Equity Compensation Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_637181768133120321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_637181768133120321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_637181768133120321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_637181768133120321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637181768133120321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637181768133120321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_637181768133120321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_637181768133120321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637181768133130321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637181768133130321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637181768133130321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637181768133130321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31403 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637181768133130321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637181768133130321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_637181768133130321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_637181768133130321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:label="axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_637181768133130321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_637181768133130321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_637181768133130321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_637181768133130321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock" xlink:label="axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock_637181768133130321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock_637181768133130321" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedTables" xlink:type="extended" xlink:title="31501 - Disclosure - Quarterly Results of Operations (Unaudited) (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_636528244978594410" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_637181768133130321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_636528244978594410" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_637181768133130321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_637181768133140326" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_637181768133140326" xlink:to="srt_RangeAxis_637181768133140326" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637181768133140326" xlink:to="srt_RangeMember_637181768133140326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133140326" xlink:to="srt_MinimumMember_637181768133140326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133140326" xlink:to="srt_MaximumMember_637181768133140326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_637181768133140326" xlink:to="us-gaap_StatementLineItems_637181768133140326" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="us-gaap_CashUninsuredAmount_637181768133140326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FinanceAndOperatingLeaseRightOfUseAsset" xlink:label="axgn_FinanceAndOperatingLeaseRightOfUseAsset_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="axgn_FinanceAndOperatingLeaseRightOfUseAsset_637181768133140326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FinanceAndOperatingLeaseLiabilities" xlink:label="axgn_FinanceAndOperatingLeaseLiabilities_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="axgn_FinanceAndOperatingLeaseLiabilities_637181768133140326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DerecognitionOfCapitalLeaseAssets" xlink:label="axgn_DerecognitionOfCapitalLeaseAssets_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="axgn_DerecognitionOfCapitalLeaseAssets_637181768133140326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DerecognitionOfCapitalLeaseLiabilities" xlink:label="axgn_DerecognitionOfCapitalLeaseLiabilities_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="axgn_DerecognitionOfCapitalLeaseLiabilities_637181768133140326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DerecognitionOfDeferredRent" xlink:label="axgn_DerecognitionOfDeferredRent_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="axgn_DerecognitionOfDeferredRent_637181768133140326" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="us-gaap_RestrictedCash_637181768133140326" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_637181768133140326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_637181768133140326" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637181768133150322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637181768133150322" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:label="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_637181768133150322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_637181768133150322" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637181768133150322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637181768133150322" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637181768133150322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133140326" xlink:to="us-gaap_ShareBasedCompensation_637181768133150322" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637181768133150322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637181768133150322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_637181768133150322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash_637181768133150322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637181768133150322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637181768133150322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Summary of Significant Accounting Policies - Contract Balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms" xlink:label="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_637181768133160329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms" xlink:label="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_6371817681331603291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms_6371817681331603291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_IncreaseDecreaseInContractReceivable" xlink:label="axgn_IncreaseDecreaseInContractReceivable_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="axgn_IncreaseDecreaseInContractReceivable_637181768133160329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637181768133160329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_6371817681331603291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_6371817681331603291" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent_637181768133160329" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637181768133160329" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_6371817681331603291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_6371817681331603291" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent" xlink:label="axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent_637181768133160329" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_636232631614369883" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636232631614369883" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637181768133160329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636232631614369883" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637181768133160329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636232631614369883" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637181768133160329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637181768133160329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636232631614369883" xlink:to="us-gaap_InventoryNet_637181768133160329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636232631614369883" xlink:to="us-gaap_InventoryWriteDown_637181768133170323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Investments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637181768133170323" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637181768133170323" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637181768133170323" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637181768133170323" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637181768133170323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637181768133170323" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637181768133170323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637181768133170323" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637181768133170323" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637181768133170323" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637181768133170323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637181768133170323" xlink:to="us-gaap_FairValueInputsLevel1Member_637181768133170323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637181768133170323" xlink:to="us-gaap_FairValueInputsLevel2Member_637181768133170323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637181768133170323" xlink:to="us-gaap_FinancialInstrumentAxis_637181768133170323" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637181768133170323" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637181768133170323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637181768133170323" xlink:to="us-gaap_MoneyMarketFundsMember_637181768133170323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_637181768133170323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637181768133170323" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_637181768133170323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BondsMember" xlink:label="us-gaap_BondsMember_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637181768133170323" xlink:to="us-gaap_BondsMember_637181768133180323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637181768133170323" xlink:to="us-gaap_CommercialPaperMember_637181768133180323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637181768133170323" xlink:to="us-gaap_AssetBackedSecuritiesMember_637181768133180323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637181768133170323" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637181768133180323" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637181768133180323" xlink:to="us-gaap_AssetsFairValueDisclosure_637181768133180323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637181768133180323" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637181768133180323" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637181768133180323" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637181768133180323" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637181768133180323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_FurnitureAndOfficeEquipmentMember" xlink:label="axgn_FurnitureAndOfficeEquipmentMember_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637181768133180323" xlink:to="axgn_FurnitureAndOfficeEquipmentMember_637181768133180323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637181768133180323" xlink:to="us-gaap_LeaseholdImprovementsMember_637181768133180323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637181768133180323" xlink:to="us-gaap_EquipmentMember_637181768133180323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember_637181768133180323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637181768133180323" xlink:to="us-gaap_LandMember_637181768133180323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637181768133180323" xlink:to="us-gaap_ConstructionInProgressMember_637181768133190324" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637181768133180323" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637181768133190324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637181768133190324" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637181768133190324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637181768133190324" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637181768133190324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637181768133190324" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637181768133190324" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637181768133190324" xlink:to="us-gaap_Depreciation_637181768133190324" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Intangible Assets - Components of Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133190324" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133190324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637181768133190324" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637181768133190324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768133190324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768133190324" xlink:to="us-gaap_LicensingAgreementsMember_637181768133190324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768133190324" xlink:to="us-gaap_PatentsMember_637181768133190324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember_637181768133190324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768133190324" xlink:to="us-gaap_TrademarksMember_637181768133190324" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PatentsAndLicenseAgreementsMember" xlink:label="axgn_PatentsAndLicenseAgreementsMember_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768133190324" xlink:to="axgn_PatentsAndLicenseAgreementsMember_637181768133200324" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133190324" xlink:to="srt_RangeAxis_637181768133200324" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637181768133200324" xlink:to="srt_RangeMember_637181768133200324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133200324" xlink:to="srt_MinimumMember_637181768133200324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133200324" xlink:to="srt_MaximumMember_637181768133200324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133190324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133200324" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_637181768133200324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637181768133200324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637181768133200324" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_637181768133200324" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133200324" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637181768133200324" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133200324" xlink:to="us-gaap_AmortizationOfIntangibleAssets_637181768133200324" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_637181768133200324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_637181768133200324" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_637181768133210315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_637181768133210315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_637181768133210315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_637181768133210315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_637181768133210315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_637181768133210315" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_637181768133210315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_637181768133210315" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_637181768133210315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_637181768133210315" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_637181768133210315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_637181768133210315" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637181768133210315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_637181768133200324" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637181768133210315" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Intangible Assets - License Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133220333" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133220333" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637181768133220333" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637181768133220333" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768133220333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637181768133220333" xlink:to="us-gaap_LicensingAgreementsMember_637181768133220333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133220333" xlink:to="srt_RangeAxis_637181768133220333" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637181768133220333" xlink:to="srt_RangeMember_637181768133220333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133220333" xlink:to="srt_MinimumMember_637181768133220333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133220333" xlink:to="srt_MaximumMember_637181768133220333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133220333" xlink:to="us-gaap_IncomeStatementLocationAxis_637181768133220333" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637181768133220333" xlink:to="us-gaap_IncomeStatementLocationDomain_637181768133220333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637181768133220333" xlink:to="us-gaap_SellingAndMarketingExpenseMember_637181768133220333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_637181768133220333" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NoticePeriodForTerminationOfLicenseAgreements" xlink:label="axgn_NoticePeriodForTerminationOfLicenseAgreements_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" xlink:to="axgn_NoticePeriodForTerminationOfLicenseAgreements_637181768133220333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:label="axgn_RoyaltyFeesPercentageUnderLicenseAgreements_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" xlink:to="axgn_RoyaltyFeesPercentageUnderLicenseAgreements_637181768133220333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MinimumRoyaltyOfLicenseAgreement" xlink:label="axgn_MinimumRoyaltyOfLicenseAgreement_637181768133220333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" xlink:to="axgn_MinimumRoyaltyOfLicenseAgreement_637181768133220333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:label="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_637181768133230323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" xlink:to="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_637181768133230323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponReceiptOfGrant" xlink:label="axgn_MilestonePaymentContingentUponReceiptOfGrant_637181768133230323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" xlink:to="axgn_MilestonePaymentContingentUponReceiptOfGrant_637181768133230323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponFDApproval" xlink:label="axgn_MilestonePaymentContingentUponFDApproval_637181768133230323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" xlink:to="axgn_MilestonePaymentContingentUponFDApproval_637181768133230323" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology" xlink:label="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology_637181768133230323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" xlink:to="axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology_637181768133230323" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology" xlink:label="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology_637181768133230323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" xlink:to="axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology_637181768133230323" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_637181768133230323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_637181768133220333" xlink:to="us-gaap_RoyaltyExpense_637181768133230323" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accounts Payable and Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_635646357612935400" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_635646357612935400" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637181768133240337" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637181768133240337" xlink:to="us-gaap_AccountsPayableCurrent_637181768133240337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637181768133240337" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637181768133240337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637181768133240337" xlink:to="us-gaap_AccruedSalariesCurrent_637181768133240337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637181768133240337" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637181768133240337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637181768133240337" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637181768133240337" xlink:to="us-gaap_DebtInstrumentAxis_637181768133240337" order="1" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637181768133240337" xlink:to="us-gaap_DebtInstrumentNameDomain_637181768133240337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="us-gaap_CapitalLeaseObligationsMember_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637181768133240337" xlink:to="us-gaap_CapitalLeaseObligationsMember_637181768133240337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637181768133240337" xlink:to="srt_CounterpartyNameAxis_637181768133240337" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637181768133240337" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133240337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CiscoCapitalMember" xlink:label="axgn_CiscoCapitalMember_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133240337" xlink:to="axgn_CiscoCapitalMember_637181768133240337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RaymondLeasingCorporationMember" xlink:label="axgn_RaymondLeasingCorporationMember_637181768133240337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133240337" xlink:to="axgn_RaymondLeasingCorporationMember_637181768133240337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_BAndBOfficeSystemsMember" xlink:label="axgn_BAndBOfficeSystemsMember_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133240337" xlink:to="axgn_BAndBOfficeSystemsMember_637181768133250328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637181768133240337" xlink:to="us-gaap_DebtInstrumentLineItems_637181768133250328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133250328" xlink:to="us-gaap_DebtAndCapitalLeaseObligations_637181768133250328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133250328" xlink:to="us-gaap_LongTermDebtCurrent_637181768133250328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133250328" xlink:to="us-gaap_LongTermDebtNoncurrent_637181768133250328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LongTermDebtNoncurrentExcludingDeferredRevenue" xlink:label="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133250328" xlink:to="axgn_LongTermDebtNoncurrentExcludingDeferredRevenue_637181768133250328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt - Terms (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_636186900581940299" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_636186900581940299" xlink:to="us-gaap_DebtInstrumentTable_637181768133250328" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637181768133250328" xlink:to="us-gaap_DebtInstrumentAxis_637181768133250328" order="1" use="optional" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637181768133250328" xlink:to="us-gaap_DebtInstrumentNameDomain_637181768133250328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="us-gaap_CapitalLeaseObligationsMember_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637181768133250328" xlink:to="us-gaap_CapitalLeaseObligationsMember_637181768133250328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637181768133250328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637181768133250328" xlink:to="srt_CounterpartyNameAxis_637181768133250328" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637181768133250328" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133260334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CiscoCapitalMember" xlink:label="axgn_CiscoCapitalMember_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133260334" xlink:to="axgn_CiscoCapitalMember_637181768133260334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RaymondLeasingCorporationMember" xlink:label="axgn_RaymondLeasingCorporationMember_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133260334" xlink:to="axgn_RaymondLeasingCorporationMember_637181768133260334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_BAndBOfficeSystemsMember" xlink:label="axgn_BAndBOfficeSystemsMember_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637181768133260334" xlink:to="axgn_BAndBOfficeSystemsMember_637181768133260334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637181768133250328" xlink:to="us-gaap_DebtInstrumentLineItems_637181768133260334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133260334" xlink:to="us-gaap_DebtInstrumentFaceAmount_637181768133260334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133260334" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637181768133260334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133260334" xlink:to="us-gaap_DebtInstrumentTerm_637181768133260334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DebtInstrumentNoPaymentsRequiredTerm" xlink:label="axgn_DebtInstrumentNoPaymentsRequiredTerm_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133260334" xlink:to="axgn_DebtInstrumentNoPaymentsRequiredTerm_637181768133260334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm" xlink:label="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133260334" xlink:to="axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm_637181768133260334" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637181768133260334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133260334" xlink:to="us-gaap_InterestExpense_637181768133260334" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Term Loan Agreements and Long-Term Debt - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_636186921909053184" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_636186921909053184" xlink:to="us-gaap_DebtInstrumentTable_637181768133270327" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637181768133270327" xlink:to="us-gaap_LongtermDebtTypeAxis_637181768133270327" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_637181768133270327" xlink:to="us-gaap_LongtermDebtTypeDomain_637181768133270327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RevolvingLoanAgreementMember" xlink:label="axgn_RevolvingLoanAgreementMember_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637181768133270327" xlink:to="axgn_RevolvingLoanAgreementMember_637181768133270327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637181768133270327" xlink:to="us-gaap_DebtInstrumentLineItems_637181768133270327" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133270327" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637181768133270327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133270327" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637181768133270327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133270327" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_637181768133270327" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637181768133270327" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637181768133270327" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Public Offering of Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_637181768133270327" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637181768133270327" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637181768133270327" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637181768133270327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637181768133270327" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637181768133270327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CommonStockIssuanceMay2018OfferingMember" xlink:label="axgn_CommonStockIssuanceMay2018OfferingMember_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637181768133270327" xlink:to="axgn_CommonStockIssuanceMay2018OfferingMember_637181768133280329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637181768133270327" xlink:to="srt_TitleOfIndividualAxis_637181768133280329" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637181768133280329" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637181768133280329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_UnderwriterMember" xlink:label="axgn_UnderwriterMember_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637181768133280329" xlink:to="axgn_UnderwriterMember_637181768133280329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637181768133270327" xlink:to="us-gaap_StatementLineItems_637181768133280329" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133280329" xlink:to="us-gaap_CommonStockSharesAuthorized_637181768133280329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133280329" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637181768133280329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133280329" xlink:to="us-gaap_CommonStockSharesIssued_637181768133280329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133280329" xlink:to="us-gaap_SharePrice_637181768133280329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares" xlink:label="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133280329" xlink:to="axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares_637181768133280329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637181768133280329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133280329" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637181768133280329" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Public Offering of Common Stock - Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_636235383586589195" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636235383586589195" xlink:to="us-gaap_CommonStockSharesIssued_637181768133290326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636235383586589195" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637181768133290326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636235383586589195" xlink:to="us-gaap_SharePrice_637181768133290326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636235383586589195" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637181768133290326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636235383586589195" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637181768133290326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Equity Compensation Plans - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636235456327489344" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636235456327489344" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133290326" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133290326" xlink:to="us-gaap_PlanNameAxis_637181768133290326" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637181768133290326" xlink:to="us-gaap_PlanNameDomain_637181768133290326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AxoGen2010StockIncentivePlanMember" xlink:label="axgn_AxoGen2010StockIncentivePlanMember_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637181768133290326" xlink:to="axgn_AxoGen2010StockIncentivePlanMember_637181768133290326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:label="axgn_Axogen2017EmployeeStockPurchasePlanMember_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637181768133290326" xlink:to="axgn_Axogen2017EmployeeStockPurchasePlanMember_637181768133290326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NewAxogenPlanMember" xlink:label="axgn_NewAxogenPlanMember_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637181768133290326" xlink:to="axgn_NewAxogenPlanMember_637181768133290326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637181768133290326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133290326" xlink:to="us-gaap_AwardTypeAxis_637181768133290326" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637181768133290326" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133300330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DirectorsAndOfficersStockOptionsMember" xlink:label="axgn_DirectorsAndOfficersStockOptionsMember_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133300330" xlink:to="axgn_DirectorsAndOfficersStockOptionsMember_637181768133300330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133300330" xlink:to="us-gaap_EmployeeStockOptionMember_637181768133300330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133300330" xlink:to="us-gaap_PerformanceSharesMember_637181768133300330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:label="axgn_PerformanceSharesBiologicLicenseApplicationMember_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PerformanceSharesMember_637181768133300330" xlink:to="axgn_PerformanceSharesBiologicLicenseApplicationMember_637181768133300330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133300330" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637181768133300330" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133290326" xlink:to="us-gaap_VestingAxis_637181768133300330" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637181768133300330" xlink:to="us-gaap_VestingDomain_637181768133300330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637181768133300330" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637181768133300330" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637181768133300330" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637181768133300330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637181768133300330" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637181768133300330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:label="axgn_ShareBasedCompensationAwardTrancheFourMember_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637181768133300330" xlink:to="axgn_ShareBasedCompensationAwardTrancheFourMember_637181768133300330" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637181768133300330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133290326" xlink:to="srt_RangeAxis_637181768133300330" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637181768133310323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637181768133300330" xlink:to="srt_RangeMember_637181768133310323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637181768133310323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133310323" xlink:to="srt_MinimumMember_637181768133310323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637181768133310323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133310323" xlink:to="srt_MaximumMember_637181768133310323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133290326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637181768133310323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637181768133310323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637181768133310323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637181768133310323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance" xlink:label="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance_637181768133310323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance_637181768133310323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637181768133310323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637181768133310323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637181768133310323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637181768133310323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637181768133320326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637181768133320326" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637181768133320326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637181768133320326" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637181768133320326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637181768133320326" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637181768133320326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensation_637181768133320326" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637181768133320326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637181768133320326" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637181768133320326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637181768133320326" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637181768133320326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637181768133320326" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637181768133320326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637181768133320326" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved" xlink:label="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved_637181768133330323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved_637181768133330323" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_PhantomStockUnitPayoutOpportunity" xlink:label="axgn_PhantomStockUnitPayoutOpportunity_637181768133330323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="axgn_PhantomStockUnitPayoutOpportunity_637181768133330323" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637181768133330323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_637181768133330323" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:label="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_637181768133330323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_637181768133330323" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:label="axgn_EmployeeStockPurchasePlanOfferingPeriod_637181768133330323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="axgn_EmployeeStockPurchasePlanOfferingPeriod_637181768133330323" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:label="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_637181768133330323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_637181768133330323" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637181768133340322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637181768133340322" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637181768133340322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637181768133340322" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637181768133340322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637181768133340322" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637181768133340322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637181768133340322" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637181768133340322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133310323" xlink:to="us-gaap_SharePrice_637181768133340322" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Equity Compensation Plans - Stock Award Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133350325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133350325" xlink:to="us-gaap_AwardTypeAxis_637181768133350325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133350325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133350325" xlink:to="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_637181768133350325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RestrictedAndPerformanceStockUnitsMember" xlink:label="axgn_RestrictedAndPerformanceStockUnitsMember_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133350325" xlink:to="axgn_RestrictedAndPerformanceStockUnitsMember_637181768133350325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133350325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637181768133350325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637181768133350325" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637181768133350325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637181768133350325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637181768133350325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6371817681333503251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6371817681333503251" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637181768133360335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637181768133360335" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637181768133360335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637181768133360335" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637181768133360335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637181768133360335" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637181768133360335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637181768133360335" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637181768133360335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637181768133360335" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637181768133360335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637181768133360335" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6371817681333603351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6371817681333603351" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637181768133360335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637181768133360335" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637181768133360335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637181768133360335" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637181768133360335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637181768133360335" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637181768133370325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637181768133370325" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637181768133370325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637181768133370325" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637181768133370325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637181768133370325" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637181768133370325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637181768133370325" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637181768133370325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637181768133350325" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637181768133370325" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133350325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637181768133370325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637181768133370325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637181768133370325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637181768133370325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637181768133370325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637181768133370325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637181768133380325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637181768133380325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637181768133380325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637181768133380325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637181768133380325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637181768133380325" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637181768133380325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637181768133380325" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637181768133380325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637181768133380325" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637181768133380325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637181768133380325" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6371817681333803251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637181768133370325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6371817681333803251" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Equity Compensation Plans - Summary of Weighted-Average Assumptions Used (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636292538095919335" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636292538095919335" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637181768133400355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637181768133400355" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637181768133400355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637181768133400355" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637181768133400355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637181768133400355" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637181768133400355" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Equity Compensation Plans - Grant Date Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636855701818778015" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636855701818778015" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133400355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133400355" xlink:to="us-gaap_AwardTypeAxis_637181768133400355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637181768133400355" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133400355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133400355" xlink:to="axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_637181768133400355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_RestrictedAndPerformanceStockUnitsMember" xlink:label="axgn_RestrictedAndPerformanceStockUnitsMember_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637181768133400355" xlink:to="axgn_RestrictedAndPerformanceStockUnitsMember_637181768133400355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637181768133400355" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133400355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637181768133400355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133400355" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637181768133400355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637181768133400355" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637181768133410340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Temporary Differences (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_635576213510601905" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635576213510601905" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637181768133410340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637181768133410340" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637181768133410340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" xlink:to="us-gaap_DeferredTaxAssetsInventory_637181768133410340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637181768133410340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637181768133410340" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsInterestLimitation" xlink:label="axgn_DeferredTaxAssetsInterestLimitation_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" xlink:to="axgn_DeferredTaxAssetsInterestLimitation_637181768133410340" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_637181768133410340" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsRightOfUseLiability" xlink:label="axgn_DeferredTaxAssetsRightOfUseLiability_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" xlink:to="axgn_DeferredTaxAssetsRightOfUseLiability_637181768133410340" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637181768133410340" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637181768133410340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637181768133410340" xlink:to="us-gaap_DeferredTaxAssetsGross_637181768133410340" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637181768133410340" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637181768133420337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637181768133420337" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637181768133420337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637181768133420337" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_637181768133420337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="axgn_DeferredTaxLiabilitiesRightOfUseAsset_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637181768133420337" xlink:to="axgn_DeferredTaxLiabilitiesRightOfUseAsset_637181768133420337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637181768133420337" xlink:to="us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_637181768133420337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsLiabilities" xlink:label="axgn_DeferredTaxAssetsLiabilities_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637181768133410340" xlink:to="axgn_DeferredTaxAssetsLiabilities_637181768133420337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637181768133410340" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637181768133420337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Effective Income Tax Rate and Other information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637181621370305320" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637181621370305320" xlink:to="us-gaap_StatementTable_637181768133420337" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637181768133420337" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637181768133420337" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637181768133420337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637181768133420337" xlink:to="us-gaap_TypeOfAdoptionMember_637181768133420337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637181768133420337" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_637181768133430338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637181768133420337" xlink:to="us-gaap_StatementLineItems_637181768133430338" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133430338" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637181768133430338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637181768133430338" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637181768133430338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637181768133430338" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637181768133430338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637181768133430338" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_637181768133430338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637181768133430338" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637181768133430338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637181768133430338" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637181768133430338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133430338" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637181768133430338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsTax1" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsTax1_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133430338" xlink:to="us-gaap_CumulativeEffectOnRetainedEarningsTax1_637181768133430338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="axgn_DeferredTaxLiabilitiesRightOfUseAsset_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133430338" xlink:to="axgn_DeferredTaxLiabilitiesRightOfUseAsset_637181768133430338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DeferredTaxAssetsRightOfUseLiability" xlink:label="axgn_DeferredTaxAssetsRightOfUseLiability_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133430338" xlink:to="axgn_DeferredTaxAssetsRightOfUseLiability_637181768133430338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637181768133430338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637181768133430338" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637181768133430338" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Employee Benefit Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_635978668645453422" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_635978668645453422" xlink:to="us-gaap_DefinedContributionPlanTable_637181768133440334" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_637181768133440334" xlink:to="us-gaap_RetirementPlanTypeAxis_637181768133440334" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637181768133440334" xlink:to="us-gaap_RetirementPlanTypeDomain_637181768133440334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen401kPlanMember" xlink:label="axgn_Axogen401kPlanMember_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637181768133440334" xlink:to="axgn_Axogen401kPlanMember_637181768133440334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axgn_Axogen401kPlanMember_637181768133440334" xlink:to="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_637181768133440334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:label="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axgn_Axogen401kPlanMember_637181768133440334" xlink:to="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_637181768133440334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_637181768133440334" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_637181768133440334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:label="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637181768133440334" xlink:to="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_637181768133440334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637181768133440334" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637181768133440334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:label="axgn_DefinedContributionPlanEmployeeContributionPercentMatched_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637181768133440334" xlink:to="axgn_DefinedContributionPlanEmployeeContributionPercentMatched_637181768133440334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_637181768133440334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_637181768133440334" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_637181768133440334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Commitments and Contingencies - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_637181768133450340" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable_637181768133450340" xlink:to="us-gaap_LeaseArrangementTypeAxis_637181768133450340" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis_637181768133450340" xlink:to="us-gaap_LeaseArrangementTypeDomain_637181768133450340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_SHNMedicalOfficePropertiesTrustMember" xlink:label="axgn_SHNMedicalOfficePropertiesTrustMember_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_637181768133450340" xlink:to="axgn_SHNMedicalOfficePropertiesTrustMember_637181768133450340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_JaColeMember" xlink:label="axgn_JaColeMember_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_637181768133450340" xlink:to="axgn_JaColeMember_637181768133450340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AshleyAvenueLeaseMember" xlink:label="axgn_AshleyAvenueLeaseMember_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_637181768133450340" xlink:to="axgn_AshleyAvenueLeaseMember_637181768133450340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_HeightsUnionMember" xlink:label="axgn_HeightsUnionMember_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_637181768133450340" xlink:to="axgn_HeightsUnionMember_637181768133450340" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_HeightsUnionPremisesMember" xlink:label="axgn_HeightsUnionPremisesMember_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_637181768133450340" xlink:to="axgn_HeightsUnionPremisesMember_637181768133450340" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable_637181768133450340" xlink:to="srt_RangeAxis_637181768133450340" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637181768133450340" xlink:to="srt_RangeMember_637181768133450340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133450340" xlink:to="srt_MinimumMember_637181768133450340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637181768133450340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133450340" xlink:to="srt_MaximumMember_637181768133450340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable_637181768133450340" xlink:to="us-gaap_TypeOfArrangementAxis_637181768133460342" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637181768133460342" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637181768133460342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_SecondExpansionLeaseMember" xlink:label="axgn_SecondExpansionLeaseMember_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637181768133460342" xlink:to="axgn_SecondExpansionLeaseMember_637181768133460342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ThirdExpansionLeaseMember" xlink:label="axgn_ThirdExpansionLeaseMember_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637181768133460342" xlink:to="axgn_ThirdExpansionLeaseMember_637181768133460342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable_637181768133450340" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_637181768133460342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems_637181768133460342" xlink:to="us-gaap_AreaOfRealEstateProperty_637181768133460342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems_637181768133460342" xlink:to="us-gaap_LeaseAndRentalExpense_637181768133460342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AreaOfRealEstatePropertyAdditional" xlink:label="axgn_AreaOfRealEstatePropertyAdditional_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems_637181768133460342" xlink:to="axgn_AreaOfRealEstatePropertyAdditional_637181768133460342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EarlyTerminationPeriod" xlink:label="axgn_EarlyTerminationPeriod_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems_637181768133460342" xlink:to="axgn_EarlyTerminationPeriod_637181768133460342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NoticePeriodForTerminationOfAgreement" xlink:label="axgn_NoticePeriodForTerminationOfAgreement_637181768133460342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems_637181768133460342" xlink:to="axgn_NoticePeriodForTerminationOfAgreement_637181768133460342" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Commitments and Contingencies - Lease Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_637181768133470339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract_637181768133470339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637181768133470339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637181768133470339" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637181768133470339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_637181768133470339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637181768133470339" xlink:to="us-gaap_FinanceLeaseInterestExpense_637181768133470339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637181768133470339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_637181768133470339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_637181768133470339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ShortTermLeaseCost_637181768133470339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637181768133470339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_VariableLeaseCost_637181768133470339" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_637181768133470339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost_637181768133470339" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract_637181768133470339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_637181768133470339" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637181768133470339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_637181768133470339" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637181768133470339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_637181768133470339" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637181768133480342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_637181768133480342" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637181768133480342" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_637181768133470339" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637181768133480342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent_637181768133480342" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637181768133480342" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LeasesFinanceAbstract" xlink:label="axgn_LeasesFinanceAbstract_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="axgn_LeasesFinanceAbstract_637181768133480342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axgn_LeasesFinanceAbstract_637181768133480342" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637181768133480342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axgn_LeasesFinanceAbstract_637181768133480342" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637181768133480342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axgn_LeasesFinanceAbstract_637181768133480342" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637181768133480342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails" xlink:type="extended" xlink:title="41404 - Disclosure - Commitments and Contingencies - Other Information Related to Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_637181768133480342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_637181768133480342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_637181768133480342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_637181768133490340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637181768133490340" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_637181768133490340" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637181768133490340" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41405 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637181768133490340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637181768133490340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637181768133490340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637181768133490340" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637181768133490340" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637181768133490340" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637181768133490340" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount" xlink:label="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount_637181768133490340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount_637181768133490340" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637181768133500339" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_OperatingLeaseLiability_637181768133500339" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637181768133490340" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637181768133500339" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637181768133500339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_637181768133500339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_637181768133500339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_637181768133500339" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_637181768133500339" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_637181768133500339" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_637181768133500339" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_637181768133500339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637181768133500339" xlink:to="us-gaap_FinanceLeaseLiability_637181768133500339" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637181768133510337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637181768133510337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637181768133510337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637181768133510337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637181768133510337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637181768133510337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637181768133510337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637181768133510337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_637181768133510337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_637181768133510337" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_637181768133510337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_637181768133510337" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637181768133510337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637181768133510337" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_637181768133520333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_637181768133520333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_637181768133520333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_637181768133520333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_637181768133520333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_637181768133520333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_637181768133520333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_637181768133520333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_637181768133520333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_637181768133510337" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_637181768133520333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_637181768133520333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_637181768133520333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails" xlink:type="extended" xlink:title="41406 - Disclosure - Commitments and Contingencies - Service Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_637181768133530338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_637181768133530338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_637181768133530338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_637181768133530338" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_637181768133530338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_637181768133530338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_637181768133530338" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_637181768133530338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_TissueProcessingAgreementMember" xlink:label="axgn_TissueProcessingAgreementMember_637181768133530338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_637181768133530338" xlink:to="axgn_TissueProcessingAgreementMember_637181768133530338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:label="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_637181768133530338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_637181768133530338" xlink:to="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_637181768133530338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_637181768133530338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_637181768133530338" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_637181768133530338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_LicenseFeeAmount" xlink:label="axgn_LicenseFeeAmount_637181768133530338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_637181768133530338" xlink:to="axgn_LicenseFeeAmount_637181768133530338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:label="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_637181768133530338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_637181768133530338" xlink:to="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_637181768133530338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails" xlink:type="extended" xlink:title="41407 - Disclosure - Commitments and Contingencies - Concentrations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_637181768133600336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ConcentrationRiskTable_637181768133600336" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis_637181768133600336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637181768133600336" xlink:to="us-gaap_LeaseArrangementTypeAxis_637181768133600336" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_637181768133600336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis_637181768133600336" xlink:to="us-gaap_LeaseArrangementTypeDomain_637181768133600336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_HeightsUnionMember" xlink:label="axgn_HeightsUnionMember_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_637181768133600336" xlink:to="axgn_HeightsUnionMember_637181768133610359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637181768133600336" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_637181768133610359" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_637181768133610359" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637181768133610359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_637181768133610359" xlink:to="us-gaap_SupplierConcentrationRiskMember_637181768133610359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637181768133600336" xlink:to="srt_StatementScenarioAxis_637181768133610359" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637181768133610359" xlink:to="srt_ScenarioUnspecifiedDomain_637181768133610359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637181768133610359" xlink:to="srt_ScenarioForecastMember_637181768133610359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637181768133600336" xlink:to="srt_RangeAxis_637181768133610359" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637181768133610359" xlink:to="srt_RangeMember_637181768133610359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637181768133610359" xlink:to="srt_MaximumMember_637181768133610359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637181768133600336" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_637181768133610359" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_637181768133610359" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_637181768133610359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_DesignBuildAgreementMember" xlink:label="axgn_DesignBuildAgreementMember_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_637181768133610359" xlink:to="axgn_DesignBuildAgreementMember_637181768133610359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_637181768133610359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637181768133600336" xlink:to="us-gaap_ConcentrationRiskLineItems_637181768133610359" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NumberOfProductsFromWhichRevenueIsDerived" xlink:label="axgn_NumberOfProductsFromWhichRevenueIsDerived_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="axgn_NumberOfProductsFromWhichRevenueIsDerived_637181768133620342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="us-gaap_AreaOfRealEstateProperty_637181768133620342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="us-gaap_AreaOfLand_637181768133620342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireLandHeldForUse" xlink:label="us-gaap_PaymentsToAcquireLandHeldForUse_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="us-gaap_PaymentsToAcquireLandHeldForUse_637181768133620342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBuildings" xlink:label="us-gaap_PaymentsToAcquireBuildings_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="us-gaap_PaymentsToAcquireBuildings_637181768133620342" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:label="axgn_EstimatedCostRelatingToDesignBuildAgreement_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="axgn_EstimatedCostRelatingToDesignBuildAgreement_637181768133620342" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:label="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_637181768133620342" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="us-gaap_BuildingsAndImprovementsGross_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="us-gaap_BuildingsAndImprovementsGross_637181768133620342" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="us-gaap_GrantsReceivable_637181768133620342" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_CashGrantsReceivable" xlink:label="axgn_CashGrantsReceivable_637181768133620342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637181768133610359" xlink:to="axgn_CashGrantsReceivable_637181768133620342" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails" xlink:type="extended" xlink:title="41408 - Disclosure - Commitments and Contingencies - Litigation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_637181768133630339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable_637181768133630339" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_637181768133630339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637181768133630339" xlink:to="srt_LitigationCaseAxis_637181768133630339" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_637181768133630339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_637181768133630339" xlink:to="srt_LitigationCaseTypeDomain_637181768133630339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_NovitzkiVsZaderejMember" xlink:label="axgn_NovitzkiVsZaderejMember_637181768133630339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_637181768133630339" xlink:to="axgn_NovitzkiVsZaderejMember_637181768133630339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_637181768133630339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637181768133630339" xlink:to="us-gaap_LossContingenciesLineItems_637181768133630339" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_ThresholdPeriodForNotFilingResponseToComplaint" xlink:label="axgn_ThresholdPeriodForNotFilingResponseToComplaint_637181768133630339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637181768133630339" xlink:to="axgn_ThresholdPeriodForNotFilingResponseToComplaint_637181768133630339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="axgn-20191231.xsd#axgn_MinimumNumberOfCandidateElectedToBoard" xlink:label="axgn_MinimumNumberOfCandidateElectedToBoard_637181768133630339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637181768133630339" xlink:to="axgn_MinimumNumberOfCandidateElectedToBoard_637181768133630339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Quarterly Results of Operations (Unaudited) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637181768133640358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_Revenues_637181768133640358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637181768133640358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_GrossProfit_637181768133640358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637181768133640358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss_637181768133640358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637181768133640358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637181768133640358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="srt_ValuationAndQualifyingAccountsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_637181768133640358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsAbstract" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_637181768133640358" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_637181768133640358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_637181768133640358" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_637181768133640358" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_637181768133650881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis_637181768133640358" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_637181768133650881" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForCreditLossMember" xlink:label="us-gaap_AllowanceForCreditLossMember_637181768133650881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain_637181768133650881" xlink:to="us-gaap_AllowanceForCreditLossMember_637181768133650881" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_637181768133650881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain_637181768133650881" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_637181768133650881" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_637181768133650881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_637181768133640358" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_637181768133650881" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_637181768133650881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_637181768133650881" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_637181768133650881" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_637181768133650881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_637181768133650881" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_637181768133650881" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_637181768133650881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_637181768133650881" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_637181768133650881" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_6371817681336508811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_637181768133650881" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_6371817681336508811" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6798222576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanMember', window );">AxoGen 401K Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan', window );">Age limit for eligibility to participate in the plan | item</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contributions | $</a></td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">$ 439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member', window );">Axogen 401K Plan, employer's contribution on first 3% of employee contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contributions</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DefinedContributionPlanEmployeeContributionPercentMatched', window );">Employee contribution matched, percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member', window );">Axogen 401K Plan, employer's contribution on next 2% of employee contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contributions</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DefinedContributionPlanEmployeeContributionPercentMatched', window );">Employee contribution matched, percent</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DefinedContributionPlanEmployeeContributionPercentMatched">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee contribution, as a percent of annual salary, that is matched by the employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DefinedContributionPlanEmployeeContributionPercentMatched</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan minimum age limit for eligibility to participate in plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6798031168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Compensation Plans - Summary of Weighted-Average Assumptions Used (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
<td class="text">6 years 2 months 19 days<span></span>
</td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">54.97%<span></span>
</td>
<td class="nump">50.99%<span></span>
</td>
<td class="nump">50.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate (as a percent)</a></td>
<td class="nump">1.71%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.12%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811414672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Other Information Related to Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 1,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-to-use assets obtained in exchange for new finance lease liabilities</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - finance leases</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - finance leases</a></td>
<td class="nump">7.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">6.28%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803711936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 10,403<span></span>
</td>
<td class="nump">$ 9,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">2,728<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">13,861<span></span>
</td>
<td class="nump">11,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 1,887<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="nump">$ 1,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806015216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Agreements and Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Term Loan Agreements and Long-Term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of long-term obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Equipment Lease Agreement with Cisco Capital for a total lease amount of </span><span style="font-size:10pt;">$59</span><span style="font-size:10pt;"> which has a </span><span style="font-size:10pt;">36 month</span><span style="font-size:10pt;"> term and requires no lease payments for the first </span><span style="font-size:10pt;">three months</span><span style="font-size:10pt;"> of the lease and </span><span style="font-size:10pt;">33</span><span style="font-size:10pt;white-space:pre-wrap;"> equal payments of principal and interest until the end of the term.  Interest on the lease is payable monthly at </span><span style="font-size:10pt;">3.5%</span><span style="font-size:10pt;"> per annum.</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Equipment Lease Agreement with Raymond Leasing Corporation for a total lease amount of </span><span style="font-size:10pt;">$30</span><span style="font-size:10pt;"> which has a </span><span style="font-size:10pt;">48 month</span><span style="font-size:10pt;white-space:pre-wrap;"> term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at </span><span style="font-size:10pt;">6.7%</span><span style="font-size:10pt;"> per annum.</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Equipment Lease Agreement with B&amp;B Office Systems for a total lease amount of </span><span style="font-size:10pt;">$32</span><span style="font-size:10pt;"> which has a </span><span style="font-size:10pt;">60 month</span><span style="font-size:10pt;white-space:pre-wrap;"> term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at </span><span style="font-size:10pt;">8.5%</span><span style="font-size:10pt;"> per annum.</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less current revolving loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less current maturities of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Long-term portion</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">  &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805991504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Results of Operations (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of quarterly results of operations</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quarter</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">First</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Second</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Third</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fourth</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,285</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,701</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,564</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,162</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,712</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,363</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (9,504)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7,022)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (5,571)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7,038)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (29,135)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss per common share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.74)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,260</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,584</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,433</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,937</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,014</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (5,644)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7,427)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (4,102)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (5,224)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (22,397)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss per common share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.60)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6669597824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Compensation Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">11.</b></span><b style="font-weight:bold;">Equity Compensation Plans </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company maintains two share-based incentive plans:  the Axogen 2017 Stock Incentive Plan, as amended (&#8220;2017 Plan&#8221;), and the Axogen 2017 Employee Stock Purchase Plan (&#8220;2017 ESPP&#8221;). </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Stock Incentive Plan</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">At the 2019 Annual Meeting of Shareholders held on August 14, 2019, the shareholders approved the Axogen 2019 Long-Term Incentive Plan (the &#8220;New Axogen Plan&#8221;), which allows for issuance of incentive stock options, non-qualified stock options, performance stock units (&#8220;PSUs&#8221;) and restricted stock units (&#8220;RSUs&#8221;) to employees, directors and consultants at exercise prices not less than the fair market value at the date of grant.  The number of shares of common stock authorized for issuance under the New Axogen Plan is (A) </span>3,385,482 shares, comprised of (i) 3,000,000 new authorized shares and (ii) 385,482<span style="white-space:pre-wrap;"> unallocated shares of common stock available for issuance as of August 14, 2019 pursuant to the Company&#8217;s 2010 Stock Incentive Plan, as amended and restated (the &#8220;Prior Axogen Plan&#8221;), that were not then subject to outstanding awards; plus (B) shares under the Prior Axogen Plan and the New Axogen Plan that are cancelled, forfeited, expired, unearned or settled in cash, in any such case that does not result in the issuance of common stock.  Following shareholder approval of the New Axogen Plan, no future awards will be made under the Prior Axogen Plan. As of December 31, 2019, </span>3,265,188 shares of common stock were available for issuance under the New Axogen Plan.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The options granted to employees prior to July 1, 2017 typically vest </span><span style="font-size:10pt;">25%</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">one year</span><span style="font-size:10pt;"> after the grant date and </span><span style="font-size:10pt;">12.5%</span><span style="font-size:10pt;"> every six months thereafter for the remaining </span><span style="font-size:10pt;">three-year</span><span style="font-size:10pt;"> period until fully vested after </span><span style="font-size:10pt;">four years</span><span style="font-size:10pt;">.</span> <span style="font-size:10pt;">The options granted to employees after July 1, 2017 typically vest </span><span style="font-size:10pt;">50%</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">two years</span><span style="font-size:10pt;"> after the grant date and </span><span style="font-size:10pt;">12.5%</span><span style="font-size:10pt;"> every six months thereafter for the remaining </span><span style="font-size:10pt;">two-year</span><span style="font-size:10pt;"> period until fully vested after </span><span style="font-size:10pt;">four years</span><span style="font-size:10pt;white-space:pre-wrap;">.  The options granted to directors and certain options granted from time to time to certain executive officers have vested ratably over </span><span style="font-size:10pt;">three years</span><span style="font-size:10pt;">, </span><span style="font-size:10pt;">25%</span><span style="font-size:10pt;"> per quarter over </span><span style="font-size:10pt;">one year</span><span style="font-size:10pt;"> or had no vesting period. Options typically have terms ranging from </span><span style="-sec-ix-hidden:_85e8adea_8926_4837_834b_5796d41281fc"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seven</span></span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">ten years</span><span style="font-size:10pt;">. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company recognized stock-based compensation expense, which consisted of compensation expense related to employee stock options, PSUs, RSUs and the 2017 ESPP based on the value of share-based payment awards that are ultimately expected to vest during the period, of approximately $10,304, $7,606 and $3,609<span style="white-space:pre-wrap;"> for the fiscal year ended December 31, 2019, 2018, and 2017, respectively.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of each option award issued under such plans on the date of grant using a Multiple Point Black-Scholes option-pricing model which uses a weighted average of historical volatility and peer company volatility. The Company determines the expected life of each award giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. </p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Activity under the Prior Axogen Plan and the New Axogen Plan during 2019 and 2018 was as follows:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:1pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Time-Based Stock Options</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term(Years)</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2017:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,304,201</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.39</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 90,473</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 656,250</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29.48</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (40,473)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.56</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (1,026,807)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.72</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2018:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,893,171</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11.94</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.95</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 41,020</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 344,176</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.07</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (287,609)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.75</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (529,557)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,420,181</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.70</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> 26,074</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Vested and expected to vest</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,420,181</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12.69</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.68</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> 26,074</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Exercisable at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,099,616</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.90</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 4.10</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> 22,712</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Restricted and Performance Stock Units</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2017:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 610,730</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.14</p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 516,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23.34</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Released</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7,150)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.95</p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (13,650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 25.89</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2018:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,106,363</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.18</p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 217,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17.60</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Released</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (86,405)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16.77</p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (123,407)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.97</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,113,697</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.62</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The intrinsic value of equity awards exercised during the years ended December 31, 2019, 2018 and 2017 was $9,553, $34,229 and $7,783<span style="white-space:pre-wrap;">, respectively. As a result of the Company&#8217;s full valuation allowance on its net deferred tax assets, no tax benefit was recognized related to the exercises of stock options.  The exercise price per share of each option is equal to the fair market value of the underlying share on the date of grant.  For 2019, 2018 and 2017, </span>$4,002, $3,884 and $1,434<span style="white-space:pre-wrap;">, respectively, in cash proceeds were included in the Company&#8217;s Consolidated Statements of Cash Flows as a result of the exercise of stock options.  The total fair value of restricted stock vested during 2019, 2018 and 2017 was </span>$1,467, $196 and $108<span style="white-space:pre-wrap;">.  The Company issues registered shares of common stock to satisfy stock option exercises and restricted stock grants.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">As of December 31, 2019, there was </span><span style="font-size:10pt;">$19,460</span><span style="font-size:10pt;white-space:pre-wrap;"> of unrecognized compensation costs related to non-vested stock options and restricted stock awards.  This cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;">2.14</span><span style="font-size:10pt;"> years for stock options and </span><span style="font-size:10pt;">2.63</span><span style="font-size:10pt;white-space:pre-wrap;"> years for restricted stock awards.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On December 18, 2017, December 27, 2018 and December 17, 2019, the Compensation Committee of the Board of Directors also approved PSU awards to certain employees related to their work on the Company&#8217;s BLA.  The PSU awards consist of a targeted total award of </span>200,000<span style="white-space:pre-wrap;"> shares. The number of shares are allocated to certain milestones related to the BLA submission to and approval by the FDA.  The performance measure is based upon achieving each of the specific milestones and will vest </span>50%<span style="white-space:pre-wrap;"> upon achieving each of the milestones and 50% one year later.  The Company estimated the  fair value of the PSUs based on its closing stock price at the time of grant and its estimate of achieving such performance target and will record compensation expense as the milestones are achieved. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation </span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">expense will be adjusted based upon the Company&#8217;s estimate of achieving such performance target. The number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on the actual performance metrics as set forth in the applicable PSU award agreement.   The amount actually awarded will be based upon achievement of the performance measures and can range from </span>zero to 200,000<span style="white-space:pre-wrap;"> shares.  The fair value of the common stock on the grant date was </span>$16.88 on December 17, 2019, $19.17 on December 27, 2018 and $27.00<span style="white-space:pre-wrap;"> on December 18, 2017.  The total unrecognized future compensation expense related to this PSU, assuming achievement of </span>100% of the target award is $17,682. Assuming the minimum of 0% and the maximum of 100% payout opportunity for the PSU, the range of total future compensation expense related to this PSU award is between $0 and $17,682 as of December 31, 2019.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The 2017 ESPP, which was effective as of January 1, 2018, allows for eligible employees to acquire shares of our common stock through payroll deductions at a discount from market value (currently </span><span style="font-size:10pt;">15%</span><span style="font-size:10pt;white-space:pre-wrap;">) of the lesser of the closing price of the Company&#8217;s common stock on the first day or last day of the offering period.  The offering period is currently </span><span style="font-size:10pt;">six months</span><span style="font-size:10pt;white-space:pre-wrap;">, and the offering prices are subject to change.  Participants may not purchase more than </span><span style="font-size:10pt;">$25</span><span style="font-size:10pt;white-space:pre-wrap;"> of the Company&#8217;s common stock in a calendar year.  As of December 31, 2019 , there were </span><span style="font-size:10pt;">600,000</span><span style="font-size:10pt;"> shares of common stock authorized for issuance under the 2017 ESPP and </span><span style="font-size:10pt;">450,305</span><span style="font-size:10pt;"> were available for future issuance.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Valuation and Expense Information Under FASB ASC 718</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of each option grant using a Multiple Point Black-Scholes option-pricing model which uses a weighted average of historical volatility and peer company volatility. The Company determines the expected life giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company used the following weighted-average assumptions for stock options granted during the year ended December&#160;31:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:68.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.76</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 6.22</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 6.16</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 54.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 50.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 50.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of restricted stock awards is based on the market value of the Company&#8217;s common stock on the date of the awards.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Based on the assumptions noted above, the weighted average estimated grant date fair value per share of the stock options and restricted stock granted for the years ended December 31, 2019, 2018 and 2017, respectively, was as follows:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.07</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.41</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Restricted and performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26.24</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806093840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">7.</b></span><b style="font-weight:bold;">Intangible Assets </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s intangible assets consist of the following:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">License agreements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,067</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,034</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less: accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (647)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (553)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">License agreements, net</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 420</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 481</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Trademarks</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 255</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Patents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 845</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less: accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (55)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Patents, net</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 761</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 445</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Intangible assets, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">License agreements are being amortized over periods ranging from </span><span style="-sec-ix-hidden:_de056e84_5c37_441e_8d70_f8b60d255c1c"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seventeen</span></span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">twenty years</span><span style="font-size:10pt;">. Patents are being amortized over periods up to </span><span style="font-size:10pt;">twenty years</span><span style="font-size:10pt;white-space:pre-wrap;">.  Amortization expense for 2019, 2018 and 2017 was approximately </span><span style="font-size:10pt;">$123</span><span style="font-size:10pt;">, </span><span style="font-size:10pt;">$77</span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;">$79</span><span style="font-size:10pt;">, respectively. In January 2019, the Company rebranded its logo and product name designs, as a result the Company recorded a </span><span style="font-size:10pt;">$104</span><span style="font-size:10pt;"> charge related to the previous logo and product design names. This charge is recorded in the &#8220;General and Administrative&#8221; in the Statement of Operations. As of December&#160;31, 2019, future amortization of patents and license agreements are as follows:</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:77.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 137</p></td></tr><tr><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 137</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 138</p></td></tr><tr><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 119</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47</p></td></tr><tr><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 603</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">TOTAL</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,181</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">License Agreements</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The Company has entered into multiple license agreements with the University of Florida Research Foundation and the University of Texas at Austin (together, the &#8220;License Agreements&#8221;). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with </span><span style="font-size:10pt;">60 days</span><span style="font-size:10pt;"> prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen pays royalty fees ranging from </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">1%</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> to </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">3%</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> under the License Agreements based on net sales of licensed products.&#160;One of the agreements also contains a minimum royalty of </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$13</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees.&#160;Also, when Axogen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">3.75%</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If Axogen sublicenses technologies covered by the License Agreements to third parties, Axogen would pay a percentage of sublicense fees received from the third party to the licensor.&#160;Currently, Axogen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">licensee under the License Agreements and does not owe any sub-licensee fees for its own use of the technologies;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Axogen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Currently, under the University of Texas at Austin&#8217;s agreement, Axogen would owe a </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$15</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.&#160;A milestone fee to the University of Florida Research Foundation of </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$2</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> is due if Axogen receives FDA approval of its Avance Nerve Graft, a milestone fee of </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$25</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> is due upon the first commercial use of certain licensed technology to provide services to manufacture products for third parties and a milestone fee of </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$10</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> is due upon the first use to manufacture products that utilize certain technology that is not currently incorporated into Axogen products.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 57.6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Royalty fees were $2,119, $1,661 and $1,195 for the years ended December 31, 2019, 2018 and 2017, respectively, and are included in sales and marketing expense on the accompanying consolidated statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805972992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,403</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,194</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,728</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Inventories</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797917072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Results of Operations (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Results of Operations (Unaudited)</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">15.  Quarterly Results of Operations (Unaudited)</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of the quarterly results of operations for the years ended December 31, 2019 and 2018:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quarter</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">First</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Second</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Third</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fourth</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,285</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,701</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,564</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,162</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,712</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,363</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (9,504)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7,022)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (5,571)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7,038)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (29,135)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss per common share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.74)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,260</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,584</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,433</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,937</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,014</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (5,644)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7,427)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (4,102)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (5,224)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (22,397)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Loss per common share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (0.60)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810953488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,262</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,517</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Accrued compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,631</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,477</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Accounts Payable and Accrued Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6801379424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for doubtful accounts</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">39,589,755<span></span>
</td>
<td class="nump">38,900,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">39,589,755<span></span>
</td>
<td class="nump">38,900,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6795125136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Litigation (Details) - individual<br></strong></div></th>
<th class="th"><div>Feb. 04, 2019</div></th>
<th class="th"><div>Nov. 11, 2019</div></th>
<th class="th"><div>Aug. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_ThresholdPeriodForNotFilingResponseToComplaint', window );">Threshold period for not filing response to complaint</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=axgn_NovitzkiVsZaderejMember', window );">Case of Novitzki vs Zaderej</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_MinimumNumberOfCandidateElectedToBoard', window );">Minimum number of candidates elected to board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_MinimumNumberOfCandidateElectedToBoard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum number of candidates elected to board.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_MinimumNumberOfCandidateElectedToBoard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ThresholdPeriodForNotFilingResponseToComplaint">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period for not filing response to complaint.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ThresholdPeriodForNotFilingResponseToComplaint</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=axgn_NovitzkiVsZaderejMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=axgn_NovitzkiVsZaderejMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806044976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">1.</b></span><b style="font-weight:bold;">Basis of Presentation </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying consolidated financial statements include the accounts of Axogen,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Axogen&#8221;) and its wholly owned subsidiaries, Axogen Corporation (&#8220;AC&#8221;), Axogen Processing Corporation (&#8220;APC&#8221;) and Axogen Europe GmbH, as of December&#160;31, 2019 and December&#160;31, 2018 and for the three years ended December 31, 2019. The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6798119744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering of Common Stock - Public Offering (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Public Offering of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock sold</a></td>
<td class="nump">38,900,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,589,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 132,964<span></span>
</td>
<td class="nump">$ 15,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses paid</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812172592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 18,651<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,764)<span></span>
</td>
<td class="num">(2,861)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,887<span></span>
</td>
<td class="nump">8,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_FurnitureAndOfficeEquipmentMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">2,203<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Processing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">2,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Projects in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 10,886<span></span>
</td>
<td class="nump">$ 4,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803695456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan Agreements and Long-Term Debt - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current maturities of long-term obligations</a></td>
<td class="num">$ (1,736)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term portion</a></td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_LongTermDebtNoncurrentExcludingDeferredRevenue', window );">Long-term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember', window );">Equipment Lease Agreement | Cisco Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember', window );">Equipment Lease Agreement | Raymond Leasing Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember', window );">Equipment Lease Agreement | B&amp;B Office Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LongTermDebtNoncurrentExcludingDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding deferred revenue, amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LongTermDebtNoncurrentExcludingDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=axgn_CiscoCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=axgn_CiscoCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=axgn_RaymondLeasingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=axgn_RaymondLeasingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=axgn_BAndBOfficeSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=axgn_BAndBOfficeSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6798101776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">License agreements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,067</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,034</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less: accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (647)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (553)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">License agreements, net</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 420</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 481</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Trademarks</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 255</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Patents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 845</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less: accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (55)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Patents, net</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 761</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 445</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Intangible assets, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:77.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 137</p></td></tr><tr><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 137</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 138</p></td></tr><tr><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 119</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47</p></td></tr><tr><td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 603</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:77.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">TOTAL</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,181</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6600071216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,724</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,294</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,724</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,294</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of balances of contract receivables and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Balances</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:44.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Receivables</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Liabilities, Current</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Liabilities, Long-Term</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Opening, January 1, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,065</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Closing, December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Increase (decrease)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,256</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (27)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Opening, January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,321</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Closing, December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Increase (decrease)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,623</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (27)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797925712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">14.  Commitments and Contingencies</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">We lease office space, medical lab and research space, a distribution center, a tissue processing center and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Certain of our leases include options for the Company to extend the lease term. None of the options were reasonably certain of exercise and therefore are not included in the measure of our lease obligations and right-to-use assets. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Certain of our lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The Company and SNH Medical Office Properties Trust, a Maryland real estate investment trust (&#8220;SNH&#8221;), are parties to that certain lease dated as of February 6, 2007, as amended, (the &#8220;Primary Lease&#8221;) pursuant to which the Company leases its approximately </span><span style="-sec-ix-hidden:_9adc0d0a_9f27_4b75_b561_f0f616fc58b6"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">nineteen</span></span><span style="font-size:10pt;"> thousand square foot corporate headquarters facility in the Progress Center at 13631 Progress Boulevard, Alachua, Florida 32615 (the &#8220;Primary Premises&#8221;). The annual cost for the Primary Premises ranges from </span><span style="font-size:10pt;">$353</span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">$363</span><span style="font-size:10pt;white-space:pre-wrap;"> through the end of the term of the lease, which expires on October 31, 2021.  On January 23, 2017 the Company entered into a lease (the &#8220;First Expansion Lease&#8221;) with SNH for one thousand </span><span style="-sec-ix-hidden:_de7536fc_c71e_45d4_b4bd_cca7546a8119"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four</span></span><span style="font-size:10pt;white-space:pre-wrap;"> hundred square feet at 13709 Progress Boulevard, Alachua, Florida 32615 (this property was purchased by Nucleic Acids Licensing, LLC in February 2019) (the &#8220;First Expansion Premises&#8221;) adjacent to the Primary Premises.  The Company has entered into the Second Expansion Lease and Third Expansion Lease, as defined below, which relate to properties that are adjacent to the Primary Premises and First Expansion Premises resulting in the Company having approximately </span><span style="font-size:10pt;">twenty</span><span style="font-size:10pt;white-space:pre-wrap;"> thousand square feet for its corporate headquarters and certain research space in the Progress Center in Alachua, Florida.  </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On November 19, 2018, the Company entered into a Lease (the &#8220;Second Expansion Lease&#8221;) with SNH for two thousand </span><span style="-sec-ix-hidden:_842590dc_0853_48a1_94e3_0974e859a7d8"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">eight</span></span><span style="font-size:10pt;"> hundred square feet at 13709 Progress Boulevard, Suites S-160, S-162 and S-164, Alachua, Florida 32615 (the &#8220;Second Expansion Premises&#8221;). Pursuant to the Second Expansion Lease, AC is to use the Second Expansion Premises for general office uses. The Second Expansion Lease commenced December 1, 2018 and expires November 30, 2020. The annual cost of the Second Expansion Premises is approximately </span><span style="font-size:10pt;">$45</span><span style="font-size:10pt;"> for the first twelve months of the term and </span><span style="font-size:10pt;">$46</span><span style="font-size:10pt;"> for the final twelve months. The Company is also obligated to pay for certain taxes, insurance costs and electricity costs incurred by SNH.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On November 19, 2018, AC entered into a Lease (the &#8220;Third Expansion Lease&#8221;) with SNH for two<span style="white-space:pre-wrap;"> thousand square feet at 13709 Progress Boulevard, Suites S-175, S-177 and S-179, Alachua, Florida 32615 (the &#8220;Third Expansion Premises&#8221;). Pursuant to the Third Expansion Lease, the Company is to use the Third Expansion Premises for general office and biomedical research uses. The Third Expansion Lease commenced December 1, 2018 and its term expires November 30, 2020.  The annual cost of the Third Expansion Premises is approximately </span>$37 for the first twelve months of the term and $35 for the final eleven months. The Company is also obligated to pay for certain taxes, insurance costs and electricity costs incurred by SNH.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On November 21, 2018, the Company, entered into Commercial Lease Amendment 3 (the &#8220;Burleson Amendment&#8221;), to the Commercial Lease dated April 21, 2015, as amended, with Ja-Cole L.P. Under the terms of the Burleson Amendment, the Company leased an additional </span><span style="-sec-ix-hidden:_2049e4b8_faac_41e8_83f3_7e116573faca"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">two</span></span><span style="font-size:10pt;white-space:pre-wrap;"> thousand five hundred square feet of warehouse/office space in Burleson, Texas (collectively with the space leased under the Commercial Lease with Ja-Cole L.P. prior to the effectiveness of the Burleson Amendment, the &#8220;Burleson Facility&#8221;).  The Burleson Facility will now comprise a total of </span><span style="-sec-ix-hidden:_0d926b8e_ab68_494b_9c97_8808ab1309cf"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">twelve</span></span><span style="font-size:10pt;white-space:pre-wrap;"> thousand five hundred square feet, all of which, pursuant to the Burleson Amendment, will be leased until April 30, 2022.  The annual rental cost of the entire Burleson Facility is now approximately </span><span style="font-size:10pt;">$113</span><span style="font-size:10pt;"> through December 31, 2020, </span><span style="font-size:10pt;">$116</span><span style="font-size:10pt;"> for the calendar year 2021 and until April 2022. The Burleson Facility houses raw material storage and product distribution while allowing same day order fulfillment for both the east and west coasts of the United States.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On October 26, 2018, the Company entered into a Lease (the &#8220;Ashley Avenue Lease&#8221;) with Ashley Avenue Associates I, LLC., a Delaware limited liability company (&#8220;Ashley&#8221;), for the lease by the Company of approximately </span><span style="font-size:10pt;">fifteen</span><span style="font-size:10pt;white-space:pre-wrap;"> thousand square feet of office space on the second floor of the building located at 1000 N. Ashley Drive, Tampa, Florida 33602 (the &#8220;Ashley Avenue Premises&#8221;).  Pursuant to the Ashley Avenue Lease, the Company will use the Ashley Avenue Premises for general office purposes.  The initial term of the Ashley Avenue Lease commenced on December 1, 2018 and expires on November 30, 2020. The Company has an option to terminate the lease after </span><span style="font-size:10pt;">eighteen months</span><span style="font-size:10pt;"> by providing Ashley with </span><span style="font-size:10pt;">four months</span><span style="font-size:10pt;white-space:pre-wrap;"> advance written notice.  The rental cost for the Ashley Avenue Premises will be </span><span style="font-size:10pt;">$381</span><span style="font-size:10pt;"> for the first twelve month period, and </span><span style="font-size:10pt;">$360</span><span style="font-size:10pt;"> for the final eleven month period. The Company will also be obligated to pay for its pro rata share of the building&#8217;s property taxes, utilities, administrative costs, common area maintenance and management fees, excluding any capital improvements or any damage due to fire, hurricane or other casualty.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On September 20, 2018, the Company entered into an agreement with Heights Union, LLC, a Florida limited liability company (&#8220;Heights Union&#8221;), for the lease of </span><span style="font-size:10pt;">seventy-five</span><span style="font-size:10pt;"> thousand square feet of office space (the &#8220;Heights Union Premises&#8221;) in a one </span><span style="-sec-ix-hidden:_8737cf0c_5377_4487_aceb_781cdeb5b2e6"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">hundred and fifty</span></span><span style="font-size:10pt;white-space:pre-wrap;"> thousand square foot office building that Heights Union intends to construct and complete on or before September 30, 2020, on an area of land in Tampa, Florida.  Pursuant to the Heights Union lease, the Company will use the Heights Union Premises for general office, medical laboratory, training and meeting purposes.  The annual costs of the Heights Union Premises ranges from </span><span style="font-size:10pt;">$2,400</span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">$3,308</span><span style="font-size:10pt;"> during the term of the lease. Axogen believes it can obtain certain economic incentives from state authorities associated with the employment at the facility; such incentives are not expected to be a material offset to the expenses of the project as a whole.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, Axogen leases space and maintains records at certain other facilities, including the Company&#8217;s prior corporate headquarters at 1407 South Kings Highway, Texarkana, Texas 75501.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The components of total lease expense for the year ended December 31, 2019 were as follows:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">For the Fiscal Year Ended December 31, 2019:</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Finance lease costs</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Amortization of right-to-use assets</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Interest on lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Operating lease costs</b></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,910</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short term lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Variable lease costs</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,994</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The short-term lease cost shown above reasonably reflects the Company&#8217;s ongoing short-term lease commitment. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Supplemental balance sheet information related to leases as of December 31, 2019 was as follows:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,133</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Tc_A4Fx7oi8o0qgiyXaY11oBA_4_0"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Current maturities of long-term obligations</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,719</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Tc_iS9N_npf70GWW2V_ErRjnw_5_0"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Long term obligations</span></span></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,565</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease right-of-use assets</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current maturities of long-term obligations</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long term obligations</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Other information related to leases was as follows:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for amounts included in the measurement of operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,773</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-to-use assets obtained in exchange for new finance lease liabilities</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average remaining lease term - finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;"> 3</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;"> 2</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average discount rate - finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.28%</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.28%</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The weighted-average discount rate for the majority of the Company&#8217;s leases is based on the Company&#8217;s estimated incremental borrowing rate since the rates implicit in the leases were not determinable. The Company&#8217;s incremental borrowing rate is based on Management&#8217;s estimate of the rate of interest the Company would have to pay to borrow on a fully collateralized basis over a similar term an amount equal to the lease payments. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Future minimum lease payments under non-cancellable leases as of December 31, 2019 were as follows:</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,664</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,573</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,644</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Future Minimum Lease Payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,720</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less future payments for leases that have not yet commenced</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (38,246)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest on commenced leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (190)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Tc_pGofsY-zPU6ke-fO75b00A_12_0"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Total Lease Liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The lease for office space in Tampa, Florida with Heights Union, LLC, a Florida limited liability company, has not commenced and is therefore not included in the measurement of right-to-use assets and lease liabilities.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As previously disclosed in our 2018 Annual Report on Form 10-K, which followed the lease accounting guidance prior to our adoption of ASC 842, future commitments relating to noncancelable operating and capital leases as of December 31, 2018 were as follows:</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,866</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,970</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,574</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,579</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Total rent expense for the Company&#8217;s leased office and lab space for the years ended December&#160;31, 2019, 2018 and 2017 was $516, $484 and $494, respectively.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Service Agreements</b></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On August 6, 2015, Axogen entered into a License and Services Agreement with Community Blood Center (d/b/a Community Tissue Services) (&#8220;CTS&#8221;), Dayton, Ohio, an FDA registered tissue establishment.  Processing of the Avance Nerve Graft pursuant to the CTS agreement began in February 2016.  Subsequent to the year ended December 31, 2018, on February 22, 2019, Axogen Corporation and CTS entered into a fourth amendment to the License and Services Agreement wherein the term of the agreement was extended such that the Occupancy Date in section 12.01 of the agreement shall end on December 31, 2021, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#8217;s right to cure, in certain circumstances), or by Axogen without cause upon six months&#8217; prior notice, </span>whereby notice cannot be provided prior to March 1, 2021<span style="white-space:pre-wrap;">.  Under the CTS agreement Axogen pays CTS a facility fee for clean room/manufacturing, storage and office space, which has been determined to be an embedded operating lease.  CTS also provides services in support of Axogen&#8217;s manufacturing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support.  </span>Pursuant to the CTS Agreement, Axogen pays license fees and the operating lease amounts, on a monthly basis to CTS which total an annual amount of approximately $2,148 for the year ended December 31, 2019, $1,931 for the year ended December 31, 2018 and $1,409 for the year ended December 31, 2017.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In December&#160;<span style="white-space:pre-wrap;">2011, the Company also entered into a Master Services Agreement for Clinical Research and Related Services.  The Company was required to pay </span>$151<span style="white-space:pre-wrap;"> upon execution of this agreement and the remainder monthly based on activities associated with the execution of Axogen&#8217;s phase 3 pivotal clinical trial to support a BLA for Avance Nerve Graft.    </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">In August&#160;2008, the Company entered into an agreement to distribute the Axoguard Nerve Connector and Nerve Protector products worldwide in the field of peripheral nerve repair, and the parties subsequently amended the agreement on February 26, 2018. Pursuant to the February 2018 amendment, the agreement expires on June 30, 2027. The Cook Biotech Distribution Agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforced such provision, and establishes a formula for the transfer cost of the Axoguard products. Under the Distribution Agreement, Axogen provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In June 27, 2017, the Company entered into the Nerve End Cap Supply Agreement with Cook Biotech whereby Cook Biotech is the exclusive contract manufacturer of the Axoguard Nerve Cap and both parties have provided the other party the necessarily licenses to their technologies for operation of the Supply Agreement.  The Supply Agreement has a term through August 27, 2027, provided, however, that after June 27, 2022, either party may terminate the Supply Agreement upon 90 days written notice.  Under the Supply Agreement Axogen provides purchase orders to Cook Biotech and Cook Biotech fulfills the purchase orders.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Certain executive officers of the Company are parties to employment contracts.  Such contracts have severance payments for certain conditions including change of control.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Concentrations</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Vendor</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Substantially all of Axogen&#8217;s revenue is currently derived from four<span style="white-space:pre-wrap;"> products, Avance Nerve Graft, Axoguard Nerve Protector, Axoguard Nerve Connector and Avive Soft Tissue Membrane.  Axogen has an exclusive distribution agreement with Cook Biotech for the purchase of Axoguard Nerve Connector and Axoguard Nerve Protector which expires </span>June 30, 2027.<span style="white-space:pre-wrap;">  The Cook Biotech Distribution Agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforced such provision, and establishes a formula for the transfer cost of the Axoguard Nerve Connector and Axoguard Nerve Protector.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:6pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">The agreement allows for termination provisions for both parties.  Although there are products that Axogen believes it could develop or obtain that would replace the Axoguard products, the loss of the ability to sell the Axoguard</span><span style="font-size:6.5pt;vertical-align:super;"> </span><span style="font-size:10pt;">products could have a material adverse effect on Axogen&#8217;s business until other replacement products would be available.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Processor</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is highly dependent on the continued availability of its processing facilities at CTS and could be harmed if the physical infrastructure of this facility is unavailable for any prolonged period of time.  In addition, disruptions could lead to significant costs and reductions in revenues, as well as a potential harm to the Axogen&#8217;s business reputation and financial results. The CTS agreement terminates December 31, 2021, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#8217;s right to cure, in certain circumstances), or by Axogen without cause, upon 6 months&#8217; prior notice, </span>whereby notice cannot be provided prior to March 1, 2021<span style="white-space:pre-wrap;">.  Although Axogen believes it can find and make operational a new facility in less than six months </span><span style="white-space:pre-wrap;">if required. In addition, Axogen acquired property which is located near the CTS facility and it is expected that renovations will be completed by the termination date of the CTS Agreement to provide a new processing facility that can be included in our BLA for the Avance Nerve Graft. However, the regulatory process for approval of facilities whether licensed or owned is time-consuming and unpredictable.  Axogen&#8217;s ability to license, renovate, rebuild or find acceptable service facilities takes a considerable amount of time and expense and could cause a significant disruption in service to its customers if it were to lose the availability of it production or distribution facilities.  </span> Although Axogen has business interruption insurance which would, in instances other than lease termination, cover certain costs, it may not cover all costs nor help to regain Axogen&#8217;s standing in the market.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In July 2018, Axogen purchased a facility (the &#8220;APC&#8221;) in Vandalia, Ohio, located near the CTS processing facility where Avance Nerve Graft and Avive Soft Tissue Membrane are currently processed.  The APC, when and if operational, will be </span>the new processing facility for Avance&#160;Nerve Graft and Avive Soft Tissue Membrane&#160;to provide continued capacity for growth and to support the transition of Avance Nerve Graft from a 361 HCT/P tissue product to a&#160;<span style="white-space:pre-wrap;">biologic product.  The APC </span>is comprised of a 70,000 square foot building on approximately 8.6<span style="white-space:pre-wrap;"> acres of land.  The Company paid </span>$731<span style="white-space:pre-wrap;"> for the land and is recorded as Land within our property and equipment account on our balance sheet.   The Company paid </span>$4,300 for the building and this is recorded as projects in process as part of the property and equipment on the balance sheet. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On July 9, 2019,&#160;Axogen&#160;entered into a Standard Form of Agreement Between Owner and Design-Builder (the &#8220;Design-Build Agreement&#8221;) with CRB Builders, L.L.C., a Missouri limited liability company (&#8220;CRB&#8221;),&#160;pursuant to which CRB will renovate and retrofit the APC.&#160; The Design-Build Agreement contains several design phase milestones that began in July 2019 and sets the&#160;date for Substantial Completion (as defined in the Design-Build Agreement)&#160;in the third quarter of 2020, subject to adjustment in accordance with the terms of the Design-Build Agreement.&#160;The estimated cost pursuant to the Design-Build Agreement&#160;is $29,000. &#160;Additional costs associated with the renovation, purchasing of furniture and equipment,&#160;validation and certification of the APC are estimated to be $14,400.&#160;&#160;<span style="white-space:pre-wrap;">These capital expenditure costs will be incurred as they arise until the anticipated full transition of material processing to the APC by early 2022.  </span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">As of December 31, 2019, the Company has recorded </span>$6,066 related to renovations and design build. These items are recorded as projects in process as part of the property and equipment on the balance sheet.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen expects to receive certain economic development grants from state and local authorities totaling up to $2,685 including $1,250 of cash grants to offset costs to acquire and develop the APC.&#160; The economic development grants are subject to certain job creation milestones by 2023 and related contingencies.&#160;</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As previously disclosed the Company previously entered into an agreement with Heights Union, LLC, a Florida limited liability company (&#8220;Heights Union&#8221;), for the lease of seventy-five thousand square feet of office space.&#160; Pursuant to the Heights Union lease, the Company will use the Heights Union Premises for general office, medical laboratory, training and meeting purposes.&#160;&#160;The Company anticipates occupying the premises by the second quarter of 2020.&#160; Associated with the lease, the Company anticipates spending up to $9,833 for leasehold improvements, equipment and furniture and fixtures.&#160; As of December 31, 2019, the Company has recorded $441 of leasehold improvements to the new facility.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Litigation </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">On January 9, 2019, Plaintiff Neil Einhorn, on behalf of himself and others similarly situated, filed a putative class action complaint in the United Stated District Court for the Middle District of Florida alleging violations of the federal securities laws against Axogen, Inc., certain of its directors and officers (&#8220;Individual Defendants&#8221;), and Axogen&#8217;s 2017 Offering Underwriters and 2018 Offering Underwriters (collectively, with the Individual Defendants, the &#8220;Defendants&#8221;), captioned Einhorn v. Axogen, Inc., et al., No. 8:19-cv-00069 (M.D. Fla.).  Plaintiff asserts that Defendants made false or misleading statements in connection with the Company&#8217;s November 2017 registration statement issued regarding its secondary public offering in November 2017 and May 2018 registration statement issued regarding its secondary public offering in May 2018, and during a class period of August 7, 2017 to December 18, 2018.   In particular, Plaintiff asserts that Defendants issued false and misleading statements and failed to disclose to investors: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company&#8217;s pricing alienated customers and threatened the Company&#8217;s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company&#8217;s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company&#8217;s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company&#8217;s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company&#8217;s key operating metrics, such as number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.  Axogen was served on January 15, 2019.  </span><span style="font-size:10pt;">On February 4, 2019, the court granted the parties&#8217; stipulated motion which provided that Axogen is not required to file a response to the complaint until </span><span style="font-size:10pt;">thirty days</span><span style="font-size:10pt;">&#160;after Plaintiff files a consolidated amended complaint.&#160;On June 19, 2019, Plaintiff filed an Amended Class Action Complaint, and on July 22, 2019, Defendants filed a motion to dismiss. Plaintiff filed opposing papers on August 12, 2019. The Court held a status hearing on September 11, 2019 and stayed all deadlines regarding the parties&#8217; obligations to file a case management report. On December 4, 2019 the parties&#8217; presented oral arguments and are currently awaiting the court&#8217;s ruling.</span><span style="font-size:10pt;white-space:pre-wrap;">  Plaintiff is seeking compensatory damages, reimbursement of expenses and costs, including counsel and expert fees and such other relief as the court deems just and proper. The Company and Individual Defendants dispute the allegations and intend to vigorously defend against the Complaint.  The amount of loss, if any, cannot be reasonably estimated at this time.</span></p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="font-size:10pt;white-space:pre-wrap;">Jackson v. Zaderej, et al., No. 8:19-cv-01976 U.S. District Court (M.D. FL). On August 12, 2019, Plaintiff Harvey Jackson, derivatively on behalf of Axogen, filed a verified shareholder derivative complaint for violations of securities laws, breach of fiduciary duty, waste of corporate assets and unjust enrichment against Quentin S. Blackford, Gregory G. Freitag, Mark Gold, Jamie M. Grooms, Alan M. Levine, Peter J. Mariani, Guido Neels, Robert J. Rudelius, Amy Wendell, and Karen Zaderej (the &#8220;Individual Defendants&#8221;) and Nominal Defendant Axogen, Inc. (&#8220;Axogen&#8221;) (collectively, &#8220;Defendants&#8221;).  Plaintiff asserts that the Individual Defendants, who are current or former Axogen officers or directors, issued a false proxy statement for the election of directors in violation of Section 14(a) of the Securities Exchange Act of 1934, breached their fiduciary duties, wasted corporate assets and were unjustly enriched by allowing </span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">Axogen to make false public statements to investors based on the same claims in the report issued December 18, 2018 by Seligman Investments (the same allegations that form the basis for the Einhorn matter and the Bussey shareholder demand).  Plaintiff demands judgment in the Company&#8217;s favor against all Individual Defendants as follows: (A) declaring that Plaintiff may maintain this action on behalf of Axogen, and that Plaintiff is an adequate representative of Company; (B) declaring that the Individual Defendants have breached and/or aided and abetted the breach of their fiduciary duties to Axogen; (C) determining and awarding to Axogen the damages sustained by it because of the violations set forth above from each of the Individual Defendants, jointly and severally, together with pre- and post-judgment interest thereon; (D) directing Axogen and the Individual Defendants to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable laws and protect Axogen and its shareholders from a repeat of the damaging events described therein, including, but not limited to, putting forward for shareholder vote the following resolutions for amendments to the Company&#8217;s Bylaws or Articles of Incorporation and the following actions as may be necessary to ensure proper corporate governance policies: (i)  a proposal to strengthen the Board&#8217;s supervision of operations and develop and implement procedures for greater shareholder input into the policies and guidelines of the Board, (ii) a provision to permit the shareholders of Axogen to nominate at least </span><span style="font-size:10pt;">six</span><span style="font-size:10pt;white-space:pre-wrap;"> candidates for election to the Board; and (iii) a proposal to ensure the establishment of effective oversight of compliance with applicable laws, rules, and regulations; (E) awarding Axogen restitution from Individual Defendants, and each of them; (F) awarding Plaintiff the costs and disbursements of this action, including reasonable attorneys&#8217; and experts&#8217; fees, costs, and expenses; and (G) granting such other and further relief as the Court may deem just and proper.  The Defendants filed a motion to dismiss on October 22, 2019.  In response, Plaintiffs voluntarily withdrew their complaint and the matter was dismissed without prejudice by the court on November 5, 2019.</span></p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="font-size:10pt;white-space:pre-wrap;">Novitzki v. Zaderej, et al, 19-CA-11745 DIV L (13th Judicial Circuit, Hillsborough Cnty., Fl.).  On November 11, 2019,  Plaintiff Joseph Novitzki, derivatively on behalf of Axogen, filed a verified stockholder derivative complaint for breach of fiduciary duty, waste of corporate assets and unjust enrichment against Karen Zaderej,  Gregory G. Freitag, Peter J. Mariani, Amy Wendell, Robert J. Rudelius, Mark Gold, Guido Neels, and Jamie M. Grooms (the &#8220;Individual Defendants&#8221;) and Nominal Defendant Axogen, Inc. (&#8220;Axogen&#8221;) (collectively, &#8220;Defendants&#8221;). Plaintiff asserts that the Individual Defendants, who are current or former Axogen officers or directors, breached their fiduciary duties, wasted corporate assets and were unjustly enriched by allowing Axogen to make false public statements to investors based on the same claims in the report issued December 18, 2018 by Seligman Investments (the same allegations that form the basis for the Einhorn matter and the Bussey shareholder demand).  Plaintiff demands judgment in the Company&#8217;s favor against all Individual Defendants as follows: (a) against all of the defendants and in favor of the Company for the amount of damages sustained by the Company as a result of the defendants' breaches of fiduciary duties, waste of corporate assets, and unjust enrichment; (B) directing Axogen to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable laws and to protect Axogen and its stockholders from a repeat of the damaging events described herein, including, but not limited to, putting forward for stockholder vote, resolutions for amendments to the Company's Bylaws or Articles of Incorporation and taking such other action as may be necessary to place before stockholders for a vote of the following corporate governance policies: (1) directing Axogen to employ an independent, third-party expert to calculate the Company's market size (including the dollar values of Axogen's total addressable market and portion of the market relating to extremity trauma and OMF); (2) a provision to control insider selling; (3) a proposal to strengthen Axogen's oversight of its disclosure procedures; (4) a proposal to strengthen the Company's controls over financial reporting; (5) a proposal to strengthen the Board's supervision of operations and develop and implement procedures for greater stockholder input into the policies and guidelines of the Board; and (6) a provision to permit the stockholders of Axogen to nominate at least </span><span style="font-size:10pt;">three</span><span style="font-size:10pt;white-space:pre-wrap;"> candidates for election to the Board; (C) extraordinary equitable and/or injunctive relief as permitted by law, equity, and state statutory provisions sued hereunder, including attaching, impounding, imposing a constructive trust on, or otherwise restricting the proceeds of defendants' trading activities or their other assets so as to assure that plaintiff on behalf of Axogen has an effective remedy; (D) Awarding to Axogen restitution from defendants, and each of them, and ordering disgorgement of all profits, benefits, and other compensation obtained by the defendants, including all ill-gotten gains from insider selling by defendants; (E) awarding to plaintiff the costs and disbursements of the action, including reasonable attorneys' fees, accountants' and experts' fees, costs, and expenses; and (F) granting such other and further relief as the Court deems just and proper.  After Defendants&#8217; counsel had multiple discussions with Plaintiff&#8217;s counsel pointing out that it&#8217;s complaint was deficient for the same reasons argued in Jackson, the Plaintiff agreed to voluntarily dismiss the complaint without prejudice, which the court so-ordered on January 24, 2020.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">These matters are subject to various uncertainties and it is possible that it may be resolved unfavorably to the Company.  However, while it in not possible to predict with certainty the outcome of the matter, the Company and the Individual Defendants dispute the allegations and intend to vigorously defend themselves.  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811668224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,724<span></span>
</td>
<td class="nump">$ 24,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">60,786<span></span>
</td>
<td class="nump">92,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $1,092 and $1,117, respectively</a></td>
<td class="nump">16,944<span></span>
</td>
<td class="nump">15,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">13,861<span></span>
</td>
<td class="nump">11,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">135,021<span></span>
</td>
<td class="nump">150,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,887<span></span>
</td>
<td class="nump">8,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">154,643<span></span>
</td>
<td class="nump">160,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">19,130<span></span>
</td>
<td class="nump">12,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long term obligations</a></td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities, current</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,880<span></span>
</td>
<td class="nump">13,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long Term Obligations, net of current maturities</a></td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,490<span></span>
</td>
<td class="nump">13,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies - see Note 14</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value per share; 100,000,000 shares authorized; 39,589,755 and 38,900,875 shares issued and outstanding</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">311,618<span></span>
</td>
<td class="nump">297,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(179,861)<span></span>
</td>
<td class="num">(150,726)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">132,153<span></span>
</td>
<td class="nump">146,982<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 154,643<span></span>
</td>
<td class="nump">$ 160,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804544592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Concentrations (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($) </div>
<div>a </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 09, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 20, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land where building resides | a</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLandHeldForUse', window );">Payments to acquire Land</a></td>
<td class="nump">$ 731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBuildings', window );">Payments to acquire Building</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_DesignBuildAgreementMember', window );">Design build agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_EstimatedCostRelatingToDesignBuildAgreement', window );">Estimated cost relating to design build agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement', window );">Additional costs associated with design build agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Expenses related to improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Design build agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Receivable economic development grants from state and local authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_CashGrantsReceivable', window );">Cash grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Vendor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_NumberOfProductsFromWhichRevenueIsDerived', window );">Number of products from which revenue is derived | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionMember', window );">Heights Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land where building resides | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Expenses related to improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionMember', window );">Heights Union | Expected | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Expenses related to improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional amount associated with design build agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_AdditionalCostsAssociatedWithDesignBuildAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_CashGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of cash grants receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_CashGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EstimatedCostRelatingToDesignBuildAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of estimated cost relating to design build agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EstimatedCostRelatingToDesignBuildAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NumberOfProductsFromWhichRevenueIsDerived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of products from which revenue is derived by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NumberOfProductsFromWhichRevenueIsDerived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of buildings (properties) whether for investment or use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLandHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of land for use; excludes purchases of land held as inventory or as investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLandHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_DesignBuildAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_DesignBuildAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811588656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,135)<span></span>
</td>
<td class="num">$ (22,397)<span></span>
</td>
<td class="num">$ (10,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_RightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment loss on intangible assets</a></td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory writedown</a></td>
<td class="nump">1,887<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Changes in investment gains and losses</a></td>
<td class="num">(972)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">10,304<span></span>
</td>
<td class="nump">7,606<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,136)<span></span>
</td>
<td class="num">(5,108)<span></span>
</td>
<td class="num">(3,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,767)<span></span>
</td>
<td class="num">(6,009)<span></span>
</td>
<td class="num">(3,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(661)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="num">(342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,920<span></span>
</td>
<td class="nump">3,711<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease obligations</a></td>
<td class="num">(1,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Cash paid for interest portion of finance leases</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract and other liabilities</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(19,872)<span></span>
</td>
<td class="num">(17,862)<span></span>
</td>
<td class="num">(9,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(4,664)<span></span>
</td>
<td class="num">(6,282)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(121,074)<span></span>
</td>
<td class="num">(114,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of investments</a></td>
<td class="nump">153,571<span></span>
</td>
<td class="nump">23,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cash payments for intangible assets</a></td>
<td class="num">(562)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by / (used for) investing activities</a></td>
<td class="nump">27,271<span></span>
</td>
<td class="num">(98,193)<span></span>
</td>
<td class="num">(1,292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,964<span></span>
</td>
<td class="nump">15,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash paid for equity offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(257)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowing on revolving loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,253<span></span>
</td>
<td class="nump">57,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments on revolving loan and prepayment penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,489)<span></span>
</td>
<td class="num">(57,624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt and prepayment penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,513)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Cash paid for debt portion of finance leases</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4,002<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,031<span></span>
</td>
<td class="nump">109,842<span></span>
</td>
<td class="nump">17,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">11,430<span></span>
</td>
<td class="num">(6,213)<span></span>
</td>
<td class="nump">6,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">30,294<span></span>
</td>
<td class="nump">36,507<span></span>
</td>
<td class="nump">30,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">41,724<span></span>
</td>
<td class="nump">30,294<span></span>
</td>
<td class="nump">36,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Acquisition of fixed assets in accounts payable and accrued expenses</a></td>
<td class="nump">3,212<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Capital lease additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability', window );">Right-of-use asset and operating lease liability</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the noncash amount of right of use assets and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_RightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_RightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>40
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W%?:]=7OWCXTO@KJ!7W>AOP!02P,$%     @ >X184)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M<VAE970Q+GAM;'U7[6[:,!1]E2@/T,0?(5 !4BF:-FF3JD[;?KM@(&H2,]M
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M9>W@W4B<QD[5QO]-=A=C53-4<4-IQ%M_K5I_O?5?.!]H.($.!#H2^L6)$MA
M8".!_%^!#P0>$+)^*GYMML**]5*K6Z)[>\^BVT7DGKO5WW4O_6+[;VYYC'M[
M7>?+[-J5&1";'D$G"#(B,E=[%*"8P(8".OTH\ @1["-B"Q$<'P)#Y\@\G4WH
M!4[G*)U[.I_09\$2042)"Q2H0 'H\T  (A:XP P5F $Z"5U&(!&;2U2BA/S
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M;]O!AS[5IU#?P5>[6Z/V^V$\M>&\NWY.N#:&]CQ_*LENWVM6_P%02P,$%
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MKZ,V$/TKB/=</+:QX2J)=$-4M5(K76W5]IF;. E:P"F0F^V_K_G8+!D/^Q+
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M>$Y9"XE0&8'B*1>(L8]*!2P4BB()*X\P,(88*V^7)!4*<<E\E 8&$C'V43$
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MZ<L"()W%+UVB0;.\:-#39+YFQ6F,K[EG-"A\S9K3P%43NUJN!2%;$/8)E)<
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MZD,T'_JI?JG*Q\O%OGKJAJ^Q_]Z<#R7/%UU]F@Y<UY=3W_O_ 5!+ P04
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MY\]F&K/)<-BG'\3F;US^!E!+ P04    " ![A%A0Q('\T+(!  #2 P  &0
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M:&5E=#$T+GAM;'U386_;(!#]*X@?4!*2M5ED6VHZ39NT25&G=9^)?;91@?,
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M#S#7\X:2N?A/< 6%X5$)YJBL\FDEU>"#U3,+2M'B9=JE2?LXW?#;&;8-X#.
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M/9ZR$!\#ODN8W.9,0B478QZ#\:DN:!($@8+*!P:!VQ7N0:E A#)^+IQT31F
MV_,S^X=8.]9R$0[NC?HA:]\5]):2&AHQ*O]@IH^PU/.&DJ7XSW %A>%!">:H
MC')Q)=7HO-$+"TK1XFG>91_W:;[)L@6V#^ +@*^ VYB'S8FB\O?"BS*W9B)V
M[OT@PA.G1XZ]J8(SMB+>H7B'WFO)TR1GUT"TQ)SF&+Z)2=<(ANQK"KZ7XL3_
M@_-]^&%7X2'"#R\H_(L@VR7((D'V:HE[,?\6R38]U6#;.$V.5&;LXR1OO.O
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M<%NC"*!P6P8$K10!@KL? :T=N64 @MPZ"&9O:D/%S4X3Z97\WMI1-K-.$^N
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M4[P8 FKKM_=NKZ>W/!E6]?.8DN5?4?P!4$L#!!0    ( 'N$6% BRJKFM0$
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M!;4+QT_^;*8QFPR'_?R#V/*-BS]02P,$%     @ >X184-ZZ9<*X 0  T@,
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M-6G2.60@+L_OZE]B[5C+63BX-^JG+'V3T3TE)52B5_[9#%]AJN>:DJGX1[B
M0GC(!&,41KFXDJ)WWNA)!5/1XG7<91OW8;S974^T=0*?"'PF[&,<-@:*F7\6
M7N2I-0.Q8^\[$9YX>^#8FR(X8ROB'2;OT'O)>7*3LDL0FC#'$<,7F.V,8*@^
MA^!K(8[\'SI?I^]6,]Q%^FX9_=-_!))5@20*)'^5>/NAQ#7,_D,0MNBI!EO'
M:7*D,'T;)WGAG0?VCL<W^0,?I_U)V%JVCIR-QY>-_:^,\8"I;*YPA!K\8+.A
MH/+A>(MG.X[9:'C333^(S=\X_PU02P,$%     @ >X184$O;:C3% 0  -P0
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M1TO H-)VFIBYG&[E%&C1SP\.65Z]_ ]02P,$%     @ >X184)$"GK_" 0
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M;:XG*B$TF%2"!_-TC1EZRX%!I>TV-GLYM?YTT**?IQI91FO^!U!+ P04
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M81( )G-@.DTR#I/.XMB! 50WR#<P*0B3 C"Y Y,",#AR6*:B&"=W#BD#43(
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M?CN)$U -9K83NK>?/R@EQNV?8%_..??<BW-=#HR_B)H0&;RVM!/KL):R?P1
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M+H9<$%''X$*#(AI/%(3@5@@78Q%=NPB1W$*>7<A,8J(,[A<;[-D-48$=<.B
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MTZVAB,FN!A-H %S6WP]"$9,L"!-( "[KD;ZF<)\GF6$C#" ! "W#,&$ :0*
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MKW7[MEW#Y>D' :>+NCCT/W:(SK^X6/T/4$L#!!0    ( 'N$6%!M95JPHP0
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MTV<F$7T(&!7*2-*V991-;)L(0[9Y@DJ&H+2O6TF_S003)5X)^++4=5O9_5_
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MFV_NYYDQ"2I)WU,OME(M?EI0.$L]3=6<#XUN6$C6C3T<33^2XC]02P,$%
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M3ZD@DM!_D9*/\G;43RJR%VJ8RC'KK@C=1-#67'^\_@Y6_ -02P,$%     @
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MS,@)8]G:B@:32DPL56&PE#N7:48]PV*PU(RY3&%FU(2Y;&U%PU&%N+8*@Z7
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M_'E"H9)ZF*@Q']O>.)&LGUHZFO]7BO]02P,$%     @ >X184,#*I@H& @
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M.<;XT%:WZ8S&FP^*=O\!4$L#!!0    ( 'N$6% &0A0*, (  'X&   9
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MZ&^IO&^'H\'P('BCCSW!>/9:_0=02P,$%     @ >X184+N./LG9 0  "P4
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MWK]4^HEDW? *B\:GX.H_4$L#!!0    ( 'N$6% !+A"FHIL  &-Z @ 4
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M%-EOW'MOXN8@P**[FERVZ*4U>>G::S#OF=T:*XW,0S*Q1]-NQ@\YOI"'IY7
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M8!88ZR!7GJ^S_"&EH6$NKU_?L-V4XJ<^@WU8-05Z]^$7,7>GEP(&@=%1S[J
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M$<HAPX2,;N WCWA,1R7#KXXU/NHT^XA#BFP_'B%VZI-9/.V;SG?3_I43.#%
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M[.EE=VS9#<[Q"4UZ&/>OKN+IP$6,F/6N'#"^WL";\S">#;Y?,/W13/(T+SO
MKXA^J>$W)F^JCP$W^[WCHV >]8E\#L<XE .(=YH934$W0UQ#V+5!;S V5VDR
MF,;C41=683CJC<8(0)XF'OW.XL&DWZ7>2[RO#@\:@-H7>FXXZ5U>?05G&,2#
M_C0>30,3'/9 L+8YPA#TQ<$XP!%FO6D_L)Q+6'U_TIWG8-J;S4*<83 $\N\'
M[B_,YVIV^F+"@G!O @@G<"Y.KAZJ5)F18%:990>G:.[6<=W"+?C*DF3@2%B4
M/ )I-;R26KYX=CGJE/-=.T5X!Z(7Y#^W8'ZVDY= )&/)B G*-LD76UM9TC_G
M:9&NLH9FYMA7K7H^73DY&SSK2#NENKXV)_#1,@@0L,M5#[L>.%FF4XDE P6,
M!6Z?%\S3;6?JBJ/'A@7(3>7F[88V]\;-S;WU<G-O<+27Y#9-NJ?D1@ "V\6Y
M0"=ZAXII[BBX(6IJEUN0RNZ$K YX%&'_T0ZN5WMO?LY!!SVSM.U.PO5![U/#
M"")([O#/,3 #PJUT*,PSQCGEP2$Z]##+!GC[%YZ6]FOE<M*2&P>[ G6>NL1-
M+@QK(UZHC2B^&ICI$'DVWVRJ).I, >3OR'G@X(R,0''@QP<<M)TYR:'#F7.V
M]L&9&P[PHBR87X#A27-A M%O2@8Q<8/WV*%)/!".7\BXR_P;#Y2) -"'<*V?
MO;YFPG-&=1)L$VEP2<,12LV#S([)\8!+G<$/U1?NS-+4'[2GB1-!'[.$O3CB
MN;0.5XGAOWPNTW5C$PK+ZC<CM4T[F6])5% :7KDSP0^1GY:TM2,OM]Y!KZ/Q
MG^%BJG";VV7 N=*LI6NI\3H1#'Z@16FK#:PMB_GJ+J5VH5R>'7:C2=*'NU8\
M31H<^P2\T_:L[@?4M=4\)L#"T06<A^,X,^UFYZ;;K'H*E%*"TU4'NVF;>Z(?
M[5?MV 'R7J9YQG5?W(>/F^'6QR=,W,SO@9YTE^$Y(<4@]VD=V1.)*D1'AI\W
M:Q5Z5/>X(#/!W&:;):(-9RB#BD?.12%*EZWO.W? 5.&WCUQNG;BR82G4!D\<
MP0YSZ-*]1PQEIP,ORIHRP&5=B>L)((FXG'(*4PL.V)B8&\]RBR9OB<;\/!94
M=A5-XSSVLB),S7:@<08Y:&V0-M"D&SD?U[D[]X<[=GEWB.N\M\F^*N'H)+6
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MV7*9I_:W"!0D-RC)<T3JO8O@/N9BZ CC5W1;H I-D$:\5;BA*-G5-4,8VJ"
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MI>J@ 3%TUZR%ZI^5L'IKH.^VF-50B]BP%J 7)A*RR$T"FAXYA1_(0>1O9E;
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MAH9/!1]!H:*Q7&1=+CE*Q)S#8LDQ4)6VP3!P,I)F[<"LLS-9H"66P$WQ^38
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MD +=65*W%,H<:#<RN^\3:H/L<F)@.Z9[PE('A\162#H/6YEYA%U(TY(>)%J
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M) A3@L\00!RS0&BTWBD\;WB77%NGZJ@210CE+70D(6G3I:Z5Q([_38<9@\'
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M;:ERTQY@07Z+?-.2BP?)J2!!?]HIH]<KS\!O^<#CJ)3O_OO&>CO249+Y=PA
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MB*U0+-8CW.@2*@?'8F=OR]7-C1OEX"N5@I[>.F?J]YO-]C__#U!+ P04
M" ![A%A0))+YP#\"  !<"@  #0   'AL+W-T>6QE<RYX;6S55MMJVT 0_95E
M4TH")9+LVB6-)&@#@4); O%#W\):&DD+>U%7*U?.UW<ONM@NH<5-B_.BG3FS
M<^;L!<W&C=XRN*\ -.HX$TV"*ZWK]T'09!5PTES*&H2)%%)QHHVKRJ"I%9"\
ML4F<!;,P7 :<4('36+3\ENL&9;(5.L'S$4(^_T;FD."'\]??6ZFO7R$_GKTY
M.PL?+JX/\7,7N,#(<WS*$QPMW^+@STDOPZ=Y3>R >O$$=3_=, V9!XE+FQCT
MBT_C0HK]/;" 828<T(:P!-\01M>*VJR"<,JV'IY9()-,*J3-YIO*D46:1Q^.
MO&?/I>?A5$CE:OL*_KONIQ\$!L\*I(R- F?8 VE<$ZU!B5OCN,D._"6$>GNU
MK8W"4I%M-%O@*<$-ILA:JAS46";" Y3&# HK1]&RLJ.6=6"#6DMNC)R24@KB
M- P9O6%H,V#LWE[:;\4>=U<@/\<>28B153&89M6].9U:Z"3OLGGN7=KP*%Y4
MTXW4'UNS'.%\>^G@3D%!.^=WQ2C L).Z9ML/C):"@U_,;PM&1Q9,8S+40954
M]-'PV:N2&0 41AM0FF:[R ]%ZA5T>KA.77&LYMD+U/S<^UR" $78KFAS]T]Y
ME_^SXOF[OY?L_BJ'@I]1HVU!+T#DXO1%SJ].7Z-M[O]69-!WG9W6MM?81A2M
M6\HT%;W<BN8Y>#WV99'@K_;)PO;:R]3?#+TF:_/4V^,WN3D4I&7ZSB[1!1,\
MV9^M\&@YSEJ-% F>["^0TY9?N8+3>S+]"5!+ P04    " ![A%A0LE)>1"$%
M  !>*P  #P   'AL+W=O<FMB;V]K+GAM;,6:WU/J.!2 _Y4,3^X#"_37]3KB
M# )>F?$"*XRO=V()F+%-V"15\:_?DW)=4\4S^W*6)VB:IE_/)/E.TIX_:_-X
MK_4C>RD+9?NM!^>V9YV.S1]$R>V?>BL4G%EK4W('AV;3L5LC^,H^".'*HA-U
MNUFGY%*U+L[?VIJ;3GB@G<B=U H*?<&=%,_V_;P_9!PJ/(DEO^^WNBW&*Z>O
M9.&$&7$G?AA=;:7:]%N]%EM+8]W"W[NN64HE2_DJ5O61?=#/U]K(5ZT<+Q:Y
MT4517^5/U!?!'>R_)7?".)DW*CI^?\N!M=_*NM#@D[3R7A;2[?JM^G\A6O 4
MG> QZCB\_>Z#>&;^2QCU>BUS,=)Y50KE]G$THO!W5_9!;FV+*5Z*?NNM"N-J
MQ<;* 0V;J'U34-<_"]QZLMH_EX.(O<,R<R;AA)FL>AZ<#G(XFRYF-Y/18#D>
ML<O!S6 Z'+/%]7B\7 2 $0(8'0V0G<QY !DCD/'_"+E8PL_/\10 9U=L-A_?
M!I ) ID<#7)X/9@&D"D"F1X/<K"X#B S!#*CA;SD5EJFUVQNA(6J'\?S-P3M
M&RW:S&RXDJ_UB7KBN:RL5,+: .\4P3NEQ5M49<G-SL=N(3=*PF4<9LA!GNL*
M9L@ \CL"^9T6<J*>H +X2(11ZW6Q6;I+BW3%I6%WO*B$#YT'M,Y?T@!$-4+L
M$<@6MJ#EW5YV?U=RZR\(Z3"'](@E,H$QJC;^IFQ@K6B&#?-&CU@<OSN^97.^
MXQ[/AP\*324@C"\A)F:.'K$ZEL*4[$9SQ08;(T3=\VK4&ZTV[66(B;FC1RR/
M>75?R)S-UFMA(/'T0V6HRQ)FPH73^6.(B=FC1ZP//SQ@I  :-&+W4_6\X*K1
M*S&'](@E,E&Y+@5;\I?F#(B)HT=LCG&Y+?1."'8IE%A+5T<LA,.$T2,VAN]E
MTKT/BR$L9* #"I4W'1)A#HF('?)7Q0TLS8H=NQ6V*ER=P<Q@UMY7#3$QDT3$
M)EE &ZL*IL+)A+5KY[TG,_ ((2:Z+"%6"IK)_(I"3$PP$;%@<,PXQ,0$$Q$+
M)DBYV,G2F]#^$;)A5HF(K?)E[K4G#3$QJT3$5CF<@1V,)N:6B-PM'U*Q@X28
M:2)BTZ Y67-D8\Z)B)V#YF0-S!BS3DQLG2^3G4^C)\:L$Q-;)TQY#O7(&'--
M3+T'AJ47["3$1#?!B%V#)AC-'HFY)B9V#:[$),3$M!,3:P?'3$-,3#LQL79P
MS"S$Q+03DVLG2#!&PG%9-,<W9IR8V#A(AN%10TS,.#&Q<;[*,'Z',]SEQHR3
M$!OG<X;1KO6C51W2$!,S3D)NG,^8-W"ILL(;/<3$W),0NP?/AL(%1(*Y)R%V
M#YX--3#15S#'W$AKN"?!W),0NP?'#-V38.Y)J)<\V'Y?(^%(,/<DQ.[!,1M]
M$[-00KW#]F6FWF93WIB0, LEQ!;","&>X6M,S$+IT=8]@%F5(29FH9380ACF
M#Q.F'BEFH93\!4ZP/&NSI0"=&Y]VCJ0?52$F9J&4V$(?,,? 5G\@P_8G0DS,
M0BFQA0[NI1],BU/T4P#J;P'096\[Q,0LE!);",5L6"C%+)026PC'#"V48A9*
MB2V$8X894HI9*#WF&Y]&AI1A%LJ(+81CAJOS#+-01OT5&HKY+<3$+)0=<Q_N
MUVF(B5DH.^H^7#C2,\Q"&?4^'/:BKS%O9IB%LMI"G;JRO3A?@="46$WA%A;*
M<U[D<\/\S_XKE"3U;XK755$,H6RF8)7CR^LVWCYMO?@'4$L#!!0    ( 'N$
M6%#:N?=7+P(  #@G   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%
MVLUNVD 4AN%;0;Z #'-^)DD5LNHFV[8W8,'PHX!M>5PUN?NZ;.I*B;\NT.<-
M"('.>3=^9(UY^I;/]7!JFW(\=67U=CDW95,=AZ'[$D+9'O.E+G=MEYOQFWW;
M7^IA_-@?0E=O7^M##K)>I]!/9U3/3].9JY?=INI?=K%:_:C[0QXV57@[AU]M
M_UJ..0\E7-_BW;A@_,E[E_]G?;O?G[;Y:[O]><G-\$'%WP55^#A(YH.$'J3S
M04H/LOD@HP?Y?)#3@])\4*('W<\'W=.#'N:#'NA!C_-!C_2@N 8RKOE)"&N^
MUA%P'?E>1P!VY(L= =F1;W8$:$>^VA&P'?EN1P!WY,L= =V1;W<$>$>^W@+T
M%K[> O26!>ZUT<TV7V\!>@M?;P%Z"U]O 7H+7V\!>@M?;P%Z"U]O 7H+7V\!
M>@M?;P5Z*U]O!7HK7V\%>NL"9R7HL(2OMP*]E:^W KV5K[<"O96OMP*]E:^W
M KV5K[<"O96OMP&]C:^W ;V-K[<!O8VOMP&];8&S;G38S=?;@-[&U]N WL;7
MVX#>QM?;@-[&U]N WL;7VX'>SM?;@=[.U]N!WL[7VX'>SM?;@=Z^P+-*]+"2
MK[<#O9VOMP.]G:^W [V=K[<#O9VO=P)Z)[[>">B=^'HGH'?BZYV WHFO=P)Z
M)[[>">B=%OBOR43O<JS[O/L^]*?F4&Y=\L_P3VLF<)?A_9QOGW&=^NG^B=+#
MN"6'Z^O-+_'KU#\185I1GG\#4$L#!!0    ( 'N$6% P;ZE,]0$  (\F   3
M    6T-O;G1E;G1?5'EP97-=+GAM;,W:RT[#,! %T%^ILD6-ZU=XB'8#; $)
M?L DTR9J$ENV"^7O<<)# A6IB%:ZFZ;).#,WJ756O7Q\=10FVZ[MPSRK8W07
MC(6RILZ$W#KJ4V5I?6=B.O4KYDRY-BMB8C8K6&G[2'V<QJ%'MKB\IJ79M'%R
M]7Y]:#W/C'-M4YK8V)X]]]6/IM./AKFG=EP3ZL:%D[0@F]QL4Y>0KLVS5 T9
MVV/"SQN'\W3?W3-YWU3TIVAVN6Q*JFRYZ=(M>7">3!5JHMBU>:B-I^HA^J9?
M?>2]-S[>FBXU9MN6?5N0'R]'?&UI=X"Q<LC),6T+VC5J++Q_\G\-_-P-I?4T
M=3Y5?6QV/%Z*=)^J@0T+#_F(-&R=BJJ]AJ?6Q_MA7ZQ?C]]WO?"O8F#CX7]O
M_7 Y!$@."9)#@>30(#D*D!RG(#G.0'*<@^3@,Y0@**)R%%(YBJD<!56.HBI'
M896CN,I18.4HL@H4606*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL$D56B2*K
M1)%5HL@J4625*+)*%%DEBJP215:)(JM"D56AR*I09%4HLBH4616*K I%5H4B
MJT*15:'(JE%DU2BR:A19-8JL&D56C2*K1I%5H\BJ4635*+(6*+(6*+(6*+(6
M*+(6*+(61Y1U/.:=:?K?DCQ9N_Z<S\;_H2W> %!+ 0(4 Q0    ( 'N$6% ?
M(\\#P    !,"   +              "  0    !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( 'N$6% GZ(<.@@   +$    0              "  >D   !D;V-0
M<F]P<R]A<' N>&UL4$L! A0#%     @ >X184 *%BG3O    *P(  !$
M         ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ >X18
M4)E<G",0!@  G"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " ![A%A0%#/H(4D#  "5#P  &
M@ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ >X18
M4/,]D5S2 P  NQ$  !@              ( !=PP  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( 'N$6% /0MZ_#@(  !$&   8
M      "  7\0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" ![A%A0.[*%-<8#   G$   &               @ '#$@  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ >X184*HO;PL9!   ZA(  !@
M             ( !OQ8  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( 'N$6%"CB I&P 4   $>   8              "  0X;  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " ![A%A0:[[R+K,!  #2
M P  &               @ $$(0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ >X184'9'6KZT 0  T@,  !@              ( ![2(
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( 'N$6%#;<MC<
MM $  -(#   8              "  =<D  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " ![A%A03H/"[;,!  #2 P  &0
M@ '!)@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( 'N$
M6%#$@?S0L@$  -(#   9              "  :LH  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ >X184-'>O_2S 0  T@,  !D
M         ( !E"H  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " ![A%A0>/1]=+,!  #2 P  &0              @ %^+   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( 'N$6%!=KX=\M $  -(#
M   9              "  6@N  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ >X184.??_.NS 0  T@,  !D              ( !4S
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " ![A%A0&#S;
M>K,!  #2 P  &0              @ $],@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( 'N$6%"KK":>M $  -(#   9
M  "  2<T  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M>X184'B\C_.S 0  T@,  !D              ( !$C8  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " ![A%A0^RC+.[0!  #2 P  &0
M            @ '\-P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( 'N$6%!)=GW(M $  -(#   9              "  ><Y  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ >X184!,X/8ZS 0
MT@,  !D              ( !TCL  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " ![A%A00<"@,;0!  #2 P  &0              @ &\
M/0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( 'N$6% M
M/L K1 (  -,'   9              "  :<_  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ >X184-$@#EG& 0  -P0  !D
M     ( !(D(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'N$6%#U%;/;M@$  -(#   9              "
M >1+  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ >X18
M4![,_P>X 0  T@,  !D              ( !T4T  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " ![A%A0L%KW[MT!   !!0  &0
M        @ ' 3P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( 'N$6%"1 IZ_P@$  #<$   9              "  =11  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ >X184/P05'[I 0  9@4
M !D              ( !S5,  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " ![A%A0K"JEZ+<!  #2 P  &0              @ 'M50
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( 'N$6% :019=
MPP(  *0*   9              "  =M7  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ >X184(TUY]$- @  WP4  !D
M ( !U5H  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " ![
MA%A0#?B86X8"  "X"   &0              @ $970  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( 'N$6% O(,CA5 (   H'   9
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M970T,BYX;6Q02P$"% ,4    " ![A%A0Y-E\F0 "  !U!0  &0
M    @ %@<   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M 'N$6%!$4\)Q0 (  .0'   9              "  9=R  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ >X184'E#E6;L @  9PP  !D
M             ( !#G4  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " ![A%A0;>)ZL!("  !E!@  &0              @ $Q>   >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( 'N$6%"*()'O?P(
M - (   9              "  7IZ  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ >X184"H9][LZ @  8@8  !D              ( !
M,'T  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " ![A%A0
M8IBDQWX%  !](0  &0              @ &A?P  >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( 'N$6%!M95JPHP0  -<5   9
M      "  5:%  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ >X184.?>6"H6 @  - 8  !D              ( !,(H  'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " ![A%A0/SN^$2X"  !4!@
M&0              @ %]C   >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( 'N$6%!L,5$&_P(  "<,   9              "  >*.  !X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ >X184%C<E!B*
M @  CPD  !D              ( !&)(  'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " ![A%A0I.9D"60"   I"   &0
M@ '9E   >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( 'N$
M6% /OR!67P0  !T9   9              "  727  !X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ >X184'J:AU4- @  R@4  !D
M         ( !"IP  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " ![A%A0VX$1G \"  !C!@  &0              @ %.G@  >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( 'N$6%# RJ8*!@(  ,T%
M   9              "  92@  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
M4$L! A0#%     @ >X184*;"K>#8 P  -!(  !D              ( !T:(
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " ![A%A0!D(4
M"C "  !^!@  &0              @ '@I@  >&PO=V]R:W-H965T<R]S:&5E
M=#8Q+GAM;%!+ 0(4 Q0    ( 'N$6%#KOWAG- ,  (<-   9
M  "  4>I  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M>X184+N./LG9 0  "P4  !D              ( !LJP  'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " ![A%A0F@+N#WX#  "F#@  &0
M            @ '"K@  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( 'N$6%"85]\1R0(  !8*   9              "  7>R  !X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ >X184 $N$*:BFP
M8WH" !0              ( !=[4  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @ >X184"22^< _ @  7 H   T              ( !2U$! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " ![A%A0LE)>1"$%  !>*P  #P
M        @ &U4P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ >X184-JY
M]U<O @  ."<  !H              ( ! UD! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ >X184#!OJ4SU 0  CR8  !,
M     ( !:EL! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $H 2@ X%
&D%T!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812402384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Components of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,515<span></span>
</td>
<td class="nump">$ 1,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,349<span></span>
</td>
<td class="nump">12,923<span></span>
</td>
<td class="nump">$ 9,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Future amortization of patents and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(647)<span></span>
</td>
<td class="num">(553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Future amortization of patents and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Future amortization of patents and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=axgn_PatentsAndLicenseAgreementsMember', window );">Patents And License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Future amortization of patents and license agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=axgn_PatentsAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=axgn_PatentsAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803900688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Agreements and Long-Term Debt - Schedule of Debt - Terms (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="nump">$ 2,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember', window );">Equipment Lease Agreement | Cisco Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payable, percent</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DebtInstrumentNoPaymentsRequiredTerm', window );">No payments required, term</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm', window );">Interest and principal payments, term</a></td>
<td class="text">33 months<span></span>
</td>
<td class="text">33 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember', window );">Equipment Lease Agreement | Raymond Leasing Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payable, percent</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember', window );">Equipment Lease Agreement | B&amp;B Office Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payable, percent</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, during which interest and principal payments are required, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentNoPaymentsRequiredTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, during which no payments are required to be made, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentNoPaymentsRequiredTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=axgn_CiscoCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=axgn_CiscoCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=axgn_RaymondLeasingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=axgn_RaymondLeasingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=axgn_BAndBOfficeSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=axgn_BAndBOfficeSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6815120048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Compensation Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2019</div></th>
<th class="th"><div>Dec. 18, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 17, 2019</div></th>
<th class="th"><div>Dec. 27, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,002<span></span>
</td>
<td class="nump">$ 3,884<span></span>
</td>
<td class="nump">$ 1,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,304<span></span>
</td>
<td class="nump">7,606<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,304<span></span>
</td>
<td class="nump">7,606<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_DirectorsAndOfficersStockOptionsMember', window );">Directors and Officers Stock Options [Member] | Per Quarter, Over One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember', window );">PSU - BLA Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.88<span></span>
</td>
<td class="nump">$ 19.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved', window );">Assumed achievement percentage of PSUs to calculate unrecognized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember', window );">PSU - BLA Milestones [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_PhantomStockUnitPayoutOpportunity', window );">Payout opportunity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember', window );">PSU - BLA Milestones [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_PhantomStockUnitPayoutOpportunity', window );">Payout opportunity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">AxoGen 2010 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,553<span></span>
</td>
<td class="nump">$ 34,229<span></span>
</td>
<td class="nump">$ 7,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to non-vested stock options and restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">AxoGen 2010 Stock Incentive Plan [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">AxoGen 2010 Stock Incentive Plan [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">AxoGen 2010 Stock Incentive Plan [Member] | Directors and Officers Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition of unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">AxoGen 2010 Stock Incentive Plan [Member] | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">AxoGen 2010 Stock Incentive Plan [Member] | Stock Options | One Year After Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">AxoGen 2010 Stock Incentive Plan [Member] | Stock Options | Every Six Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">AxoGen 2010 Stock Incentive Plan [Member] | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition of unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember', window );">AxoGen 2017 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock', window );">Discount from market value on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_EmployeeStockPurchasePlanOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear', window );">Maximum amount available to participants per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember', window );">AxoGen 2017 Employee Stock Purchase Plan [Member] | Every Six Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember', window );">AxoGen 2017 Employee Stock Purchase Plan [Member] | Directors and Officers Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember', window );">AxoGen 2017 Employee Stock Purchase Plan [Member] | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember', window );">AxoGen 2017 Employee Stock Purchase Plan [Member] | Stock Options | Every Six Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember', window );">AxoGen 2017 Employee Stock Purchase Plan [Member] | Stock Options | Two Years After Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_NewAxogenPlanMember', window );">New Axogen Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance</a></td>
<td class="nump">3,385,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,265,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance', window );">Number of unallocated shares available for issuance</a></td>
<td class="nump">385,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for future issuance</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation Cost Not Yet Recognized, Assumed Percentage Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Discount from Market Value on Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EmployeeStockPurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EmployeeStockPurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Unallocated Shares Of Common Stock Available For Issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PhantomStockUnitPayoutOpportunity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payout opportunity of Phantom Stock Units, as a percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PhantomStockUnitPayoutOpportunity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_DirectorsAndOfficersStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_DirectorsAndOfficersStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=axgn_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=axgn_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axgn_NewAxogenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axgn_NewAxogenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6791794144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of long-term obligations</a></td>
<td class="nump">$ 1,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Long-term Debt, Current Maturities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term obligations</a></td>
<td class="nump">$ 1,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Long-term Debt, Excluding Current Maturities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_LeasesFinanceAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">$ 87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current maturities of long-term obligations</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long term obligations</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LeasesFinanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LeasesFinanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804029136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate and Other information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Taxes - Net of Federal Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Permanent items and other deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.80%)<span></span>
</td>
<td class="num">(24.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,056<span></span>
</td>
<td class="nump">$ 5,519<span></span>
</td>
<td class="num">$ (10,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DeferredTaxAssetsRightOfUseLiability', window );">Deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsTax1', window );">Change in retained earnings related to income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DeferredTaxLiabilitiesRightOfUseAsset', window );">Deferred tax liability</a></td>
<td class="nump">951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DeferredTaxAssetsRightOfUseLiability', window );">Deferred tax asset</a></td>
<td class="nump">$ 961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DeferredTaxAssetsRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from right-of-use liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DeferredTaxAssetsRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the related income tax effect of a cumulative effect on retained earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800070288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Compensation Plans - Stock Award Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Employee Consultants and Directors Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Time-Based Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">3,893,171<span></span>
</td>
<td class="nump">4,304,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted (in shares)</a></td>
<td class="nump">344,176<span></span>
</td>
<td class="nump">656,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="num">(287,609)<span></span>
</td>
<td class="num">(40,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="num">(529,557)<span></span>
</td>
<td class="num">(1,026,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding at the end of the period (in shares)</a></td>
<td class="nump">3,420,181<span></span>
</td>
<td class="nump">3,893,171<span></span>
</td>
<td class="nump">4,304,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest</a></td>
<td class="nump">3,420,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable (in shares)</a></td>
<td class="nump">2,099,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 11.94<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">18.07<span></span>
</td>
<td class="nump">29.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited (in dollars per share)</a></td>
<td class="nump">22.75<span></span>
</td>
<td class="nump">9.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">5.21<span></span>
</td>
<td class="nump">3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">12.69<span></span>
</td>
<td class="nump">$ 11.94<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">12.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">5 years 4 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">5 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 26,074<span></span>
</td>
<td class="nump">$ 41,020<span></span>
</td>
<td class="nump">$ 90,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">26,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 22,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_RestrictedAndPerformanceStockUnitsMember', window );">Restricted and Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted and Performance Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Beginning Balance</a></td>
<td class="nump">1,106,363<span></span>
</td>
<td class="nump">610,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">217,146<span></span>
</td>
<td class="nump">516,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released</a></td>
<td class="num">(86,405)<span></span>
</td>
<td class="num">(7,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(123,407)<span></span>
</td>
<td class="num">(13,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Ending Balance</a></td>
<td class="nump">1,113,697<span></span>
</td>
<td class="nump">1,106,363<span></span>
</td>
<td class="nump">610,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted Average Grant Date Fair Value, Beginning Balance</a></td>
<td class="nump">$ 22.18<span></span>
</td>
<td class="nump">$ 21.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Grant Date Fair Value (per share)</a></td>
<td class="nump">17.60<span></span>
</td>
<td class="nump">23.34<span></span>
</td>
<td class="nump">$ 26.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released, Grant Date Fair Value (per share)</a></td>
<td class="nump">16.77<span></span>
</td>
<td class="nump">8.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Grant Date Fair Value (per share)</a></td>
<td class="nump">22.97<span></span>
</td>
<td class="nump">25.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted Average Grant Date Fair Value, Ending Balance</a></td>
<td class="nump">$ 21.62<span></span>
</td>
<td class="nump">$ 22.18<span></span>
</td>
<td class="nump">$ 21.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_RestrictedAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_RestrictedAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>216</ContextCount>
  <ElementCount>428</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Fair Value of Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureFairValueOfInvestments</Role>
      <ShortName>Fair Value of Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Term Loan Agreements and Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebt</Role>
      <ShortName>Term Loan Agreements and Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Public Offering of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock</Role>
      <ShortName>Public Offering of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Equity Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureEquityCompensationPlans</Role>
      <ShortName>Equity Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Quarterly Results of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnaudited</Role>
      <ShortName>Quarterly Results of Operations (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureInventories</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Fair Value of Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsTables</Role>
      <ShortName>Fair Value of Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureFairValueOfInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Term Loan Agreements and Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtTables</Role>
      <ShortName>Term Loan Agreements and Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Equity Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureEquityCompensationPlansTables</Role>
      <ShortName>Equity Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureEquityCompensationPlans</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31501 - Disclosure - Quarterly Results of Operations (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedTables</Role>
      <ShortName>Quarterly Results of Operations (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnaudited</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Summary of Significant Accounting Policies - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Fair Value of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails</Role>
      <ShortName>Fair Value of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Intangible Assets - Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Intangible Assets - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails</Role>
      <ShortName>Intangible Assets - License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails</Role>
      <ShortName>Term Loan Agreements and Long-Term Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt - Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails</Role>
      <ShortName>Term Loan Agreements and Long-Term Debt - Schedule of Debt - Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Term Loan Agreements and Long-Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails</Role>
      <ShortName>Term Loan Agreements and Long-Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Public Offering of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails</Role>
      <ShortName>Public Offering of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Public Offering of Common Stock - Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails</Role>
      <ShortName>Public Offering of Common Stock - Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Equity Compensation Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails</Role>
      <ShortName>Equity Compensation Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Equity Compensation Plans - Stock Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails</Role>
      <ShortName>Equity Compensation Plans - Stock Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Equity Compensation Plans - Summary of Weighted-Average Assumptions Used (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails</Role>
      <ShortName>Equity Compensation Plans - Summary of Weighted-Average Assumptions Used (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41104 - Disclosure - Equity Compensation Plans - Grant Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails</Role>
      <ShortName>Equity Compensation Plans - Grant Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Income Taxes - Temporary Differences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails</Role>
      <ShortName>Income Taxes - Temporary Differences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Income Taxes - Effective Income Tax Rate and Other information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate and Other information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Commitments and Contingencies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Commitments and Contingencies - Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41404 - Disclosure - Commitments and Contingencies - Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41405 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41406 - Disclosure - Commitments and Contingencies - Service Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Service Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41407 - Disclosure - Commitments and Contingencies - Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails</Role>
      <ShortName>Commitments and Contingencies - Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41408 - Disclosure - Commitments and Contingencies - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails</Role>
      <ShortName>Commitments and Contingencies - Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Quarterly Results of Operations (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedDetails</Role>
      <ShortName>Quarterly Results of Operations (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="axgn-20191231x10k0cc357.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="axgn-20191231x10k0cc357.htm">axgn-20191231x10k0cc357.htm</File>
    <File>axgn-20191231.xsd</File>
    <File>axgn-20191231_cal.xml</File>
    <File>axgn-20191231_def.xml</File>
    <File>axgn-20191231_lab.xml</File>
    <File>axgn-20191231_pre.xml</File>
    <File>ex-10d51.htm</File>
    <File>ex-21d1.htm</File>
    <File>ex-23d1.htm</File>
    <File>ex-23d2.htm</File>
    <File>ex-31d1.htm</File>
    <File>ex-31d2.htm</File>
    <File>ex-32d1.htm</File>
    <File>ex-4d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>axgn-20191231x10k0cc357003.jpg</File>
    <File>axgn-20191231x10k0cc357004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6672863600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:1pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Time-Based Stock Options</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term(Years)</b></p></td><td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2017:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,304,201</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.39</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 90,473</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 656,250</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29.48</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (40,473)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.56</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (1,026,807)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.72</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2018:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,893,171</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11.94</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.95</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 41,020</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 344,176</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.07</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (287,609)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.75</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (529,557)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,420,181</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.70</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> 26,074</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Vested and expected to vest</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,420,181</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12.69</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.68</span></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> 26,074</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Exercisable at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,099,616</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.90</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 4.10</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> 22,712</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of stock unit activity</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Restricted and Performance Stock Units</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2017:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 610,730</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.14</p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 516,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23.34</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Released</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7,150)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.95</p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (13,650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 25.89</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2018:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,106,363</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.18</p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 217,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17.60</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Released</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (86,405)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16.77</p></td></tr><tr><td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (123,407)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.97</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,113,697</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.62</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions for options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:68.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 5.76</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 6.22</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;"> 6.16</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 54.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 50.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 50.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Summary of weighted average estimated grant date fair value per share</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.07</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.41</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Restricted and performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26.24</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811884912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash and cash equivalents balance outside of FDIC limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_FinanceAndOperatingLeaseRightOfUseAsset', window );">Right-of-use assets recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_FinanceAndOperatingLeaseLiabilities', window );">Lease liabilities recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DerecognitionOfCapitalLeaseAssets', window );">Derecognition of capital lease assets</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DerecognitionOfCapitalLeaseLiabilities', window );">Derecognition of capital lease liabilities</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DerecognitionOfDeferredRent', window );">Derecognition of deferred rent</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,556,818<span></span>
</td>
<td class="nump">2,621,440<span></span>
</td>
<td class="nump">2,253,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,514<span></span>
</td>
<td class="nump">$ 11,773<span></span>
</td>
<td class="nump">$ 6,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,304<span></span>
</td>
<td class="nump">$ 7,606<span></span>
</td>
<td class="nump">$ 3,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable', window );">Age of doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable', window );">Age of doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the age of specific types of trade accounts and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DerecognitionOfCapitalLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of capital lease assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DerecognitionOfCapitalLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DerecognitionOfCapitalLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of capital lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DerecognitionOfCapitalLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DerecognitionOfDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of deferred rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DerecognitionOfDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_FinanceAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance and operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_FinanceAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_FinanceAndOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance and operating lease, right of use asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_FinanceAndOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803367088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Investments (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 87,597<span></span>
</td>
<td class="nump">$ 105,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">26,812<span></span>
</td>
<td class="nump">12,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">4,544<span></span>
</td>
<td class="nump">15,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">17,754<span></span>
</td>
<td class="nump">31,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">24,679<span></span>
</td>
<td class="nump">27,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">13,808<span></span>
</td>
<td class="nump">17,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">31,356<span></span>
</td>
<td class="nump">28,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">26,812<span></span>
</td>
<td class="nump">12,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">4,544<span></span>
</td>
<td class="nump">15,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">56,241<span></span>
</td>
<td class="nump">76,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">17,754<span></span>
</td>
<td class="nump">31,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">24,679<span></span>
</td>
<td class="nump">27,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 13,808<span></span>
</td>
<td class="nump">$ 17,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806044976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Public Offering of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Public Offering of Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">10.</b></span><b style="font-weight:bold;">Public Offering of Common Stock </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Axogen,&#160;Inc. Classes of Stock</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen,&#160;Inc.&#8217;s authorized capital stock consists of 100,000,000 shares of common stock, par value $0.01 per share. The authorized capital stock is divisible into the classes and series, has the designation, voting rights, and other rights and preferences and is subject to the restrictions that the Axogen Board of Directors may establish from time to time. Unless otherwise designated by the Axogen Board of Directors, all shares are common stock. Axogen has not designated any shares other than common stock.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Public Offerings</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">On May 8, 2018, the Company entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the &#8220;2018 Offering Underwriters&#8221;), pursuant to which the Company agreed to issue and sell </span><span style="font-size:10pt;">3,000,000</span><span style="font-size:10pt;"> shares of the Company&#8217;s common stock in an underwritten registered public offering at an offering price of </span><span style="font-size:10pt;">$41.00</span><span style="font-size:10pt;white-space:pre-wrap;"> per share (the &#8220;2018 Offering&#8221;).  The Company granted the 2018 Offering Underwriters a </span><span style="font-size:10pt;">30</span><span style="font-size:10pt;">-day option to purchase up to an aggregate of </span><span style="font-size:10pt;">450,000</span><span style="font-size:10pt;white-space:pre-wrap;"> additional shares of common stock, at the public offering price, less the underwriting discounts and commissions, which was exercised in full on May 9, 2018.  The 2018 Offering closed on May 11, 2018, and the Company received proceeds of approximately </span><span style="font-size:10pt;">$132,707</span><span style="font-size:10pt;"> from the sale of the shares (including the sale of </span><span style="font-size:10pt;">450,000</span><span style="font-size:10pt;"> additional shares issued upon exercise of the 2018 Offering Underwriters&#8217; overallotment option), after deducting the underwriting discounts and commissions and estimated offering expenses.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797828896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">6.</b></span><b style="font-weight:bold;">Property and Equipment </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Property and equipment consist of the following:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Furniture and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,059</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,763</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Processing equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,772</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,349</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Projects in process</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,886</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,906</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, at cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (3,764)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (2,861)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Depreciation expense for the years ended December 31, 2019, 2018 and 2017 was $933, $774 and $488, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6600071216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of fair value financial assets measured on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,812</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. government securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,544</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,544</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,754</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,679</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,679</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,808</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,356</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 56,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 87,597</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,947</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. government securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,923</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,923</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,495</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,869</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,869</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,025</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 28,870</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 76,389</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 105,259</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797899440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>Schedule II - Valuation and Qualifying Accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Schedule II &#8211; Valuation and Qualifying Accounts</p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:1.8pt;text-indent:-1.8pt;margin:0pt 0pt 0pt 27pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AXOGEN, INC.</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SCHEDULE II &#8211; VALUATION AND QUALIFYING ACCOUNTS</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THREE YEARS ENDED DECEMBER 31, 2019, 2018 AND 2017</b></p><p style="font-family:'Times New Roman';font-size:12pt;padding-left:1.8pt;text-align:center;text-indent:-1.8pt;margin:0pt 0pt 0pt 27pt;"><span style="font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">Balance at Beginning of Year</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">Additions</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">Deductions (Chargeoffs)</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">Balance at End of Year</p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Allowance for doubtful accounts</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 272</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 223</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (34)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 514</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (539)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,092</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Valuation allowance for deferred tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (10,754)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,357</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,357</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,519</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,876</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,853</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6793540176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 8,262<span></span>
</td>
<td class="nump">$ 4,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,237<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">7,631<span></span>
</td>
<td class="nump">6,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="nump">$ 19,130<span></span>
</td>
<td class="nump">$ 12,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811468064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering of Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 11, 2018</div></th>
<th class="th"><div>May 08, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,900,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,589,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,964<span></span>
</td>
<td class="nump">$ 15,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=axgn_CommonStockIssuanceMay2018OfferingMember', window );">May 2018 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Public offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 132,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=axgn_CommonStockIssuanceMay2018OfferingMember', window );">May 2018 Offering | Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares', window );">Number of days to underwriter to purchase additional common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days to underwriter to purchase additional common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=axgn_CommonStockIssuanceMay2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=axgn_CommonStockIssuanceMay2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=axgn_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=axgn_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6799979008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Results of Operations (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,162<span></span>
</td>
<td class="nump">$ 28,564<span></span>
</td>
<td class="nump">$ 26,701<span></span>
</td>
<td class="nump">$ 23,285<span></span>
</td>
<td class="nump">$ 23,433<span></span>
</td>
<td class="nump">$ 22,660<span></span>
</td>
<td class="nump">$ 20,584<span></span>
</td>
<td class="nump">$ 17,260<span></span>
</td>
<td class="nump">$ 106,712<span></span>
</td>
<td class="nump">$ 83,937<span></span>
</td>
<td class="nump">$ 60,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">23,281<span></span>
</td>
<td class="nump">24,054<span></span>
</td>
<td class="nump">22,457<span></span>
</td>
<td class="nump">19,571<span></span>
</td>
<td class="nump">19,793<span></span>
</td>
<td class="nump">19,196<span></span>
</td>
<td class="nump">17,478<span></span>
</td>
<td class="nump">14,547<span></span>
</td>
<td class="nump">89,363<span></span>
</td>
<td class="nump">71,014<span></span>
</td>
<td class="nump">51,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,038)<span></span>
</td>
<td class="num">$ (5,571)<span></span>
</td>
<td class="num">$ (7,022)<span></span>
</td>
<td class="num">$ (9,504)<span></span>
</td>
<td class="num">$ (5,224)<span></span>
</td>
<td class="num">$ (4,102)<span></span>
</td>
<td class="num">$ (7,427)<span></span>
</td>
<td class="num">$ (5,644)<span></span>
</td>
<td class="num">$ (29,135)<span></span>
</td>
<td class="num">$ (22,397)<span></span>
</td>
<td class="num">$ (10,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share - basic and diluted</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6812922176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 2,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">4,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">2,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">2,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">2,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">27,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Payments</a></td>
<td class="nump">41,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount', window );">Less future payments for leases that have not yet commenced</a></td>
<td class="num">(38,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on commenced leases</a></td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease Liability</a></td>
<td class="nump">$ 3,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:LongTermDebtCurrent us-gaap:LongTermDebtNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Payments</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on commenced leases</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total Lease Liability</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 516<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents lessee operating lease lability future payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811747216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 106,712<span></span>
</td>
<td class="nump">$ 83,937<span></span>
</td>
<td class="nump">$ 60,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">17,349<span></span>
</td>
<td class="nump">12,923<span></span>
</td>
<td class="nump">9,311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">89,363<span></span>
</td>
<td class="nump">71,014<span></span>
</td>
<td class="nump">51,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">71,950<span></span>
</td>
<td class="nump">56,617<span></span>
</td>
<td class="nump">37,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,514<span></span>
</td>
<td class="nump">11,773<span></span>
</td>
<td class="nump">6,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">31,305<span></span>
</td>
<td class="nump">23,124<span></span>
</td>
<td class="nump">14,731<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">120,769<span></span>
</td>
<td class="nump">91,514<span></span>
</td>
<td class="nump">59,066<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(31,406)<span></span>
</td>
<td class="num">(20,500)<span></span>
</td>
<td class="num">(7,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Investment income</a></td>
<td class="nump">2,364<span></span>
</td>
<td class="nump">1,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(1,127)<span></span>
</td>
<td class="num">(2,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Interest expense - deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">2,271<span></span>
</td>
<td class="num">(1,897)<span></span>
</td>
<td class="num">(2,494)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (29,135)<span></span>
</td>
<td class="num">$ (22,397)<span></span>
</td>
<td class="num">$ (10,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">39,235<span></span>
</td>
<td class="nump">37,127<span></span>
</td>
<td class="nump">33,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share - basic and diluted</a></td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797878688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_OrganizationAndBusinessAbstract', window );"><strong>Organization and Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">2.</b></span><b style="font-weight:bold;">Organization and Business </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Axogen is a global provider of innovative surgical solutions for physical damage or transection to peripheral nerves.  Axogen is focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen&#8217;s products are designed to restore nerve function and are used to treat patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Axogen&#8217;s portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site, Axoguard Nerve Connector, a porcine submucosa extracellular matrix (&#8220;ECM&#8221;) coaptation aid for tensionless repair of severed peripheral nerves, Axoguard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, Axoguard<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissues in the surgical bed.<span style="white-space:pre-wrap;">  Along with these core surgical products, Axogen also offers the Axotouch Two-Point Discriminator a measurement tool for use by healthcare professionals detect changes in sensation. The Company&#8217;s portfolio of products is available in the United States, Canada, Germany, South Korea and other European and international countries.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Avance Nerve Graft and Avive Soft Tissue Membrane are processed in the United States by Axogen at its processing facility in Dayton, Ohio.  </span>Axoguard Nerve Cap<span style="white-space:pre-wrap;"> is manufactured by Cook Biotech in the United States for sale by Axogen and Axoguard Nerve Connector and Axoguard Nerve Protector are manufactured in the United States by Cook Biotech and are distributed worldwide exclusively by Axogen.  The Axotouch Two Point Discriminator is contract manufactured by Viron Technologies, LLC (formerly Cybernetics Research Laboratories) (&#8220;Viron&#8221;) Tucson, Arizona.  Viron supplies the Axotouch unpackaged and they are packaged at Axogen&#8217;s distribution facility in Burleson, Texas.  Axogen maintains its corporate offices in Alachua, Florida and is the parent company of its wholly owned operating subsidiaries, AC, APC and Axogen Europe GmbH.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_OrganizationAndBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_OrganizationAndBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6814635376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 26, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 20, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 21, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 06, 2007 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember', window );">SNH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_AreaOfRealEstatePropertyAdditional', window );">Additional leased office space in square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember', window );">SNH | Second Expansion Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_AreaOfRealEstatePropertyAdditional', window );">Additional leased office space in square feet | ft&#178;</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember', window );">SNH | Third Expansion Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_AreaOfRealEstatePropertyAdditional', window );">Additional leased office space in square feet | ft&#178;</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember', window );">SNH | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember', window );">SNH | Minimum | Second Expansion Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember', window );">SNH | Minimum | Third Expansion Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember', window );">SNH | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember', window );">SNH | Maximum | Second Expansion Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember', window );">SNH | Maximum | Third Expansion Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_JaColeMember', window );">Ja-Cole</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_AreaOfRealEstatePropertyAdditional', window );">Additional leased office space in square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_JaColeMember', window );">Ja-Cole | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_JaColeMember', window );">Ja-Cole | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_AshleyAvenueLeaseMember', window );">Ashley Avenue Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_EarlyTerminationPeriod', window );">Right to early termination of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_NoticePeriodForTerminationOfAgreement', window );">Notice period for termination of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_AshleyAvenueLeaseMember', window );">Ashley Avenue Lease | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_AshleyAvenueLeaseMember', window );">Ashley Avenue Lease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionMember', window );">Heights Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionPremisesMember', window );">Heights Union Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionPremisesMember', window );">Heights Union Premises | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionPremisesMember', window );">Heights Union Premises | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_AreaOfRealEstatePropertyAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional area of a real estate property due to agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_AreaOfRealEstatePropertyAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EarlyTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after which the reporting entity has the right to terminate the lease before the expiration of the lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EarlyTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the notice period for termination of the agreement by either parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=axgn_SHNMedicalOfficePropertiesTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=axgn_SecondExpansionLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=axgn_SecondExpansionLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=axgn_ThirdExpansionLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=axgn_ThirdExpansionLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=axgn_JaColeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=axgn_JaColeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=axgn_AshleyAvenueLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=axgn_AshleyAvenueLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=axgn_HeightsUnionPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6669520800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Compensation Plans - Grant Date Fair Value (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Employee Consultants and Directors Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated grant date fair value per share</a></td>
<td class="nump">$ 18.07<span></span>
</td>
<td class="nump">$ 15.05<span></span>
</td>
<td class="nump">$ 8.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_RestrictedAndPerformanceStockUnitsMember', window );">Restricted and Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated grant date fair value per share</a></td>
<td class="nump">$ 17.60<span></span>
</td>
<td class="nump">$ 23.34<span></span>
</td>
<td class="nump">$ 26.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_RestrictedAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_RestrictedAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806758688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">8.</b></span><b style="font-weight:bold;">Accounts Payable and Accrued Expenses</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Accounts payable and accrued expenses consists of the following:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,262</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,517</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Accrued compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,631</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,477</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Accounts Payable and Accrued Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797993104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">4. </b></span><b style="font-weight:bold;">Inventories</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Inventories are comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve&#160;Protector, Avive Soft Tissue Membrane, Axoguard Nerve Cap, Acroval Neurosensory and Motor Testing System, Axotouch Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value and consist of the following:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,403</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,194</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,728</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Inventories</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,982</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">For the years ended December&#160;31, 2019, 2018 and 2017, the Company had recorded a provision for inventory write-downs of $1,887, $1,343 and $1,438, respectively, primarily relating to product expiration.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806107040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">12.  Income Taxes </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax basis, as measured by enacted state and federal rates as follows:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:-0.13806152%;padding-left:0pt;padding-right:0pt;width:100.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Inventory write down</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 273</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Depreciation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Amortization</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Interest limitation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Allowance for doubtful accounts</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 274</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 285</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Right-of-use liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Stock-based compensation</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,140</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,335</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 520</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred tax liabilities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Depreciation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (81)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Amortization</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (206)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Right-of-use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (809)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract liabilities</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (39,932)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (33,876)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (28,357)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The difference between the financial statement income tax and the income tax benefit using statutory rates is primarily due to the increase in the valuation allowance.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December&#160;31, 2019 and 2018:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:11pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';"> </span><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:27.84%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December</b><b style="font-family:'Calibri';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.85%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Federal tax rate</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> 21.0</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> 21.0</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">State Taxes - Net of Federal Benefit</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> 4.1</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> 4.1</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Permanent items and other deductions</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (4.3)</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (0.5)</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (20.8)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (24.6)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Arial';font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Arial';font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2019 and 2018, management assessed the realizability of deferred tax assets. Management evaluated the need for an amount of any valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, <i style="font-style:italic;">Income Taxes</i>, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the Company&#8217;s deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more likely than not (a probability level of more than 50%) that the Company may not realize the benefit of its deferred tax assets. In assessing the realization of the Company&#8217;s deferred tax assets, the Company considers all available evidence, both positive and negative. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that &#8220;a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.&#8221; Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2019.  The valuation allowance increased by </span>$6,056 and 5,519<span style="white-space:pre-wrap;"> during 2019 and 2018, primarily as a result of current year increase in the net operating loss carry forward.  During 2017, the valuation allowance decreased by </span>$10,754, primarily due to the remeasurement of the Company&#8217;s deferred tax assets and liabilities as a result of the Tax Reform enacted on December 22, 2017.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">As of December&#160;31, 2019, the Company had tax-effected net operating loss carry forwards of approximately $36,250<span style="white-space:pre-wrap;"> to offset future taxable income which expire in various years through 2039.  Federal net operating losses incurred in tax years beginning on or after January 1, 2018 are carried forward indefinitely.  A portion of the net operating loss carry forwards may expire due to limitations imposed by section 382 of the Internal Revenue Code.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. In the normal course of business the Company is subject to examination by taxing authorities throughout the country. These audits could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with federal, state and local laws. The Company&#8217;s tax years since 2017 remain subject to examination by federal, state and foreign tax authorities.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842 &#8211; Leases, on January 1, 2019. Under Topic 842, the Company is required to recognize the assets and liabilities that arise from most operating leases on the balance sheet. Upon adoption, no change in retained earnings was recorded related to income taxes as the Company maintains a full valuation allowance. As of the implementation date, an adjustment of $951 was recorded as a deferred tax liability and an adjustment of $961 was recorded as a deferred tax asset. See above for more information about the non-income tax impact of the adoption of the new leasing standard.</p><p style="font-family:'Times New Roman';font-size:5pt;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017, subjects a U.S. shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</span><span style="font-size:12pt;"> </span><span style="font-size:10pt;">The Company has elected to account for GILTI in the year the tax is incurred.</span>&#160;</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company had no<span style="white-space:pre-wrap;"> income tax expense or income tax benefit for 2017, 2018 and 2019 due to incurrence of net operating losses.  The Company does not believe there are any additional tax refund opportunities currently available.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6666393824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of total lease expense</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">For the Fiscal Year Ended December 31, 2019:</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Finance lease costs</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Amortization of right-to-use assets</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Interest on lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Operating lease costs</b></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,910</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short term lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Variable lease costs</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,994</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of supplemental balance sheet information related to leases</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,133</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Tc_A4Fx7oi8o0qgiyXaY11oBA_4_0"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Current maturities of long-term obligations</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,719</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Tc_iS9N_npf70GWW2V_ErRjnw_5_0"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Long term obligations</span></span></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,565</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease right-of-use assets</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current maturities of long-term obligations</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long term obligations</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock', window );">Schedule of other information related to leases</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for amounts included in the measurement of operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,773</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-to-use assets obtained in exchange for new finance lease liabilities</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average remaining lease term - finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;"> 3</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;"> 2</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average discount rate - finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.28%</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.28%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,664</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,573</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,644</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Future Minimum Lease Payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,720</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less future payments for leases that have not yet commenced</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (38,246)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest on commenced leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (190)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Tc_pGofsY-zPU6ke-fO75b00A_12_0"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Total Lease Liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock', window );">Schedule of commitments relating to noncancelable operating and capital leases prior to adoption of ASC 842</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,866</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,970</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,574</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,579</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance and Operating Lease, Liability, Maturity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Future Minimum Payments for Operating and Capital Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the information other information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tabular disclosure for supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811581392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms', window );">Net Receivables, Opening balance</a></td>
<td class="nump">$ 15,321<span></span>
</td>
<td class="nump">$ 11,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms', window );">Net Receivables, Closing balance</a></td>
<td class="nump">16,944<span></span>
</td>
<td class="nump">15,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_IncreaseDecreaseInContractReceivable', window );">Increase/(decrease)</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">4,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract Liabilities, Current, Opening balance</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract Liabilities, Current, Closing balance</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent', window );">Increase/(decrease)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract Liabilities, Long-Term, Opening balance</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract Liabilities, Long-Term, Closing balance</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent', window );">Increase/(decrease)</a></td>
<td class="num">$ (27)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_IncreaseDecreaseInContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Contract Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_IncreaseDecreaseInContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Contract with Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Contract with Customer, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 310<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118388040&amp;loc=d3e49354-109356<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>axgn-20191231x10k0cc357_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:axgn="http://www.axogeninc.com/20191231"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="axgn-20191231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_G8SJ8nYBukqnwXb72_TUaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_QdTP5uBuUkm8aCMGR4HRdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_yxMu6JmduUiQWUtieKQOwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_4dIDit0lLkGoGloMyIZncQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_sonit0BwD0-XslHO4fwUog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_rHiawjIyP0aw2fguf5ppEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_YOXkkYOqUke7VD_DZQQEDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_UAgoENraVE6_3zK-NyR0vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_UBoSuOgnDkyJox-_uA5moQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_SJai84u14EuDL2IY6ZP7lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_SVGvuAZnpEa4kIr4fmffiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_5pNCsEIErU22bwU3noUy8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_JiZrmI4fMUOvyhPBobtrAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_7M-n1WyHmkSuJh3oSbSVVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CS4l3RjFjkG4cuMVEIJHOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OqYgr00JsUa249PGlgCbJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5iFiNf4eCU2t-jlDjLdgiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UsFg6g1V3k-jJJ9z3zX3kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-KZyjfz9K0yURx8oujgc-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36RWqiIIvUqIM5o6-tTfQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rABqkECIXEmoFHY4P39Btg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yopO1vpWDkSdAu8pQTBE6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_NvaE0ZF610qmwkn-m_kZkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_FuweD_vKdkCOcnSUpC4lMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_dOpDEESlqEODYTZJx6VStA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_ts6ch1E1YkaKgRGi-KlCzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_wAZ3pu-l8kyAOvBDAXRqzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_0ysv9tohn0Cnci0yKK3WTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_18_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_KoTtJ_qtIEWdKLFBvghyAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="As_Of_12_18_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_CGrwMnPP4UGYxvkC4Exm0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_AsMXpgQA50yoxCfsHEU1FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:NewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_5M4EtFIS2UiIB7rFpvlMjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_14_2019_To_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_GGHIBITd6ES9mOn1M2PF1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:NewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-14</startDate>
            <endDate>2019-08-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_j1ICqH5Z30Cj6yv7xX0hUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_17_2019_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_h_z9vINimUO30zz-EdrkPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-17</instant>
        </period>
    </context>
    <context id="As_Of_12_27_2018_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_XKWVUmRIiEOgStCdW6dO9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-27</instant>
        </period>
    </context>
    <context id="As_Of_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_kDpRBjGQ4ky9c7CfmO9qDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_kf1nPeinvkG_Rhf00UpwCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_C62IeF_A8kyKJEMkteQh9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_JJoSoSTdZU-4AUZvS_2qqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_zBQhnBxudEOrta0F6gp39g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:RestrictedAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_G1UD6bCPNE6Vk1FLD8sFmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Lew-fDnf_U63JMTITTXx7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_w1MuJpPwoUuQdyD6mVgyFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tXs-JMVGQEyiTIr2x0PXlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_8GcfaDwiVke9uA8EDTn7hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_CC9WNsq1-kOINeRZ-7lGZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_CzAjyxtOdk2O6kk_VYsVbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_6eAKFDAAb0yer27HykbH7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_VestingAxis_axgn_ShareBasedCompensationAwardTrancheFourMember_sY50ARTqmkOIAcnOP5sbtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">axgn:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember__vQAw7VfUE6OunzRu1K-bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_VxZyqVXjoUyc4jYXo3Wsgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_bxzrSUd6ckqbGlbKCkkNcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_ACgwMpqi40GSjcz2QnxS7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_OZPWCWKOxEOV_X4bbR494w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_gm7Ekd16kESYJkPMrHphbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_BvPsE8K_qU2AmBwEqGDfYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_05CtstIR4U6B9g5bHnLHdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_P3IHq2_ZwUq82grKCaDpZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_axgn_FurnitureAndOfficeEquipmentMember_eHb9YcMz8EqbrCnNH59ieA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_mTPBmF_K80agEXOisxdU-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_IKe6rTfzZ0ud8WUCTvHEOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CLATC9jILkmHQd664S3WNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_3Y3Zposxo06m_ckziI2URQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_axgn_FurnitureAndOfficeEquipmentMember_DX67Y23vfUOHXqqejMx78g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_11_2018_To_5_11_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_8cxhdgof3UO6xB-FFbptDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axgn:CommonStockIssuanceMay2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-11</startDate>
            <endDate>2018-05-11</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_31_2018_pDS8UW-ipEGiRfiHlv5kzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="Duration_5_22_2018_To_5_22_2018_us-gaap_LongtermDebtTypeAxis_axgn_RevolvingLoanAgreementMember_8N4ZVro1vU-SRjTtIMuL6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">axgn:RevolvingLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="Duration_5_22_2018_To_5_22_2018_i3ypW9J1CEa7OLr3rjoRmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_okKh-SdZMEibF5PgZHtNtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MOuFDoRprUic4VVjiNOb9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yAQQYV4FD0OLKehglkYWNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_fWIoGNsj7Ui2pXQ3bkgU4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_V4e6rd3wUEG9C3qE3Hpw-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:JaColeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_NnCe9k1NpUacLG-xMiiljw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:AshleyAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_bByFAiGDsEK9OCAVsqZANg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_KuQDicj1c0SnADAaZVmqbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:JaColeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_ZUL32-Ode0O5GUOiGbojiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:AshleyAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_NXRoZ-NBZ0ePelC05RSaqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:ThirdExpansionLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-19</startDate>
            <endDate>2018-11-19</endDate>
        </period>
    </context>
    <context id="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_oujYrCpym0y45N14NxtAYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:SecondExpansionLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-19</startDate>
            <endDate>2018-11-19</endDate>
        </period>
    </context>
    <context id="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_IsEezefk-Eu1CFK7CxX86A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:ThirdExpansionLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-19</startDate>
            <endDate>2018-11-19</endDate>
        </period>
    </context>
    <context id="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_U9D1ulBaeUqvJJI4uvH5oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:SecondExpansionLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-19</startDate>
            <endDate>2018-11-19</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_ZBGX0n3gPUucFdPYU_PIgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_Pwl4eK2_UkO9SelPSqHkRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_FBZq-druJEiz_96TJNFlGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksMember_BbMESX-_v0KHSgS-XLTLvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksMember_Qd3k0h7qbE2DTTVHMaRmbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">axgn:PatentsAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_KC2GzeBS4kutQdKGNYDCsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_tm6tkYZA0UC_UdKqm7L5gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_PgGkObwHFk-tbBS04WJSyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_XpCasb7z-kOfYQrkb2g_dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_dGmAPQbXTkiY-aJQtxRmkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_V4yhWdQNTEehyUOL8K5GIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_3FvL10D5nEOeSMDNANv2Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_Ql1wJMAwvk-Sb_JOHEvrvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_R1UTHSkFFkGQk_FG_stL9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_QtnKkZ4CLk2X_HFK_HYUZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_aTc0csteMkS0guuaxwtDRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_22_2018_dzFQMjgQyUeSU6fLKCFqYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2018-05-22</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5zA3fXbvx0ylwp-9i_-FOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:RaymondLeasingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_1eKp0lMU00OTf_T3kLb7qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:BAndBOfficeSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_kNscByhTbEyGSk9W2JNlqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:RaymondLeasingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_7a23qUYeEESFI9Qda8I25Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:BAndBOfficeSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_GGJc28kiH0yWr2MZBgPxCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:RaymondLeasingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_K3AS51eTEE-YvIQB0nBIfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:CiscoCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_nwTNdrPqO0CQRQSSHeR4zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:BAndBOfficeSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_R55K8zUulUecXnhoaiBPkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:RaymondLeasingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5AiGbGmjpkCdVyBcVv8E_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:CiscoCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_wW9WLuWZOE66fVKEdCy_HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:BAndBOfficeSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_dwnRMOuleUGG7WL91vnSAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x8gKvx5oDUisUyE4r4cbmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qFCNsryetU6naqT7GbcEhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B8IECFly_kaRlwUWZ1F6ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TJlFr_r_RkuXuvZTAhvzYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_YTJ3Sc6qnUeCcLNGzq1uxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">axgn:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axgn:CommonStockIssuanceMay2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-08</instant>
        </period>
    </context>
    <context id="As_Of_5_8_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_IP-Mn3x-6EudoUgdTXzq8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axgn:CommonStockIssuanceMay2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-08</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_Or2PNLcVTkK03OOF11rmZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_NtuCJ8sKq0qVnPGFTPpTwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_2g6PdNw7sEqA9_PlVqHxDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_QK4ED2K6qEOV1Xg1-zGj_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_75NcZ12IJk-eikFk1KM3Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_cdH2QUZpnki1Cwgvsjs8vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_ANmFTxutV0-xFOoQ8_7FPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_j8zL172gGUqB0hFUPl1x4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Y5SbtUl8VkmtgzZCsagCyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_5jPMRknfREqoJu62tcfW5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_QEj-hDcpYE6iU9rJ3XeK7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_A0SgF-lS8EWuSRhFGPu_kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_fkX6ZqT47Uy7zsyx_wxs1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_x6KsE8qyC0SgbIbxY0R8XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_728oYVG9_kqeLbE5u8GVGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nysdIkyyg0WkBDmiLHyfzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ftL9sDUwHkWRUwmRLPxn4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Ljo8XdXd1UOQhteaj6n1Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_N02mc_9XDEmaoa7UwF0qCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_285oEZVmiEuWMlWvMBhBKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_Z-mVrl7y0E-H9TTKDpOGrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_0r35qKuFtEOBMm3qfUnZew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_yZ1Iu5dLmECLNXvQICHt7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_iTCpB9orK0Sjz-9gGwsP8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Psoi6DhJ7E2efXXbLdjXyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_puZ9vioqskyMdjdeNUCdsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_HEXGxa8jpUKp0M7bjLh6dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VRqBUSVw9EGAy-ARzd86JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_t1faoeA6yEG9189EF_P-Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KEeGgwBLD065_sx2yO_BVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_tglKryFxhkq8-SAK4HEuzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_A-7j6YugD0yFLat26CFF9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:JaColeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_x4yTeLpiWEyE5kq91aXN1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:AshleyAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-26</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_kMJbk8ZcGUK3JDwkyBnNog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_08A0hhoaQ0qebYXFMpGy1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="As_Of_2_6_2007_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_IQT4Hnendk61jLbD3SyI3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-06</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_4tCIYMnwyk6Ob6QqnDHXvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:HeightsUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2018_9F5KGFk5ekOKV8bdqwW0vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_UDTsEyjMukWLzOkrt7d4_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3xXv5tKLESPI6qfsNRBAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ix9c_2i7sEuWHRfmxUztXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2019_9ic9jzQW1ECZSI_uvWQc5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_21_2020_kNbwNoscBki-6ondKdMYyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="Duration_2_4_2019_To_2_4_2019_ln_X-b6a80Wb7o__1q1OhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zPNTOe5UAku8lMq39V0WUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pgmLVwXuIUS__MSTlzniug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2011_To_12_31_2011_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_vqWblD6hEkiSy0wcGyIdzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-12-01</startDate>
            <endDate>2011-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_xxA6d2qDA0KMb3nNUfKzyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_NdmkMgAetEmBY0Ox4RWwMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_YaU4fSuYCEqRjlrkJR8zFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_OFAgoTompkmEhOalHj3_sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_raPo7Sf_yUa4X4qkmt6ISg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:NewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_XwSdGg8qkECo4xeg2jamwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_8_2018_To_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_95CgkAkKI0mIpKKHiaq65w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">axgn:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axgn:CommonStockIssuanceMay2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-08</startDate>
            <endDate>2018-05-08</endDate>
        </period>
    </context>
    <context id="As_Of_11_11_2019_srt_LitigationCaseAxis_axgn_NovitzkiVsZaderejMember_IYCkqEqibkCICffbHpaANQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">axgn:NovitzkiVsZaderejMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-11</instant>
        </period>
    </context>
    <context id="As_Of_8_12_2019_srt_LitigationCaseAxis_axgn_NovitzkiVsZaderejMember_zFX_2N4KPUasTY6aVIbF6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">axgn:NovitzkiVsZaderejMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-12</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_w7VPQT2pRkub_N0KQzm0eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:TissueProcessingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_re7GROPgKUaFj-ZkUJDT4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:TissueProcessingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_xCSHLZgiMUuIzNw6sSuFGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:TissueProcessingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_do694XF7Vkun4p0EqDCKIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_26_2018_To_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_DNUFWr2HVU6UI2RUpDclJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:AshleyAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-26</startDate>
            <endDate>2018-10-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_1_2019_0uPXfB4sV0SD97KHNevlsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_7eeOyFQI-kyot4WSOxp9WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_rhwnZKQoVkSq-3aU8DS-_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanEmployerMatchingContributionTranche2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_WwMtZh6dN0OytTHyKURZmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanEmployerMatchingContributionTranche1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_pv52m7zoikuufdq5oJOf0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_OuSBR749Ck6rO9M9pD5hrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:CiscoCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_8IfuLyTmxkeeHIrn5HAHCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axgn:CiscoCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_18_2017_To_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_vVyhRlB3k0qQ8T_w4fLYmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-18</startDate>
            <endDate>2017-12-18</endDate>
        </period>
    </context>
    <context id="As_Of_7_9_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_1bIsEkV_FkmHurO56ABv6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-09</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2018_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_mqnOkqMEd06V_dbWfNINVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:JaColeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_19_2018_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_V5WUDuaOrka-roEinNbOxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:ThirdExpansionLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-19</instant>
        </period>
    </context>
    <context id="As_Of_11_19_2018_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_oohE1k3520KrPLNnlA6-yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axgn:SecondExpansionLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-19</instant>
        </period>
    </context>
    <context id="As_Of_1_23_2017_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_VHd28wBFnkarvgZ3-fAtGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">axgn:SHNMedicalOfficePropertiesTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-23</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_jWuqQcWDKE6x_Rz8ykfOzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_zbj4-_iSt0mMZxIh6JETbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_9_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_k2AvsINLE0CA1hy04sZUqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-09</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_bQ28F0w6C0GKznH2O5VZSw">
        <measure>axgn:item</measure>
    </unit>
    <unit id="Unit_Standard_individual_c5Uqr2HKeUq8VhVxnbwwzQ">
        <measure>axgn:individual</measure>
    </unit>
    <unit id="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_acre_uQoen29RI0aO7YAQ0QAY8Q">
        <measure>utr:acre</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      id="Tc_tMtHerkBPUaU0ej7Uz8Cww_31_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      id="Tc_XQ1rYkr1_0-yQNzIOG0Jkw_31_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ"
      xsi:nil="true"/>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tc_rqrQ3ho-OUOyVr7owf06qA_1_0">MN</dei:EntityIncorporationStateCountryCode>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="INF"
      id="_c344fd47_2394_4dca_b707_ae51747fa418"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">38900875</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="INF"
      id="_f512fdbf_b9ff_4859_8380_dfc91859b80e"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">39589755</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_xxA6d2qDA0KMb3nNUfKzyA"
      id="_de056e84_5c37_441e_8d70_f8b60d255c1c">P17Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_2_6_2007_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_IQT4Hnendk61jLbD3SyI3A"
      decimals="0"
      id="_9adc0d0a_9f27_4b75_b561_f0f616fc58b6"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">19000</us-gaap:AreaOfRealEstateProperty>
    <axgn:AreaOfRealEstatePropertyAdditional
      contextRef="As_Of_1_23_2017_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_VHd28wBFnkarvgZ3-fAtGg"
      decimals="0"
      id="_de7536fc_c71e_45d4_b4bd_cca7546a8119"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">1400</axgn:AreaOfRealEstatePropertyAdditional>
    <axgn:AreaOfRealEstatePropertyAdditional
      contextRef="As_Of_11_19_2018_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_oohE1k3520KrPLNnlA6-yg"
      decimals="0"
      id="_842590dc_0853_48a1_94e3_0974e859a7d8"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">2800</axgn:AreaOfRealEstatePropertyAdditional>
    <axgn:AreaOfRealEstatePropertyAdditional
      contextRef="As_Of_11_21_2018_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_mqnOkqMEd06V_dbWfNINVg"
      decimals="0"
      id="_2049e4b8_faac_41e8_83f3_7e116573faca"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">2500</axgn:AreaOfRealEstatePropertyAdditional>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_A-7j6YugD0yFLat26CFF9g"
      decimals="0"
      id="_0d926b8e_ab68_494b_9c97_8808ab1309cf"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">12500</us-gaap:AreaOfRealEstateProperty>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tc_IJWfjyMus0uvUNKT0625tA_2_1">0000805928</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tc_A8V_Ke3pz0KPObwGFiYoiw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tc_XKDgGrkTgESuoE3GyMx0ig_4_1">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tc_sCTDJzlxpkKC914YJsrHsQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_1r3g88ErGkW29bOhTFOohA">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      id="Tc_A4Fx7oi8o0qgiyXaY11oBA_4_0">us-gaap:LongTermDebtCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      id="Tc_iS9N_npf70GWW2V_ErRjnw_5_0">us-gaap:LongTermDebtNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      id="Tc_pGofsY-zPU6ke-fO75b00A_12_0">us-gaap:LongTermDebtCurrent us-gaap:LongTermDebtNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_CzAjyxtOdk2O6kk_VYsVbA"
      id="_85e8adea_8926_4837_834b_5796d41281fc">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_20_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_08A0hhoaQ0qebYXFMpGy1A"
      decimals="0"
      id="_8737cf0c_5377_4487_aceb_781cdeb5b2e6"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">1500</us-gaap:AreaOfRealEstateProperty>
    <dei:DocumentType
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_8X4WO4XfTU-Kg8cLgqsjeg">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr__csxq1N-yUelg0a1YjKpHQ">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_v5Oeh3IiEUSKE1WH2ArXUw">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_sQKrMY1EAEe_iJAboO6NAw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_Ftr6OvsUr0GwUIWUqB0rmA">001-36046</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_Ug_7ZWupSEidP8ye_cEBNQ">AXOGEN,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tc_tWRCuR-yt0GniZQ93WZkDg_1_2">41-1301878</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_T5hG_LKVCECTa9f8Kzwqcg">13631 Progress Blvd., Suite&#160;400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_N7M2yrg27kagPQ3qpFkx-A">Alachua</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_IB9FN2G18kKvp8e-BjXtRw">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tc_gCnq_dYBV02aUXB-CSF3yQ_5_2">32615</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_ClOeacAogkqsk_Mo1bhRbg">386</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_FkF0XwwA40SZaKYXgIfBWQ">462-6800</dei:LocalPhoneNumber>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_5l3khw2ZWEKu4et0vKNq2g">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_NP5W7N72V0idCjyFEke1OQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_dQY0qcW9_0aVRqmRzDSkeQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_RiTbQmABiEOMcdU0q3CMGQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_kaLf2K7mbUC5brYVy2lPsw">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_wc2v1-ozOUOf25UVJtpIQg">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_dGx3c6kddEGmvf-o6Bilqw">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Narr_WhWbluA9x0-5EMppaQurOw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2019_9ic9jzQW1ECZSI_uvWQc5g"
      decimals="0"
      id="Narr_vuQU9CKl3kSgI7TKXvdozw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">539757783</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_21_2020_kNbwNoscBki-6ondKdMYyQ"
      decimals="INF"
      id="Narr_DdadIm_9EkW8KVK2Gmgd8w"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">39731078</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_kwkVALLapk69Lq2WgJTR3w_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">35724000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_lVYgP93J8UuJ6xvPebsrkg_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">24294000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_89lYeUehfEWypTM-sywO3w_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_GPpvlC7S-kC-PT-s3fcgVQ_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6000000</us-gaap:RestrictedCash>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_yCb4dC6Sok2GAKWlpx4xbw_8_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">60786000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_h4Y2C1tW8E-imJxLDNzr2A_8_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">92311000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Narr_XEZAWaPOy0S356fQXDmNrQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1092000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Narr_J20H-_D4O0O5-zT_d7O-AA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1117000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_WhP1NhhxOkq6odO2cJBgaA_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">16944000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_VUORrc7ZFkWl4L0zdTBtWw_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15321000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_YtcdAMdIPku8Lf6F91dbyw_10_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">13861000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_8me8hasd-0u94icanVW_RQ_10_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">11982000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_oFlkEngcg0uuihayQSiyxA_11_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1706000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_DNbC_XYM_0Ku2el_jLDvpA_11_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1045000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_O_vju-o1YU-OJxsyvSs4Ag_12_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">135021000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_YPJTRr6wwUaowZIFXrLnJg_12_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">150953000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_3IdwaVja8E-iHF0qxB6jGg_13_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">14887000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_FhuaHXCHTkuzu03umdtWxg_13_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">8039000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_u8fBj3Z3p0Crwxrv_ViOtA_14_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3133000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_Iz5WHezojkW-1NmRj38oTA_15_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">87000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_oQDQfK-uOUCLJJe_q00gFQ_16_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1515000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_lfbwaT6UAkiguPzkxEutaQ_16_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1181000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_r23VunldY0aQDz2Mjb-9jw_17_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">154643000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_drWvHLn8lEaq2JPeGa818g_17_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">160173000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_NjylFXLXmEm9Dhp38uYUWA_21_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">19130000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_7Us7hxbUfEa63mOXPBX3Nw_21_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">12998000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_9x5tZ2TzrEWPY0-inEZJBQ_22_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1736000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_R5yQoldO6Eyqt0o0Mf5VsA_22_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_c3pcsRqGPEuru5PK2q7_MQ_23_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">14000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_WiMWXhxyOEGimBwwctOrYg_23_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">18000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_69Xv3KrPaECrztt3h03fMg_24_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">20880000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_SBE4Fo_gAkaJapjaCckPWg_24_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">13044000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_t7eehxLbj0iGL0FDUwwgEA_26_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1595000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_Qq3HPDQieka9ESVX1pP1Yg_26_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">35000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_i3pEBHCgpkeYYtAKc446Aw_27_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">70000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_PZUWLAFRpUKY4j9r-ueaOA_28_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_kOSda7hiFkOofDKFS4FlwQ_28_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">42000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_t_KaaYgID06E_PI6TEIT2Q_29_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">22490000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_TqVpDJ975ECrwcYSBI-yrQ_29_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">13191000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="2"
      id="Narr_OHwwhzgOtk-3EcAskUdaWQ"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="2"
      id="Narr_Z1xn36EVoEC0R1CgTPd3iA"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="INF"
      id="Narr_LEgo6wZ9r0SFsVIDLoGlMw"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="INF"
      id="Narr_xZY35HbGkEeDu_htN9amwQ"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="INF"
      id="Narr_FdmXMEOR9UueVMwOhWxGyg"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">39589755</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="INF"
      id="Narr_wip7ONGEukqy_P1w3NGyRQ"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">38900875</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_H2F1WIW-A0CpVcy3z3VTTw_34_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">396000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_rlPRHZGd-Em18NtVDFXBtg_34_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">389000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_yvGBl3tBRke8aWK5jHTK4g_35_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">311618000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_oVEF76FY1kWEw36u2yG-IQ_35_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">297319000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_oBgjgfaMy0un2ArtyO4FJA_36_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-179861000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_ESrmnJaSX02lZG3_gfqY5g_36_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-150726000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_QfIbWWJwpEaOOAuW93gi2w_37_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">132153000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_5jWgI6X580mcD9jIJusYXg_37_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">146982000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_i8Sybx3MUk6kpKmNWi85-g_38_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">154643000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_wTPlgUPuH06NLi-QZOQoCw_38_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">160173000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_5uFeZ4e2p0-x_dOhHHI5iw_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">106712000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_RjVqx7GbBU2b34y4I2Pf6g_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">83937000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_9YcdTeiDG0Cgqb-FVCxRVA_5_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">60426000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_G-zvTTVKfUiA-hYaOx8jlg_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17349000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_zs2hvCRNpUi1_DaJysU-fg_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">12923000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_vwHAbV6rakqYe-UeAxy-rA_6_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">9311000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_ifXCWwAqP0mJgtLoJSJxOw_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">89363000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_5raCIm-PrkiaHzGUUp5yMA_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">71014000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_0bDfhXhZZEu5K-Bn05X1Kg_7_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">51115000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_8lDr95AUCE-I5f3Rk2q5cw_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">71950000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_mOY63Dm9e0WOi3QLwKRcgg_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">56617000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_WRwaOvYPbUWW4-fydV3ZmA_9_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">37636000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_NsPKuXk-DEyDtf3oKYCR9w_10_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17514000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_9M7JHFtDc0-cer588SiLRA_10_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">11773000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_HdTmSlQaCUuYQyfb4Vxq0w_10_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6699000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_KUWTu1X1pEy2uwbkEkQgZg_11_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">31305000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_TCBJgj4nqEyvjgljVrTsBw_11_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">23124000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_l15cH3v2O0e16hVMeU_NZA_11_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">14731000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_24KR8pZ8GEmBH1GEHuifeQ_12_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">120769000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_2Rd__A8bm0WSVNMzlSEMMQ_12_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">91514000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_dR1oYmFu9kaTmCzifsBrqQ_12_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">59066000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_Fqm7JHA6QU2eJ7JBlNYUqA_13_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-31406000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_yKNNeFAfQUCoz9-mcqEjSA_13_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-20500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_D5v-x9nbK0S2yx9JXs36mA_13_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-7951000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_iZBua7vlUk-wI81SPzbw9g_15_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2364000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_eR2jCufa5kSfWivWOU15jw_15_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1525000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_IEYl6oDfmEWaB9wKgiIxzg_16_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">40000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_0FI5nf3UbkWcFzSSMytCvA_16_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1127000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_qc63ZJ8HF0KmsQ3wwqu0jQ_16_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2217000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_4zo40exa5UekUFeGSStgJw_17_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">81000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_7emt1B4qRk6j2_kfogh8Pw_17_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">246000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_ZGqMFS3ywEaf7jSKs_xV_Q_18_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-2186000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_11RyFo8AlkKXtI7s6NQ3og_19_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">53000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_zIYZBslg_EWV_ghrPJDkLA_19_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_zHgD4VjqRkGehCLvFO_REA_19_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">31000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_CLjySgKXtkexI6F07HTl0w_20_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2271000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_MtzCHwqll0i1yBjYeuFW7w_20_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-1897000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_dOK9Hbvf2kys1LTYQAXPTA_20_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-2494000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_YarWz0sEwEGltC0F-9N4dw_21_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-29135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_3wi4iEdKuE-uuHXXzW0--w_21_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_HqTzVRBgRE2xWBErq-YFVQ_21_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-10445000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="0"
      id="Tc_RoZBkJMPG02ySQhYyvrvvg_22_3"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">39235</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="0"
      id="Tc_JCaVtSicqkGgoPP64k40Mg_22_6"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">37127</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="0"
      id="Tc_weOGJ45qr0W6msYVNPImzA_22_9"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">33323</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="2"
      id="Tc_Djw7cIuOWEuulABL8_By-w_23_3"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="2"
      id="Tc_XZuLDYKP2UC7keC3CtJj6A_23_6"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.60</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="2"
      id="Tc_f5V4kBeMKkmxm8xWQ585Sw_23_9"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TJlFr_r_RkuXuvZTAhvzYA"
      decimals="-3"
      id="Tc_rIUI8C5B4UyQUaxpFDgS1A_4_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">33009000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TJlFr_r_RkuXuvZTAhvzYA"
      decimals="-3"
      id="Tc_VT9Rcw8K4ES9MX4-E-mArg_4_5"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yopO1vpWDkSdAu8pQTBE6w"
      decimals="-3"
      id="Tc_Wy6gT2FRi0uNGanSebgJ-A_4_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">132475000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rABqkECIXEmoFHY4P39Btg"
      decimals="-3"
      id="Tc_8jTdj6cLh0m7OkNYZTKxLQ_4_11"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-117884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2016_Or2PNLcVTkK03OOF11rmZw"
      decimals="-3"
      id="Tc_ztl9qNqCxU2xjxV93QnAug_4_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">14921000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ix9c_2i7sEuWHRfmxUztXA"
      decimals="-3"
      id="Tc_n7Kq84l1dUS5TMsVeh5nXg_6_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_uRh3Z4Xr_U2UzIESBlewgQ_6_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ"
      decimals="-3"
      id="Tc_vlz6cp98WEG_1CN6t8J35w_7_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">536000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ"
      decimals="-3"
      id="Tc_HWyOMgB4SkOnt7yBtKURRA_7_5"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ix9c_2i7sEuWHRfmxUztXA"
      decimals="-3"
      id="Tc_SuMLSMZY9kSU2u1otpEyew_7_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1429000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_DZwpC2ylc0W3ebw-ulNSYg_7_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1434000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ"
      decimals="-3"
      id="Tc_lmJxXcNG5UqKy_ZXvV31AQ_8_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">805000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Gy2D2qCbdEC1J7_3BAbnYQ"
      decimals="-3"
      id="Tc_B7KVGkxhaUK8-tSSekQnPw_8_5"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ix9c_2i7sEuWHRfmxUztXA"
      decimals="-3"
      id="Tc_IWwFJ8UrjUmHaa7peGD80A_8_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15655000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_4AkVdSSlIkSJ24Q854Z3ow_8_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15663000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yAQQYV4FD0OLKehglkYWNQ"
      decimals="-3"
      id="Tc_jjWYk1owRkWrtry5Q3fIIQ_9_11"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-10445000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_r42jY2XB-EGaa6afOjaVMw_9_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-10445000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B8IECFly_kaRlwUWZ1F6ow"
      decimals="-3"
      id="Tc_kZQWTBvxq0ySwVkpN7_smw_11_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">34350000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B8IECFly_kaRlwUWZ1F6ow"
      decimals="-3"
      id="Tc_krLB0g7JOEWp6yNq83SEnQ_11_5"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36RWqiIIvUqIM5o6-tTfQw"
      decimals="-3"
      id="Tc_lvyc9jw6bEmUB3QKyhCEyg_11_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">153168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-KZyjfz9K0yURx8oujgc-A"
      decimals="-3"
      id="Tc_hr_55x_h_U246unZTY6CHg_11_11"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-128329000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_niMj4QeCeUGESsaE3ZBkxA_11_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">25182000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3xXv5tKLESPI6qfsNRBAg"
      decimals="-3"
      id="Tc_JQya2kSwNka3o1vkiokESA_13_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_MxlGPcay206K3mcIQduWug_13_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg"
      decimals="-3"
      id="Tc_yirINkaCfUeMx63-5B8JkA_14_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">1101000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg"
      decimals="-3"
      id="Tc_7ukawtFr9UawYLVZLIZ9pw_14_5"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3xXv5tKLESPI6qfsNRBAg"
      decimals="-3"
      id="Tc_7hH1_dYq0EqZrb2YrD0hmg_14_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3873000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_KmZioDU370ekA6a4ivZxtw_14_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3884000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg"
      decimals="-3"
      id="Tc_bwpi45b1ok6B8dbZn5-0tg_15_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">3450000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fLBhedDj6USD58jFPQheTg"
      decimals="-3"
      id="Tc_43Lakk0FoUW1IQ_d0DRv8A_15_5"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">35000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3xXv5tKLESPI6qfsNRBAg"
      decimals="-3"
      id="Tc_N-LzobPW7kqbhgCL2GZnzg_15_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">132672000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_tS-LLSUx_UCPJv47tuZk6g_15_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">132707000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MOuFDoRprUic4VVjiNOb9g"
      decimals="-3"
      id="Tc_CHu6F50uMESN_q5t8og96Q_16_11"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_AS1ZzhL5jU6xIuY7wI77-g_16_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qFCNsryetU6naqT7GbcEhw"
      decimals="-3"
      id="Tc_cIuLBqyaeUW125a6cPra2A_18_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">38901000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qFCNsryetU6naqT7GbcEhw"
      decimals="-3"
      id="Tc_2XCZ0S7xIkiNYfFe5tPR9A_18_5"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UsFg6g1V3k-jJJ9z3zX3kw"
      decimals="-3"
      id="Tc_95Inbj9ZIkmg-AGcPBfrGw_18_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">297319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5iFiNf4eCU2t-jlDjLdgiQ"
      decimals="-3"
      id="Tc_U7BsptEW-EeK32VPkyhHQw_18_11"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-150726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_ccSkS0V-4EuiniV0Uzfj7w_18_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">146982000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zPNTOe5UAku8lMq39V0WUg"
      decimals="-3"
      id="Tc_6xmPvuiPn0qfPl5OQEAfkg_20_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10304000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_PPi_Mb-D2UC6EzbuDrITDg_20_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10304000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pgmLVwXuIUS__MSTlzniug"
      decimals="-3"
      id="Tc_9qbA69Uxa0muH-J-3yJOLg_21_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">689000</axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pgmLVwXuIUS__MSTlzniug"
      decimals="-3"
      id="Tc_d1O3G6yySUCBATsGO1vGZA_21_5"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zPNTOe5UAku8lMq39V0WUg"
      decimals="-3"
      id="Tc_hkY5o_m29UapZFwKG_ml0A_21_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3995000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_P9l4Nz7lJUmcpZudplkLoQ_21_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4002000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_okKh-SdZMEibF5PgZHtNtA"
      decimals="-3"
      id="Tc_dJzKYXshRUKEshZBjdDhbw_22_11"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-29135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_4MLupdImFUyg7TFeqETVzA_22_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-29135000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x8gKvx5oDUisUyE4r4cbmQ"
      decimals="-3"
      id="Tc_4y3-anFJPkOlUY-yLkRV1Q_24_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">39590000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x8gKvx5oDUisUyE4r4cbmQ"
      decimals="-3"
      id="Tc_8zw5r5K0oEisMP6waDKIHg_24_5"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OqYgr00JsUa249PGlgCbJA"
      decimals="-3"
      id="Tc_1lVsxW0cDkaesHdgmi-YnA_24_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">311618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CS4l3RjFjkG4cuMVEIJHOA"
      decimals="-3"
      id="Tc_m2zMuoBGtkaXOBCZRTYjvA_24_11"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-179861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_T0PQf0l_YE-A2KnwddHNXQ_24_14"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">132153000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_VFPw03bdYUC7e2w3dsb42A_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-29135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_VPPkyeLaT0C8jVUR7l965Q_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_xiu7nMpoHE2dmfPWwBeAeg_5_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-10445000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_qNHDc_-8dkCoMxN4PYzXtg_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">933000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_23qXT-xvME2UyY2bjB8mEQ_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">774000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_cQwLyTFHzkaf2FegS4fPqg_7_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">488000</us-gaap:Depreciation>
    <axgn:RightOfUseAssetAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_UMpgGNJkkkCFUkZ-vm1XgQ_8_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1821000</axgn:RightOfUseAssetAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_JZlZF7BwK0GghLp8dtemfw_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">123000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_8Dn7JGhLeEmaog74Ahh5bQ_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">77000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_GJP_buW6J0WKTDNbV_9-2A_9_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">79000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_nqmBWbLW0USh6Nahr4RRFQ_10_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">104000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_POeaxBhaRUChHTtOrEPL-g_11_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">81000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_xhpuOHVjDUmGsuj5vmCFeQ_11_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">246000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_XDkYGnIE3kyqkXzEUJ0W3w_12_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-1000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_7x20Y_yH5E6hZKCz5yFzHA_13_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-2186000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_IpidGCSAsE2BEEVyG1Nmjw_14_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">514000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_gVtVL4mlREuz-AA4CwcPjw_14_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">852000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_jI-t9IBYUU21kdbudcUrSA_14_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">223000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_u4J7NJOJZEiOWRb-rK6d7w_15_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1887000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_1Nfqus3x00SRmWUxdN_dhA_15_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1343000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_sgXYfNcNsU6-tarfOFnvRg_15_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1438000</us-gaap:InventoryWriteDown>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_yGvbNYNOCUiuRcgsa_tPtQ_16_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">972000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_i8NDlRNFw0WQa6fXGrI4XA_16_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">721000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_7kpRdGwmtkWrAY-FLgeU1A_17_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10304000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_7p72__I0bk2jmLDet4GoTQ_17_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7606000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_2ZhsTdn3R02EFK5_54GNZg_17_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3609000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_nNFQvmITvkSpMpIw5ebpKQ_19_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2136000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_WVnYUUzYMkCqI7Vvzyf7Wg_19_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">5108000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_ZJyIZXaXkEWrBppK6C21bw_19_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3236000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_QPPGOjYnmk6CM0iXObUOIw_20_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3767000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_e4INEmEw_EuamPSCB_IQVQ_20_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6009000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_0x3bzeqITUeM95pa1-J8Sg_20_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3295000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_SlSne_HpzkaaB7-YRaoSAQ_21_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">661000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_a1TFaqaGj0KVRuYQU4E70g_21_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">192000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_WpYpth3S80m4KnCKh4YMVA_21_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">342000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_LSb6Xi16RU25HMj7ph5PvQ_22_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2920000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_DnInC6doQUGVv5Odgj6jTQ_22_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3711000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_KccQJj7WokK2ZOfZGxVl5A_22_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1927000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_JvUSKvMZekmsB_4XzJzv1Q_23_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1773000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_MmvMO8Kma0CaG4_YitzBDQ_24_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_cj8FpJCWpUCp3QHko5OrEQ_25_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-30000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_su_GIImviU6LdTLsHZOsNg_25_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-66000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_TgnzewHMlEyGSul9hMlxKQ_25_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">70000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_NTV66NuLv0GbTYGYST8OWw_26_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-19872000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_2iTl1SUdeEGi0Zhvase9Xw_26_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-17862000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_I6dxkaih7EODq-ysX4nvjg_26_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-9238000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_vRjUNMEfXEyNe4pPd1knkQ_29_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4664000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_L7TFzIdCJU2UaOq2RmVG2A_29_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6282000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_BagK7tNyAkqC-ir0ElFJTQ_29_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1105000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_CUV27eQ7xU-KgVUwWL8skA_30_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">121074000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_rqjIh59-KkOfCUOPUDyjeg_30_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">114736000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_qGNU5-G74UOAF8GK-H8RXA_31_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">153571000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_I-oTT1OOFkqCHklc5v0PCA_31_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">23146000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_NsgqWsOrdUKU1gu-izU14w_32_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">562000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_CbJB8hy5mESoKlr1Y6mkVA_32_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">321000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_nzuG9NETREaj9SEoeME_5Q_32_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">187000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_ScWSIqKOnkyHn_D-sFV13A_33_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">27271000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_kXrQimHr3UyKIWjmHeDRJw_33_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-98193000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_wtoJYZBR0EmlCzc3F35uug_33_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-1292000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_YVfTMwYXCk28pNo10UbeVg_36_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">132964000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_npGVblWDzUalL9Hx4adBsA_36_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15891000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_u4h_lv0fxUGaxi8K-OYQOA_37_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">257000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_NmUeHJtmNk6Vkbf2consHg_37_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">228000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_esaWjXNYz0m2E3nE1LhoGA_38_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">26253000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_NxMHJ8ku1Ee_kGtleOVRfg_38_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">57599000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_rzVhOsAlOE-RbBL-pe2R3w_39_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30489000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_UtZnHF6FtESdY3B1F6myWQ_39_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">57624000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_wDdSbw5ZYkiEEkKiKLzlqw_40_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">22513000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_Xl411Leh0UKo_g8zhLpiRw_40_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">21000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_ghyUuE7ASU2A2lBtqxnGvQ_41_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">29000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_bhg7fjmKg0yBgaiI0_TKcA_42_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4002000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_GzE5sxrfFku89QlbMTQyfQ_42_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3884000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_NTe_7vmwD0GW4W0Pe2_yxg_42_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1434000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_ASwSDfoe_k2-UJqp_JIcZw_43_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4031000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_Feuhl0VALkCegsaLqn7s3A_43_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">109842000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_ImkgTGOoikiltwpoRYk5Aw_43_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17022000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_BatDMI1BKEqqMRxnnqIofg_44_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">11430000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_FbcYUqT-_kS_EAuVb73cZw_44_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-6213000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_1OigzP8q3EyrfG4XqJhxYg_44_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6492000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_0Q6mebTXDEegr3VR_bGH3Q_45_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30294000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_2vNny78Nv06hOgoTQI8LCg_45_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">36507000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2016_Or2PNLcVTkK03OOF11rmZw"
      decimals="-3"
      id="Tc_be9HspyXRESWCpxd9-VD6g_45_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_RubPa-mok02vQj2MAG7Ztg_46_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">41724000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_KGu54C1Qb0-AyR_ILq3GMA_46_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30294000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_AtsNVyGzN0a9PdLioC5qMQ_46_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">36507000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_DxYPwnUDpkaEXPqnDR7RvQ_49_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">34000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_-8Hatbxg50K50v5Xz_3sqw_49_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1325000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_uL4k7Bx9AUW5Jh5Ic7m9Tw_49_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2198000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_vkoMEz8sGUW8ikWa96eCDg_51_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3212000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_yCP4k_AwVEul2PZ8ATIhDQ_51_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">335000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_6CNkvNWP2EaASbjUEhAgEA_51_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">55000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Tc_d54KzXJNz0ubWakCk1ypmA_52_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">62000</us-gaap:CapitalLeaseObligationsIncurred>
    <axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_Y9iDW22RXES_NQCBLJVAXA_53_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">26000</axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability>
    <us-gaap:BasisOfAccounting
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_1v7u51TSg0GoqNf80GsuOA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Basis of Presentation &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The accompanying consolidated financial statements include the accounts of Axogen,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;Axogen&#x201d;) and its wholly owned subsidiaries, Axogen Corporation (&#x201c;AC&#x201d;), Axogen Processing Corporation (&#x201c;APC&#x201d;) and Axogen Europe GmbH, as of December&#160;31, 2019 and December&#160;31, 2018 and for the three years ended December 31, 2019. The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_YHNSelNOo06izqu0VKqrYA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Organization and Business &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Axogen is a global provider of innovative surgical solutions for physical damage or transection to peripheral nerves.  Axogen is focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen&#x2019;s products are designed to restore nerve function and are used to treat patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Axogen&#x2019;s portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site, Axoguard Nerve Connector, a porcine submucosa extracellular matrix (&#x201c;ECM&#x201d;) coaptation aid for tensionless repair of severed peripheral nerves, Axoguard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, Axoguard&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissues in the surgical bed.&lt;span style="white-space:pre-wrap;"&gt;  Along with these core surgical products, Axogen also offers the Axotouch Two-Point Discriminator a measurement tool for use by healthcare professionals detect changes in sensation. The Company&#x2019;s portfolio of products is available in the United States, Canada, Germany, South Korea and other European and international countries.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Avance Nerve Graft and Avive Soft Tissue Membrane are processed in the United States by Axogen at its processing facility in Dayton, Ohio.  &lt;/span&gt;Axoguard Nerve Cap&lt;span style="white-space:pre-wrap;"&gt; is manufactured by Cook Biotech in the United States for sale by Axogen and Axoguard Nerve Connector and Axoguard Nerve Protector are manufactured in the United States by Cook Biotech and are distributed worldwide exclusively by Axogen.  The Axotouch Two Point Discriminator is contract manufactured by Viron Technologies, LLC (formerly Cybernetics Research Laboratories) (&#x201c;Viron&#x201d;) Tucson, Arizona.  Viron supplies the Axotouch unpackaged and they are packaged at Axogen&#x2019;s distribution facility in Burleson, Texas.  Axogen maintains its corporate offices in Alachua, Florida and is the parent company of its wholly owned operating subsidiaries, AC, APC and Axogen Europe GmbH.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_hY-iMNnWbk6kPCh-MFsc5A">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Summary of Significant Accounting Policies &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Cash and Cash Equivalents and Concentration&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying consolidated financial statements.  The Company has not experienced any losses related to these balances; however, as of December 31, 2019, &lt;/span&gt;$35,224&lt;span style="white-space:pre-wrap;"&gt; of the cash and cash equivalents balance was in excess of FDIC limits.   As of December 31, 2019 and 2018, the Company had restricted cash balances of &lt;/span&gt;$6,000&lt;span style="white-space:pre-wrap;"&gt; as collateral for an irrevocable standby letter of credit.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,724&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,724&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company invests primarily in U.S. Government securities, corporate bonds, commercial paper and asset-backed securities and classifies all investments as available-for-sale. Investments are recorded at fair value. The Company has elected the fair value option (FVO) for all of its available-for-sale investments.  The FVO election results in all changes in unrealized gains and losses being included in investment income in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;On January 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 606, &#x201c;Revenue from Contracts with Customers&#x201d;, utilizing the modified retrospective method applied to contracts that were not completed.  The adoption of the standard did not have a material impact on the timing and amounts of the Company&#x2019;s revenue, processes or internal controls.  Upon adoption, the Company did not have any material remaining performance obligations, significant judgements, or material costs to obtain or fulfill contracts with its customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection.  Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products and services to the Company&#x2019;s customers.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract.   These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#x2019;s cost.   The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and, therefore, the Company has determined it is appropriate to recognize revenue when:  i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement.  Determining the timing of revenue recognition for such contracts is subject to significant judgment, because an evaluation must be made regarding the distributor&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company.  Changes in these assessments could have a significant impact on the timing of revenue recognition from sales to distributors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#x2019;s contracts vary; however, as a common business practice, payment terms are typically due in full within &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;60 days&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material.  The Company has several contracts with distributors in international markets which include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In connection with the Acroval Neurosensory and Motor Testing System, the Company sold extended warranty and service packages to some of its customers who purchase this evaluation and measurement tool, and the prepayment of these extended warranties represent contract liabilities until the performance obligations are satisfied ratably over the term of the contract. The sale of the aforementioned extended warranty represents the only performance obligation the Company satisfies over time and creates the contract liability disclosed below.  The opening and closing balances of the Company&#x2019;s contract receivables and liabilities are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contract Balances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:44.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Receivables&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contract Liabilities, Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contract Liabilities, Long-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Opening, January 1, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,065&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Closing, December 31, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,321&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Increase (decrease)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,256&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Opening, January 1, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,321&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Closing, December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Increase (decrease)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,623&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company evaluates the collectability of accounts receivable to determine the appropriate allowance for doubtful accounts. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in general and administrative expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The Company&#x2019;s history of write-offs has not been significant.  The allowance for doubtful accounts balance was approximately &lt;/span&gt;$1,092 and $1,117 at December&#160;31, 2019 and 2018, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company&#x2019;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Inventories&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Inventories are comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve&#160;Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane, Acroval Neurosensory and Motor Testing System, Axotouch Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company monitors the shelf life of its products and historical expiration and spoilage trends, and writes-off inventory based on the estimated amount of inventory that will not be distributed before expiration or spoilage.  To estimate the amount of inventory that will expire prior to being sold, the Company reviews inventory quantities on hand, historical and projected sales, and historical expiration trends. The Company&#x2019;s calculation of the amount of inventory that will expire prior to sale has two components: 1) a demand or consumption based component that compares projected sales to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being sold. The Company&#x2019;s model assumes that inventory will be sold on a first-in-first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that a significant portion of the Company&#x2019;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written-down involves significant judgments and estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02&#x2014;Leases (Topic 842) (&#x201c;ASU 2016.02&#x201d;), as of January 1, 2019, (the &#x201c;Application Date&#x201d;) using the modified retrospective approach. The Company will continue to report financial information for fiscal years prior to 2019 under the previous lease accounting standards. The modified retrospective approach provides a method for recording on the balance sheet as of January 1, 2019, leases that have commenced on or before the Application Date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company elected the package of practical expedients permitted under the transition guidance, which allowed us to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Company also elected the practical expedient allowing us to not separate the lease and non-lease components for all classes of underlying assets, apart from equipment. &#160;The Company did not elect the practical expedient to use hindsight to determine the lease term for leases at January 1, 2019. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company made an accounting policy election to not recognize right-to-use assets and lease liabilities that arise from short term leases, which are defined as leases with a lease term of 12 months or less at the lease commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Adoption of the new standard resulted in the recording of right-to-use assets and lease liabilities of approximately $3,786 and $3,823, respectively, and the derecognition of capital lease assets, capital lease liabilities, and operating lease deferred rent of $96, $63, and $70, respectively, as of January 1, 2019 with zero cumulative-effect adjustment to retained earnings. The new standard did not materially impact our consolidated net earnings.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Net Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Basic and diluted net loss per share is computed in accordance with FASB ASC 260, &#x201c;Earnings Per Share&#x201d; (ASC 260), by dividing the net loss by the weighted average number of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, options and awards of 1,556,818&lt;span style="white-space:pre-wrap;"&gt;,  &lt;/span&gt;2,621,440 and 2,253,399 which were outstanding as of December 31, 2019, 2018 and 2017, respectively, were not included in the computation of diluted net loss per shares because dilutive shares are not factored into the calculation of net loss per share when a loss applicable to common shares as they would be anti-dilutive. See additional outstanding shares as disclosed in Note 11, &#x201c;Equity Compensation Plans&#x201d; that could potentially be dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Research and Development Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Research and development costs are expensed as incurred and were $17,514, $11,773 and $6,699 for the years ended December&#160;31, 2019, 2018 and 2017, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company measures all employee stock-based compensation awards using the fair value, including stock options, restricted stock, performance stock and stock purchases related to an employee stock purchase plan.  The share-based compensation recognized under ASC 718 for years ended December 31, 2019, 2018 and 2017 was &lt;/span&gt;$10,304, $7,606,and $3,609, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#x2019;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company estimates the fair value of time-based options on the date of grant using the Multi-Point Black-Scholes option-pricing model (Black-Scholes model). The Company&#x2019;s determination of fair value is affected by the Company&#x2019;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#x2019;s expected stock price volatility over the term of the awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company estimates the fair value of restricted stock based upon the grant date closing market price of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company also has an employee stock purchase plan (ESPP) which is available to all eligible employees as defined by the plan document. Under the ESPP, shares of the Company&#x2019;s common stock may be purchased at a discount.  The Company estimates the number of shares to be purchased under the ESPP at the beginning of each purchase period based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model and records estimated compensation expense during the period. Expense is adjusted at the time of stock purchase.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;With respect to performance stock units (&#x201c;PSUs&#x201d;), the number of shares that vest and are issued to the recipient is based upon the Company&#x2019;s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company&#x2019;s closing stock price on the grant date and its estimate of achieving such performance targets. For further discussion and disclosures, see Note 11 &#x2013; Equity Compensation Plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Management believes the critical accounting policies regarding revenue recognition, allowance for uncollectible accounts receivable, investments, inventories and share-based employee compensation affect our more significant judgments and estimates used in the &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;preparation of the Company&#x2019;s consolidated financial statements.  Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:13.5pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In February 2016, the FASB issued ASU 2016-02. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-11, Targeted Improvements to ASC 842, Leases (&#x201c;ASU 2018-11&#x201d;).  ASU 2018-11 provided entities with an alternative modified transition method to elect not to recast the comparative periods presented when adopting ASC 842.  The impact of the adoption is disclosed in the Leases section of Note 3, Summary of Significant Accounting Policies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In August 2018, the FASB issued ASU No. 2018-15, Guidance on Cloud Computing Arrangements (&#x201c;ASU 2018-15&#x201d;).  ASU 2018-15 provides guidance on implementation costs incurred in a cloud computing arrangement (CCA) that is a service contract and aligns the accounting for such costs with the guidance on capitalizing costs associated with developing or obtaining internal-use software.  Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized.  This update is effective for annual and interim reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently evaluating the impact this standard will have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2013; Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;).  The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  We are currently evaluating the impact the standard may have on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In May 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses, Topic 815, Derivatives and Hedging and Topic 825, Financial Instruments (&#x201c;ASU 2019-04&#x201d;).  ASU 2019-04 clarifies certain aspects of accounting for credit losses, hedging activities, and financial instruments.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In May 2019, the FASB issued ASU No. 2019-05, Targeted Transition Relief (&#x201c;ASU 2019-05&#x201d;).  ASU 2019-05 provides transition relief for entities adopting ASU 2016-13, Measurement of Credit Losses on Financial Instruments.  The amendment allows entities to irrevocably elect, upon adoption of ASU  2016-13, the fair value option on financial instruments that (1) were previously recorded at amortized costs and (2) are within the scope of ASC 326-20, Financial Instruments &#x2013; Credit Losses: Measured at Amortized Costs, if the instruments are eligible for the fair value option under ASC 825-10, Financial Instruments: Overall.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In November 2019, the FASB issued ASU No. 2019-11, Credit Losses (Topic 326), Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses.  This amendment amends certain aspects of the new credit loss standard, ASU 2016-13 (ASC 326).  As the Company has not adopted ASU 2016-13, the effective date of this amendment is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) (&#x201c;ASU 2019-12&#x201d;), Simplifying the Accounting for Income Taxes.  This amendment simplifies the &lt;/span&gt;accounting for&#160;income&#160;taxes&#160;by removing certain exceptions to the general principles and improve consistent application or and simplify accordance with accounting principles generally accepted in the United States for other areas of&#160;Topic&#160;740&#160;&lt;span style="white-space:pre-wrap;"&gt;by clarifying and amending existing guidance.  This update is effective for annual and interim reporting periods beginning after&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#333333;"&gt; December 15, 2020. Early adoption is permitted but requires simultaneous adoption of all provisions of ASU 2019-12. &lt;/span&gt;The Company does not expect this standard will have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company&#x2019;s consolidated financial condition, results of operations, or disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_00v7js9cYk20f5gT3vUdSA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Cash and Cash Equivalents and Concentration&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying consolidated financial statements.  The Company has not experienced any losses related to these balances; however, as of December 31, 2019, &lt;/span&gt;$35,224&lt;span style="white-space:pre-wrap;"&gt; of the cash and cash equivalents balance was in excess of FDIC limits.   As of December 31, 2019 and 2018, the Company had restricted cash balances of &lt;/span&gt;$6,000&lt;span style="white-space:pre-wrap;"&gt; as collateral for an irrevocable standby letter of credit.  &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Narr__icn5YWTK0ibfOQM11JqkQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">35224000</us-gaap:CashUninsuredAmount>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Narr_8fosJphQQUOJr4kyDZtWQA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6000000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_v2wuM0mXK0ugPpxZQ1m_4A">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,724&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,724&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_9eHQ6CneW0K3mMn8uGgRaw_3_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">35724000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_9NUPj35v8k239uZv3-R3Gg_3_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">24294000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_BcQBzEjJcUqrlBeColgVAw_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_X_li6WjOVU6wo67tHBUfQw_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6000000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_j4omIA5MJEKo-QZUdC1ksA_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">41724000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_bhoH6l3ifkSKzVkkaM_2pw_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30294000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_fGGfXei8Ek62mo2Sy9rC-w">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company invests primarily in U.S. Government securities, corporate bonds, commercial paper and asset-backed securities and classifies all investments as available-for-sale. Investments are recorded at fair value. The Company has elected the fair value option (FVO) for all of its available-for-sale investments.  The FVO election results in all changes in unrealized gains and losses being included in investment income in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_VzalU1m2K0mzyfGvLixbZg">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;On January 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 606, &#x201c;Revenue from Contracts with Customers&#x201d;, utilizing the modified retrospective method applied to contracts that were not completed.  The adoption of the standard did not have a material impact on the timing and amounts of the Company&#x2019;s revenue, processes or internal controls.  Upon adoption, the Company did not have any material remaining performance obligations, significant judgements, or material costs to obtain or fulfill contracts with its customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection.  Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products and services to the Company&#x2019;s customers.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract.   These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#x2019;s cost.   The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and, therefore, the Company has determined it is appropriate to recognize revenue when:  i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement.  Determining the timing of revenue recognition for such contracts is subject to significant judgment, because an evaluation must be made regarding the distributor&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company.  Changes in these assessments could have a significant impact on the timing of revenue recognition from sales to distributors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#x2019;s contracts vary; however, as a common business practice, payment terms are typically due in full within &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;60 days&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material.  The Company has several contracts with distributors in international markets which include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In connection with the Acroval Neurosensory and Motor Testing System, the Company sold extended warranty and service packages to some of its customers who purchase this evaluation and measurement tool, and the prepayment of these extended warranties represent contract liabilities until the performance obligations are satisfied ratably over the term of the contract. The sale of the aforementioned extended warranty represents the only performance obligation the Company satisfies over time and creates the contract liability disclosed below.  The opening and closing balances of the Company&#x2019;s contract receivables and liabilities are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contract Balances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:44.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Receivables&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contract Liabilities, Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contract Liabilities, Long-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Opening, January 1, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,065&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Closing, December 31, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,321&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Increase (decrease)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,256&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Opening, January 1, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,321&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Closing, December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Increase (decrease)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,623&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <axgn:AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_jWuqQcWDKE6x_Rz8ykfOzA"
      id="Narr_WFtelxmamEe-pZn2Zpvi-w">P30D</axgn:AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable>
    <axgn:AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_zbj4-_iSt0mMZxIh6JETbg"
      id="Narr_KHzHpjgu20-egmgbNJlczg">P60D</axgn:AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_RDYfXMSQEkWHejVyRI9I7Q">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contract Balances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:44.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Receivables&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contract Liabilities, Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contract Liabilities, Long-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Opening, January 1, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,065&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Closing, December 31, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,321&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Increase (decrease)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,256&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Opening, January 1, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,321&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Closing, December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Increase (decrease)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,623&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_xnDYQoVsMEySOEi3BWl1vA_3_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">11065000</us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_MJzUc6byLEmG5fmNG_TFeQ_3_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">32000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_LJwzZQUiG0CSsZl3Fts6fw_3_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">69000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_m4qct9GOukaBrlC2mhyWqg_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15321000</us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_I5vxFbGJKkGgN27nirsgfg_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">18000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_kcytb0psrk-NcyY1eScO5Q_4_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">42000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <axgn:IncreaseDecreaseInContractReceivable
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_NKxveS7ozkaC5Pc98nuGdg_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4256000</axgn:IncreaseDecreaseInContractReceivable>
    <axgn:IncreaseDecreaseInContractWithCustomerLiabilityCurrent
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_2SJtIGEg9k6_pFbr1BLnkg_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-14000</axgn:IncreaseDecreaseInContractWithCustomerLiabilityCurrent>
    <axgn:IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_XK_3jprjkUKaAJW69FwyTw_5_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-27000</axgn:IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_TWj36lLZjEqOW49nbFBL7Q_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15321000</us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_X2FYaBnltEW-nCCPanNsVg_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">18000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_-awDT7axskaWpDVhborX0A_7_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">42000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_5dJ07_OGeEm4ve7Zby5rDg_8_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">16944000</us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_43kTwNW0LkGXdWicMA02kg_8_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">14000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_J4940l26FkeZ4HekW19J-g_8_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <axgn:IncreaseDecreaseInContractReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_kIVzn7aghUmm5xo5O5smFw_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1623000</axgn:IncreaseDecreaseInContractReceivable>
    <axgn:IncreaseDecreaseInContractWithCustomerLiabilityCurrent
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_dHhOSQ-K0UqaghE2-4RwGQ_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-4000</axgn:IncreaseDecreaseInContractWithCustomerLiabilityCurrent>
    <axgn:IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_v6NKOYAZ3UetlBXEj105xA_9_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-27000</axgn:IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_wwueKyll0UiHqwCyEj4bLg">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company evaluates the collectability of accounts receivable to determine the appropriate allowance for doubtful accounts. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in general and administrative expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The Company&#x2019;s history of write-offs has not been significant.  The allowance for doubtful accounts balance was approximately &lt;/span&gt;$1,092 and $1,117 at December&#160;31, 2019 and 2018, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company&#x2019;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures.&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Narr_yf-spbULykSthXtyRpiXIQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1092000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Narr_t_6iNfTDx02eo-VlgIP85Q"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1117000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_f6FjdIxpEEaY4EXfOJWSQA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Inventories&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Inventories are comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve&#160;Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane, Acroval Neurosensory and Motor Testing System, Axotouch Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company monitors the shelf life of its products and historical expiration and spoilage trends, and writes-off inventory based on the estimated amount of inventory that will not be distributed before expiration or spoilage.  To estimate the amount of inventory that will expire prior to being sold, the Company reviews inventory quantities on hand, historical and projected sales, and historical expiration trends. The Company&#x2019;s calculation of the amount of inventory that will expire prior to sale has two components: 1) a demand or consumption based component that compares projected sales to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being sold. The Company&#x2019;s model assumes that inventory will be sold on a first-in-first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that a significant portion of the Company&#x2019;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written-down involves significant judgments and estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_ixyEznbs_0yKPG6KvBLlCg">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02&#x2014;Leases (Topic 842) (&#x201c;ASU 2016.02&#x201d;), as of January 1, 2019, (the &#x201c;Application Date&#x201d;) using the modified retrospective approach. The Company will continue to report financial information for fiscal years prior to 2019 under the previous lease accounting standards. The modified retrospective approach provides a method for recording on the balance sheet as of January 1, 2019, leases that have commenced on or before the Application Date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company elected the package of practical expedients permitted under the transition guidance, which allowed us to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Company also elected the practical expedient allowing us to not separate the lease and non-lease components for all classes of underlying assets, apart from equipment. &#160;The Company did not elect the practical expedient to use hindsight to determine the lease term for leases at January 1, 2019. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company made an accounting policy election to not recognize right-to-use assets and lease liabilities that arise from short term leases, which are defined as leases with a lease term of 12 months or less at the lease commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Adoption of the new standard resulted in the recording of right-to-use assets and lease liabilities of approximately $3,786 and $3,823, respectively, and the derecognition of capital lease assets, capital lease liabilities, and operating lease deferred rent of $96, $63, and $70, respectively, as of January 1, 2019 with zero cumulative-effect adjustment to retained earnings. The new standard did not materially impact our consolidated net earnings.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <axgn:FinanceAndOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Narr_bNGcuZ0OYEe5r06J18YHRQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3786000</axgn:FinanceAndOperatingLeaseRightOfUseAsset>
    <axgn:FinanceAndOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Narr_BJReYRWUCEuQ5fuC2gvkpg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3823000</axgn:FinanceAndOperatingLeaseLiabilities>
    <axgn:DerecognitionOfCapitalLeaseAssets
      contextRef="Duration_1_1_2019_To_1_1_2019_0uPXfB4sV0SD97KHNevlsw"
      decimals="-3"
      id="Narr_-nwvswrMLEenlNVxNKmQJA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">96000</axgn:DerecognitionOfCapitalLeaseAssets>
    <axgn:DerecognitionOfCapitalLeaseLiabilities
      contextRef="Duration_1_1_2019_To_1_1_2019_0uPXfB4sV0SD97KHNevlsw"
      decimals="-3"
      id="Narr_H6Fe_Na2BkOUnmJaZRjSFA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">63000</axgn:DerecognitionOfCapitalLeaseLiabilities>
    <axgn:DerecognitionOfDeferredRent
      contextRef="Duration_1_1_2019_To_1_1_2019_0uPXfB4sV0SD97KHNevlsw"
      decimals="-3"
      id="Narr_pOAiHCQGaU2M8iVrKEcaAQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">70000</axgn:DerecognitionOfDeferredRent>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_nBf81xwpyEGafL1wDKDmlQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Net Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Basic and diluted net loss per share is computed in accordance with FASB ASC 260, &#x201c;Earnings Per Share&#x201d; (ASC 260), by dividing the net loss by the weighted average number of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, options and awards of 1,556,818&lt;span style="white-space:pre-wrap;"&gt;,  &lt;/span&gt;2,621,440 and 2,253,399 which were outstanding as of December 31, 2019, 2018 and 2017, respectively, were not included in the computation of diluted net loss per shares because dilutive shares are not factored into the calculation of net loss per share when a loss applicable to common shares as they would be anti-dilutive. See additional outstanding shares as disclosed in Note 11, &#x201c;Equity Compensation Plans&#x201d; that could potentially be dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="INF"
      id="Narr_32ME4rRE8UC25CPpkaDvZg"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">1556818</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="INF"
      id="Narr_-_jXuud6QkOIV1sppvbZZQ"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">2621440</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="INF"
      id="Narr_2w1Jwq7gJ0CrqFRnY24ttA"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">2253399</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_bNpjyNKkxEqjEANo_xstfA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Research and Development Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Research and development costs are expensed as incurred and were $17,514, $11,773 and $6,699 for the years ended December&#160;31, 2019, 2018 and 2017, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_02Tq9wY32UeTybgNilxHxA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17514000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_kpuuhDsghUi6_FqKZUCdfg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">11773000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_DIkeopdZX0meldAYlfgtxA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6699000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_PVlrW7NABkuSCZQw2HX8-g"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6699000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_0K4rPQmX8Eau8d3czyzpsQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company measures all employee stock-based compensation awards using the fair value, including stock options, restricted stock, performance stock and stock purchases related to an employee stock purchase plan.  The share-based compensation recognized under ASC 718 for years ended December 31, 2019, 2018 and 2017 was &lt;/span&gt;$10,304, $7,606,and $3,609, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#x2019;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company estimates the fair value of time-based options on the date of grant using the Multi-Point Black-Scholes option-pricing model (Black-Scholes model). The Company&#x2019;s determination of fair value is affected by the Company&#x2019;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#x2019;s expected stock price volatility over the term of the awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company estimates the fair value of restricted stock based upon the grant date closing market price of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company also has an employee stock purchase plan (ESPP) which is available to all eligible employees as defined by the plan document. Under the ESPP, shares of the Company&#x2019;s common stock may be purchased at a discount.  The Company estimates the number of shares to be purchased under the ESPP at the beginning of each purchase period based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model and records estimated compensation expense during the period. Expense is adjusted at the time of stock purchase.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;With respect to performance stock units (&#x201c;PSUs&#x201d;), the number of shares that vest and are issued to the recipient is based upon the Company&#x2019;s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company&#x2019;s closing stock price on the grant date and its estimate of achieving such performance targets. For further discussion and disclosures, see Note 11 &#x2013; Equity Compensation Plans.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_W-u6B01LtUOCQStj1zU8Nw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10304000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_scnEyarDe0KFT23Ws9pEVw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7606000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr__nzfifaVwUGkn0pmC8q6Fw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3609000</us-gaap:ShareBasedCompensation>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_6BFuq8P08k-yRmw2cXNvYw">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Management believes the critical accounting policies regarding revenue recognition, allowance for uncollectible accounts receivable, investments, inventories and share-based employee compensation affect our more significant judgments and estimates used in the &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;preparation of the Company&#x2019;s consolidated financial statements.  Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_s6y00AWIqkK_o2YPQam09Q">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In February 2016, the FASB issued ASU 2016-02. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-11, Targeted Improvements to ASC 842, Leases (&#x201c;ASU 2018-11&#x201d;).  ASU 2018-11 provided entities with an alternative modified transition method to elect not to recast the comparative periods presented when adopting ASC 842.  The impact of the adoption is disclosed in the Leases section of Note 3, Summary of Significant Accounting Policies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In August 2018, the FASB issued ASU No. 2018-15, Guidance on Cloud Computing Arrangements (&#x201c;ASU 2018-15&#x201d;).  ASU 2018-15 provides guidance on implementation costs incurred in a cloud computing arrangement (CCA) that is a service contract and aligns the accounting for such costs with the guidance on capitalizing costs associated with developing or obtaining internal-use software.  Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized.  This update is effective for annual and interim reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently evaluating the impact this standard will have on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2013; Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;).  The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  We are currently evaluating the impact the standard may have on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In May 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses, Topic 815, Derivatives and Hedging and Topic 825, Financial Instruments (&#x201c;ASU 2019-04&#x201d;).  ASU 2019-04 clarifies certain aspects of accounting for credit losses, hedging activities, and financial instruments.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In May 2019, the FASB issued ASU No. 2019-05, Targeted Transition Relief (&#x201c;ASU 2019-05&#x201d;).  ASU 2019-05 provides transition relief for entities adopting ASU 2016-13, Measurement of Credit Losses on Financial Instruments.  The amendment allows entities to irrevocably elect, upon adoption of ASU  2016-13, the fair value option on financial instruments that (1) were previously recorded at amortized costs and (2) are within the scope of ASC 326-20, Financial Instruments &#x2013; Credit Losses: Measured at Amortized Costs, if the instruments are eligible for the fair value option under ASC 825-10, Financial Instruments: Overall.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In November 2019, the FASB issued ASU No. 2019-11, Credit Losses (Topic 326), Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses.  This amendment amends certain aspects of the new credit loss standard, ASU 2016-13 (ASC 326).  As the Company has not adopted ASU 2016-13, the effective date of this amendment is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) (&#x201c;ASU 2019-12&#x201d;), Simplifying the Accounting for Income Taxes.  This amendment simplifies the &lt;/span&gt;accounting for&#160;income&#160;taxes&#160;by removing certain exceptions to the general principles and improve consistent application or and simplify accordance with accounting principles generally accepted in the United States for other areas of&#160;Topic&#160;740&#160;&lt;span style="white-space:pre-wrap;"&gt;by clarifying and amending existing guidance.  This update is effective for annual and interim reporting periods beginning after&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#333333;"&gt; December 15, 2020. Early adoption is permitted but requires simultaneous adoption of all provisions of ASU 2019-12. &lt;/span&gt;The Company does not expect this standard will have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company&#x2019;s consolidated financial condition, results of operations, or disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_wlt_XxvwLEafjM0dOJmKWw">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:21.6pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;4. &lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Inventories&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Inventories are comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve&#160;Protector, Avive Soft Tissue Membrane, Axoguard Nerve Cap, Acroval Neurosensory and Motor Testing System, Axotouch Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value and consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,403&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,194&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,728&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,334&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventories&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;For the years ended December&#160;31, 2019, 2018 and 2017, the Company had recorded a provision for inventory write-downs of $1,887, $1,343 and $1,438, respectively, primarily relating to product expiration.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_XtI4zGGBMUW7TN9bypI0fg">&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,403&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,194&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,728&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,334&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventories&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,982&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_xRnBQpznUEug30mwUjyKpA_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10403000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_zksoGwzOe0W6JQ0uIVNcZw_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">9194000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_n_Tk_sO7uU2H3ZXIfdF6VA_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">730000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_BGrtFjb3uEaJwH_CqXaCGQ_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">454000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_8g5cPV7IpEe8DtpCwCBStA_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2728000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_9wvCQgyJTEybwqm5idq6jg_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2334000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_YBOJ06gJSEa3vMS5SVdmfQ_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">13861000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc__0TJSzBtr0CfOav5fc0V4Q_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">11982000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_-P3IXPAZLUyRWuyGLTOPfQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1887000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_eX9wK4EQDEiYqUb2vmaOMw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1343000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_5MOl3nmSHEKuK0BfNkiCDQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1438000</us-gaap:InventoryWriteDown>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_Hib_b4c3fUmQJtc0Lt6dLA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:21.6pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;5.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Fair Value of Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company has elected the FVO for all investments in debt securities.  Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company classifies cash and investments in U.S. government securities as Level 1 within the fair value hierarchy.  Accounts receivable, short-term other assets, accounts payable and accrued liabilities are also classified as Level 1.  The carrying amounts of these assets and liabilities approximate their fair values due to their relatively short-term nature. Investments in corporate bonds and commercial paper are classified as Level 2 within the fair value hierarchy. The fair value of long-term debt is estimated by calculating the net present value of future debt payments at current market interest rates and is classified as Level 2. &#x2003;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table represents the Company&#x2019;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December 31, 2019:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,812&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,544&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,544&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,679&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,356&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 56,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 87,597&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,923&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27,869&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 28,870&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 76,389&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 105,259&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;There were no changes in the levels or methodology of the measurement of financial assets or liabilities during the year ended December 31, 2019 and December 31, 2018.  The maturity date of all of the Company&#x2019;s investments is less than one year.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_AvQbec-YOUmWKlmegsgWNA">&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,812&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,544&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,544&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,679&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,356&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 56,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 87,597&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,923&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 31,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27,869&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 28,870&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 76,389&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 105,259&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Y5SbtUl8VkmtgzZCsagCyg"
      decimals="-3"
      id="Tc_qX7Kc8o-vEKARu0Mw6fdJg_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">26812000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_QEj-hDcpYE6iU9rJ3XeK7w"
      decimals="-3"
      id="Tc_jfXcsGvCXEitHlQAxBaheg_4_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">26812000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_j8zL172gGUqB0hFUPl1x4w"
      decimals="-3"
      id="Tc_Jdqq0tKyoUuIab2WykA7lA_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4544000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_5jPMRknfREqoJu62tcfW5Q"
      decimals="-3"
      id="Tc_H9GkLkhN3k202yIw3nlFpw_5_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4544000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_cdH2QUZpnki1Cwgvsjs8vw"
      decimals="-3"
      id="Tc_nu7gHFbDdk6TJM_RoSvdfg_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17754000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_fkX6ZqT47Uy7zsyx_wxs1Q"
      decimals="-3"
      id="Tc_T04Puau3PECxdR2BSDLv7A_6_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17754000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_75NcZ12IJk-eikFk1KM3Og"
      decimals="-3"
      id="Tc_ALnhK0cFvEa2s9PAU_xtAQ_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">24679000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_A0SgF-lS8EWuSRhFGPu_kw"
      decimals="-3"
      id="Tc_Yt6dWdzVRkKUYu17Yu-oAg_7_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">24679000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_ANmFTxutV0-xFOoQ8_7FPA"
      decimals="-3"
      id="Tc_dsvhqcttoEK2WXpDoEKAsA_8_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">13808000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_x6KsE8qyC0SgbIbxY0R8XQ"
      decimals="-3"
      id="Tc_1uSQpDRsmE--2MRsEkPAZQ_8_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">13808000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nysdIkyyg0WkBDmiLHyfzA"
      decimals="-3"
      id="Tc_FiIW3SYj-06NvzhlgLEwpg_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">31356000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_728oYVG9_kqeLbE5u8GVGg"
      decimals="-3"
      id="Tc_6cN2Miohc0-j8qyGIcxLWw_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">56241000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ftL9sDUwHkWRUwmRLPxn4w"
      decimals="-3"
      id="Tc_qdIz-w4MakGBAVCzpOwC4Q_9_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">87597000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_0r35qKuFtEOBMm3qfUnZew"
      decimals="-3"
      id="Tc_wCVpezpd_0Gm3JM522f9cA_14_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">12947000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_iTCpB9orK0Sjz-9gGwsP8Q"
      decimals="-3"
      id="Tc_yA0esCMPHUuteLI6uDbCBA_14_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">12947000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_Z-mVrl7y0E-H9TTKDpOGrg"
      decimals="-3"
      id="Tc_4qjzBbkAHE6ASbG9oD2OpQ_15_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15923000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_yZ1Iu5dLmECLNXvQICHt7w"
      decimals="-3"
      id="Tc_pacgkdgkdkqoTZxW5bKqJw_15_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15923000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_N02mc_9XDEmaoa7UwF0qCw"
      decimals="-3"
      id="Tc_L8r_1iB4ekiEX6kZApVe4g_16_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">31495000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_BondsMember_puZ9vioqskyMdjdeNUCdsw"
      decimals="-3"
      id="Tc_hNP7XVpGRUWc_9bPX__WUQ_16_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">31495000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Ljo8XdXd1UOQhteaj6n1Lw"
      decimals="-3"
      id="Tc_nc75SjuD-0qxct5K6KQgGg_17_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">27869000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Psoi6DhJ7E2efXXbLdjXyA"
      decimals="-3"
      id="Tc_oO5k74mTjUObX8s0-YCPsw_17_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">27869000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_285oEZVmiEuWMlWvMBhBKQ"
      decimals="-3"
      id="Tc_-Y8yHHWiRUSkEPgxYFC0Jw_18_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17025000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_HEXGxa8jpUKp0M7bjLh6dw"
      decimals="-3"
      id="Tc_uSKKW8fnKkevOwHbrYAE2w_18_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17025000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_t1faoeA6yEG9189EF_P-Mw"
      decimals="-3"
      id="Tc_kvu223o-1k6porUItV3P4A_19_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28870000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VRqBUSVw9EGAy-ARzd86JA"
      decimals="-3"
      id="Tc_fxC242c-Cku3VqH2dFPmXA_19_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">76389000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KEeGgwBLD065_sx2yO_BVw"
      decimals="-3"
      id="Tc_TcxuplfSIka2ny5Xqa5WLg_19_12"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">105259000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_WkHYpXt68kWcRuuFavco5Q">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:21.6pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;6.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Property and Equipment &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Property and equipment consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,059&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,763&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Processing equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,772&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,349&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Projects in process&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,886&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,906&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment, at cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,764)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,861)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 14,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,039&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Depreciation expense for the years ended December 31, 2019, 2018 and 2017 was $933, $774 and $488, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_yXwkpiCo2Eig7yzafBmVOQ">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,059&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,763&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Processing equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,772&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,349&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Projects in process&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,886&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,906&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment, at cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,764)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,861)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 14,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,039&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_axgn_FurnitureAndOfficeEquipmentMember_eHb9YcMz8EqbrCnNH59ieA"
      decimals="-3"
      id="Tc_L2UmNW_KiEuw_FEQJoMcCg_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2059000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_axgn_FurnitureAndOfficeEquipmentMember_DX67Y23vfUOHXqqejMx78g"
      decimals="-3"
      id="Tc_ceFy4nOSHU2f3K4093lyeA_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1763000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_gm7Ekd16kESYJkPMrHphbA"
      decimals="-3"
      id="Tc_DENUJGIzvkWE_lv0pp1vDA_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2203000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_mTPBmF_K80agEXOisxdU-g"
      decimals="-3"
      id="Tc_zU3qVxjbeES1Ctukg8mOtA_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1151000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_05CtstIR4U6B9g5bHnLHdA"
      decimals="-3"
      id="Tc_4d8Q6SjpfEmC2Eg6Ys6wHA_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2772000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CLATC9jILkmHQd664S3WNQ"
      decimals="-3"
      id="Tc_YWvN_o31Y0KLuaEBHpsihA_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2349000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_BvPsE8K_qU2AmBwEqGDfYA"
      decimals="-3"
      id="Tc_hatFt3FsqU6J72MSlACbzw_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">731000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_IKe6rTfzZ0ud8WUCTvHEOw"
      decimals="-3"
      id="Tc_bHU1RxD5EUmox3T1G1LU9g_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">731000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_P3IHq2_ZwUq82grKCaDpZg"
      decimals="-3"
      id="Tc_JwBVJ1NckEmsR5lSFlhjNQ_8_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10886000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_3Y3Zposxo06m_ckziI2URQ"
      decimals="-3"
      id="Tc_0ZTAaNCDmU2zqS3MoYFR3Q_8_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4906000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_iQl1YOv__kWXMhQ4H4f8JQ_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">18651000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_0GpNtP_Cq06yJ0qAiD4e_g_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_FP_HHq_-cUGYoeK_Yy3Nzw_10_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3764000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_nxzk8b2apUGBmHB-rsH3Xw_10_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2861000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_FxTLzshwO0aIQsvnpaxhsw_11_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">14887000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_XkKBQJCOuE6AyCmIOpzpZA_11_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">8039000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_qotLgJBJrkifP44wbEl6jA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">933000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_utJCmHyf0kqCBMQZCJzs0Q"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">774000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_nZnsnYO8e0mXXU2iHikObQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">488000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_67WHsYfW10mc0koC4LgBIg">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:21.6pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;7.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Intangible Assets &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s intangible assets consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;License agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,067&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,034&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (647)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (553)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;License agreements, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 481&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Trademarks&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 334&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 255&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 845&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 500&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (55)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Patents, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 761&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 445&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intangible assets, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,515&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;License agreements are being amortized over periods ranging from &lt;/span&gt;&lt;span style="-sec-ix-hidden:_de056e84_5c37_441e_8d70_f8b60d255c1c"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;seventeen&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;twenty years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. Patents are being amortized over periods up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;twenty years&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;.  Amortization expense for 2019, 2018 and 2017 was approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$123&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$77&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$79&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, respectively. In January 2019, the Company rebranded its logo and product name designs, as a result the Company recorded a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$104&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; charge related to the previous logo and product design names. This charge is recorded in the &#x201c;General and Administrative&#x201d; in the Statement of Operations. As of December&#160;31, 2019, future amortization of patents and license agreements are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:77.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;TOTAL&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;License Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company has entered into multiple license agreements with the University of Florida Research Foundation and the University of Texas at Austin (together, the &#x201c;License Agreements&#x201d;). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;60 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Axogen pays royalty fees ranging from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;1%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;3%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; under the License Agreements based on net sales of licensed products.&#160;One of the agreements also contains a minimum royalty of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees.&#160;Also, when Axogen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;3.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;If Axogen sublicenses technologies covered by the License Agreements to third parties, Axogen would pay a percentage of sublicense fees received from the third party to the licensor.&#160;Currently, Axogen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;licensee under the License Agreements and does not owe any sub-licensee fees for its own use of the technologies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Axogen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Currently, under the University of Texas at Austin&#x2019;s agreement, Axogen would owe a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.&#160;A milestone fee to the University of Florida Research Foundation of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; is due if Axogen receives FDA approval of its Avance Nerve Graft, a milestone fee of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; is due upon the first commercial use of certain licensed technology to provide services to manufacture products for third parties and a milestone fee of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; is due upon the first use to manufacture products that utilize certain technology that is not currently incorporated into Axogen products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 57.6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Royalty fees were $2,119, $1,661 and $1,195 for the years ended December 31, 2019, 2018 and 2017, respectively, and are included in sales and marketing expense on the accompanying consolidated statements of operations.&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_3hEmrE97_USNBpNvdhbPiQ">&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;License agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,067&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,034&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (647)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (553)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;License agreements, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 481&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Trademarks&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 334&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 255&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 845&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 500&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (55)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Patents, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 761&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 445&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intangible assets, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,515&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_tm6tkYZA0UC_UdKqm7L5gQ"
      decimals="-3"
      id="Tc_4X5HNR-xJkizS2in3A9bkA_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1067000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_XpCasb7z-kOfYQrkb2g_dg"
      decimals="-3"
      id="Tc_4HG4FiwhdkCtcUhb9ZfuPg_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1034000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_tm6tkYZA0UC_UdKqm7L5gQ"
      decimals="-3"
      id="Tc_Slx5NIVQa0-sujDoCRDBoA_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">647000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_XpCasb7z-kOfYQrkb2g_dg"
      decimals="-3"
      id="Tc_uShwaRv5iEC95xRUkXFGKA_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">553000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_tm6tkYZA0UC_UdKqm7L5gQ"
      decimals="-3"
      id="Tc_BAI05aJ67kCl4uXk1lRtjQ_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">420000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_XpCasb7z-kOfYQrkb2g_dg"
      decimals="-3"
      id="Tc_ItEN6yiJ5Eer7uuaMpQLVw_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">481000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksMember_BbMESX-_v0KHSgS-XLTLvA"
      decimals="-3"
      id="Tc_zGIasJBZ6kKq96hi0ZkiCw_8_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">334000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksMember_Qd3k0h7qbE2DTTVHMaRmbQ"
      decimals="-3"
      id="Tc_WZLlLN_tHEuD4dE8Q3geTw_8_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">255000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_KC2GzeBS4kutQdKGNYDCsg"
      decimals="-3"
      id="Tc_WHdoaVntA02tf4vWwx6yUA_10_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">845000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_PgGkObwHFk-tbBS04WJSyQ"
      decimals="-3"
      id="Tc_PlKfcfc2YkCgCmTPoYBTLg_10_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_KC2GzeBS4kutQdKGNYDCsg"
      decimals="-3"
      id="Tc_DHd5Fw7L7kmmer6VaqavXQ_11_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">84000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_PgGkObwHFk-tbBS04WJSyQ"
      decimals="-3"
      id="Tc_g2QHSBeR10qHqi2c69qgFA_11_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">55000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_KC2GzeBS4kutQdKGNYDCsg"
      decimals="-3"
      id="Tc_4UQq386GQECKKYW9JWV7Og_12_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">761000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2018_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_PgGkObwHFk-tbBS04WJSyQ"
      decimals="-3"
      id="Tc_byrGP_83-kCfq7uW81X8Rg_12_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">445000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_4dMMVqeKEUWEZkV1av2WlA_13_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1515000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_wFdp-UjEcU69RnHbEiP-gg_13_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1181000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_OFAgoTompkmEhOalHj3_sA"
      id="Narr_3B0Fl7P8ckO4FHcKQK889A">P20Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_FBZq-druJEiz_96TJNFlGQ"
      id="Narr_4k9ZacAAGE-Q06EDUw1MsQ">P20Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_LipcdIRxdUuUxM_u6Mh7IA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">123000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_QKuPYMMuFUqlmFCtz1GYrQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">77000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_JeUMAS-L4E-ha0YNKr6loQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">79000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2019_To_1_31_2019_UDTsEyjMukWLzOkrt7d4_A"
      decimals="-3"
      id="Narr_GcX7mABs20asghx-GmKIHA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">104000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_ai1ti-GmSE6t7IxofKVyig">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:77.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:77.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;TOTAL&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ"
      decimals="-3"
      id="Tc_gejYu5JofkSiC2c8uzjgAA_2_1"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">137000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ"
      decimals="-3"
      id="Tc_1q1DYbIt0Eq9x7422dbOpA_3_1"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">137000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ"
      decimals="-3"
      id="Tc_fWIBvUKUFki6A39_SOtUMQ_4_1"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">138000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ"
      decimals="-3"
      id="Tc_K9Vp-nEgbUmK5Kzd8eG90g_5_1"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">119000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ"
      decimals="-3"
      id="Tc_y2b-4nNADkG5X6tkD2qkdw_6_1"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">47000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ"
      decimals="-3"
      id="Tc_L5QKPJH5Z02RCGnXEf-kRA_7_1"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">603000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_axgn_PatentsAndLicenseAgreementsMember_FsmXsRt8uEG7vsvLNzONWQ"
      decimals="-3"
      id="Tc_C1ozrCz6_kiUzqc1ZQ6-Qw_8_1"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1181000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <axgn:NoticePeriodForTerminationOfLicenseAgreements
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg"
      id="Narr_1qlT5e5_T0aDta_4mPDKMg">P60D</axgn:NoticePeriodForTerminationOfLicenseAgreements>
    <axgn:RoyaltyFeesPercentageUnderLicenseAgreements
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_xxA6d2qDA0KMb3nNUfKzyA"
      decimals="2"
      id="Narr_ggiCQNbvzEmQ3TKhdCCbpw"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.01</axgn:RoyaltyFeesPercentageUnderLicenseAgreements>
    <axgn:RoyaltyFeesPercentageUnderLicenseAgreements
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_OFAgoTompkmEhOalHj3_sA"
      decimals="2"
      id="Narr_LaRlxLUUE0KFyRfkkjaztA"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.03</axgn:RoyaltyFeesPercentageUnderLicenseAgreements>
    <axgn:MinimumRoyaltyOfLicenseAgreement
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg"
      decimals="-3"
      id="Narr_9yNAQt04OUK0itJjsNCaJw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">13000</axgn:MinimumRoyaltyOfLicenseAgreement>
    <axgn:PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_OFAgoTompkmEhOalHj3_sA"
      decimals="4"
      id="Narr_w0vpdgTWGUyus72sxz9TDA"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.0375</axgn:PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors>
    <axgn:MilestonePaymentContingentUponReceiptOfGrant
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg"
      decimals="-3"
      id="Narr_ChitVy6K80aTbPyCoxF_Bw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15000</axgn:MilestonePaymentContingentUponReceiptOfGrant>
    <axgn:MilestonePaymentContingentUponFDApproval
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg"
      decimals="-3"
      id="Narr_7GmafeS6mk-N9N-4Mts3eQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2000</axgn:MilestonePaymentContingentUponFDApproval>
    <axgn:MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg"
      decimals="-3"
      id="Narr_0mPt3CVHYUCtojh-ndRYwg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">25000</axgn:MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology>
    <axgn:MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_NIniOQl2W0WlESh6vSQ-qg"
      decimals="-3"
      id="Narr_Xj3BgDWL6UylkVyVqw9E-g"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10000</axgn:MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_bxzrSUd6ckqbGlbKCkkNcA"
      decimals="-3"
      id="Narr_ZeYlrIHUsEyPHgxTyZd05g"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2119000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_ACgwMpqi40GSjcz2QnxS7Q"
      decimals="-3"
      id="Narr_Wj3a5yEUGkeHRAcIULl8aw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1661000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_OZPWCWKOxEOV_X4bbR494w"
      decimals="-3"
      id="Narr_SYe2Bn5ikEWjnLK3o6VyEA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1195000</us-gaap:RoyaltyExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_fqa9zVfkOEmzHCUkIZcNBA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;8.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Accounts Payable and Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Accounts payable and accrued expenses consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,262&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,517&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,004&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,631&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,477&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Payable and Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_QtMZvKdedUa89f4NopvFcw">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,262&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,517&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,004&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,631&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,477&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Payable and Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_E5LSEXg_jUGCGJxrND1fQw_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">8262000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_FD_WwVuHfkqqrILXv5PnSQ_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4517000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_HoldUTZgZEizfrqDhfsm9Q_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3237000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_kF9HBbh3h0yV3n_lecRnRA_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2004000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_anDZPv1UqkKc0ejfqJoY2Q_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7631000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_EtI37-N2NUCE9Z486LA_pQ_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6477000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_od7FLwBZGU-HWzV7VtVxsA_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">19130000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_yIZYcT8RJUWH_eTs4lMFkQ_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">12998000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_gMzWAr3Z-EumZMyj5uYggA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;9.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Term Loan Agreements and Long-Term Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Term Loan Agreement and Long-Term Debt consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Equipment Lease Agreement with Cisco Capital for a total lease amount of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$59&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; which has a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;36 month&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; term and requires no lease payments for the first &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;three months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the lease and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;33&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; equal payments of principal and interest until the end of the term.  Interest on the lease is payable monthly at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Equipment Lease Agreement with Raymond Leasing Corporation for a total lease amount of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$30&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; which has a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;48 month&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;6.7%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Equipment Lease Agreement with B&amp;amp;B Office Systems for a total lease amount of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$32&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; which has a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;60 month&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;8.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less current revolving loan&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less current maturities of long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (28)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Long-term portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;  &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Credit Facilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;MidCap Term Loan Agreement &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On October 25, 2016, the Company entered into Term Loan and a Revolving Loan with MidCap Financial Trust (&#x201c;MidCap&#x201d;) maturing on May 1, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company had the option at any time to prepay the Term Loan in whole or in part, subject to payment of a prepayment fee and an exit fee.  On May 22, 2018, the Company exercised its option and paid &lt;/span&gt;$22,599 to prepay the Term Loan in full, which included exit and pre-payment fees totaling $1,470&lt;span style="white-space:pre-wrap;"&gt;.  In addition, on May 22, 2018, the Company charged to interest expense the unamortized deferred financing costs associated with the Term Loan of &lt;/span&gt;$473.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company also had the option to terminate or permanently reduce the Revolving Loan prior to the maturity date subject to its payment of a deferred origination fee. On May 22, 2018, the Company exercised its option to terminate and paid $2,958 to prepay the Revolving Loan in full, which amount included fees of $236.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_PoKJJYQkoEudEcSXHF3dlA">&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Equipment Lease Agreement with Cisco Capital for a total lease amount of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$59&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; which has a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;36 month&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; term and requires no lease payments for the first &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;three months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the lease and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;33&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; equal payments of principal and interest until the end of the term.  Interest on the lease is payable monthly at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Equipment Lease Agreement with Raymond Leasing Corporation for a total lease amount of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$30&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; which has a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;48 month&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;6.7%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Equipment Lease Agreement with B&amp;amp;B Office Systems for a total lease amount of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$32&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; which has a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;60 month&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;8.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less current revolving loan&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less current maturities of long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (28)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Long-term portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;  &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5AiGbGmjpkCdVyBcVv8E_g"
      decimals="-3"
      id="Narr_bUam91XP_kCj3WjYW2Rfmw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">59000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_K3AS51eTEE-YvIQB0nBIfg"
      decimals="-3"
      id="Narr_zs1FU35tmUa60REaciUidA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">59000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_8IfuLyTmxkeeHIrn5HAHCA"
      id="Narr_U5rJP8XkPE2aNWjh07_VzA">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_OuSBR749Ck6rO9M9pD5hrg"
      id="Narr_lMBM027tkUqqzs7ScTElxw">P36M</us-gaap:DebtInstrumentTerm>
    <axgn:DebtInstrumentNoPaymentsRequiredTerm
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_8IfuLyTmxkeeHIrn5HAHCA"
      id="Narr_ZM22oZi840SbRNhbem5l2A">P3M</axgn:DebtInstrumentNoPaymentsRequiredTerm>
    <axgn:DebtInstrumentNoPaymentsRequiredTerm
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_OuSBR749Ck6rO9M9pD5hrg"
      id="Narr_J-1_hDCV2UGB4msd1S5XjQ">P3M</axgn:DebtInstrumentNoPaymentsRequiredTerm>
    <axgn:DebtInstrumentInterestAndPrincipalPaymentsTerm
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_8IfuLyTmxkeeHIrn5HAHCA"
      id="Narr_VdO8hoFmJkSp7IqbTUcZuQ">P33M</axgn:DebtInstrumentInterestAndPrincipalPaymentsTerm>
    <axgn:DebtInstrumentInterestAndPrincipalPaymentsTerm
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_OuSBR749Ck6rO9M9pD5hrg"
      id="Narr_-AEX652ohEyh0941XGE-cQ">P33M</axgn:DebtInstrumentInterestAndPrincipalPaymentsTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5AiGbGmjpkCdVyBcVv8E_g"
      decimals="INF"
      id="Narr_MDi02j-q5Ee8Ots6HRzSmQ"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_K3AS51eTEE-YvIQB0nBIfg"
      decimals="INF"
      id="Narr_ocXXUKib60O7wvz8DmXBJA"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5AiGbGmjpkCdVyBcVv8E_g"
      decimals="-3"
      id="Tc_k5tX3KbZS0mJo8IYCqjxYw_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_R55K8zUulUecXnhoaiBPkA"
      decimals="-3"
      id="Narr_07ZOdumfgEGBvV-5wR3v9Q"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_GGJc28kiH0yWr2MZBgPxCQ"
      decimals="-3"
      id="Narr_klXg-NIbME2faE48OpawvA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_kNscByhTbEyGSk9W2JNlqA"
      id="Narr_6n2qAeY13kKfyGF77Ig81w">P48M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_5zA3fXbvx0ylwp-9i_-FOg"
      id="Narr_3DaEjdx_rkSn9TcdESWPTg">P48M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_R55K8zUulUecXnhoaiBPkA"
      decimals="INF"
      id="Narr_PlzUuNVO00-jwBrxCDwMog"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.067</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_GGJc28kiH0yWr2MZBgPxCQ"
      decimals="INF"
      id="Narr_0odxvd6XLke4vFzotveQvA"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.067</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_RaymondLeasingCorporationMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_R55K8zUulUecXnhoaiBPkA"
      decimals="-3"
      id="Tc_ZQmgaVhTkEW8qrmjIZhWQA_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">22000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_wW9WLuWZOE66fVKEdCy_HA"
      decimals="-3"
      id="Narr_kkKGO2Bkdkqh9UffoQF26g"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">32000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_nwTNdrPqO0CQRQSSHeR4zg"
      decimals="-3"
      id="Narr_OHQoc8mXoUKJCLW8v7KjCA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">32000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_7a23qUYeEESFI9Qda8I25Q"
      id="Narr_fSwQ9D4bFUiJ7TEkS340Jg">P60M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_1eKp0lMU00OTf_T3kLb7qw"
      id="Narr_iWL6yXBqNk-mMDzVrxHRVA">P60M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_wW9WLuWZOE66fVKEdCy_HA"
      decimals="INF"
      id="Narr_gFTVLbWLvUuaC0Zdasvzjw"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_nwTNdrPqO0CQRQSSHeR4zg"
      decimals="INF"
      id="Narr_vaDsDTlH-U-aXmk222FOhQ"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_axgn_BAndBOfficeSystemsMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_wW9WLuWZOE66fVKEdCy_HA"
      decimals="-3"
      id="Tc_DT8ucecaz0S8GaH65x30ww_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">26000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_SWeppeFtKk6u8J1bJS0ltA_10_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">63000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_wgbr7gXhZ0qyLBxUs1-1cA_12_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28000</us-gaap:LongTermDebtCurrent>
    <axgn:LongTermDebtNoncurrentExcludingDeferredRevenue
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_-vuEZwZyb0C_fEPH8oxQpw_13_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">35000</axgn:LongTermDebtNoncurrentExcludingDeferredRevenue>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_5_22_2018_To_5_22_2018_i3ypW9J1CEa7OLr3rjoRmw"
      decimals="-3"
      id="Narr_a8lOLtgQhEmCN3xckelhWg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">22599000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="Duration_5_22_2018_To_5_22_2018_i3ypW9J1CEa7OLr3rjoRmw"
      decimals="-3"
      id="Narr_RCHqJaNG9ES0VRt0Z9vioQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1470000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_5_22_2018_dzFQMjgQyUeSU6fLKCFqYQ"
      decimals="-3"
      id="Narr_sM8SRpCja0qR7pnOLrbtMg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">473000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_5_22_2018_To_5_22_2018_us-gaap_LongtermDebtTypeAxis_axgn_RevolvingLoanAgreementMember_8N4ZVro1vU-SRjTtIMuL6Q"
      decimals="-3"
      id="Narr_M1mbTzWcSkiqv2Wt_FaWog"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2958000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="Duration_5_22_2018_To_5_22_2018_us-gaap_LongtermDebtTypeAxis_axgn_RevolvingLoanAgreementMember_8N4ZVro1vU-SRjTtIMuL6Q"
      decimals="-3"
      id="Narr_0iuyK7aYXUebtZBnVnqQ0A"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">236000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_JZ1yb41Z4Ea_8cAazA4Utw">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;10.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Public Offering of Common Stock &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Axogen,&#160;Inc. Classes of Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Axogen,&#160;Inc.&#x2019;s authorized capital stock consists of 100,000,000 shares of common stock, par value $0.01 per share. The authorized capital stock is divisible into the classes and series, has the designation, voting rights, and other rights and preferences and is subject to the restrictions that the Axogen Board of Directors may establish from time to time. Unless otherwise designated by the Axogen Board of Directors, all shares are common stock. Axogen has not designated any shares other than common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Public Offerings&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On May 8, 2018, the Company entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the &#x201c;2018 Offering Underwriters&#x201d;), pursuant to which the Company agreed to issue and sell &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3,000,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of the Company&#x2019;s common stock in an underwritten registered public offering at an offering price of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$41.00&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; per share (the &#x201c;2018 Offering&#x201d;).  The Company granted the 2018 Offering Underwriters a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-day option to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;450,000&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; additional shares of common stock, at the public offering price, less the underwriting discounts and commissions, which was exercised in full on May 9, 2018.  The 2018 Offering closed on May 11, 2018, and the Company received proceeds of approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$132,707&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; from the sale of the shares (including the sale of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;450,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; additional shares issued upon exercise of the 2018 Offering Underwriters&#x2019; overallotment option), after deducting the underwriting discounts and commissions and estimated offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="INF"
      id="Narr_NdtCumbmdUmu5AmZEiibng"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="INF"
      id="Narr_mQdxV7yI-EWjkCC-85ar7A"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="INF"
      id="Narr_o0Psfn2Nz0OJEJyTo3THGQ"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="INF"
      id="Narr_V_baPHa0EEiIZ3iics96zQ"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_5_8_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_IP-Mn3x-6EudoUgdTXzq8Q"
      decimals="INF"
      id="Narr_j6O_xqLeuUy7W7Qii3PF6Q"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">3000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="As_Of_5_8_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_IP-Mn3x-6EudoUgdTXzq8Q"
      decimals="INF"
      id="Narr_5zygemKSnEWgidkNDfN4mQ"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">41.00</us-gaap:SharePrice>
    <axgn:NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares
      contextRef="Duration_5_8_2018_To_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_95CgkAkKI0mIpKKHiaq65w"
      id="Narr_fTh9obCvLk6DKCuas4eFAA">P30D</axgn:NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_YTJ3Sc6qnUeCcLNGzq1uxA"
      decimals="INF"
      id="Narr_hzWuGI16r0yNmGgxoTyGEg"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_5_11_2018_To_5_11_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_8cxhdgof3UO6xB-FFbptDQ"
      decimals="-3"
      id="Narr__Et0-Lcd7UiVGNDoIfpCLg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">132707000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_5_8_2018_srt_TitleOfIndividualAxis_axgn_UnderwriterMember_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_YTJ3Sc6qnUeCcLNGzq1uxA"
      decimals="INF"
      id="Narr_674PoPN7SE-14yhJv5TzCg"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_dmMWaC-ppEq1jHqIr8kE2w">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;11.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Equity Compensation Plans &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company maintains two share-based incentive plans:  the Axogen 2017 Stock Incentive Plan, as amended (&#x201c;2017 Plan&#x201d;), and the Axogen 2017 Employee Stock Purchase Plan (&#x201c;2017 ESPP&#x201d;). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Stock Incentive Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;At the 2019 Annual Meeting of Shareholders held on August 14, 2019, the shareholders approved the Axogen 2019 Long-Term Incentive Plan (the &#x201c;New Axogen Plan&#x201d;), which allows for issuance of incentive stock options, non-qualified stock options, performance stock units (&#x201c;PSUs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;) to employees, directors and consultants at exercise prices not less than the fair market value at the date of grant.  The number of shares of common stock authorized for issuance under the New Axogen Plan is (A) &lt;/span&gt;3,385,482 shares, comprised of (i) 3,000,000 new authorized shares and (ii) 385,482&lt;span style="white-space:pre-wrap;"&gt; unallocated shares of common stock available for issuance as of August 14, 2019 pursuant to the Company&#x2019;s 2010 Stock Incentive Plan, as amended and restated (the &#x201c;Prior Axogen Plan&#x201d;), that were not then subject to outstanding awards; plus (B) shares under the Prior Axogen Plan and the New Axogen Plan that are cancelled, forfeited, expired, unearned or settled in cash, in any such case that does not result in the issuance of common stock.  Following shareholder approval of the New Axogen Plan, no future awards will be made under the Prior Axogen Plan. As of December 31, 2019, &lt;/span&gt;3,265,188 shares of common stock were available for issuance under the New Axogen Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The options granted to employees prior to July 1, 2017 typically vest &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;25%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;one year&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; after the grant date and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;12.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; every six months thereafter for the remaining &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;three-year&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; period until fully vested after &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;four years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;.&lt;/span&gt; &lt;span style="font-size:10pt;"&gt;The options granted to employees after July 1, 2017 typically vest &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;50%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;two years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; after the grant date and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;12.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; every six months thereafter for the remaining &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;two-year&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; period until fully vested after &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;four years&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;.  The options granted to directors and certain options granted from time to time to certain executive officers have vested ratably over &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;three years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;25%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per quarter over &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;one year&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; or had no vesting period. Options typically have terms ranging from &lt;/span&gt;&lt;span style="-sec-ix-hidden:_85e8adea_8926_4837_834b_5796d41281fc"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;ten years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company recognized stock-based compensation expense, which consisted of compensation expense related to employee stock options, PSUs, RSUs and the 2017 ESPP based on the value of share-based payment awards that are ultimately expected to vest during the period, of approximately $10,304, $7,606 and $3,609&lt;span style="white-space:pre-wrap;"&gt; for the fiscal year ended December 31, 2019, 2018, and 2017, respectively.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company estimates the fair value of each option award issued under such plans on the date of grant using a Multiple Point Black-Scholes option-pricing model which uses a weighted average of historical volatility and peer company volatility. The Company determines the expected life of each award giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Activity under the Prior Axogen Plan and the New Axogen Plan during 2019 and 2018 was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:1pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Time-Based Stock Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2017:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,304,201&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.28&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 90,473&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 656,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (40,473)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.56&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,026,807)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2018:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,893,171&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11.94&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 41,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 344,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (287,609)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.75&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (529,557)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,420,181&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt; 26,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,420,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt; 26,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Exercisable at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,099,616&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.90&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 4.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt; 22,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Restricted and Performance Stock Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2017:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 610,730&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 516,433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23.34&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Released&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 25.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2018:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,106,363&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 217,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Released&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (86,405)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16.77&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (123,407)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,113,697&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.62&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The intrinsic value of equity awards exercised during the years ended December 31, 2019, 2018 and 2017 was $9,553, $34,229 and $7,783&lt;span style="white-space:pre-wrap;"&gt;, respectively. As a result of the Company&#x2019;s full valuation allowance on its net deferred tax assets, no tax benefit was recognized related to the exercises of stock options.  The exercise price per share of each option is equal to the fair market value of the underlying share on the date of grant.  For 2019, 2018 and 2017, &lt;/span&gt;$4,002, $3,884 and $1,434&lt;span style="white-space:pre-wrap;"&gt;, respectively, in cash proceeds were included in the Company&#x2019;s Consolidated Statements of Cash Flows as a result of the exercise of stock options.  The total fair value of restricted stock vested during 2019, 2018 and 2017 was &lt;/span&gt;$1,467, $196 and $108&lt;span style="white-space:pre-wrap;"&gt;.  The Company issues registered shares of common stock to satisfy stock option exercises and restricted stock grants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;As of December 31, 2019, there was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$19,460&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; of unrecognized compensation costs related to non-vested stock options and restricted stock awards.  This cost is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;2.14&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years for stock options and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;2.63&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; years for restricted stock awards.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;On December 18, 2017, December 27, 2018 and December 17, 2019, the Compensation Committee of the Board of Directors also approved PSU awards to certain employees related to their work on the Company&#x2019;s BLA.  The PSU awards consist of a targeted total award of &lt;/span&gt;200,000&lt;span style="white-space:pre-wrap;"&gt; shares. The number of shares are allocated to certain milestones related to the BLA submission to and approval by the FDA.  The performance measure is based upon achieving each of the specific milestones and will vest &lt;/span&gt;50%&lt;span style="white-space:pre-wrap;"&gt; upon achieving each of the milestones and 50% one year later.  The Company estimated the  fair value of the PSUs based on its closing stock price at the time of grant and its estimate of achieving such performance target and will record compensation expense as the milestones are achieved. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;expense will be adjusted based upon the Company&#x2019;s estimate of achieving such performance target. The number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on the actual performance metrics as set forth in the applicable PSU award agreement.   The amount actually awarded will be based upon achievement of the performance measures and can range from &lt;/span&gt;zero to 200,000&lt;span style="white-space:pre-wrap;"&gt; shares.  The fair value of the common stock on the grant date was &lt;/span&gt;$16.88 on December 17, 2019, $19.17 on December 27, 2018 and $27.00&lt;span style="white-space:pre-wrap;"&gt; on December 18, 2017.  The total unrecognized future compensation expense related to this PSU, assuming achievement of &lt;/span&gt;100% of the target award is $17,682. Assuming the minimum of 0% and the maximum of 100% payout opportunity for the PSU, the range of total future compensation expense related to this PSU award is between $0 and $17,682 as of December 31, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Employee Stock Purchase Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The 2017 ESPP, which was effective as of January 1, 2018, allows for eligible employees to acquire shares of our common stock through payroll deductions at a discount from market value (currently &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;15%&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;) of the lesser of the closing price of the Company&#x2019;s common stock on the first day or last day of the offering period.  The offering period is currently &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;, and the offering prices are subject to change.  Participants may not purchase more than &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$25&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; of the Company&#x2019;s common stock in a calendar year.  As of December 31, 2019 , there were &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;600,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of common stock authorized for issuance under the 2017 ESPP and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;450,305&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; were available for future issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Valuation and Expense Information Under FASB ASC 718&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company estimates the fair value of each option grant using a Multiple Point Black-Scholes option-pricing model which uses a weighted average of historical volatility and peer company volatility. The Company determines the expected life giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company used the following weighted-average assumptions for stock options granted during the year ended December&#160;31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:68.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2017&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 6.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 6.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 54.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 50.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 50.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.71&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.70&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The fair value of restricted stock awards is based on the market value of the Company&#x2019;s common stock on the date of the awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Based on the assumptions noted above, the weighted average estimated grant date fair value per share of the stock options and restricted stock granted for the years ended December 31, 2019, 2018 and 2017, respectively, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2017&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.07&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Restricted and performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_raPo7Sf_yUa4X4qkmt6ISg"
      decimals="0"
      id="Narr_7hgKKQPqrUecQT8LDV0CUg"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">3385482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_8_14_2019_To_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_GGHIBITd6ES9mOn1M2PF1Q"
      decimals="0"
      id="Narr_v3YWd4O2ZEa3f9J_9aSnLA"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <axgn:NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance
      contextRef="As_Of_8_14_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_raPo7Sf_yUa4X4qkmt6ISg"
      decimals="0"
      id="Narr_c-U1u8kC50uQomv19bTUug"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">385482</axgn:NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_NewAxogenPlanMember_AsMXpgQA50yoxCfsHEU1FA"
      decimals="0"
      id="Narr_ogu7OEJlo0uGBMljve0F1Q"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">3265188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tXs-JMVGQEyiTIr2x0PXlw"
      decimals="2"
      id="Narr_og3ReeO1f0y_rWAIlnjuSA"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_tXs-JMVGQEyiTIr2x0PXlw"
      id="Narr_hoOpqKFslUS1Rrf7Yhq7Gg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_w1MuJpPwoUuQdyD6mVgyFA"
      decimals="3"
      id="Narr_QhAWMemgqUqOpBRy9EywZA"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_w1MuJpPwoUuQdyD6mVgyFA"
      id="Narr_MlL-DpIE3UqcAVqOiaQdXw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_CC9WNsq1-kOINeRZ-7lGZA"
      id="Narr_hXbEZ0OsZU2cgZhTl0RNoQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Lew-fDnf_U63JMTITTXx7Q"
      decimals="2"
      id="Narr_LRs8RrWFP0eFxtPd4TJk8w"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Lew-fDnf_U63JMTITTXx7Q"
      id="Narr_3ji6jK4_gUaaw3kZOxfseA">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_G1UD6bCPNE6Vk1FLD8sFmw"
      decimals="3"
      id="Narr_zRVR9gMMBEaHI7HlDUmnNA"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_VxZyqVXjoUyc4jYXo3Wsgw"
      id="Narr_ALB2soxmO0SI1_XD3YDOSw">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_8GcfaDwiVke9uA8EDTn7hA"
      id="Narr_noFZHkIJQUaemmJy3PCwSw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember__vQAw7VfUE6OunzRu1K-bQ"
      id="Narr_4gDHhHAkPUeRg4z9eFiOow">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_VestingAxis_axgn_ShareBasedCompensationAwardTrancheFourMember_sY50ARTqmkOIAcnOP5sbtw"
      decimals="2"
      id="Narr_9mJERlbD0ECYCINMLvV9dQ"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_VestingAxis_axgn_ShareBasedCompensationAwardTrancheFourMember_sY50ARTqmkOIAcnOP5sbtw"
      id="Narr_BQJpiM8CjUmeSTT2Sv5M-w">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_6eAKFDAAb0yer27HykbH7g"
      id="Narr_ND9jiTG5SEGxUZMbCCbH-g">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_-tru8YDdlEaGF3QvS9irnA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10304000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_M0bDFRBJ_02qOlncLCLqZA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_Sgst3B-EHU6xlbfJLMC0Ow"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3609000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_0QIEGDgXDka45hZ6tdM4zw">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:1pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Time-Based Stock Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2017:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,304,201&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.28&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 90,473&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 656,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (40,473)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.56&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,026,807)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2018:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,893,171&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11.94&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 41,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 344,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (287,609)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.75&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (529,557)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,420,181&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt; 26,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,420,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt; 26,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Exercisable at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:16.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,099,616&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.90&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 4.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt; 22,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_FuweD_vKdkCOcnSUpC4lMw"
      decimals="INF"
      id="Tc_dtfmz7OAokWY1-Pp958BJA_6_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">4304201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_FuweD_vKdkCOcnSUpC4lMw"
      decimals="2"
      id="Tc_gE4cRUTej0SuTfxLM9jfqQ_6_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_dOpDEESlqEODYTZJx6VStA"
      id="Tc_KFnqEPU6HUmQkO3cv3Kjew_6_7">P5Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_FuweD_vKdkCOcnSUpC4lMw"
      decimals="-3"
      id="Tc_llEqhUL_DU-x2fO4AsH6HQ_6_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">90473000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ"
      decimals="INF"
      id="Tc_u6MEJHDmKEeuAyu_kFErSw_7_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">656250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ"
      decimals="2"
      id="Tc_MXgSc7wEhkqM6dt3ucaS-w_7_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">29.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ"
      decimals="INF"
      id="Tc_R-qP6J9f-024Pl0pmXsgSQ_8_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">40473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ"
      decimals="2"
      id="Tc__1rKPeU2QUq0yi6NcR8ZPQ_8_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">9.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ"
      decimals="INF"
      id="Tc_g21QhloOIkyjX_9-S0VfKA_9_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">1026807</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ"
      decimals="2"
      id="Tc_7rLrHtJ0DkewxKm5XWSWfw_9_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">3.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_NvaE0ZF610qmwkn-m_kZkw"
      decimals="INF"
      id="Tc_YXtqHhvgzUKGFN7LhnOWCw_10_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">3893171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_NvaE0ZF610qmwkn-m_kZkw"
      decimals="2"
      id="Tc_5TYw0J2AN0CJRrQOX1CPJw_10_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">11.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ"
      id="Tc_hax3tgcHlUizJdIyVdJj6Q_10_7">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_NvaE0ZF610qmwkn-m_kZkw"
      decimals="-3"
      id="Tc_XgGNUHN4NUeOaLWD40kfFQ_10_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">41020000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      decimals="INF"
      id="Tc_YMPzJDPPL0-eCeBefdv8Qw_11_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">344176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      decimals="2"
      id="Tc_4wM7jOPxmUqypn-BYzYHhg_11_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">18.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      decimals="INF"
      id="Tc_YIxeouN6oEK77vDa6qaEOA_12_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">287609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      decimals="2"
      id="Tc_d3BEItKGSkGKZ-rWuGivUQ_12_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">22.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      decimals="INF"
      id="Tc_VZquvzaoG0mAvSth9i-c0Q_13_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">529557</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      decimals="2"
      id="Tc_i8IJfGbcSkuwtIU4NCrKYg_13_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">5.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"
      decimals="INF"
      id="Tc_DCM3_zySTUmvKJIoTmHq8A_14_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">3420181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"
      decimals="2"
      id="Tc_wIyFsjv380CQ9E7UeDwwkA_14_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">12.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      id="Tc_xKl6VvLkdUShDnne6beP6A_14_7">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"
      decimals="-3"
      id="Tc_LlB0Le_uxkeE-kJ6IZcRfg_14_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">26074000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"
      decimals="INF"
      id="Tc_LldVqm480U2UQwaUCzFm9g_15_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">3420181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"
      decimals="2"
      id="Tc_EN5tLauKLUGQygt4rVgVTA_15_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">12.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      id="Tc_BPYobo-dJ0qeTseRpmp2ww_15_7">P5Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"
      decimals="-3"
      id="Tc_ekjGOqcp-Uum3hIjdxxFEA_15_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">26074000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"
      decimals="INF"
      id="Tc_Gw9RtdiN3U6ARWdz81MQ0g_16_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">2099616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"
      decimals="2"
      id="Tc_Mh58Is31HEaBA92QsLdevA_16_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">7.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      id="Tc_WILEy3pclU2Bjag8TcloPA_16_7">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_l62dCPdjzE-CU_4xdLghNA"
      decimals="-3"
      id="Tc_soPjGZfZDke871TMHdVacA_16_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">22712000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_1506ocbMwU6IPu5iK3iqbQ">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Restricted and Performance Stock Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2017:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 610,730&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 516,433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23.34&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Released&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 25.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2018:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,106,363&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 217,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Released&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (86,405)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16.77&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (123,407)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,113,697&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.62&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_JJoSoSTdZU-4AUZvS_2qqw"
      decimals="INF"
      id="Tc_TTPWeGK3GEiVnMunDZCuSg_5_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">610730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_JJoSoSTdZU-4AUZvS_2qqw"
      decimals="2"
      id="Tc_NJ3Uk0zTvkynIppgp2zTFA_5_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">21.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ"
      decimals="INF"
      id="Tc_vNcChWf6nEyqqRFxvrTjKg_6_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">516433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ"
      decimals="2"
      id="Tc_01zdKahyAkStKABfgCZhdw_6_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">23.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ"
      decimals="INF"
      id="Tc_8lv051MAsEWmPBLHzQcNfQ_7_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">7150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ"
      decimals="2"
      id="Tc_aCJcEU7zEk6MP-9Y_Z3GCQ_7_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">8.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ"
      decimals="INF"
      id="Tc_5hmDUDnMWk6yz5C_eCxDWA_8_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">13650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ"
      decimals="2"
      id="Tc_lov3FIoAU0WNC_kWkQeJPA_8_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">25.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_C62IeF_A8kyKJEMkteQh9g"
      decimals="INF"
      id="Tc_X-nTubOR1E2pCT92IZcsDg_9_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">1106363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_C62IeF_A8kyKJEMkteQh9g"
      decimals="2"
      id="Tc_MyhvyKd3PEq0PPMPPdoAVA_9_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">22.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw"
      decimals="INF"
      id="Tc_ao4j9mzeY0-jdKH-0jwq4Q_10_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">217146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw"
      decimals="2"
      id="Tc_7ZEUnoZxv0m4wEQjKRCJBA_10_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">17.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw"
      decimals="INF"
      id="Tc_EaZVpOqeNESGPwW3MP6lKg_11_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">86405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw"
      decimals="2"
      id="Tc_NLALTKyMaEWn59GA2lkrHw_11_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">16.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw"
      decimals="INF"
      id="Tc_V4X6aXWwP02fyO8FAQEX6g_12_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">123407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw"
      decimals="2"
      id="Tc_ZaCjBcpCe0iUsqJ7wRFS3A_12_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">22.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_kf1nPeinvkG_Rhf00UpwCw"
      decimals="INF"
      id="Tc_3OsS8B-L_kaaFKmG1JQDSg_13_2"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">1113697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_kf1nPeinvkG_Rhf00UpwCw"
      decimals="2"
      id="Tc_FJTnn-JzC0ilB3qp0KNKEw_13_5"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">21.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_ts6ch1E1YkaKgRGi-KlCzA"
      decimals="-3"
      id="Narr_8F6fZ12quEOfrlCdN2q6bA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">9553000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_wAZ3pu-l8kyAOvBDAXRqzw"
      decimals="-3"
      id="Narr_VTGoYgmvY0SLZSBTqRfikw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">34229000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_0ysv9tohn0Cnci0yKK3WTQ"
      decimals="-3"
      id="Narr_cVM0s_8MIEWWywaV67DXzw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7783000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_Ho5IEtSXlUGzaNyUFAUCdg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4002000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_3Wg8yroaYUGsfADvSmZ_Zg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3884000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_bvZCRYC5nkiC14eGABnLMA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1434000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_nK1CVjx8i02s8fnVyKtUHw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1467000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_CWW_xJF5cUKEw3EoYdh5Rw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">196000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_5w9mwtQ4kkGmZ8INEhUgFw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">108000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_R1UTHSkFFkGQk_FG_stL9w"
      decimals="-3"
      id="Narr_Clti2_7Ng06YWvmJVX_rgg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">19460000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_DirectorsAndOfficersStockOptionsMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_Ql1wJMAwvk-Sb_JOHEvrvw"
      id="Narr_wGa2w3_cMkqHZspSRhX7bA">P2Y1M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_axgn_AxoGen2010StockIncentivePlanMember_3FvL10D5nEOeSMDNANv2Kg"
      id="Narr_FeG0mh-oO0GkRLPzsj1D8g">P2Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_kDpRBjGQ4ky9c7CfmO9qDw"
      decimals="INF"
      id="Narr_cXOU29X6FEedj-m_m6vMxw"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_12_18_2017_To_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_vVyhRlB3k0qQ8T_w4fLYmg"
      decimals="INF"
      id="Narr_XRJu-Md-yU6NxsYxCnuhYQ"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_18_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_KoTtJ_qtIEWdKLFBvghyAw"
      decimals="INF"
      id="Narr_pPi9D_E2Y0aTzDnv1c5JPg"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_18_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_CGrwMnPP4UGYxvkC4Exm0Q"
      decimals="INF"
      id="Narr_b7OjGuc4R064QBeWswUBmA"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_17_2019_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_h_z9vINimUO30zz-EdrkPQ"
      decimals="INF"
      id="Narr_qCV-hATKsU27fF8RHWWN4w"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">16.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_27_2018_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_XKWVUmRIiEOgStCdW6dO9w"
      decimals="INF"
      id="Narr_kmRjuy7svUK_TMFmmJLfwg"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">19.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_kDpRBjGQ4ky9c7CfmO9qDw"
      decimals="INF"
      id="Narr_9caEiLfPOEC2uPGHLihLfA"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">27.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <axgn:CompensationCostNotYetRecognizedAssumedPercentageAchieved
      contextRef="Duration_12_18_2017_To_12_18_2017_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_vVyhRlB3k0qQ8T_w4fLYmg"
      decimals="INF"
      id="Narr_TTNpGzfqd0KiSP2vCYCCcg"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">1</axgn:CompensationCostNotYetRecognizedAssumedPercentageAchieved>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_V4yhWdQNTEehyUOL8K5GIg"
      decimals="-3"
      id="Narr_xoKfYtwMQU-kY3F9wBo1xA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17682000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <axgn:PhantomStockUnitPayoutOpportunity
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_NdmkMgAetEmBY0Ox4RWwMg"
      decimals="INF"
      id="Narr_BaNson-ZxE61U8Lm7_lfxw"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0</axgn:PhantomStockUnitPayoutOpportunity>
    <axgn:PhantomStockUnitPayoutOpportunity
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_YaU4fSuYCEqRjlrkJR8zFA"
      decimals="INF"
      id="Narr_j8BnE-q9Ck6ixrT1MLaB8w"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">1</axgn:PhantomStockUnitPayoutOpportunity>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_dGmAPQbXTkiY-aJQtxRmkw"
      decimals="-3"
      id="Narr_hNxnWRb07EKGIXNfsGEtJg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_axgn_PerformanceSharesBiologicLicenseApplicationMember_V4yhWdQNTEehyUOL8K5GIg"
      decimals="-3"
      id="Narr_mSMv2Ml1a0mQOnYGOjJmOg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17682000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <axgn:EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_do694XF7Vkun4p0EqDCKIw"
      decimals="INF"
      id="Narr_oGqYvIoGPkKutocleBGLQQ"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.15</axgn:EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock>
    <axgn:EmployeeStockPurchasePlanOfferingPeriod
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_do694XF7Vkun4p0EqDCKIw"
      id="Narr_dia8s1s9c0qJOy9ecf1bGg">P6M</axgn:EmployeeStockPurchasePlanOfferingPeriod>
    <axgn:EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_do694XF7Vkun4p0EqDCKIw"
      decimals="-3"
      id="Narr_YA7NSBDr4EeiP2TbLkZePA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">25000</axgn:EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_5M4EtFIS2UiIB7rFpvlMjQ"
      decimals="INF"
      id="Narr_QvIVFn7KHkGZK2cI-8JPDA"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_axgn_Axogen2017EmployeeStockPurchasePlanMember_j1ICqH5Z30Cj6yv7xX0hUQ"
      decimals="INF"
      id="Narr_xINPs2bhoUSm8O55smvTrg"
      unitRef="Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q">450305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_8nFpBqc4O06YDszATG17hw">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:68.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2017&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 5.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 6.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 6.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 54.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 50.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 50.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.71&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.70&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tc_glMSXcQLUk-_-CPmbw8BIg_3_2">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      id="Tc_ftBfTK_750yMgs0jl0wdSQ_3_4">P6Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      id="Tc_eH9Q8WRGd0Cs1j2iNvHOUw_3_6">P6Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="4"
      id="Tc_a5TQzErUlEe1ehVtB7u2_Q_4_2"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.5497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="4"
      id="Tc_hVJsEAJk-02OnBlh4-1ejA_4_4"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.5099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="4"
      id="Tc_6efmFC0F1kWtJ5-T76_hEQ_4_6"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.5043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="4"
      id="Tc_yKKs8O58Ok-SQko1TMc_8Q_5_2"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="4"
      id="Tc_oFA5Esu7dkWJeXwoVLRjuA_5_4"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.0270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="4"
      id="Tc_XfeuTb7vwEOkHjmRmc6qUw_5_6"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.0212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_wmwJxR2MA0GuDwLANws1rQ">&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2017&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.07&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Restricted and performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 17.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw"
      decimals="2"
      id="Tc_JA_eFekv10ScHBF-_axoLw_2_3"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">18.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_AShOkZ0Tk0uRR90Ue26nfQ"
      decimals="2"
      id="Tc_jpHUBdNU00yEj6ngoq-rLQ_2_6"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">15.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_dOpDEESlqEODYTZJx6VStA"
      decimals="2"
      id="Tc_fMAsg1V-uEiR5uqMBQcmOg_2_9"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">8.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_tj2oDthZ2k-qdkqMApfJSw"
      decimals="2"
      id="Tc_S0-UmaJGlE-HpKYR3Xyh9Q_3_3"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">17.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_MpsE45yhjUeaufYRqZfVbQ"
      decimals="2"
      id="Tc_EHZdfkeY-UWipk-F-yrsfA_3_6"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">23.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_axgn_RestrictedAndPerformanceStockUnitsMember_zBQhnBxudEOrta0F6gp39g"
      decimals="2"
      id="Tc_3hMUrGAXTUe2LkCPW1ne0w_3_9"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">26.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_G4RfHp9gQEGJvkD7HKgaFA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;12.  Income Taxes &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company has temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax basis, as measured by enacted state and federal rates as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:-0.13806152%;padding-left:0pt;padding-right:0pt;width:100.27%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:50.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2017&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,588&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Inventory write down&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 317&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Interest limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Allowance for doubtful accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 274&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 285&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Right-of-use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,140&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,335&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 520&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (81)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (206)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (43)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (809)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,932)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,876)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,357)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The difference between the financial statement income tax and the income tax benefit using statutory rates is primarily due to the increase in the valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December&#160;31, 2019 and 2018:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:11pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt; &lt;/span&gt;&lt;span style="font-family:'Calibri';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:27.84%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&lt;/b&gt;&lt;b style="font-family:'Calibri';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.85%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Federal tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; 21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; 21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;State Taxes - Net of Federal Benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; 4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; 4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Permanent items and other deductions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; (4.3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; (0.5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; (20.8)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; (24.6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial';font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial';font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2019 and 2018, management assessed the realizability of deferred tax assets. Management evaluated the need for an amount of any valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the Company&#x2019;s deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more likely than not (a probability level of more than 50%) that the Company may not realize the benefit of its deferred tax assets. In assessing the realization of the Company&#x2019;s deferred tax assets, the Company considers all available evidence, both positive and negative. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that &#x201c;a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.&#x201d; Based upon available evidence, it was concluded on a more-likely-than-not basis that all deferred tax assets were not realizable as of December 31, 2019.  The valuation allowance increased by &lt;/span&gt;$6,056 and 5,519&lt;span style="white-space:pre-wrap;"&gt; during 2019 and 2018, primarily as a result of current year increase in the net operating loss carry forward.  During 2017, the valuation allowance decreased by &lt;/span&gt;$10,754, primarily due to the remeasurement of the Company&#x2019;s deferred tax assets and liabilities as a result of the Tax Reform enacted on December 22, 2017.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December&#160;31, 2019, the Company had tax-effected net operating loss carry forwards of approximately $36,250&lt;span style="white-space:pre-wrap;"&gt; to offset future taxable income which expire in various years through 2039.  Federal net operating losses incurred in tax years beginning on or after January 1, 2018 are carried forward indefinitely.  A portion of the net operating loss carry forwards may expire due to limitations imposed by section 382 of the Internal Revenue Code.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. In the normal course of business the Company is subject to examination by taxing authorities throughout the country. These audits could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with federal, state and local laws. The Company&#x2019;s tax years since 2017 remain subject to examination by federal, state and foreign tax authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842 &#x2013; Leases, on January 1, 2019. Under Topic 842, the Company is required to recognize the assets and liabilities that arise from most operating leases on the balance sheet. Upon adoption, no change in retained earnings was recorded related to income taxes as the Company maintains a full valuation allowance. As of the implementation date, an adjustment of $951 was recorded as a deferred tax liability and an adjustment of $961 was recorded as a deferred tax asset. See above for more information about the non-income tax impact of the adoption of the new leasing standard.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:5pt;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017, subjects a U.S. shareholder to tax on global intangible low-taxed income (&#x201c;GILTI&#x201d;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.&lt;/span&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;The Company has elected to account for GILTI in the year the tax is incurred.&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company had no&lt;span style="white-space:pre-wrap;"&gt; income tax expense or income tax benefit for 2017, 2018 and 2019 due to incurrence of net operating losses.  The Company does not believe there are any additional tax refund opportunities currently available.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_-bZ1P7Y_tEyTnXkTH3tedA">&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:-0.13806152%;padding-left:0pt;padding-right:0pt;width:100.27%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:50.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2017&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,588&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Inventory write down&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 317&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Interest limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Allowance for doubtful accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 274&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 285&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Right-of-use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,140&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,335&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 520&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (81)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (206)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (43)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (809)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,932)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,876)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,357)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_JflhykEOy0WQWXFHepHdLQ_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">36250000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_xgnL-3NVI0SVVFzclo5M8w_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30588000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_mIkFgAK49ESPhhxKF-ujBw_4_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">27578000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_4MmfXD92KE-HvUIbMt5XUw_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">317000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_ovH9VVrh2U62ssCFqPPQNg_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">273000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_ZAHEqcldf0y3LwToLbmZ9g_5_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">206000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_0IoFfPWnGUaPhnBu-K0HYA_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">136000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_G4odTc6jpEqjwGh4EqzVvA_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">117000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_Fhh_Bpj8-E6slNx6YAaorw_7_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">23000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <axgn:DeferredTaxAssetsInterestLimitation
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_MR92_RFB3E26PAn-9hk9aw_8_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">336000</axgn:DeferredTaxAssetsInterestLimitation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_TSzfYD9vnE6qzjoLiu3q6g_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">274000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_KWukBJu2AkO0pOI7ltlH6g_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">285000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_SHZidhchekCoHfc83lOK1A_9_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">117000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <axgn:DeferredTaxAssetsRightOfUseLiability
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_ggpjVMTbf0yBI0B-417psg_10_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">837000</axgn:DeferredTaxAssetsRightOfUseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_BBNOGHOusEymC4gSJtCnlw_11_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3140000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_rdmYKrSENUm0_EGoe-sc9A_11_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2335000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_-ydBbq_KvkOZF_BTmU3L4g_11_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">520000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_pxEUhmKZOUKmffTlX5bRoQ_12_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">40954000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_5_mUH2sVB0mLgYieu5Q0qQ_12_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">33934000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_th-gR6duGk2LrLz57GWn3g_12_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28444000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_CNJ_95c_50ylgqLvOvHo3w_14_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">81000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_JYr_f4zgPUyrcXXH9MrWJA_15_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">206000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_DkFLbPZ4SkeCr_I1a-IQkw_15_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">43000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_Oum9iiH_BkGsiCoWB4cctg_17_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_qMx7u-i3AEOAqKUYmJuB8A_17_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_xZ80x8VNn0W6zLTSXV_C-g_17_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <axgn:DeferredTaxAssetsLiabilities
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_3jwLyHJIEkClVI6RrVMHrA_18_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">39932000</axgn:DeferredTaxAssetsLiabilities>
    <axgn:DeferredTaxAssetsLiabilities
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_vxXOefsnskGfeg-3Qd1vLQ_18_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">33876000</axgn:DeferredTaxAssetsLiabilities>
    <axgn:DeferredTaxAssetsLiabilities
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_jzmeEB38NUW66wdykjDf4g_18_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28357000</axgn:DeferredTaxAssetsLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_Pd27ZU8u-kqswWrxguy_gQ_19_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">39932000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_HV8YeF9KNkO1uuaqjWZ7Hg_19_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">33876000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA"
      decimals="-3"
      id="Tc_h50k-PBrR0i-Xt_zWxNPjA_19_9"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28357000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_fTQ9UJHKpEC1yuHGm74Y5A">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:11pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt; &lt;/span&gt;&lt;span style="font-family:'Calibri';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:27.84%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&lt;/b&gt;&lt;b style="font-family:'Calibri';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.85%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Federal tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; 21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; 21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;State Taxes - Net of Federal Benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; 4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; 4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Permanent items and other deductions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; (4.3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; (0.5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; (20.8)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial';"&gt; (24.6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial';font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial';font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="3"
      id="Tc_XzFf4b7iMkyNW2Bkw-XVyg_3_3"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="3"
      id="Tc_qipR0PSKikyasIu8oOgeKA_3_6"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="4"
      id="Tc_RAM13ccpZ06Ng17s33UnjQ_4_3"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="4"
      id="Tc_KfoYyzf4vUaju_5rlgruRg_4_6"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="3"
      id="Tc_YdnqLVxiIEW0Ar1ofbsDuQ_5_3"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">-0.043</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="3"
      id="Tc_99cgwxrJHkemu3ZOttMXtg_5_6"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="3"
      id="Tc_8QJZ5G0vvEGSMvSrxpnGww_6_3"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">-0.208</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="3"
      id="Tc_IZsqQrJ9f0KMl-mDtN8PXA_6_6"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">-0.246</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_9jwquxZQA02xha9r0Gl3tw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6056000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_aDo5fondqEG7N9MXIPROUg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">5519000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_S53zTb_BMEGsJugnaJuOdg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-10754000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Narr_x90ienZlp0uJ_3tTKuISoQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">36250000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:CumulativeEffectOnRetainedEarningsTax1
      contextRef="Duration_1_1_2019_To_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_dwnRMOuleUGG7WL91vnSAg"
      decimals="-3"
      id="Narr_aw0s_VHLB0GFKtGHikWLAw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">0</us-gaap:CumulativeEffectOnRetainedEarningsTax1>
    <axgn:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_pv52m7zoikuufdq5oJOf0A"
      decimals="-3"
      id="Narr_M-TF5yj-Qka10WWIXAmIqQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">951000</axgn:DeferredTaxLiabilitiesRightOfUseAsset>
    <axgn:DeferredTaxAssetsRightOfUseLiability
      contextRef="As_Of_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_pv52m7zoikuufdq5oJOf0A"
      decimals="-3"
      id="Narr_NOgZszpolEmqwEmJXwIAKw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">961000</axgn:DeferredTaxAssetsRightOfUseLiability>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_qxMuVEAtD0CgAKiROdYzdQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_l9IK_i6Q70uTcIA8T9r-LA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_835OmAkTW0mctVu1U0Yp9w"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_7eOEQFCcPEiZSOp-KZLK_w">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;13.  Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company sponsors the Axogen 401(k) plan (the 401(k) Plan), a defined contribution plan covering substantially all employees of the Company.  All full-time employees who have attained the age of &lt;/span&gt;21 are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of 3% on the first 3% of the employee&#x2019;s annual salary and 1% of the next 2%&lt;span style="white-space:pre-wrap;"&gt; of the employee&#x2019;s annual salary as long as the employee participates in the 401(k) Plan. Both employee contributions and Company contributions vest immediately.  The Company contributed &lt;/span&gt;$988, $650 and $439 in matching funds during the years ended December 31, 2019, 2018 and 2017, respectively. &lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_7eeOyFQI-kyot4WSOxp9WA"
      decimals="0"
      id="Narr_0VPW2CBFFUiUJOqkGcig1w"
      unitRef="Unit_Standard_item_bQ28F0w6C0GKznH2O5VZSw">21</axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_WwMtZh6dN0OytTHyKURZmg"
      decimals="2"
      id="Narr_oAX4h2PgNUOhUwFW3chJFQ"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <axgn:DefinedContributionPlanEmployeeContributionPercentMatched
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_WwMtZh6dN0OytTHyKURZmg"
      decimals="2"
      id="Narr_1_C62FbWpka6r1-MKxEZVQ"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.03</axgn:DefinedContributionPlanEmployeeContributionPercentMatched>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_rhwnZKQoVkSq-3aU8DS-_w"
      decimals="2"
      id="Narr_SHowmfyiiEiAAiT78gD9Rg"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.01</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <axgn:DefinedContributionPlanEmployeeContributionPercentMatched
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_rhwnZKQoVkSq-3aU8DS-_w"
      decimals="2"
      id="Narr_p85CemymtkGUH8kXWmQqlg"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.02</axgn:DefinedContributionPlanEmployeeContributionPercentMatched>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_7eeOyFQI-kyot4WSOxp9WA"
      decimals="-3"
      id="Narr_MKWAO9HoOUWW0oHohoHrqQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">988000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_QtnKkZ4CLk2X_HFK_HYUZQ"
      decimals="-3"
      id="Narr_syw-e69-bEa4RvN27ezMMQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">650000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_aTc0csteMkS0guuaxwtDRQ"
      decimals="-3"
      id="Narr_CZ2l2rhUF0uC07Ho1nJQQw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">439000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_1FNV_e0a8UGT3elVOhd27g">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;14.  Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;We lease office space, medical lab and research space, a distribution center, a tissue processing center and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Certain of our leases include options for the Company to extend the lease term. None of the options were reasonably certain of exercise and therefore are not included in the measure of our lease obligations and right-to-use assets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Certain of our lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company and SNH Medical Office Properties Trust, a Maryland real estate investment trust (&#x201c;SNH&#x201d;), are parties to that certain lease dated as of February 6, 2007, as amended, (the &#x201c;Primary Lease&#x201d;) pursuant to which the Company leases its approximately &lt;/span&gt;&lt;span style="-sec-ix-hidden:_9adc0d0a_9f27_4b75_b561_f0f616fc58b6"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;nineteen&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; thousand square foot corporate headquarters facility in the Progress Center at 13631 Progress Boulevard, Alachua, Florida 32615 (the &#x201c;Primary Premises&#x201d;). The annual cost for the Primary Premises ranges from &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$353&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$363&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; through the end of the term of the lease, which expires on October 31, 2021.  On January 23, 2017 the Company entered into a lease (the &#x201c;First Expansion Lease&#x201d;) with SNH for one thousand &lt;/span&gt;&lt;span style="-sec-ix-hidden:_de7536fc_c71e_45d4_b4bd_cca7546a8119"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; hundred square feet at 13709 Progress Boulevard, Alachua, Florida 32615 (this property was purchased by Nucleic Acids Licensing, LLC in February 2019) (the &#x201c;First Expansion Premises&#x201d;) adjacent to the Primary Premises.  The Company has entered into the Second Expansion Lease and Third Expansion Lease, as defined below, which relate to properties that are adjacent to the Primary Premises and First Expansion Premises resulting in the Company having approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;twenty&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; thousand square feet for its corporate headquarters and certain research space in the Progress Center in Alachua, Florida.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On November 19, 2018, the Company entered into a Lease (the &#x201c;Second Expansion Lease&#x201d;) with SNH for two thousand &lt;/span&gt;&lt;span style="-sec-ix-hidden:_842590dc_0853_48a1_94e3_0974e859a7d8"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;eight&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; hundred square feet at 13709 Progress Boulevard, Suites S-160, S-162 and S-164, Alachua, Florida 32615 (the &#x201c;Second Expansion Premises&#x201d;). Pursuant to the Second Expansion Lease, AC is to use the Second Expansion Premises for general office uses. The Second Expansion Lease commenced December 1, 2018 and expires November 30, 2020. The annual cost of the Second Expansion Premises is approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$45&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; for the first twelve months of the term and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$46&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; for the final twelve months. The Company is also obligated to pay for certain taxes, insurance costs and electricity costs incurred by SNH.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On November 19, 2018, AC entered into a Lease (the &#x201c;Third Expansion Lease&#x201d;) with SNH for two&lt;span style="white-space:pre-wrap;"&gt; thousand square feet at 13709 Progress Boulevard, Suites S-175, S-177 and S-179, Alachua, Florida 32615 (the &#x201c;Third Expansion Premises&#x201d;). Pursuant to the Third Expansion Lease, the Company is to use the Third Expansion Premises for general office and biomedical research uses. The Third Expansion Lease commenced December 1, 2018 and its term expires November 30, 2020.  The annual cost of the Third Expansion Premises is approximately &lt;/span&gt;$37 for the first twelve months of the term and $35 for the final eleven months. The Company is also obligated to pay for certain taxes, insurance costs and electricity costs incurred by SNH.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On November 21, 2018, the Company, entered into Commercial Lease Amendment 3 (the &#x201c;Burleson Amendment&#x201d;), to the Commercial Lease dated April 21, 2015, as amended, with Ja-Cole L.P. Under the terms of the Burleson Amendment, the Company leased an additional &lt;/span&gt;&lt;span style="-sec-ix-hidden:_2049e4b8_faac_41e8_83f3_7e116573faca"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; thousand five hundred square feet of warehouse/office space in Burleson, Texas (collectively with the space leased under the Commercial Lease with Ja-Cole L.P. prior to the effectiveness of the Burleson Amendment, the &#x201c;Burleson Facility&#x201d;).  The Burleson Facility will now comprise a total of &lt;/span&gt;&lt;span style="-sec-ix-hidden:_0d926b8e_ab68_494b_9c97_8808ab1309cf"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;twelve&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; thousand five hundred square feet, all of which, pursuant to the Burleson Amendment, will be leased until April 30, 2022.  The annual rental cost of the entire Burleson Facility is now approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$113&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; through December 31, 2020, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$116&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; for the calendar year 2021 and until April 2022. The Burleson Facility houses raw material storage and product distribution while allowing same day order fulfillment for both the east and west coasts of the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On October 26, 2018, the Company entered into a Lease (the &#x201c;Ashley Avenue Lease&#x201d;) with Ashley Avenue Associates I, LLC., a Delaware limited liability company (&#x201c;Ashley&#x201d;), for the lease by the Company of approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;fifteen&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; thousand square feet of office space on the second floor of the building located at 1000 N. Ashley Drive, Tampa, Florida 33602 (the &#x201c;Ashley Avenue Premises&#x201d;).  Pursuant to the Ashley Avenue Lease, the Company will use the Ashley Avenue Premises for general office purposes.  The initial term of the Ashley Avenue Lease commenced on December 1, 2018 and expires on November 30, 2020. The Company has an option to terminate the lease after &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;eighteen months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; by providing Ashley with &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;four months&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; advance written notice.  The rental cost for the Ashley Avenue Premises will be &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$381&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; for the first twelve month period, and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$360&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; for the final eleven month period. The Company will also be obligated to pay for its pro rata share of the building&#x2019;s property taxes, utilities, administrative costs, common area maintenance and management fees, excluding any capital improvements or any damage due to fire, hurricane or other casualty.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On September 20, 2018, the Company entered into an agreement with Heights Union, LLC, a Florida limited liability company (&#x201c;Heights Union&#x201d;), for the lease of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;seventy-five&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; thousand square feet of office space (the &#x201c;Heights Union Premises&#x201d;) in a one &lt;/span&gt;&lt;span style="-sec-ix-hidden:_8737cf0c_5377_4487_aceb_781cdeb5b2e6"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;hundred and fifty&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; thousand square foot office building that Heights Union intends to construct and complete on or before September 30, 2020, on an area of land in Tampa, Florida.  Pursuant to the Heights Union lease, the Company will use the Heights Union Premises for general office, medical laboratory, training and meeting purposes.  The annual costs of the Heights Union Premises ranges from &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2,400&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$3,308&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; during the term of the lease. Axogen believes it can obtain certain economic incentives from state authorities associated with the employment at the facility; such incentives are not expected to be a material offset to the expenses of the project as a whole.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In addition, Axogen leases space and maintains records at certain other facilities, including the Company&#x2019;s prior corporate headquarters at 1407 South Kings Highway, Texarkana, Texas 75501.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The components of total lease expense for the year ended December 31, 2019 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;For the Fiscal Year Ended December 31, 2019:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance lease costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Amortization of right-to-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short term lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,994&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The short-term lease cost shown above reasonably reflects the Company&#x2019;s ongoing short-term lease commitment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Supplemental balance sheet information related to leases as of December 31, 2019 was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Tc_A4Fx7oi8o0qgiyXaY11oBA_4_0"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Current maturities of long-term obligations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Tc_iS9N_npf70GWW2V_ErRjnw_5_0"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Long term obligations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Current maturities of long-term obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Long term obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Other information related to leases was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,773&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-to-use assets obtained in exchange for new finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average remaining lease term - finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average remaining lease term - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average discount rate - finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.28%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average discount rate - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.28%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The weighted-average discount rate for the majority of the Company&#x2019;s leases is based on the Company&#x2019;s estimated incremental borrowing rate since the rates implicit in the leases were not determinable. The Company&#x2019;s incremental borrowing rate is based on Management&#x2019;s estimate of the rate of interest the Company would have to pay to borrow on a fully collateralized basis over a similar term an amount equal to the lease payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Future minimum lease payments under non-cancellable leases as of December 31, 2019 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,664&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,007&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,573&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,581&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,644&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total Future Minimum Lease Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,720&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less future payments for leases that have not yet commenced&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (38,246)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less imputed interest on commenced leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (190)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Tc_pGofsY-zPU6ke-fO75b00A_12_0"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Total Lease Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The lease for office space in Tampa, Florida with Heights Union, LLC, a Florida limited liability company, has not commenced and is therefore not included in the measurement of right-to-use assets and lease liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As previously disclosed in our 2018 Annual Report on Form 10-K, which followed the lease accounting guidance prior to our adoption of ASC 842, future commitments relating to noncancelable operating and capital leases as of December 31, 2018 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Capital&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,866&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,970&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,574&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,579&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Total rent expense for the Company&#x2019;s leased office and lab space for the years ended December&#160;31, 2019, 2018 and 2017 was $516, $484 and $494, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Service Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;On August 6, 2015, Axogen entered into a License and Services Agreement with Community Blood Center (d/b/a Community Tissue Services) (&#x201c;CTS&#x201d;), Dayton, Ohio, an FDA registered tissue establishment.  Processing of the Avance Nerve Graft pursuant to the CTS agreement began in February 2016.  Subsequent to the year ended December 31, 2018, on February 22, 2019, Axogen Corporation and CTS entered into a fourth amendment to the License and Services Agreement wherein the term of the agreement was extended such that the Occupancy Date in section 12.01 of the agreement shall end on December 31, 2021, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#x2019;s right to cure, in certain circumstances), or by Axogen without cause upon six months&#x2019; prior notice, &lt;/span&gt;whereby notice cannot be provided prior to March 1, 2021&lt;span style="white-space:pre-wrap;"&gt;.  Under the CTS agreement Axogen pays CTS a facility fee for clean room/manufacturing, storage and office space, which has been determined to be an embedded operating lease.  CTS also provides services in support of Axogen&#x2019;s manufacturing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support.  &lt;/span&gt;Pursuant to the CTS Agreement, Axogen pays license fees and the operating lease amounts, on a monthly basis to CTS which total an annual amount of approximately $2,148 for the year ended December 31, 2019, $1,931 for the year ended December 31, 2018 and $1,409 for the year ended December 31, 2017.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December&#160;&lt;span style="white-space:pre-wrap;"&gt;2011, the Company also entered into a Master Services Agreement for Clinical Research and Related Services.  The Company was required to pay &lt;/span&gt;$151&lt;span style="white-space:pre-wrap;"&gt; upon execution of this agreement and the remainder monthly based on activities associated with the execution of Axogen&#x2019;s phase 3 pivotal clinical trial to support a BLA for Avance Nerve Graft.    &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In August&#160;2008, the Company entered into an agreement to distribute the Axoguard Nerve Connector and Nerve Protector products worldwide in the field of peripheral nerve repair, and the parties subsequently amended the agreement on February 26, 2018. Pursuant to the February 2018 amendment, the agreement expires on June 30, 2027. The Cook Biotech Distribution Agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforced such provision, and establishes a formula for the transfer cost of the Axoguard products. Under the Distribution Agreement, Axogen provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In June 27, 2017, the Company entered into the Nerve End Cap Supply Agreement with Cook Biotech whereby Cook Biotech is the exclusive contract manufacturer of the Axoguard Nerve Cap and both parties have provided the other party the necessarily licenses to their technologies for operation of the Supply Agreement.  The Supply Agreement has a term through August 27, 2027, provided, however, that after June 27, 2022, either party may terminate the Supply Agreement upon 90 days written notice.  Under the Supply Agreement Axogen provides purchase orders to Cook Biotech and Cook Biotech fulfills the purchase orders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Certain executive officers of the Company are parties to employment contracts.  Such contracts have severance payments for certain conditions including change of control.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Concentrations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Vendor&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Substantially all of Axogen&#x2019;s revenue is currently derived from four&lt;span style="white-space:pre-wrap;"&gt; products, Avance Nerve Graft, Axoguard Nerve Protector, Axoguard Nerve Connector and Avive Soft Tissue Membrane.  Axogen has an exclusive distribution agreement with Cook Biotech for the purchase of Axoguard Nerve Connector and Axoguard Nerve Protector which expires &lt;/span&gt;June 30, 2027.&lt;span style="white-space:pre-wrap;"&gt;  The Cook Biotech Distribution Agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforced such provision, and establishes a formula for the transfer cost of the Axoguard Nerve Connector and Axoguard Nerve Protector.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:6pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;The agreement allows for termination provisions for both parties.  Although there are products that Axogen believes it could develop or obtain that would replace the Axoguard products, the loss of the ability to sell the Axoguard&lt;/span&gt;&lt;span style="font-size:6.5pt;vertical-align:super;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;products could have a material adverse effect on Axogen&#x2019;s business until other replacement products would be available.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Processor&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Axogen is highly dependent on the continued availability of its processing facilities at CTS and could be harmed if the physical infrastructure of this facility is unavailable for any prolonged period of time.  In addition, disruptions could lead to significant costs and reductions in revenues, as well as a potential harm to the Axogen&#x2019;s business reputation and financial results. The CTS agreement terminates December 31, 2021, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#x2019;s right to cure, in certain circumstances), or by Axogen without cause, upon 6 months&#x2019; prior notice, &lt;/span&gt;whereby notice cannot be provided prior to March 1, 2021&lt;span style="white-space:pre-wrap;"&gt;.  Although Axogen believes it can find and make operational a new facility in less than six months &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;if required. In addition, Axogen acquired property which is located near the CTS facility and it is expected that renovations will be completed by the termination date of the CTS Agreement to provide a new processing facility that can be included in our BLA for the Avance Nerve Graft. However, the regulatory process for approval of facilities whether licensed or owned is time-consuming and unpredictable.  Axogen&#x2019;s ability to license, renovate, rebuild or find acceptable service facilities takes a considerable amount of time and expense and could cause a significant disruption in service to its customers if it were to lose the availability of it production or distribution facilities.  &lt;/span&gt; Although Axogen has business interruption insurance which would, in instances other than lease termination, cover certain costs, it may not cover all costs nor help to regain Axogen&#x2019;s standing in the market.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In July 2018, Axogen purchased a facility (the &#x201c;APC&#x201d;) in Vandalia, Ohio, located near the CTS processing facility where Avance Nerve Graft and Avive Soft Tissue Membrane are currently processed.  The APC, when and if operational, will be &lt;/span&gt;the new processing facility for Avance&#160;Nerve Graft and Avive Soft Tissue Membrane&#160;to provide continued capacity for growth and to support the transition of Avance Nerve Graft from a 361 HCT/P tissue product to a&#160;&lt;span style="white-space:pre-wrap;"&gt;biologic product.  The APC &lt;/span&gt;is comprised of a 70,000 square foot building on approximately 8.6&lt;span style="white-space:pre-wrap;"&gt; acres of land.  The Company paid &lt;/span&gt;$731&lt;span style="white-space:pre-wrap;"&gt; for the land and is recorded as Land within our property and equipment account on our balance sheet.   The Company paid &lt;/span&gt;$4,300 for the building and this is recorded as projects in process as part of the property and equipment on the balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On July 9, 2019,&#160;Axogen&#160;entered into a Standard Form of Agreement Between Owner and Design-Builder (the &#x201c;Design-Build Agreement&#x201d;) with CRB Builders, L.L.C., a Missouri limited liability company (&#x201c;CRB&#x201d;),&#160;pursuant to which CRB will renovate and retrofit the APC.&#160; The Design-Build Agreement contains several design phase milestones that began in July 2019 and sets the&#160;date for Substantial Completion (as defined in the Design-Build Agreement)&#160;in the third quarter of 2020, subject to adjustment in accordance with the terms of the Design-Build Agreement.&#160;The estimated cost pursuant to the Design-Build Agreement&#160;is $29,000. &#160;Additional costs associated with the renovation, purchasing of furniture and equipment,&#160;validation and certification of the APC are estimated to be $14,400.&#160;&#160;&lt;span style="white-space:pre-wrap;"&gt;These capital expenditure costs will be incurred as they arise until the anticipated full transition of material processing to the APC by early 2022.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;As of December 31, 2019, the Company has recorded &lt;/span&gt;$6,066 related to renovations and design build. These items are recorded as projects in process as part of the property and equipment on the balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Axogen expects to receive certain economic development grants from state and local authorities totaling up to $2,685 including $1,250 of cash grants to offset costs to acquire and develop the APC.&#160; The economic development grants are subject to certain job creation milestones by 2023 and related contingencies.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As previously disclosed the Company previously entered into an agreement with Heights Union, LLC, a Florida limited liability company (&#x201c;Heights Union&#x201d;), for the lease of seventy-five thousand square feet of office space.&#160; Pursuant to the Heights Union lease, the Company will use the Heights Union Premises for general office, medical laboratory, training and meeting purposes.&#160;&#160;The Company anticipates occupying the premises by the second quarter of 2020.&#160; Associated with the lease, the Company anticipates spending up to $9,833 for leasehold improvements, equipment and furniture and fixtures.&#160; As of December 31, 2019, the Company has recorded $441 of leasehold improvements to the new facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Litigation &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;On January 9, 2019, Plaintiff Neil Einhorn, on behalf of himself and others similarly situated, filed a putative class action complaint in the United Stated District Court for the Middle District of Florida alleging violations of the federal securities laws against Axogen, Inc., certain of its directors and officers (&#x201c;Individual Defendants&#x201d;), and Axogen&#x2019;s 2017 Offering Underwriters and 2018 Offering Underwriters (collectively, with the Individual Defendants, the &#x201c;Defendants&#x201d;), captioned Einhorn v. Axogen, Inc., et al., No. 8:19-cv-00069 (M.D. Fla.).  Plaintiff asserts that Defendants made false or misleading statements in connection with the Company&#x2019;s November 2017 registration statement issued regarding its secondary public offering in November 2017 and May 2018 registration statement issued regarding its secondary public offering in May 2018, and during a class period of August 7, 2017 to December 18, 2018.   In particular, Plaintiff asserts that Defendants issued false and misleading statements and failed to disclose to investors: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company&#x2019;s pricing alienated customers and threatened the Company&#x2019;s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company&#x2019;s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company&#x2019;s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company&#x2019;s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company&#x2019;s key operating metrics, such as number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants&#x2019; positive statements about the Company&#x2019;s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.  Axogen was served on January 15, 2019.  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;On February 4, 2019, the court granted the parties&#x2019; stipulated motion which provided that Axogen is not required to file a response to the complaint until &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;thirty days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;after Plaintiff files a consolidated amended complaint.&#160;On June 19, 2019, Plaintiff filed an Amended Class Action Complaint, and on July 22, 2019, Defendants filed a motion to dismiss. Plaintiff filed opposing papers on August 12, 2019. The Court held a status hearing on September 11, 2019 and stayed all deadlines regarding the parties&#x2019; obligations to file a case management report. On December 4, 2019 the parties&#x2019; presented oral arguments and are currently awaiting the court&#x2019;s ruling.&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;  Plaintiff is seeking compensatory damages, reimbursement of expenses and costs, including counsel and expert fees and such other relief as the court deems just and proper. The Company and Individual Defendants dispute the allegations and intend to vigorously defend against the Complaint.  The amount of loss, if any, cannot be reasonably estimated at this time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;Jackson v. Zaderej, et al., No. 8:19-cv-01976 U.S. District Court (M.D. FL). On August 12, 2019, Plaintiff Harvey Jackson, derivatively on behalf of Axogen, filed a verified shareholder derivative complaint for violations of securities laws, breach of fiduciary duty, waste of corporate assets and unjust enrichment against Quentin S. Blackford, Gregory G. Freitag, Mark Gold, Jamie M. Grooms, Alan M. Levine, Peter J. Mariani, Guido Neels, Robert J. Rudelius, Amy Wendell, and Karen Zaderej (the &#x201c;Individual Defendants&#x201d;) and Nominal Defendant Axogen, Inc. (&#x201c;Axogen&#x201d;) (collectively, &#x201c;Defendants&#x201d;).  Plaintiff asserts that the Individual Defendants, who are current or former Axogen officers or directors, issued a false proxy statement for the election of directors in violation of Section 14(a) of the Securities Exchange Act of 1934, breached their fiduciary duties, wasted corporate assets and were unjustly enriched by allowing &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;Axogen to make false public statements to investors based on the same claims in the report issued December 18, 2018 by Seligman Investments (the same allegations that form the basis for the Einhorn matter and the Bussey shareholder demand).  Plaintiff demands judgment in the Company&#x2019;s favor against all Individual Defendants as follows: (A) declaring that Plaintiff may maintain this action on behalf of Axogen, and that Plaintiff is an adequate representative of Company; (B) declaring that the Individual Defendants have breached and/or aided and abetted the breach of their fiduciary duties to Axogen; (C) determining and awarding to Axogen the damages sustained by it because of the violations set forth above from each of the Individual Defendants, jointly and severally, together with pre- and post-judgment interest thereon; (D) directing Axogen and the Individual Defendants to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable laws and protect Axogen and its shareholders from a repeat of the damaging events described therein, including, but not limited to, putting forward for shareholder vote the following resolutions for amendments to the Company&#x2019;s Bylaws or Articles of Incorporation and the following actions as may be necessary to ensure proper corporate governance policies: (i)  a proposal to strengthen the Board&#x2019;s supervision of operations and develop and implement procedures for greater shareholder input into the policies and guidelines of the Board, (ii) a provision to permit the shareholders of Axogen to nominate at least &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; candidates for election to the Board; and (iii) a proposal to ensure the establishment of effective oversight of compliance with applicable laws, rules, and regulations; (E) awarding Axogen restitution from Individual Defendants, and each of them; (F) awarding Plaintiff the costs and disbursements of this action, including reasonable attorneys&#x2019; and experts&#x2019; fees, costs, and expenses; and (G) granting such other and further relief as the Court may deem just and proper.  The Defendants filed a motion to dismiss on October 22, 2019.  In response, Plaintiffs voluntarily withdrew their complaint and the matter was dismissed without prejudice by the court on November 5, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;Novitzki v. Zaderej, et al, 19-CA-11745 DIV L (13th Judicial Circuit, Hillsborough Cnty., Fl.).  On November 11, 2019,  Plaintiff Joseph Novitzki, derivatively on behalf of Axogen, filed a verified stockholder derivative complaint for breach of fiduciary duty, waste of corporate assets and unjust enrichment against Karen Zaderej,  Gregory G. Freitag, Peter J. Mariani, Amy Wendell, Robert J. Rudelius, Mark Gold, Guido Neels, and Jamie M. Grooms (the &#x201c;Individual Defendants&#x201d;) and Nominal Defendant Axogen, Inc. (&#x201c;Axogen&#x201d;) (collectively, &#x201c;Defendants&#x201d;). Plaintiff asserts that the Individual Defendants, who are current or former Axogen officers or directors, breached their fiduciary duties, wasted corporate assets and were unjustly enriched by allowing Axogen to make false public statements to investors based on the same claims in the report issued December 18, 2018 by Seligman Investments (the same allegations that form the basis for the Einhorn matter and the Bussey shareholder demand).  Plaintiff demands judgment in the Company&#x2019;s favor against all Individual Defendants as follows: (a) against all of the defendants and in favor of the Company for the amount of damages sustained by the Company as a result of the defendants' breaches of fiduciary duties, waste of corporate assets, and unjust enrichment; (B) directing Axogen to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable laws and to protect Axogen and its stockholders from a repeat of the damaging events described herein, including, but not limited to, putting forward for stockholder vote, resolutions for amendments to the Company's Bylaws or Articles of Incorporation and taking such other action as may be necessary to place before stockholders for a vote of the following corporate governance policies: (1) directing Axogen to employ an independent, third-party expert to calculate the Company's market size (including the dollar values of Axogen's total addressable market and portion of the market relating to extremity trauma and OMF); (2) a provision to control insider selling; (3) a proposal to strengthen Axogen's oversight of its disclosure procedures; (4) a proposal to strengthen the Company's controls over financial reporting; (5) a proposal to strengthen the Board's supervision of operations and develop and implement procedures for greater stockholder input into the policies and guidelines of the Board; and (6) a provision to permit the stockholders of Axogen to nominate at least &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; candidates for election to the Board; (C) extraordinary equitable and/or injunctive relief as permitted by law, equity, and state statutory provisions sued hereunder, including attaching, impounding, imposing a constructive trust on, or otherwise restricting the proceeds of defendants' trading activities or their other assets so as to assure that plaintiff on behalf of Axogen has an effective remedy; (D) Awarding to Axogen restitution from defendants, and each of them, and ordering disgorgement of all profits, benefits, and other compensation obtained by the defendants, including all ill-gotten gains from insider selling by defendants; (E) awarding to plaintiff the costs and disbursements of the action, including reasonable attorneys' fees, accountants' and experts' fees, costs, and expenses; and (F) granting such other and further relief as the Court deems just and proper.  After Defendants&#x2019; counsel had multiple discussions with Plaintiff&#x2019;s counsel pointing out that it&#x2019;s complaint was deficient for the same reasons argued in Jackson, the Plaintiff agreed to voluntarily dismiss the complaint without prejudice, which the court so-ordered on January 24, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;These matters are subject to various uncertainties and it is possible that it may be resolved unfavorably to the Company.  However, while it in not possible to predict with certainty the outcome of the matter, the Company and the Individual Defendants dispute the allegations and intend to vigorously defend themselves.  &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_fWIoGNsj7Ui2pXQ3bkgU4Q"
      decimals="-3"
      id="Narr_U2ylJFekxkav2rbvpwB7Ow"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">353000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_bByFAiGDsEK9OCAVsqZANg"
      decimals="-3"
      id="Narr_m5y9sYQeM0SXEriISDmrtA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">363000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_tglKryFxhkq8-SAK4HEuzg"
      decimals="0"
      id="Narr_8COppuYo-EOgBtzv81RDlg"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">20000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_oujYrCpym0y45N14NxtAYQ"
      decimals="-3"
      id="Narr_tya6AOvpnESnPQoK5QAtBA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">45000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_SecondExpansionLeaseMember_U9D1ulBaeUqvJJI4uvH5oA"
      decimals="-3"
      id="Narr_Y-1jPOQN8keA3_JpVT8p6Q"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">46000</us-gaap:LeaseAndRentalExpense>
    <axgn:AreaOfRealEstatePropertyAdditional
      contextRef="As_Of_11_19_2018_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_V5WUDuaOrka-roEinNbOxA"
      decimals="0"
      id="Narr_kfJxqomY90CUM1foeQZQVw"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">2000</axgn:AreaOfRealEstatePropertyAdditional>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_NXRoZ-NBZ0ePelC05RSaqg"
      decimals="-3"
      id="Narr_2kKvzcWOVkqYRvZyt3_KZQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">37000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_11_19_2018_To_11_19_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_us-gaap_TypeOfArrangementAxis_axgn_ThirdExpansionLeaseMember_IsEezefk-Eu1CFK7CxX86A"
      decimals="-3"
      id="Narr_gtO3_urEu0CkDQdMcV0qaA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">35000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_V4e6rd3wUEG9C3qE3Hpw-w"
      decimals="-3"
      id="Narr_-8XkohERV0S7stot3Ms8dw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">113000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_JaColeMember_KuQDicj1c0SnADAaZVmqbQ"
      decimals="-3"
      id="Narr_Rt_hdB_1lE-CLUIcxTpVxw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">116000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_x4yTeLpiWEyE5kq91aXN1A"
      decimals="0"
      id="Narr_xjYPBbAP40KBrOQ0JQiBXw"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">15000</us-gaap:AreaOfRealEstateProperty>
    <axgn:EarlyTerminationPeriod
      contextRef="Duration_10_26_2018_To_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_DNUFWr2HVU6UI2RUpDclJQ"
      id="Narr_eHnKIlW5ukujpy8wd4MAAA">P18M</axgn:EarlyTerminationPeriod>
    <axgn:NoticePeriodForTerminationOfAgreement
      contextRef="Duration_10_26_2018_To_10_26_2018_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_DNUFWr2HVU6UI2RUpDclJQ"
      id="Narr_bRqt2VW5sEK62kQMlRxlqg">P4M</axgn:NoticePeriodForTerminationOfAgreement>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_NnCe9k1NpUacLG-xMiiljw"
      decimals="-3"
      id="Narr_sW5S5MIRb0mig9caCmxxjQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">381000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_AshleyAvenueLeaseMember_ZUL32-Ode0O5GUOiGbojiA"
      decimals="-3"
      id="Narr_S0ZbmkKhnkaW-oXTLDSZSQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">360000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_20_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_kMJbk8ZcGUK3JDwkyBnNog"
      decimals="0"
      id="Narr_HChMeb8vUUSfrujLoM3oYQ"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">75000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_ZBGX0n3gPUucFdPYU_PIgg"
      decimals="-3"
      id="Narr_OJORAtvft0qJ3IkrntpjXA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2400000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionPremisesMember_Pwl4eK2_UkO9SelPSqHkRg"
      decimals="-3"
      id="Narr_J4-enbzRUUme2ijAw0HtUA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3308000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_t4KvIghRlUK_d8SSgmSeUA">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;For the Fiscal Year Ended December 31, 2019:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance lease costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Amortization of right-to-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short term lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,994&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_uPZSIXRCLUq-WFWXOlJtbA_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">22000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_nGjx_d1jwU6wZ3zKLhS61w_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_BU2pGiXtqEaxfbeaSkxOBA_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1910000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_cK0qEWaCpkC8KbHeI-mPKA_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">41000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_vOue4WYqKUSfShtxZYTptA_8_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_QHdVLRsdcEKQ706augjTWA_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1994000</us-gaap:LeaseCost>
    <axgn:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_ZzB_Gw_SHUaRWetZkYyZMw">&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Tc_A4Fx7oi8o0qgiyXaY11oBA_4_0"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Current maturities of long-term obligations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Tc_iS9N_npf70GWW2V_ErRjnw_5_0"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Long term obligations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Current maturities of long-term obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Long term obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</axgn:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_H8aUcCLkkEq1B_z62y0IAA_3_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3133000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_aRB8_r_DEEeqkTWxfUF2-A_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1719000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_9MJpl1n8_0KWbUcV4f216A_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1565000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_aS9s_fxNkUKAg3Wy4XT5bg_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">87000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_XCzsWLNfHkGtiz2mvo1v5w_8_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_sldT4kiTGkyDZhapHglLRw_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <axgn:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_1uWn7DRPdkqHxfdePtYbVw">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,773&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-to-use assets obtained in exchange for new finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average remaining lease term - finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average remaining lease term - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average discount rate - finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.28%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average discount rate - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.28%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</axgn:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_LGteJM8PUEqaTucB89_OxQ_2_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1773000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_lreyMzE3LEGp0oe4M57ZfA_3_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">16000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      id="Tc_bGPOge2tNU65eWg-JgTRpQ_4_3">P3Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      id="Tc_3i7cU-OsN0S3C6VZE-2Lsg_5_3">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="4"
      id="Tc_rMUthb2qNEas4dVdnyoiXw_6_3"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.0728</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="4"
      id="Tc_yzzyRxl8CEemdnXRdHL0BQ_7_3"
      unitRef="Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q">0.0628</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <axgn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_RQylyzh-1E62bEvnJbCMeg">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,664&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,007&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,573&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,581&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,644&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total Future Minimum Lease Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,720&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less future payments for leases that have not yet commenced&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (38,246)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less imputed interest on commenced leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (190)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Tc_pGofsY-zPU6ke-fO75b00A_12_0"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Total Lease Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</axgn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_jQ7ijQjzok6vEBHsRT6m9Q_3_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2664000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_LUTTeHjl2kCHcaZ14sFmcw_3_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">19000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_EKQSx63wWUKdT8Qjhzj8hw_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4007000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_GFLQbA4NKEu682toRuPtVA_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">19000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_kNj4wal26E-Fcli9HHeQdQ_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2573000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_1vx6GuDslEOgkP4gqG5Zyw_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_Gp7p4SpnuUSjRGeiSJ9rbQ_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2581000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_5h8iSKnMoEebX76U0OEdiQ_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_6qmNS66Oekm6EsYYcWqxjA_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2644000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_Pcn1j929aEiv0dwRj6wbDA_7_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_XbwSRyPFMkGYuWwqGZOJFQ_8_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">27251000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_xHHQ_i5oVEG72G6450kZIQ_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">41720000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_sxJtbnqGgkCA9CP8gyaB2w_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">52000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <axgn:LesseeOperatingLeaseLiabilityFuturePaymentsAmount
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_ChxF1u4sSE6bT2Kb0y6uFg_10_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">38246000</axgn:LesseeOperatingLeaseLiabilityFuturePaymentsAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_59mNXASw4EqyynsAoOPFLw_11_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">190000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_DcWAgnVxB0iSn8Z9lkDp6g_11_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">5000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_SKvStTcQ2UGb9I4KH2kEpQ_12_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3284000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw"
      decimals="-3"
      id="Tc_i5kmAdzrVUSt0qylsTCo-Q_12_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">47000</us-gaap:FinanceLeaseLiability>
    <axgn:ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_XWsjmXWyZkOIxsoOIuhdFg">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Capital&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,866&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,970&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,574&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,579&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</axgn:ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_4q4nKL5lYUiUaVfTmXfiTw_3_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1866000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_d_wo1B_uxUymvx3RiLDb7Q_3_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_dbnJ2PcF30yHDdkMuz_ETQ_4_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2540000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_z5hCbHN_706w-MByAgmxPw_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">13000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_t-jjKoNuVUWbRpxaNxgiiQ_5_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">3970000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_omkhM29lZEO_dye52rbQ2g_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">15000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_aatYkIGaCkSloEd8lFVmtw_6_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2518000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_f1fj7snzIUWAT_9vqtEh6w_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">7000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_MVHXTLgPl0ufKEZw0BOABA_7_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2574000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_3tImnYJ25UKDNqwMk0UAgg_8_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">30111000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_ju98FT1Ci0610eFmTUIpzg_9_3"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">43579000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue
      contextRef="As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ"
      decimals="-3"
      id="Tc_Ab1dpZ7PYUuRQjTlHM6XyA_9_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">63000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Narr_kSXXSg4rmU65EaD-WsDxfA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">516000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Narr_037Kkv6Bz02nMMBfQGakPA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">484000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="Duration_1_1_2017_To_12_31_2017_yc4BKvGffUmKsOTdz6ruxA"
      decimals="-3"
      id="Narr_RN3jqktS00OJQ2uQYD_ZFg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">494000</us-gaap:OperatingLeasesRentExpenseNet>
    <axgn:LicenseFeeAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_w7VPQT2pRkub_N0KQzm0eg"
      decimals="-3"
      id="Narr_6TyLd2Dack-sf9ZJy_vMyw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2148000</axgn:LicenseFeeAmount>
    <axgn:LicenseFeeAmount
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_re7GROPgKUaFj-ZkUJDT4A"
      decimals="-3"
      id="Narr_6a4T44UZS0GPQTo8OX7RjA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1931000</axgn:LicenseFeeAmount>
    <axgn:LicenseFeeAmount
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_xCSHLZgiMUuIzNw6sSuFGw"
      decimals="-3"
      id="Narr_CKa10Z2_n0yZRyqgOCiiVA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1409000</axgn:LicenseFeeAmount>
    <axgn:ServiceAgreementAmountPaidUponExecutionOfAgreement
      contextRef="Duration_12_1_2011_To_12_31_2011_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_vqWblD6hEkiSy0wcGyIdzA"
      decimals="-3"
      id="Narr_x5SYQJTCBk6w50i8ggYEgA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">151000</axgn:ServiceAgreementAmountPaidUponExecutionOfAgreement>
    <axgn:NumberOfProductsFromWhichRevenueIsDerived
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_XwSdGg8qkECo4xeg2jamwA"
      decimals="INF"
      id="Narr_Fwuy7K3aFkKJGGxK64ow-Q"
      unitRef="Unit_Standard_item_bQ28F0w6C0GKznH2O5VZSw">4</axgn:NumberOfProductsFromWhichRevenueIsDerived>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_7_31_2018_9F5KGFk5ekOKV8bdqwW0vQ"
      decimals="0"
      id="Narr_i5SCw2SC10e_SzVLoSiUHg"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">70000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfLand
      contextRef="As_Of_7_31_2018_9F5KGFk5ekOKV8bdqwW0vQ"
      decimals="1"
      id="Narr_Y77DPVpZFk6M6b_yxB1QjQ"
      unitRef="Unit_Standard_acre_uQoen29RI0aO7YAQ0QAY8Q">8.6</us-gaap:AreaOfLand>
    <us-gaap:PaymentsToAcquireLandHeldForUse
      contextRef="Duration_7_1_2018_To_7_31_2018_pDS8UW-ipEGiRfiHlv5kzg"
      decimals="-3"
      id="Narr_lKOra9J210yLnvS3Oj8yQg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">731000</us-gaap:PaymentsToAcquireLandHeldForUse>
    <us-gaap:PaymentsToAcquireBuildings
      contextRef="Duration_7_1_2018_To_7_31_2018_pDS8UW-ipEGiRfiHlv5kzg"
      decimals="-3"
      id="Narr_fMn0OWlVVUumKFHafJtLlg"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">4300000</us-gaap:PaymentsToAcquireBuildings>
    <axgn:EstimatedCostRelatingToDesignBuildAgreement
      contextRef="As_Of_7_9_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_k2AvsINLE0CA1hy04sZUqg"
      decimals="-3"
      id="Narr_wG_0zDYkP0ijcjJaMh9JBQ"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">29000000</axgn:EstimatedCostRelatingToDesignBuildAgreement>
    <axgn:AdditionalCostsAssociatedWithDesignBuildAgreement
      contextRef="As_Of_7_9_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_k2AvsINLE0CA1hy04sZUqg"
      decimals="-3"
      id="Narr_stdi_CF4EEGX2kYF0OkP8A"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">14400000</axgn:AdditionalCostsAssociatedWithDesignBuildAgreement>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="As_Of_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_QK4ED2K6qEOV1Xg1-zGj_A"
      decimals="-3"
      id="Narr_tsp6z14StUqFFg4DoMb5Bw"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">6066000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_7_9_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_1bIsEkV_FkmHurO56ABv6Q"
      decimals="-3"
      id="Narr_Da19SMgVaUu6XGdu8deKWA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">2685000</us-gaap:GrantsReceivable>
    <axgn:CashGrantsReceivable
      contextRef="As_Of_7_9_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_DesignBuildAgreementMember_1bIsEkV_FkmHurO56ABv6Q"
      decimals="-3"
      id="Narr_xfPGGviueEuZbE-X15QTbA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1250000</axgn:CashGrantsReceivable>
    <us-gaap:AreaOfLand
      contextRef="As_Of_9_30_2018_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_4tCIYMnwyk6Ob6QqnDHXvg"
      decimals="-3"
      id="Narr_X2cYLHJZfkaJ16q9aMjUXQ"
      unitRef="Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA">75000</us-gaap:AreaOfLand>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="As_Of_6_30_2020_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_NtuCJ8sKq0qVnPGFTPpTwQ"
      decimals="-3"
      id="Narr_VrlpJA7tXEKQ7Rd3mcbo-Q"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">9833000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_HeightsUnionMember_2g6PdNw7sEqA9_PlVqHxDA"
      decimals="-3"
      id="Narr_FQZMR0ntg02e38mP4wXEeA"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">441000</us-gaap:BuildingsAndImprovementsGross>
    <axgn:ThresholdPeriodForNotFilingResponseToComplaint
      contextRef="Duration_2_4_2019_To_2_4_2019_ln_X-b6a80Wb7o__1q1OhQ"
      id="Narr_jiGmRpj86kmGBPGmZ5zCbw">P30D</axgn:ThresholdPeriodForNotFilingResponseToComplaint>
    <axgn:MinimumNumberOfCandidateElectedToBoard
      contextRef="As_Of_8_12_2019_srt_LitigationCaseAxis_axgn_NovitzkiVsZaderejMember_zFX_2N4KPUasTY6aVIbF6Q"
      decimals="INF"
      id="Narr_RipZ_TRogECH_54qD_PA4w"
      unitRef="Unit_Standard_individual_c5Uqr2HKeUq8VhVxnbwwzQ">6</axgn:MinimumNumberOfCandidateElectedToBoard>
    <axgn:MinimumNumberOfCandidateElectedToBoard
      contextRef="As_Of_11_11_2019_srt_LitigationCaseAxis_axgn_NovitzkiVsZaderejMember_IYCkqEqibkCICffbHpaANQ"
      decimals="INF"
      id="Narr_7qaHi8Eg5kOmkw3h8PEBdQ"
      unitRef="Unit_Standard_individual_c5Uqr2HKeUq8VhVxnbwwzQ">3</axgn:MinimumNumberOfCandidateElectedToBoard>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_qroj44DO1kOYyh-H2igJIQ">&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;15.  Quarterly Results of Operations (Unaudited)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following is a summary of the quarterly results of operations for the years ended December 31, 2019 and 2018:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quarter&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;First&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Second&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Third&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fourth&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,285&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,701&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,564&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,162&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,504)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,022)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,571)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,038)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,135)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Loss per common share - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.24)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.74)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,260&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,584&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,660&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,433&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,937&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,196&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 71,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,427)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,102)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,224)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,397)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Loss per common share - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.60)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_vAOJbljVB0muyYrkxwH5_A">&lt;p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quarter&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;First&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Second&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Third&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fourth&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,285&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,701&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,564&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,162&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,504)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,022)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,571)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,038)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,135)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Loss per common share - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.24)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.74)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,260&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,584&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,660&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,433&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,937&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,196&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 71,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,427)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,102)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,224)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,397)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Loss per common share - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.60)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw"
      decimals="-3"
      id="Tc_uVtV6574W0WFhAPddRljew_4_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">23285000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg"
      decimals="-3"
      id="Tc_K_lyCgFIZkeX-_CAUZFhBQ_4_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">26701000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg"
      decimals="-3"
      id="Tc__MSenSayT0-ej2zFP3pG2w_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28564000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg"
      decimals="-3"
      id="Tc_kKijsOmx-UO7RoaKo3WX9g_4_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28162000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_bxOCOJX190CfOdMJyN9FwQ_4_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">106712000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw"
      decimals="-3"
      id="Tc_awZiZuFZyEK_n-kZydB8kQ_5_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">19571000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg"
      decimals="-3"
      id="Tc_9QBdHDzF3kymw5oaLb7a1w_5_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">22457000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg"
      decimals="-3"
      id="Tc_OcSVxFNQYU-wEvdG_ixFrA_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">24054000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg"
      decimals="-3"
      id="Tc_QGNIeseffE-jMdfg4MB8bA_5_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">23281000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_id1wwklyrU-c8B8Q9i0DHA_5_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">89363000</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw"
      decimals="-3"
      id="Tc_p6UEQvFYD0e8NPuLUz-7dA_6_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-9504000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg"
      decimals="-3"
      id="Tc_96I6eaVlhUGzZhSHyfGI9A_6_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-7022000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg"
      decimals="-3"
      id="Tc_-SwQ3Jo-ukW72s-A3iGTyg_6_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-5571000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg"
      decimals="-3"
      id="Tc_DroqQIwtk0-S0B29CY20cA_6_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-7038000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="-3"
      id="Tc_NzODcg6TjEOoONzlvuWYuQ_6_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-29135000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_3_31_2019_Mvyv6VR68kGT5ZR4EP_dmw"
      decimals="2"
      id="Tc_Fr8-dCwwIkCfdUKfnfjeEA_7_2"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_4_1_2019_To_6_30_2019_YanxvWlEsEejFy87ExaOLg"
      decimals="2"
      id="Tc_d89zT8za4kSTx1k-4ZKe3Q_7_4"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_TN6VG2lfmUiuuxKhsNAsMg"
      decimals="2"
      id="Tc_bRULy3HxWUqq4PxqpvysOQ_7_6"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg"
      decimals="2"
      id="Tc_vgyhW0gvYE-Rxf-QjLZnRg_7_8"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      decimals="2"
      id="Tc_nP1g8F3zJ06NctK_YgPA5Q_7_10"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA"
      decimals="-3"
      id="Tc_FGczl3bu9kSt1a6TuNRI5A_10_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17260000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw"
      decimals="-3"
      id="Tc_BtA0IhWScUyFKglQLL5BNQ_10_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">20584000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA"
      decimals="-3"
      id="Tc_iER5mvrggkWfne0LxGSriQ_10_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">22660000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug"
      decimals="-3"
      id="Tc_HmdnI6Pbz0yKeHyvNBgEfA_10_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">23433000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_gVhkNYno5UyLfkYdnXtRZw_10_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">83937000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA"
      decimals="-3"
      id="Tc_nb4TQSjOW0iMCRcX3zT4kw_11_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">14547000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw"
      decimals="-3"
      id="Tc_kPOW6JY3PUuxJ5-i_Qd5qw_11_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">17478000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA"
      decimals="-3"
      id="Tc_piF1cl2o3UKOAD_FPFC2mg_11_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">19196000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug"
      decimals="-3"
      id="Tc_NaDGWYgupEiFnVosth0RaA_11_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">19793000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_LqsAUAZ-C0GAv7aC713blQ_11_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">71014000</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA"
      decimals="-3"
      id="Tc_UqLy5rTvN0CWbms4JrzCdw_12_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-5644000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw"
      decimals="-3"
      id="Tc_eQbeqACZ3UG0RQP25OnvbA_12_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-7427000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA"
      decimals="-3"
      id="Tc_Kg7nb6LP6U2RUh81JJ7cKw_12_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-4102000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug"
      decimals="-3"
      id="Tc_g-k7xJ3arUCGIsAxcoxk4g_12_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-5224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="-3"
      id="Tc_6bM65j6PqkmewFqu-dEwXQ_12_10"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">-22397000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2018_To_3_31_2018_NPWShI_KTUKjhJhomPr4kA"
      decimals="2"
      id="Tc_9dsJ3_0UdUeztezjeRC1eg_13_2"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_4_1_2018_To_6_30_2018_BPeXgdyMhUyq0-qJKlCAWw"
      decimals="2"
      id="Tc_PVrv2nWXbEG12gqoPYzjVA_13_4"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2018_To_9_30_2018_-caDAILuWECmA8eLjoV_FA"
      decimals="2"
      id="Tc_IIVeVt9KX0KFiOEtMiq8BQ_13_6"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_10_1_2018_To_12_31_2018_GfngmwA9qU6gj7kMhl-8ug"
      decimals="2"
      id="Tc_BPC8cOLoMk-zsr2xtcap0Q_13_8"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2018_To_12_31_2018_D3Tyqw-QjUOsj5WIZEb_NA"
      decimals="2"
      id="Tc_t5uBWPpm4UeHBmwsL2epmg_13_10"
      unitRef="Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA">-0.60</us-gaap:EarningsPerShareBasicAndDiluted>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g"
      id="Tb_NGWBZu_OhUCxVYgvrtW7hA">&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Schedule II &#x2013; Valuation and Qualifying Accounts&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;padding-left:1.8pt;text-indent:-1.8pt;margin:0pt 0pt 0pt 27pt;"&gt;&lt;span style="font-size:10pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AXOGEN, INC.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;SCHEDULE II &#x2013; VALUATION AND QUALIFYING ACCOUNTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THREE YEARS ENDED DECEMBER 31, 2019, 2018 AND 2017&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;padding-left:1.8pt;text-align:center;text-indent:-1.8pt;margin:0pt 0pt 0pt 27pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;Balance at Beginning of Year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;Deductions (Chargeoffs)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;Balance at End of Year&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Allowance for doubtful accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2017&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (34)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (196)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 514&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (539)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,092&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Valuation allowance for deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,754)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,357&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,357&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,519&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,853&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_7M-n1WyHmkSuJh3oSbSVVQ"
      decimals="-3"
      id="Tc_r15BRZLMUkCUMCwffpmC7A_3_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">272000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_rHiawjIyP0aw2fguf5ppEA"
      decimals="-3"
      id="Tc_gCIht4eRVU2GsV3EyBhJ0g_3_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">223000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_rHiawjIyP0aw2fguf5ppEA"
      decimals="-3"
      id="Tc_2fBLG4UEskGPMj8o5k_XhA_3_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">34000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_5pNCsEIErU22bwU3noUy8w"
      decimals="-3"
      id="Tc_517rf0oBGEOPCyp5IKCifg_3_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">461000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_5pNCsEIErU22bwU3noUy8w"
      decimals="-3"
      id="Tc_SwVbAN4iBUig1fMLnkzz-A_4_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">461000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_4dIDit0lLkGoGloMyIZncQ"
      decimals="-3"
      id="Tc_-I6QW5aIhk-0aJCb44Axbg_4_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">852000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_4dIDit0lLkGoGloMyIZncQ"
      decimals="-3"
      id="Tc_tEDFQQ_ZIkOk_sYKgreYlQ_4_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">196000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_SJai84u14EuDL2IY6ZP7lQ"
      decimals="-3"
      id="Tc_g_k4HwfvjEeeXV1F_iT-Kw_4_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1117000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_SJai84u14EuDL2IY6ZP7lQ"
      decimals="-3"
      id="Tc_eCFYMTRA2UCWi-DEaL-KfQ_5_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1117000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_yxMu6JmduUiQWUtieKQOwg"
      decimals="-3"
      id="Tc_I1vrDWROXkSkdai0NXxM-Q_5_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">514000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_yxMu6JmduUiQWUtieKQOwg"
      decimals="-3"
      id="Tc_DSLFa9rhmkGITuCNK1HHfQ_5_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">539000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_UAgoENraVE6_3zK-NyR0vg"
      decimals="-3"
      id="Tc_uBZ-Ox9ws0-XmXqxYhZU-w_5_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">1092000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_JiZrmI4fMUOvyhPBobtrAQ"
      decimals="-3"
      id="Tc_FF5O0FELjE6BHRkCnTiMfw_8_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">39111000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_sonit0BwD0-XslHO4fwUog"
      decimals="-3"
      id="Tc_LQcbhnp7vU6-9yXwUnbnhA_8_6"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">10754000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_SVGvuAZnpEa4kIr4fmffiA"
      decimals="-3"
      id="Tc_mW1Z2qOvu0aYaEjKShi_EQ_8_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28357000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2017_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_SVGvuAZnpEa4kIr4fmffiA"
      decimals="-3"
      id="Tc_O8hY5yooDkG-u5BlIrjtiw_9_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">28357000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_QdTP5uBuUkm8aCMGR4HRdQ"
      decimals="-3"
      id="Tc_BCVW6iqB70eyDf22Gq2fug_9_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">5519000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_UBoSuOgnDkyJox-_uA5moQ"
      decimals="-3"
      id="Tc_pjrwRZ19kU68BCUEzxVXng_9_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">33876000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_UBoSuOgnDkyJox-_uA5moQ"
      decimals="-3"
      id="Tc_SELEmu38Q0SrLU2Ak-7kIQ_10_2"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">33876000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_G8SJ8nYBukqnwXb72_TUaw"
      decimals="-3"
      id="Tc_6f_YHAzhR02mgxCewt1U-g_10_4"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">5977000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2019_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_YOXkkYOqUke7VD_DZQQEDg"
      decimals="-3"
      id="Tc_v1rg6IdciE6TKoRuYX64sg_10_8"
      unitRef="Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ">39853000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6795125136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">1,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800029760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Temporary Differences (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 36,250<span></span>
</td>
<td class="nump">$ 30,588<span></span>
</td>
<td class="nump">$ 27,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory write down</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DeferredTaxAssetsInterestLimitation', window );">Interest limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DeferredTaxAssetsRightOfUseLiability', window );">Right-of-use liability</a></td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,140<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">40,954<span></span>
</td>
<td class="nump">33,934<span></span>
</td>
<td class="nump">28,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Amortization</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome', window );">Contract liabilities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_DeferredTaxAssetsLiabilities', window );">Net deferred tax assets</a></td>
<td class="nump">39,932<span></span>
</td>
<td class="nump">33,876<span></span>
</td>
<td class="nump">28,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (39,932)<span></span>
</td>
<td class="num">$ (33,876)<span></span>
</td>
<td class="num">$ (28,357)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DeferredTaxAssetsInterestLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DeferredTaxAssetsInterestLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DeferredTaxAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DeferredTaxAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DeferredTaxAssetsRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from right-of-use liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DeferredTaxAssetsRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "axgn-20191231x10k0cc357.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 216,
   "dts": {
    "calculationLink": {
     "local": [
      "axgn-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "axgn-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "axgn-20191231x10k0cc357.htm"
     ]
    },
    "labelLink": {
     "local": [
      "axgn-20191231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "axgn-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "axgn-20191231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 553,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 12,
    "http://www.axogeninc.com/20191231": 3,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 21
   },
   "keyCustom": 53,
   "keyStandard": 375,
   "memberCustom": 30,
   "memberStandard": 32,
   "nsprefix": "axgn",
   "nsuri": "http://www.axogeninc.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Inventories",
     "role": "http://www.axogeninc.com/role/DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Fair Value of Investments",
     "role": "http://www.axogeninc.com/role/DisclosureFairValueOfInvestments",
     "shortName": "Fair Value of Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Property and Equipment",
     "role": "http://www.axogeninc.com/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Intangible Assets",
     "role": "http://www.axogeninc.com/role/DisclosureIntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Term Loan Agreements and Long-Term Debt",
     "role": "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebt",
     "shortName": "Term Loan Agreements and Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Public Offering of Common Stock",
     "role": "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock",
     "shortName": "Public Offering of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Equity Compensation Plans",
     "role": "http://www.axogeninc.com/role/DisclosureEquityCompensationPlans",
     "shortName": "Equity Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Income Taxes",
     "role": "http://www.axogeninc.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Employee Benefit Plan",
     "role": "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Commitments and Contingencies",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Quarterly Results of Operations (Unaudited)",
     "role": "http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnaudited",
     "shortName": "Quarterly Results of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "role": "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Inventories (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureInventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Fair Value of Investments (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsTables",
     "shortName": "Fair Value of Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Term Loan Agreements and Long-Term Debt (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtTables",
     "shortName": "Term Loan Agreements and Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Equity Compensation Plans (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansTables",
     "shortName": "Equity Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31501 - Disclosure - Quarterly Results of Operations (Unaudited) (Tables)",
     "role": "http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedTables",
     "shortName": "Quarterly Results of Operations (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Summary of Significant Accounting Policies - Contract Balances (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails",
     "shortName": "Summary of Significant Accounting Policies - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2017_Ojsf9feapkmvpBx0qXyHiA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Inventories (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureInventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ftL9sDUwHkWRUwmRLPxn4w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Fair Value of Investments (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails",
     "shortName": "Fair Value of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ftL9sDUwHkWRUwmRLPxn4w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:SellingAndMarketingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Intangible Assets - Components of Intangible Assets (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
     "shortName": "Intangible Assets - Components of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_1_31_2019_UDTsEyjMukWLzOkrt7d4_A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_bxzrSUd6ckqbGlbKCkkNcA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Intangible Assets - License Agreements (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails",
     "shortName": "Intangible Assets - License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_bxzrSUd6ckqbGlbKCkkNcA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
     "shortName": "Term Loan Agreements and Long-Term Debt - Schedule of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Term Loan Agreements and Long-Term Debt - Schedule of Debt - Terms (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails",
     "shortName": "Term Loan Agreements and Long-Term Debt - Schedule of Debt - Terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtInstrumentFaceAmount",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_srt_CounterpartyNameAxis_axgn_CiscoCapitalMember_us-gaap_DebtInstrumentAxis_us-gaap_CapitalLeaseObligationsMember_K3AS51eTEE-YvIQB0nBIfg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_5_22_2018_To_5_22_2018_i3ypW9J1CEa7OLr3rjoRmw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Term Loan Agreements and Long-Term Debt - Narrative (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails",
     "shortName": "Term Loan Agreements and Long-Term Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_5_22_2018_To_5_22_2018_i3ypW9J1CEa7OLr3rjoRmw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2018_cDKG1HnYik-lEdHAmbF4vQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Public Offering of Common Stock (Details)",
     "role": "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails",
     "shortName": "Public Offering of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_5_8_2018_us-gaap_SubsidiarySaleOfStockAxis_axgn_CommonStockIssuanceMay2018OfferingMember_IP-Mn3x-6EudoUgdTXzq8Q",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Public Offering of Common Stock - Public Offering (Details)",
     "role": "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails",
     "shortName": "Public Offering of Common Stock - Public Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Equity Compensation Plans - Narrative (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
     "shortName": "Equity Compensation Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TJlFr_r_RkuXuvZTAhvzYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "role": "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TJlFr_r_RkuXuvZTAhvzYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_NvaE0ZF610qmwkn-m_kZkw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Equity Compensation Plans - Stock Award Activity (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails",
     "shortName": "Equity Compensation Plans - Stock Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_4rrE29SGy0KcUjagNjOD_Q",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - Equity Compensation Plans - Summary of Weighted-Average Assumptions Used (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails",
     "shortName": "Equity Compensation Plans - Summary of Weighted-Average Assumptions Used (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - Equity Compensation Plans - Grant Date Fair Value (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails",
     "shortName": "Equity Compensation Plans - Grant Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_axgn_EmployeeConsultantsAndDirectorsStockOptionsMember_X48OSYahR0KvF61mGKtmCw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_emFalh41X0aNwPWdtLLVbA",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Income Taxes - Temporary Differences (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails",
     "shortName": "Income Taxes - Temporary Differences (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Income Taxes - Effective Income Tax Rate and Other information (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails",
     "shortName": "Income Taxes - Effective Income Tax Rate and Other information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_iuiHOvOjkEiojVcw-Js22Q",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_7eeOyFQI-kyot4WSOxp9WA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_bQ28F0w6C0GKznH2O5VZSw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_RetirementPlanTypeAxis_axgn_Axogen401kPlanMember_7eeOyFQI-kyot4WSOxp9WA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_bQ28F0w6C0GKznH2O5VZSw",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_7_31_2018_9F5KGFk5ekOKV8bdqwW0vQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unitRef": "Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Commitments and Contingencies - Leases (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
     "shortName": "Commitments and Contingencies - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_LeaseArrangementTypeAxis_axgn_SHNMedicalOfficePropertiesTrustMember_tglKryFxhkq8-SAK4HEuzg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41402 - Disclosure - Commitments and Contingencies - Lease Expense (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails",
     "shortName": "Commitments and Contingencies - Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41403 - Disclosure - Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails",
     "shortName": "Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "axgn:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41404 - Disclosure - Commitments and Contingencies - Other Information Related to Leases (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails",
     "shortName": "Commitments and Contingencies - Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "axgn:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": "-3",
      "lang": null,
      "name": "axgn:RightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "axgn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41405 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "axgn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2019_kCj2_qTUzkCFDhbOp2hGRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_w7VPQT2pRkub_N0KQzm0eg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "axgn:LicenseFeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41406 - Disclosure - Commitments and Contingencies - Service Agreements (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails",
     "shortName": "Commitments and Contingencies - Service Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_axgn_TissueProcessingAgreementMember_w7VPQT2pRkub_N0KQzm0eg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "axgn:LicenseFeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_7_31_2018_9F5KGFk5ekOKV8bdqwW0vQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unitRef": "Unit_Standard_sqft_WZCl5l7hZkOe1niH_Li4FA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41407 - Disclosure - Commitments and Contingencies - Concentrations (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
     "shortName": "Commitments and Contingencies - Concentrations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_7_31_2018_9F5KGFk5ekOKV8bdqwW0vQ",
      "decimals": "1",
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_acre_uQoen29RI0aO7YAQ0QAY8Q",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_2_4_2019_To_2_4_2019_ln_X-b6a80Wb7o__1q1OhQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "axgn:ThresholdPeriodForNotFilingResponseToComplaint",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41408 - Disclosure - Commitments and Contingencies - Litigation (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails",
     "shortName": "Commitments and Contingencies - Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_2_4_2019_To_2_4_2019_ln_X-b6a80Wb7o__1q1OhQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "axgn:ThresholdPeriodForNotFilingResponseToComplaint",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Quarterly Results of Operations (Unaudited) (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedDetails",
     "shortName": "Quarterly Results of Operations (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_10_1_2019_To_12_31_2019_Bc9AdcbNqUeTsu2l8ZkIpg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_SJai84u14EuDL2IY6ZP7lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)",
     "role": "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "As_Of_12_31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_AllowanceForCreditLossMember_7M-n1WyHmkSuJh3oSbSVVQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_LLpZb15vxUaDLwfjbPC0hQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Basis of Presentation",
     "role": "http://www.axogeninc.com/role/DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Organization and Business",
     "role": "http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20191231x10k0cc357.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_Pn6JqOQY0UqzfkZ4I_8j5g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "axgn_AdditionalCostsAssociatedWithDesignBuildAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the additional amount associated with design build agreement.",
        "label": "Additional Costs Associated with Design Build Agreement",
        "terseLabel": "Additional costs associated with design build agreement"
       }
      }
     },
     "localname": "AdditionalCostsAssociatedWithDesignBuildAgreement",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the age of specific types of trade accounts and notes receivable.",
        "label": "Allowance for Doubtful Accounts Receivable Age of Accounts Receivable",
        "terseLabel": "Age of doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_AreaOfRealEstatePropertyAdditional": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the additional area of a real estate property due to agreement.",
        "label": "Area Of Real Estate Property Additional",
        "terseLabel": "Additional leased office space in square feet"
       }
      }
     },
     "localname": "AreaOfRealEstatePropertyAdditional",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "axgn_AshleyAvenueLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ashley Avenue Lease [member]",
        "label": "Ashley Avenue Lease [Member]",
        "terseLabel": "Ashley Avenue Lease"
       }
      }
     },
     "localname": "AshleyAvenueLeaseMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_AxoGen2010StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The AxoGen 2010 Stock Incentive Plan.",
        "label": "Axo Gen2010 Stock Incentive Plan [Member]",
        "terseLabel": "AxoGen 2010 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "AxoGen2010StockIncentivePlanMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_Axogen2017EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AxoGen 2017 Employee Stock Purchase Plan [Member]",
        "label": "Axogen2017 Employee Stock Purchase Plan [Member]",
        "terseLabel": "AxoGen 2017 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "Axogen2017EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the first tranche of the AxoGen 401K plan where the employer matches a percent of employee contributions.",
        "label": "Axogen401k Plan Employer Matching Contribution Tranche1 [Member]",
        "terseLabel": "Axogen 401K Plan, employer's contribution on first 3% of employee contribution"
       }
      }
     },
     "localname": "Axogen401kPlanEmployerMatchingContributionTranche1Member",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the second tranche of the AxoGen 401K plan where the employer matches a percent of employee contributions.",
        "label": "Axogen401k Plan Employer Matching Contribution Tranche2 [Member]",
        "terseLabel": "Axogen 401K Plan, employer's contribution on next 2% of employee contribution"
       }
      }
     },
     "localname": "Axogen401kPlanEmployerMatchingContributionTranche2Member",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_Axogen401kPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the AxoGen 401K plan.",
        "label": "Axogen401k Plan [Member]",
        "terseLabel": "AxoGen 401K Plan"
       }
      }
     },
     "localname": "Axogen401kPlanMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_BAndBOfficeSystemsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to B&amp;B Office systems.",
        "label": "B And B Office Systems [Member]",
        "terseLabel": "B&amp;B Office Systems"
       }
      }
     },
     "localname": "BAndBOfficeSystemsMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_CashGrantsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of cash grants receivable.",
        "label": "Cash Grants Receivable",
        "terseLabel": "Cash grants"
       }
      }
     },
     "localname": "CashGrantsReceivable",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_CiscoCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Cisco Capital.",
        "label": "Cisco Capital [Member]",
        "terseLabel": "Cisco Capital"
       }
      }
     },
     "localname": "CiscoCapitalMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_CommonStockIssuanceMay2018OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to May 2018 offering.",
        "label": "Common Stock Issuance May2018 Offering [Member]",
        "terseLabel": "May 2018 Offering"
       }
      }
     },
     "localname": "CommonStockIssuanceMay2018OfferingMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_CompensationCostNotYetRecognizedAssumedPercentageAchieved": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Compensation Cost Not Yet Recognized, Assumed Percentage Achieved",
        "label": "Compensation Cost Not Yet Recognized, Assumed Percentage Achieved",
        "terseLabel": "Assumed achievement percentage of PSUs to calculate unrecognized cost"
       }
      }
     },
     "localname": "CompensationCostNotYetRecognizedAssumedPercentageAchieved",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_DebtInstrumentInterestAndPrincipalPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, during which interest and principal payments are required, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Interest and Principal Payments, Term",
        "terseLabel": "Interest and principal payments, term"
       }
      }
     },
     "localname": "DebtInstrumentInterestAndPrincipalPaymentsTerm",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_DebtInstrumentNoPaymentsRequiredTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, during which no payments are required to be made, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, No Payments Required, Term",
        "terseLabel": "No payments required, term"
       }
      }
     },
     "localname": "DebtInstrumentNoPaymentsRequiredTerm",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_DeferredTaxAssetsInterestLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest Limitation",
        "label": "Deferred Tax Assets, Interest Limitation",
        "terseLabel": "Interest limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestLimitation",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DeferredTaxAssetsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Assets (Liabilities)",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilities",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DeferredTaxAssetsRightOfUseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from right-of-use liability.",
        "label": "Deferred Tax Assets, Right-of-use Liability",
        "terseLabel": "Right-of-use liability",
        "verboseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightOfUseLiability",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails",
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 4.0,
       "parentTag": "axgn_DeferredTaxAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from right-of-use asset.",
        "label": "Deferred Tax Liabilities, Right-of-use Asset",
        "negatedLabel": "Right-of-use asset",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails",
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DefinedContributionPlanEmployeeContributionPercentMatched": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee contribution, as a percent of annual salary, that is matched by the employer.",
        "label": "Defined Contribution Plan, Employee Contribution, Percent Matched",
        "terseLabel": "Employee contribution matched, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeeContributionPercentMatched",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined contribution plan minimum age limit for eligibility to participate in plan.",
        "label": "Defined Contribution Plan Minimum Age Limit for Eligibility to Participate in Plan",
        "terseLabel": "Age limit for eligibility to participate in the plan"
       }
      }
     },
     "localname": "DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axgn_DerecognitionOfCapitalLeaseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derecognition of capital lease assets",
        "label": "Derecognition of capital lease assets"
       }
      }
     },
     "localname": "DerecognitionOfCapitalLeaseAssets",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DerecognitionOfCapitalLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derecognition of capital lease liabilities",
        "label": "Derecognition of capital lease liabilities"
       }
      }
     },
     "localname": "DerecognitionOfCapitalLeaseLiabilities",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DerecognitionOfDeferredRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derecognition of deferred rent",
        "label": "Derecognition of deferred rent"
       }
      }
     },
     "localname": "DerecognitionOfDeferredRent",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DesignBuildAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to design build agreement.",
        "label": "Design Build Agreement [Member]",
        "terseLabel": "Design build agreement"
       }
      }
     },
     "localname": "DesignBuildAgreementMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_DirectorsAndOfficersStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an officer or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Directors And Officers Stock Options [Member]",
        "terseLabel": "Directors and Officers Stock Options [Member]"
       }
      }
     },
     "localname": "DirectorsAndOfficersStockOptionsMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_EarlyTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The period of time after which the reporting entity has the right to terminate the lease before the expiration of the lease term.",
        "label": "Early Termination Period",
        "terseLabel": "Right to early termination of lease"
       }
      }
     },
     "localname": "EarlyTerminationPeriod",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_EmployeeConsultantsAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee, consultant or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee Consultants And Directors Stock Options [Member]",
        "terseLabel": "Employee Consultants and Directors Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Discount from Market Value on Common Stock",
        "label": "Employee Stock Purchase Plan, Discount from Market Value on Common Stock",
        "terseLabel": "Discount from market value on common stock"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year",
        "label": "Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year",
        "terseLabel": "Maximum amount available to participants per year"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_EmployeeStockPurchasePlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Offering Period",
        "label": "Employee Stock Purchase Plan, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanOfferingPeriod",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_EstimatedCostRelatingToDesignBuildAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of estimated cost relating to design build agreement.",
        "label": "Estimated Cost Relating to Design Build Agreement",
        "terseLabel": "Estimated cost relating to design build agreement"
       }
      }
     },
     "localname": "EstimatedCostRelatingToDesignBuildAgreement",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_FinanceAndOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance and operating lease liabilities",
        "label": "Finance and operating lease liabilities",
        "terseLabel": "Lease liabilities recorded"
       }
      }
     },
     "localname": "FinanceAndOperatingLeaseLiabilities",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance and Operating Lease, Liability, Maturity [Table Text Block]",
        "label": "Finance and Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments"
       }
      }
     },
     "localname": "FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "axgn_FinanceAndOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance and operating lease, right of use asset",
        "label": "Finance and operating lease, right of use asset",
        "terseLabel": "Right-of-use assets recorded"
       }
      }
     },
     "localname": "FinanceAndOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment and tangible personal property commonly used in offices.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_HeightsUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for Heights Union, LLC.",
        "label": "Heights Union [Member]",
        "terseLabel": "Heights Union"
       }
      }
     },
     "localname": "HeightsUnionMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_HeightsUnionPremisesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Heights Union Premises [member]",
        "label": "Heights Union Premises [Member]",
        "terseLabel": "Heights Union Premises"
       }
      }
     },
     "localname": "HeightsUnionPremisesMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_IncreaseDecreaseInContractReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Contract Receivable",
        "label": "Increase (Decrease) in Contract Receivable",
        "terseLabel": "Increase/(decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractReceivable",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_IncreaseDecreaseInContractWithCustomerLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Contract with Customer, Liability, Current",
        "label": "Increase (Decrease) in Contract with Customer, Liability, Current",
        "terseLabel": "Increase/(decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiabilityCurrent",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Contract with Customer, Liability, Noncurrent",
        "label": "Increase (Decrease) in Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Increase/(decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_JaColeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ja-cole, the lessor of the reporting entity's warehouse and office space located in Burleson, Texas.",
        "label": "Ja Cole [Member]",
        "terseLabel": "Ja-Cole"
       }
      }
     },
     "localname": "JaColeMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_LeasesFinanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Leases Finance Abstract",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "LeasesFinanceAbstract",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "axgn_LesseeOperatingLeaseLiabilityFuturePaymentsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount represents lessee operating lease lability future payments.",
        "label": "Lessee Operating Lease Liability Future Payments Amount",
        "negatedLabel": "Less future payments for leases that have not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityFuturePaymentsAmount",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LicenseFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License fee amount",
        "label": "License fee amount"
       }
      }
     },
     "localname": "LicenseFeeAmount",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LongTermDebtNoncurrentExcludingDeferredRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding deferred revenue, amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Noncurrent Excluding Deferred Revenue",
        "terseLabel": "Long-term portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentExcludingDeferredRevenue",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment for clinical research and related services.",
        "label": "Master Services Agreement For Clinical Research And Related Services [Member]",
        "terseLabel": "Master Services Agreement For Clinical Research and Related Services [Member]"
       }
      }
     },
     "localname": "MasterServicesAgreementForClinicalResearchAndRelatedServicesMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_MilestonePaymentContingentUponFDApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of milestone payment due if AxoGen receives FDA approval of its Avance Nerve Graft.",
        "label": "Milestone Payment Contingent Upon F D A Approval",
        "terseLabel": "Milestone fee upon FDA approval"
       }
      }
     },
     "localname": "MilestonePaymentContingentUponFDApproval",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of milestone payment due upon first commercial use of certain licensed technology to provide services to manufacture products for third parties.",
        "label": "Milestone Payment Contingent Upon First Commercial Use of Certain Licensed Technology",
        "terseLabel": "Milestone fee upon first commercial use of certain licensed technology"
       }
      }
     },
     "localname": "MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of milestone payment due upon first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products.",
        "label": "Milestone Payment Contingent Upon First Use to Manufacture Products Utilizing Certain Technology",
        "terseLabel": "Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products"
       }
      }
     },
     "localname": "MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_MilestonePaymentContingentUponReceiptOfGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement.",
        "label": "Milestone Payment Contingent upon Receipt of Grant",
        "terseLabel": "Milestone fee upon receiving a Phase II Small Business Innovation Research"
       }
      }
     },
     "localname": "MilestonePaymentContingentUponReceiptOfGrant",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_MinimumNumberOfCandidateElectedToBoard": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum number of candidates elected to board.",
        "label": "Minimum Number of Candidate Elected to Board",
        "terseLabel": "Minimum number of candidates elected to board"
       }
      }
     },
     "localname": "MinimumNumberOfCandidateElectedToBoard",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axgn_MinimumRoyaltyOfLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements.",
        "label": "Minimum Royalty of License Agreement",
        "terseLabel": "Minimum royalty of agreements"
       }
      }
     },
     "localname": "MinimumRoyaltyOfLicenseAgreement",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_NewAxogenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information relating to New Axogen Plan",
        "label": "New Axogen Plan [Member]",
        "terseLabel": "New Axogen Plan [Member]"
       }
      }
     },
     "localname": "NewAxogenPlanMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the noncash amount of right of use assets and operating lease liability.",
        "label": "Noncash Right of Use Assets and Operating Lease Liability",
        "terseLabel": "Right-of-use asset and operating lease liability"
       }
      }
     },
     "localname": "NoncashRightOfUseAssetsAndOperatingLeaseLiability",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_NoticePeriodForTerminationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the notice period for termination of the agreement by either parties.",
        "label": "Notice Period For Termination Of Agreement",
        "terseLabel": "Notice period for termination of contract"
       }
      }
     },
     "localname": "NoticePeriodForTerminationOfAgreement",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_NoticePeriodForTerminationOfLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notice period for termination of license agreements.",
        "label": "Notice Period for Termination of License Agreements",
        "terseLabel": "Notice period for termination of license agreements"
       }
      }
     },
     "localname": "NoticePeriodForTerminationOfLicenseAgreements",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_NovitzkiVsZaderejMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for case of Novitzki v. Zaderej.",
        "label": "Novitzki Vs Zaderej [Member]",
        "terseLabel": "Case of Novitzki vs Zaderej"
       }
      }
     },
     "localname": "NovitzkiVsZaderejMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of days to underwriter to purchase additional common shares.",
        "label": "Number Of Days To Underwriter To Purchase Additional Common Shares",
        "terseLabel": "Number of days to underwriter to purchase additional common shares"
       }
      }
     },
     "localname": "NumberOfDaysToUnderwriterToPurchaseAdditionalCommonShares",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_NumberOfProductsFromWhichRevenueIsDerived": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of products from which revenue is derived by the entity.",
        "label": "Number Of Products From Which Revenue Is Derived",
        "terseLabel": "Number of products from which revenue is derived"
       }
      }
     },
     "localname": "NumberOfProductsFromWhichRevenueIsDerived",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axgn_NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Unallocated Shares Of Common Stock Available For Issuance.",
        "label": "Number Of Unallocated Shares Of Common Stock Available For Issuance",
        "terseLabel": "Number of unallocated shares available for issuance"
       }
      }
     },
     "localname": "NumberOfUnallocatedSharesOfCommonStockAvailableForIssuance",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "axgn_OrganizationAndBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "n/a",
        "label": "Organization and Business"
       }
      }
     },
     "localname": "OrganizationAndBusinessAbstract",
     "nsuri": "http://www.axogeninc.com/20191231",
     "xbrltype": "stringItemType"
    },
    "axgn_PatentsAndLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patents And License Agreements [Member]",
        "label": "Patents And License Agreements [Member]",
        "terseLabel": "Patents And License Agreements"
       }
      }
     },
     "localname": "PatentsAndLicenseAgreementsMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements.",
        "label": "Percentage of Capping Royalties for Multiple Royalty Payments to Licensors",
        "terseLabel": "Royalty stack cap for royalties paid to more than one licensor for sales of the same product"
       }
      }
     },
     "localname": "PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_PerformanceSharesBiologicLicenseApplicationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares or units awarded based on Biologic License Application milestones.",
        "label": "Performance Shares Biologic License Application [Member]",
        "terseLabel": "PSU - BLA Milestones [Member]"
       }
      }
     },
     "localname": "PerformanceSharesBiologicLicenseApplicationMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_PhantomStockUnitPayoutOpportunity": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the payout opportunity of Phantom Stock Units, as a percent.",
        "label": "Phantom Stock Unit, Payout Opportunity",
        "terseLabel": "Payout opportunity"
       }
      }
     },
     "localname": "PhantomStockUnitPayoutOpportunity",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_RaymondLeasingCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Raymond leasing corporation.",
        "label": "Raymond Leasing Corporation [Member]",
        "terseLabel": "Raymond Leasing Corporation"
       }
      }
     },
     "localname": "RaymondLeasingCorporationMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_RestrictedAndPerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted and Performance Stock Units [Member]",
        "label": "Restricted And Performance Stock Units [Member]",
        "terseLabel": "Restricted and Performance Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedAndPerformanceStockUnitsMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_RevolvingLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revolving Loan Agreement [member]",
        "label": "Revolving Loan Agreement [Member]",
        "terseLabel": "Revolving Loan Agreement"
       }
      }
     },
     "localname": "RevolvingLoanAgreementMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_RightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset.",
        "label": "Right Of Use Asset Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetAmortization",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_RoyaltyFeesPercentageUnderLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty fees percentage under license agreements.",
        "label": "Royalty Fees Percentage under License Agreements",
        "terseLabel": "Royalty fees range under the license agreements"
       }
      }
     },
     "localname": "RoyaltyFeesPercentageUnderLicenseAgreements",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_SHNMedicalOfficePropertiesTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SNH Medical Office Properties Trust, the lessor of the reporting entity's corporate headquarters.",
        "label": "S H N Medical Office Properties Trust [Member]",
        "terseLabel": "SNH"
       }
      }
     },
     "localname": "SHNMedicalOfficePropertiesTrustMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Future Minimum Payments for Operating and Capital Leases [Table Text Block]",
        "label": "Schedule of Future Minimum Payments for Operating and Capital Leases [Table Text Block]",
        "terseLabel": "Schedule of commitments relating to noncancelable operating and capital leases prior to adoption of ASC 842"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumPaymentsForOperatingAndCapitalLeasesTableTextBlock",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "axgn_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the information other information related to leases.",
        "label": "Schedule of Other Information Related to Leases [Table Text Block]",
        "terseLabel": "Schedule of other information related to leases"
       }
      }
     },
     "localname": "ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "axgn_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tabular disclosure for supplemental balance sheet information related to leases.",
        "label": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]",
        "terseLabel": "Schedule of supplemental balance sheet information related to leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "axgn_SecondExpansionLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second Expansion Lease [member]",
        "label": "Second Expansion Lease [Member]",
        "terseLabel": "Second Expansion Lease [Member]"
       }
      }
     },
     "localname": "SecondExpansionLeaseMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service agreement amount paid upon execution of agreement",
        "label": "Service agreement amount paid upon execution of agreement"
       }
      }
     },
     "localname": "ServiceAgreementAmountPaidUponExecutionOfAgreement",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_ShareBasedCompensationAwardTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fourth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Four [Member]",
        "terseLabel": "Per Quarter, Over One Year"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheFourMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan",
        "terseLabel": "Exercise of stock options and employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan",
        "terseLabel": "Exercise of stock options and employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_ThirdExpansionLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Third Expansion Lease [member]",
        "label": "Third Expansion Lease [Member]",
        "terseLabel": "Third Expansion Lease [Member]"
       }
      }
     },
     "localname": "ThirdExpansionLeaseMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_ThresholdPeriodForNotFilingResponseToComplaint": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period for not filing response to complaint.",
        "label": "Threshold Period for Not Filing Response to Complaint",
        "terseLabel": "Threshold period for not filing response to complaint"
       }
      }
     },
     "localname": "ThresholdPeriodForNotFilingResponseToComplaint",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_TissueProcessingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment for minimum annual purchases from a tissue processing vendor.",
        "label": "Tissue Processing Agreement [Member]",
        "terseLabel": "Tissue Processing Agreement [Member]"
       }
      }
     },
     "localname": "TissueProcessingAgreementMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_UnderwriterMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwriter [member]",
        "label": "Underwriter [Member]",
        "terseLabel": "Underwriter"
       }
      }
     },
     "localname": "UnderwriterMember",
     "nsuri": "http://www.axogeninc.com/20191231",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r99",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case Type [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails",
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails",
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails",
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails",
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information reported for future period.",
        "label": "Scenario Forecast [Member]",
        "terseLabel": "Expected"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r179",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r136",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r104",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms": {
     "auth_ref": [
      "r50",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract.",
        "label": "Contract Receivable",
        "periodEndLabel": "Net Receivables, Closing balance",
        "periodStartLabel": "Net Receivables, Opening balance"
       }
      }
     },
     "localname": "AccountsReceivableBilledForLongTermContractsOrPrograms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r20",
      "r137",
      "r138",
      "r204"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $1,092 and $1,117, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r43"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Compensation Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r173"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r215",
      "r217",
      "r250",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r217",
      "r244",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Allowance For Credit Loss [Member]",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r26",
      "r139",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for Doubtful Accounts Receivable, Current",
        "terseLabel": "Accounts receivable, allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r64",
      "r86",
      "r286"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of deferred financing costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r86",
      "r286"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Financing Costs and Discounts",
        "negatedLabel": "Interest expense - deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r86",
      "r162",
      "r167"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Area of land where building resides"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Size of building space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r143",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r134",
      "r322",
      "r338"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r55"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r218",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt security, in which the authorized issuer owes the holder a debt and is obliged to repay the principal and interest (the coupon).",
        "label": "Bonds [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "BondsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r5",
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Expenses related to improvements"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Acquisition of fixed assets in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Capital Lease Obligations Incurred",
        "terseLabel": "Capital lease additions"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Equipment Lease Agreement"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases.",
        "label": "Capital Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Capital"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r36",
      "r88"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r89",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Concentration"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r82",
      "r88",
      "r94"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r82",
      "r282"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Cash and cash equivalents balance outside of FDIC limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r48",
      "r178",
      "r331",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies - see Note 14"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r177",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Par value of common stock"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails",
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Shares of common stock sold"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails",
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value per share; 100,000,000 shares authorized; 39,589,755 and 38,900,875 shares issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Differences between the carrying amount of assets and liabilities for financial reporting purposes"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r123",
      "r124",
      "r279",
      "r280",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r121",
      "r123",
      "r124",
      "r125",
      "r279",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r123",
      "r124",
      "r279",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Projects in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Schedule of balances of contract receivables and liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r201",
      "r202",
      "r204"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Contract Liabilities, Current, Closing balance",
        "periodStartLabel": "Contract Liabilities, Current, Opening balance",
        "terseLabel": "Contract liabilities, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r201",
      "r202",
      "r204"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "periodEndLabel": "Contract Liabilities, Long-Term, Closing balance",
        "periodStartLabel": "Contract Liabilities, Long-Term, Opening balance",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesContractBalancesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods Sold (COGS)",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CumulativeEffectOnRetainedEarningsTax1": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the related income tax effect of a cumulative effect on retained earnings.",
        "label": "Cumulative Effect on Retained Earnings, Tax",
        "terseLabel": "Change in retained earnings related to income taxes"
       }
      }
     },
     "localname": "CumulativeEffectOnRetainedEarningsTax1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r330",
      "r345"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Capital Lease Obligations",
        "totalLabel": "Long-term obligations"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Term Loan Agreements and Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r323",
      "r324",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r285",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest payable, percent",
        "verboseLabel": "Interest rate stated (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Note Payable"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r46",
      "r100",
      "r195",
      "r196",
      "r197",
      "r198",
      "r284",
      "r285",
      "r287",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term of debt"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r190",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized deferred financing costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 1.0,
       "parentTag": "axgn_DeferredTaxAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r255",
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory write down"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r254",
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r254",
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r254",
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "auth_ref": [
      "r255",
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 5.0,
       "parentTag": "axgn_DeferredTaxAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "negatedLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r255",
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 2.0,
       "parentTag": "axgn_DeferredTaxAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": {
     "auth_ref": [
      "r255",
      "r262",
      "r263"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails": {
       "order": 3.0,
       "parentTag": "axgn_DeferredTaxAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.",
        "label": "Deferred Tax Liabilities, Tax Deferred Income",
        "negatedLabel": "Contract liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost Recognized",
        "verboseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r86",
      "r171"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "verboseLabel": "Equity Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Loss per common share - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r102",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r257",
      "r258",
      "r264"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Federal tax benefit rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r257",
      "r258",
      "r264"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r257",
      "r258",
      "r264"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "verboseLabel": "Permanent items and other deductions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r257",
      "r258",
      "r264"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State Taxes - Net of Federal Benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Total future stock compensation expense related to nonvested awards",
        "terseLabel": "Unrecognized compensation costs related to non-vested stock options and restricted stock awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period of recognition of unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Unrecognized compensation expense related to PSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Processing equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r271",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of fair value financial assets measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r212",
      "r272",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r274",
      "r275",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value of Investments"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Investments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r208",
      "r209",
      "r212",
      "r272",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r208",
      "r209",
      "r212",
      "r272",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r276",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r296",
      "r301",
      "r311"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r298",
      "r305"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "negatedLabel": "Cash paid for interest portion of finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finance Lease Liabilities, Payments, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r294",
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total Lease Liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current maturities of long-term obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long term obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payments, Due",
        "totalLabel": "Total Future Minimum Lease Payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest on commenced leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r297",
      "r305"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Cash paid for debt portion of finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r296",
      "r301",
      "r311"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r308",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r307",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term - finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r166",
      "r169",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]",
        "terseLabel": "Future amortization of patents and license agreements"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r166",
      "r320"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets",
        "verboseLabel": "Intangible assets consist of:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r163",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Amortization period of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r86",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "verboseLabel": "Impairment loss on intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Receivable economic development grants from state and local authorities"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "verboseLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r133",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r132",
      "r283",
      "r286",
      "r334"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r81",
      "r83",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r160"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r52",
      "r156"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureInventoriesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r53",
      "r95",
      "r112",
      "r157",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r160"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r160"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Provision for inventory writedown",
        "verboseLabel": "Inventory write-downs"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureInventoriesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Annual Lease Expense",
        "terseLabel": "Annual lease expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r309",
      "r311"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finance Lease, Cost [Abstract]",
        "terseLabel": "Finance lease costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of total lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest on commenced leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r326",
      "r342"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less current maturities of long-term obligations",
        "terseLabel": "Current maturities of long term obligations"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long Term Obligations, net of current maturities",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Term Loan Agreements and Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r46",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r116",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by / (used for) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r84",
      "r87"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r57",
      "r58",
      "r61",
      "r87",
      "r110",
      "r333",
      "r346"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r302",
      "r311"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "auth_ref": [
      "r114",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total Lease Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturities of long-term obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long term obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r299",
      "r305"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Operating lease obligations"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r308",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r307",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r43"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Miscellaneous Accruals Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Exit and/or prepayment fees paid"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Cash paid for equity offering",
        "terseLabel": "Offering expenses paid"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBuildings": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for acquisition of buildings (properties) whether for investment or use.",
        "label": "Payments to Acquire Buildings",
        "terseLabel": "Payments to acquire Building"
       }
      }
     },
     "localname": "PaymentsToAcquireBuildings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Cash payments for intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLandHeldForUse": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for acquisition of land for use; excludes purchases of land held as inventory or as investments.",
        "label": "Payments to Acquire Land Held-for-use",
        "terseLabel": "Payments to acquire Land"
       }
      }
     },
     "localname": "PaymentsToAcquireLandHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r218",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails",
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r77",
      "r101"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowing on revolving loan"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r72",
      "r73",
      "r142"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r247"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r172"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r174",
      "r343"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r63",
      "r147"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for Doubtful Accounts",
        "terseLabel": "Provision for bad debt"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r17",
      "r325",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r17",
      "r325",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment Excluding Longterm Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails",
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]",
        "terseLabel": "Service Agreements"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": {
     "auth_ref": [
      "r17",
      "r325",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Table]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Results of Operations (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "verboseLabel": "Quarterly Results of Operations (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r27",
      "r95",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r78",
      "r101"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Payments on revolving loan and prepayment penalties"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt and prepayment penalties",
        "terseLabel": "Repayment of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtNarrativeDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r253",
      "r348"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r95",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r94",
      "r321",
      "r340"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r199",
      "r341"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r210",
      "r211",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r210",
      "r211",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r60",
      "r130",
      "r131",
      "r135"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r306",
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-to-use assets obtained in exchange for new finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty fees included in sales and marketing expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r46",
      "r100",
      "r195",
      "r196",
      "r197",
      "r198",
      "r284",
      "r285",
      "r287",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of long-term obligations"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax basis"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate differs from the statutory federal income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r163",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails",
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r163",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r38",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Summary of quarterly results of operations"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureQuarterlyResultsOfOperationsUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r228",
      "r233",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Activity [Table Text Block]",
        "terseLabel": "Summary of stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r218",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumptions for options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future amortization"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense.",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling And Marketing Expense [Member]",
        "terseLabel": "Sales and Marketing Expense"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, Grant Date Fair Value (per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Grant Date Fair Value (per share)",
        "verboseLabel": "Weighted average estimated grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, Ending Balance",
        "periodStartLabel": "Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted and Performance Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Outstanding, Weighted Average Grant Date Fair Value, Beginning Balance",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released, Grant Date Fair Value (per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock Option Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average estimated grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Summary of weighted average estimated grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r224",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Options, Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Time-Based Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r216",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansGrantDateFairValueDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Two Years After Grant Date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Three [Member]",
        "terseLabel": "One Year After Grant Date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "Every Six Months"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r95",
      "r218",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Public offering price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails",
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails",
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockPublicOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r240",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansSummaryOfWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r327",
      "r328",
      "r329",
      "r337"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r303",
      "r311"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r49",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails",
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails",
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Statements of Changes in Shareholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails",
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r194",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r194",
      "r199",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansStockAwardActivityDetails",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r194",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r194",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r141"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets",
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Public Offering of Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Public Offering of Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow activity:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Vendor"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "U S Government Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureFairValueOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Changes in investment gains and losses"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r126",
      "r127",
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Change in Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "Valuation Allowance Of Deferred Tax Assets [Member]",
        "terseLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances and Reserves, Balance",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances and Reserves, Deductions",
        "negatedLabel": "Deductions (Chargeoffs)"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r304",
      "r311"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/DisclosureEquityCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.axogeninc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(ColumnA))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=SL77927221-108306"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5144-111524"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918631-209977"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919372-209981"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=118388040&loc=d3e49354-109356"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r349": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r351": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r352": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r353": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03"
  },
  "r354": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r355": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797917072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">13.  Employee Benefit Plan</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company sponsors the Axogen 401(k) plan (the 401(k) Plan), a defined contribution plan covering substantially all employees of the Company.  All full-time employees who have attained the age of </span>21 are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of 3% on the first 3% of the employee&#8217;s annual salary and 1% of the next 2%<span style="white-space:pre-wrap;"> of the employee&#8217;s annual salary as long as the employee participates in the 401(k) Plan. Both employee contributions and Company contributions vest immediately.  The Company contributed </span>$988, $650 and $439 in matching funds during the years ended December 31, 2019, 2018 and 2017, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797955920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Agreements and Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Term Loan Agreements and Long-Term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Term Loan Agreements and Long-Term Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">9.</b></span><b style="font-weight:bold;">Term Loan Agreements and Long-Term Debt</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Term Loan Agreement and Long-Term Debt consist of the following:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Equipment Lease Agreement with Cisco Capital for a total lease amount of </span><span style="font-size:10pt;">$59</span><span style="font-size:10pt;"> which has a </span><span style="font-size:10pt;">36 month</span><span style="font-size:10pt;"> term and requires no lease payments for the first </span><span style="font-size:10pt;">three months</span><span style="font-size:10pt;"> of the lease and </span><span style="font-size:10pt;">33</span><span style="font-size:10pt;white-space:pre-wrap;"> equal payments of principal and interest until the end of the term.  Interest on the lease is payable monthly at </span><span style="font-size:10pt;">3.5%</span><span style="font-size:10pt;"> per annum.</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Equipment Lease Agreement with Raymond Leasing Corporation for a total lease amount of </span><span style="font-size:10pt;">$30</span><span style="font-size:10pt;"> which has a </span><span style="font-size:10pt;">48 month</span><span style="font-size:10pt;white-space:pre-wrap;"> term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at </span><span style="font-size:10pt;">6.7%</span><span style="font-size:10pt;"> per annum.</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">Equipment Lease Agreement with B&amp;B Office Systems for a total lease amount of </span><span style="font-size:10pt;">$32</span><span style="font-size:10pt;"> which has a </span><span style="font-size:10pt;">60 month</span><span style="font-size:10pt;white-space:pre-wrap;"> term with equal payments for principal and interest until the end of the term.  Interest on the lease is payable monthly at </span><span style="font-size:10pt;">8.5%</span><span style="font-size:10pt;"> per annum.</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less current revolving loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less current maturities of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Long-term portion</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">  &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Credit Facilities</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">MidCap Term Loan Agreement </b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">On October 25, 2016, the Company entered into Term Loan and a Revolving Loan with MidCap Financial Trust (&#8220;MidCap&#8221;) maturing on May 1, 2021.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company had the option at any time to prepay the Term Loan in whole or in part, subject to payment of a prepayment fee and an exit fee.  On May 22, 2018, the Company exercised its option and paid </span>$22,599 to prepay the Term Loan in full, which included exit and pre-payment fees totaling $1,470<span style="white-space:pre-wrap;">.  In addition, on May 22, 2018, the Company charged to interest expense the unamortized deferred financing costs associated with the Term Loan of </span>$473.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company also had the option to terminate or permanently reduce the Revolving Loan prior to the maturity date subject to its payment of a deferred origination fee. On May 22, 2018, the Company exercised its option to terminate and paid $2,958 to prepay the Revolving Loan in full, which amount included fees of $236.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805991504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">5.</b></span><b style="font-weight:bold;">Fair Value of Investments</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company has elected the FVO for all investments in debt securities.  Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows:</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Level 2 &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company classifies cash and investments in U.S. government securities as Level 1 within the fair value hierarchy.  Accounts receivable, short-term other assets, accounts payable and accrued liabilities are also classified as Level 1.  The carrying amounts of these assets and liabilities approximate their fair values due to their relatively short-term nature. Investments in corporate bonds and commercial paper are classified as Level 2 within the fair value hierarchy. The fair value of long-term debt is estimated by calculating the net present value of future debt payments at current market interest rates and is classified as Level 2. &#8195;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following table represents the Company&#8217;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December 31, 2019:</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,812</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. government securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,544</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,544</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,754</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,679</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,679</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,808</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,356</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 56,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 87,597</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,947</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. government securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,923</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,923</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31,495</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,869</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,869</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,025</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 28,870</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 76,389</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 105,259</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">There were no changes in the levels or methodology of the measurement of financial assets or liabilities during the year ended December 31, 2019 and December 31, 2018.  The maturity date of all of the Company&#8217;s investments is less than one year.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797974112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax basis</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:-0.13806152%;padding-left:0pt;padding-right:0pt;width:100.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2017</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Inventory write down</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 273</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Depreciation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Amortization</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Interest limitation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Allowance for doubtful accounts</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 274</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 285</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Right-of-use liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Stock-based compensation</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,140</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,335</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 520</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred tax liabilities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Depreciation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (81)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Amortization</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (206)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Right-of-use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (809)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract liabilities</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (39,932)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (33,876)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (28,357)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate differs from the statutory federal income tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:11pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri';"> </span><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:27.84%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December</b><b style="font-family:'Calibri';font-weight:bold;">&#160;</b><b style="font-weight:bold;">31,</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.85%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:1.86%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:10.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Federal tax rate</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> 21.0</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> 21.0</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">State Taxes - Net of Federal Benefit</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> 4.1</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Arial';"> 4.1</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Permanent items and other deductions</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (4.3)</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (0.5)</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (20.8)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Arial';"> (24.6)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Arial';font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Arial';font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810991504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,724<span></span>
</td>
<td class="nump">$ 24,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 41,724<span></span>
</td>
<td class="nump">$ 30,294<span></span>
</td>
<td class="nump">$ 36,507<span></span>
</td>
<td class="nump">$ 30,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805964656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Furniture and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,059</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,763</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Processing equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,772</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,349</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Projects in process</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,886</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,906</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, at cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (3,764)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (2,861)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811527312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents and Concentration</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Cash and Cash Equivalents and Concentration</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying consolidated financial statements.  The Company has not experienced any losses related to these balances; however, as of December 31, 2019, </span>$35,224<span style="white-space:pre-wrap;"> of the cash and cash equivalents balance was in excess of FDIC limits.   As of December 31, 2019 and 2018, the Company had restricted cash balances of </span>$6,000<span style="white-space:pre-wrap;"> as collateral for an irrevocable standby letter of credit.  </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Investments</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company invests primarily in U.S. Government securities, corporate bonds, commercial paper and asset-backed securities and classifies all investments as available-for-sale. Investments are recorded at fair value. The Company has elected the fair value option (FVO) for all of its available-for-sale investments.  The FVO election results in all changes in unrealized gains and losses being included in investment income in the Consolidated Statements of Operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Revenue Recognition</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On January 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 606, &#8220;Revenue from Contracts with Customers&#8221;, utilizing the modified retrospective method applied to contracts that were not completed.  The adoption of the standard did not have a material impact on the timing and amounts of the Company&#8217;s revenue, processes or internal controls.  Upon adoption, the Company did not have any material remaining performance obligations, significant judgements, or material costs to obtain or fulfill contracts with its customers.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection.  Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products and services to the Company&#8217;s customers.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract.   These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#8217;s cost.   The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and, therefore, the Company has determined it is appropriate to recognize revenue when:  i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement.  Determining the timing of revenue recognition for such contracts is subject to significant judgment, because an evaluation must be made regarding the distributor&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company.  Changes in these assessments could have a significant impact on the timing of revenue recognition from sales to distributors.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of sales.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#8217;s contracts vary; however, as a common business practice, payment terms are typically due in full within </span><span style="font-size:10pt;">30</span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">60 days</span><span style="font-size:10pt;white-space:pre-wrap;"> of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material.  The Company has several contracts with distributors in international markets which include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In connection with the Acroval Neurosensory and Motor Testing System, the Company sold extended warranty and service packages to some of its customers who purchase this evaluation and measurement tool, and the prepayment of these extended warranties represent contract liabilities until the performance obligations are satisfied ratably over the term of the contract. The sale of the aforementioned extended warranty represents the only performance obligation the Company satisfies over time and creates the contract liability disclosed below.  The opening and closing balances of the Company&#8217;s contract receivables and liabilities are as follows:</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Balances</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:44.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Receivables</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Liabilities, Current</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Liabilities, Long-Term</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Opening, January 1, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,065</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Closing, December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Increase (decrease)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,256</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (27)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Opening, January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,321</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Closing, December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Increase (decrease)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,623</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (27)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company evaluates the collectability of accounts receivable to determine the appropriate allowance for doubtful accounts. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in general and administrative expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The Company&#8217;s history of write-offs has not been significant.  The allowance for doubtful accounts balance was approximately </span>$1,092 and $1,117 at December&#160;31, 2019 and 2018, respectively.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company&#8217;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Inventories</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Inventories are comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve&#160;Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane, Acroval Neurosensory and Motor Testing System, Axotouch Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company monitors the shelf life of its products and historical expiration and spoilage trends, and writes-off inventory based on the estimated amount of inventory that will not be distributed before expiration or spoilage.  To estimate the amount of inventory that will expire prior to being sold, the Company reviews inventory quantities on hand, historical and projected sales, and historical expiration trends. The Company&#8217;s calculation of the amount of inventory that will expire prior to sale has two components: 1) a demand or consumption based component that compares projected sales to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being sold. The Company&#8217;s model assumes that inventory will be sold on a first-in-first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that a significant portion of the Company&#8217;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written-down involves significant judgments and estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Leases</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02&#8212;Leases (Topic 842) (&#8220;ASU 2016.02&#8221;), as of January 1, 2019, (the &#8220;Application Date&#8221;) using the modified retrospective approach. The Company will continue to report financial information for fiscal years prior to 2019 under the previous lease accounting standards. The modified retrospective approach provides a method for recording on the balance sheet as of January 1, 2019, leases that have commenced on or before the Application Date. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company elected the package of practical expedients permitted under the transition guidance, which allowed us to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Company also elected the practical expedient allowing us to not separate the lease and non-lease components for all classes of underlying assets, apart from equipment. &#160;The Company did not elect the practical expedient to use hindsight to determine the lease term for leases at January 1, 2019. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company made an accounting policy election to not recognize right-to-use assets and lease liabilities that arise from short term leases, which are defined as leases with a lease term of 12 months or less at the lease commencement date.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Adoption of the new standard resulted in the recording of right-to-use assets and lease liabilities of approximately $3,786 and $3,823, respectively, and the derecognition of capital lease assets, capital lease liabilities, and operating lease deferred rent of $96, $63, and $70, respectively, as of January 1, 2019 with zero cumulative-effect adjustment to retained earnings. The new standard did not materially impact our consolidated net earnings.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Net Loss Per Share</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Basic and diluted net loss per share is computed in accordance with FASB ASC 260, &#8220;Earnings Per Share&#8221; (ASC 260), by dividing the net loss by the weighted average number of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, options and awards of 1,556,818<span style="white-space:pre-wrap;">,  </span>2,621,440 and 2,253,399 which were outstanding as of December 31, 2019, 2018 and 2017, respectively, were not included in the computation of diluted net loss per shares because dilutive shares are not factored into the calculation of net loss per share when a loss applicable to common shares as they would be anti-dilutive. See additional outstanding shares as disclosed in Note 11, &#8220;Equity Compensation Plans&#8221; that could potentially be dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Research and Development Costs</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred and were $17,514, $11,773 and $6,699 for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Stock-Based Compensation</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company measures all employee stock-based compensation awards using the fair value, including stock options, restricted stock, performance stock and stock purchases related to an employee stock purchase plan.  The share-based compensation recognized under ASC 718 for years ended December 31, 2019, 2018 and 2017 was </span>$10,304, $7,606,and $3,609, respectively.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of time-based options on the date of grant using the Multi-Point Black-Scholes option-pricing model (Black-Scholes model). The Company&#8217;s determination of fair value is affected by the Company&#8217;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#8217;s expected stock price volatility over the term of the awards.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of restricted stock based upon the grant date closing market price of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company also has an employee stock purchase plan (ESPP) which is available to all eligible employees as defined by the plan document. Under the ESPP, shares of the Company&#8217;s common stock may be purchased at a discount.  The Company estimates the number of shares to be purchased under the ESPP at the beginning of each purchase period based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model and records estimated compensation expense during the period. Expense is adjusted at the time of stock purchase.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">With respect to performance stock units (&#8220;PSUs&#8221;), the number of shares that vest and are issued to the recipient is based upon the Company&#8217;s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company&#8217;s closing stock price on the grant date and its estimate of achieving such performance targets. For further discussion and disclosures, see Note 11 &#8211; Equity Compensation Plans.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Use of Estimates</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Management believes the critical accounting policies regarding revenue recognition, allowance for uncollectible accounts receivable, investments, inventories and share-based employee compensation affect our more significant judgments and estimates used in the </span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">preparation of the Company&#8217;s consolidated financial statements.  Actual results could differ materially from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In February 2016, the FASB issued ASU 2016-02. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-11, Targeted Improvements to ASC 842, Leases (&#8220;ASU 2018-11&#8221;).  ASU 2018-11 provided entities with an alternative modified transition method to elect not to recast the comparative periods presented when adopting ASC 842.  The impact of the adoption is disclosed in the Leases section of Note 3, Summary of Significant Accounting Policies.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In August 2018, the FASB issued ASU No. 2018-15, Guidance on Cloud Computing Arrangements (&#8220;ASU 2018-15&#8221;).  ASU 2018-15 provides guidance on implementation costs incurred in a cloud computing arrangement (CCA) that is a service contract and aligns the accounting for such costs with the guidance on capitalizing costs associated with developing or obtaining internal-use software.  Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized.  This update is effective for annual and interim reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently evaluating the impact this standard will have on the Company&#8217;s consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;).  The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  We are currently evaluating the impact the standard may have on our consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In May 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses, Topic 815, Derivatives and Hedging and Topic 825, Financial Instruments (&#8220;ASU 2019-04&#8221;).  ASU 2019-04 clarifies certain aspects of accounting for credit losses, hedging activities, and financial instruments.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In May 2019, the FASB issued ASU No. 2019-05, Targeted Transition Relief (&#8220;ASU 2019-05&#8221;).  ASU 2019-05 provides transition relief for entities adopting ASU 2016-13, Measurement of Credit Losses on Financial Instruments.  The amendment allows entities to irrevocably elect, upon adoption of ASU  2016-13, the fair value option on financial instruments that (1) were previously recorded at amortized costs and (2) are within the scope of ASC 326-20, Financial Instruments &#8211; Credit Losses: Measured at Amortized Costs, if the instruments are eligible for the fair value option under ASC 825-10, Financial Instruments: Overall.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In November 2019, the FASB issued ASU No. 2019-11, Credit Losses (Topic 326), Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses.  This amendment amends certain aspects of the new credit loss standard, ASU 2016-13 (ASC 326).  As the Company has not adopted ASU 2016-13, the effective date of this amendment is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) (&#8220;ASU 2019-12&#8221;), Simplifying the Accounting for Income Taxes.  This amendment simplifies the </span>accounting for&#160;income&#160;taxes&#160;by removing certain exceptions to the general principles and improve consistent application or and simplify accordance with accounting principles generally accepted in the United States for other areas of&#160;Topic&#160;740&#160;<span style="white-space:pre-wrap;">by clarifying and amending existing guidance.  This update is effective for annual and interim reporting periods beginning after</span><span style="background-color:#ffffff;color:#333333;"> December 15, 2020. Early adoption is permitted but requires simultaneous adoption of all provisions of ASU 2019-12. </span>The Company does not expect this standard will have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company&#8217;s consolidated financial condition, results of operations, or disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001558370-20-001238-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-20-001238-xbrl.zip
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M>71Q7PB(/0=LO6'4'Q(/WV7VMO(BS"!_2NN.H2#+EZ0&WJ@@Y4&3%*T%%+&
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M%-PRHX[:VZUC=@YN2LO>USF?K*D-<*62P+[+FFT%E"_V-3>\;ZK*\6NP!DS
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M*@\V=&_]2WL)0]O+86)-CX49BWHXZ_1.^Z927!*LKFWVD1Z#]8%[;6,?^K.
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M;1@RPAII,:45DYF2S$&7JDU))A:A\HC#$]9(4RJMF,R4M(N8GP]AG9WT3%^
M&_NKN%@,RY'+W !+V4,1F65HOL)8#)"=O1'(.C>Y,W$#[$ !>,8[>P%2"]ZW
M^T!N #WI(88K):\P0FJG=UIU3.@?,+:H:R0S(>ZJ9>4K7@S5)?NV>QR1W"%
M/[O1]HBDK/9TO66;]:U/:.@0C=%GHT7G)WA9]+.</7G;<6A*%;[P/&5+A^Z%
M*,@!P UNB/:2W=WABPT]ZI[?($R_F0 GPK&F. <I5,4TP6 .H1(S3F!N-@WF
MHUJR70M30!/L9C]E:'N7<$<'*K4?+\S71)N0TH&V]P@9^EEM3I;U:7<(T,\X
MM/5I9;6G:SR1PH!+([&.XYH%UV\ .S  K+ALPGQ%+72)%C1=>9%E4."L2.M
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M4\4123+$AOVF[6@&*#FQN80IX2\?!IO69L1=B@4<D> JL^)31IB[XBP8=CL
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MM,VJS,G*DK:O[*R-22(B,6*0T7SDHS_]P0$^(_@ 09!P1O4?,UW* /Q%^ ^
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M#YQNP_QV\#-2?VI3)%])5']#Z#NM(HY>1P"UV8?2.@A2Q[^G^S!J6IZV-%O
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M51B].%';2<%P*LB]6-,L!T\>#"&!V.]U-=&_W"#YD&]RCM^*T&*%:1Y:)%^
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M%>L;3@8QBHS11CO3I%*6I\IU121?X5<%9UF89FZ@4<B+M6(Z*.AW]O[(=/9
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MPIB"@VD4,'@- FJ1;3;,I073#W3W2*,#DRAW0NK+PY0N2PWV]<">)Z:N@.X
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MF/=RW#\,->1FG#UKY79P)$&Q7BSS@F%'???ILW@BR'5\-X5@[>$>^_C]VA%
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M?<*P/-0"&,"Z^^V*7&XB!#^)*/VD7Z;'@ -B^E[H^TX4EPG:IQ+>1V?_KL.
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M&-BG"TO6P#!U=.\D"AU(10D"6EB<1A;VM088M?8YECN/#-Z[M1G_W43#P*B
M)S[KF/^8)B<C<]*=\!PU@9$P3%TC(F2G-J\A^L*#ICN\4;01'Z-]KSKW/*<G
MR8E/:",^C\F92T.,$YZBQE@#PUS4'8$[M>G&QM<:-*]4!%SN:4QE]K[F"K(@
M9NZ4+_]T\5O"G#"EJ2>Z*UIGAAW?)]49 XK7-@V%G!.^PC-GA5O#=E]OMY$H
MUW5H*$Q!+/,)")69I;# +.@\1IX31^_1GVJ&W*Q^84X8_<?;!,/LT!EOJFT
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MC87%*4QNE5<9\,UL X7[:J<UG8\X:Z152;*O<D+3,A#^V:RBUM<ZD<WZ98O
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MD*.FR]S8 <P7@!Y&;,3QX\=EX,<5-[<!LV5D3@@]JH;1!0^@<2+845-E9N@
MWOB1PXB%.'#\M!#@8,\FUAT9F5,"CHIAM(&#TS@5X*BJ,C=P<-X+  X3%N+
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M\J&Q]4@3M][KAH6!J(%Y4.2'L'BHJ#FCO0EF C$$7+!)BSQV:C%U?U">R9R
M=>H%^*4;([/.X-V1(<T,0,6"2T)R"+M'KCJ?A<'Y?+FD/EF\QN))3C5):60Q
MLU,;Q(*65(+8^:C5[T&)Z/RWWF;[UW-('8 X]6!D#AJL"\[E,FZ!+E/NDG>&
M@UK_0V;*'1Z 8^$C[XJ-6!T0-SMIUFT5HDA9R01@[7A<@QS"N0\C=ZT/F7&E
MIT*KO ?E1%Y9YGP1=Q^I=@E7*3RQ*%4OWS9+3BA2>YJ+RM6F5_:DD>ITX79
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M-$PI>LVZ0QG7^N93B7A#%,?EPKR6"\(D5&W"'8/4JL/=H&YZ9H\E^J_)[\.
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MTXCG3T1Y>2Z&"A=L(ZZ'3Y^+$6,(L2W?7Y$[;J[EZ86..I#GH567U ZH=%&
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M05.0C"F*5(.D+_7K%^!%(D4"!$A  "'%Q'3YB+AEY@<@D<A,_/5_?2Z]P3M
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MH^P:6CE^J/WI/D&T)[RN$8/.$.T):VC/F%-$>PJ9K1EQCB"Z4^"GM^;;W[I
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M(RXK#8")0AD+W6':A8N2>9G8AGT7>J!$_DO R?>&Y4M%5_N-TIUQU!+_PAN
MQ^O"A-<4D!:+& >NG<F["K5&OC#6P];9(2C6J"F):)[,,6GC, 11,<5.G6F)
M4?P@X98\4K @;' R,B'5U3T6O+^ KU[*$;X$5]N5#OCJQ"E+@EG(LQ(?T",)
MAK?(OE^N'(B(."CPXJEZ )D$?DER':.Y)&HR6+*RSW$M:.4J9<Z-AJ/1<&^1
M)LPG!3XUVF],2)8ZPN2)_^QX8#+';,:,C;[(M5$2Z+9BK6U<E0^8D\*QKDXV
M#8G?-+G@[R:OY %U+9C5U:_!3, EW TQ)34/.E.PQJIR@%D'/BE(1:4]DR5)
M-^[CMK]^Q\, -\$'S4Y5+7C DC!W)%TTUR-(D\K_PT? \<AKT1MM89/$GK9(
M-=0Z8*L;JW+CZ-"NW3#/&EB..Z#=W]<6/B"K%8=R0*GQO],$IZK[T9JG6:!+
MPPTC?P,'V$GC6@Y%-7<!F@P;59[DJBB6#8#OC*21/%6-@U]'#/" BI,+7?TJ
MC'GSHLJ!7"N%U'A=9IU]!$T3^=:\LU,E_0F!E0-G-QD=>=Y_?Y8\^,"\E&S7
MV#[BJS5?K'F:A[Y0/SE?9)4FSZ*Z+HKQ**'S"KU$Q1#>^UB-E1E\,AP=C:P'
M7FN^6)+9;\W0!\(/S 66=:*^L/VP$:!;\<,^FMY^2J]5P4/*S?39O8P-$S^?
M*;0H+;[*]J.H Q\4WQIJ>\YRF\/$%Y=P]'<8O5WC<S@^<:,F> FV8C_.9#!$
M:32T)KCQNX1WCOLQ#F2[#MKHPB=9WH;Z7SVKXT)Z1:$H!$VP<>-@JBX$309G
M+(F^R/77EV#L_BN&")3<ET@&@@:',?X&C .80G34>%)TXY,U%M@*'YKOP5E5
M#J 2XHP2T^Q&F3O7Y@#F C +[[ D4B?,\;L#/6+#N0L0^>49N#%*N,YP0!1M
M9L^Q)X-;"H))M-^8UTQ*KJBEQGIE#IYBC?MRG_#6BCU=+;/&[)O\O.Y\2MAO
MG'7DDZR($C,/K.N0&A4'5L'&C8.IN@.K#,Y8$K=95#M(-CUB1<?\WJ2SXE#N
M:NL9!R>%6&!K<_SLL3'A8*YG9._XYLQ@A6>RJNPYK$0YH_B JNFVH3B['J /
M2,8Y3 KD.8F6RN\YFH388N/9<@I6ZQG% R1J^?T&DAA;E)PAS8)2X"]> %HR
MC&.TXF6.G>%3E9G)OG8 I":N*'8'TA0=6?1D>4(0\WA%7D)A^HXQZ^PWHL19
MH^"I#NW/MI6,RP+/=#36VV]PM6./6:\A[-J^U=F&M=^0Z\@G6?D$-)M3"0O(
M_Y-+_G?' TG(%>8C=/%.3CZ,_5GYAT+)]*&(JB>?Z\4D7?OMI_OF^ LPQ5K!
M[7P.J&;7W0[".-A+,,\:P$%9H09]GA J\'V *P]#)-UN51^./F"PGN5'!Q!6
M.2+IQ+/]%HF6;!WQ:N4E'':\G,/W_CQ RU3,#<]O\-4N<_$<<['_L.I"NH(#
MC9Z0F3QN",ZPFDT-B2F5,@\+'019A04/M9:\$I$SZS'P7?SGQD'%G]6<KFY@
MZ'I!&"/0L*9T;=8\@,G9PZ3S1$&J/#TP3.+2DBC]&8PPU2$^T\1D_%=Q]!A$
M_P#);*3"C:^Z<;!2@HDZZ'7@CS4K7<*#Q"8^>?7@(K5$Y7Q@(XM6:\\!)<06
MI2]+"-]_4EX@R?BV]6I&2/*&E$+V:3'$[1K9-QA)Y))2!XVU%!0\)[EAVI43
MPI#D_-ZT]5-)R)07)(^&^/\&WP:;EO _DL8&P7RPU9S!3T9.T,+QLX3[F[<U
M"=C]69&*=3)^Q]L\NTE11"6UJ6.CRN"0Y9&A/T!;*5>>'Q?ZW'&D"K2X[?"1
MK$QA4;H*%)F&^705A\2GB.\MV:/A<74E*#8X</S9H-"DDM6 LJ52"*-,7+XJ
M6FY[':(X3^:;6TS:K6ZEH#$S4T0@I0M8/I+Z.?.>X^7205^3^3-<^' .71)+
MO5YBGO#JY1:N\!LFXJ@Z$;/VR:9<Z&&PZ6)0Z,/@?;K*$\H<9A748A]GR?4%
MB_+*H\=\\%4V9H8W"ZED &]/7#_G>DVFUH8)?5*=T.5&#)ZQZ]<2N VWS!I:
MW\W8#*AIQK*J&#-/!414^_X%+VW]G*9W#D1_=[P8D/<D*ZD]&F;L:77&DO8&
M28-D%RXW:?#\7;-A0TQ36"R[BA;?[IH1-4UA9ITRSB^'H^-CO7.81TPE]VQA
MZI3&2(YV,J7S5$5UZ: :)O19=4+GK24'VV)[!L]F:K(FRI3F**_)K;Y^6/P[
MM$@3Q?DP&N)=[>A,SVSG%M^6LWPW2ONY?].RU31,]/,Z73MO:;!NRN Y3G^F
MN-EY0K"N)F\ARKB:E?+&FL;,]%9"W'(@:D5L/R<[->-]]N@"[^R_J,[^O.E!
MUG:RW6>M#PK-&[PB9",/<[8X'DV%9Y;4\L@XQU,&_"M R]:,614X!%EZ1EPB
MN?U<%T@<\T/@^.,% MG=GC^KBQ)O6!<NJ^L":6% VAYL&D_6!M+\M^1KUH'!
M*P,98:-20"ND8STHRJYIMM>6-68NLUE?G,;\=/1SDC[%KQYT)W,\0A*A69<$
MBST]CX8UI_.DT4'>*K&YI>T.\H8-GI;)$-\"#TLS),>UZ.LQB)KLYDV5M%Q[
MU8Z)?\/FKF_,M!838>DBK!.M_9SZ*9W%%VF)E8)36S^J\3U+&QP46QSD31H\
MX0L^.//BV*? (SE2DCQCR0N^9("S/(T&;;_NV)B.A8)[S%?%,3<M'QU;+4\T
M8@<_U:0K2(%'<;%1P1E)2] [0*_!;BV%Y!7D%^>3UTQP5./JEC8RR%LQ>*U9
MD]NH^#-+:GI<:WM S48_>A5CYC>'2+8>PQ*CJ:?*P7+E!5\ 7 $?S&%$MG'.
M^5GC 9<W-LA:&V3-&3Q1B^MR$EP>003*%S=-,9#\+201A.<79V<D@/#H='12
MNM'>I;$2#S@=;O),[A/>B=!ZW)GP!$Q^;9LS9FV0)<N:BT&9K.GG$D-, C#*
M#8-IFBA<FM_9]JC&-Z_0:&(0W&[6["6'QH_&14>PKI8 3)XA-JTH8HT8LXZT
M$FTIX+([W?U<)/XC=A#NTON:@C#V2(K430S"#]^)9S J+ SLY:+&,7#=_"!K
MG]@J-ST,_FW=Q[^;O7BL"5F'5!7R7W#K+,*MZ%A(F(-L6D#X*ANS<'04;W$)
MZ4"Y$N-"34)]M6$^[AN8Q1ZXA\3W,E?E,%<\./]*XIG3"UO.Q:3&*3'O87!_
MC_^U[B710S;]# H=[6Y!"5%4F&'X7]NS"__T3S9C*&N'2$4)RP47(;DD)G/V
MR)H5CXZME:;3T5"?K[*X>,G:H8)Z"WR9^2(&A2('CX?X_]I'#@[^+?_+<#VE
MMT&$69;![7RL9&Q?C:<6GKK&+!5B(83M:;,DL= FFH@/#-3R/06 &#V6/'D^
M!>_ C\$4N %>EY.[<R[A-];K*0C:T67)<X*8:H 7/N(<^H*<&<B-NKEFM/D^
M]KS@@SS-<1>@FR!^C>:QMW8431A&Q8V\+GH+,<4LD)45W8#]* D1YM^.ZHKW
M%"5"Y,AZ9U>SQ!] &(+TM1].A911HZ=R%Z6(FOY;AP!O'82/F@ORND/B]\,G
MQ(9:/15D&ZHLR<4]Q2+!["3'J1NL3WE!$BF:A3DUJ >--7L*A[:469(8>>,&
M6'1!2%_<2L(37<P-^ X2-ULF1%JTU%/(R*(T@]"E I?*W8+H1P@F\]LP@DLG
MHKY%5B[44]%S$)%;G88]7QD>P4>!-RCP\9]N&@F78II/B1!MIJ? D$)F#IV>
MN5#PW5:\)"=KKKN*T?!X..IR5Y'V=;BI4*0SK"_LZFWS"?<;@[^$&BE/ER-]
M#Y\):@K=B;3D$H-XE!$N_0ZCM^LXC((E0$GN"A*RG2=@YP).BY9ZBAY9E"J[
M$ME5)DVAK>.DNG44FNK)WB UL28&Q=GQZ/B,Y&R\O+@\O[@8Z=XXUJ.])N]Y
M^)'@EL&N;LQT;RL;UD;2@O1^.N;6I^@46@I.JTL!-5%G3Q8&NS)VIMFKO@.'
M#&HV\:> O.^#M\?D(0;N))Z<S1BW+K3.Z]F%8 O<X^I2?0HM#&?5A:$^X6=/
M5@7;,W^VSO=IWMR7F^73QHU_.[FAT,P^K]/^MS)\]F126Y[J<Z/2WD$?1N !
MOH/*8 7/!=PME:?+\7!TK.E!O,ZI0&41;XF=*6='P&+'74Q>&QHO Q1ESQ1E
M][U"<)/1A7TX5,:5?EJQ&G/7"NUN%]7=C2N#;4]V//Y4MAPU2)Z$L^'9R=G)
M\<G)Y<G%^<F)[HV.)V6KX(XGWJ0Q2TY;&;+V0$GLZ*?BW)@/5VBMN:RN-9Q9
M<7NRVO0N/>X&YF14]SX>2\R5*:^YHC&+ G_BW)9$]36/'269ILB4)F8![I2:
M?9G$^YY;L]X9<8P05KS37$]?E52/XP\'S5)_Q?#O(,2D$9L2UA5=_.=+0'Z:
MQ%&(=?=9^B;[[2= +@R3C9-+/]$Z*',6,^F9/0UDK&6&@\F<PF,W@N^\/BKM
M&K,9M_(88DF ;QU'BA,V21B>S]IU7HPPC)?I;ZUQV+Z3/<.G9$99$HO<=0?Z
M%1>,PGO_"2 8S'X'</%&=B2L3SL+D'R\P3)<WW3O1-WH-":;9X5Q?%460KVK
M'.1"Y[4:+_AB)O*>'-%ZG)*\:&-(X84'EUYE%'QPQ:VV0JV5)\)(WP(CF,A<
M)KG6'3)NYW- =-[-VC#%2R%);^*[F"UISD0Q4(DWV7]D2:*YGW>+C)R]0MM,
MC<<\,\MU3_8=R]-=)ZDHB%+'M4Q02ANS G1.8"U"H/;=Q/E<^(E<CXXSJ9)?
MBJ?0>+7R$A7;\:X<C^0:>GX#("IDU,W4^I<@S4G"1('DUON/FETP1+NAJA%E
M27HK.9 2:LHZ_'2G7KMUB *6-)=WD@LM35KO+Q*:UO&'WYTH1DUV\2Y-60(6
MF=1K3R37N+*DCG[?H0^7\3(W-=T%:$U[$@N]@GB]%5]K.C9N":#4\D-9YCK]
MCWD(G8VZ/>G1DY.2EK<]2.3KZ?$%<>P[OSB]/#DA&7/T&F78+UB(66,$VC)F
M09(I29;5IBMOE(8P[NBQ$*Z<.3<@<J#'MU:=#&L>1A1)FI-U9OA:94'6G-Q)
MF;P 'A)W6K+]9U/!7VS2#"<S@=L#G*NU\G3"D#G6]))ZVSPZW:FE+AZ[>CMF
M2FY/QY]P.U%>Z9LQ@E(A@HV FVEFK/7YBBWG+5-^V7T'RU> :-)+OQHCOV8.
MUTB#08-VVVE[X64G)*KX2M_-$R!C7&41-M/19R$ZGVPA%K_W68B-=&BW+TO2
MB[  $M,[UJ7!/?Z3ED"V6M 8\:K=) 490,6%KE>M?N!#4)*H9KPD/*&(MZ:D
M>?+EDT!5=+S$[>9DJ^A.8$K\^R;S'V$:[2UR![!5M?^"[TRM@M6])DV3XMLA
M6,D&SEO-<@0T4:K@.G C_2-)TK\!:/,<%TEQN[EB2-W\ZF3?6,D2R;>C4]+-
MGJ=!Y USGJ^F_<+GG/E=+]YVA8#<M7<**HI=4W$[9=U((?5AJ%T+6(Z"/P5A
MA" ))24Z+D6W+Q?JO^ %Z%+P=%0'C5[2'0SC_</-T39+4$R!A% ;]B"F.]D*
M'IZ2;4H7!Y0?P1GT8N+)_TQRV2;[X^VGZ\4S,+O#K"<!:'$JXLE\^PDWIEU!
M2MME29SJ>Y6F.P"5L4/2<U;UP#R5I+[PS;_QHF#"V_Q<I^!T:K#_L%+$ Q6/
M:'4 DS15B?[4(%USHM?I/WS:DZGBK2SMRG1]P#7M/J2VL#V8$* O!X,::^E:
MUS3 (ZP<VIB^*R7J)7;<P4OLVZ \ E*'C,$Z]S&>"KHNU*H/B8VC:P>A+SS*
M)),"XXJML:YQ"XC@HUFM:51Z]]97ZTSOY,]!C-*K-4VZ)2%V"_-E3N Y4?ZA
M4)*Q7+1NL^<PDD^[K"N]@-PDZ'EWAT]%R9\MS )IA9W8N[S\^FV0]S[(NS]H
M)KLEH'"TOX*>!V9W <J34.?""2?H"04+Y%"=O=HU5IYX9WCB7?9IT9%(M"1E
M9I5D[L)'.!31CT4'F!U?:H[8TH0S>5D.4J#=^C-E7FOWOHO(!?P-2/][[^<T
ML@V\//5ZNNYTH\\L'R59.8.J3RZO(_39%YH\57N*D\XD2G)K8NU&%_L"F%[M
M-.UIE.0'1=]79-THTM=/ 4QT:*FG:XILBB6Y51GE9\-DQF/@N^W7ETWMGN)'
M!I62?+-8VY(N<Z FY-BS.361*<D-B[X_G>O9GZC@Z-983U<9!40K=9/:C1WX
MWG_';> N18V[)]4,)86V^F*IS8?\Q9T:B5&#),\Y'AV?87P<G8S.+B\NA(.S
M)%-%WF\-W\",/ D;/H)H,B?>.>B]$M<A4-.XZ2\JD>KNT99J,V/OV\/E]P#]
M<>\_H< %H1A<Z#5MAHL@U99$^:_)GSH?WQT\&NAX8FBA5K09+&)$:T\B*QDK
MCY4@\KHB-LN?1IZL#+ %9P*]FPA67\%-\$'S=:T6++/E'+-E9(W4V41*LHSN
M_ 7;]3M/DSFA-$PSWXH=(&K2L9)F!TF[Q$&DT')?CA-KOFS(:G+]8%?1,9/7
M(ZI[X.<[/C63Q"<3?THBCE":DAB?DU'^SRLGA"$KWZ&T]HU;-WC$7UPEU')B
M9^GVVB/LZBNCDLSR.P3^%0/?_:I)J"A0TUQ4*)$R U6"/.H!7NKHN0F6#J0I
M&QPUS<6+H/P82!"DWA*[1AWYX7J:U:8=%*EJ+G $Q<T''"[R;4/.U=?ZS]\@
M0"2N\>N!1#7R[5&,RN:B9_?;E"B;&(8T W>JL$J>\)Y%;<-<&(F+E7,=$F*%
M;0O2O;^*HS#AXQ'?#E:M82YF6HN9 1U.^BT&RK$P4([W'"@L^BVYQ2F\UQ)&
M*$[>>V?H-/6ES07(KI08 ;XPKG0T:RTOR/%#C%W"KV> WB%);#V9UQ 7ON"Q
MA/6?F$J-S"[,0YT "JH84LX:2[:V[X$/OKX[Z \0W<7^+&3N:O6%C4..<ME7
MX2; &4N \^/YU^ =()_PZ@:\1IM<:4P(-54[@*DECRS1H*Z"ID6H4*+,B(N]
M!$L3.RSQ>2%OP0)$&/7DK !B(J2V[ $K(HS1_H*RI%AX<F"Y<MP_P(QS?V+4
M."!(G#W*GDGNG_?&0\/S35+[, ZKVBY"E'&3L43JSA:=D%SC-\-:\^K*6XDB
MME0I2QXW=RQX>OD)!5@YB+XP\TC.KE5Z#!'Q0CRK>B'FC0X<?S98-]L7%\1\
M]$\>R>A5X O%#Y&CO-XGEJD#Y'M3F5W=F&6#6VSU;RFWH%+EX\GR4'OU1?1!
MQLT$1TUCA"Q%;E48M&5!/Q! 2&!>+7#4- X!;44F(/P&ZK7;=FGO$,;(AQ&)
MN/!GD_D<NF!-4>UIF*]2?P#0(+8- #H0KE3STW222%YD>PN\V?URA8+WU#6
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MN"=++ BCJ1.E&9UGFV1V7%!A-6 U>(0)5QK3J^G.=VM]!FC)9Z''!:T&!Y5
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M=BGS1]X(#G-(CB^5',8KR&3<RQE48WS3,8T$AW&82U+GD@SN6YF^N#-G*T]
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MGFLO.A^$RE+H9]228!<Q[[11-;UDWN8@:S1Y]ZDO3F=;L:Y848 HP1.W$YI
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M15L$7:8(\L&"^-3U8GWZX<^R"Q(PN_UT<=%:V'5JJ\3KTZ'^^.)=KUQ"C,E
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MS9/T0OK>=Q%)(7T#TO^V EI]4P?<B3!&Z;6NIB")!BT"D'0(Y"JVW3EM7?T
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MY&AD2VUR!N3;FU)C6@ZH=P5M3#:95312$=/)+(IUF:PH*4 6LPREJ$!.RS1
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MOCF$%*=;Q=G&T1'/US(*8UJ<]81[HU JCF1^2H_*G3BX>1]PNEA6Y,>NEM.
M-#4F\VE^2<YN@HH>AQ3,UNRS)SM342G6RE3%NM6-A,FI%78BEU+Q.W?B2+,_
MI#ZS@ 0<.%.HI8/=[$A!=Q5[=X?A2D6B:T*>NCH@?  'D+QL1NO!Z]I,OYOO
M9%.Y@I%Q^%PC-RVF1_&[T RM9>^CRZH0Y1%AGE2!!ROHQQ3=VN/V'$F_E!U_
M*97W\8!EJII?#WJ3I0% I>I8Z0I;*<3.S%\ ^^D)1EJDF.TEM-6GHV[%F/>#
M4<?,)PURUF9ZXB*EU6_C&[?$>\,$]C&H@ZKY'C1];YR2Q8<0OF)_Q!N77XO
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M.UZH>V BRFV:*9&+3($LU^ZM"LVG^W?=Q:,78ABA!][SOO7>85%)"S.'KM2
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M]+'M)CQRT#M@Z)OAF1G=1(_X"_V8_470*%Y<N? Z/EARB@Z6/+4Z"D>]5C#
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MK^^KK\.G'GZ[  ^_L7UG_16D1/2M[T9?_DU,I #=*#S758 NT%Y(CIHP;=M
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M!.%)B9%%V)$M-/('V$*@>Q9<D>(%ZD'(AVH"]HQ. ,&ET+8%.Y/<<$( 229
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M[<@A=%]P6"_RHM1"'+0U(07HGBL KFR:C!G=C9BOC%S'*S5*B,-R.* PD:N
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MH[_/$(]_>4['&\ALI_F" _*DVM$@33+053T5PMSV?O2CP[ 5Q];=J86&S]2
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MH#D. ,WJ=4#)YW416=2U]?%\8U=<(?6>6HVF9458]%N0U=A@?]T='D5C /
M00L0V9OPU0$&KM-2V%2$+)-A!7QC >K,8=W4]P6P> YD<7:EF$07\F"4K>V_
M)2$/ 3';6@O:*8B%:O'^NJT/VDA;382"(DGA^;R@IP="@DK#\%K\*V5 -K4E
M@.%54.88AP3JKMB1TX[ZTP7-45@H#(O>962J7%UMAV5H-IP,0D!!B8* YG)!
M;/. G.->AF.U76*CK61(IHJO]7\BW6(;]89K,VEQU(U.8O[Q[";E4U=+./F
M0L+_KLG7268KI^(<5%&AS3YXT$XO(_SE18#;)$)MEB:52FM]E\:,![>7"N&I
M+JC.K^^KKM.G,Q&@2-I%UNZ63P:2=W#IS6!NVK)+,EF9I;("@M2L:$Z]#9]S
M,Y*LXOE??PF]6"H_TW:8'7OQ]/R2)QU 8< .;,\=H_WP\-W:YAI$<^N9-D.*
M-H X1IX.VHEL6S8IK4[34G#>Q9X0SI7^NB:IJB$<[D4A''2"D5E[)<LQS2>U
M8*[2E&>KU$[5MM/<7?0+0TLRUV.5!=%!YA?:+%M#2_P(#^87S,'4((1EA).
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M?CX8TNEG\O;YP4[A<N)PHBVYO_5L?:G=AM:*],0'!$DX[B$)/23A>X(DV!H
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MV<!MSQ0U55("0EMS$B]]6IFM@Y<^ /L_R74.QS$ZITT*<H_72;H0:P^?7,6
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M/5$B!'SH+0=2X7>''SDO,S#A\*=Z[['AO2GK,5@*I39>H5:X*F'1(>_<+>A
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MJ4Y&^JC_*Z_)1YNB;K^GR)1&-F):Y-/#8#K;0..8-2X=W4WT+APN\F$JV2_
M5KL;A'GG  .XK3U5<BTFY3)-MEO+FV T ,4VG,;/&U'23H;C3N2< 64N8LF#
M9E&[9E@W.7?+L!;+H^3U9DOM5#TFQ?]+KU=^?W3W?F-W3M :PS?%GCG-ZIK
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MX$QIU*)'(#E=5R08$PR*CJ/BY[DB_4O"4SW9X:EV>*JO"4\%E%1J;:SA^TF
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MKG1!K<SL!^2L<7NY9UGUP2DTNF^0&:ZHRPL%S6,=Z3NVA;;0TBXTG/RH7]P
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MLT7&N\Y.\BK[X/0':<J" S)K/SV1<"<1\B^B_G,VPKF.XN*,:!:\=I28'0)
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M K(%J+0^IS0"91]*-ZA<=H<K9Q%>49L1K.5>1'@&?/[M-_CO,I94SVI %VO
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MVWDM+.PUAK@F.:M;[D&$:*S3\3-]/[C<R#A$OC*Y0VMS_][3XW<G^-?1T[L
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MEMX]!9U(Y6?$^0'_Z(_;CEMJ7_T)O 9&1X)F3V$^[EI6^(8[T<1NU(664,1
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MVJ!_B?/[Q<CQ1PS7FQ@M!7<'<L8>TA:+WL--#9 Y6YQ)0?0VH5A+FF,XT1C
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M>OT5R?X<D<_&/U@)2_.SK%PB'(\U+0QJ07*O;*AP;Q4E1E$1$9(_VU&3:V.
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M0WSV$)^O&.+SV<UE=K^"O;/%#7570]ZA$28;,[:#5^II?L55_S2M=3M-Y/>
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MN8UKA[<$:B.*A)F)0^X0D]T]3)<&1O=Y%J+]XK38=VX/TE&#/1*T9.YLJ_9
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MW@(FPIX7T(QJR,4:T;<X"0Q" Q2$-"Z)E;8G+2Z=?H@:%D<W!UG;E?(4# H
M"NZ$X&U":;7CW@;.,O?1NF_(S*$>=;YC&56_9_.B[CEEIG^71FH@@ C&!T\X
M5;O#MH'BZ;O)KHCM7?,:$ZOQ!U"VWTCY_V3E LH&,JH\@!K]/V^I&GDYH-I2
MBJB^0H<!!,%-MRFWDF$!R=XN$,GUG'+<CLI_(:J"D J)@?B+L8K+5HP/\J_B
M+BEU3-=5,W:"CK<UJ@(@*X_OC090:+U#\"JG*ZDWW3")Q"2']$="B/$O.+9N
MQ,9 QA#4;F"]50SRH!&FH,7(&_@([BCWHC8EC8&L 7FPFDO@M3/6)NQ@26"%
MW.,E@#-F%*3%Y3WA9(&;>,_]^?S@(\,,Y"6+!GJ;.5W$H*4)E C:2V#PHG#F
M%YNW>;P<WKR-XON3+4\_:[O3SWVXOO8@XW?[(.,^R'A3@HS7(\Y[[33'B?/@
MG:9]U]7S#W\"2=Z?=.WRQ@E]X^<W:"J&*/*-BQXU'"N2=/"<U[2E-;6I::5/
M@P+^+%;/[YSGU)'8-NTO3/NQPTK[?FJ!4^L<<:$R9_K?W_HZ=&$;_=S]@[[T
M2]8NLM^2DPS4IM1"C]X')E8)_(98FT8G$*Y$'_NV4]A56?S6%XOAN!&-RS^Z
M[QTF?\NW 30S+V#R,XO%\ /6R%X0J[C?+6%YG0/7YF)_9=O$]A)P07OF3"$&
M"[;B^T2  ^+^'@TL\XU2]0U"%TUHPC.*,A.LC#R\HEZP_R;491L?A(SY@>4Q
M00:G5T1L6A#[2FZ"8Z$9[>_2_MYTD%R@IS3<\1 "#$!_X?2=>B%;LLOD>3[/
M007_X"A-[M\[^BYEWMJ/$D=-W WY\#]4ZNJ^HW@P=@#KBV?$6^M$63$C^ FY
MN^A0N"@:4!N[?S+5+J*1G(.FQS@;P:2=L86YVXS0@X@3PY(8 <S//9O:,.8^
M5#J4A%;<:!)H$QT<2-'4 G$0WQGXPHNOW;3-F,KL(O09ER[?.G)>'.XL2=%C
M(XS((P#^XH<?!?/98\)<I]=8*=7U%*G0Z*R<ZJ!LRX2B28T'!6A](8VK/2<?
M<YBCQ:S@P7%0XN$TW@UA  ZK*EE?3!^B .G[,E&&K_M6^$1((P[S.%L6'3_O
M19VYGYMK1"FT;>L'"ELSF8KQB)WA!PN+>&]9@H,T,)P*Y+GV&(0,V2V-B.R"
M3WP]U/A()K=T;D5G3U_?7(6  ,1FY:3!MYG]/S_^XGEB<?WK1:)6!J-(R]3G
M2(RVT_Z0IDX'G=TJ[H-N6HX'K)]PMB_42+'G'D8%63%,\2F]89M@L".+Y+DO
M)4*JX97PMC"*0YZ4ZC0O_).VDQV=S5F:$4IJGIIOEYMA_G3BO( ?'83^V\Y-
M"(N$BB2H8DE_1[T@O__]1V/?"7)?Q'H=KW]9]D0K[>G^^0C1.1 #P7=58/V>
MD%UEFS]P8%>EW:='Q27LBG"R0W)Y<++YJMK7YM]:(;3R$%B:Q=ECG+=XM5%R
M;EUF>ZFYO5(3],FY@J7V335OKSADW!X!6" WX6(-J_(\$Q[[5EW=$;GZ7H7<
M7IFIJIKP:"NEA3&55'!K>ZYAB/.K>X&YM0+C(\J"CO1:1;G+][)Q:V4C5B;;
ME =0\[8@C3KB<+:T3;5^D5K19DTGA5?N[U14T26$TN@EN#J7"!"%.8INM6?\
MO-VR9SI_HLOR'% KI&#^'WMOVMPVDB6*?K\1]S\@W%43=@3,QK[8W1VADNUJ
M][AL/\L]\^9]822 A(@V2; !4++FU[]S3F9BX2+1MF1QR8F8:HLD$GGV-4]B
M+89562VK'=3 HS66YAKD&F7%\(P)1Y6SE*6D+_RF.P"C6>1D603,CNAB["F7
MMJ]1.\B:7U;X95#@'O:?J+/@O:J@3/%!2*YN"-:L<[*L(V^5+JN;81@.3((]
MAJ*??$Y-#!>-&K2"A4I8=]ZUEFL..ED.6JT8*SM58[-,>Q2R*6HQ;$X>R>GT
MD%!!BRG@0W/1R7(13\MY.8,0O"MOXM2\:BX/<6H'YY2Y0W1U FC/Q;^,U0IZ
M5Y92]05D),TPI\HP4H-<J1$9;4/=\"3[L(\BXW5:%8EJ>2YJU=&%AQR,-^)7
MJK&K5H?69H,3<(QF%MZ4J,7(&<=0;KKW<[WW_,!48.D#4_K U!X?F+J?*9G#
M/M'! (]^]6*M7:QO#>G$O)B[5#=J&ML5-<A7' 4-EE*_-;LN2'5P@DXT=+V9
MQ89#"W2B5W2#WK2MSEU^P>SG&M(IP^O512:K-YVD/5930&Q94-. FD!'AROD
M\NUXFO564OA1"XAJ(>WABPU>/3*,=[W1*&OO7*Y8AG:NE#RVVQV:5E.5S/9<
M#5@7[+OK#QD2_=K='7']QE<:%4H;'DQ*0F-QZ[1C.1!&3%]:G3]3S88G=BE&
M7Q\K<PA=X,PHLK\^&?]]^L5U?">*'?^)$.Y':P^?&_]@\R4.,HS509R/4QJE
MD^?PYF)JO"[FD[("7Z#$!NL)F^9(TDDQJ_DT[R*:6MU=B5WZQ+O(1W@[:H9#
MCI:-& \QD!D4!'H9GF#B=$]%.YBH'8RU[03,<*BC"9HA'0%WBDE JK.O/?PC
M-BH/!1E/I>_S%GCGJLBPR^<5S_D\ SY63I"<J[9RZ@%0%!H?\,@\[O:?V"5_
M#;OB\@WP=;3EZZ?H>:O1'W*F.,*W<0^BC5ON<M/64D;5.4"NI(]Q-5I!!4>T
MPO^^+T=&],*.GZ=7S\%M"&+CZ1^C5R/CS73T#'1'1VXQHDVVW'8O%;<-Y&Q:
M<WDY#![6D(7 AK<IM10K.X*P+7#G*YKT?7DESGT1'OM3&;K%U&UP8D::NMRF
MQB Z0T9=+),IQ-*EPC*\>K@L$N(/=B.(<6_O4"L*MLCDU$')T#)RP];CY>42
MN#(TQ5Y 6[=GW?!97 &0CG:L?]CA;B+(#0LRT%RYC70@Y<A(ZN#5\EJ?0;]U
M_<)X:C_K1LM($H$\7<I#?60)U.QH>1"1IKU!H  &%1/NF)-_:3QUUM?I#?$O
M4D+1%,P:&:04$%/.E*@TX&KA?"J>;7Q<SD@&Q_<:G!OCJ2M?Q6:)RNG6R^J2
MP_\*#YN&,,Y6!O:)&W7RU7,HF_<K<GOP+D^^2UAKN3I-V^L-\JIQZ+\X'%I*
MYZ&=D@%K^!M0C(<4VUM_::J<4<_P2J7ND ?!1,/])C3HL7MXP8IL,*5=$2&X
MA0ATQ/:2AI,8LS+CT_:@W9Q0B#OJ#0#KCJFH\UCIA-' PKI9@O*<7\+[P@V0
MD: @MX %GS"Z\QKQ5EP)UA$UG(K+"96L_0(<'K#MX!AL>E%T"V";5Q0T4FL2
M !@]X1!U-<R>_*<*Q\!).A;SG&:%S#@>J$2$QAL Q .Q:,G4K5HTN7(N_ \,
M@NO^V!/!-RL $=/+W<CY;')+\$K;N@56K)QW/:9RGZ:\2:3N,8\\K"Q;-=1U
MY3B>AC1$1GDC>)D4?W-U;* <V<XO2SI=-+0[>)!9!!57?*!Q$CR!M&G?W13
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M&O;3K"@[EAD&>ABUAOVD2\JQ_?,:*P[/E]' GTHMS8]-*[BMXU6S@@;^!.3
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M4) :']X8;]X"[.=OS]X9YQ_>OWK[6?WFT^N+?[[[3#_Y\/'UIS/\@F[-NW^
MGOSMHKV/;S\T[0^HOF\Q0R0F10.2D*Y?4P=",>%&7DZGY34>H"KF.4H/XL^H
M)^5RFAD)-T#;9?"5D9;S?RWG*7U[7303 Z%RK)<7?,K3AF?&&W$2BTWI D3Z
MUGZ)CS4,*$1KO&WXS A0"IM)41MOX'6@#I__IVF4RPI_2K=7LJ8[UX7)^08^
MF*'(TLFO!O8\+QO $_RKXDVYX171IE?@@W+/YVR)<+#JQGA?@F_&C4_\DE6H
M6/&):_CG\W=E^07_OFA?OQ&DCZQJ_N-/=F"UY/U&*FP1-GL3"'+[GXKZB_&&
MI4U9;=X4(<$^V[2$0F&)V!N0G"T6H/ 09#ZM^34B%[X'TN#/0+ 6*%NP?G(#
M/)'#MWCC93%O2G/E): A7@%3L<I@,S"M0+?V][0[^C5M,308O00^*I<U;*TV
M#?XUY6 U%K [*LNH14;[YRX]]+6B'R!RN"KX]:GIKBTB\=^<V 6Y%TPS"6M:
MSN"Y&U!BZ;(&[JH7/"UR#+:F-T8YI]_6:8&L9QH9O^+3<C&CZU_F> GO;,8K
MU#'%_PH10'GAZ60.QN,23YJ"<" C%@L0!M!$<R '*L1+#O^20@/K5'S!B@JX
M7FYPP>H:M4L#?R;ELC$F?+K W8*NJG@-4LO75\V5;L45_[UD2 7<S[3(.3ZX
M@/>1#B3=NYC<U BED;$9^*0HHTW%YC47:^#O5UY0&XNJO"HRH>CGY14Y+J:1
M@OF4^,(?<+$!,*3S<B8_AQ@6UR70$5*\8YCTIT!0O:PN.?Z!#TXXF\+^4L(#
MO9!7]<CXN&4W@IH VP3]:%H.'2YC5@*6:,&:@U$ /5V#+\>FJ/3!7;^<(%KQ
MT:3,;D;&:Q"4&\#%C0EPEPMP].HE;)J0LD3UE@+,_UI62%-8E]R&RY)V3EB$
MS8!N6E9D5%AC%,!5J7A!2Q?2I;Q89XAZ)/3_QQ6: !'8VH]-\5NDUP0UG^AU
MOB&*527\>HK:%; _!Y2OOPKH!6("^UQ.&Z$W01;*NL;=S99U.B56**M+^)7:
MN3GXE<)GSCE0_I+4N]@*N+2M% "9YR/C*./FNW71V=<2)%RZML"IX..CE=RF
M#4@D<H[GT_%P.NFDBD\ SR@R8#7AZ6E1$EJK,ENF#9 1+.IT2<)X=H571_^E
M7B[6,1&.,#!#!U<%:Q1_8!Q'.!HFEN!C0I(=>HBCY>)O@ +<X^\51*M@^HVD
M(,TFQ)H)F2[S_#DPP/,:M%0N)*%&53H!P9E+(.'WY24N(B2T*K)+W'H-"A7/
MX*_K&E122D0!'V65@.81A_?KN@25BXX$:3(&JP"[9YTP0FP%>@F)L 0_[$$1
M<R[DK*P0.4"I%!:$C22S95K6#%P1T!\IGTZ7Z,R 'JF*K\93Z82]/O]#^E[/
M $2V:*1!*#)"4H/T+^=30*;B$9*^+1C[20!_K,!SW@XPP*1XU"!["FH)C2]I
MXH5X5FC2C507QI!\RE1H=B4CZ-HWU5)&#Y-BBM8!<#%OB(]*X*RFJ.LEL%K3
ML'1"_O;/8@*VV!T;"@GKFMW@ +VP6 N&GG(/ 7E5SH0OLJPHVT1>]ORJJ,HY
MN2/D&<"+Q$-]1P69YF:V:$IAQE %@6[.E_C6)2S+Z)UG5R#*#X2E"Z3.9T&=
M/_@L 3^#$\)65,5RAOH:)1B"!73T000RGK4^ GT%> 05 $^#K@2M0$F9/OD3
M5H&5KD8[):&-,YP=(O0(X*U&75/Q@5F7ZO8:=5B-.IB\ L QL%93+M-)&[4]
M".X^7Y?//Y: "N-54:=5,0.+3]*G^&G&&6R72Q,,S"*T2(;:0SB Z-["3W(
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M=SB-*:_*F5$N.!93RKF^J4%G'8ZA#7-7$_/4M4W/"IYI!CA5!G#BD?<SR']
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M0(&R.P/IAC"I0HD!)D9$*&\#(HP[M3F\QK;BD?5KZWST-70<CJ*3=S$NA T
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M&X,I\*N?*!N8%(O_:;H&DUR_J!BL7FQS[%VPVH^WCK>J6QAI/[$]]*_:-&8
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MD,*.6$B>*J3AXA%#BQE-%8^H#4FF%D7^0<I-TX)"S Q9=]Q0C"G^--T'U,,
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M-^1?@'2XU6<?]KHD)07 R-H'Y UG3%0\IX\]$Y;(MLYLQG<I;0TLQ\]O$^:
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MU ;K(:6V&COJ\?'HMBT4'AY;VL[QV+IKGU7Y[OD/TJ0-/DC>JGAJW<+:.DG
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ME[5QOJS?&==9#?B^HN+;N"H.AL X.W:[GSDF/LTQL:99@1_K@-C8=,%5:!(
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MMK^!&;8IUE9F5*V54;4$61L7@G,SV V4GM8<5)]LR]MV[PE98Z6^DN.+R^4
M;I2QM.Z1MR6LJ&-L>&:YSH!S1B9%RFP^3N9SWRR?.W+XG^FVP.J4>H>=@Z'N
M#$PD:^#R<%A89P&[W[T?E [W*\7SEF@>E@ZW^Z<WK?N**D@L#"?S\^S^5Q:'
MRWA"QA/28\V]D2=,CDY/S=V*==ZJ.D]*?J#?U^X:A"=@Y(W/%?CY8LY5\X1O
M8/-EH;=O&WK[#!ZQ8M/PC3QBI_"0?U2&[2.^(4X>E<-K3RH."(\ ,[&44PKS
ML;:5LHATVX]KW="M[G=-E[,)6G _673M5];4+>N"E77!^A[F2X;.&3I_9\W[
MJVN6TG#FK*G;>G/K%$8=:+W/P?#!]'RL]F(Z9!912$W?IU2[2;Y[5?6* PE3
MNJ4>@5-GZ(0^@D6#6&ZW ZWTT&_U\N.#LM X>VJ/E8XJ%#"0(.:DXJ=GZZ=/
M#\\80<8(UB]Z\$9&8%Z(=]7 T@J]AG5E/US56T+A;HR, +LKY KBI]?U?0,+
M9FW;Q:4:&%_>TP'/*HBK#9:DVL19,TO&-UU@A6&%2>;]SOHTI3^NN'(S@A+-
M\W5[![6;?M'9L0:U*VU;&1]U[(/')[ <BF@YR$NF&FR">9#1W7>BNY5K[:_1
M';][4!A:4JO=N])WGQJ-DXE??:@@W1%%71#G^SI_$.E] X7\J_7N+R3%SU69
MOT%JS>ND>*\7I=O#\OXN?S3PSJ7Q^#[@[\Z1%!5TGHD+6JQ_!"FFVS9(2_@C
M:32$-A\@DV6ZKFEPECW4ACIL@=:P9^&1U'A%/XH)?Q]/YR<X-%*INF<XO+XX
M_ V4_<K  2 _D4_6K=U0H(3EGCNVI\/-^(OJ/>4G1^;-1ZW0,GNM77.OT? [
MAV-5(%/7RY^<Q?L];(.U==:O(ZUGUL3GT7K)'/C"MGQ_T2O>B6K/<CK=\AFA
M=30SY$^N]$NW];%61@8IW@9,!I2$KP2VUR7Y5HX%2-;.9KQL4M;$VJM;;S 9
M-L$RR)!T'9'T&]@$>YH]]% PF%Y]6$L(AKJU V+AI?*^V[W[D]V&-!G7-*MT
MUSCRU,=+]5R%76()<$XH+ZDK;*3^_]5J?AK.O,ZI-QNEQZ;#BTYK4$,7>N8B
MS_J/9/U'TI,#1*@WGC;\?"14$"XFNTZYTN\=7?L'):]X>BXY'54@@^0+\W/9
MLEY$&2_(>$&*S)(W\(*G@YO;;:_?46M7EVJGZYX=[O2.*\@+T @I9Z&)K ?1
M5X<NU@@$WR"T\1;>L-_9D2_O[B]Z>V:W>ORP6U<O:H0WX*CZK/E0^B(92T_Z
M<!;V(\IQ0]//>A)M@'J7>BWN>]6)Q_DU+1!]GFM7C^\FC0Y8=CWS\:"XRY?V
MFWU^#-NB1>)B:;D)39M@QF7DG!9R_@9&V4LT_&R,Z,1_JNZ/[_M]WA8FVW<W
M9K![52+$3.I'RDI6/Y(- ,G,JJ\WJ_Z(NHWZD;+??K#$WL03CILWYY7KLV8%
MJ9N4I,C*?#^7K"1E/8-IKYE5IZ;/8:) -NXC<Z=G[O2465^FOUS#[AO-O7KB
MO=JXMM?WJ_QN7CF5#=#6!&)Z*3E!FN_+DP77,FZ0<8,TV7'+<@-I;,MVS3@*
M:OD@V+^^?KKB\WG"#3"T)N:D98VW++R6A=>R\%I*[,!EN</^??/I\F*[<U$3
M'Z^V:^Y]_F;W\ARY ]A^ I^3Y4_6%=)M%7ZU\7=%K#W3X#38B=8Q 0<' \!>
MKZNYL(H3^!YB+G8@")L3M#7/UCGX)6?8_0#>S:)J?ZS72<"V#"=H]\VU9MT?
MH;^MU5&7C:M1,E!EUZV)2F-OPA_IK3NM<WI7WU$_W+CCW\"O0[JM4+(]#09M
MTZU;#=QO?4JTVTBKI/*34&K$S_F(GU\XM]N]PY.S/5Z<-,Z[-Y,']^&AHXHB
M&?*HY,0%ME\6=\L(/B/X]]MO7T+PAU7MTF_8^GUOK^.<G17EGLR?$(('\TXJ
M+>SMEH7F/BPTMU94L=K8W%H=]1,8P-M-M"]A &.SOG<H%^Y=_JHX\&XN3\\.
M!D\59 "8'BGEI/_/WI?V**XLVWY_TOT/:-]WI7,DZ.,) [WOVY(Q9I[!3%\L
MVQ@P-C9X8/KU+S,--9FNKNJ"*KO((YW:751BYQ K,F)E9 05ODJ!3^^B>GJ'
MTCNL->>9X_8^7PV?X=V(M?\$!?AL=O[OIY/R7ZOBW\"[%?2M/M40ZW;2[-JJ
M*)L+AAP1<G/7'DZ]>GV@<-?VY:AW:'9!=BPP36Y;<Y V#ZOP%VS<HRXO+'<9
MM>*WAH+OFUR^GI7R!\C5T]![(WYDWAB(@<_ML ; &N"ZSMTG:8#1Q*\7QK4V
M)?(90^-IWJLN60YJ !9J /:-.?+Q6=TGG=5].XT0,;?OTS3"^[V]3]((L_2
M,?):HV:L]JOL?MA)9],]9!/DH$; %^!>]_O^X\E =*/2KUO'=_876D)6@>\(
MWGB IWR6[8%'0Q\2=%T'XC]W9#.QEAV4,M!;:"X\([306;OL/:8H!XU<#WP
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MBB#HC273T7A-+ D]5Q;H2=[8<PAUS%__4.DDF:5P@AX<>X//"7#L#18%'&.
M8V\P+C N<.P-!@:.O<&Q-U\N&G>-"PP+''OS#<F%KXZ]>4]-[R]76*'>?Y_
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M261P_@S,VV%GX!.=@=<1ZVR6E44ZEZH9K1DOMMIBX;#4YA"Q,'J79)*9UPM
M1TR<(R6]=XI8G%#D*M:M8X-.34^1""Z [1OL7,RP19 ^CWFH$:Z \N=[\0G#
M10#A'D!P:\9M9=V$N=J+M@,_Z6FJ[Z"XHH*F7/+@-Z6FF$Z5,HS8XHK94BU5
MSG9''.PPM*C3=#*=>5M5!:P:(LC/Q5PUX*(K7ZD:*BF[WR=;K:*QX<N&J::W
M1)M'J@&8[A2=))FPY1X_=,0##%@SQ,P'B)*I?\H+'?CMY]S0LC7748U"5*@1
M4V0XSP7.<_&Y1/<9@K\LE=ITYYNAVW*F8DTDYWY*/XHDLY-H5)<P?;-K[_<
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M=DLH!N#7T\ 8\D<F?86U>2Y=:!'HQY7X7SFQ<*"E\]_]%G])\MZZ_,&O\(L
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MKNT<4 EDV73AQFC[<^ ,>.BKBCT]@,>_F!$P!7)XS4Y;*]A63J>D<*;@ONV
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M=-$!&J7_*^ ZF@!-LN=_\92MCJG;)_^,%5@#O@!:57U]9F,#M BL"30UD]7
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M)9>SEI]EB,W:<.DR.VL0ZV*]J"K=NW$YMP ';NC L@/[Q-!&?T!*0YZU ,Y
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M$ SM7>AZ=I-SVC(6;JLN;^CE@LZU=&9CV;/[27,-MHKH,K19@&:6_1,R7P\
MP(< @$*$B'7X-_E0)$7RRL[P7C(AY%G7<4F=O>C.NW#]I&<*)P?+['J2((?"
MP)V*+4G95(!,^P?P]-2),K^7=VU>J)'NYR$D&XXS+UKB?"A13&E9?QH6^!E4
M#8E8.GWLVKR*9_/CFLF%@52LRH)N\$]C7!44/C=19J(-T>BGP:'SJ)BC="N7
MEYU^X:F[)BOC3!P@"Q6C3BA=Q\@#C3JHRGCI/X(&5:?3MQA?U<#NS#-[:14
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M^$TT^8A&3Q36N^_@?2H*WD?!^QL-WK\2CG\U&OJELG/'O-\C.\D8$'><K@I
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M&]L5B_=I^<12X1B.U5!?4]TT]2EL?0YKI;OA03X? GR&]7O*3F%]<[\(-JK
MZ0 N"]NH[AHE1^ATA$Z)'3H-C[GG_G1@[53=]$\!+-7VCDG3@W/P&_MY15KW
MCX4:2_LM#,)=MW[NL9Q7S0B$$^S,R%ISO]_!@7HQ?.@_8"(L]:1Y#2MVF@8D
M^H!QA)JTG9*9L(^35ZG>\I4-C[58<X ;<8_4O$X0Z$AC05U["Z@++L(K5'J7
MXTQ8=S?<\!XB"[#C]/U6^-"Z_#Y)'##*O*80JC>KAT#6#H7@[ >S&L#< AH%
M[ T!!H(-[7<%-"JP-0\I)1,+2EP!WA':C<;:#FP?73T$)F!+!F)*V%2'7;*\
M\K\JL))0\7P#V!FF5W7YQ&[(MZ$\.*(31==$;TE(3X2-+BP;;0Q1)!"6G!,8
MF:@_EQVTDM_/,7/@9KP)P'GXZHD=])P**!DUR@"S8R9J[X%PR3J]DP?(/(AL
MZC<)XB*>Q.=MI&Z\:105-8T2HJ91?U^A:=2N,T*JL$QP>%9[HEVR(N3CV65?
M-$[VN5CA3F/$][./M.JLG\9#H5=2AN*I/A?)5:]06N')UK"-CV;ND$LT:WDX
M,O-\I%PCDX^/^4I:+M25]23=8>Q^"[Z=()X/Y8N5K?XTWVYI-_U4*S3E0D]H
MYACRN"V$E-OBQ&#0,>C1K(>O'7?5H+8BDS@>V5@*"U;NM&UYV5&G\UHJU<&Y
M]:GF&7J[1=K)*M/'XVI36#)X8Y2DUJ>:9^C%1GY9J?:6<EQ2[.P\36YG2NY4
M\PQ\D]PVLHE6%J>>^ :>ZJAQ2Q:]"U.'(Q^EO/SHB,,MOJQ,9_%FMN9VTO#M
M1P!=46H)[[ 6-ZR;(R:_H4BR584CL\]'<BUG5AT;3PJ]S#_&FZU$NK,FX#J/
M0;_J2\V\LQFUA@6*<FJM<5ENS;LGNWPT"U8O(W,3FEU*+6W8H8A61_32L ]'
M6NF>HQ>%=D<N3)S*9E7B%\,X''FTT,?M;-1<]_KQH:N65*57;5?ZA9.=0V8K
M::[FML,.3=I$P;"L2EX<K[V4P<.1FUD5'S)K=3X4%F[/-0;U'-&'(X_>OJ$?
M.P[=2M?P=JFI;2J#[&);RYWJ1E*KFX6TQ+DY6NV;KL#I75%]$KT@^[,Y%X5.
MJF^79+JP,7JU55*AGU WDJ.WI_6*_K2DRPVZ/),;U6XSB=<*.29S_'963V7+
MY4&U.Z2,:FY6V8@-'%^#D4=O7VC::BL3)BOW,UDJFZAU76(%1QZ]W:CUVVW'
MY@'%2^L!R>1SME(6F>SQVW-<UQIIV752)FERLA7MZ231A2./R&,QF334Q*JP
MI4<%OC&-/YK)))L#(X_(0Y;7FW1UUBCC]<U*>"P5\2=R#><\0OK.9+R5C<?N
MFE8'A7&1+4_7&WL-1A[MJ*<_%1V'S',TE<I5QH10+>4R73#R&.FK@ENKY)_H
M+EU>ZHNB;'<K? HPL1.<T6S:RVT3;[7HME-0EZ.FNTBLUW#HT::J8M&>9!L$
M.>QOAS-^770'&W#TQ G>Z"Q%VEG')6K8-Q)CM;!04Y:&AAXO=HSWC$J%;)NT
MP-?7/6*B:V:Y"UWQ1T?5G6MN/S5*M6BJKJ5RV6(S6Q3!M"?88[R_KA73EI3#
MR\IHW9MOZ#A)@EE/\,?N8)K?SNW12&X7N]NTW2Q-.U XG&"0K52^DQY2*6>H
M<K6IQ)?HI@U.BSC!(1_%=#E/M.:5H9/6V-)Z@6^F;;2 (W[2U[:#S69)=F0V
MWVKFS!I;B*MHUB/ ]H2L.5FEY23>KT_,\71B);,--.L1OA2RY0QI-+)5VG&5
MDF;:;"TU1$./SV"4>JPLC.Q&DIURW%TG,\N&"S";.,$FW0PUH113&<B  10M
MI;U*]<9=./1H7TU73Y:GF?:*5EN]LCGC2M7-= V''BV6J13GPX%HY&1V.D@;
M7+?8Y #[(TYPRB0S+I?3<M^0R]O&$*]-G.QR(<*A1^RB7^+6A:'LCF15+G-]
M?CM)=HI=./1H 8-^6G6+!;N,N^/5D]+,+3<+B+$GF.5H4UJ-9-XJ#84Z(S"T
M-=,=2H1#CQ;0I#=3.I\:BSB9'*0I:>-LQO!D3[!+<>+T:DRYH.)J/EOOC>)$
MO""!M9[@EX;1S7>81DH?2K;6;(T =74W:SCT: %VWEE2?7LUQT?#1$U=CW/N
M)B'"H4<+J/26]&-F1'>& LT_I7ES0HV DD*<8)F=?E-M#<U%<=AF4QG5:C9&
M4TA<)WCFS.5KF90][LIQ<NK0PWJC2\->9">89KY?%'+F-B?B(PEO=Z3-4U\T
MT0*.R*#U.*N+=J-4D\MJO5(EDK3\F$<+.-K69(5/L[1E)&EJ43!'VY&1J=70
MT!T9O-!/]-5HW.5:\NWZ[F!>TQA3\ UAZV3_NY.A >2%AM[H73\\W\&@AOK.
MAPUT#6.A0P08TO#%4]:2++_C\T&!51@9O4X[H%U@-8<6WO37W=9ZP2KS<)''
ML=;<JCL5N/BD/51'=4451$L<P12$Z[8%^FS,[U-]@J[7!.BEY*P$_D EHD+N
M7U!!GWP@LA'@+PAX/_DPD8F@?'$H)Q\241^.K^$B$=PC)O(]H)QX2$9]PR(F
M\OW@'C&1:S(1BHK '#&1;P?WB(E<DXFD(DWD-\#\NWTB/NVMNI$,H L4:'_+
M771;.__=&OX>CJ<>OK8BTH>[R?SI9PW^==&6,F](VN^("<F'S!<4 SH#*I 1
M*IR=*>#)NT2%Q/=#A6": ECBU)0.'O]$1;US\8KLG?&*@6ZSRGF;/UY1@\*/
M\.3=;3\OWKCOOK2FS^/\&V;A-;OW_%84_?<A\58DZD> XI9D1$0-7T@-;X54
M?@0H(FKX\2CPOMC CP#%+5'#F>V'B$;.02.ON[[O"Q1GZ$%PLY:4EU_[Z]WV
MTR?W^3U,J$\78[X$8[B7S5_&EKJ3W7\+[3!"^T]L_C)&TYWL/D+[G[KYRUA'
M=[+[;VS]1,3P*6*XA!ETN:+5[^K"\66FS*[DC%<+JZEK@AL4_9F!PSI'K]>[
MM%.^G":/3,YSU/6_@.'P+,1Z7+<?ENRY9B\-_[HKL[ONFG=W'RO!=5X4^,]M
M).MXN%="$0T@FB@B>FK*YKZ>9\D4EHZ@<>[I^4(CK=U-V^<3!Y>*JYIEFPX<
M>S 9HLLF(LL2I$K_\4FJ/[6'2N915FUQ^U2P6+'@?KYBNN>W.%%_^43'@N4X
M7><R>GQ%UW,]!V^NJ1E?@]5J8#\V*I8A+M*QX!YUX&_*2<YOBWV8DZ +^^0Y
MNO)&>'5#>'5N8^>'X=5EC)=OBVWGMB;N01^Z">6E2R_B\R)G3&A*&F;-6F(L
MU-.?[WGV$>5E,1MS5GE5&-.275&ZN4V>G0M0>2'(=V@O]QRZ>F;OO5P!. I<
M1=Z;NPA<W0._O7O[<]@O[YA$49C:_1V?\"=:9+8-(DV*Y>$RC\]+PXY";)+7
M8>8U?KG$[;JK#YTJ.R5'KIQ+*SDF!2W19"R5O&Z3X'NT)"+6=IO!R7,:+A%^
M1_A]:U'("+^C<.-]@B1R&]R SIE:=)H]69OUZ*5><RC2YF:CU.=;-']$YZQD
MRW)#GK<2,HF3;G6=T)22L08Z)W0@O*5TWE]8N'#8VR:*"=\NX[SV'F_ H+]O
M=WV$E.??XPV88G?D92)OQ<N4U_?1 8ZOD-WADZ')$E%8BRMK8656UW$H:4Y:
MK)2F15ZF!K4FT]/[*WXF,A3LQD"D8^G4^SQ*$>_YH;SGELWD.T#*;QJ_OIN=
M1[;M=27=3!Y33\M!,CUTTUO+W3#KC45<QXP=X,F.PSJ)#EW8\#TRWR\V5ND<
MD'30C'U3U'VC.'CA6:/6*/K]G9R)-[/YVS:6[]F%?C-'_*/Q.[*[[]+NWDN_
M#A1^_M/I5(M[(LAJ38X+DER2B7HST;[.Y8)<0YO7<:ZTHEG2RG9R0V9CY[I,
M&EK@9#)&I;-13D?$T**8]QWC]XT'>+^/^1_%O._(+W!:$N?POEB**_T,/7+Z
MO7FIW'$8^3J^\(E-\2-^^]B3Z\.)0Z0G3ES/P2[F*%/^+5%\?Y%N!)LXI!F!
M?R,;_B>8_9]BF]<L\'R#,/",_"^L<OW= P014G]51/VFD3JR_#^N;R!QET?2
M[BB]+M=22X.-8S_B\4VIK7<S3+K4R5U%Z^"MU7S) 22CZ^1H;!3!?W-6CLF@
M"'PBEL$S400^XF6_%Z&_:5YVWP+Z-N+8MXCJMP$9SY*_:0+X]I;^:Y)W0]4M
M.K-T"\#NGU:GFPG>RXRODQ% ./VN4>Q9*AV/D\V>1<N=W%,72%Z4$?"6Z/T6
M&0&(COW6/QB+8!>E US4SWK(B1* $_&Z,U6$B[&BM^N(G#GD?_4=WCJSO=D;
M\9IK\579=45\).>+JM2HN+/M=:R>DE0=)?J311RG6JOM7!$;]-H0F2R\R)X@
M8HD4%44]([YTUE2-B"_=BT<G36;TR6,YR\A+H3&E4TZF_%B^3C8&Q;7(IJ3/
M.3R^ %IIN<IM&J,UX$O4'_^DJ!B9)"*^%/&ELV9<W#9?BE(R(M2_6(+%;:/^
MW?IE9G8C:Q6'ZXH\Z@W7:J_1V6A7*E"UY*O;^#K99.5R/O=8V!KM=2'9!?(3
M^E0RZ5@JF[ZW'(K;\^K?I1OE'K+2[K^@P.UM\AY5V A7OTD_J@A7?RBNWF$3
MJ3O U=L(Z7Z??/6O3TN_9C^H&PZ/WI%;[+Z4?[!5^./__D'^\5E >*B?>OC:
M-(Z3#:-?:XS\)_*58\1?EV^-?$=*R]GP(?F02=TE0I 10ER(0>#)NT2(Q+=$
MB#,K3&?D&]D[XQLH.>L016[23WH407AU5T6!0\YJ+$'$,!(G,B\1P;=6CU[?
MXP7-G;<0\I4M'AWF!?9\&<?HS6[ZEAAWA,MGWO-E'*<WN^D(E[_EL5[2L7JS
MF[XE7+ZJ!_(G8_@E7*Q?M>G[\L)^S(+PTE)^7=YXOD.#XJYK ]W,YN\R/>.>
MG4:WLO>?C?9WF>D1H7V$]K=6__".=O]]+)J(&&ZS .(U,TUNS91Y5GBOJ6N"
MBX$_RX*-S9RHR]S7T>21R7GRVLO7&P[/@HA??7DE<U?WW-];IP3191.19<G9
M-RW!S41J67=*-MW.-]7$<C;4GH3K7*=9%QX-86OP#%Y6$[5FBB1G62['$$EX
M3YX@8]GD:]=I[LJ_&;&26VTS<-\%NB*\NL-J[W> 5[>1$7XWV/;-ZZF?5(AN
M0GN1!@4CG]7-.MY?;.-9L;RV.IGK%%AS<[A@%9J=RM"QA4:5<HK30AYI+ZC"
MVEOJRST'KYY9?,.'_@,F[EJ\OU%M/0I=1?Z;FPM=W0/#O7L+=-@O[YA$49C:
M1^4RG^+JHZFD79R.5[*#0;UHM,OF=4HC)9>+;7XJYRHTE>M/RUF]2+:-+D.D
MD"V:BF7)1%0;*6)N=QF@/*?M$N%WA-^W%HF,\#L*.=XG2"+/P0UHG>X34752
M?$.E"XW6>-6M%BIV^CH1$( 2HLR#_Y.7^N!I,TI-Z\O:&FJ=R(?PEMIY?\'A
M@FX:NLG: C;5H\CP3;/.^R\7]L-\]A%2WD-=L'L0T#=;._N],C^O[T,$+9Q4
M.28[+M(JJ[/IX;J$+PO7$>^-C,D04CXIR!(]IN2GG/$H)$6&H&#![0012V93
M48)#Q'SNTU*^ Z3\IE'LN]EY9-Y>5]09SE-V)>E+2W:;_((76L,";UU'U,U;
MG?3XT2CWAB,@;*>=,<.,AETHZJ E^Z:L^T;1\'WG=\R K=^C&/AW<BC>S.9O
MVUR^9S?ZS1SQC\;OR/*^2\M[+_TZ4/CY3S<6>F;,CWEBV.[.;8%=4!K1N(YB
MHG'I5'_A%./X<L/9J3I5[XIE8(.GH0U.IF,9*ALE=D0<+0I\WS%^WWB4]_LX
M *+ ]QUY!DZ+XHZE2U1Q7DO3I# ;CZ<-?C%VK],65V^GY'12'2R&[>DX8^'Q
M2:%CK:$HACZ"-V7Q_46[$7#B4]0;_HVL^)]@^)^A3^!EBQG?( Q.=1V_:D7G
M[QXCB)#ZJZ+J-XW4D>W_<84#B;L\DG9'279D)J733X^J1#NCIC):-?/S?/TZ
M%_7BDXQ;J8RDWK OTQUQ,RD5<)ADEX$> "(=P\DH"A\QL]^,TM\T,[MO"7T;
ML>Q;1/7;@,RI;M<W1@#?WM9_3?16Z'%YPV86QK!NX,WT=-&84_QUG.].OUX?
M969:7196[75E:DYR-(E$+\IO?TOV?HNL $3(?J,;C$7 BU("+NIJ/61%"<"*
M>-V9*L+%>-';)47.'/:_^@YOG=O>[-UXFYBQNI"C7+J<)3)9NL1TXLWK,%]Y
MY9!D0H\3,F7HYK!J/R8ZR1Q#9.&5=C(3RZ3Q*/(9,::SYFM$C.E>G#J/O65^
MV']<9^ERSHWG>EL^0]6N$P>:;0IDDN3B!=E)/"XK)%_JJ&/$F*@__DE3L40F
M2LF(&--YTRYNFS%%>1D1ZE\LR^*V4?]N73-U6BB+ZWRCB%,IQMJ0;IO)/UY'
MLQ]P&\=09OVJS)*:FQHOV=2H(4(!BMPJ>"I&IM[,I/B/S0(D^"<8UG)4P92X
MBXL[]/43';]^ Q4E#<QJ_R(RKZXS3$:&*<01(?WQSV NF *VAO]H.L;-64T$
M;Y0TS)X+F )5-0O334P5[+G. VH574R?H3^J>^2!/\T"%Y[O!()/*1*+MBZ!
M*7D'(A=ZTA58$Q/ JGGL>2?A+ 8(XNC7S .&#> K61OZ_ER,AR46P$M910F6
M4]!5L%L7B9KTWW +*\&R$6ICD@6V8EE@'("'KGDK>#C@P0!+()U)FL-ZV'2C
M>,(&1+)]2J9*2:78D/MY:E9_&EB+0@YHF0P@D?_^APV-+.<7+2X]M5W:K=4R
MTUY5LT;9-1B9>C[2DJPE/=P4%;D@; JK)[6_HHTN0Q[/R:V:4BXM,BM<FJ9'
MT_FX->@H(AAY-*?9(VK5>5>4Y7:764R>G@J3BI%CD@S^?.1C=IML-I+#K2RX
MM/$X[ V2G607C#QZ>U,5ID)*9&BYGI%2<X(K)M<5..?1V[L.^']ZW#>'))T=
M.87'?,;=KIG4\=N+EM[N-EKCMES74JEXO+[.#L$ZJ>.1(VV2;A:%M8J7!SK@
MF4U=*5A=)GT\4IAELJ65RM&X4WS*QW5]FJRK(I,Y'NEJJ55V*P['<KQA#]HD
M]]3,M==,]GAD.S'&TYN9V:;9RFC4(#OY%-[M,@1^/+1++5H;5W YF<WIJ9&;
MKS,D+/I'' \=YILB71B[MCPJ:DQ;V2ZHQ0@-/0)^W=4<NC$I;_&VSO9&>3E)
M$<0:#@V@?\!Q#\17T3$1>0'D0_(KRPSTO33+,AV-JBW;W0D^7&YG\E.RRF06
M*?&Y+.F8N@%4!;>CL)J=TWAZZ4@&JG^SDRH#\,:\HG.R+U2FS$BN3(RQ367D
M$==SG!*[XO04D*X"$#\&F-PV'>$\2L\!V?.292BL^TO2%$D3XE.XI@.V#9_Q
M55CBP<NKVW=.]/4C7Y'YT)*\KW :<!A 2"O'+">DR"C"#+Z9>O Z,GK\YK4&
MCL$9('Z].P!LU]#Q-UIM!O(L^9"\@*%Y"4%[  QA!PR ^8"CVH&$FNF*HJ^A
M^HD6\F54<DP;[G@M&U)!)VE)3+M;=I97']OGH(VC,WU=1_G<B2)%;V=<>-8
M(!R%-2SA5_ AO"IJ;PG$(>*'38,X4NE#5$G@^/_ ==IF\(JY1PB$M_[WM:9-
MXP^)KVI0=JU(^1>&YJZ7)O%EW16OMD6 J=]\BU_G$+TBGG[53;1KXNGW/T8J
M>1];?$\J"^O8^DL^OJ\6DIG?,,G?<F^^MN^KR=*,\78C^]?T_?_W+X+"_S[^
M]ZB#.]@S!,W__D'^<5:($,1#^KRR]W=!<N"E>G<G^\]APWDYW7= AO/*M_O!
MA;/+A.L@0R0@;EQ [&WU5_#@<K"YL-BX8OKV[](3=/'<E33YOIASW2L19T"<
MS'V)GJ_$G'L72.=,KKH= 72IG=^/5?+%W/3F!<T]T,9EW&^OY!W=,"@NXZ:[
M3UA\G3OOHSL_P]6T2PG(HWA[R3$UR79,X3#\&MU"NUABZ25*5UXQ;_3L$:X;
MRPK-[C(]7\P!R+L#UQ!05BB[$35F1T-@4'LVDSAA-]3/!Q4JT^R$:VXS]')J
M%K16)965A,]?J'AQ9653MZQ3S2;(H=H:,76)=M9,B>[6]"97$)DDNNT5PU]-
M"/T>Z>8W1/]?TK?^G/3_U;6EKY46?D8&4!Q3Z0F96,V&[<IXN106S4TZ\_GN
MQ1]F )Q0<I-:NU\9DK-$/8EG$XHKP*1/6.8FEJ:NV\#XOG6YKU;9&@)K"7-@
MGF*2:ICZRKN"<-\Y2)]GS+>G?P41G!O,)KHQ5OLQ72L8N\/_:@C]?3XKJFE:
MY@E*ION3FMQIFA5C/KVBHE6D6\-:N;I=R2.:45:X81"K8HY)>8H60.6HFMB-
MY&1=EFPC%>EC=*L..GFUQ-0S."O2X[9D;?AA_(KZT7:86#YN%E.![A,%VY'%
MC-JV(=TB_8A($9>@V_M6@V[6I04.GQ,L"UZ8B_Q9W\"?]3)CCIQ:%U6TGANQ
M>*I@6W:UEQQ2^:R8FE:T1H6_HG*5Y#-=JK\P9K1:(&F1FE@4O+E(><I5.DU&
M7JSOX\6Z#M5'>MK;9%]HY :%[*+:D-5*EZ>H9#\Q:GV^//.'R7XR6K48/4%,
M\'K#8>E\Q;"D.21[V*0IEDA>UWE]WTK;5^MF#8#0D:?JUJ_+76^/D>)UTE(&
M+_69;W[5L>A,G5D.R9R:7]/+<G$VN:+.-6?MDITH6<LA54N3S;Z2*TRW:R8-
M=:YTXB)F\3TJ5E^N/]W@'B/UZBWBKM8%RAS,MD^XPV=&P\)@5:';GR\3]6'B
MGE:&1&]33-%#5=\D!D29: RS(H/:7UZ(N.];?;IEG]="X&Q4?,KP_%^1R^NB
M+J\;:_=P,\!!&MT/;OCP.8VOH*/>#6A!50T\*9J A(.VC(EJ94DR3^OA,D.*
M9KW %HVG*P9':NO\8XUH<3*M6KV4TB\I\T6KRV2@#DC@L4R&BAQO5W6\1;SG
M-8WS!S.?SVFDKS*?Q"3Q9.C61L<IE>'DK50EA[TK>O_PIT&.;16*ZI#<+ON)
MICXI]1*0^0 =-1G+XM?E/?>MOGZUEOK^HGB[P&T,8V$M.,M^Z7+F3]!<(\_A
M3_0<RH4%R2P'PZU<*!7GT[9!SLN]*WH'I*Y"3-HKAI%'X^:\FZPD9YE:ET$M
M8HA,C+I,4LP]:G>1]^]'>O^X8KU,5+2)),<5FJ_DU&DIN;JF:E0V6G:'*2QQ
MRJWARYQ43 J,R*!6*< NR^+OZ^'THU2@F_7@-8#*_0MC.<Y1'86U!1Z@D6$"
M3$'5;)%2Q*HZ6.,6_1!Y][Z-=^\(%:Z5\'9#AC)DUW_>F4*5V]-J,42JX+,B
MP ^ A>="%/LB>S_!V4L=IE)9,G%N6)[H0IV9N(G6=@WKU /=*Q%+4\DCSOY7
MY'+[+BZW+V((M^4ZNP)'.+L&=T&.H&VV<F9*LL:PG%<K^;AI51)CQ!%0%ER&
M.C;&+LH1[EL+_&IE[U..,$V(G&"_I\?=1 >W,ZAJ/ZM/V_4\82WAI#*V&32V
MUGS=QMEJUUII!KN96ZAG#W2$)6.93#IRA/V&(^Q[T.B/[[Q^+6_8:2(=R_5\
MMU9H.S25<PMJM6ULC:<<)%*@'V5B>.)]MP2^N19TWKZ.=]IP*JR:8\+&$#0+
M]I<R=^T5K9?Z*WK]%)%>!CZDL35K8?\^,UU]MG_5)\DL#(SG9-5B39-9ZG9#
MK.5KIBS-.LGD>DHKU"+WQS_9Q'$M@]C%H9$Y@$:&*28&[G(=[RZ&;6N1&E6?
MZ"G3^GQZ_)O0<.Q:0:VX,UQ>%O+-[E.AMK7P[A__I-/''AF$)Y<&2/H (&G&
MY9+Y^JH\FPW5NM4>\%O*=#87!(CVI%G:I)T1<'4\'I)219+;4P"09"9S CU,
MP3($\&4E*.[#KG?H%3O,OI=C\M+JG_^"?X)I. 7P!2@.YOZ[=E(>SGK8[.RW
M9?EAU5HRN9?COBS/ID.K1/_^W_\37NVQD>\K(*%M^(W82"2T1"$^-056CK,S
M\.9?K+)F72NPA[-[ ^373H>!^\:@WI/Z'RST&>[_"'@JNXF'0'30/<Y_[+"!
M7/"C;DD0<7Z9@L)"I(&S'\R+3L+6C:#]HPJ^^AM+$@_IU!G.YA"]T"$D]B?Q
M7Q:;FY N_S5H%TZAWGDZ3OH_'?><'*#V??H,*T >@<I ^5C,O@>3#\_E%+AW
MG4M9MU^;"5:7&,;;2[=>K6GX9'JR9>ZPG>.;*RN5QT=5O)JL4R4JSYULF<L2
M1-EJ+O&%K+9'I7S68/1,.7>J92Y)$B5^^#A9T/T,1TZ*INYN:[E3+7,MVTBF
MC>6ZC+.$."ZU)4?LKTZVS%TLXM:34$O(0[?;Q E+'M5=0SS5,I=-V,UJM:+1
M0Y)^U%/;:6O;G:]/M<PMN)44VZ!K79Q<*#8M]36WELR=:IE;-UUZ-2CIPV']
M<;TNNG0Q+[+BJ9:Y1K(U$LU5R\+=BI19<XM::]'O@I%'ZTSA#I6?9QHZK38?
ME7J5UZQ*$<YYM$ZWEADEGIR%.W3BM)4LX8D6.>F>:JZ;S8V%VJ.H.$.UF(W/
M^%%.8OC3+7/S?+QJQ;LSBR9STY8Y&B\KHI [V3*W5\S6ZIWM<#6D.&O%+?6^
M.&1$*,B.AIJ%Z62\-IF5W%Y5RK4&V2\^&FCHT?ZSBUEA4^X5,[0T'/"9QWQ=
MC!?1T", %(E'LEF<%.KR*$.QJK%IS,IKL-;$B=;*1EM.I[*E!%YV-YG&?&7T
MB]TU''JT@$6U)!8'ZWY%=FK.+$^O<4XOBW#HT0(65=*F\^FJ/*0>\Z/5JESG
MK!JDIZ/WJX_=!L]W-C(N**->6^PD!]0(MHL^&LF7K$&\*@P*PV6GENLXFP5;
M,T7FQ)ZDK"55"%KD\7Z/XN>.,,P[B_4I*JEM6C2YF6P><7(CTU5]-1DT<B<Q
M>CZ9I@:/5;>.ESEZP/-VGRBUUJ<PVE4?&W*N7<;I.$.9\RFU[G71O:.CD<R*
MZBYF178R+$PF;(_0A].1O [AZ:4;P58UH*&)$N"R.=29_;4NR51Z5+$FLQ&!
MJQPNZX5D0\Q714]_DS1'X'/V*^,8.(R(>BH?R+?TNWLJ[P\*\T[JA[93'@ C
MMJ"KX!TN?".1_AM>"MO!AO5@\[7=E?O<7. =16C/2A*P@H0&4#;XYY2&5)MC
M(DO,:=6DLVE@,;7R1FO%SZ<=Z5SMEL]]P)_JKNRKM4@]1I7R_1\\W1C]<NT&
MS,1#EGC-SQ72+T/SZV#.&<"K $3!]SCTH/WR#(XU ,J;BKYO:Z$7!T/9J:4K
MCBV<6<%_Y=P_:C[Z__YN$.#5-.<(\!<"//&0>C7\$@'^0H#//B13$> C5O-S
M !^QFHC5_"S OQ4VC0#_.N#/TW[Q+:7^)_4#?EWTW6A;Z$NV9L0?LC^U27B$
M#1$V1"WC(Q%Q6:;P71M_>ZSBOCI_7[QE?(0ZWQ5UHJ;Q5VX:_W4BZ:L[(%^&
MCUQJY_>CBWZOIO%WA"+GY92O.U%_4*?TM]R:/P@4]W8_XQRU2LXO((\2BAH2
MARY-L*(IO-Q]](S%![X!4_OT/>MS\[6CT[QHO^CS,R/\=6;T=?5^7\EERKM-
M=J&;!86UK,-B\(B2 #QR.U+RZV[:*F7+DZ<</BPP0[Z^5-.-E/CYZW2O+.[%
M=EOC5*75BV]JLK3MDY*6R&6G<LYK&D_$<.I]MUXC+A!Q@>_/!3(7X@)CH\!:
MT_0V+K=GDZXI3TF1X3]_V^\S7*!23I:D]9R7"S8WG$^S3S.G(P:=X_'$\;VW
MJ.S(I\J.7$-O.ZHQ]U9)N9_ I#_%B[]9"?9/\?.?52WJ_A6]4'FJ<!FJ$TR_
MKVQ2K>ICE\7CEK,HZH5>,:_[;>RIY+'B=[+45,0[(MX1\8YOHAZ^GW<X_?F:
M[:U2$EW(IC:]H3PNE>N0=P"%,94Z+AIQ#MYQWVKAS?KY7@U^'CL!7RU1%_D!
M(C_ ]_<#W+^2>+J\5CY7Q5-LC4K+!27IC&5"Z=D+6(, *(1)\GUUYB,.$'&
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M &LTL;4IV> H,0TM_ '+ ?W"PR#%C06XAO+/(0KPPHP%K"'FX[1N>L>].VN
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M@(Z8;<0&U"+/;_-M<Y$7H:CSC'/DY]P\<164R04*R==H&<<TP1.A9\Q_GV"
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M!#]1P/,(P.<!O '-_R#XZ *(M!4Q]B*30<9&RL-IOG#:%40P( -CTWX6&AY
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M24=%#V&P@[1=8B:*[$KE.-U7RZUZ<UOTO- )^O6V0.]H(D1\SI1X^1X3Z,R
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M%Y1YE9Z-2^V;S'A],^>%,^+3E+86^UAT*I0+46SJSN/-(8ZA%MIX\@&/G]9
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M^SLHOEO%K"%5+3*]WLKENF0R^P0([D_R(4D=R3/?%OG;P&=FBNCR+"!_'R(
M*,Q$>#>IJ*X>([05X>!'CFI#.0P%+5PCIZ^@0L"3_UB1L:.J2%*C54<X535<
MU,<9_ (@0$07;;"Q8]$T@62VN66$LRS1MAXBNH%^'8FZ.)9M))--D3<D'>@*
M(8(N[8+?,-!; YEOP6E8J$.TX>W>8R32V1H0F<';W2,S(/T1[$'J@^,G_O"(
M;$%MPJG!@\>PZRO000J8YD;?P#]XO:Q74+_X#]+1YP*8%APC05  7IXSS&,Z
MYB'BZ\IKZYF7KJ?]('$W3 , :,'*F8:V?;UP0+3"4<HL&(DB8[>?5#:_YFHK
M-D>S&4'Z]2?^@&&'..CZ<CX;ZZSF;K0Y9>O6--$K#IC1\!.W(G]LDV(]B5J9
M!M=G\]:8SB[:VF X )L4>Z"HPW9 7R)F5WP\75[DQV-6*UOUCK F36=Y[7T:
M+0:95C^3T!4Y@\?%/)W6*U4:.@WBQ]HFO5O,/0#(&>$Y:P)DAS>_B"N:$(CR
MJ@/QI*P?E7SP$F[H0$=R"FR]C80]DE 9^+0<D(1 ?AZ*T(VL>D&6V5#^>Y)I
M(Y+,YX;YWE<\2R6 P"^AW.\AA*X5Y$>*]]#(VR9&O8QGNM,E)6.$18WU[JIL
MLP47$2-YZ+VZ>\EV0SN?Z?6&RU(NP;/ KHXQ1E^8)%IPYU.'B>K?05C>T-8G
MW)3FVLVXHN2U 56L,1-6RL&MQXY4#9T@?WTYYPM4@,DL1X3H3Y+!Q"!.]#Q6
M4.[QAJ89NB_S &:#NV"-5SMR<PL=PG,_$)4(JEF/GW->W*A/Y7/3^O6'1KM\
MQ&,":4;<UB&O/^?<S/:B(_)#%E\+9SN%MI++*?FF,LSEAY9=27W<-&>TF6JL
M1+$MF@M@;1SGU(TW$3&EA=AL^^\9P[)KAMT7P8(#L^>XX%-MF1@F:Q)&]GL+
MK=1]&IJ2! 4?T#G',NC?/*X7V!)2@J-O&6'\UG3!+Y9M;=MEX*51'X7LH)CC
M3.@Y[Q#G QL,/@S98DL(P[SGC<1M Q#>ZPR0D^N[8J.<YXN%EAT06G"JP4)W
MW*7G2@#(RF NMF%:M"[4QV-PRJ:U#5E]POH45395W"U5:7>A1-NC8:E>8!;F
MPMVAPZ@E\K\!QH/NS:M1H:<7@&'K?P3'X5L$Z>8YPHT-^:HR+PRL6;LU>4I"
M+][K$H) _=%]6;?GXG[UB[YO%^S*$3J[%!$$GSX'.9[#&JTV>X[CC^46%1S+
M)G2F+K:KV1I=6Q!EZ?://R?F,6T2->I87FE5&FMKBF<IZ>WCA[T/WGW\+XFJ
M9YIX6=)\2X7_=A#E% 16UY]U/DX]^"ZKS4=$<LN8?!Z8W ('D6TR@K]HLFV+
M&_=9V@"'@*!%($@C0,\:$6X&C.P%.*M&FPT".D#V _%J<\#.%GVBMO8<@, 4
M=@U3"9QP^Z9XND+[F'+KL4 (6 !0PDEP$1OLD.@]#QK7:,BA$KE$0@@PRMZZ
M96,[>(K>D)8-U9!DO@(86[=$>C9391[M=!!2S<Y:Z6D>0/)5BD]FQEH]-<]^
M16:(E^]1'WOSIAU[8I@[2 ;;=E@_U5DB]43F&%&81K6A1BZJ2V!'$!CV@&%'
MH,P)E.S;"H_H]/7@[N+ @H".6^B2Y@-:"@@-,!J0&X9^0&F0EB*6,]* 50(I
M 7P*F<"C6T YHQ4:E<L&%#?;NKM0$SG+@:XC*S*".Q5Q9M GSD]D<0'=-)XG
MVN,0Z("2 ;#8G@I\DRM#ASKXY)VT.0,O'LJ.7*@OZE.%D8UIEW>C)8L@7K1C
MGXG34XD7(=5%=S5IJ>F8@LV;5&?HQL>5OO;9#C^CMTEUM$^JZ!]H^X*3:$%4
M:8'%0+4,8.6&7*/$%KT^M4I.M"I$5RQ96UK]949W)OWFKS]'6AC^=1*MOD(.
M>U20P/X"PLZ+:T<@?9I[1C-<A^;1+?ATSUMH>Y(PH$(_%,.KAH7B&4A->H$2
MSD:#P;.>HQIH O +P3N0"-W,VG+ K+>IWI.MS\0+4;RY9SU H _( [I#]U<+
M610]7!0>(W4(^^T]MO(POZ=V#EC\P$DP 6M"\W!4;_KJRN,G.,&1Z+D;O'M'
MX0,#]M^9[DZ*$3AJR#^R[L6XP">"O/CS7_!/<-Z\"HX))A5-?%6\R1E"&,9/
MC,3^.DMFT.[-AD1\JS;' P XC+',@FFB?__G_VU/]S!+RL]GVEK'Q+L<D4"I
M39(8'9DBIT2Y,7CU;TYUN9459.6F'C>I4K\W*5$Q5"J$/<82?T6V?H8;<+![
M&K>,;NV1GTD55<6Q_=O_6O 9RHK:? C(&1[(;W2$ %S#I^\\%QV%;<Q^PP0<
MB)/ K_["XOAC,G&&P]E-:D.G$'L^BO]RD8D)A>Z_.O7,,<1XZOE[O\(O K$#
MV$+=N?G3_VB+2.#FP80:F%*$(A)0 >CP2EV?L+D_6S3R$BGOGLNQ[=[C#2\;
M:C04M&J/RT1G,V:.3POSHDDI#.$.X5#"TT;@&\ JL=\:'3M/WO,ITCD044AV
M #G!"5,'>3>V5/DQ\/DN*?D"3A%$%6RHZ:$0(#_EF8QB2:\**>1$V7*9P%#3
MLZ0-EK%1 ? Y0%O!X/<N9H'F$PI464"*@\_M21#RXCQM#FEH ZPCG&2*2-$"
MC816PVE E-C^LU4_3TL4]F:PI?O0MP,]=00_>>OFP6*04H^,34.[(E*W3'O8
M@B]&L ?^5I5U67.T/:O_+/"H;'3LTG!N%YF>4*[DT@MILJ)?1?+(*0 H"!A$
M@B7JEX+R"TY6X<GG#!,E0!Y%]+.&G,H.&:*/<9UU5E_@?*+4D'[]68NF<1B5
M ;3]-<?'+2]U?)F\Z5;U1B/.YOO+A9*),TL-^XK>W1\YO5&R/LT[?+R%D?%F
M6NQ9+IO6Z#/98T@T',+2':SF2R4/=:+,FM.#UI],< :$\I8/^/W4,!FN4XMB
M3=;8>@Q;KZ.,8"J-F^SD_O%<9T0Y\TPW.J$[98LEDN,<U2KT>K6XBZK:J<.8
M(#SG(UZDRQXPD7RS0^3[#_BIW.NR6JLH,W6I;6>$'BG44[==D?.Q U:TUM19
M):T%6QYVJCE-*U7&+@HZ/>*'>0X[![SC/+PP$W]KW]JESSC%<XQ<&3?J3(9P
M&OE"19Y4QE#\)Q\_*OR-(W[EG:RFG?CBV($%J<<=!3M>.=F"^/,!YHXZ&BK-
MW,61H:=LF_#@ZW^_%>6AX5:B8(_O J-]'\QQ5UBG4YOEU^.Y@)7E=H-89/J9
M# _EP1%*^2O0]8%C")D-\OEK+@Z2!*X*_;KQU:0G-&L=1IRLV'J%*B?RQ8\G
MN5TLGO?\).]+^U+D:-+!TBB/^[9;;;)1I1_+I=RT@2]ATF7R@:0.4WAAJKC/
MFIY[#]E+B#4OQI/'P[E7-=YJ@J94)5JT&2W=Q^K+>*OG5C_*L0UP)+:?& LW
M!Z@"P['KLQFPR.&NK8YS9IJK688>'2P9$F>IBI8<JF,85#G&EX$[0?.XXD;.
MYW(LVN?8^+CM]#/,O#553:74HM8Y^KKG,Z72.A.=IS(**2_-#EZM<&G*?4ER
MSM!#(\;S4U&0VW?H>RYPSRD"9:R7*/P^+?HLCD>B[8JB_B5B^7(\*>0UNM$<
M/744N1_E2DU[V=*4&\SU^I!8GM26>J\UPI),.5]\JHVM/&.7I&/,?I$4V%#A
M7NQDM79U0515G,.T9EWOY^O3DE:77E2XT%U[+''S\?MEN^S.8K3S##_^,3)4
MP9N^ &./Z&1^>Q5<LB[N_V4OZ/7K3T )$23;(PW'Y"?@^"(P6>N__QE]LPRB
MSZ8,0V,.%9@P[4;C(0),07Z"_';B>.S5U/C$6>)TAS-7$?^^J0>O.-#+VA)5
M69)A7.$YXP=F6O# Y 6Z[#FT:SCF?GC7-!QI A6E::@J8'[!X?U\0&!J1 39
MXE$X @4-=BK[_N8=TP0K5E>GY31?&AJ]J_I80MF$R8W0@IL1$.I64J%@D*GX
M4R[951P]/L.8>393+G[ >8$0SXLOR_J;# NYJFB+D9>AKF?04:'QQ]&0D9_W
M%T4CWU#*#ABEBNE\I=D$8NZP=>]?'\]D_G=@@:JB97F!-N1[]A,@O-2'%PI:
MCSFHQ[)I00?U*F+ ;(S@9^\!!B![5(3EI2GX[HZ]3R'>.B2_T[-6KTDK1Q)0
M]V)-KU-'W5]ZT/!P<_B"S%$6;J5X;%ZJKU(B/\9'^3<S1RUY&0$G8D^L\^6/
M/FQ,H>=S@D3AI:-8SF@*)!G*%YM = /.M,'!!C+R#):2 +&RBNB&'9D%FD(S
MP-=L,/9KJB5N0[*<A+Y>)QT?/=(HHKP)8G6,[=T'9-5'^=!'4%2?3M;:Z:P9
M9T2Y071&%64@-J!+\]@ETY^IDWA3<L@Z4$9P@O D41H7(*(7JFTBFW(;^,\Y
M==,Y.IA]AF@2U3ACYXIM@I6+Z:29FRW4ZO0&PJ.OYZDV%\5N3D^6"TI^4";X
M8I0J-;* BLB7XJ*GG-A+^6K<9BX(&,'L-)0+@> KHK,-V-JI>+@R>7RJO\V)
MU#+%BYEY(3&(89DIN5HDET_8A/U*:J$% :4\<>I)=+,LUAH6,9H8;%NCZHF$
MI2TZ)FQ[D, >8D<N)SB-;I!0X )9B(C$=_D$M'+NTL;X8_PF+)7K6'_=Y^8E
M@+T8WW-6U#TR@Y^SB!5S=#L=H=N92!)>EG<^J_"6=OOM]ES[^<?6<QN5YWY=
M6PU7O-P.!^%N+E*%.;DSF$YFR.#CM,KQ2K3-3PP52D;TC2@$8G"T9@BBZIN7
M#BKNW50#1H)J0/"RB0SDJ E[^T46!DQ,5%&O,'"4,U%$QB.:[_/?'G?RJ 71
M%DU-UOV%; H257DL1B09Y?*A2A)  AXU^'4"4#B:?CX=?(3U@+*,4>X?/P%6
MJ>KGL<T,RXX&?QH_]^'=G0=:(?+NRI82'9LBZH0FPNJFB(FR"SU31 8R5 ;S
M6\FB*FR9%,\" A+L8QL\W439=)OZ:E>V)RA!$-C8"PA,8/*@QLDZBMJ %7A%
M#LL@9WJG3\[NOO@ "'F2'R/?C1$NTJ?R_I+(8V$2>9A$?I4D<BYHHJD*[F)2
MJ8L=)M,J]M>)P3)?3;D <&*_O+=M1A:JLX4VEG,\XY3U!-F)SQ.6) W155"[
M(V.B,1H-:@K/B&0!&[8'7=MMPF?&]T?VLDPGDY;G-;:NK/EF4FL-DR4:C"3W
M1\Z3F%%06T]KI>T6H@FJV>U8D^8P=CA/+I:4U!86HUF-S_!ZSN[46R-W&#\<
MV9R.ZP,J)_+*O"KI!!EWC(P+1\;V1XHUK2\_K5.4$ATF[,RTT\XY*0F,3.R/
MS'0'^>G2F4B*)DGE9,)I,*X$GYG<'RFMZK&\:FMM)N/,BGJ-$4MN0QHF#N>Y
MI"M2CN-G<Z:=(=-3>=A?\$DX\F">V3DGM'%F$F5Z*CY(#Y0XB3>:8.3!/.M\
M,[7 G-)<:1<U?-'K97-/% U&'LQ3&=*9-%_"V@PXIVJ_A*<,76\.R<-YBJ08
MM^/C<H8%X(-T6T)<%' 7C#R@D):;K GTK-;%5DZZ,2Q@5#M*P6<>K$@NEP=/
MMNHLL,QD6,W*IMG/SR0P\H"6GM0BAF7L<I/M.=E"Q[5R:RQ'@Y$':^^VIZHR
MKRT$EFB;"YO'2RL["Y]Y0'5COL:N[ ;)* 0[?<KV,"8M5.$\#W9IW*IWLAS/
M8"S7+]&Z/N\5]>51[N@2PU0TU5(EAA.HY9/8;N:<07.('\Y3*'-TBB%G/"L7
M1LMLC>W8S3Q\)K4_TJF)92X][:J*9@F=*1M/) L)>D@<GE%NP(B&:I<HC$@6
M!KPB5"O)/!QY,,],AJECBA*+LUR9J@C4M!E;8-*0.)PG4\.>8OTN-L3D)!^-
M+8ABC&C D0?SE-I%M9)>R$6L;C2T6E6E#65$;W'Q^XM;/EZN<CKR=BR_Z&]L
MP'@*1&\'73)0HIS?)N&P<8+DW9>]WS]WKWVN=U= #/^-9/S'&RR\U QLSU;W
M,;/OHCDPR;>;;VPL-OIYF4A)=<"<TBH*/OAG1>FY67K.Q^L8V<]::[J3QY,3
M]Q<P7WAN!EYOFX[X895]!?2*>D)O()?7CQS +96;6>+OX(?M>9&;27C8AW-L
M(_C  S[HDQU\M-6_W!]SB#AM,YB%CWUP;XFG74]&4H_$JU=V;H&'K>?#)C!C
M0./!%@6_(T_L;P]-PM#$FRC.1]+HQ<%0;F09JF.+9T9OKYS[.\R%9]3]Z?N/
M4N'&?\7&)Q\31+CQ7[#QQ&.2##<^I/B?L_$AQ8<4_[,V'G],OGIU4[CQKV_\
M*5?R(3OA!%!_Q7LE#S,57PX(_OK3/[1I4<K%)GCWUN51K^W 1_'VA];\HN/^
MA%WPS/C#?R^Z"YY@O#)E?&:7O+L=+[@CGHZ^]CVT;VW)<<E"!;&"[3TZTX5L
M/X6:J.]%3:$4NA+=)"^LG9+7O0W[.G1S3CCS%3=>WIK /3N(^6)E!'8"?OC_
M_8K_.J\8QAX3KUK>=[M1Q'DW"J5W?)-M.M=UYA>0-P<)D\RFOS[,[_I;UKW&
MV?^^[,W"YQ8>!\NZ_#7F;WEV/DVQ;][O>X&(ZXF=Y3_<87?3;F8K+AM08 <0
M(+ZY+5=2J^TGOEEAE>@PFFEH(Y=*%Z4AN@S\C73H!("^+Q4"79 @WO*QGIT@
MSI1W&++'R7=DW0Y[C.WTN%,>)A/8JBI9V%3%7*$-\\OB;[('^4@0(7N$['$Z
M>YQZC]GML(=82#6I7BLO8!D+GQ)R;5&HLRY@#_($]L"_0GN\%:^XD23U%^#M
MS:#8YR*.8X=U3SCURP4*]DZ!<O5&46_?(1J_1BG@:U*INR''%F<?WB$!T[\3
MG>::,5F5$7%Q\O^S]V7-J2M+NN\WXOX'Q>H^'?M$&!])" %[]UT1 L1@YAGS
MHA!2 4)" @T,_O6WJB0Q&-G&7HRV.CK.]K)+4E56YE>963ET[%3<H86ZP" ]
M-\8\)@]+:9Z 64Y_%A\P]K_V?7$A?W^^VL?'G5KO@+_'G2>+YY[4"$E7]90V
M9B(4F'"0OQG4)>4QF0SY^Z?P]^?;X=X!?[-@.,VFR2RE=NVG6*059X4QC_";
MQ?S-1,_!WZ=7%@_Y^S[=F0W%4@F<&XM28D,G9H@Z=Z0U(N;-0MXM>&G=;V'.
MNEBT$M58HJI&FG75H%IE24B@M#FH,T)HH(Z"G-OUZWS^K W%X3LJF<>*@Y'E
M8KSEQ&6U^P1Z2Z-3:DP<E!O*H*:R\:!J/*$XA.)P;SKIL>+0&P*G-8@OEGQ5
MS4^FC:G$SMM+* XL;K%]6"GVOMR:G]14KZV0;CR3,FYDHLM6Z)B\-(C@^GOT
M*19S"^@>TC^D_[7H?P4X_P].<#^\B[O9A/QS57?8KZ"&- !(!W2R>%4BW9[V
MBK7?SW.OOO4G"AK+7K_2314OZT\*Q]\#C5-[;5!WRF/H!BXH-S 6P&VO<5!D
M;MMJ>Z=1X<Y^S8#I%O?<M';?J[:!:L =[*=?@L-O[H'#\H*2E=Q6>9M^:DB-
M?4"OF[FEUK7U ZZ]+EI>.1#K0N4ZOJK[>B4\<(LRJZ"[-:(_[%_V1G6/Y73Y
MM&K098[,.9EEB:LL+<JLGZBZQTV4\KA<G8ZW#@466A7),-?R.DFN879Q2/@?
M1/CD(Q4+"1]R?$CXD/ AU'Q/PH<<'Q+^9Q$^A)KK%JOYLF5[&WZ#,]4!.$."
MRKE6?JZL9(I\3,3OJAS"V<O4G(<QOE]"^UVRSGEKTEP/4Q(AI)RRYLP)(H(O
M>.0>7#$V=V]?SAS]<D>'Z,TO_F C__N<\_](*;]Z]%L&1Q3A%J!>FSXPS8K:
MF*%ZI%A9UKJR72IU!MS7VO0%-&3WN_.EH=@XFHWNYSA=SB@FD&S#M'8+\'O]
M^GI,HMI\%L<-LKC(LM0T5[2GZ;V6H/0EPNF^=J7XNH-?2Q*>. %D@;J@R*:4
M3V4CD"Y&:2G0J!$(E7@DC\O6NUT)"^$EA)?3PLM;C89/ B]<<UQ5^V1+)9U&
M(TFV <WJP_K]PLMDEF^GY$J;)-?\A-5'QCQBENH07EC4__PQL$'H/4E8""\A
MO)P67E['[Y\47J!@9WB^J<WY:N:YU7]:L9VFS=TOO S+G#6B.A&'5QHQ9UY.
MU:5I%36^2O[ZG7ADWLL;.SZR_IJ&76,;1.>V=S7Q[J!FV6Y0'6+!TP3@WR$T
MAFO\J2CY"1MO*T(0'&M; <+PB*;D@Z,]H8V,/>[3:F0NJ_,R-QL^-2]OVO%S
M![)(08>S=M OK:H]!F9K+.HG@\TF&6E/Q:><QD?RL^)S(]I;CY.HUAHR^N*/
M['$)AJ'T_<@U_A"$^829=S3"E&<6S\36XTD;B,[PN3'O#SN#RUMW%T 8/M^7
MARIXCK2[RDR-9"-KTQIR;KDZ.OH894*$"=?XPQ'F$Y;>T0CSDJJ/]=3*D?FJ
M:8MDEAW-HLG1=T28Z+C<-G-<K]4&=$E-U[J4#DA4$!.:?C3[2+^',&=(PYLJ
M>L2+9"(?#\RX-T3J$Q)U EMR;Q*[PC<S 8ZP0HQ/^!_='7RLU+]J'GTCP57;
M-NX5(TU''*M-5I][@VZE6C<F'=3.^Z!)-[M(TU9-9B2R&*V6QXE^L=>@ED'-
MQ-OT\S!9(A?]-HCPU5&A;+>X5F S<6%5(@=RC:-)EAPEJP-&'NDO]:!FXO$"
M/:D_K\EG,MUNLL\Q/K:83I8[3;HW(V."(C%1>=WFFV,9=&V>H8L+5(ON8&1>
M7/5[]:XQ)1VM(LZ-F11/42.W*N.K!N640M<7SW:JO69C6HMM5<!80B,/5I2O
MU:GZ9!WMJ=4%B'<F)6&0$99PY,&*6C$AE:CU6@:YSO2*SRH]F=53J(+#P3SY
M!N@O!A%5YZ>5^FST5"U$NK/ 9O?+;&Q06#1 EV<C=+R7RBE*J8%&)E^/3,8<
M,[JLCF?J5#<J57$VG2 G=/SPG92]RL=K\[+>GJ<[;2H1&T?ZPR4<&7T]LE>B
M5F*+S8CM+C7*\7IVQ3HU],Z#%O9*0@.M[FPQ(,':L7HO3GW2+7-"(J U?'QM
MK])-.4?.RQ%GT67G]<QS'8X\^#J?%OJ==7PND$Y=:/4R4J?6999PY,':IUG&
MS&<2RI)/.Q'>R,(OU$1.2!Y^O=Y_BLNQ?B_'5YVYPW EID!#*E'DX5#&-$O)
ML;D4^&9_2G97+]$NIXS0T(/53YW<H*2)+TVUF,V!=*Q#]FHC_-:#J6:$U&I0
M3;5H<EI<KFQ)KF=6"4Z@ N23?RFHUBSZ9))-\-QHJND<-8:4@(?IP5"R5M=&
M3D>N\SE3=:IJLU56TO"M =)4BJ4[ [D#8NU<*Q5YB3S90C$&I3Y G)JE0E^D
MZ;K$5Y5^K-])DHUT%@\]V*OEBPBBLVC448$YUQQJ"=+1 1YZ0"RZG^[/JHG4
MO)T;M#-+@QLMJ&<XUP YZ7,3.Q%U,A+)@D1K9)<9FVK@H0=T'4Z<%(CG;5X%
M)4IE1%G+*#E(K""9$FL],^+,&;4+F$+L.3HIMF4.#3U8EB))U:2=,_/J7%<D
M2FUHC9&$WWJPK(0TG@R6Y2C35@9<O[M^*K4JTA(-/9@K6W3RY8(6G;=!GV+U
MYC#./!<A9P7(:DK,+)AQ;$2VNVI>'YC]8FV]@&\-$*R1,8P-UEIS1%9;T5Y$
MF?7UXAHN*T *TF0DS:]DR2%952[T5K.9J2M+-/0 *)?)09;B+3G/K]5U(L9'
M\D.R@-]Z@)3SFB;.7AC DG-K9D7'B^0S#3$5#O6A\MS)RP5=,J:@):XRBB5I
MAN68 ;G%.:8QS,^2(R@K3PLU$\\71V+6TV+AH0X5-/N=<0(:1IT@$_E0<WD[
MF.L-/8:B'PG"73,!%PT_M8GWN@T+Z5PU%;Q*",18M @;3&>&*9IK0E:&0V "
M:#%8Q #82P#<H@"2:)IK:%D1XM1P=!LE\XN6!6PW@U]31+P2!5@X:7^HZ-#H
M4$2-, %\L8T>G#GFS+" ^P!\I6+N9.H3BKL#MKA"-1P4ZP$E[4^!B-A/)@9K
M NBB5R$ %1A [Q@"&1H!&JYV>84<?VD,9$<#U6$&0(K!64+NX3!)H.55VA+D
MC>S\R*!/U>+/@LVO6WI/;>6CR*SY3MGY[B3<Y/P(^4A%$R1+H8(PGTG;?Z3C
M?Y:YCU\4(\.6R-?*JV*9D/!7(7PT+$QQ%<+3CV%"VW4X/A%B? @U/XGP3)@\
M&V+-#R-\B#77(3SU& NQ)F3Y^R/\GU9(V/4@7#AU]?A$U9VRF&?.8T;V_!UE
M\.Z6--XO;_R*2F=+>HX^)N^*8A<HHY"XK"A]US(+,7PDWQ=KG;O,PH59Z\\H
M\F9L#>'>0AWPY"UR(?V8O#LNC)^9"]_7V+XKEYU2T[I6J90_%;/3*UO?YR"\
M:1G[3K3YX KB1]/F \_=SZ9-*%-?]K7_:.*$0A4*U5=H\Y%3^4<3Y[:LB&U?
MO,$G5?YC&F2?0>O_3' H<J"Z47PX!-$-;?S[:"/QRX56SJ'?WTV5F7/@XKTL
M_MP:^NO$Q=NFQKG5ASNCQID5AONBQMGU[OLBQUE$Y6X6_Y./C+/KRG<F"'?#
M"Y]LS7T15?BH#.\*L EC!E"ZC#XB-,.RW#R@H6'BMJBG+%9QAYKPU3GV8%L#
MRRI>734EWX<9(OJ9BAI-6]1ER'RXID:I-.L/J-ABU18SI>5P,JBER7%]OY@&
M9PG5X6Y^EYJ>T,*\U7Y1T]G,>%"=T>-<8Z]Z5R3ZB=(7!^E?55]B2E!@TKOR
MLBE.$=U651YJX[7*5]=DM][M9?-@EI=+=0%G!T?9!SIVI@I;=ZA%?%-Q.[U^
M>U/REA"D3#%'Y?5G18UHO)SGIH,LLZA?2=Y6([T4B58Z!;+9Z61?),V(E1.H
M$@4+Y8U\B"42WT;>_->DX1P'IK+W^&?B*7^$%)Y>N;XI*8P+U8DU3 Z!.%.G
MBUEJ1<Y[Z[S"74D*IP4U.^**3))OUL;C53$;<28I)(6H)%/\(18_DQ1>P60X
MI13>E;/]* NCH"^ ;AOFFEB:< @A&TO](L;C'9H;/]!RO@?'^TWA_/FMFXW$
M!L Z4YX.>YDD7>0C^46[,"C;L5X;%>]"Q@QUZ08Q=VCBW+6(GT??O.%[A)N2
M_//;6>])OK'()SL=<TRW61JJ?]EYK5:OC*#DHRJ^\>CWE_P;9_X0#T*+[]06
MWWMXT.?R_%S2Y"&YCI:6+:,TF/:3" ^0@4>R%\:#.V?^N[T_R@#X3TG!U=;"
MNZ*;Y]E+KS$TQ?X,@&LFNIRUUS5-U&U.Q[749ZB(>@ @DP4C.ZQU]5Q;K(WU
ME!,IDOEG3L#E6JGH<8!\#WK83Y#3VW#LA_;4!<4WQQAR2V(G,WX^6>;&##]_
MZ2R0^*+NF$=Z5NY!?&^#M7^N4%_=*$)+HNA_PEW\CK<]W!35@G[YR!X(;WGN
MU>J]F<5?V[1X!\;NVLUY,QM\[^#^'2\XOBO3W_B^AZ)P>VKLO?OV<X8A+Q5-
M@V9I08>S'2D##;A_"K!.L^.QD)I-$A&>M;3*BGWF1,-$S;"0M__2EW]W+@UW
MZ^POH&QR8-F$IDP5._3YWX?!^M-\_J?T+]RA_GT/+'D;GK"K:]-WXMY&78>#
M8@/<PZ"T.0L"U(9R(TD+C6PJRM-LC=,CR;&:%%%O2I2+\8WNI&Z#H7^N*%_=
M&@B=VM_9J8V:#J(6Z[CSH6PX WOH:(0H2:A1XGLYTJ&?^UX-OIM9_+75Z7L/
MH4%M;KW?\:L9T"W0 !8P%P U\>0DR73@1S82GC7,C"??G"?> 6I-J_DR?,XD
M%SK/SE\F1DEQHG-V)"11J T=9[Y_+/3-2,>]'Y;?\9+@3LR:BR)&L>NHJ2>'
MYM0J.:L6XIJMY3%BH.R)1.S[(\:-"TV(([=G4]W[#<LY<*29[ROR6!H#-6WD
MAU(BJE6+% =Q)'E\E& H-/=^$=- DA,QAA'' H3F-:)?AW<Q-\^]/^TNYDZ,
MQV /-Y:RZK!M@9(O8@&(/!K-)IUR:S DUZD"F8HP5'QFC02*1,9@(OI] K=_
M@GS>AC?[ZA;<G5^AWL8N_ES^O;KE$-[&?./;F*9M2&ID(%H =3R<(L,J3#>X
MF(_DTCU=[X4X6-.^)'&^IR;^"6=*>D?V.5U. 1T,%=MJCD43I! Z[ Y(&U90
MTF4J5:GF\E7'XM?3-#-J/MEI75L*%(7K63U0S'&U>>_:,WLS(G2+^'+C/EK7
M4OBQL'.-NZ!3P(XI3Y^+9I.OM*>DP.<,N+E2DD.P@ZZ#'J+1\$+HVI(5@M$7
M+XQ^+!A=XT+I%& 46<NIP5PH+M1J/RND6M-VM,2,$!@E?_V.T9?6@+Z?O7UM
ML[IEV*(&F?"@^V%X4W2_9\%5;I)^++:?W[[-F885=.$_6_'M\;38K[:+T^&P
MI?5B@X91QS/[]9LA'Y*QX\(-[T$E#.7Z5CSXH5UY9KOR+7&/"=-VGK8Z*7):
M&CTKP(G5R3D6=YPQ]9",?A]QOPU6#T$@M.>N58+A#1"PQY%1@Y6=G$J7S-)+
M+)[KZM$1FAFJMI!X8)@S@<#WL[UN]Z[SZ$[U?GR? L)V]=_/]W SBP_;U8?M
MZD/!"+O3WZ*E<#N+_\F"$':GOSHO?/.;BK#GR#>,2?YI.2]W'CS_$UCR-OQK
M89K'B56#V]C6LS#T?9+BXHD@B*O_NE^W<&GKZOM,ZYATY4E(QB0A1JZUT;RT
MJ"[R1G0I4+C9>H(Z\!7_.V3S>_<>'Z4HA\TXOKDY>#.+O[3.?0&</V?(SP[.
M?ZX,^].S*0R9EU&MO3:E7B^?+)O=)TZ@</_UH*ZK@5 ?^@+O5>!O/ +\XA;-
M!7#@G+% 7\:!C)HM#6I]IJF"M"D4*#%2J*M+A /LK]_,83^&.X2!V[!X;ALM
MOAF-;KEN0,@(W^X>8:^*%LZ("&\3KL_*-[;&JU@V"3)Y&A_-'>KG]\"$M^%=
M#>\/OL,N_ES^O65U[Z?MXO=S?J?A&Y#YNQL_'3K!?V#5A)LASJVET'X?)_I.
M882"+AE3$. RJSK3I*+DA92:LY2TT4TQDF2/!"J.7.>'55KOT&-V+W)PBR!Q
MXYZQF\O'_3Z.]V.P8UY>Q9V($N7X*C<OMI^G3TXJP2'L8'_]I@Z+-=TA>'PS
M5_)5,.:;T?#F\G^_3W37,:"SZB?(5:)3T<DN^U)J-7L=(1W!"DORU^^+W_2'
MMQ9GMVLKP ZK-'VO0@YAE::[K-(4W ]D![\#X#HZ69;6^:<"KZ:U3H%MF)UR
MWH0Z8@*7$DX^)*/TMZG<$HKVK?C0;\XPO--"35^1^,6J5P5#2[?4W!",(M&Z
M3"U*=23Q;JVF1#QL<!_B0%BKZ0(X<#*S[2LX,'F9 CX5353:799=RFMUDAFB
M KH)KUQ3-':F)F#AG>/%;+..J#DXCX80_8:=X2WB!9UW48AELN$,-' V,-NC
MSG]?^B;P @O\OE>!+DIO9'334S< K&LR'>^W$TY$G5O+KKD:.6MA!)6VY#MF
MVAVZ\^]*U.]8DH/LKV\ORN<OCWN4*.<[B6>0318K:I5R''$^Z?;C^1$2Y;?M
MK^\GRC=^B73O AYD6'U[ 3]_Z=NC!'P<(]5(+64V2"72LX67[JI2FW!(P-\V
MK.[P&NS2)M=_;!&R[F^?=!5G"DQ%NA5-XP_D1='A6^V_J<3K:;7&@)"5(>1!
M #F-& !["8!.V/#70T6'W*>(&ORL: -488-0\)6L>P6GRWC8SJ\&;I,=PK'@
MSN.G'-LPUX0)'[<(Q2)F)A0!$TZ;D!WXB.&_P 2BA7[ _UX<&I2/7UP__>'Z
M;WA;4(,B45_C4.SX/Q8!I1) 25[LD1R1UMM BQB:QA23<$OZ(8#H#+?P]2,B
M'&T@\J+_FOBA-1#A.P"<DDQD@ 2F V#^SW]1+/E/E'H@D)V"]QQI.7_CA>\)
MR1YH9AP3[Z! "9Z%TS)V[9V:SC[-J_5GLCU_&:I]IB D)K'1:VAL2F,@.QJH
M#GE_Z6Y( ,3*!EQ$ \!O2G"#\+=:2'1;< 8IS9!4#RD'PK!53[:?\L49GZ;6
M3CXWC3//,<[%>$5W@,S9[XP3T##J%P$@ L_@U&S3 7]VJ7].3GP-6P?_EI7%
M[_^%_^-_1M+@GB-L'WMSV9SCZ*L>LI/DOTYR6DMPW<#T%TTS6R^HYPFE2,9=
M!IXF_M__^W]VIWMX6'DZQLXZQFZY<!H?02,0&4!L42/B$'[Z;U%;BFO+6U<\
M^1CUU9>_-VH*6CA!D8_1V+^(G9\1 0ZH-Q57D1T:>2=>1 -#N+_N8_[OL*:R
M^:5A*8AC_S:!)B*N1F_?>R_>"MN8_4U3CRQB%/A/;V$,]1B/G6!S]@\HO O1
M[5;\KTB,323)_]6JIM\[>C_:?_>?Z$'(B5 ETMS?>$7=O5_M, DB'L(_),R$
M,<2Y"I!OMOD)XN\='GF+E??W)8C<XJ9>0"?=JUCU.<?/FXZ^6(K-4C531[#U
MR_W:9F0UUDSF&QEYJ#KR?-6OM S;T)<";C?T:B1;6/*-WI!O3],Z2$QRM5ZA
M7!=PIY+]D<*DLQ:6:GK,1[3\HCQE6EVQ5!>B OEZ9(4K3H=/@Z:ATD_#CE%G
MAXLG;@E',J]'6KQEF#-M)JBTVFPS%?)9K)/HG?'7(Y5V/6WF)K4I.;><E9R9
M#ODG<2DPAU^W]$A'EG)II1V)F:OR<VV0%I6E$#L<N38'O42&:[75*9^TK*X=
MR28K=8$]')EZII^CHI0'[6ZG# 0A]@(6'4Z('X[L% 9#4K2J;77-F(;8JD6;
MH\E2B!]2?M1YZ;[88X93(V.#%/JT^0P*(SCR@$KC<;O2J(HLRT^%9W8DE5XF
M2:8NQ _WJ$J-,E6VDRZVE3I5X#/S:6K50B-]>D*4]4X35VWQ3IX<TQCF9\E1
MG<\]+=1,/%\<B=G-B?+Z_'EG-.+$-[[Q[JD%]7PL1CYZNI8:1$Y-G%G@;_^'
M79%EMYJ[BV,[JKP'8H<G@VWZG_ PBG(QY,W[FRD\PS3@O85E'YEWD]UVA'SG
M_09\YQ#J+_Z!Z/\;ISG][:+^$J[X0[3=_%T<6(;FV. ?!+PQN#3;%'4+&7)_
MXY_@T^ O\B$"__3O$\/O.\?_)T[_[;'YP?W9'OVIQT1(_JN0_QUG6;@CM[4C
M4'%CPRVYI2V)/KY[#1QNR!50*Q21V]J1$+4NO24?N<FCCXEKPI;GW<$?/MB<
M>R#\48%10_Q_KV\P/F=T?'[YU'O>KJ-O,% \H$> CP>?Z@+S"()]I)-^FEZ'
M_L_WVOX1N+W? 45V!WV2&'#IZ)?_[U?LUU<)\Y:0TW$LY:]"3A]C,_M\0:>)
M([CO/0(_ ]$D^#W?/R;YX'T.#'B3>V40\/#^L"CU<'S+QN!]^%.PO8U;O1O'
MM3]EK--+[LW!V+<@S_O.B(MBV=%BEO O&&Z(7*[.?4WL_R#?X%UV1+>S?PK+
M?VBYWYTF<7J!NS0#A0)W38%+?$L]Z$;28<YM]1W$7&:]@!L_TN9/@N[.J[I\
M.D]M=X^]&(7ME>"U@VE/39S[CR_^R/MW;H9YFV"<J8B:Z^LX+EAWYIA 4!PE
M7UU4)RJO&)..M(P\633]*EKWJX%GV^#=S\3N'A.6QMD>(C3]F+R]P9O8W@B]
M">[MO62'S""NE-5UI4NGU&6DUUF/A"CN9$,]D@$IDW_,39=6V@Z!\U]GQH<3
MRT*(#]\!'Q)[^) 0,M'6>KZ,U"?MJC6)=0M]?B!4N!O#A[DR:Y"U9E%1UZ)5
M<!)&=02*',0']IKX<&H=\SV .+Y$U5OSO80JB'84$' CX2,1 M6P,H:$KQ^F
MW%CY([+=SZP%7J/3_,_5[D*0OH02QYP8I+$D<[I<,N#6;<;ME+S80><&5Z:B
MDC3KDVQE1,6M:+2M3^H"@[0WYO&PY>SQS')Q'>T6ZUU]&STN1()+J&O71(+B
MT'A>OPR915N<.$+,U$:FTQA!)&#/CP3?Z^;S1GQ[-0 Y2<=YD#:86C@=SK#'
MP(0,)SMX$P-KDH;^OM#?]PWM^2,/A6,S\N_8R9?9B#\\!R"IX#$0=" \R_J\
MU%DI!;Y+<B9E# =6QJD+,5<U#.Q->W^.O;NJL?-MM,D01>[?%7@DBB23TFBY
M,I_R*I@ZT7[5MLL]>R3@!M?D8V#+C>_@_MO71TY;T/[BFN2111-_G'[X)34P
M+'M[;%C,E5N4W 3.7U];3(]%?00''%?ZZ>V#(%%_ZL=RY&+!YYKE1=-<S?3<
M<BFP^)Z8?$Q\ZB3X 6KCE[3#$%Q"<+DG)?)4X%+H6_.Z^90<DL6R%IEF[$JB
MUN,@N*!+9N8QL'YDZ+Z\:?<E_U8!L=!G>3F?Y47K97X7=\0M%1G]1*OTF_71
MO1=;<RXW6\CX(>/?H%OI2U%EYSJR[\8 ^#[7;^'*KW<S\(FE>S;<-?P UW!U
MW,:.?Y_KL9#7?U*JX&X9]]VJF3=;N/D<)<0Y"X6;^\4\B(,:W@\$?*<X<NNZ
MHW[*\/_=BNXF@!OQXO9U6Z.7!+1>?B3*VZ>!6[+=>UP'\ =45!Q219Q")1#'
MO8OZ.JBR.QX8\'X"#2(FCJE8LH(=3*)&#$1+@5]NC17+_R9VXMEPIB^05+AJ
MO2E.P=(P5>RG$Q4=OE;1":Z9)N(,^4#\K[*_5>CGOQ4;KEB"1',=:V[,/F2?
MWP_$<@Q, %^P2RPXES7Z'EP%X=916@!,5QV,<-DE.#M%Q@7UQ86H:+@*JVCC
M^0U$#:_;&@/4U!IE"-@&I( -S"F<+/H>CBA#[X:DL=!T9H:)%PK): <4A@\B
MWU*!S^N&30S\_03R(]&&S(**O4/ZC1Q%1A-Y@&0.VI>I8^&'@86$28'3E=_<
M*SAGG5!L5.%_:IB T!05:&OX'<@!: Y_B<3,- 8^1VE@ 32T&#P8CT*5O]!/
M]NX"(<W7^'EO 2[]O!X#\''%#ES[(U'0/89&;0AV./J31'S8FPQD)PMNJNEN
M^W9?_:U^(%#QZ6!^>"1^6@.#O6GM'C<S$^"R95C8$%$ES4$G#!)X1.ZM7.\!
MU$R##\O88:T,X8&&4&<Z&R- 0$_ZW+PGZO"STIC S2LLE[G0XFGR'Y&0G*GC
M5D@C-,.RT&,F0,5;O"X(\*WBWL=F"OPSXIU#$<=OA@^@+@R*Y&@V$FA4H@U!
MR2/^)/4/D1(1O#HS)&0!O ,Y>BE:/CW@2(Q_2$ BKC1%D)Q$L$3C1>.O(DX,
M%$B(63N2X^)/\'GP2!"MX*8;F\8<,C%8^U7)_OO$[77^_';V4]UV#B]!7M^3
M^/<G'#ZY7K?>J8BF*20GR[FSZM<YDEZ-Q:1)YK2HO?SUFWT@8X?W(A@(SDRU
MSU\[79YJ8L:(00B1YWPN7DF6>X5:H]H>_?H=>XBAFC.O8^&/P ]"ANH!1(Y7
M:LVVR8R(I-@$%I))R/N2 Z?LB?A!UQD=I>?- *(K?"4&!0E.>XVHM(1[ ^4D
ML_E<_.&M3C6(Q!<7FOC>]L>%M<2DBHO<<-B>%JUJ2WYA36=UT>U_=:^XRP?-
M6/2E-1!293YG/3DC77QRJO((=?]XB,>8 T9X"&X:9,)C0;0<TST=/J$8(3[1
MMDV+7_,(>@U<%0'I#,E# !U.PT7C#7+2-$;.^(]K2K1O4>RW!MK7E<8BIGG$
M;5D$Y ^E"[]9G$$M<04WVT;:XZF%YN)-5ZO^>DMPN6FT6G^Q@7*Q2I(*T/O:
MC'2>A*C=*CJ%IE'_]3O*/M"Q@)SN8P 2*2+#(9P,,71LQ\0WOE@9\"Z 70T)
MK&:*B8%P >7,<"Q/";+'IN&,QG!_HTA-\#.7#_<2-??2,;IB6PM)F_N& 8#<
MHWO:';((41L>XDF$]CC<>Y=U$H0(/XZX07%-#$0B C'A4($;#5D!?IM[;0-]
MS%#(>/!6YN&&IDRAH8<#; EE"A5U%Z0MX/)7-$'[;R^@*G[(XFQ 4T5W$&/+
MJ G9N>0+8<*K9D@['<"(H:+!U[8?FX^;?EX(QK!FNW>7#^ FZUB;W;6<D34(
M+1.XN>MM7S: 16Z')-ALPJ3%37F@[#BFA57> >KG!JVI/1&'*JCE#":0=HBT
M8 4IH+MG(20IG SZDNC88\-T<=9C)L-Q33P)'13F&AGS 'Y%A#: C=1?1T-[
MCW5@[Z6^#6?#J:)WPH5OO0K;O"L7@- Y+&WL/(\T<#A\T.=M1*A]ZJ!7PH$S
M>"R@$QP3RZ/S@T=D?&J@E#]"$Y?8!7%XVFS9'I(+O@>=$>B<$N%VO$VJ@ ]!
M%@;P '5/K2T)OWK>_ 'CB;(Q0_#-27B_$/U]W+603&#K"*_D+\^T@L:79_'\
MFV@9,T4B$@SM7A5"(ZB$-".X5?"!?1!(^KZ)S3,/K[G-!'-'P8>Y@6PU ]IF
MGDO@C9/=M9#@1@.W,=[4L/8P \_%-SOWW#)P,MA.0ZO'ANA%C![_9^] $3AY
MXE@VTF^LK&'"O=WN0LTT=/BCA+4?BULIUO:IS:#-3K5GR,T$W\V2=!F?W8*\
MU!OEJJ.!=BX7[Y:2U$)O<N^951&(DNC\0V7&+:"_/OS2&WO:#3*JZ@W@.M]X
MT40B;,%CD0JV"Y:D)73RI129RQ;M7%Y1NR4.6E.Z<6A*25C/=*UUS[<'O/=C
M\QGQA8FL9US_W.65+3ZZVMZ^@TG!/D*D PX=:$P']9XD7+T'MZJ$((%I[HY!
M9'W ;L[-5J&19])<+LD?LT6,GL9?#$5UG*$\CQE/U2'Y>0M"7(WT7<6HM!7/
M!HHNJ [;%L#:4B!KE".M;&P]B=15D2*[W4*/FQ;F4"5*Q@Z3I_?W'VOU>^J_
MCPQK]P0)]^S8/7.5V>UV^7NX#MRR2G74MUYFAL9/YTM^^M1;%K@BE.8D^_DM
MP[C^2#0!A/B!L7#O"K#/6-'=96!!'?@Z!7QW9$<;@L(*/^2+K@_F6P5RB8\
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M1##F<P!V&SAUA/53G0'3[>E^A/US$S!U*3/GZF!T.7T^U+:NA$\;Z=M<\@?
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MB(34([@AF[Z'[S1F01QWT3!;3WOC=/F-W/*RFPNU?B/,ME%?:^N7<83B67K
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MF;$CA!;(A_$>5ES?AW%\YRG4K#&BK"(NF_\-USW+&4/K.?)2:[,JB RK\=B
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M6'70_0]\;S=@>@.A):UKV:;=P8?1(V29)QZJ-#(SU\#RF5D"Q#]4AI^%#!M
MI6R)\=]PH"FA:P_) W%2#$BCV8KQ_4#T;P+FZH-!%0)89.ZXF$8NBL#?(Q"M
MCN%YP%(,89K A&9N?"/WO9GY$J]>-_ LVR(_RY;PLVS_?L)9MF\_?U1YT_FC
MV8]QS(>48#FPO@)/XX$$ *_CAM(_\J.=L:F%D8G^P+1IWDJDPEP:\ %I&'W!
ME).+<IX=4AIDNC"@/8PPV)9.%]T-3@Y'$!@$J-6ANTH?9IM+D*+),%Q6']D%
M/D#YR7[]2%0WT1'R5VA_%0M["2Z1[2QS03?%GL8XK@>^HJ&:Z&6:YAQ P@$V
M!X&')J[&&@CCJ<?@QCZ 7=IV[/ZB&7L@J/K-UIE<V!6'N;*X=_AD[<NU[.5M
M??B^$,P$0YP;;F][=#$:$(IXA=?46>#+F;DV0+2NAW5]KU.X[U7*MO)(.O*=
MVA].(%K5D]T)2"OM$@UA+3R9S276!*9UXN-#:^W3P$7<A>6YPG#6.5O$JKO#
M%BZ"LL08E+4[]$?YPXRZVSL\V-M[/,PI]C!]]N,?C'Z_#\L*7=74'(@H->V&
M1#C&S"^3J$?I ?5)W6Y[80(#KB5H K3& Y.;^@Q6S!_2XPZR^H)[%?K@8VN[
M_<IPGIE%$$<,<8V E2:QC<7263@ \CH4]MPN;(*7].9AY3XTJF?H[&("CE/I
M4>ML0V))(M$NLI_BB $RWYBNZ)'M#AE#DM0=#[BS14 D/F > EIYOJF#N'L@
MICW -!"[1<F67C^D/SID8&+N[%P4C,$KINU&EJ7*EIQ"U0142ORV>9EAL77=
M0K=F*J/=]0?@,F)B^(OW2FSAH_FR>5%F4 7,%:#PN:K#TT&HD'8;DVB0?2>U
M70O$E45@,CYH13/ 7((%H!L3PWCQ!9@%\J :)CHKRZ;U))EE\\K3"JLSR8*8
M[W*MLB2MY\==O("7P2SKPHI3FVQ Z .1K)'I(E\U)%'&E\"F!M#O8)P?&"1+
MT7"5Q_*6+#W@H!9J%*>/D"EC[T%WY-* E&&U'144H4_!S2A0%F5>&<A$$7-0
M>84.)[S7M,$)U&DLQ*91$4QR _E5!=- 9TYC"BT&QQ\P!Y(-!=Q[JN9<$ L&
M>+,J=5)=C^D_AR!?!OYF:+6BL@5613%$4<R!C5 "2@*<5!@B>4X& -_[WC@Q
ML0U2V-(,6H;@^B8ZQA<SJ6@1ENE^H1S %,-@<PE( 8QTW#Q=!@^ 3=+I;O75
M'AF#WBC[!0O8<4R>%A"42Q5C/+UQKIIY9CC $6%NP-8D\0:#4[4@<P#F#B.!
MMS*C%%C#M#4:%+8P-R3,K(L&AQ. "1DN+7;1/!H" &H ]\M^8   [!!0=0O9
MO#\P"5[2&D6IKB%%49,PA'SBN7LTF8'M2+ RLP)AQ%Z*R]HB 8I#8R<">"11
M]'E^:O&6L#^.!&"8LP,&)AB$H_ ]3"!@+M^#2OW.F!0"&J)<$(0U=&J7##'Q
M$@,MP V@,"S7[^-8<:E\"W9%-S1:%15Y(1$+Q"R2X(FI<"7I7RW?,.D[&/%H
M&AEX+&TR2*:/#<T#LD))@@. M7/H=>/D1,JJU, .BI3&DI0QKSHAOL9"CB48
ML]?!.%%":[[KV7W$[ P4V2#&'/H;&%O,&)L5ZZ%Y0L,\SJ37-9[$.+USAIUH
MLFLH_PQ$Z\?C<WT&]S$:IO8/E2?P"Y,A@;E$.8JE>\9(,07+\$#B^*"+UJ/A
MT1 0R@CV.Z(03*I;,(,N,0<X9Z ?O&EJ8_&]%%<,PNR@1'O$XV'1Y\*BYBA(
MR \C8X%/JL<SIG_B2@:%"*73<EB(@&M\B5".::AA,<)<(39/CE"E,*\ X65
M@;HP8]0I>#)*6ZIY8728I$V8>@8FB8G[5"0?@]5G(=/Y8FZ<1,-R1A8?(;L^
M)DO'1I>FPAZ$3^\X]M#KAHYZF,(3^=I&E TTNT048U.%3$X2]LL7OT_#@H^
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M?7JX^YCU'52_8 L%"VYS/1^DI]6!]^7GS(PR"E)+6$=KT )HXX&1#ATJ%K@
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M7?^Y+1#.C<%M\^+<[E3*^\VL<K_3/"TIPQ__N,;CG)/:WPUO:>&0&$5%?DY
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MZ1,:V$%BDL>2#OVPJ7-X, 6UAU"%T.J2N&L.]@NH9JI/@#LP3!C][0:YV_
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MM-I^.'3[@$QM1O]_?-A)QS0L,OU+""8&3/_C'YR&4-P2@ID(U1,!YB),3$;
MV0AL.A<E_*)V$GZLGNS1&W9Q#<K5TA'>6CZJU1OGM#W/*L9<B1K_)(.$/B @
M0Y8KS*2NV!;9^L <7W[Z\OB&2'DI7RCDF[E\06\J&5EOMN2BWB1J.Z=+Q4Q1
MS8N3?..1?K%4AG<ZMNF"N#QU;(WH/LCX1+-*7+\.')*F&C;DG]*6()1K)Q?G
MM:,Z98?3\UJYLM,XK]2_!*TNWI>K\J":3, +=EO8,5S-M%W87"'<<8H'C_?\
M2RS/R\QVT<79]^$=(Z&O&I8'_^\*^')9_*N/5TB+K] @6B%ZH?174%VP4]I
MJ+I@6,*Y;^)/4D[\*V74M)3]27ZQCWBWE-7C7U$:%SP81YUHOF-X!DRG\JAU
M5:M#A)+FX5X!LRHI? L8.7"]+OS$&X)AQB\.!O0K!4]4/0&Q?IV@K0/W>+9
M+#H;^IMA,6L*R<$A][[AL&M:< N;.'QNC03?Q3DY9& [GBL,B= V3"+8CN#Z
MK;[A">,)3(S:<.$>#0U;/<56S'7Q3]?OPP[ ]NAT+=ESX</0\+KP'GR.!UN*
M,0O#UEW!'8"%US;8RM)EJI1QEE+^+[QAO-(3!/:,0, 7XJ3=%'TW70;7U[H3
M:P$#5S7-[_NFZ@6#Q-@)V, :_0*6R/8=H!9+[1#8#B\%MVNFCV8Y_67@P&=C
MH)H">80M]8P'6*YVV]!@F1CYA+\#Q:CP)_P5_,[&M6VKCLY8%);0LQV7[?T
MEA%NAE&D<!2J:=I#NECFB)K)+@P?5[T#M^-@HET=$S+(PH^QU*?HKU5P>M4*
M. %7!E>9!-(PV+77F3T5VW-*V_"L)Q@1):-%;K=L>(+G 1ET8>.&Q#3Q6HT
M@3 ZLX'HD<92@@9+"+>BHR78%NRO0U37MM"M %* UP#=(%4!J78-\H"30-[
M&>*&VZT[(!QX;D#IP+4600X$SH.'H5B(LSQ0%GR+JW#GZQTZ/V"VV +ALS7;
M]=(M8H&<P^F;E%O<KC' 80QL%W;6) NL0Z(MIU6KX#(5D%2B5L$W=BS@_4#[
M"K4'H(S=2"2<4\D(J_]9:GAFN.OE5J0Y&P69ZHR EGS'I03?\EW0LRX0-A"U
M8X-XM5#^$:O+6 *(."[-W9$+1JV+BHR AH$5]@<=1Z7R$=2M@[0>7@,ZS>@/
M3,K@^+L%@P=3W]T2P$P @A[B/\#$VG@3V>N"C0P(7K!Q(\>RW0DWDDD*6Z/O
M!:D,VC[@+:_K$"+TX?ZN*S -OP/\VF_!@S)22L!3'-C=716T"<P-M"/(?V#E
M=ALX'44&C)[Q=2 H1H)I]'!I/'OVAM3;1OZM>?8XDOJ1W5&R+#]B4:"1Y#'S
M&GFW-F$=,4/0'8"NH H"6%,@+@)D!BB/0!>'IC=^7I@HJ5%$S3>XH8_O>=$&
M;\_:X.%7B]B.('JF;5PPIF+^0T0<,Q-@\H4-<&R+A^I]KF8?&W'X4M"VALIV
M$T7@/-'"[%DPF^$KU8F<O/&E$WB?;CS\\Q_X)YRS9A+50;2Z&VQEB$5G<$M#
MK%K\KZ5 SAK!!0II1E;&%5]!U9>$=4_1,.F___?_Q(<[FX 7  &Q>709#\L4
M,^^0= O6N9=6V_#J/ZHY5$=N,*]\<2L30O!_(JP=)RY(XE8F^U]"[&]<@)G5
MZZN/Z=@:!1!]VB1M[T]P6_@=A=NC+VW7H#@'LZ8>"#Y]XKET*SQ[\$>6MG+(
M9_ QF)@B;>6S2]B<2:E"=R$SWHK_J *HIO;__OC71:T\3^(LNO_L(][XQT+E
M;$Z8&\%7,2+!Q4/_G/(%$#+*5: ;-R)C=1%2GMR7><N]#.6Q@/0 @>=1<>@R
M ?@8B(B![\"PF"T!7B<0(65_=(;I9Y]9(H'+"")-Z( %[C!-KFEDX(T=8PS.
MP*<ZOLK%-2O1L(-*90-S4:FW N\#>]TT-$0:)FUS:F/\V0 /D098(G' PF<@
M"DQUX)(_X1]_W\$$H> ;[S+E/RK"\)UI4QV!T?FG;3P2/<Y\H0!A,YS,&V67
M97+LMZF0X9L(;RJ^2-<9QO="A+$P$S3\[W\5<_GBW^EQ3$46XWLT*60_@^]/
M89XJTK5-29O:!\0*G5X&++DACA57H3J!^TR*X* KC6R"H(]J.-2);IM@_#*3
M&Q2MR^)W;I 'ZX82@G(/&LB@D(GGCBEO)L+W/O:8U!"%*89)3W%,I!U# GJ!
M?0*2I0_F[,39*62GEVQ-RD63[$#]2 ;>HI$=8D?4EQR L6UXSQN:,54W1ZG-
M45]S]5P,H45&A-$08^ Q3B6/ _"1#8]J+!QKB^#-?34$R^8I4Q\4GV,\J1/\
M'7-3F @(\-:_^)%S/>?ZK\OU8P\3./D!$2]D9&<<3_"(%C*W;X7L0]GUWC>8
MGDP)ODM#03'=.:DZ&0<#?YLZ@Z[4"(L2"$6B$#UA\+)%DYYHC&6>--GZ\ORX
M"C!FFVBJSY!3PT(4$T2=:8  9X(0Q&P(3] K%D4R^^I(L&POI!U* Y1BA+[A
MQO9,*)FN3>-_=T2+1"]&6\E$,)K1 OAD".VBEFG[*-ZC*"!*>=>G48W0)G0,
MMQ>25Q!HP%&U"!:'P51 &]S#"\ D] G>$^ VH!O@>MT(IH\43_4?C9YT$(:%
MX< C!J8QUAX460E=)MN)>TSX3IPZC!,-SB^(E+YA6,]XO[47XZ7EKD':0B6*
ME=9BL5+VVQA'K85QTH!\"$.])LDG@.H8V!8+K,6DT^MA*K1[, 0[#<-O"4+5
M@MGT&#B'T6*0=*[+9N;-P0-C1H;O!@/6'(-*00&$)"("0&.M47@W<*?'Z+".
ML*E-PP0UIZ-:<?L%+[X T:X/@0+I7:Y+X]>S:'0:O^C0T**PZZA],K2=GO 3
MII/Y!?/95G%83 X;3HPS@_F\?7]H7!/QAI@)M\"2TP!+M)=;&X!#K(NCYN/.
M.D'#F(6G.P9(=0PS#?R6B:6>8RN[;3C]%%"V:2.A"?^M]@=_A0O;U^"A1T>G
M*6'8M<%@UHV0O5[5S2&\%&!1QIP(R2Y8*8(DI@]38 C #6"(T*BW@!%QUPOS
M4,++YW+UF)/FH.S/ZJKG&?FB2X,3])TN@\TB9;#X\X?P@FBHE*35P8"HCHOS
M0.Q9*$B,85]<EZ6D9JR?OC^2L?SV%,=,3B.97$YKRK)8:"HM66^JF5:^F=6+
MFM:6"WE%FY,:O%V[V*^<5T]V:^?'I8MJ[:0I9[+9?'CE!B8Y;@/UT$D)XUFM
M+,?WY!L$,3^:X[NJE-Y6OJ6T=-(4<ZK>5 H%&>@]EVEJ4E')B1D]I\B%@(H3
M'^3+\B ?#_)]2I"/,<]IZ?RB6JTV)3E;D+,?DO7/$OH"Z20X#*%:?44Z@V#_
MH)1];8S+DDFH@"1QIWI>*5_4SNN5ZTJY<5&]K-1V=ZOERGF]=+)3KIV?UC96
MN0(C"T(TOY00S5 (ITC+"N@DSTL7%6&O=EDYQY*;RLI4\-8W4,'5>0GJU$L&
M.]I R(IFS])"O\###.![86B8)B:RC[WK<9:ZI@[H(\/L>7.,<T;YUF%>?Y#A
M1_.*#&K>@[?Z.!I[/C2:CY?(HBR"[4^-^SXA07X2!MZI<V0[ YOYWXC!P6-;
M-!J)>)SV_3"C-^WL-!97#_9+ROU4?PESTK+BA1*IMY#"Y).W::HS0S6&%G%H
MJG.4QT>];S8L3BS)(1;<58I<T)J-"$>+P7*IN=>,_7H,+CK>U$W,JZ<U0D'P
M(LP!#L!HQ.!@HT"-:%T@-5K(,Q*Z(.2!<"A&C/'4/A*E8-E@X9'QO=,XSFSY
MQUN(N!Q2C["'B(7%*?13BLCF;)JJVRR^#3NL4S*L ,UJF+E.R026$JQ5CT&O
MN.A#T@+CE0A=SQO\^?W;<+9*CW:' &%K6T \OSO1AFYI[7Z0_4+K@DQ#HS8T
MJPH2"(@F>T2(.QG5WA*N"".E,/=4LP<&B:+AX3"W@Q1[M,=U7V.Q<39V*H)M
MWT/Z=T#<^H. *XGK;0D7MF"W:-Z.BH\&7AN H>X2 3?'FY@CUH\A,XSHEPYR
M8?0@G$;5>H"_<!G/PU*3E""!JRMA@6+'P>%MFP_Z5DJH^_A 11130LE4M:ZO
MIH3=(R$CYZ0L3!EU!B8@!Z$CRLW(APQ&A'$,5> $QXT@ND66X6? NYC(A\D#
M$ULPCZDU"I3/%(2E8M5@,80V+!>SG1!^-/%:C#S!2#$  /]%L8@7NP80L>H(
M;=]B(;9?$Z*+9D[I5-H$%1!(=2QQ^IF%L$"NNO&M"@L"7[IKX#NNKUILD85R
M4%LQ!706TH=+$P\K!19;N:*>45N%IE+4]*8B%0M--5_,-Y6<K$EJ*R<6B_D9
M8%&2(M^@7#L^K9S4&;H([F8F]S&/<ZT.D 0.T-CKB4^-.S@KM6S>XL=$H@49
MGU@N?>[F:/X5\7%!4=2")&:;LI*3@(\+K68KVQ*;F4*^D!4S1)'T["P?RW4@
M]O/JQ4WMZ@3\^_WJ:6T7'/V+4O5DNW)2 :^_NKG<+ ,WA_,3H@D*M5TAF*(0
MSK%T%/Q. 8[CTDEICW8=H1_/*T>EB\J.4-\OG5?V:T<[E7.XY.*BLKKF(E^C
M8<,R48_(,7V;F\O<D[%;B]AKD'$]X_8&(B3U\NTQLQ>MI.ED@7&G!/@UE%@P
M.6\T(:Z$4U/%](5H"39'?GV>:9*5]$R[W9*;K;S8:BJ97*Y9$!6UF94SV59+
M*^3$G#8KTC(!<U.V!<V-/(_8;,#&%^>E9+=#>E&D9;#'2R"\)B8X(:EPCO52
MF?Z8"EHI,517J)[L5,"HV:F<E'EKI$1+KWGX!OU-DO]&4@A$2)@+,T8_8J(G
M%';GL38&3'+1;V#,%[%\^ T30I\0\VD6<DJFE<%>^DH6S"J=R$VUD&\W%27;
M)DJN!:)HCGNDG)Y73\K5T]+1N&'9;J6"8JA>.;^LEBOUS95!"LB@:'[Q%FPX
M0RIM@CER\RC1 N8<'M[&7C]!4*@T&-B&Y5'^AH]CR8+@1I1E=\JR[$IC#&?7
M</H;)CE6:[XD@R@# 9;+M11-;^6:K58QVU1(46VVBGJA*;8T-:/G5"TO*YN2
M2)/CB30\D>8S$VE4QZM>KCF!YG(MZ3&Y=V7'9"O7^]7MZ@4:.E$SUOH%."6T
MAVMYO[*SN79/EH+#;'Y3[6:C*0ITCHVCH.7F*HP?(6'&SV855[Z)W)91/_E3
M_?5*[61$)"LKG!Q3W(04'5>SU,<%#FB"S?E!J&M=HF.O(49^2RI-G%-V2-=P
M8\H.%ZUAF5M,$K?KL24QR!A,R,$:0.P]2HM,Z/>%*&8;6,S.W+**:(]HR6)4
MJD+K45N$@&U.LT!TK!VDQ9+@%; FB7A]++8+-GKLDO$XI]J'3A;#T/:ZX_*9
M9ZD+WD7K3\"6]^PEU#Y]*@TQ91<N=+-:;5Z&163-P"=R)_" IJPJF6([WVZV
MBYE64RFTY*8JB;EF45=T_$%6LNK$'7AJBW-[_73N#1\JQ"KG,J=9]3%CG^%Y
M M-7GN;4]O6.5+MN[!UL[W65?E,N:$.X4IF^<CCL#\Z/[).=WNBFJ1]F#K:W
M:[L=N#(W?66]UU3VK&OO2LQ5"W>'S99XHAIX96'Z2OMQ[^BLZ5[JC7M)EZI/
M6LX_.BHUY:8X?>7 ?MRQSN126;P?%?:NZZ9\I1P/FYG9*\^M8O7H]MZ\;.1N
M;G2_6Q9/#LQ24YF]4A$?SNS]6O9)-+2;9F9TNIO-M3O-[.R5QY?[0^)>]X:]
M\E"Y/L[T3[W[PTXS/WMEVQRTE(..>R^.;F_V-67O>J=6*34+LU?>M0[$>J9D
MRY7#XY/&SD'7/QB0#EPYL_)[@R.O7Q?M$_'JKI;6#XQVWBV7FL799U[73SM-
M1W2-2EE^<HI.M]ZQAQVX<G:/KL_4_#"KI\7<D6O)7O[@IG0RQ"-89AYJ].]'
M3>DJ?=Y+YYJW)VKVKC:J=O#2\*D3IS>\>)A%<>(PBV+SU,H=W-?.;L3&_5.[
M=ZM4FX6[;"<\I,)UO#\AJ]3:$:.4+/T,A)C1'H$6#)EFW*7[ EZ^;=I:+SBI
MHM4\V;O:OO6;M6ZC_'AYTWEPO*M\M_1#(*ZF#N ]GN.3Y;2X"D<K5*L,:Y7^
M"M&XJ?0:CSS$0-P/R*Y)IW!KMC9_ZYGB?#F?0"WY3C^G=%W;JYRDA.I)^2/9
M$!\=1FBZ3^Q]Z:A!@RS4X#]KE(ZJNS?TN D&>WX$B?SH>"_VSRL5X:92.J\+
M&-'9$78JY<KQ=N4\*OVD_Q;HV.&/_ <]A^>(=6+\2R/?F1FOOOD+>WEN>JIB
M[ N&U,S"7YX3OB( 8J3 ^WCOB4F9[%8N]]*9R3%P(_9*#!6U37L8+DGXF=JB
M?QC:-81%>!5EBCE?T:5J"\P[WR-+1I=>((3%MSF&"G[PK"IY*R?QA5_APK,Y
M<.+FQ/T%%Y[-(;LE9_DR<_K^>@O/YB!OB5Q^KXF^,WSA5T[?XE:6BY$/+#,-
M#4Q&7F:B\ZKOV=,AE@][1<F(B4V1VE*F_IIFV_R91W[!&H\)GH?";*LF3;Y4
M/6&;P-<LY:HMW!#5X=O]P>UFEG+"=KRD!WTS^?9^<'N9H9BP[=TA6.9*^TO^
M+-/Z7KO==N>>];ZLS7[1:/LJF\VLIH1M=DQZ5RQ]5FYOD*DR$ZXJX<F8=':8
M5JO;?LMK^U&!-9=>RY_YR[#EUYWW-][QU["\KSOU;[SIKP%<7W?J7]]8>7;3
M7T-]$C3U1:R6?VD:(>UV$@T7EHVPP#Z^<PY?0W*]<_++ME&FC&R: A%/ZLA,
ME.D(03K9KL.J2@7?,E@R&9[;UZQ[JJ6KCMYLU'>:1T>#VY:4?7ALJ#M'P_9=
MZ[0L=L]^3*2@E=QFK3W..<LU?3?=4=7!./$RLH+=DJ6?$Y<X#\2]& U(Z=%P
MH\NCJW9MI^P0</"/;-<]IKW2F_GCM"5=C?;[O;I_T,W8]5;]\A(&@J?-]U73
M_=\?Z<P/@26__N\/X]'[8_E]W?:"W\.$M^!=?UX>6N"1_!!<V%.X*_,C3-5S
MI.SV^>W1<:-7;AR7A^WVH%_.EYH9S/N4\_)_?D\N[4JIZ'NST/*-OO5RT70B
M9WXBD3._$J9R]@UU>%<=G8KJ4&YW_'9V,*B45L14I_0 G:JEX2%09(>P_\[A
ML4ZYVO44<G[9D/?<RTQEM-T]$#O 8PKPF)SA//9I/+9\&_L5'D.^^LD9ZVV,
M-09+YS"3W-X^VE,:%;>W=WI\5["SO>9U%Q56[L<_&66&EQ:#6-_/3%_ <7DO
M,RW?=TF4V;<:1LH.3LINI5IQ&K+<&C8REMT8%8:?;O9EI;S3%NWMO4KMM#P:
M9*N'9:.-*JGPXQ\E)[V@DN:X@<GT]@KSB/\[:$ONNWT3)JX/+UNE$\78;A@=
MJ7U\9/6>GM)8MR:_QL2<(;ZS)U:8,!@+*V$11:_N&)YH'O7V[#W3/AY5;RUM
M5?#&PIY8NIH[N\JJU6XO+:H'Y9:BE!Y;'> 8\,0*V<70#LXQW\2O^G)L\J)?
MY55V=L_.FK?57JW7=&\..PZY,<^ -<"ODHJYQ1RK[^ _<3=IPL):#5_4#U2C
MH/B24O%WCN3J3>[V-&]^/CK>:?:4_6'[X:Y"R/6EM-LT+M*'0V *<).DE(01
MI;<X2AL6+RMR()+'R[A$F) (I+Q[<WQQ7I(;Y2LCO5-1C]*'[;-F%GVNUR0"
M9R(>,7N+ 3K=^F05;#5Z//9S!WW=;QAG5PW/((=GM6%GW7Y:57IP=J[.:]>]
M>D]7#?'D^O$XC5P&?EI6FD7Y.8_QB-EW9JP7/;N=^M&N6G2Z_=Y>]<(OGQQ*
M^_M498%GE\T4><B,A\R69/FMAI,:I8Y=.7'4RTJNF7DZ3)^,SL6'57'2\Y:?
MOWV;KCT6AZZ8ONY?WS_>=&\;Z2&P$?4%Q>)+Z&$B@V8+,$[XF#(,LN48$[>_
MI5AW\Q#41,Q\#:4?B9CW-][QM91^)&+JWWC3UU+ZD8BIK\4<3,3,UU/ZL<RI
M;SC '6NR.EG3BF>^8.MI3WT45-<E"U:U<GAA_3CX!DW]>^_[UZAPY5N?"$1Q
M@V;/X:\-F7TB$9MY0?JY1:W?02#QD/L22E1G+Z^U=P(#^$)]+%'S-\!A#XQ;
MIU]5VL>-VL.H>[IMMSRG]/D1^-W=;$W<K1S=57+;^^>]LG5A'+>'S0)&X#/%
ME"3QQ.?D@$]OY)+@L&&^7]\X.+ND<L:W2#;7AI&+V\,=,7WMFOLUI3ULV&N)
MU1Z=::VN-<@_-'+IXNAZV+!:5A</ \(L7#&5SRY8X?@=S-+U6Y^)L@$^A5/J
MEWL/?NG6&E14I5=UE':_W39650?\O W0OY)NY?O:@R^J-VKE[K#>-9J5,V"3
M MC$A50F^[43<^>6-G)T(H& ))<0:Y(0M4+W)CNR[9W>7MK/;IM5Y\XSALTB
M[6OSFH3@3)5TM'>]?+6B2K&WL-F9?G&:];?]1J]?4,O'>^?*_KF^]OK*[?+E
M5<ZXW\Z+9+33EN6]>[GMXVF2F+>;RDJSR8:<Z38'9U^>,\_A]&3"Z8DR5SY%
MCC:V[;I?ZU@[O=&!_9AN^J5LW_Y\4'-PYPS/;Z5BKY$K;)<;E:?'RVL+!2<X
M-)E,JI"?+<#=P%C%W(+"[R#4N1?R/=FZ7CFJ]/U,X4RL.T<-N=1+YWO5,SP(
M6UZ KSF/?&>G8DE%2F_AFKU"_:!@W6S[O7MK>-W*R\V+AKJJOD8+.Q6Y=O-F
MO_34/1?E?N>Q3(:>U$C3T^2I5U',+^;*<Q[:+!_A.[@"W.)?3OW86X3<3>VZ
MU[NIW3=Z)'^YT]RY/3NK['Q^.=F#Y'1R55TS*KF+0_O<O[G.*2Z5:@6:QU#(
MOM08F)K\O^E!\_^$EYWX?1"I6E)(/1FC8"=$Q@ZZU$RB.LAIW>!=X;%1&7SJ
M1T^ZG&*GR=.A9&7,3 %#26'^UO@XR__[?R;.Y9P!"X(SK6+S",X#E:D\Z) T
M._93;<.K_ZCF4!VYP;SRQ:U,>%K6G^A8+)RX *(ED_TO(?8W+L#,ZO75QW1L
MC0+QDS9)V_L3W!9^Y[!#2H,O7SE^--@*SQ[\D:6M'!("? PFIDA;^>P2-F>2
MON@N9,9;\1]5Z#HHE/YU42N_5#OQVOZSCW@C<"5($9-],V23";Z*$0DN'KS_
M ID9#PLKHX"D9VD%9*PN0LJ3^S)ON54J>EJ5QRXPCN<V"UDY6\S]8"]8@H/_
ML_5+^$]KXCG!G%NVJ<,%X9O_\[N5)!'Q 2XW+'@J$'EA>E@772PF08V )W>2
M8.*"ZA#!L#33UXD.?PA>UX O+<M73<$A ]OQ!%"JNT BP(3I0\%V\'+;@5]4
M#VYIC> R4&L$BU7H_61\]9:0H$6EJBD28NQ\/A!@ICIPR9_PC_@@<F-KAHF3
MF'D3R))9 >TYX2MB9R+C]]UY9/@,Z[UXP*"T)18WXUCFR1.1N\M<A*T\/WK]
MK2;'*C:BD-^2E,W8B9E%"$!JSJ^?0*MOMH^YU.!2XXOOQ$=X8AQ@6[*<^L2#
MBV=,U$5,]?^T'.'W/R<^ B>1U;X*,?'<0GB.:L'&@,'K+1W;>^44YV<(J1!Z
M>/$%6QC]6P%??S(-O;9J+U'5#G$UQQB@!)BDIM<CV)X]F,LZB!BL]L#O*5*9
M4Q+Q:;CP0GHU(3+TQ0F-=W.2B#]G-]=4,#I#PI];N)/9DCBIO6@'+6,Z(8C8
M];S!G]^_A\/AEDNTK8[]\+OD:%VPCMS?1.^HSF]=]=3?!3%;E N_@<JE;+:0
MR8M2491$*9?]31[3&5W:ZGK]-6"1I3ZQ$*)2+5TX)ZY'P:<2KJL)K[/;0C5"
MI3 *!%^4'NT.L5+XPU:X.9\]:N'G\V"99PN!32, (^!'Q,[*=A_&.*)1R/Q?
M5SCS50=4FCF"64^C<6<IH6V8\%SX[@2,8;2)A%Q*P+C5KZT9L#8!,N'=FJOP
MQ137TN;SR<)D.;/9 ,TD;PXM?6?-)&;RQ0S33/*Z-%-,SPCK4C1SU>/VR%2'
M[M;"2DA^3@F5?0?]W6D55$@?QC30L3H29*Y\-D!@<.63:.7S;X7[19^H?4!Y
M*&MS:V+X$_HL=:+YCN$9S*69Y\%\"8'*<:BD,,%W@9H4;M!O@D%?@#_E7.&W
M^MBQTM@?0)(S$GE4Y*):%-6BNB8I?4XZANL%T-(Y7NL*I8Y#"%C=7DK0J5VM
M,IGM=WS7$V0&PV130HMX0T*L"6%.S?2*ZY)'X<JV=1,^NL*N#U]6KU/"T=;I
MHC:[\KS-7F(Y7),F^W__2\J)?VDB%S86QOM&1'4$YCSL$(UA2!F)CCXW8=W#
M!@KL^_POKHVX_$CN=!*OC?Y'$KF)GVA])!4SDIR50!EE<P7EMRYGBGDQIY-'
M25R7JW"J8@ZV<&1HQ'+)*_HG@X):1/4SHLIF4@N!LAB'2O!G5 3;MNKH^ C0
M=ICLC7_B]PT+ULEQ8>/QFPOR""^JCUR/]!=44DCL;T>6QJJGIGGV.+(A<7 I
MT<*"@TN)5STR5SZ;JGS6%N28%U\(BRM!TFNF[\*,9K63,#2\KE#W6R;]!6M/
M+HC3=R>UUBYI.;[JC 29>AAB[BV*:U)![9JV8^@JCI)0GV472]7H'8'SM;#6
M>D<\Y+MH+>XS)47,?!>?B>HM#N(E66\%(%X.Y'=.4B(0+R?FQ2Q57E)+:4GK
M4F%UHMF@,:@FHYHI$.[O5VTG]I90RDJ*F!)(NTTTK#0(%-J!;XZ$;(BB)4&7
M?<P'H_.1 ECPB^DR[H$E0_!\(P\LLSG4] WUV O^5V9=RLO0,03C&9:P;=@>
MT;J6;=J=D;!#'HAI#Z@^JEJN9WB^1U W^"W5LYW7X,(Z&7@LYL,B5L]Z7K'
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M,]+-4TYC3#VEA,J5L$]4T^MJJ@,Z674\BSBN$!V]>T2(8UB]V"]'9:JU'3(
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M_/CGU!X2AT9]89$=BXRVDD9)7)YQ>;9^*EQ GF4X2/K)=FEF?2!I&=>@#:M
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M.#8(>L1).!#L'FRX[D2;I'EFUWII;Y7V^9H)]U-*N9,F.9(M.HY5"_P;*@J
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M_//;X>9AR%E6]#AL![P4>%Y[GHD$OCA A-Y,<EAQJS56R(8JC&MS_:Q_2$C
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MIP8&];6O6OL$-FNS24L[5KT*<K)M"MVX67'%',=GQ.TVT8CGN'$BR^<\[,3
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M03EJJ,$_XXM,[NNW']Y13\# 8&O?J5H&.J'O>3V%#S>ID$!XXR'LVF:-,;,
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MN= E;+$(T+VYZE"8H![?1_QZ&7A!3X;)]E*^'^,C6[BY-NNM%>@*0#""-)'
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M@N9]&^[AND7V27_CNF6L_8_2==J;^9(31W<5KF3,*;F)XB*ZQDFC&HXY>94
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M'!#XND$]-$[_<);2,>+Q32LXN+?GPJ&<MG3%+/J/2N1OF+*7RRZ?5JM(4K+
MZSJSP!<0C<HPC]U4PY#4O,OB"'1T5)BJRBAV#-Q<,'-Z0?\E:Y7L>RD ^]PC
MH.K^5#3B +[3)-S(JT)T^"9,<UC0Y&/'*3<M?E+VP*&V.I7W+)KF78,SM:_
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M&?/K2(EJB6PPX9F5%BX8E'EVX,V^SR@_> C"M_@CS9GJ'S37^;<$E?#F,^_
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MSFOP&?8D5KJU:1 ]\S5[.!I;8<IRT<L^06R?%=Z'.=TT?IUOW8WJV1#$8^9
M:4_"NJAW'=M+$3GN\:>5A2M^>']$]//E2I3.F^T>HR3$.>Y(R/+<K<^:JLB
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MD 8N&#OFL^GH%6?O!6L&_-WM&<7P/#?KDLB!<*B E,Z._OF14?>I&;$.U'/
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M@&K3D(QK%>7),MO1*12M<'''2I8[< HM)L9"CQ4]8VBW6X^>#5%C&J1M???
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M#A?PVI\+]@Z1@5A35;39!EA#0?^I'4;\;>UH13,R%_P")D*K*4<N[P[>OK=
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MN-$$[OP(;O,L:#YG!=:Z0+L$(X/@S+_)W^5)X^ORJ^RUBPESXDR;B[H9%=O
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MX5^Y55 [(WA9A.\BZ+VO#>#/TRPW1?;ZL.^<(5]KP\/')M890AJS"'AX(BX
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M,Y/RRBA51PPJX-A<XN"MA?>/)/=XE>;LY9T3 WV$K\Q9>#?;I8?*&TX;T5/
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ML$MB*=86JXG2\J,T05!LN87@ZLV.&S2A2&BH<2(?%>1 '1/ 'QA55^IUPAH
M\O9;81:>WCW<G+A4[FORL&L8#>P"V(JM'F'HOX\1*]&2IPEY4< ?N_3!6OX1
M@&O)K]]6TS+]!IP+1\MGKBX24YIVY(NO?05K4GP5K9FXK]0OW)O0V,>$8>\4
MX;8-'/$V*ZX)OU/V*IJ##L9\V(C_H/L(F/J=@5DZT:6#D5UJ][%8:WY8;94W
M3X/N&,_U$: ]P>E.[2/WL#AF&,0A@XMS-=-E0#9I>R=0HFL=,RLX H?X8NX;
MSE'XMJ#/VI!\SXCEI8YH%= ,*ICKBL:WBTFV#;=3)TSMKLQ% L2=9LY-6JG.
M^[82[ 4KMIIQHMEYA'8EH*1+IK/YT7Z@P93MB-)U),<[;WE[.;"KWC0IJ*DM
MS-:$DLH/?R5Z!N]<,528Z,JNJW[0L[O 9KS?!&6@-K(#CJ@M T5'I-L/"9B4
MHH&?J(DJF(>\V:Z$<PX>(71?>G<,BI4O&MREZ\_L3OZ>XNG+M;5(,O9 5MK)
MYYPJ(%K[1:D,-"#0@#LL-+<TWD3218XQ>J=M1PSD%E\62XC>8@J0+L_ 0*2(
MYB<;KLS;J3=+[>ITBB&1:?TIT2.VV*!(<'4K>ZR?FC.<^WK.L94^D@>KVR_'
M73,4HH#3ZLMT6J6(*&7+/,FNI_#F<_ Y'(T&79BWXIK/A^%Q.YQ?0L,_F#R^
M2M.\DL"01LL2KH+98WCR8&4;3LA*4O.L*D= @E\HTF8UX%-\YC7U3U![3MQQ
MY()/]DWKK3[@B4%%< +#K_<D3LX30^R"#I.7F>@/ :T6"9H]RTXZ-XG==GA7
M@4H0&6>@2Z26^63')C+F5 @NS)*[XMIG\C<G+*G9PK'3%?/R$"WY1I]Q'P30
MU>WJ0?0G2"AG=P6P(%6B+QB*);LW$=>V"JGR@[WR>M]2-0VJJEUN2;:):DV/
M#S_[-*I)5]RQ\@@@\M;P@=,ZGGL_]DZT<7&@M6_?(1RP[_WZA*+C@1TC26^<
M:$U_!#<,TG2R9^!0^# FF[>;R!WC[I.MI9?AEF[%>S%G$)-SQ=/1C%C=T#+F
M7$F:R3Z(-\!A4M972MAT-<N^.%BT#&)N=>21Q9KW..H">"IV8(8E&@@FJ^#L
M+%E$S4ID,=DNQ%UZNJS61N/<>4TZWW^XZ9Z3>JDG>H2KTG_=C<&N23Z5"CJY
M5*N U[D24/0G;U8R&UEGXE&[&BJP9G@5W:YC0\"2C7R7NH]9.M@XBE1^]^9$
M,?1..4// #AMS*-Q/Q@@%" 6U5YKB.5^N0HI:?% 3,Z4O7CWM=A4ZP>[R.*1
MEJ=MTTGAZCC1OLUATEBPJEGQ1YF+U>9/QX/0U)[@_=?3QJ<0_,\DGZD/:SP!
M9Y@P5R.K4GG%"H@-F15SH41329/M/!B!7,,&=Q)7S8D3Q<2DF93KE _#S-T^
M7C.C! ?V"3B03*3:%^^M/?$/]$H[YI;P%F<-:\*+H5"SVDX8?Y(X,O<,#*>5
MQ'!OBZ+%7855,-O!."%<5K(3EF :X$BOJJ4*;R@ZW/;@L&H4ZNWX?1(N1(_4
M(D]$[I(A!TO>_M;M6XCKV!+1:K/A3#/EW.)5[L<2=W.HOC!#KU:[ATVMD&-M
MWTT2X-P.[\ZFXGC7:EQWQTE?VH,@N:XOVG*8=WFSJI'Y)%#LA#;=@85\<7.1
M-G[9UAU.D/R>J;=1XL1/<08TWFV'-#N2*Q$4F?J#3)2,O4F$OR#W3NIX\W,I
M=]#R=O.<?1"=]FM7_6QGTG154?*"+&^?X^:??,'G%I7F<3:F)1O40K)K>)-7
M>3T/%,>?$Q*)P8/A-6RVH>^2!^"6R.,W'HBN'%9*PX3)B6.M*BTU854;.^5#
MMJK7="FPG3&1]?8>2"=<FL0W&:C\)5Y*PO,'WNF=/+G0"MG>EL>V-062'X%N
M]I5RKGFIR))T$S13F*&&A";'W+7U6N/D!Q=(+*:_^,AJ^<"I/"NL ;\;?MF!
M.+]6=DI0$^DMWRPG?5FU"\TX+HE*BKY ;\X3>"NVV4F(6=!M"1<^]@BP##UG
MUE@<5L1L!'($S<?941_/Z2[A>&NN@0F4JD/:H:IZNHT?T]1KV._F3Z*FUFM$
M""!YDUGU5<<7Z5;$?@/T!V(CJYI4$-6UR_!$%1XDV="Y-=@Y])J]%'-_3L[T
M4 K\J)\H"C]ECCG3>6]A/N2E)T-<'@$$H#N00Z[591I9PBKO^%O;C]7&-(N^
M*3$&GDM$WDY%NUA^9E;M"W!WHU+)@;&>V!U4S=\J8F6+F==37?M/F/AOV."H
M_ 4#EQ>6(KN+_("K,G:1):U]KW]]#!XQ]ISR(_5VJAOC\AHBD!_7/6#C[DHS
M6<J;[Z$^*=GJIGB)TYXTG)Q7G<[5,T?S0A\)->Z3OF"25+(3:SIWJO5I"O8(
M2L+=B2BY]O%6M]]+KB9@[PE&[-BO>EL<$I.7%-&>X#4[9&^YJ?,8GI!S"8ST
MRG7U!C:LOEV!R33^JRFW%3]LQ<R=>AHWJGG T2LC=E%!DQJN0<E;B;V3=P6/
M@!=#E48F NN/ !3 ]'%+@"_3S@-U1=TDQ-6+)OY]_V6WJ*;@'63J3NF$)[**
M83_SN/K[# ,5?H*Z_T!@VO<#/<!]UGG$2V\^8*,+N<DQT\]CBQ[M1H75+\S$
M6S)1F)"6A%(2G,"C)$#;A*#9B9/*3#'VGGP:O?<&-D4YKG[=%MU.TF'S&Z O
MYUA7G+O!Z!!J,,[!YUXODZB%O3$N9O$EN8G-IGJ?K^TYWZ<_?%H%\W1!T9*"
MOW=E#M"2&@70PW79^%+>&7GE4\5)^C%_9UC(BR>\F2GP%AN_TP5?F4,IT.?!
M.2<V@_ -R(2DB >J5P.K+-'+6B"IW$K9-WO?HO#@UV9BF?I+1"R'E$MH;C%#
M*&.71*@%FE>%3KH RM'+6YU"NLI1(*!:AY34;-+>D-F-IL0:9J#.97BC+NY1
M >-..WSTH%/=UT)_^[I#,:[!W71R0</"U@2H:R+9Y_T.['<Y?1<=:.J?IWWY
M9<)WK+S5@\5N.;VC^_T%%!&\\>P0]P:*_.R$VKLCT.3Q6V?AG4::/+NJA8?P
M,:3&#'2/YY2NHIW\W B^[&_(&S(QT(P5.AU4-\G-/0AE_:.OA\@F7;6V^1N,
M\J_B-$#GGVUYL?^0^?@3$T#]5OU-)X _3EZKF<[\H<>R P^[3(IR>=6?ZV-]
M3>U(C*#*6DD/>G1_3HG!DB)DO%':NOHM#3(GKTN$$8]JBN?,4Q$./!1H=PQ%
M0)W@G'RKF/EY/1GY'TC>&)*N4Q_X$A@L$$Q%&O?K,C YZ^[3[UX+QK++>N"?
M?<T?"+H@U4!]&,;73C8'4\)3, E%VYP8+%SD# O6^1T%RE_$/ZRG7PX!W*D>
MADYA15;=R-F&<:<A(?L;F302MQ(J#;$?-K$!]Y)>K%#-VUB_)<XE2(G(U, ,
MA?TH4IC6PW"]<Z+MI4[VYH3#BYCCM;3U"'6P](7C&#& <^'#(5]E7TJPGB]L
MD^?TA@9SCJFM;*\!_^0CP,KP4/81X#V*-%+Y,$S\LW_N*GC!>&3!V>FNH/H1
M4&F>2?,(D)D!$[&-41D!MQ6K2B^?_FBVO)5[!#@JWF[Z"[Y\&'9CZ^8&]KX5
M_@BI*W ^FNW'-XV]U6(F:J-Z%7@3?LE3KQ+!+2.L.MQOUC0.KH>-):5?IT/T
M%TQ3G)WHT+OV#,[@77,J-;S=K!_B6:$(?,.Y4>5#3I(F;$5+9'ZSVD !8?&;
M&GC>/%.$E%(T)*9?H .,=PS@CJM#O&OJS4.L0(X9GZ@8>I%."I-*.UI>&/8)
M;4Q_LF >.!UG3XF[GI&_@/3<U'FN'1*';ZX8++Z;I>_M=HT1);UOZ:! T!W"
M/;YR[7L=$:R!XBZ2ZD)A7B-D].7A"K?-^>=3K3T4]N/W!4[1+(:WRZ-PTXNX
M1@-H1E&?Z7\NATLDAA'>Q"/^N(!T>S^_/6EH8O3"P,@MHC]E<T55[-* EWLX
M!P)EQCKQZ;W3,FU8T564_)4YMX;C2YU%#+8>&E/RO*1SU.0@9W6LOHZ"#8?%
MW%N=1\ (WW-# :>HCX#9"5$O[>:V? -I1^G#P6(4N$/ D(V[Q/)]5'+6?73G
MZIRVF;'Q/#BTIQHX+CQ9UY/(^KR9J[*<SF(@\HL3IL/Z$8 H2%"H^T9IQ\JH
MOZUQP(#PUBF-\1'P11 F^RKKW425;G>2 -!BT)P*#C.1K,O%T-I Q(U59)\X
M !C/(2[>RUW>RS3SM'S<&+CEOU)Z*P*:C,*4H#I[!$1-"6E>.(V95GZUTHF?
MU)0^) D@0EI&!,X*3]<B#3R_( IKO;6!Q.<-WJT6=%^<MF59VL;:!@*W\9+V
MWK>?/(\QN<;<\UH]D<(/3'5O7RATMY</$Z"%D$DZ4U@;^+FQ4NP3(XS'I#^-
M^JH_'R:*.YS<<?579X46ZW 7$[:O%GY"CP#^]"X*]-^8N#OX4+-.!1!"I>V7
M_5\J(F]]@)E>_BQCC75O7SX",+EXH(F\IQM_]LH== S;EN!WIAE +-'H>ZQW
MU;4;(S.$Q0L6R]*!Y[KE@FR*>?F$IV M!.&[0(/HBYPV8;U&O[*G$3VYK?-X
M!!B-(B5O^\'>L?[<+=O%&O!PH*%SS![.<;J"T;\?BH3L)RHI8+,/8'0+2-D[
M,H[\4RTC0JUZ8\Q=39LZ*:O0-AQ!VP/\N#<>'M2JV22YP'O&REY&<!D-(V7Z
MXF?NK/6TH_;2G+2#'65']QIEN!\TD<;#\>2A+>L 6".LUW+9EH'Y=M(7X"[W
M\*#[??%PC'1= HY>\L:4N.@1@+:SHGC]\ 3GH]5'P G7GHBUWJ>-9VL,=,T2
M:4A\\BT 'A1W'"U!WO?IMI/E-2)[!#/WT#U!O.,6R6/F]4L=YTN5/O8@82\X
M?XX)@.>,YH4_2X=-' );9-HYZS^=H8?U'( <;T:;%.E95T.]V0SGT>3YHW\\
MM'PM2@?JX6S\ :DAA/5OD"KJ'3P"/GL+K2K%[A&K-ZUU#N>/!\83@4O_8:U)
M[AK&\I?J<RSSA;>C2 )/,V]IZ]+O-[\> 4MT=Y:/@"#-9;L;?!N_H[@'KLF_
M8;@:=P",/G<\[YGGA&G]=8=]#,HM$%K[=9_)QU&]J/I]8AN):\)*&.5X)F3+
M*Y5.NKKJ>PEJ-X;#]71?@W+ZPD#/+6),R;<"<KTFD3I19'AE1;,7,7C=,"3!
MUL-OWS+&0WKEM=IDD0%HGPLBH1$/AW^0I*LYQCGD.[*?!$[1=+T>2:3L'>*1
M/WZ(RYQE3DO_"(^_ZXBE&?' 97<@GW[N^'MDGA,5PGL_W_@(*+.$%2@".@ 9
M3JE6%(]18IA!%ZR'5-LB_FJ:!*\.LF%HX -@&%28QX/@!A+S+NEA*G:J5=DY
M$\K9(C8^M+45J0,:5/^BE/_H,R!FY\)^4=:-K!'H0-G1BT2;FW@O_RQ2QPK)
MNSM[1MRL[;?.)^Q]E9X7_@98KPF646ID*V?DB$>"R!B%?6-Z]QG#/W\U(WQ'
M ]>0Q0 7L]9J]4#QKO(Y)^ 14/%\Y.!%R]$GT6I_TE!JI/LV!0)KA[_L?]P'
M[/!08E![&^R/^NEVSM?AB0DD5#TL*7R[%N[WG=2V:C42L*GC-KQ/FQ<*'5SS
M_K&"B//\YH'G$P[/^I\(/ ?RL8)_\>6,[1_B%,6X96ZY.WXB73RX.=W[BE?K
MDI>Z5T@0^8N<7G*]YV&T)J(SA'0_Z"XS^6%RPMC3*P<!8'ZI3#Z1S".@*#'7
M=R7KX)]&CL+_5O>K9KT[37[JD _8;ROE&3<(AE</7TTB ],[IWW+5WPP#<.,
MIYP'O+)5O](8A!P7,=FW -UF6>EYH3[6?O^:K['DL@BJ9([P]Z37&14Q-9RZ
M[K1Q<L<$054"+1"K^M<YC?<\F6?1W=4/TXU_&4J+M=Z3A?WY=!R/14THJ4[N
M;US!Q8JY0UQ="G3Q^XC>>='W7;^'W@E:U3S9Z'MHX/>+"[G.$()TNM[=+GPD
M9 F[O6R<=)(=B!'>,1HQ:?A7]Y[[4>#^MSW!*.24$W*?^"W!1E?HFE)4=O7<
MPB9?0-8N'<_^\,3(X5]<)VUA]T+S([RU6_H*.<0Q?TZ/46J))H_%[W/:.0]T
MYB\<^-/$OL@QLZ*68G1$)NJ25?+Y>YX;^Z>\C!=S[\MY6)U!QAQE'3*:-&-6
M(%N0B? [?9%:ALT#N>?&I0FOY!^4P.IF?OOZE?_SJC\])M*5NZ&B)^<7PZIY
M!EG3N0&X2>+2/'?4=JCD;[=JXM?%!,JQ*FJJ7_WXYV]U3OXUK'_[=XE_O##7
M!W]2'".3HTWR$S%?:SO)/#!'UB)'N\O*+A@4$X&6EEOB _9XRN!79A4WSR1&
M%;H^/#'EGH%"W!)4)8(M 9CF_,7J#;D6'$M1@RJ&./M@/$'7-AVAD6BXRX#C
M:JJJ7IGPR:Y@QM %_B#VB6T0_4F9P6V] :RWRVI-C)C_F  ==.;O*?UUXKWJ
MUK/.7'2E9%2RI.3K\>_IEXZ_J0^)$^8HS+\@45O^"0ZFD20G$.&R_.\N(%:=
MQ/_[_.-?FM6%N]Q8NQK8T'ZYXD"2$.5#QBE<F.A<2T4S5]N2THVF9*-W5K@L
M4S<HOYX5:^@SV:JR'P$DMH4ZTP6T<>8LU)5>I<D(RNUK2[25+%P'IM#>C@XW
MV5-L4CWI'C+/421Y28OMN#ZG3*@"!UO,JH;Q@E/XZ%.]3*@J,[;[YZ\L['(&
M'.4.T2H8 Z]'$0>QOF=!'2;3A"&O'6N(IXLO-1SZ<N7-(]^B'5"542-%H.Q*
MBXFB/DOXO9W_[!FA^E&"E#ZD,,)!"\?0>N;RK"-7J(JM=8YT.'O]UNAVLMH-
M&EG]$STM>U1N(D!Y&1XF6DD!8/NLTJ[FU&WV:>P#*AJ<(AT@76YSK6GZG(\F
MJ5U7!C05'O1#UEBL;=L2+AL.!8'9Q"IQI@7D12;1[Q'@$2!3JV=!V&7SY[Y(
M>-7N\<P@WE>?[@IUMK)/\!X!<WF0FE%;NK<I^#@9O?OV"M+ (FM- YJ:@,UV
M(.%[C"YR2:,MZC1ZN)P_\D'K$8TQ;WMZ9T7BA<)09(B$XX>D5_6E/&BTG/E2
MJ/'HAA1/,C"2PK><?>0>SO3JP@]G#^*--;1F UU&<IS5 ,J2$F[VS,RO4PH^
M$B>T7F0@6(;5R7HQQJC,<*"ET31&Z$DX?<15["_*PD9J1K>RO(FH"7"W4**K
M\8D:N-1:XZ-(!5@_2[RHR6,1L+*:*XDP!JHU/8R4Q2Z_,FZ$.?S 1(84!F5C
M:)AHCTEM(.&]V?3GEV,,CLDGD^I]WP>)#W\[HH+!H?FL23\R[<(S7JS0KR,T
M3 A;N.)P%"=*(%AYD<Y1/=0"EM6;3[HH RTD=K@Q<F.3'&"=]!A LE;VPDJJ
M2/@.B9(T(_"99SAA\OZHR8@1A;/G4;BG"0U9[.E4057$C2N\XJA!UUHL(OP]
MDY #,^?9>4NGCL]T@V=?#R[W1,E > C)'+/MAXY=,,_2H!'LV9[A.IU3=J4/
M"V11R>O9.6Z5@^QL$Q  L(TH'#[B7#D\MJZF:;JJ)@HD+J^][(9<C<?8&A>U
MM5C_UA'F/ /A.5R8;XV]]22JF$U1.0AN5 /O_#!/./?"TRI A :.^CWRL =A
M6ZZ$3^$O@[F.@J;& <<YI5:4 \$T1Y]\N)]_9$=KYR.R"N!5B]*2.S4[E-+&
ME\1K4]H]/O*S2)<@9Z!?319;Y^4#5(M^U$R="Z1C0<4<\D9,4-^M%_46DP8(
M,>4^0U(0XT?&BYS0WA.>2Q*1''F]<?=HY23M6#(,*\%<Z%*3V+W5S8<\/[=2
M1;RIRCGZ,+GN09*ZK7# ]O/]HHRTH<G?$BL**%+5I\[A\K2J^I._?PT7ZFLM
MSA!4*).;\?0=M&4JKXQ^_^>%)B3ZW/\T2D3@COLJY148WO"T*E57D#O;)_:N
M$7"S(>H"O*?^Z#ANL<&(R*BSN?;D0B5I=09LMJE%SLFQ\?[>TTF2RH &_8B9
M &;AVI C(Q%EH/^148KH]AU_O8]CMZ?.%2GYNP'',:'4*0#FG5'M95]Q]<QY
M\.>**^MUV#KTB]![_O,,C*CP@>.#P4M/O.)+A(B2'T\4H?/MR;[-@$]&H.;
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M&(QJ>; JNS4H<]^84 O=/'R[F#K@O.U[6#(1*K9QO&1G,78Z&/D-9G+*6QI
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M@K:58Z8)8",5S#N%BD]I0E>0]VPK@[ODU*;::<RT\D6648*C_8A>Q\ <:LK
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MR 8]'7WI-_*7/SQ1^I.[IK$-M.=V+E_J54U<JP ^J!F=W2@A24J:UH15J34
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M]<%HZC(=-C5ONA-1YUCR)0(^ZJ)<W:W?6_K6-V6)Z_^Q*)+@DPDWXZ$Y0Y'
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M'PS.8^/+X,",8*03;//5PI6V. >=IX,T4I]TON4PA2]S<R$N=SW-#)"R11T
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MK)'_C@5491HCW1#U5]2=$8FMM^((*%DL5(2L>=DC;-T)X_RB:LGK)FZ#$;^
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M'^,24J@G_2BS:*BRMC,LZ))69:WM9.^6Q;:L?"> BD2R;0\4G\.TZ#/83K;
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MF4&\O_7/S_LGET>KREJUL[-\VBKN(7SNM65<=$6O0^F!4CETVD *3Q/W@#2
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M2-3?*LX45,7NTN$4QZ8B!,7J6+/#+*NYT4]5)T<6>D5,AFQ;6G: '6P0D$T
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M2_]$/L1:J*6YKH!L;G%]*>U/.=*(LPYV^1RK(*0_J:\1NBM^F0 ![3'1C@\
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MA +D?5842+=;%^3M\_:MH@#?=4)WX(1>7!Q]//DT.+E<Q<G!Z=R!TZE;(!
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MP_G-;#)NP_GYU7/S_GER_CR]OF"<4U)@4<8J:!I*:/+<HO!IZ](M2[7G?$T
M4"BK7GV@W%G,?Y7:_8MB^X^.X\,:"D(\:KFM(=QC] =/69 EM6))R0>++/!@
M%9);P<HCW?T98I)\6$JQYFFY[Q$RW'?,9Y#DN&/$0Z#.FFKN83RKC4;HU'.'
M/@89RE\C?'J1T61?9)LW)2]?1+9Y[?(O4$L#!!0    ( 'R$6%!IQQ(,6@,
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MNU@KT-^C\.?P4E_K,:F>CG#2,NM1ZP]02P,$%     @ ?(184.E^G[]D"
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M%;Z#LA%X-],_>MOWAR?CT<%H?S >'1V2HP-R?#(ZW!\=#[Z0@]'A "[AZN@
M*(8GY/CWDV^_#P['9'Q$O@WWD:6T5Z>'O.//PWZH][X-3CX.#H??FD=_?!G^
M20;[8QSL=3IWL>D/V*8[&97+&#0-NMNM[?RQ?7#4(,<,=HE\I9I3R1LD8MKR
M9$YL2FVP-NM8LVWOMLB(I'3*B&93SF:0<6S*#:%2%E3 PUQI"TF('"B=^;5U
M.\W_$960P9F:,-GP#T<R:JW/JM?,2+T6^4B-*P9(-B>G4LT$@ZJAX6U5&BE6
M,*M44&Z +,HEV'!."FEUP4 R%!.N%@'#49+!':!,D(1&\$@3E7%+K/)T*P22
M1<P8JN=(DM%3!O/69!IX%H,R,*7 '<$YD"#B&@H@()/ #IK$@.Y9RJ.4F +_
M6_#/F&:E$%Q QHV ZH3+B2^9-#,YBYR"*#<'U50,RYP"6TS">7T;UL>J]W#"
MK=;.HZN[]1TG9"3A$LR,'K,P:P,\$,AA6-?&N4P@E%#+00Z7D2ABD FN4[-A
M ]R.:S$G.5@>G1:=&6KE<Z\L'<)<F!H</^8HN($4A0 "<$4%_N*F,TZ?B)J4
M)$+-3.6GFDVXL9K"1!0?>KU!RT;-W4RES(JVZV/"-?.X[189+YGGU]=GO4[W
M_:XIG:JL$#!.J"3A<.M-/")4,^<D8'0>"H;&) P\,Q3<I$B/9!D$20R4> ^3
M1T*9 O@P?&HEO*A<JXC%\-B0-^ <,0-O\QXP/(M2*J%U&T!D.BD$,V5ZW*+-
M[LX;MNEO44AW)_:/-IU,CM6@]/Z*,Q$,9#4W]FZ%6MUNRF1UR@2FQ+5?='.@
MP*2_/KYP*]<EU3_HP78N:$^:W7>/KCW=_-[XBLR;ZE)?%_+5^VR\SVF,2=1M
M2;>WV!?7I+N=K#ZN:[B<<EM+G-]=\"=FH/$!KW69_GIP-; (B6AA;LZ"U4#(
M ![E3+Z^4(4& 1"RI]RX1 !43#HYV$<L4D@]#6DFJ,-;66 LD-(H4Q0.<D@G
MH(M1@L?N:,84H>$QAWX%%\!]&>02HT1)A<'2Q$4JX^H8ES:48:"0A32%3#D%
MH$>%H)CM8%E.B46) QR^8*K7>7 5,B2$A 3\+%Y;6*PWJ,/G#>H;9[$5;-\\
M_]T8XA 6ICQ&Y%*C),643PV@'EL/A#/5<04M #NG(1?<SK$ O&Q:##0.A0Y@
M/D8LD=9:%U=9G)4+R@N= \"-*UBC2.G8*>":&.B5H0X5@',883D&$"2!!LUC
M&0(-SR&EKRT>UAO-T7-#\W!*1>'R&+HZ2Q)HJ/@4G-1<TA@M*N\;)&9_>WFS
MY- +C)!4C6_)0E78JU6X2>E SZD9]IO)]8<$)*PZ61>0F-\*T&<7A:^K"Z\W
M ./G!L!/WK57(8+G=F6CYT8N!^(MLB@6OBJ*"HU(J%69EXG-E+$P@*\L0)B)
M0-+?!52I(/O-53P)@!HRW 7R4O<(H.9.'>7RH?*FURNEYKPHQ]SH@@"+7='@
MMJ1,Z',B^"D3Y1'D!?K&_7?I^2#_QS?S.W<_V'&O*N(*.8U%(,>\4O?=14Q'
MY[M%L;K2 RZ4H] (6E7J@D3N <C,,FXM8]_+FZ&"&A0)8@X:.BEOP,4A31E,
M@_")_6B%3/9WP6$!#H2%C-SIY>;=7H*]G-:\G-9<DXD& EH::+$X0 V/!_'(
M,>(,H%%6<^>G)C-&3[$\\RV.*]!<<^;>(57G[+<"7'G X0]L+XGU- 9&P\Y#
M_=7@+'LZX & 0>O5\$6B@0K1%!GL-NR*6TV99B]])?%\TL"3T_[9G:<,H,Y+
M-.20!H" N<0','(O0$N\-7R-Q.54B2G#0DG22?D>5Y>YDF6Y4',&H[-4^?Q(
ME] ,Z'N80K*UKIYUN_+H<77[!*8.R $+=8$OV'O;#8+?]'N:REZ]D;5O^\UX
M;%.O# #!NL.XB E1 NW#1F?#W9N<1M5]R1I"V&:Z&2DA:&Y84%WL>IF@::?E
MY7IEK?87<!63J?NRU8<-J_*-95UV/%<I'<:#+GBG5)*1UY_>XU]2#?KO*%XU
M&BIK57;U>/D=QI7ARD"@QG+$J5;RT-9=GA !C6^\@Y3'@,(EV]=UN/Z+=X[)
M\_S&SL-C7EFA;>,7@]S+()T[VV,)FY?9!*[TG7#S"-MS132Z74"ZMR/6O,F]
MY2.O.^X/N!.-3B=:%3+&X*1T0%[3PJJGO#5MTU[^1N6+:SQ C+K@%T]X_2^V
MO[?MG_ *]U/.$G)P7J0?^6.RF]@9+K F*W^G\90KRW_IER156P8J?MCH;NR1
MVJX]\)0YM&O-4#-ZVJ0)X#&@4\7Q-POU&5:22QE>=B/!J X@*Z55_0#]:1F1
M@DXY=[!UWF[5.U>WC,K"_;;[D<_//_7;[A=#_P=02P,$%     @ ?(184#5#
MV==6!0  !RL   L   !E>"TS,F0Q+FAT;>U:;6_;. S^W '[#[P4&SH@=FPG
MV1HG+9!E*19L?4&; ;O[,BBVG.@F2SY9:9/[]4?YI4OZ<NNZ=FL+IT@CFQ(I
MD@\IRG+O#\MZ/][_"*$,YC$5&@)%B:8AG#$]@[%,$B)@GRK%.(>WBH53"M"Q
MV[9GMRQK]_FS'G(8%&.D\,%K>*V&YW@.>'ZSZ3O;<+2?=YSIF./O1F]&26@:
M&SW--*=9<X,LIN++</&EZ=EN1FN<$WN-<D1O(L/E;B]DIY#J):<[M9BH*1,6
MIY'V7<?V.BW7??.Z]<9I;V^_Z!94Q::SJ\BUW5X#>=TEPVSJR3HSWTETES-!
MK1DM!CHONIHNM$4XFPH_8]>-I-!61&+&E_X "1/%\GLI^Y?ZX!HNN8"-GKE?
M"@E9FG"R])DP,M;8C%E,4SB@9W L8R+JV74]I8I%>;^S?$(3R<,5686HX>?W
MH[>C\4LQ29.N\4NO8?KD.C:2QZ;KJFJY3G>A3X!!0]7#<]Y@>#P>[8T&_?'H
M\ "./AV??.H?C&%\""?#@;F7FZ#CO(;#/1B_'\))__AM_V!X B\W%Y[CMKJ'
MGS\._X3^8&QZ>([C/7)[W34 F A1&=_=3GX_H$<" BD$#323(D_>>D:A+\2<
M<#BFB50:9 3]A9Q24<_5'XG ABW3+W?YH#N0,2;\97[YKOL*4SKL217G_5W'
M^@"15!GK)24**)H@A'<TH/&$JB)3N'5$B]L!DD+$>+F6F#$G-)@KIAGJ140(
MPT4P(P)7%!0;LS0U4U^;3C[O\]F4TZ[#!Z*H@+](2!7]NPZ#&:,1LD/VFIU2
M.(PB%E"5"3FBB#?8)XH1P<JN>TP0$3 T3=&U#OA/LVA9AV2NTCE!%VD)[C9\
MLD_L@6VF;DQ;&*+9=NI&/Q+*Q*Q\JV/6>IKX0K-GRA,U(8*FUN&"TR7T@\PA
M)J[J9ICI,J%I=C->PE<AS]!V:!P](]I_.DC]H<B#\NNU[>WV]_0#RW7M5OL!
M*.G:]\#VD@97:;EJ#]-GM9XQUPD)0R:FF7';WPR<U4*92\J?.YU_<TW"?5A\
MC.%3I+EHSOD2TV&<<)-ISK./HO_,F:*FS$U-E%T(Z2WR*F]B@G/;6V%Y%5U,
M7>=IJPAAM]-L=4VN>>*@OG7D=FZDXT-0T:OB]C?$+1-85,0D*UVPBM$$.89X
M-PN\,J@)4QC5B:*IB=^Z(1/<D^(P9(P+.1(2#&BDF%'1^0*/#$.6L3;5 /::
M\SS\94)5)C,M5^BB^K&?-,2OC^*57? 9"_4L5P+=K\F$4RR0."]0N%-S:MEU
MFI"@O"Z&3J3"JLP*).<D2:E?-KHY3U30L7.^N8Y:Y0ULA7":;1)V:EHFM?6Y
MM/-1!7>D^RY:7DA!8?-=Q_Q!2<SW[M=1)U)K&5]/+_;VE\BE8W$:Z^%8:G)-
M17:5O]>1\L;N>"\N\)>G5$5<GODS%B)^5MRX)O'[$,E=?]GSI=>S)RUAY8('
MX@)LJ5L%QLVM<2E-_4!&^B5)Z:>AN8*O5'(6PJ:3?1!@)/@Z57(N0I.@I/)A
MD\RU?.36:Z2-]1UQ!;#[!5B9^RZ@ZW&;J$+0KT#0XS;"-0_:*K14:+G""'MT
MHN9$+<%KF4?"GE/AI,+);8Q0@:.JBF]5%:\=_E0 JZKB'S91A:!J_;I957SI
M3+E"2X66NZJ*L6$>PA<OK/WOB<1UA_Q7/?%<5=V]V<'#$WEYZN<.-G^/C>_I
M;<7R8 ^GN%-S:[NP L@[%IF0*;4FBI*O%HG0]3XYE2PT9TPK$BZ5HT4IT0TX
M)<K'.G96/JKWT)YY]>$[A6R_63JI;'Q[S[,,GEXC>Y'T^;->(WLK]3]02P,$
M%     @ ?(184/7NM7U5"@  7BT   H   !E>"TT9#$N:'1M[5IM<QHY$OZ<
MK=K_H&,O&Z=JP+S820S$5=@AB:MBQV63VWS;$C,"M)Z1)I(&S/WZZV[-# .!
M3;R7;'F3N,HV(*G5ZI>GG];0_U>]_GIT_H9%.LP2H1P+C>!.1&PAW8R-=)IR
MQ<Z%,3*.V8F1T50P=M0X;+0;!_7Z\<\_]4'":;Y&JRYK[[</]MO-=I.UNYU.
MM]EFE^=^XLPE,?Q_T)\)'N&+!WTG72SHY0-^.U6_#V]_/VBT:&B_'.OO%POZ
M8QTMC_N1G#/KEK%X7DNXF4I5C\7$=0\;SYZU.X?MHX-6Z^F3@Z</>_FHD=/9
MMN':<7\?9'U)@:1ZNBZLVTP=P]\6_.DY<>OJ/)93U24QO8E6KC[AB8R7W9%,
MA&478L&N=,)50.\#*XR<^'E6_E=TO2"_V8,^?EYL&$F;QGS9E2J62MQ-]$+0
MJ<8ZCD#V\'8FQ](Q<$=_'\?]T?;3NQTQA) 2YIZ>\<7P^O3J[')T]O:"O7W)
M1J^'[&KXZNQZ=#6X&/WZRVV[V3KJ7;/KX>F[J[/1V? Z'QY>#5^PRW=7U^]@
M'AN]Q1DDI-4NY%36#-^?OAY<O!JRP>D(AUM'G8._9E*I(C!GM_,DO1=14SL>
M6*8G[(4(13(6AG5: 4.;!<S-!(!!O&1AS"U-LB+,C'12T+O!K9X*%; S%38"
MQMFY5$I8[3@+M4FUX4YJQ?90C/?#:>]4)P!%2__V1>]QP(R82@O1!<"3@64,
MNQ8AK0,WP!ZX^'JUZ_ VG'$%Z#4('0ZC&V!KRSC 7B2B@$D+NR<)"+!.AS<!
M2[EA<QYG@OV[V6BV6 I[V!DW@NU5M,(%U[B@5*WQJQK;M.?_CD"--=V/>I95
ME^&^,1X$\9.TON VXA_8*4^EXS$[Y^9&N/R,.&Z7"41P:9G!^U<7Q=Z-;R*R
M0AUKT_VE23\@^%UY](\L.?#>8UQ%[$I81W5H8)P,8Q]J$&*[0JJ85HFIRA[H
M%YZYF39PQH@Y#1]8B(4LQ=>M9C-H^E\?$[19U:]_$C\-YC/GI1B;C)LE:U/F
MM)L!ZQP%3R&/FD^?[1#+%A#Q7A5_:ITY.+:*I)K>V?L?AP"KTT?W( @^ NS-
MJ'@AYQ)TCFS _J,=')]=X61+5GDC/V0R(J=_DRF!L#(#JPCCX75KK'39GGSL
M86C&YX*)#QF/ 3BYX^-8,./-!=$<%:9D$Z,3-LGP92RF/ 8,YW,N8UH V6'$
M1)N +68(W]S;6DY8) #I$8G'2\JA$\U-1,5!&D!E[;6L9%< JA6Z(:*"K9'O
M49YYC/5:0AHJ!FK 7E:@;TME0 _0VSHCQQGE-JS\I$4@>^%EO J. &58'7L1
M('(A*94PS=<U7F$.GTRX-):.4)PATDQIQ\C,J1$B29V<BX#9;&Q#(]-"?*C5
M'#3$=V85K618AJ=6&NI:1,O] BO5#>J#/@')>BYQ,2Q+TUB&*[? Z5'2GISO
ML*I6@LVU$Y4RIKUI$^X<6FTQD^',#Q6&3/C2+\*ISL\6 I-M9>1\;@-+K( <
M@JC0J-)"6O BQ)S, P/1.7/"H^P*H^^"["?+F"_ \E6U\200?S+RNW 8^ -
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M2P$"% ,4    " !\A%A0<?DT\:$3  "#. $ %0              @ $*%
M87AG;BTR,#$Y,3(S,5]C86PN>&UL4$L! A0#%     @ ?(184$91V8>4*@
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M8S,U-S P,RYJ<&=02P$"% ,4    " !\A%A0VK0K47&.  !XJP  '@
M        @ '<$08 87AG;BTR,#$Y,3(S,7@Q,&LP8V,S-3<P,#0N:G!G4$L!
M A0#%     @ ?(184/_*8G(^5@  )EH"  P              ( !B: & &5X
M+3$P9#4Q+FAT;5!+ 0(4 Q0    ( 'R$6%#4;87M5P(  !T*   +
M      "  ?'V!@!E>"TR,60Q+FAT;5!+ 0(4 Q0    ( 'R$6% F-9Y.'P0
M .@1   +              "  7'Y!@!E>"TR,V0Q+FAT;5!+ 0(4 Q0    (
M 'R$6%!IQQ(,6@,  -P-   +              "  ;G]!@!E>"TR,V0R+FAT
M;5!+ 0(4 Q0    ( 'R$6%#I?I^_9 @  +$T   +              "  3P!
M!P!E>"TS,60Q+FAT;5!+ 0(4 Q0    ( 'R$6%"S?R,O70@  *,T   +
M          "  <D)!P!E>"TS,60R+FAT;5!+ 0(4 Q0    ( 'R$6% U0]G7
M5@4   <K   +              "  4\2!P!E>"TS,F0Q+FAT;5!+ 0(4 Q0
M   ( 'R$6%#U[K5]50H  %XM   *              "  <X7!P!E>"TT9#$N
9:'1M4$L%!@     0 !  ] ,  $LB!P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803880432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty fees included in sales and marketing expense</a></td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="nump">$ 1,661<span></span>
</td>
<td class="nump">$ 1,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_NoticePeriodForTerminationOfLicenseAgreements', window );">Notice period for termination of license agreements</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_MinimumRoyaltyOfLicenseAgreement', window );">Minimum royalty of agreements</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_MilestonePaymentContingentUponReceiptOfGrant', window );">Milestone fee upon receiving a Phase II Small Business Innovation Research</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_MilestonePaymentContingentUponFDApproval', window );">Milestone fee upon FDA approval</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology', window );">Milestone fee upon first commercial use of certain licensed technology</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology', window );">Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_RoyaltyFeesPercentageUnderLicenseAgreements', window );">Royalty fees range under the license agreements</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_RoyaltyFeesPercentageUnderLicenseAgreements', window );">Royalty fees range under the license agreements</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors', window );">Royalty stack cap for royalties paid to more than one licensor for sales of the same product</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_MilestonePaymentContingentUponFDApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment due if AxoGen receives FDA approval of its Avance Nerve Graft.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_MilestonePaymentContingentUponFDApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment due upon first commercial use of certain licensed technology to provide services to manufacture products for third parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_MilestonePaymentContingentUponFirstCommercialUseOfCertainLicensedTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment due upon first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_MilestonePaymentContingentUponFirstUseToManufactureProductsUtilizingCertainTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_MilestonePaymentContingentUponReceiptOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_MilestonePaymentContingentUponReceiptOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_MinimumRoyaltyOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_MinimumRoyaltyOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NoticePeriodForTerminationOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notice period for termination of license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NoticePeriodForTerminationOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_RoyaltyFeesPercentageUnderLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty fees percentage under license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_RoyaltyFeesPercentageUnderLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6798127904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Agreements and Long-Term Debt - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 22, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term obligations</a></td>
<td class="nump">$ 22,599<span></span>
</td>
<td class="nump">$ 22,513<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Exit and/or prepayment fees paid</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized deferred financing costs</a></td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=axgn_RevolvingLoanAgreementMember', window );">Revolving Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term obligations</a></td>
<td class="nump">2,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Exit and/or prepayment fees paid</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=axgn_RevolvingLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=axgn_RevolvingLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805999376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">3.</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies </b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Cash and Cash Equivalents and Concentration</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying consolidated financial statements.  The Company has not experienced any losses related to these balances; however, as of December 31, 2019, </span>$35,224<span style="white-space:pre-wrap;"> of the cash and cash equivalents balance was in excess of FDIC limits.   As of December 31, 2019 and 2018, the Company had restricted cash balances of </span>$6,000<span style="white-space:pre-wrap;"> as collateral for an irrevocable standby letter of credit.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,724</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,294</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,724</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,294</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Investments</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company invests primarily in U.S. Government securities, corporate bonds, commercial paper and asset-backed securities and classifies all investments as available-for-sale. Investments are recorded at fair value. The Company has elected the fair value option (FVO) for all of its available-for-sale investments.  The FVO election results in all changes in unrealized gains and losses being included in investment income in the Consolidated Statements of Operations.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Revenue Recognition</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On January 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 606, &#8220;Revenue from Contracts with Customers&#8221;, utilizing the modified retrospective method applied to contracts that were not completed.  The adoption of the standard did not have a material impact on the timing and amounts of the Company&#8217;s revenue, processes or internal controls.  Upon adoption, the Company did not have any material remaining performance obligations, significant judgements, or material costs to obtain or fulfill contracts with its customers.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection.  Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products and services to the Company&#8217;s customers.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract.   These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#8217;s cost.   The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and, therefore, the Company has determined it is appropriate to recognize revenue when:  i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement.  Determining the timing of revenue recognition for such contracts is subject to significant judgment, because an evaluation must be made regarding the distributor&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company.  Changes in these assessments could have a significant impact on the timing of revenue recognition from sales to distributors.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of sales.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers. </p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#8217;s contracts vary; however, as a common business practice, payment terms are typically due in full within </span><span style="font-size:10pt;">30</span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">60 days</span><span style="font-size:10pt;white-space:pre-wrap;"> of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material.  The Company has several contracts with distributors in international markets which include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In connection with the Acroval Neurosensory and Motor Testing System, the Company sold extended warranty and service packages to some of its customers who purchase this evaluation and measurement tool, and the prepayment of these extended warranties represent contract liabilities until the performance obligations are satisfied ratably over the term of the contract. The sale of the aforementioned extended warranty represents the only performance obligation the Company satisfies over time and creates the contract liability disclosed below.  The opening and closing balances of the Company&#8217;s contract receivables and liabilities are as follows:</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Balances</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:44.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Receivables</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:15.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Liabilities, Current</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract Liabilities, Long-Term</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Opening, January 1, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,065</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Closing, December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Increase (decrease)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,256</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (27)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Opening, January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,321</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Closing, December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Increase (decrease)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,623</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (27)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company evaluates the collectability of accounts receivable to determine the appropriate allowance for doubtful accounts. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in general and administrative expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The Company&#8217;s history of write-offs has not been significant.  The allowance for doubtful accounts balance was approximately </span>$1,092 and $1,117 at December&#160;31, 2019 and 2018, respectively.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company&#8217;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Inventories</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Inventories are comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve&#160;Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane, Acroval Neurosensory and Motor Testing System, Axotouch Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company monitors the shelf life of its products and historical expiration and spoilage trends, and writes-off inventory based on the estimated amount of inventory that will not be distributed before expiration or spoilage.  To estimate the amount of inventory that will expire prior to being sold, the Company reviews inventory quantities on hand, historical and projected sales, and historical expiration trends. The Company&#8217;s calculation of the amount of inventory that will expire prior to sale has two components: 1) a demand or consumption based component that compares projected sales to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being sold. The Company&#8217;s model assumes that inventory will be sold on a first-in-first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that a significant portion of the Company&#8217;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written-down involves significant judgments and estimates.</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Leases</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02&#8212;Leases (Topic 842) (&#8220;ASU 2016.02&#8221;), as of January 1, 2019, (the &#8220;Application Date&#8221;) using the modified retrospective approach. The Company will continue to report financial information for fiscal years prior to 2019 under the previous lease accounting standards. The modified retrospective approach provides a method for recording on the balance sheet as of January 1, 2019, leases that have commenced on or before the Application Date. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company elected the package of practical expedients permitted under the transition guidance, which allowed us to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Company also elected the practical expedient allowing us to not separate the lease and non-lease components for all classes of underlying assets, apart from equipment. &#160;The Company did not elect the practical expedient to use hindsight to determine the lease term for leases at January 1, 2019. </p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company made an accounting policy election to not recognize right-to-use assets and lease liabilities that arise from short term leases, which are defined as leases with a lease term of 12 months or less at the lease commencement date.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Adoption of the new standard resulted in the recording of right-to-use assets and lease liabilities of approximately $3,786 and $3,823, respectively, and the derecognition of capital lease assets, capital lease liabilities, and operating lease deferred rent of $96, $63, and $70, respectively, as of January 1, 2019 with zero cumulative-effect adjustment to retained earnings. The new standard did not materially impact our consolidated net earnings.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Net Loss Per Share</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Basic and diluted net loss per share is computed in accordance with FASB ASC 260, &#8220;Earnings Per Share&#8221; (ASC 260), by dividing the net loss by the weighted average number of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, options and awards of 1,556,818<span style="white-space:pre-wrap;">,  </span>2,621,440 and 2,253,399 which were outstanding as of December 31, 2019, 2018 and 2017, respectively, were not included in the computation of diluted net loss per shares because dilutive shares are not factored into the calculation of net loss per share when a loss applicable to common shares as they would be anti-dilutive. See additional outstanding shares as disclosed in Note 11, &#8220;Equity Compensation Plans&#8221; that could potentially be dilutive.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Research and Development Costs</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred and were $17,514, $11,773 and $6,699 for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Stock-Based Compensation</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company measures all employee stock-based compensation awards using the fair value, including stock options, restricted stock, performance stock and stock purchases related to an employee stock purchase plan.  The share-based compensation recognized under ASC 718 for years ended December 31, 2019, 2018 and 2017 was </span>$10,304, $7,606,and $3,609, respectively.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur.  </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of time-based options on the date of grant using the Multi-Point Black-Scholes option-pricing model (Black-Scholes model). The Company&#8217;s determination of fair value is affected by the Company&#8217;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#8217;s expected stock price volatility over the term of the awards.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of restricted stock based upon the grant date closing market price of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company also has an employee stock purchase plan (ESPP) which is available to all eligible employees as defined by the plan document. Under the ESPP, shares of the Company&#8217;s common stock may be purchased at a discount.  The Company estimates the number of shares to be purchased under the ESPP at the beginning of each purchase period based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model and records estimated compensation expense during the period. Expense is adjusted at the time of stock purchase.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">With respect to performance stock units (&#8220;PSUs&#8221;), the number of shares that vest and are issued to the recipient is based upon the Company&#8217;s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company&#8217;s closing stock price on the grant date and its estimate of achieving such performance targets. For further discussion and disclosures, see Note 11 &#8211; Equity Compensation Plans.</p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Use of Estimates</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Management believes the critical accounting policies regarding revenue recognition, allowance for uncollectible accounts receivable, investments, inventories and share-based employee compensation affect our more significant judgments and estimates used in the </span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">preparation of the Company&#8217;s consolidated financial statements.  Actual results could differ materially from those estimates.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:13.5pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In February 2016, the FASB issued ASU 2016-02. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-11, Targeted Improvements to ASC 842, Leases (&#8220;ASU 2018-11&#8221;).  ASU 2018-11 provided entities with an alternative modified transition method to elect not to recast the comparative periods presented when adopting ASC 842.  The impact of the adoption is disclosed in the Leases section of Note 3, Summary of Significant Accounting Policies.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In August 2018, the FASB issued ASU No. 2018-15, Guidance on Cloud Computing Arrangements (&#8220;ASU 2018-15&#8221;).  ASU 2018-15 provides guidance on implementation costs incurred in a cloud computing arrangement (CCA) that is a service contract and aligns the accounting for such costs with the guidance on capitalizing costs associated with developing or obtaining internal-use software.  Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized.  This update is effective for annual and interim reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently evaluating the impact this standard will have on the Company&#8217;s consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;).  The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  We are currently evaluating the impact the standard may have on our consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In May 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses, Topic 815, Derivatives and Hedging and Topic 825, Financial Instruments (&#8220;ASU 2019-04&#8221;).  ASU 2019-04 clarifies certain aspects of accounting for credit losses, hedging activities, and financial instruments.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In May 2019, the FASB issued ASU No. 2019-05, Targeted Transition Relief (&#8220;ASU 2019-05&#8221;).  ASU 2019-05 provides transition relief for entities adopting ASU 2016-13, Measurement of Credit Losses on Financial Instruments.  The amendment allows entities to irrevocably elect, upon adoption of ASU  2016-13, the fair value option on financial instruments that (1) were previously recorded at amortized costs and (2) are within the scope of ASC 326-20, Financial Instruments &#8211; Credit Losses: Measured at Amortized Costs, if the instruments are eligible for the fair value option under ASC 825-10, Financial Instruments: Overall.  This update is effective fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In November 2019, the FASB issued ASU No. 2019-11, Credit Losses (Topic 326), Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses.  This amendment amends certain aspects of the new credit loss standard, ASU 2016-13 (ASC 326).  As the Company has not adopted ASU 2016-13, the effective date of this amendment is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  Early adoption is permitted.  We will adopt ASU 2016-13 as of January 1, 2020.  The Company is currently assessing the impact the guidance will have on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) (&#8220;ASU 2019-12&#8221;), Simplifying the Accounting for Income Taxes.  This amendment simplifies the </span>accounting for&#160;income&#160;taxes&#160;by removing certain exceptions to the general principles and improve consistent application or and simplify accordance with accounting principles generally accepted in the United States for other areas of&#160;Topic&#160;740&#160;<span style="white-space:pre-wrap;">by clarifying and amending existing guidance.  This update is effective for annual and interim reporting periods beginning after</span><span style="background-color:#ffffff;color:#333333;"> December 15, 2020. Early adoption is permitted but requires simultaneous adoption of all provisions of ASU 2019-12. </span>The Company does not expect this standard will have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company&#8217;s consolidated financial condition, results of operations, or disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810925648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AXOGEN,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1301878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">13631 Progress Blvd., Suite&#160;400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alachua<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">32615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">462-6800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,731,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000805928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 539,757,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6814299056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">$ 461<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Additions</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions (Chargeoffs)</a></td>
<td class="num">(539)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation allowance for deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">33,876<span></span>
</td>
<td class="nump">28,357<span></span>
</td>
<td class="nump">39,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Additions</a></td>
<td class="nump">5,977<span></span>
</td>
<td class="nump">5,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions (Chargeoffs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,754)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 39,853<span></span>
</td>
<td class="nump">$ 33,876<span></span>
</td>
<td class="nump">$ 28,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6798027712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Service Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_TissueProcessingAgreementMember', window );">Tissue Processing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Service Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_LicenseFeeAmount', window );">License fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,148<span></span>
</td>
<td class="nump">$ 1,931<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember', window );">Master Services Agreement For Clinical Research and Related Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Service Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement', window );">Service agreement amount paid upon execution of agreement</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LicenseFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License fee amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LicenseFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Service agreement amount paid upon execution of agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_TissueProcessingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_TissueProcessingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6811139744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 132,475<span></span>
</td>
<td class="num">$ (117,884)<span></span>
</td>
<td class="nump">$ 14,921<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">33,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,445)<span></span>
</td>
<td class="num">(10,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">15,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares (in shares)</a></td>
<td class="nump">805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">536,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">153,168<span></span>
</td>
<td class="num">(128,329)<span></span>
</td>
<td class="nump">25,182<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">34,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,397)<span></span>
</td>
<td class="num">(22,397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">132,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares (in shares)</a></td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">3,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">297,319<span></span>
</td>
<td class="num">(150,726)<span></span>
</td>
<td class="nump">$ 146,982<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">38,901,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,900,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,135)<span></span>
</td>
<td class="num">$ (29,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="nump">689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 396<span></span>
</td>
<td class="nump">$ 311,618<span></span>
</td>
<td class="num">$ (179,861)<span></span>
</td>
<td class="nump">$ 132,153<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">39,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,589,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
